<SEC-DOCUMENT>0000950170-24-089238.txt : 20240801
<SEC-HEADER>0000950170-24-089238.hdr.sgml : 20240801
<ACCEPTANCE-DATETIME>20240801160334
ACCESSION NUMBER:		0000950170-24-089238
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240801
DATE AS OF CHANGE:		20240801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aldeyra Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001341235
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36332
		FILM NUMBER:		241166475

	BUSINESS ADDRESS:	
		STREET 1:		131 HARTWELL AVENUE
		STREET 2:		SUITE 320
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-761-4904

	MAIL ADDRESS:	
		STREET 1:		131 HARTWELL AVENUE
		STREET 2:		SUITE 320
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aldexa Therapeutics, Inc.
		DATE OF NAME CHANGE:	20130102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Neuron Systems Inc
		DATE OF NAME CHANGE:	20051012
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aldx-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-01T13:56:44.9724+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:aldx="http://www.aldeyra.com/20240630" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_1db5701a-2432-477d-8543-8af568c033b3" name="dei:AmendmentFlag" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312">false</ix:nonNumeric><ix:nonNumeric id="F_36dee27a-22e8-4e58-b336-3f200b8ff37a" name="dei:CurrentFiscalYearEndDate" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312">--12-31</ix:nonNumeric><ix:nonNumeric id="F_3a4a7988-6450-466b-a1e8-15750269339c" name="dei:DocumentFiscalPeriodFocus" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312">Q2</ix:nonNumeric><ix:nonNumeric id="F_dc2b3bf1-1b25-4bef-91fd-9e286e214934" name="dei:EntityCentralIndexKey" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312">0001341235</ix:nonNumeric><ix:nonFraction id="F_8287f335-848f-4569-a5bd-ca1496b4c0cc" name="us-gaap:CommitmentsAndContingencies" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_a72334fc-b806-4b63-90f8-3649fbd0921f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" unitRef="U_USD" xsi:nil="true"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="aldx-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="C_808346d8-8add-488a-af8a-fcb254ad94f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_820ae58a-8aa6-4607-9edd-93c8f14eda0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aldx:JefferiesSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_841e49f2-f8fa-49e5-99ce-5c3d05827d57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_843cc0d2-4659-45e9-803e-1d495953e509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_847ea9b6-7712-40f6-975a-e4c8f6744f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_872d021d-8d7a-415c-aeb0-071a12408727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88eff217-da00-447c-80f0-c097fab822a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a0ad11e-9a2d-4592-8375-3c6294aa068f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ae5248f-56fc-4d37-937d-6f7c458af533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b1c90f6-18eb-4001-b78a-e6751c433d4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fc74b92-85f2-4f9d-916a-762e069ff326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_930eaf0d-182d-457d-8a25-2eb7dc5ce169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_960aacbe-fbab-4c63-a85d-c2285ac66c3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96d3e115-830a-4157-ac6e-d8edcdd92568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97b19cd6-75ad-4456-99d8-09b2da452e22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a212d05-0e21-49b7-9210-0c109f941d60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a06e8e4e-16e8-4dde-9e9b-ffb7963feb18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a07ad80e-09c8-499d-9ae3-f20d8016d887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a171b1df-4c92-4175-9e5f-fc3f4bc0789f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a65476d8-e4fe-4f45-94fc-12a4ca98f051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8750d12-9271-493b-9774-aab5b1395f5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9120b8c-dabf-419b-a873-3175c3e4920e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9ad5259-f5a0-4de2-8a29-68603609c343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae29fbf4-5256-4883-8903-abc42ff33b2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">aldx:SecondAndThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3aea01f-e989-48fd-b9f6-75afb86f910e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5f0f1f6-82d5-4d52-a257-4f738b44ebd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7b49075-22e7-4aa3-8ae8-65ddb24b9fd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b945516c-a2fe-4ef4-b522-ac7685c78c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba4aaa8b-9a25-4dae-b1bb-126e2ff2adc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba8fec32-6fe2-4982-8ac2-8fed75b0a26a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb0d2bfe-e96f-4d70-8e2c-d454ec91262c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb794176-2e9b-4405-a8ac-a7adab3cce8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc7df239-76b6-4890-8a10-e0ed9e21e2ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2017d1d-743c-43c9-91e8-cd1670c08fa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c420c777-2dcb-48fa-9456-2026963c27cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c67b96d9-fd6c-4b3b-b38e-25799171694d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">aldx:SixthAndSubsequentAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c884d0fc-bcef-447d-a229-a6c5ade380f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb6f8aff-b5a2-43c0-b4c7-168cf4972773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce7c4b72-5b97-4a0e-8ea7-eeb870e832ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce9c8181-658b-4601-b349-c64cda3f969b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aldx:JefferiesSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d16b308a-5d1b-46ab-9b7e-ef142ccd89bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2057004-303c-4ec3-b98a-2fce3b615d82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3f16ce7-5180-4c42-a5f4-7353119a3125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d409ba4a-341b-44fb-b178-554996db8456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d45352fc-bf96-470b-b41f-a3eef457e016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d46ad5a4-f2a8-4980-bd43-14f2b037e22b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7a4bb9b-dbe9-47e8-b920-116470b0af89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7bd3f39-df0b-41ee-912e-1db77d9d2cbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d81bffd9-e22d-4296-b634-a77b7d9776fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9ab5c6a-9d40-4195-839e-643b592547c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc6e015f-4534-4370-bdb9-a7945e9ca45d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0139f32-b214-4275-ae8a-16f436e3203c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0ad43ee-c467-4100-b399-f7960579d117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e51b1aea-5294-4784-b720-49da7b57163b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5cc0746-8061-4e14-bb40-9336a2e95fc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aldx:FoundersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e699a756-602d-48a6-8707-937ab2672bce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eada7cb9-d8f4-4796-a84a-8755760815f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebf661ea-8dd4-4850-bc1d-1fc69b508bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ece659b6-3cda-4818-924c-f705aecc6e99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeb1ebd5-f0dc-4d5a-a53d-de4340ddcb8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa2877a2-040d-4ca1-96d6-0276098a9d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faf7cb0d-6157-4f20-a7ac-312439f84084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb79a21e-fd07-4da1-8098-c1db3735b70c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd697598-618c-412c-a894-2682ae77ed63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff12ec68-2fd5-4170-ba6e-4b15c2ff223c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0075fb28-2a17-4b2b-92f6-1abe0f5ca0ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01391853-2657-4f02-b4dd-642d3c6e71c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05cced33-c667-4b68-9ab8-068003720e62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06ea7345-51c9-4c36-a9ba-2e750192f04f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09af761f-3d1e-47a3-ba56-29b402f55cba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c6b3071-64d9-4ac6-879c-7ab5b8feecfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cb4447a-186f-4c30-9fe1-b6650981eee1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d3c720f-35ff-43af-affa-e0f2ff358760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:TaxGrossUpPaymentChangeOfControlOrDivestureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e649ed4-2953-4514-be22-df39d5e87435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fa013e6-439f-4984-ad30-ef4b14ba2cf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10f6bf02-b7a9-406c-8bc5-35aafa92828a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-21</xbrli:startDate><xbrli:endDate>2023-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1580d899-1ef3-48b3-8ee0-2947a0996507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16a2a60d-0d62-4933-959e-b7fe028a37cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1992e0d5-9cc7-4f34-b9f5-65c44191df0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2083538c-d3e8-425e-af11-ff49a4b2d8a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20b130d8-eac8-40f7-93bd-c629812ee1cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_215ae863-6dc1-4301-a3a7-f9b85b618132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2168d68b-67be-44e7-815f-cebd869819ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2183c4fb-95a9-45e8-8593-0a184fe3bf8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2377695c-39c4-4859-bd6c-1d4b3b5420f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23d2488d-1f43-4650-839c-3f8956faa50b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26f21088-fd82-4099-b10a-e221c702905e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_270782a4-00d0-4755-8b0e-33d563f70df1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-21</xbrli:startDate><xbrli:endDate>2023-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_282ada39-a478-4e55-91a1-d5ab8c59d75f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2869d481-18dc-4588-a73e-4a7189c37ae7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_296f06b9-5d06-47d8-9d77-8c2beb9797c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bff6b01-34c7-4499-90bb-790707bd6958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36d41454-9864-4202-a51e-8d9e3f172bf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3731cf74-643e-408a-91dd-f3a385d27749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39c1e011-e9ae-4875-9500-c3cd89afff9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">aldx:StateAndFederalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40f99af9-00a1-419c-baf2-fe6d585df1ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42d94c98-9934-4c6a-b0fa-52973f777316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aldx:CsbuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44cef7b4-5749-4aaa-83b1-0dd0b0576672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_459e57d8-3560-4c3f-bc51-fdf45eed3a01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_481f3f0a-8710-4898-94d3-26fd583c6860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a2131ac-d9f6-43b3-8527-47305ed8f104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ac1801a-8726-4753-a2ce-890bbc37f3b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4db1176e-71d2-415e-8ae0-552b66496538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fd7b4a8-0fb4-40c1-9d8f-860b5e3f8919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50415d91-456c-4345-a9e8-9a5bd2f7cfa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51da8247-a19b-484d-a0e4-e21be178c20a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5695a349-fc70-4db4-9dda-882a4f8e1db0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5701f4e9-face-49d1-84bc-81d336191ded"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5763b0ce-896c-424b-adb7-cf75ae931b87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57c845a6-299a-49d1-989a-c6184ab8153e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60a5b99d-584e-4c7b-9492-7224c914dd08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61a04340-64f4-46ee-a35b-1ebbc1c4f8bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_621f912c-92a3-433e-800f-cd9932a4b216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6498b198-4aa0-4c05-874e-e075d11990e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64ca8519-f2dc-42f4-84f7-7cd8b17311a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_659d8673-bb33-41b8-8d04-af77a63be73c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b7f665d-724a-4e0d-8cda-8a1d42dfea6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dcdd5b4-ccce-449a-a571-48929e89299f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_733f6dcb-0419-40ba-b628-e28799994562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7357fd5b-2efe-455b-b17d-fa82ed547f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76203581-137d-4ed8-9232-5c729556d7ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7749ab03-e4ad-4f5d-a02f-52988e9238db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">aldx:FourthAndFifthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_783ee973-e8a0-419e-baed-08fbad7a4c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_788bedd8-2721-4594-a783-b6f8bc8b6ea1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a559121-6521-4d20-bd8a-c5e91210cc67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-19</xbrli:startDate><xbrli:endDate>2021-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b436d9e-9e0b-472d-a52a-b050edddbb87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b9cc316-d571-44e9-92d7-4c988cd04578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e21e7ea-a69c-43f3-9f0d-2bd41f8e3aad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fa87fa1-8b12-44f5-9947-3868ccbde0f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001341235</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>aldx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc" fromRefs="F_0af89e23-8908-4fe4-9ba6-b0ecea824388 F_1596e311-0cd3-4557-b4fd-9f9789a40315 F_77f5a3ca-c112-4eff-8efd-da8e3b426a55 F_8a18a13b-2e56-4f52-8d8e-86a080dff483 F_f7ced53b-382a-4a06-a70b-8fce9e588d56"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106" fromRefs="F_3453c0eb-9dcf-4d01-9356-9c5099a2c7c2 F_739cd3a2-b214-4a13-b917-4203bde874f2 F_af0160b3-c1dc-40ec-922e-82ab9dfbe5e5 F_575d2373-7b15-4e51-b573-da3f4a24b4d9 F_92f32549-80f2-467c-8b2f-9bd83c82e5dd F_e7700661-4e7e-4e18-abc2-e29bf3ec936e F_6611f187-f013-435b-90d2-dfd90060d602 F_ed4915a9-4dd2-4265-b77f-6e7637b60391"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6" fromRefs="F_0315416b-5579-44c4-842d-4b8c907151f8 F_f5561c5f-8c9a-4cc7-a79b-057551894955 F_b339e8f1-33fe-4895-bdab-41ed31907311 F_fea16ee6-10de-47de-b9fd-0d0c2d08937b"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627" fromRefs="F_4bc8c274-18f6-4bcf-8af9-2e9390ef3502 F_6f61ddbd-5136-4d1d-8f38-bf73865d4de4 F_879dbe73-3269-4a4c-8715-2f118e4c2e4c F_ff6ecb51-d83d-41b3-be2e-efc0e60d8dd4"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_30fce50e-09e3-4718-8fe5-35e6214b0ffd" fromRefs="F_8895e7b1-3343-430f-859a-51f2f0401b45"/></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">Form </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfa364d7-85e5-466e-bfca-390d21bf4e43" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_978e64ad-d237-4ff4-a157-f25a29d564e9" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13833983-6292-4cde-84ad-0ab01dab5492" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c78eae54-681d-464b-98de-17b0152b2694" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed2f6cc6-b6f5-4ae3-8bb5-d52559c4a66d" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                              </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                             </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00b75560-0f08-4601-a317-2d8ea08119c5" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-36332</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0794fec9-5834-4820-9394-3fb653c62ba1" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49%;"/>
    <td style="width:2%;"/>
    <td style="width:49%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f07dbd2d-c2dc-423e-a48f-7a4bbb7dc530" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_93cac57c-f4fa-452a-b176-733064fa8e87" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20-1968197</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a495083c-c6eb-4502-b2ea-0f2a8ec3cfd1" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131 Hartwell Avenue</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_4a57d2c8-5f49-48e5-8b3e-3eaf9a3fbc09" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 320</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_50ec8c99-f345-4fd5-bf38-8a1f2dc6216c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lexington</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_0dbedaa3-0be0-4e59-8ca2-b0864c849e91" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c7ef64fb-3b46-4729-aafe-ad3b9a3f5043" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02421</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10710ff9-b03e-4a8e-889c-7a1efca4eabc" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">781</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e0a0022-dc55-4e4f-a730-74078e4fb08f" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">761-4904</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:82.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.024%;"/>
    <td style="width:28.049%;"/>
    <td style="width:32.927%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_6fa2291c-8a88-4a76-9903-68801d4ed226" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3d0e5827-063d-4865-9444-b0c76890ea02" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ALDX</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d63feb4c-c9e7-47b2-9bc5-f2fef72cd34c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.      </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_167cf4ae-55d7-4b28-8a7e-e85ccbf181aa" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   &#9746;      No   &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).      </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73c927e2-0126-4e00-a019-462423504769" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   &#9746;      No   &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of the &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;non-accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:45%;"/>
    <td style="width:25%;"/>
    <td style="width:5%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4b35e902-b480-48ad-b95f-48fe9f2e35c6" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d5047737-b1a6-4df1-87ed-84f96355f419" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_43d47a48-18c7-40f2-8bee-3db816656051" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      Yes   &#9744;      No   </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80f393ba-3153-483d-9300-f0989cdfd5da" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of July 29, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36f29a5b-fee7-4a9a-be9c-c1d3c8055d62" contextRef="C_7e21e7ea-a69c-43f3-9f0d-2bd41f8e3aad" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,421,551</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the registrant&#8217;s common stock issued and outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quarterly Report on Form 10-Q</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Quarter Ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:84%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:5.75pt;padding-left:0.1in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:5.75pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.0798611111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I &#8211; FINANCIAL INFORMATION</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_condensed_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Financial Statements:</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets at June 30, 2024 (Unaudited) and December 31, 2023</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations_unaudited"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_comprehensive_loss_unaudited"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the three and six months ended June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows_unaudited"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (Unaudited)</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_financial_statements_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Condensed Consolidated Financial Statements (Unaudited)</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 2.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 3.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 4.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II &#8211; OTHER INFORMATION</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 1A.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 2.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 3.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 4.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 5.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ITEM 6.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_i_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Part I &#8211; FINANCI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AL INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_condensed_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.	Condensed Consolidated Fi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nancial Statements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(unaudited)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44c5bde9-1204-41e3-8c51-cf5df75a99c4" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="aldx:CashAndMoneyMarketFunds" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">31,029,723</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef7336c1-76b8-414b-ad04-b203579cb661" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="aldx:CashAndMoneyMarketFunds" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">142,823,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalent - reverse repurchase agreements</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dd17309-44fd-45bb-94e8-803019eb5dd9" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="aldx:CashEquivalentReverseRepurchaseAgreements" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e763a030-d946-4a4e-900f-ac23e98dc36f" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="aldx:CashEquivalentReverseRepurchaseAgreements" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70afc0ab-b47d-4167-9222-883085ef2034" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_859f5ef2-595b-4aba-98e6-164188da1829" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c82d8f7b-b71b-4973-9a19-4dff55a06d45" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,317,836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1a0754a-6d11-4967-b795-604eda6a82d9" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,987,317</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_204f1711-adc5-4eee-8fa0-ae697aa77210" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">125,649,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_697115ba-7932-4dda-a534-a12b9c046e4d" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">147,810,333</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eec8b14-e851-4638-b874-612cc01eb13b" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">391,595</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a167534-4dd3-4700-a7a5-216e245b0286" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">510,814</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee1ba0ee-a15f-4665-bcec-bb58ae8a8752" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,720</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0069c31-0fd5-4918-8536-618dd9023678" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,764</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fce968b4-cd40-4b7d-9413-3fe07052f6d1" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">126,043,834</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94b88877-6dc6-4b46-9782-13420e251eb4" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:Assets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">148,326,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f79b7cf6-d698-4661-b104-e2c75c606ca2" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">254,434</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64f98db2-f5df-4e6d-9b66-5be27775a59a" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,338,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bfcd022-2aec-4e80-95c9-d3efd5ebe82c" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,842,802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4049e3e0-57c5-464c-98b6-e9a29021669d" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,536,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05578a97-18ef-4b24-8f86-ec5766ac3cd3" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,242,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9723fcc-18b0-4700-b6cd-dbbe86bdd4af" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,146,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e282e04e-aa9d-44cb-b6a4-6d0120e52dea" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">255,039</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae89c379-626d-4e45-a441-b23ca3a01295" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">239,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83686550-f2b6-4400-ac2c-875f9df963fd" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,000,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34f1a0e5-9521-4dec-9073-80907e34aba3" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd7457f8-4229-4db4-b9bf-ce0431a325a4" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,594,602</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9030d672-f380-4dcf-9adc-5ce66cb1ccd7" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">22,260,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred collaboration revenue, long-term</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_964b931c-91b6-457c-b023-d2e4c53b1b07" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:DeferredLongTermLiabilityCharges" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8597f0-a347-4273-99f1-0be594b76c1f" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:DeferredLongTermLiabilityCharges" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,000,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, long-term</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97460426-7761-44bc-832f-698e4dec4e43" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">138,893</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a97ce88b-911a-4707-97a2-436348e36c12" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">271,631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5e05d6c-5493-43a9-9be9-461b9c1f2c69" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:Liabilities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,733,495</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_441ba01b-8765-4e2f-bc7b-dd654780b903" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:Liabilities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">28,531,881</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_8287f335-848f-4569-a5bd-ca1496b4c0cc;"><span style="-sec-ix-hidden:F_a72334fc-b806-4b63-90f8-3649fbd0921f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(Notes 3, 9, &amp; 14)</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_324cb96f-4703-450b-9035-c479926ab922" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_93914d99-0ccc-4e1c-a8f3-b8b5e6ca96ba" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32316664-c5df-4bd3-a464-edc291c61d01" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_83738169-0799-4d35-a965-ae735532f4ef" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_029495e1-b352-4e2e-baea-03f7769acf10" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_66459643-5d55-42e6-9d15-0fde31977657" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9fe53245-95f2-4e99-b396-4ad8f97ee520" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0ff5a964-1f99-4a09-9cc5-dadb57c2c34b" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>&#160;&#160;&#160;issued and outstanding</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d479d6e-9dbb-4b96-ba6d-629c6290af85" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PreferredStockValue" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfec83b8-0a2f-4536-a977-e0c07d69c3c5" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PreferredStockValue" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, voting, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85112325-b538-4881-b5da-722dbdd71d98" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0fa47543-c507-452c-b51b-4496c86ef6f0" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de42a599-2ad3-4691-9f1f-dad7c9b8b6b6" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1184121a-cdab-4848-a16d-700195d6c3dc" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;authorized and<br/>&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_932e6316-01f2-4330-a6ad-1aa5c84978a1" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2c9cf937-a9bb-4304-b28f-529b3016450e" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">59,414,489</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f89a320-b389-40dc-827c-686e12ccb51d" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d11e9536-2c89-4689-a40d-7a3f4c43cc4d" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,195,951</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7a6154e-fdd5-4c9e-b467-45a9977aa82b" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">59,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ecfdf79-5ef7-4ab7-9de9-386fa3be8f48" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:CommonStockValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">59,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_440b149a-5bc2-42ff-a513-1fa23b8dd6ee" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">517,449,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_482c6a35-bec2-4d72-9d9f-7a41bdf73f29" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">513,994,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3cec0ab-dcf6-4241-b45b-365fc0a618ea" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b673ba7-c002-4411-9e5e-a564f5cb7d60" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5702612-cb46-483f-8356-c8ab05d04e3f" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">419,188,842</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f599add6-be86-4006-91ff-68a7b3c15904" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">394,259,148</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cb4cdc6-a888-4e13-8646-caac8668c667" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">98,310,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dbdbf64-02dc-4285-9e52-146d9ecd0442" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">119,795,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b20f2b4-53d4-4750-bd58-bb1350869b60" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">126,043,834</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afec82f6-286f-4986-92f1-baba12e634b1" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">148,326,911</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_unaudited"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TIONS (Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.71%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.962%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.962%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.042%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.322000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f24ba6a-e856-4d7f-a98c-eec5571fd420" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,969,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c16d8d7-5ba0-4a09-94c3-5741af72ec78" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,962,907</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_074d7ced-0ef2-4de4-8b37-dc28650ea451" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">21,153,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efa03baf-b74f-4cc4-b4d1-075bbcd9d745" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,198,767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b677e6-70b8-4c0e-a029-fb4897d9f22f" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,038,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71410d4c-9d1f-4728-8202-2332739d839a" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,379,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40951b9b-5697-4b09-a7eb-2210bffa3e4c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,248,420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d1e9f4-e742-436b-b67d-6df4d7845df6" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">8,947,167</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eedae99b-6472-4e9c-bdb3-558fb373800e" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">18,007,807</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d120443-456e-4947-a242-8f20064a2a71" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">10,342,657</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_334293d5-1255-4ee4-9e1a-70af58f28495" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,401,671</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fc3b847-6e42-4924-8df4-458023931ad2" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">27,145,934</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc1faae8-cdbb-4275-91ce-eba49a1abbe4" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,637,836</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74a7649e-da5a-4268-b970-6464250077df" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,882,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2483409-55d5-4684-ba1e-3d178e5a4806" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,448,105</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8f6e577-75ba-4399-a02b-e8d7bc2553f9" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,561,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8487a070-8008-42f9-ae0e-22d18a62e74f" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">477,601</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cabf363-7f1c-44bf-a0a6-de87bb5b47b3" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">527,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6723b2e2-9198-4644-b210-15ed52b592a8" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">976,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7a27d7e-afd9-4f4c-99e3-c468c69bb747" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:InterestExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,018,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_633a300b-7ba9-4155-9e16-414939380e56" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,160,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6275db2-4c2e-450b-b89b-97eb3f98cd03" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,355,659</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_480503a0-7427-4989-8083-039d36429735" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,471,977</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82f1a8de-0346-4c84-aa4c-cc6fcd8692e6" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,543,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8de94615-6b8e-414c-a516-f23defa9f17f" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">16,847,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab7d2e7e-bd81-4cf8-9360-b6ae7a4477d4" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">8,986,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4739dbda-43da-4fe9-abdf-f342a827ec53" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,929,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c921fbea-8bad-4f99-8dee-98210657bc33" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,602,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share - basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d159496c-57a9-42da-bada-e69988f5e70a" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bf2229c5-8e4e-49f7-84c7-427687df43cc" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.28</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1c425a-4153-40c4-8d34-0a3e409aa57c" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_49bb99ab-217a-4739-ac5f-c9a32a11463d" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.15</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fde7a6f2-0d99-4c24-a29a-b9416a6438e7" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9e5f8502-c46b-493a-b59f-cf1d04ad944a" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ace4f3c7-fe3f-4526-8948-5d4707fccbd1" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_19a811bb-f91d-412d-9eba-23e96de3fe95" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.42</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common shares outstanding - basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbd960cf-b48f-4a06-8bb1-bbfab1c803e8" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a563cece-34a2-40a1-a825-684f57bb5023" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,414,489</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d2e879a-d2ae-4de5-a6c7-741f00f97161" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0421445a-7342-4349-8e51-096db1016ab5" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,791,920</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3456004b-50fe-4262-8e82-0b917cd2dbac" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_454d35db-9f88-4a91-8dc0-71f0558fc619" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,414,489</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd63faa2-a304-41dd-a717-4bd4089f36fe" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4b7c07ef-9dfa-4bb7-aefc-d1679accdfcc" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,791,762</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_comprehensive_loss_unaudited"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF COMPREHEN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIVE LOSS (Unaudited)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.83%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:8.938%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.938%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.938%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.098%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b348098b-1793-4fe4-bc88-ea3a4c74c935" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">16,847,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_901a9346-182a-483f-ba0a-f06b55788b4a" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">8,986,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_198c5297-12b0-480f-8296-566fae44d4ad" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,929,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee6015c-09c3-4f91-9416-2ac553fe2f83" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:NetIncomeLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,602,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive (loss) income:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net unrealized (loss) on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_607fe22e-d47c-4b40-b282-c013b730e07d" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">6,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e585e3-7b2b-4ba7-9862-6b2b7214e522" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_165d10cc-ec66-491b-8e44-5c569dfa48c9" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f762e905-e77e-4e09-b653-750829b5861a" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reclassification of losses to net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c466c693-8379-48da-a8b1-37e7d1054464" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">103,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive (loss) income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_730ea2ab-6b0b-4cf1-85ff-a8b8812f896c" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">6,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92799375-8c7a-4240-b10e-c25cb84a0e91" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ffc1d08-7900-47c2-8de0-90e4a95d8164" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd4a1278-e8da-4ff0-be18-894f932601e2" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">103,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f792bfe1-e230-4eb8-9801-50b265c23155" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">16,854,201</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7188c171-01e8-4844-8283-2699e701cc2e" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">8,986,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51f4264b-6d94-4ea1-a8c1-5b436b876556" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,939,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65011c18-3c52-429b-896f-539a956055e8" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,498,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;" id="statements_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.306%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.582%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders' Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other<br/>Comprehensive<br/>Income/(Loss),<br/>net of tax</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders'<br/>Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffe4ac15-9c5a-425c-acc4-29333f7ee0ce" contextRef="C_d7a4bb9b-dbe9-47e8-b920-116470b0af89" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,195,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2ea0aaa-0e8f-4dae-a29e-611e1b65792e" contextRef="C_d7a4bb9b-dbe9-47e8-b920-116470b0af89" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">59,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ca62164-5491-4a59-ac10-3b21fac9539f" contextRef="C_a9ad5259-f5a0-4de2-8a29-68603609c343" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">513,994,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78088a47-dd9f-4a93-a464-af2db8518ebb" contextRef="C_9a212d05-0e21-49b7-9210-0c109f941d60" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">394,259,148</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42645eb6-efad-4b5f-ad71-f0581a44cbf8" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">119,795,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b268d44-b9fe-42b7-b8bd-c484e15885e3" contextRef="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,436,470</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_362d210f-85b6-4af7-ad8a-31fcb213e9ee" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,436,470</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, employee<br/>&#160;&#160;&#160;stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f3f37d7-ce5c-414d-b592-49a313c8c8ee" contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,097</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99556b5c-068d-4e0a-a855-94945195158e" contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1480089-816a-40db-be7c-5b14b34dbd1a" contextRef="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_825bcab8-277d-428d-a704-3c24154fa7af" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, vested<br/>&#160;&#160;&#160;restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51660a93-4e89-4f00-8b1d-78ca08ffdc5b" contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">212,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76670b6c-25ff-4c9a-8ad6-e74fc2c28351" contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3705426-0257-41c0-b8aa-b2ee4ed8c16f" contextRef="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25a75d04-2a91-4d2c-9da5-f40874ddaf52" contextRef="C_0fa013e6-439f-4984-ad30-ef4b14ba2cf3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80a923a0-1041-4b9b-af8a-c6bf824105e2" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dea655b8-fd2a-4f64-91d3-315e95d81516" contextRef="C_c884d0fc-bcef-447d-a229-a6c5ade380f5" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,929,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9538e707-cdf8-49fb-a949-ac7e637a927b" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,929,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, June 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_075341fb-abe7-4cda-9ba1-410f301ee44c" contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,414,489</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd823c65-fb90-4aa3-89b0-bed0c4a9fb9c" contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">59,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3a506b2-9822-4f3f-a3d3-747766201586" contextRef="C_a07ad80e-09c8-499d-9ae3-f20d8016d887" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">517,449,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9506abe-0c3b-449c-9c61-a8e0932bcdda" contextRef="C_872d021d-8d7a-415c-aeb0-071a12408727" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99d04920-db2a-43fb-b9af-b74b23bc18ab" contextRef="C_8b1c90f6-18eb-4001-b78a-e6751c433d4d" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">419,188,842</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c43cc4e6-047a-4a31-9ade-6d489a1db073" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">98,310,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e70b38a-73a4-4fb5-8ec5-db62fad72e6b" contextRef="C_8a0ad11e-9a2d-4592-8375-3c6294aa068f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,560,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ca3b9e5-2be4-4ddc-bf8e-bf9dc85d2e78" contextRef="C_8a0ad11e-9a2d-4592-8375-3c6294aa068f" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">58,560</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15af6f9c-1f78-433e-9710-4e4a180ee940" contextRef="C_60a5b99d-584e-4c7b-9492-7224c914dd08" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">507,770,045</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c3ec55c-8c61-483b-b926-f81c59991398" contextRef="C_788bedd8-2721-4594-a783-b6f8bc8b6ea1" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">103,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb9eba5f-f78b-4b5c-98d5-2c95342c2ad7" contextRef="C_930eaf0d-182d-457d-8a25-2eb7dc5ce169" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">356,716,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70e85790-6484-4dd5-8144-94c056fccff8" contextRef="C_26f21088-fd82-4099-b10a-e221c702905e" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">151,008,029</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cf4ab51-73e5-41e9-909c-0ede9ef37b1c" contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,316,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79615e9e-11dc-4da8-8f86-1022b2d222ef" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,316,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, exercise<br/>&#160;&#160;&#160;of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_daea1828-79bf-4560-abbc-545aa28ec959" contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9d67b85-2060-40d5-a625-fbf41d8ec759" contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e62ee9a-6b66-47ab-9fd2-c583d0e69101" contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f124d11-cd45-4e15-b279-4d01742cec68" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, employee<br/>&#160;&#160;&#160;stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d786b59-d4b1-4562-9461-5055d8606b16" contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d020af-c83d-4e69-9ff0-15aee6bbc1a2" contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54cddac3-4dbe-434c-9a1a-c8b0d5445f60" contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">52,542</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b268ea39-1931-428b-891e-b268ca2af545" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">52,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, vested<br/>&#160;&#160;&#160;restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90199538-5385-46ed-b518-5001b3b2265f" contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">215,253</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23a4070e-321b-42e4-aea1-839625dcd85c" contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a99649df-adf7-48cb-a52a-e0fe82f24218" contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c6a4ac5-5447-4895-842a-54644f8e6ef8" contextRef="C_ece659b6-3cda-4818-924c-f705aecc6e99" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">103,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6d62279-b621-4bdf-82d8-d05b66c5eee7" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">103,938</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f00f4ec-470d-4231-b6af-ca2ff47c1045" contextRef="C_61a04340-64f4-46ee-a35b-1ebbc1c4f8bd" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,602,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cf54bdd-dde0-443b-b678-570d68e54939" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,602,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, June 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8936b811-b903-47f9-b393-9795dca64120" contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,801,207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8d5cb55-b242-421a-b0ca-e7a6740d9f71" contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">58,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b32f7cc-2161-4ad3-a2d5-112ac6f4d1af" contextRef="C_2183c4fb-95a9-45e8-8593-0a184fe3bf8a" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">511,143,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9282d56-6d64-4578-9308-3a3d0bb0b658" contextRef="C_36d41454-9864-4202-a51e-8d9e3f172bf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">381,319,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2e9c2a5-eb57-4808-80db-86476bc9db07" contextRef="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">129,883,199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.306%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.582%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
    <td style="width:1.1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.122%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders' Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other<br/>Comprehensive<br/>Income/(Loss),<br/>net of tax</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders'<br/>Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4fd502e-3b8a-4c59-926a-3ad4f6e4f98b" contextRef="C_4db1176e-71d2-415e-8ae0-552b66496538" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,414,489</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5953f943-4415-4d4c-adab-a242de779d4d" contextRef="C_4db1176e-71d2-415e-8ae0-552b66496538" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">59,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf553e12-30fc-479e-a602-dec1662fa992" contextRef="C_6498b198-4aa0-4c05-874e-e075d11990e9" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">515,704,325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a4d6b08-54db-411f-af36-ca164573393b" contextRef="C_fb79a21e-fd07-4da1-8098-c1db3735b70c" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">3,029</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eb0bdd2-82eb-4d23-b2d4-070b2c88ffcc" contextRef="C_64ca8519-f2dc-42f4-84f7-7cd8b17311a4" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">402,341,270</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c389d26c-ea3b-42c0-ad4f-70a0713d5179" contextRef="C_a8750d12-9271-493b-9774-aab5b1395f5f" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">113,419,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a74dc15-fea4-410a-bb4d-b6e884c06832" contextRef="C_cb6f8aff-b5a2-43c0-b4c7-168cf4972773" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,745,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43ca3c4f-e1d3-477d-b183-11b99ec9136c" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,745,099</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_710dd1ee-bead-4ed9-a202-b7a9d184bd4d" contextRef="C_960aacbe-fbab-4c63-a85d-c2285ac66c3e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">6,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88706ea4-c654-4c35-8240-d4986bcea54e" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">6,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce3c6e9c-f6c4-4745-9f94-d075a2c8c8b5" contextRef="C_d46ad5a4-f2a8-4980-bd43-14f2b037e22b" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">16,847,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d72210c-93c8-4c31-846e-1fa6236cdc94" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">16,847,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, June 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ced665d6-9e28-4679-be56-3f0a5a341d86" contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,414,489</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2371905-7686-41bb-b537-63ad4a457e47" contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">59,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88ce522f-3453-403c-9de8-2440300a2dae" contextRef="C_a07ad80e-09c8-499d-9ae3-f20d8016d887" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">517,449,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79685bb0-3e2b-4ef6-9d3a-f38d7d0092ca" contextRef="C_872d021d-8d7a-415c-aeb0-071a12408727" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">9,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d9490bd-eab2-4de9-b04a-955334202a45" contextRef="C_8b1c90f6-18eb-4001-b78a-e6751c433d4d" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">419,188,842</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2561f52b-8781-49be-a1b7-05f274832fc6" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">98,310,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d1fb261-6382-4046-ab8c-f50ae2c79e0e" contextRef="C_2377695c-39c4-4859-bd6c-1d4b3b5420f4" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,791,603</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce3e6f88-cab0-4a3e-8692-9f87158f870c" contextRef="C_2377695c-39c4-4859-bd6c-1d4b3b5420f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">58,792</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d14106f-1882-4d98-89a1-c2b1ba638fd6" contextRef="C_e0139f32-b214-4275-ae8a-16f436e3203c" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">509,516,738</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4927102f-89d3-4b41-956b-aab88ab78938" contextRef="C_51da8247-a19b-484d-a0e4-e21be178c20a" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">372,332,317</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_231fc2f7-312e-4e71-a891-6d05de6b1dd9" contextRef="C_eeb1ebd5-f0dc-4d5a-a53d-de4340ddcb8c" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">137,243,213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92fc3ef9-be9f-4573-b504-1e64dcba31cd" contextRef="C_7357fd5b-2efe-455b-b17d-fa82ed547f0b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,621,692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37e25880-c3a1-4e6f-980d-3e8c11fffe76" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,621,692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, exercise<br/>&#160;&#160;&#160;of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea92bb9-8bb6-46dd-86c4-c10a6371c12d" contextRef="C_1992e0d5-9cc7-4f34-b9f5-65c44191df0e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,604</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b32df5c0-d819-4cec-a593-d1ac815dd976" contextRef="C_1992e0d5-9cc7-4f34-b9f5-65c44191df0e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29e18d14-ce80-4d92-8039-40b2ee87732e" contextRef="C_7357fd5b-2efe-455b-b17d-fa82ed547f0b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79f5ede1-63b8-4a76-ad71-2a26b3d2e6ae" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2f3d35f-690a-428f-9122-e471175d7b83" contextRef="C_843cc0d2-4659-45e9-803e-1d495953e509" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">8,986,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_616338de-2ad8-4da7-84d3-f6a981d796bf" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="aldx:NetLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">8,986,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance, June 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aace4f6-63ae-4fd8-a75b-b6bb7cd90998" contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,801,207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52428a29-8c9d-4d27-a9d1-7f678bc37dd3" contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">58,801</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76bc4059-9e61-42d0-b56d-cdfbc1def660" contextRef="C_2183c4fb-95a9-45e8-8593-0a184fe3bf8a" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">511,143,713</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5114c7d0-a6f9-47b9-9f3b-c5e4d769f9b5" contextRef="C_36d41454-9864-4202-a51e-8d9e3f172bf9" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">381,319,315</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f6944c1-c429-48e9-a2c1-09909daced7e" contextRef="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694" name="us-gaap:StockholdersEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">129,883,199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows_unaudited"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CASH </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FLOWS (Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.64%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:12.700000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:12.700000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80d96e08-0a6c-478c-bd8c-b5fd0bfc2f4f" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,929,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b16304f-1a2c-4d91-8534-b2fd7a42f1eb" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ProfitLoss" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">24,602,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bfa6182-05b3-49de-8bb0-0fb522a5009d" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,484,366</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8828539-78bc-475e-9787-595af2602177" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,763,896</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a02b1d9-5145-491f-be26-7b07e73079e4" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">95,781</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9458cc82-ae60-4991-bda6-df533dc17bbc" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">187,501</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net amortization of premium on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1a16400-83a8-4c7b-994e-9778726211a0" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">697,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_945333eb-0a56-4cd9-89e0-f3363e5547b7" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,542</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98375feb-dbc7-4c2a-93e5-c2baf774513b" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">122,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_870bd640-fc5e-4c87-98dd-e02692a63142" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:Depreciation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">131,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd82aeb3-bd4b-4664-9033-d4ba41ed3609" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">330,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d624454e-de50-4257-bbdf-49db16423355" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">2,918,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6228272-6940-4b2b-be4f-52e946379ce7" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">1,083,623</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6ed6c8d-c949-4170-989e-cd3a9d74245a" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">137,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61add888-5a93-4291-a6db-deda2b2a954f" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">141,560</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f28cdbcd-aa7f-42f3-965e-703a76f3e52d" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">7,323,007</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1e8045a-d4f7-4a9d-bb30-128c6211a735" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">23,196,985</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51223eb9-0a3e-4451-8ab0-9289115dc29c" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">22,801,654</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6730f315-3fb6-4d39-a1a7-ec5c876b845c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">60,614,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d25f1b7e-41c1-4794-a823-a8f3c4baac8b" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6402bf6-502b-409c-b327-3e1be84be5b3" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">12,000,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7597a7ff-656e-47fd-99fb-45a97d5f2645" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd017d97-efac-43ba-b2a7-3c07fc5ddc89" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">48,614,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9859d13-b7ec-472c-9e0e-5c1534746a50" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">30,000,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53033399-83b1-401b-b1d0-dc158da6e570" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de8706af-0b83-45d9-9ef4-a950f7c63797" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b34208e8-ea18-442a-87f0-6757249c93f2" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99bedfa9-7dd2-4906-a371-e6cad6d0f2bb" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">52,559</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9432ba9d-cc41-4eee-a8f4-ff3b500fab98" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">18,191</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb51f953-026b-4854-8747-6e53bdc3fb65" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">57,851</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec6d2f4b-6e27-4129-8c0a-db3251f28928" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" sign="-" format="ixt:num-dot-decimal">71,793,293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c7e4773-c913-4d42-a09a-d862c9ccf928" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">7,256,197</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_377a201a-b41a-4cf3-818e-238b4d295d86" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">142,823,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9373263-55df-4dbf-8876-cd174cf5ad7f" contextRef="C_26f21088-fd82-4099-b10a-e221c702905e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">144,419,364</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CASH AND CASH EQUIVALENTS, END OF PERIOD</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ced7fc4-0806-4e9c-96bc-2bd4c811a5b0" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">71,029,723</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8ef33f4-e8d6-4ad4-8234-0046c7a4a22b" contextRef="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">151,675,561</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid during the period for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ca5b831-a7b6-47c2-aaf4-4cda9672f3bf" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:InterestPaidNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">884,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cc8bb49-7db4-45c0-9413-d0390ae68ab5" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:InterestPaidNet" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">823,521</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALDEYRA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_financial_statements_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED CONSOLIDATED FINANCIA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">L STATEMENTS (Unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_593aa239-2d4b-4b13-b709-eb4913cdd0fe" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NatureOfOperations" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF BUSINESS </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the &#8220;Company&#8221; or &#8220;Aldeyra&#8221;), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ebd2804-b36b-4b3a-9db8-442ef2413c2f" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BASIS OF PRESENTATION </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 7, 2024 (2023 Annual Report).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial information as of June 30, 2024, and the three and six months ended June 30, 2024 and 2023, respectively, is unaudited. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for the fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented, have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company&#8217;s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its current operating plan, and excluding any potential licensing and product revenue, the Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund the Company's currently projected operating expenses and debt obligations for at least the next 12 months from the date the financial statements are issued. The Company has based its projections of operating capital requirements on its current operating plan, which includes several assumptions that may prove to be incorrect, and the Company may use all of its available capital resources sooner than the Company expects. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company&#8217;s planned research and development activities and regulatory activities; commence or continue ongoing commercialization activities, including manufacturing, sales, marketing and distribution, for any of its product candidates for which the Company may receive marketing approval; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional funding, it could be forced to delay, reduce, or eliminate its research and development programs and its reproxalap commercialization efforts, whether alone or with others.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Curtailment of operations would cause significant delays in the Company&#8217;s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f75027bd-91fd-4fc3-88c4-e209c3f653b3" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_f75027bd-91fd-4fc3-88c4-e209c3f653b3_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_f75027bd-91fd-4fc3-88c4-e209c3f653b3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company&#8217;s management evaluates its estimates and assumptions on an ongoing basis. Management&#8217;s most significant estimates in the Company&#8217;s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5041913-821c-417e-b48a-1a4f2cf9acc3" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes to significant accounting policies during the six months ended June 30, 2024, as compared to those identified in the 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Annual Report.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_deb033ef-a16b-4f87-8f99-51946cd6cab1" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to this new standard. However, given the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a75437f-ce24-405e-83aa-1f2dd423500c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment, this policy is not expected to have a material impact on the Company's consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to this new standard.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae862508-82df-408a-aeef-fc6486d1953f" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Helio Vision Acquisition</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2019 (Closing Date), the Company acquired Helio Vision, Inc. (Helio) and thereby obtained rights to ADX-2191 pursuant to an Agreement and Plan of Merger dated as of January 24, 2019 (the Merger Agreement). As a result of the acquisition, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2b819b3-3702-4868-9522-6fba187d7a9d" contextRef="C_ebf661ea-8dd4-4850-bc1d-1fc69b508bcd" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,407,006</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the former securityholders and an advisor of Helio, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2924875c-2607-4add-81f9-af2d21f86c63" contextRef="C_e5cc0746-8061-4e14-bb40-9336a2e95fc4" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">246,562</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued in January 2021, pursuant to the terms of the acquisition agreement. In addition, the Company, subject to the conditions of the acquisition agreement, is contingently obligated to make additional payments to the former securityholders of Helio as follows: (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_282b0520-a62d-45c5-a420-28c34474422a" contextRef="C_bb0d2bfe-e96f-4d70-8e2c-d454ec91262c" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of common stock following approval by the FDA of a new drug application (NDA) for the prevention and/or treatment of proliferative vitreoretinopathy or a substantially similar label prior to the 10th anniversary of the Closing Date; and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4254215c-d353-4940-8cc4-8555ae759663" contextRef="C_847ea9b6-7712-40f6-975a-e4c8f6744f6d" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of common stock following FDA approval of an NDA for an indication (other than proliferative vitreoretinopathy or a substantially similar label) prior to the 12th anniversary of the Closing Date (the shares of common stock issuable pursuant to the preceding clauses (a) and (b) are referred to herein as the Milestone Shares), provided that in no event shall the Company be obligated to issue more than an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5013f1a-fa13-4272-bd34-f44cf9a6c4ec" contextRef="C_ce7c4b72-5b97-4a0e-8ea7-eeb870e832ed" name="aldx:BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,248,885</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in connection with the Helio acquisition. If the Company ceases to use commercially reasonably efforts to develop and obtain regulatory approval for ADX-2191, subject to the terms and conditions of the Merger Agreement, ADX-2191 and related intellectual property rights may revert back to an entity designated by the representative of the former Helio stockholders. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, in the event of certain change of control or divestitures by the Company, certain former convertible noteholders of Helio will be entitled to a tax gross-up payment in an amount not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc003cda-7d47-46b0-9d7b-f1ddc9050035" contextRef="C_0d3c720f-35ff-43af-affa-e0f2ff358760" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that liability accounting is not required for the Milestone Shares under FASB ASC Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 480). The Company also determined that the Milestone Shares meet the scope exception as a derivative under FASB ASC Topic 815, Derivatives and Hedging (ASC 815), from inception of the Milestone Shares through June 30, 2024. Accordingly, the Milestone Shares are evaluated under FASB ASC Topic 450, Contingencies (ASC 450) and the Company will record a liability related to the Milestone Shares if the milestones are achieved, and the obligation to issue the Milestone Shares becomes probable. At such time, the Company will record the cost of the Milestone Shares issued to the Helio founders as a compensation expense and to the other former securityholders of Helio as an in-process research and development expense if there is no alternative future use. No milestones related to the remaining Milestone Shares are considered probable of being achieved as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8b5385f-3e05-4970-a358-ff78da72d575" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NET LOSS PER SHARE </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three and six months ended June 30, 2024 and 2023, diluted weighted average common shares outstanding is equal to basic weighted average common shares due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98dcf468-6fc6-4da6-a9d8-0de1891f3f39" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"/>
        <td style="width:1.92%;"/>
        <td style="width:1%;"/>
        <td style="width:21.78%;"/>
        <td style="width:1%;"/>
        <td style="width:1.92%;"/>
        <td style="width:1%;"/>
        <td style="width:20.38%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Three and Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf7c1721-e5ac-49ee-857b-924ae6743b1c" contextRef="C_a65476d8-e4fe-4f45-94fc-12a4ca98f051" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_232e6cdd-71ed-4c43-9572-b5c00cb942e8" contextRef="C_ba4aaa8b-9a25-4dae-b1bb-126e2ff2adc7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,033,741</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_039b7e66-8758-4a81-88f8-2e21a6d2d291" contextRef="C_ba8fec32-6fe2-4982-8ac2-8fed75b0a26a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_89b1194a-7a6f-4a0c-9c77-7a8c8800166f" contextRef="C_d81bffd9-e22d-4296-b634-a77b7d9776fb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,567,153</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30ee5d6d-c372-4ee7-b157-277ca78177b4" contextRef="C_b945516c-a2fe-4ef4-b522-ac7685c78c1a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_117e09e3-425d-48f3-8b56-2139980a3f4a" contextRef="C_c420c777-2dcb-48fa-9456-2026963c27cd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">732,056</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a42aa1aa-74c9-4430-afc0-fbbfa275a81e" contextRef="C_b3aea01f-e989-48fd-b9f6-75afb86f910e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e2bf309b-9143-485d-8151-8032e5d38dce" contextRef="C_20b130d8-eac8-40f7-93bd-c629812ee1cd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,208,100</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total of common stock equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b4e9ccb-1928-448e-872e-b3ad36536a48" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_157a24a6-5a95-4344-8e6f-2af7b84f3a0d" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,765,797</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a0d1ca6-c281-4c52-8653-b23f47ede748" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bc65e839-08ef-469f-85e9-e084dce46397" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,775,253</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5e7e38c-7d75-4c35-8583-ba9da2f2ab1e" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48751ec2-5a71-4294-86e4-6d88605f7fcc" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" escape="true" continuedAt="F_48751ec2-5a71-4294-86e4-6d88605f7fcc_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, cash, cash equivalents, and marketable securities were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.56%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:7%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:6.4399999999999995%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized<br/>Gain</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized<br/>Loss</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and Cash<br/>Equivalents</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current<br/>Marketable<br/>Securities</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49ce7676-35db-472d-a6d6-a334fb8ec953" contextRef="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43" name="us-gaap:Cash" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,434,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33d00b83-48d9-48a5-bd2b-592afa219c78" contextRef="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,434,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cdbd174-d936-4562-9ed0-8443817362bc" contextRef="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,434,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf6f354a-793f-4c75-8f65-c9ac33ed957f" contextRef="C_8fc74b92-85f2-4f9d-916a-762e069ff326" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,595,519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39785e84-3da2-44b8-81c7-379458b3585f" contextRef="C_8fc74b92-85f2-4f9d-916a-762e069ff326" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,595,519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ca5e037-2bd1-466c-96e6-e14c696c8428" contextRef="C_8fc74b92-85f2-4f9d-916a-762e069ff326" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,595,519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse repurchase agreements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_240af1b3-2ae3-4c10-80c6-90dcb825c7c0" contextRef="C_01391853-2657-4f02-b4dd-642d3c6e71c3" name="aldx:CashEquivalentReverseRepurchaseAgreement" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72d4446a-952d-4ff4-9d28-d82ad0809656" contextRef="C_01391853-2657-4f02-b4dd-642d3c6e71c3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_652bbc33-4b92-42bc-a53c-f66945f0462c" contextRef="C_01391853-2657-4f02-b4dd-642d3c6e71c3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02750459-1ba8-4fd1-8972-8843943f02cb" contextRef="C_621f912c-92a3-433e-800f-cd9932a4b216" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">71,029,723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19db3acd-7a2d-4ded-902a-e7bf5a4a0832" contextRef="C_621f912c-92a3-433e-800f-cd9932a4b216" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">71,029,723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cadb8cf4-a218-4389-ab5e-419c2a947040" contextRef="C_621f912c-92a3-433e-800f-cd9932a4b216" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">71,029,723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4c8a285-03f7-4978-9e2e-b5cad2101f68" contextRef="C_659d8673-bb33-41b8-8d04-af77a63be73c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,311,618</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98f340c4-cbcb-4dc4-b4c3-fa8a3e556e7e" contextRef="C_733f6dcb-0419-40ba-b628-e28799994562" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">486</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64806c9b-7a9d-45a8-b35d-32d4ac78b5c7" contextRef="C_733f6dcb-0419-40ba-b628-e28799994562" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e4becd1-40a1-49d3-843b-2db55a5daa97" contextRef="C_659d8673-bb33-41b8-8d04-af77a63be73c" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e5955e4-7748-4852-958c-f4c0103ba26c" contextRef="C_659d8673-bb33-41b8-8d04-af77a63be73c" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Available for sale marketable securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1596e311-0cd3-4557-b4fd-9f9789a40315" contextRef="C_09af761f-3d1e-47a3-ba56-29b402f55cba" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,311,618</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7ced53b-382a-4a06-a70b-8fce9e588d56" contextRef="C_50415d91-456c-4345-a9e8-9a5bd2f7cfa1" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">486</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77f5a3ca-c112-4eff-8efd-da8e3b426a55" contextRef="C_50415d91-456c-4345-a9e8-9a5bd2f7cfa1" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0af89e23-8908-4fe4-9ba6-b0ecea824388" contextRef="C_09af761f-3d1e-47a3-ba56-29b402f55cba" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a18a13b-2e56-4f52-8d8e-86a080dff483" contextRef="C_09af761f-3d1e-47a3-ba56-29b402f55cba" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and current marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae1f3f4-34e2-44f7-a7ea-d342370dc8ce" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">71,029,723</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a721f03-0e7f-4769-9c47-f90f8a64eb48" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contractual maturities of all available for sale securities were less than one year at June 30, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_48751ec2-5a71-4294-86e4-6d88605f7fcc_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, cash, and cash equivalents were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.689%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.598%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.598%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
        <td style="width:1%;"/>
        <td style="width:10.598%;"/>
        <td style="width:1%;"/>
        <td style="width:1.38%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and Cash<br/>Equivalents</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93b754b2-493a-4b27-b44c-0a15e414fd99" contextRef="C_1580d899-1ef3-48b3-8ee0-2947a0996507" name="us-gaap:Cash" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">128,510,451</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cc68392-a1e3-4f44-bea7-8e52861760ce" contextRef="C_1580d899-1ef3-48b3-8ee0-2947a0996507" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">128,510,451</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6baacc8d-2dab-4568-8ce2-24b0c0e77370" contextRef="C_1580d899-1ef3-48b3-8ee0-2947a0996507" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">128,510,451</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bee8a18d-e217-4956-b99e-6f6a1402ba8e" contextRef="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_209fc7ac-4111-442a-a393-9923107b3f49" contextRef="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de7502a6-2aa8-4b76-a53f-92a00c1bef5c" contextRef="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c60b978-f3e3-4077-a2e2-10b85e7e9648" contextRef="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">142,823,016</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4973bf7-58dd-48c6-93ac-8a41cf491ebd" contextRef="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">142,823,016</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fd492d8-f194-4b81-b39a-229267a097df" contextRef="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">142,823,016</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e54d341-0cd9-4e3e-bd29-45d6e4a1c6b6" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:MarketableSecurities" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> marketable securities held at December 31, 2023.</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd951b08-fb08-4469-94c7-2a355282663d" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FAIR VALUE MEASUREMENTS </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Quoted prices in active markets that are accessible at the market date for identical unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f722cbe-9a74-475c-8739-6c85591e6e64" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s assets measured at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.429%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3453c0eb-9dcf-4d01-9356-9c5099a2c7c2" contextRef="C_bb794176-2e9b-4405-a8ac-a7adab3cce8f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,595,519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed4915a9-4dd2-4265-b77f-6e7637b60391" contextRef="C_4fd7b4a8-0fb4-40c1-9d8f-860b5e3f8919" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af0160b3-c1dc-40ec-922e-82ab9dfbe5e5" contextRef="C_ff12ec68-2fd5-4170-ba6e-4b15c2ff223c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6611f187-f013-435b-90d2-dfd90060d602" contextRef="C_b5f0f1f6-82d5-4d52-a257-4f738b44ebd5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,595,519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities (b)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b339e8f1-33fe-4895-bdab-41ed31907311" contextRef="C_88eff217-da00-447c-80f0-c097fab822a1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fea16ee6-10de-47de-b9fd-0d0c2d08937b" contextRef="C_481f3f0a-8710-4898-94d3-26fd583c6860" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5561c5f-8c9a-4cc7-a79b-057551894955" contextRef="C_d409ba4a-341b-44fb-b178-554996db8456" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0315416b-5579-44c4-842d-4b8c907151f8" contextRef="C_808346d8-8add-488a-af8a-fcb254ad94f8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">49,301,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse repurchase agreements (c)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff6ecb51-d83d-41b3-be2e-efc0e60d8dd4" contextRef="C_8ae5248f-56fc-4d37-937d-6f7c458af533" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bc8c274-18f6-4bcf-8af9-2e9390ef3502" contextRef="C_5701f4e9-face-49d1-84bc-81d336191ded" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_879dbe73-3269-4a4c-8715-2f118e4c2e4c" contextRef="C_a06e8e4e-16e8-4dde-9e9b-ffb7963feb18" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f61ddbd-5136-4d1d-8f38-bf73865d4de4" contextRef="C_44cef7b4-5749-4aaa-83b1-0dd0b0576672" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_889dd24f-a8a7-4e02-bbb8-d88c02be6acd" contextRef="C_5763b0ce-896c-424b-adb7-cf75ae931b87" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">76,897,479</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_582802f7-993c-4717-81e8-75babff112dc" contextRef="C_7b9cc316-d571-44e9-92d7-4c988cd04578" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">40,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cef5da1-9aad-49ae-aea9-c2a59496ec5b" contextRef="C_0c6b3071-64d9-4ac6-879c-7ab5b8feecfa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ba98038-9c17-4380-a84f-75283ca325e3" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">116,897,479</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.429%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
        <td style="width:1.339%;"/>
        <td style="width:1%;"/>
        <td style="width:14.554%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_575d2373-7b15-4e51-b573-da3f4a24b4d9" contextRef="C_b7b49075-22e7-4aa3-8ae8-65ddb24b9fd6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92f32549-80f2-467c-8b2f-9bd83c82e5dd" contextRef="C_d9ab5c6a-9d40-4195-839e-643b592547c8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_739cd3a2-b214-4a13-b917-4203bde874f2" contextRef="C_fd697598-618c-412c-a894-2682ae77ed63" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7700661-4e7e-4e18-abc2-e29bf3ec936e" contextRef="C_97b19cd6-75ad-4456-99d8-09b2da452e22" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_668e5531-0c4d-40de-8c7f-1c08d290a6c6" contextRef="C_a9120b8c-dabf-419b-a873-3175c3e4920e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b6f5e5-ea9b-437d-97eb-fefe3650290a" contextRef="C_16a2a60d-0d62-4933-959e-b7fe028a37cb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6ad3385-8325-4a0e-9ec6-ad68cc0a08bf" contextRef="C_eada7cb9-d8f4-4796-a84a-8755760815f4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d35af3d6-4ed0-4dcb-846b-468382e9fe41" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">14,312,565</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.</span></ix:footnote></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. government agency securities are valued based on observable market prices in active markets.</span></ix:footnote></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. </span></ix:footnote></div></div></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2e0acac-7405-4b68-aacc-50dc71d9503b" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_98428a4e-e296-4181-809e-58396c720cdc" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> liabilities measured at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 or December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments including clinical trial prepayments to contract research organizations and accounts payable are carried in the condensed consolidated financial statements at amounts that approximate their fair value based on the short maturities of those instruments. The carrying amount of the Company&#8217;s term loan under the Hercules Credit Facility (as defined in Note 9) approximates market rates currently available to the Company.</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2ef8d34-a100-4f5f-9d60-a4183989da0e" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PREPAID EXPENSES AND OTHER CURRENT ASSETS </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_700185b0-db8d-48bb-ab19-dd9d36721ae9" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.52%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.440000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.440000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred research and development expenses, and deposits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d31dcd35-956f-48f1-b58a-930587900dfe" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,859,927</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52520f6a-3dd5-46b2-b0d1-7565410cdf50" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,463,783</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1642bff-e51a-460f-bcc1-3abd590e8c41" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PrepaidInsurance" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,036,223</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d9b357-5dbe-4b1d-b102-213869a5290f" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PrepaidInsurance" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">340,388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Miscellaneous prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c220812b-c455-4ada-ad57-8eec1aec7d93" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OtherAssetsMiscellaneousCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">421,686</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78e0b7ea-3203-46a4-a75c-31940ea13d94" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:OtherAssetsMiscellaneousCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">183,146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74ea60db-3481-4f34-ab6d-2a63588ff974" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,317,836</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63177ec8-a694-40c7-a20d-3a2db8f6d81b" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">4,987,317</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f5a498c-d0b6-4b27-8817-ae222934e56c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACCRUED EXPENSES </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c32b5b7d-d366-4c52-846a-aa0b84a380b0" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 were:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.457%;"/>
        <td style="width:1.429%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
        <td style="width:1.429%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7b02a6f-3b49-441d-acb6-4d05540d954e" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,571,463</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ff542aa-0c7a-42a8-8a4a-612a7f34b6fb" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,087,937</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52770bf3-6919-4ae3-a8b2-a975c0682ace" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="aldx:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,411,867</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f4a1dd1-a69d-4fb8-9784-d52607d1ef5f" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="aldx:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,687,327</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fc53578-10b9-4fa0-b52c-ea14e14c7065" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">859,472</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1714bdac-eab0-4738-879c-2bbeee08e850" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">761,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5896f1b-de79-4b6f-ba00-4d4fc415e55c" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,842,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc5f1f9-9b61-46d3-8cbb-a6e2921943fa" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,536,464</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_484ec839-92d4-4570-ac05-c7eb2368b154" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:DebtDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CREDIT FACILITY</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s current and long-term debt obligation consists of amounts the Company is obligated to repay under its credit facility with Hercules Capital, Inc. (Hercules). In March 2019, the Company entered into a Loan and Security Agreement (Loan and Security Agreement or Hercules Credit Facility) with Hercules and several banks and other financial institutions or entities, from time-to-time parties thereto (collectively, referred to herein as Lender), providing for a term loan of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4bf9e0a-c100-42d0-9f8f-75d73e1ecad1" contextRef="C_783ee973-e8a0-419e-baed-08fbad7a4c7b" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, subject to the satisfaction of certain conditions contained therein, that is secured by a lien covering all of the Company&#8217;s assets, other than the Company&#8217;s intellectual property. The Loan and Security Agreement provided for (i) an initial term loan advance of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72c8550c-f4c9-4d0d-8e0f-fd9a4dc11ac1" contextRef="C_0075fb28-2a17-4b2b-92f6-1abe0f5ca0ed" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at the Company&#8217;s option, which expired unutilized on April 15, 2019; (ii) three additional term loan advances of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_197ad312-b6da-43a1-81d5-616c9ec17121" contextRef="C_0e649ed4-2953-4514-be22-df39d5e87435" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each, at the Company&#8217;s option, available to the Company upon the occurrence of certain pre-specified funding conditions prior to September 30, 2019 (2019 Tranche), March 31, 2020 (2020 Tranche), and March 31, 2021 (2021 Tranche); and (iii) a final additional term loan advance (Fourth Loan Tranche) of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b21b552-50c6-454a-918e-ca2e9caaa074" contextRef="C_e0ad43ee-c467-4100-b399-f7960579d117" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million prior to December 31, 2021, at the Company&#8217;s option, subject to approval by the Lender&#8217;s investment committee. The 2019 Tranche was drawn down in full by the Company in September 2019 and the 2020 Tranche and 2021 Tranche expired unutilized prior to the Company satisfying the funding conditions for such tranche. On April 20, 2021, the Company entered into the First Amendment to the Loan and Security Agreement (First Amendment). The First Amendment, among other things, (i) increased the Fourth Loan Tranche from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1f30db7-a9fc-4bc4-9935-ffcd63a59968" contextRef="C_06ea7345-51c9-4c36-a9ba-2e750192f04f" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1604da5e-e08e-4f2c-ba74-a1e366d734c5" contextRef="C_7a559121-6521-4d20-bd8a-c5e91210cc67" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and extended the deadline for drawing down the Fourth Loan Tranche to July 1, 2022; (ii) lowered the variable per annum rate of interest on borrowings under the Loan and Security Agreement from the greater of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49635f68-16ad-4127-9a15-522e69718d32" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (b) the prime rate (as reported in the Wall Street Journal or any successor publication thereto) plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef48ae65-b00a-466e-aeb2-cce6863ed51c" contextRef="C_0cb4447a-186f-4c30-9fe1-b6650981eee1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to the greater of (x) the Prime Rate (as defined therein) plus 3.10% or (y) 8.60%; (iii) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are required from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7797f81e-bc45-49b9-bbac-3fa5d8161141" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="aldx:LineOfCreditFacilityInterestPaymentPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 1, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to July 1, 2022; and (iv) following the satisfaction of certain conditions, which conditions were satisfied in April 2021, further extended the expiration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e86ccdf7-285b-460f-800a-c76ca16a624a" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="aldx:LineOfCreditFacilityInterestPaymentExtensionPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC Topic 470, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and did not result in extinguishment.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 22, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (Second Amendment), which became effective as of December 31, 2022 (Second Amendment Effective Date). The Second Amendment, among other things, (i) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2023 to May 1, 2024; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0098b5d-00a8-4be2-a401-ba80ca9c8575" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="us-gaap:LongTermDebtDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extended the Maturity Date from October 1, 2023 to October 1, 2024; (iii) extended the availability of the Fourth Loan Tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dac0efd-cd85-40eb-a014-5030d0f9a4be" contextRef="C_c2017d1d-743c-43c9-91e8-cd1670c08fa8" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which remained conditioned on approval by the Lenders&#8217; investment committee,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from May 1, 2023 to May 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and (iv) amended the Prepayment Charge (as defined therein) to equal </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f1503c4-3e12-4f05-8420-44c027430b77" contextRef="C_2bff6b01-34c7-4499-90bb-790707bd6958" name="aldx:LineOfCreditFacilityPrepaymentFeePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the amount prepaid during the 12-month period following the Second Amendment Effective Date, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba1389ef-f96d-4826-8978-d130fa0aa646" contextRef="C_5695a349-fc70-4db4-9dda-882a4f8e1db0" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% thereafter. In addition, a supplemental end of term charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b537df2-55b8-4dfd-a5dc-e166d8bba5b6" contextRef="C_282ada39-a478-4e55-91a1-d5ab8c59d75f" name="aldx:SupplementalEndOfTermCharge" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">292,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Supplemental End of Term Charge) shall be due on the earlier of (A) the Maturity Date, as amended, or (B) repayment of the aggregate amount of advances under the Loan and Security Agreement. The initial end of term charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e5d14f9-d00d-44af-82ab-62ff8a7b3036" contextRef="C_282ada39-a478-4e55-91a1-d5ab8c59d75f" name="aldx:ExistingEndOfTermCharge" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,042,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (End </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of Term Charge) was paid</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2, 2023. The Second and Third Amendments were determined to be modifications in accordance with FASB ASC Topic 470, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and did not result in extinguishment.
</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 29, 2024, the Company entered into the Third Amendment to the Loan and Security Agreement (Third Amendment). The Third Amendment, among other things, extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2024 to October 1, 2024. On May 1, 2024, the Fourth Loan Tranche commitment expired unutilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Hercules Credit Facility, the Company incurred a commitment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d5b5cce-87d2-4e6c-84fd-707386dec074" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="aldx:LineOfCreditFacilityCommitmentCharge" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, transaction costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36d9d07c-b8be-45e1-ba71-bc1ca2b97cf0" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="aldx:LineOfCreditFacilityTransactionCosts" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">273,186</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6b134e1-cecd-4b41-826f-eee771a0e2c2" contextRef="C_e699a756-602d-48a6-8707-937ab2672bce" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">375,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon closing, the End of Term Charge, which was paid in October 2023, and the Company will be required to pay the Supplemental End of Term Charge. The fees and transaction costs are amortized to interest expense from 2019 through the Maturity Date using the effective interest method. The End of Term Charge was amortized to interest expense from 2019 through October 2023, and the Supplemental End of Term Charge is amortized to interest expense from December 2022 through the Maturity Date, both using the effective interest method. The effective interest rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ecaf0dd-9b8e-4ec3-adb9-8bc2d7e60cf1" contextRef="C_96d3e115-830a-4157-ac6e-d8edcdd92568" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024. At the Company&#8217;s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus all fees and other amounts due under the Loan and Security Agreement as of the date of such prepayment.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0d0bd48-5f10-49a5-b58b-c6aad7258473" contextRef="C_96d3e115-830a-4157-ac6e-d8edcdd92568" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been funded under the Loan and Security Agreement and no additional amounts were available to the Company for borrowing.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed17e823-1c1f-4813-bbb8-ea5b3e0ef797" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term debt consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.05%;"/>
        <td style="width:1.333%;"/>
        <td style="width:1%;"/>
        <td style="width:15.809%;"/>
        <td style="width:1%;"/>
        <td style="width:2.613%;"/>
        <td style="width:1%;"/>
        <td style="width:15.196%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4940af1d-1701-44d6-94fb-761291f68adc" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LongTermLoansPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9146644-cd7a-4dac-b5cb-35675d87ce3e" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LongTermLoansPayable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,000,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental end of term charge</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d05e8099-3bc6-4a19-9772-0ecf10407e74" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="aldx:SupplementalEndOfTermCharges" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">251,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6ce8772-0352-4f51-baee-d31a2f575413" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="aldx:SupplementalEndOfTermCharges" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">173,646</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a44277c-921d-4a47-96e6-90673bdcd239" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,316</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ff83abf-35ea-4aa0-abfe-a70992fd4df1" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">27,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0802ff9e-0a47-405c-aea3-99caceeb9489" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LinesOfCreditCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,242,327</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2f66d91-b10f-42e2-9979-558122fea7bb" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LinesOfCreditCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,146,546</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11161256-911f-4c70-adfc-855af1ae59f4" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76109eb2-0c00-41b5-8c03-58912c08621b" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac3d5515-46b0-46e1-b1ea-d5b3d1ee0b37" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future principal payments, including the Supplemental End of Term Charge, are as follows for the years ending December 31:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_873277a6-aab2-4cd7-bccf-b64ba06e86b2" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,292,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d8667eb-22cc-4656-b700-f62a071f9276" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LongTermDebt" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,292,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan and Security Agreement also contains certain events of default, representations, warranties and non-financial covenants of the Company. As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company was in compliance with all covenants of the Hercules Credit Facility in all material respects. In addition, subject to the terms of the Loan and Security Agreement, the Company granted the Lender the right to purchase up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cba11e1-123a-4c5c-a038-03f9b12608c5" contextRef="C_4a2131ac-d9f6-43b3-8527-47305ed8f104" name="aldx:LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s equity securities, or instruments exercisable for or convertible into equity securities, sold to investors in financings upon the same terms and conditions afforded to such other investors.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5852bb68-aaf3-4190-8fbd-89421505faca" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company entered into an Open Market Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with Jefferies LLC (Jefferies), as sales agent (2021 Jefferies Sales Agreement), under which the Company had the ability to offer and sell, from time to time through Jefferies, shares of common stock providing for aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_965b2d39-c220-40b0-bc39-712b846cfab9" contextRef="C_820ae58a-8aa6-4607-9edd-93c8f14eda0f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd9c33d6-daee-4da8-8bb4-282f55c58b0c" contextRef="C_ce9c8181-658b-4601-b349-c64cda3f969b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock may be sold under the 2021 Jefferies Sales Agreement, and no sales had previously been made pursuant to the 2021 Jefferies Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88e5b16f-7190-4127-a922-d1c3627d5f0d" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INCOME TAXES </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6e69f08-a9f4-4f04-a5e9-f819907109bd" contextRef="C_39c1e011-e9ae-4875-9500-c3cd89afff9e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> current or deferred tax provision expenses for federal and state income taxes have been recorded as the Company has incurred losses since inception for tax purposes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realizability of net deferred taxes in accordance with Accounting Standards Codification (ASC) 740, Income Taxes (ASC 740), the Company considers whether it is more likely than not that some portion or all the deferred tax assets will not be realized. Based on the weight of available evidence, primarily the incurrence of net losses since inception, anticipated net losses in the near future, reversals of existing temporary differences, and expiration of various federal and state attributes, the Company does not consider it more likely than not that some or all of the net deferred taxes will be realized. Accordingly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b94da37-7730-4b25-ba1a-9bcc767962f5" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="aldx:DeferredTaxAssetsValuationAllowancePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% valuation allowance has been applied against net deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended (Section 382 and 383), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7efccabf-e043-47cc-9167-aea28a24ddb6" contextRef="C_6dcdd5b4-ccce-449a-a571-48929e89299f" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percentage points over such stockholders&#8217; lowest percentage ownership during the testing period (generally three years). Transactions involving the Company&#8217;s common stock, within the testing period, even those outside the Company&#8217;s control, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#8217;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#8217;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Section 382 and 383 limitation (including the additional limitation for recognized &#8220;built-in-gains&#8221;) is sufficient so that no current impairment of its pre-ownership change tax attributes is required. The Company does not believe an ownership change has occurred from December 31, 2021, through June 30, 2024, based on a review of its equity history during that period. Any future ownership changes, including those resulting from the Company&#8217;s future financing activities, may cause its existing tax attributes to incur additional limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the Company is subject to tax in the U.S. (Federal and Massachusetts). The Company is open to examination for the tax years ended December 31, 2023, 2022, 2021, and 2020. In addition, any loss years remain open to the extent that losses are available for carryover to future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions pursuant to ASC 740-10 which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. Accordingly, in the provision for income taxes, the Company recognizes interest accrued related to unrecognized tax benefits and penalties; however, management is currently unaware of any uncertain tax positions. As a result, the Company does not have any liabilities recorded including interest or penalties for uncertain tax positions.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act (IRA) was enacted on August 16, 2022. Based on review of the IRA, the Company does not expect any impact to its tax provision. In particular, the Company does not expect to pay Corporate Alternative Minimum Tax (CAMT) in the next few years based on its projected losses. The IRA introduces a 15% CAMT for corporations whose average annual adjusted financial statement income for any consecutive three-tax-year period preceding the tax year exceeds $1 billion starting in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_3eb90b74-3f1e-4f98-bc06-7ec4314d9bda" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCK-BASED COMPENSATION</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company approved the 2013 Equity Incentive Plan in October 2013, which was amended in June 2016 and June 2018, (Amended 2013 Plan). The Amended 2013 Plan provided for the granting of stock options, restricted stock units (RSU), stock appreciation rights, and stock units to certain employees, members of the board of directors and consultants of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company's Board of Directors approved the 2023 Equity Incentive Plan (2023 Equity Plan) to replace the Amended 2013 Plan. On June 30, 2023, the Company's stockholders approved the 2023 Equity Plan at the Company's 2023 annual meeting of stockholders. Pursuant to the 2023 Equity Plan, the Company will not make any further grants under the Amended 2013 Plan following June 30, 2023, though awards previously granted under the Amended 2013 Plan will remain outstanding. The 2023 Equity Plan is effective for a period of ten years after June 30, 2023, and a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb638100-ab18-4d53-aeee-3f39575bbcf3" contextRef="C_d7bd3f39-df0b-41ee-912e-1db77d9d2cbe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,450,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, in addition to shares of the Company&#8217;s common stock that are subject to awards granted under the Amended 2013 Plan that are outstanding as of such date and that are subsequently forfeited, cancelled, or expire before being exercised or settled in full, are authorized for issuance under the 2023 Equity Plan. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51ed82d5-cf1f-4275-a8e5-a8180eaaaa08" contextRef="C_fa2877a2-040d-4ca1-96d6-0276098a9d96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,542,805</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock available for grant under the 2023 Equity Plan.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022 the Company granted cash awards under its Management Cash Incentive Plan, as amended (the Management Cash Incentive Plan). The Management Cash Incentive Plan provides its participants with the opportunity to earn cash incentive awards for the achievement of goals relating to the performance of the Company and was adopted in 2016. The cash awards vest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in four annual installments from the date of grant based on continued service and entitle the employees to receive a cash payment, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value to the amount by which the then value of the Company&#8217;s common stock exceeds the base value. As of June 30, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f49b9376-8c8f-4429-a816-615217e79e08" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was accrued as compensation expense for vested cash awards. There was no unrecognized expense as of June 30, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company granted performance cash settled bonus awards (CSBUs) under its Management Cash Incentive Plan. As the performance criteria had been met, the awards will vest in four annual installments from the date of grant based on continued service, and entitle the employees to receive a cash payment for each vested CSBU, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value of the closing price per share of the Company's common stock on the Nasdaq Capital Market (Nasdaq) on the payment date. As of June 30, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b40ad5f-f243-4c53-a81a-de7413edb14e" contextRef="C_42d94c98-9934-4c6a-b0fa-52973f777316" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was accrued as compensation expense for CSBUs as the Performance Criteria was met in February 2023. There was no unrecognized expense as of June 30, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense over the requisite service period. The Company's share-based awards are accounted for as equity instruments, except for cash awards and CSBUs, which are accounted for as liabilities. </span><span><ix:nonNumeric id="F_a425bff8-af48-42fe-bd55-945c9dc16b9a" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_a425bff8-af48-42fe-bd55-945c9dc16b9a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amounts included in the consolidated statements of operations relating to stock-based compensation associated with the two equity incentive plans, cash awards, and CSBUs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_a425bff8-af48-42fe-bd55-945c9dc16b9a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.53%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.222000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.142000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.222000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f24e8b8-2692-4758-939b-8d437e451042" contextRef="C_6b7f665d-724a-4e0d-8cda-8a1d42dfea6c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,034,174</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84d5e98c-e77a-4e2a-95b3-174e56f4d9df" contextRef="C_a171b1df-4c92-4175-9e5f-fc3f4bc0789f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">862,370</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_799edaa2-4934-442b-8a73-bb925d198d42" contextRef="C_296f06b9-5d06-47d8-9d77-8c2beb9797c4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,898,358</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a234032f-28ae-4657-b795-1d6a7daaf9a8" contextRef="C_7b436d9e-9e0b-472d-a52a-b050edddbb87" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,053,738</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12637a31-23b7-4e3d-9719-db3814bdebae" contextRef="C_2083538c-d3e8-425e-af11-ff49a4b2d8a7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">901,355</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_099e3531-3d16-42f9-95f7-93645e6a0434" contextRef="C_05cced33-c667-4b68-9ab8-068003720e62" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">711,170</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23cbfc1c-6f08-4035-9f05-b9b10b4f9159" contextRef="C_2869d481-18dc-4588-a73e-4a7189c37ae7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,586,008</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_374ecc00-977d-4b16-8fe9-c9f7da23b1cd" contextRef="C_bc7df239-76b6-4890-8a10-e0ed9e21e2ff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,710,157</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a89dba84-c8b5-4a67-95a6-af078709d442" contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,935,529</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa21d2c-46e5-4e14-a076-0780b1832c33" contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,573,540</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fff1029-7e10-45a3-b72e-61f3957b9efe" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,484,366</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84e019a5-52f8-46f1-ae87-946a816ca99e" contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">5,763,895</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fa16303-c789-47b5-882a-7104cfa0c862" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes activity relating to stock options under the incentive plans for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Term<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value(a)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f25a7d6f-d8d6-4ddb-8cb3-f20a823bb12a" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,868,816</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_906502d5-da95-4876-83ea-310d734711b2" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_37d69f58-e7fa-4844-b039-26c82db2b7ca" contextRef="C_dc6e015f-4534-4370-bdb9-a7945e9ca45d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.44</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8895e7b1-3343-430f-859a-51f2f0401b45" contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,996</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c602021-f3a4-4f0c-b1e8-92e056cac67c" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,376,328</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33b9c0aa-4320-4fbc-b98e-0925815ad2b7" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.67</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79531353-d9fa-4aa4-a0af-962a337f01a6" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">179,897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58bbf816-243b-4d8d-aadb-adce7267a04f" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b4089f1-c1a7-4ee1-ab4a-52b123634fdf" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">31,506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9211eecf-93ba-4598-8739-071c7022845e" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faa65864-c002-4ee8-9d30-d29e56fc3fd9" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,033,741</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea4c26b8-a96b-45e0-93f3-e5b2463283e3" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.57</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_79749130-9217-47d0-b861-4e4685e93a00" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.19</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b75f7c6e-5d56-445c-9288-be277e5962dd" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,829,541</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfc8c25e-0289-494b-814f-5539709aac1f" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_4cb487c4-2c67-4ebe-a34b-b3aae9ee234e" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.86</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_30fce50e-09e3-4718-8fe5-35e6214b0ffd" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#8217;s common stock on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5323937a-25b3-46db-8cb3-c3402b409934" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the per share exercise price of the underlying options.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, unamortized stock-based compensation for stock options outstanding was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5500879-5c11-426c-94f5-42a78220bf37" contextRef="C_215ae863-6dc1-4301-a3a7-f9b85b618132" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59256f85-8495-45d4-b6bf-cf90db83a4b8" contextRef="C_3731cf74-643e-408a-91dd-f3a385d27749" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.66</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. Total unrecognized compensation cost will be adjusted for future forfeitures, if necessary.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd973f3a-ec71-416c-8f6b-5414b97edac0" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes activity relating to restricted stock units (RSUs) for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.746%;"/>
        <td style="width:1.2%;"/>
        <td style="width:1%;"/>
        <td style="width:11.658%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:13.277000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number<br/>of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22e300e6-7f9d-4440-b6b4-652972f12a89" contextRef="C_d3f16ce7-5180-4c42-a5f4-7353119a3125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">944,497</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8056629-75a5-43f6-9d0b-a08f6afab5e4" contextRef="C_d3f16ce7-5180-4c42-a5f4-7353119a3125" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settled in common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2055e61-cc7a-4f16-9dba-2d9d8aaa1806" contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187" name="aldx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">212,441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f14a042-435f-4eb9-a28c-f93e46fc6c66" contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187" name="aldx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de5d5895-16f6-4167-bbe6-e1f53c0222d1" contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">732,056</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c8d903b-19ce-424b-b57a-38f64edeefe9" contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.29</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77f14ba0-9656-4b66-a287-95b1ae68e448" contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The total grant date fair value of RSUs vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fee1ed23-1799-4714-a1c0-ca833ce36781" contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024. As of June 30, 2024, the outstanding RSUs had unamortized stock-based compensation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a15981ae-3d77-44ab-b90a-1ba532104fa2" contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with a weighted-average remaining recognition period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e123be98-bd02-4e3d-966a-ae4656d516bd" contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.07</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and an aggregate intrinsic value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e0f4743-ead4-4a7a-8922-67169123f89e" contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8944c9a0-f59f-4406-9f3b-f72d56ebd5c9" contextRef="C_4ac1801a-8726-4753-a2ce-890bbc37f3b6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,928,226</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2016 Employee Stock Purchase Plan (2016 ESPP). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40691c4a-6a10-4003-a95d-31d21fe5ffed" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" escape="true" continuedAt="F_40691c4a-6a10-4003-a95d-31d21fe5ffed_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the weighted-average grant-date fair value, and total stock-based compensation expense recognized related to the 2016 ESPP are as follows:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_40691c4a-6a10-4003-a95d-31d21fe5ffed_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.389%;"/>
        <td style="width:1%;"/>
        <td style="width:18.676%;"/>
        <td style="width:1%;"/>
        <td style="width:2.26%;"/>
        <td style="width:1%;"/>
        <td style="width:18.676%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average grant-date fair value per share</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_236b345b-919d-460f-a565-c63e06bc5587" contextRef="C_faf7cb0d-6157-4f20-a7ac-312439f84084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.44</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaa80e8d-f566-4ffe-9d27-76b64c66de74" contextRef="C_841e49f2-f8fa-49e5-99ce-5c3d05827d57" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_242b91e9-b1de-4515-afec-835e7eb3d386" contextRef="C_faf7cb0d-6157-4f20-a7ac-312439f84084" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,505</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5b08a28-2fe9-4d68-a2a9-8d687ecdf1d2" contextRef="C_841e49f2-f8fa-49e5-99ce-5c3d05827d57" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">26,734</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_55922230-581a-41af-8d3e-70c478c7b405" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LEASES</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company currently leases an office used to conduct business. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise, the Company includes the renewal period in its lease term. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. In November 2023, the Company entered into a lease amendment that extended the lease by 12 months through December 31, 2024 and contained two options to extend the term of the lease for an additional 12 months each. Each option shall be exercisable, if at all, by giving a nine month written notice to the landlord. In April 2024, the Company extended the option to extend the term of the lease for an additional 12 months into December 2025, which will have no impact on the balance sheet as the option to extend the term of the lease for an additional 12 months was accounted for as of December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the Company maintained an unamortized Right-Of-Use asset with a corresponding operating lease liability of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_116ae19f-5ca2-4814-96ff-9e74ede143d2" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on the present value of the minimum rental payments in accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The weighted average discount rate used for leases as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ae17582-053f-43fa-b72e-747a99f840ab" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The weighted average remaining lease term as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78c3e64d-b42e-4403-a7a7-46774d0da402" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.50</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The operating lease expense for the six months ended June 30, 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_081bc664-a00e-488f-ae4e-2b9dc96e0dde" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-2" format="ixt:num-dot-decimal">140.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e2c2e3f-3dda-4a6f-9035-140478762874" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_7e2c2e3f-3dda-4a6f-9035-140478762874_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities and balance sheet presentation of the Company&#8217;s lease liabilities for all operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 is as follows:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_7e2c2e3f-3dda-4a6f-9035-140478762874_1"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 remaining total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83749ca6-b9fa-46cf-80b9-05bd85d85c77" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">423,132</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: effect of discounting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38b45052-ff82-4846-a9dc-90188c5cabea" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">29,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a444cfc6-cc0f-4d8e-bf44-eac4495a4e3b" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">393,932</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5467b1e8-93e9-412a-9edb-284ce2bfc7d6" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">255,039</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ae893d5-e157-4c24-8b01-09ad4a2d315f" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">138,893</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d4d08fc-5eb9-4054-9202-a09208f3b0e5" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">393,932</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s gross future minimum payments under all non-cancelable operating leases as of June 30, 2024, are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.829%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1.06%;"/>
        <td style="width:7.902%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1.06%;"/>
        <td style="width:7.902%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1.08%;"/>
        <td style="width:7.902%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1.08%;"/>
        <td style="width:7.902%;"/>
        <td style="width:1%;"/>
        <td style="width:1.06%;"/>
        <td style="width:1.08%;"/>
        <td style="width:7.902%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:23.05pt;vertical-align:bottom;padding-right:0.01in;"><p style="margin-left:23.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease obligations</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1681ee0a-7ae5-43d6-9e59-9f869016c95e" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">423,132</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d8537ae-d0aa-4fed-accc-8658bd84140a" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">137,928</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce8d4c02-fc10-404b-9d4f-b00e50057205" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">285,204</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_918737af-3c79-444a-b95f-a56895918021" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_301946c8-c057-410e-81cf-87592afb5a49" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25ef7d49-428c-4d2d-a0b6-9bdfa69476cd" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMMITMENTS AND CONTINGENCIES </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime. Through June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company had not experienced any losses related to these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">indemnification </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obligations and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4af45cee-3cef-45fd-b350-d2a36271bc84" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="aldx:IndemnificationObligationsClaimsOutstanding" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f64432d-0e26-4bef-9e6c-6ae1779ad4e0" contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6" name="aldx:CashReserveForIndemnitiesAndGuarantees" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related reserves were established.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-License Agreements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MEEI Agreement</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is developing ADX-2191 pursuant to an Exclusive License Agreement with Massachusetts Eye and Ear Infirmary (MEEI) originally entered into in July 2016 between MEEI and Helio Vision, Inc., as amended, (MEEI Agreement). The Company assumed the MEEI Agreement in connection with its 2019 acquisition of Helio Vision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant and subject to the MEEI Agreement, the Company obtained an exclusive, worldwide license from MEEI to develop and commercialize ADX-2191 under certain patents and patent applications, and other licenses to intellectual property (MEEI Patent Rights). The Company has agreed to use commercially reasonable efforts, to develop ADX-2191, and to meet certain specified effort and achievement benchmarks by certain dates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration for the rights licensed under the MEEI Agreement, Helio Vision issued MEEI a number of shares of its preferred stock and Helio Vision agreed to pay non-creditable non-refundable license maintenance fees to MEEI of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_788931a1-d0b9-4a39-a50a-7a3d1b97f6da" contextRef="C_ae29fbf4-5256-4883-8903-abc42ff33b2e" name="aldx:NonCreditableNonRefundableLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on each of the second and third anniversary of the MEEI Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ded39bb5-0f37-4f45-83ee-196ffaa4450a" contextRef="C_7749ab03-e4ad-4f5d-a02f-52988e9238db" name="aldx:NonCreditableNonRefundableLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on each of the fourth and fifth anniversary of the MEEI Agreement and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66f8fc5e-48c0-4aeb-aa66-1f282c0a5317" contextRef="C_c67b96d9-fd6c-4b3b-b38e-25799171694d" name="aldx:NonCreditableNonRefundableLicenseMaintenanceFees" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the sixth and each subsequent anniversary of the MEEI Agreement during the term of such agreement. In addition, Helio Vision was obligated to make future sales-dependent milestone payments to MEEI of up to the low seven figures in the aggregate, as well as royalty payments to MEEI at a rate which, as a percentage of net sales, is in the low single digits for products that incorporate or use the MEEI Patent Rights in the United States and as a percentage in the low single digits for products that incorporate or use the MEEI Patent Rights outside the United States. The Company is also obligated under the MEEI Agreement to pay MEEI a percentage of certain sublicense revenue that it receives in connection with entering into any sublicensing arrangements with any third parties, at a percentage rate which tiers downward from low-double digits to mid-single digits based on the date of the sublicense. Following the Company&#8217;s acquisition of Helio Vision, the Company became obligated to make any future payments owed under the MEEI Agreement. There is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7202da4c-a1ff-475f-8e45-b1dbaeb1a0e3" contextRef="C_e51b1aea-5294-4784-b720-49da7b57163b" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional equity consideration issuable under the MEEI Agreement.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MEEI Agreement will remain in effect until the expiration date of the last to expire patent licensed under the MEEI Agreement. The Company may terminate the MEEI Agreement with timely written notice to MEEI. MEEI has the right to terminate the MEEI Agreement if it, subject to certain specified cure periods, ceases all business operations with respect to licensed products, fails to pay amounts due under the MEEI Agreement, fail to comply with certain due diligence obligations, defaults in the Company's obligation to maintain insurance, one of the Company's officers is convicted of a felony relating to the manufacture, use, sale or importation of licensed products, the Company materially breaches any provisions of the MEEI Agreement or in the event of its insolvency or bankruptcy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of an early termination of the MEEI Agreement, all rights licensed and developed by the Company under the MEEI Agreement may revert back to MEEI. The Company has agreed to indemnify MEEI for certain claims that may arise under the MEEI Agreement.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 31, 2023, a purported stockholder filed a putative class action lawsuit (the Securities Class Action) in the U.S. District Court for the District of Massachusetts, against the Company and certain current and former officers, captioned Juliana Paice v. Aldeyra Therapeutics, Inc., et al. (No. 23-cv-11737). On January 2, 2024, the lead plaintiff filed an amended complaint. The lawsuit alleges violations by the defendants of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The plaintiff alleges that the defendants made false or misleading statements or failed to disclose certain information concerning (i) the New Drug Application (NDA) for and the prospects of ADX-2191 for the treatment of primary vitreoretinal lymphoma and (ii) the NDA for and the prospects of reproxalap for the treatment of dry eye disease. The lawsuit seeks, among other things, compensatory damages on behalf of herself and all persons and entities that purchased or otherwise acquired the Company's securities between January 7, 2021, and October 16, 2023, as well as attorneys&#8217; fees and costs. On March 4, 2024, defendants filed a motion to dismiss the amended complaint, the plaintiff filed its opposition to the motion on April 18, 2024, and defendants filed a reply to plaintiff's opposition on May 20, 2024. Oral argument on the motion to dismiss was heard on July 24, 2024. The Company disputes the plaintiff's claims and intends to vigorously defend the suit. At this time, the Company cannot reasonably predict the outcome or estimate potential losses, if any, that could result from this matter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2024, a purported stockholder of the Company filed a derivative complaint in the U.S. District Court for the District of Massachusetts, captioned Fawaz Al-Jaljouli v. Todd C. Brady, et al. (No. 24-cv-10585), against certain of the Company&#8217;s executive officers and directors, and naming the Company as a nominal defendant. The derivative complaint alleges, purportedly on behalf of the Company, breach of fiduciary duty and violations of Section 14(a) of the Securities Exchange Act of 1934. The claims are based on substantially identical allegations as the complaint in the Securities Class Action. The lawsuit seeks, among other things, an award of damages, certain changes to the Company&#8217;s corporate governance, and attorneys&#8217; fees and costs. On June 24, 2024, the plaintiff voluntarily dismissed all claims without prejudice.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, from time to time, the Company is subject to litigation and claims arising in the ordinary course of business but, except as stated above, the Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceedings against them that the Company believes could have a material adverse effect on the Company's business, operating results, cash flows, or financial condition.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47cfd135-9d10-417c-8cfb-923ad1676470" contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNIFICANT AGREEMENTS</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AbbVie Option Agreement</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023 (the Option Agreement Effective Date), the Company entered into an exclusive option agreement (the Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which the Company granted AbbVie an exclusive option (the Option) to obtain (a) a co-exclusive license in the United States to facilitate a collaboration with the Company to develop, manufacture and commercialize reproxalap in the United States, (b) an exclusive license to develop, manufacture and commercialize reproxalap outside the United States, (c) a right of first negotiation for compounds that are owned or otherwise controlled by the Company in the field of ophthalmology relating to treating conditions of the ocular surface, and (d) a right to review data for any other compounds that are owned or otherwise controlled by the Company in the fields of ophthalmology and immunology before such data is shared with any other third party (the Collaboration Agreement). AbbVie has paid the Company a non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6ca0e37-f3a1-4d14-b73f-57e60f4fbf27" contextRef="C_d45352fc-bf96-470b-b41f-a3eef457e016" name="aldx:NonRefundablePayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in consideration of the Option (the Option Payment).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 21, 2023, pursuant to the Option Agreement, AbbVie extended the period during which it may exercise the Option (the Exercise Period Extension) by paying the Company a non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eac7d1ce-be6f-40f3-be53-e78e9688a772" contextRef="C_40f99af9-00a1-419c-baf2-fe6d585df1ee" name="aldx:NonRefundablePayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Option Extension Fee). As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to the Company at any time during the period following the Option Agreement Effective Date until the earlier of (a) the tenth (10th) business day after the date, if any, that the Company receives approval from the U.S. Food and Drug Administration of the NDA for reproxalap in dry eye disease (the FDA Decision) and (b) the date that is eighteen (18) months after the Option Agreement Effective Date. If the Collaboration Agreement is entered into, the Option Payment and the Option Extension Fee will be credited against the upfront cash payment payable by AbbVie.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon AbbVie&#8217;s delivery of the agreement execution notice and the parties entering into the Collaboration Agreement, AbbVie would pay the Company a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0845df52-0992-4fd7-bbba-afaebd38d002" contextRef="C_40f99af9-00a1-419c-baf2-fe6d585df1ee" name="aldx:UpfrontCashPayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront cash payment, less the Option Payment and the Option Extension Fee. In addition, the Company would be eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d9c2cc-b387-4b59-b799-737fcc1b6e94" contextRef="C_270782a4-00d0-4755-8b0e-33d563f70df1" name="aldx:MilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">300</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in regulatory and commercial milestone payments, inclusive of a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd26199b-20c0-4d81-81f3-1f4e69544aba" contextRef="C_10f6bf02-b7a9-406c-8bc5-35aafa92828a" name="aldx:MilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment payable if the FDA Decision is received prior to or after the execution of the Collaboration Agreement. In the United States, the Company would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0614faf3-ff0e-4e9d-90c1-6621abd7fad4" contextRef="C_40f99af9-00a1-419c-baf2-fe6d585df1ee" name="aldx:SplitProfitsAndLossesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for AbbVie and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64941569-90f2-4c60-ae9c-c4025151819d" contextRef="C_d16b308a-5d1b-46ab-9b7e-ef142ccd89bb" name="aldx:SplitProfitsAndLossesPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for the Company. Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap. As of August 1, 2024, AbbVie has not exercised the Option.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_577899ef-60a0-4743-895d-d557379d70e8" contextRef="C_459e57d8-3560-4c3f-bc51-fdf45eed3a01" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> collaboration revenue and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32dfcc79-35da-4443-8b0a-5df01e826e3e" contextRef="C_7fa87fa1-8b12-44f5-9947-3868ccbde0f8" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of deferred collaboration revenue, long-term, related to the Option Agreement and Exercise Period Extension. During th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e three months ended  June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the deferred collaboration revenue was moved from a long-term liability to a current liability on the Company&#8217;s balance sheet as a result of the Option expiring pursuant to the terms of the Option Agreement in less than one year if not exercised. The Company concluded, using ASC 606 by analogy for recognition considerations as the Option Agreement was not considered to be a vendor-customer relationship, that the transaction price is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94fa04a4-9e92-4903-be12-3e29f0cd14f3" contextRef="C_7fa87fa1-8b12-44f5-9947-3868ccbde0f8" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Transaction Price), and all other amounts are excluded from the Transaction Price as they relate to fees that can only be achieved subsequent to the exercise of the Option. The Transaction Price was allocated to the single unit of account, the Option to enter into a future Collaboration Agreement which is a material right, as the Option Extension Fee and the Option Payment are creditable against the upfront payments payable by AbbVie if the Collaboration Agreement is entered into. The Company concluded that all other performance obligations were immaterial promises in the context of the Option Agreement and did not represent additional units of account. The Company will begin to recognize revenue, if and, when the Option is exercised or when the Option expires.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.	Management&#8217;s Discussion and Analysis of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various statements throughout this report are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;contemplates,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;design,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans to develop and commercialize reproxalap, and any other product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay in or failure to obtain regulatory approval of reproxalap or any of our other product candidates, including as a result of the U.S. Food and Drug Administration (FDA) not accepting our regulatory filings or requiring additional clinical trials or data prior to review or approval of such filings;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the likelihood and timing of the FDA&#8217;s potential approval of a potential resubmission of the new drug application (NDA) for reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the adequacy of the data included in the potential resubmission of the NDA or the supplemental responses to the FDA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the likelihood and timing of the exercise of the exclusive option (the Option) by AbbVie Inc. (AbbVie) pursuant to the exclusive option agreement with AbbVie;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to maintain regulatory approval of reproxalap or any of our other our product candidates, if received, and the labeling for any approved products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertainty as to our ability to commercialize (alone or with others) and obtain reimbursement for reproxalap or any of our other product candidates following regulatory approval, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth of the potential markets and pricing for reproxalap or any of our other product candidates following regulatory approval, if any, and the ability to serve those markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance of any of reproxalap or any of our other product candidates following regulatory approval, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of enrollment, commencement, and completion of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and success of preclinical studies and clinical trials conducted by us and our development partners;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, expansion, and costs of developing and commercializing our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our expenses and future revenue, the timing of future revenue, the sufficiency or use of our cash resources and needs for additional financing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding competition; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our anticipated growth strategies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract or retain key personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing, and manufacturing capabilities and strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain development and commercialization partnerships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully integrate acquisitions into our business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding federal, state, and foreign regulatory requirements; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">political, economic, legal, social and health risks, public health measures, and war or other military actions, that may affect our business, results of operations and financial position, or the global economy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments in the United States and foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain intellectual property protection for our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the anticipated trends and challenges in our business and the market in which we operate.
</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely on the forward-looking statements we make or that are made on our behalf. We undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly, or current reports that we may file with the Securities and Exchange Commission (SEC).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We encourage you to read &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Risk Factors,&#8221; as well as our unaudited condensed consolidated financial statements contained in this quarterly report on Form 10-Q. We also encourage you to read our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 7, 2024 (2023 Annual Report), and which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described above and in our 2023 Annual Report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the SEC from time to time, including Forms 10-Q, 8-K, and 10-K, which may supplement, modify, supersede, or update those risk factors. There can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that our results will lead to the expected consequences to, or effects on us. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., including its wholly-owned subsidiaries (we, us, or the Company), is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. Our preclinical RASP platform includes ADX-248, ADX-743, ADX-631, and other product candidates in development for inflammatory and metabolic diseases. Our development pipeline, as of the date of filing of this quarterly report on Form 10-Q is illustrated below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img130887665_0.jpg" alt="img130887665_0.jpg" style="width:707px;height:223px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023 (the Option Agreement Effective Date), we entered into an exclusive option agreement (the Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which we granted AbbVie an exclusive option (the Option) to obtain (a) a co-exclusive license in the United States to facilitate a collaboration with us to develop, manufacture and commercialize reproxalap in the United States, (b) an exclusive license to develop, manufacture and commercialize reproxalap outside the United States, (c) a right of first negotiation for compounds that are owned or otherwise controlled by us in the field of ophthalmology relating to treating conditions of the ocular surface, and (d) a right to review data for any other compounds that are owned or otherwise controlled by us</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the fields of ophthalmology and immunology before such data is shared with any other third party (the Collaboration Agreement). AbbVie paid us a non-refundable payment of $1 million in consideration of the Option (the Option Payment).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 21, 2023, pursuant to the Option Agreement, AbbVie extended the period during which it may exercise the Option (the Exercise Period Extension) by paying us a non-refundable payment of $5 million (the Option Extension Fee). As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to us at any time during the period following the Option Agreement Effective Date until the earlier of (a) the tenth (10th) business day after the date, if any, that we receive approval from the U.S. Food and Drug Administration of the NDA for reproxalap in dry eye disease (the FDA Decision) and (b) the date that is eighteen (18) months after the Option Agreement Effective Date. If the Collaboration Agreement is entered into, the Option Payment and the Option Extension Fee will be credited against the upfront cash payment payable by AbbVie.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon AbbVie&#8217;s delivery of the agreement execution notice and the parties entering into the Collaboration Agreement, AbbVie would pay us a $100 million upfront cash payment, less the Option Payment and the Option Extension Fee. In addition, we would be eligible to receive up to approximately $300 million in regulatory and commercial milestone payments, inclusive of a $100 million milestone payment payable if the FDA Decision is received prior to or after the execution of the Collaboration Agreement. In the United States, we would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of 60% for AbbVie and 40% for us. Outside of the United States, we would be eligible to receive tiered royalties on net sales of reproxalap. As of August 1, 2024, AbbVie has not exercised the Option.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of our development plans and timelines are subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, completion, or reporting of clinical trials. Regulatory review timelines are flexible and subject to change based on the regulator&#8217;s workload and other potential review issues. The timing of ongoing clinical trials depends, in part, on the availability of clinical research facilities and staffing, and the ability to recruit patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to execute on our strategy of expanding our product candidate pipeline, we may license or acquire new immune-modulating approaches with novel therapeutic potential. In January 2019, for example, we acquired Helio Vision, Inc. (Helio) and thereby obtained rights to ADX-2191.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.62%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no products approved for sale in the United States or elsewhere. We will not receive any revenue from sales of our product candidates that we develop until we obtain regulatory approval. We intend to commercialize our products, if approved for sale, through collaborations. Although we may receive commercial and license revenue in the future, we have to date primarily funded our operations through the sale of our common stock, convertible preferred stock, convertible promissory notes, warrants, and borrowings under debt facilities. We will need to raise additional capital in the form of debt or equity or through partnerships to fund additional development of our product candidates, and we may in-license, acquire, or invest in complementary businesses or products. In addition, contingent on capital resources, we may augment, diminish, or otherwise modify the clinical development plan described herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we entered into an Open Market Sales Agreement </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with Jefferies LLC (Jefferies), as sales agent (2021 Jefferies Sales Agreement), under which we had the ability to offer and sell, from time to time through Jefferies, shares of common stock providing for aggregate sales proceeds of up to $100.0 million. As of June 30, 2024, no shares of common stock may be sold under the 2021 Jefferies Sales Agreement, and no sales had previously been made pursuant to the 2021 Jefferies Sales Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2019, we acquired Helio and thereby acquired rights to ADX-2191 pursuant to an Agreement and Plan of Merger dated as of January 24, 2019 (the Merger Agreement). As a result of the acquisition, we have issued an aggregate of 1,407,006 shares of common stock to the former securityholders and an advisor of Helio. Subject to the conditions of the acquisition agreement, we are contingently obligated to make additional payments to the former securityholders of Helio as follows: (a) $10.0 million of common stock following approval by the FDA of an NDA for the prevention and/or treatment of proliferative vitreoretinopathy or a substantially similar label prior to the 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> anniversary of the closing date; and (b) $2.5 million of common stock following FDA approval of an NDA for an indication (other than proliferative vitreoretinopathy or a substantially similar label) prior to the 12</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> anniversary of the closing date, provided that in no event shall we be obligated to issue more than 5,248,885 shares of common stock in the aggregate in connection with the acquisition. If we cease to use commercially reasonably efforts to develop and obtain regulatory approval for ADX-2191, subject to the terms and conditions of the Merger Agreement, ADX-2191 and related intellectual property rights may revert back to an entity designated by the representative of the former Helio stockholders. Additionally, in the event of certain change of control or divestitures by us, certain former convertible noteholders of Helio will be entitled to a tax gross-up payment in an amount not to exceed $1.0 million in the aggregate.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2019, we entered into the Hercules Credit Facility, which provided for a term loan of up to $60.0 million, $15.0 million of which has been funded as of June 30, 2024. In April 2021, the Hercules Credit Facility was amended to, among other things, increase the amount which may become available for draw-down prior to May 2023, subject to the satisfaction of certain conditions contained therein, from $10.0 million to $20.0 million. In December 2022, the Hercules Credit Facility was further amended to, among other things, (i) extend the expiration of the period in which interest-only payments on borrowings from May 1, 2023 to May 1, 2024; (ii) extend the Maturity Date from October 1, 2023 to October 1, 2024; and (iii) extend the availability of the $20.0 million draw-down from May 2023 to May 2024, subject to the satisfaction of certain conditions contained therein. The Hercules Credit Facility contains customary affirmative and negative covenants and events of default. Affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, and maintain insurance coverage. Negative covenants include, among others: restrictions on transferring any part of our business or intellectual property; incurring additional indebtedness; engaging in mergers or acquisitions; paying dividends or making other distributions; making investments; and creating other liens on our assets, in each case subject to customary exceptions. On April 29, 2024, the Hercules Credit Facility was further amended to, among other things, extend the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2024 to October 1, 2024. The Hercules Credit Facility, as amended, is described in Note 9 to the notes to the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, $15.0 million was outstanding under the Hercules Credit Facility.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expense all of our research and development expenses as they are incurred. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense until incurred. Research and development expenses primarily include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-clinical development, preclinical research, and clinical trial and regulatory-related costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses incurred under agreements with sites and consultants that conduct our clinical trials; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee-related expenses, including salaries, benefits, travel, and stock-based compensation expense.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, substantially all of our research and development expenses have been incurred in connection with reproxalap and ADX-2191, as well as the proof of concept trials with ADX-629. We expect our research and development expenses to increase for the foreseeable future as we advance ADX-248, ADX-743, ADX-631, and other compounds through preclinical and clinical development. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We are unable to estimate with any certainty the costs we will incur in the continued development of our product candidates. Clinical development timelines, the probability of success, and development costs can differ materially from expectations. We may never succeed in achieving marketing approval for our product candidates. The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per patient trial costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of sites included in the trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries in which the trials are conducted; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays of, or other effects on, clinical trials resulting from public health measures, and war or other military actions, or for other reasons;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of time required to enroll eligible patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of drug manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients that participate in the trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of doses that patients receive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of assay development, assays, or other assessment of clinical trial endpoints;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of vehicle or active comparative agents used in trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the drop-out or discontinuation rates of patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential additional safety monitoring or other studies or clinical trials requested by regulatory agencies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration of patient follow-up; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the phase of development the product candidate is in; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of our product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in research and development are expenses associated with asset acquisitions. Assets purchased in an asset acquisition transaction are expensed as in-process research and development unless the assets acquired are deemed to have an alternative future use. Acquired in-process research and development payments are immediately expensed, and include upfront payments, as well as transaction fees and subsequent milestone payments. Development costs incurred after the asset acquisition are expensed as incurred.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect reproxalap or any of our other product candidates to be commercially available, if at all, before at least the first half of 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the six months ended June 30, 2024 and 2023, our general and administrative expenses consisted primarily of employee-related expenses, including benefits and stock-based compensation for our full-time employees. Other general and administrative expenses include insurance premiums, consulting including pre-commercial costs, and professional fees for auditing, tax, investor relations, and legal services, including patent-related costs. We expect that general and administrative expenses will increase in the future as we expand our operating activities and continue to incur additional costs associated with being a publicly-traded company, including costs associated with maintaining compliance with exchange listing and SEC requirements. Increases in general and administrative expenses will likely include higher consulting costs, fees for commercializing our product candidates, legal fees, accounting fees, insurance premiums, and fees associated with investor relations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income (expense) consists primarily of interest income we earn on interest-bearing accounts and interest expense incurred on our outstanding debt.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive loss</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. For the six months ended June 30, 2024, comprehensive loss is equal to our net loss of $24.9 million and our net unrealized loss on marketable securities of $9.7 thousand. For the six months ended June 30, 2023, comprehensive loss is equal to our net loss of $24.6 million and $0.1 million of losses on marketable securities reclassified to net loss.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. Our significant accounting policies are more fully described in the notes to our unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no material changes to our critical accounting estimates during the six months ended June 30, 2024, as compared to those described in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our 2023 Annual Report. It is important that the discussion of our operating results that follow be read in conjunction with the critical accounting policies disclosed in our 2023 Annual Report.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including the progress of our research and development efforts, the timing and outcome of clinical trials, and regulatory requirements. Our limited operating history makes predictions of future operations difficult or impossible. Since our inception, we have incurred significant losses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Three months ended June 30, 2024 compared to three months ended June 30, 2023</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Research and development expenses were $15.0 million for the three months ended June 30, 2024, compared to $7.0 million for the three months ended June 30, 2023. The increase of $8.0 million was primarily related to an increase in external clinical development costs and drug product manufacturing costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $3.0 million for the three months ended June 30, 2024, compared to $3.4 million for the three months ended June 30, 2023. The decrease of $0.4 million was primarily related to lower personnel costs, consulting expenditures, and legal costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income (expense), net, was $1.2 million and $1.4 million for the three months ended June 30, 2024 and 2023, respectively. The decrease in net other income of $0.2 million was due to lower interest income for the three months ended June 30, 2024, compared with the three months ended June 30, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Six months ended June 30, 2024 compared to six months ended June 30, 2023</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Research and development expenses were  $21.2 million for the six months ended June 30, 2024, compared to $18.2 million for the six months ended June 30, 2023. The increase of $3.0 million was primarily related to an increase in external clinical development costs and drug product manufacturing expenditures, offset by a decrease of $1.5 million in personnel costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $6.2 million for the six months ended six months ended June 30, 2024, compared to $8.9 million for the six months ended June 30, 2023. The decrease of $2.7 million was primarily related to lower personnel costs, consulting expenditures, and legal costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total other income (expense), net, was $2.5 million and $2.5 million for the six months ended June 30, 2024 and 2023, respectively, which reflects consistent interest income for the six months ended June 30, 2024 and 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have funded our operations primarily from the sale of equity securities and convertible equity securities and borrowings under credit facilities. Since inception, we have incurred operating losses and negative cash flows from operating activities and have devoted substantially all our efforts to research and development. At June 30, 2024, we had total stockholders&#8217; equity of approximately $98.3 million, and cash, cash equivalents, and marketable securities of $120.3 million. During the six months ended June 30, 2024, we had a net loss of approximately $24.9 million. We expect to generate operating losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we entered into the 2021 Jefferies Sales Agreement under which we had the ability to offer and sell, from time to time through Jefferies, shares of common stock providing for aggregate sales proceeds of up to $100.0 million. As of June 30, 2024, no shares of common stock may be sold under the 2021 Jefferies Sales Agreement, and no sales had previously been made pursuant to the 2021 Jefferies Sales Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2019, we entered into the Hercules Credit Facility (the Loan and Security Agreement), pursuant to which a term loan of up to an aggregate principal amount of $60.0 million may be made available to us. The Loan and Security Agreement provides for (i) an initial term loan advance of up to $5.0 million at our option, which expired unutilized on April 15, 2019; (ii) three additional term loan advances of up to $15.0 million each, at our option, available to us upon the occurrence of certain funding conditions prior to September 30, 2019 (2019 Tranche), March 31, 2020 (2020 Tranche), and March 31, 2021 (2021 Tranche); and (iii) a final additional term loan advance (Fourth Loan Tranche) of up to $10.0 million prior to December 31, 2021, at our option, subject to approval by Lender&#8217;s investment committee. We drew down the 2019 Tranche in full in September 2019 and the 2020 Tranche and the 2021 Tranche expired unutilized prior to us satisfying the funding conditions for such tranche. On April 20, 2021, we entered into the First Amendment (First Amendment) to Loan and Security Agreement with Hercules. The First Amendment, among other things, (i) increased the Fourth Loan Tranche from $10.0 million to $20.0 million and extended the deadline for drawing down the Fourth Loan Tranche to July 1, 2022; (ii) lowered the variable per annum rate of interest on borrowings under the Loan and Security Agreement to the greater of (a) the Prime Rate plus 3.10% or (b) 8.60%; (iii) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are required from May 1, 2021 to July 1, 2022; and (iv) following the satisfaction of certain conditions, which conditions were satisfied in April 2021, further extended the expiration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to May 1, 2023. On December 22, 2022, we entered</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">into the Second Amendment (Second Amendment) to the Loan and Security Agreement with Hercules, which became effective as of December 31, 2022 (Second Amendment Effective Date). The Second Amendment, among other things, (i) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2023 to May 1, 2024; (ii) extended the Maturity Date from October 1, 2023 to October 1, 2024 (Maturity Date); (iii) extended the availability of the Fourth Loan Tranche commitment of $20 million, which remained conditioned on approval by the Lenders&#8217; investment committee, from May 1, 2023 to May 1, 2024; and (iv) amended the Prepayment Charge (as defined therein) to equal 0.75% of the amount prepaid during the 12-month period following the Second Amendment Effective Date, and 0% thereafter. In addition, a supplemental end of term charge of $292,500 (Supplemental End of Term Charge) shall be due on the earlier of (A) the Maturity Date, as amended, or (B) repayment of the aggregate amount of advances under the Loan and Security Agreement. The initial end of term charge of $1,042,500 (End of Term Charge) was paid on October 2, 2023. On April 29, 2024, we entered into the Third Amendment (Third Amendment) to the Loan and Security Agreement with Hercules. The Third Amendment, among other things, extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2024 to October 1, 2024. On May 1, 2024, the Fourth Loan Tranche commitment expired unutilized.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan and Security Agreement contains customary affirmative and negative covenants and events of default. Affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, and maintain insurance coverage. Negative covenants include, among others: restrictions on transferring any part of our business or intellectual property; incurring additional indebtedness; engaging in mergers or acquisitions; paying dividends or making other distributions; making investments; and creating other liens on our assets, in each case subject to customary exceptions. As of June 30, 2024, $15.0 million was outstanding under the Hercules Credit Facility and no amounts remained available for borrowing.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023 (the Option Agreement Effective Date), we entered into an exclusive option agreement (the Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which we granted AbbVie an exclusive option (the Option) to obtain (a) a co-exclusive license in the United States to facilitate a collaboration with us to develop, manufacture and commercialize reproxalap in the United States, (b) an exclusive license to develop, manufacture and commercialize reproxalap outside the United States, (c) a right of first negotiation for compounds that are owned or otherwise controlled by us in the field of ophthalmology relating to treating conditions of the ocular surface, and (d) a right to review data for any other compounds that are owned or otherwise controlled by us in the fields of ophthalmology and immunology before such data is shared with any other third party (the Collaboration Agreement). AbbVie has paid us a non-refundable payment of $1 million in consideration of the Option (the Option Payment).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 21, 2023, pursuant to the Option Agreement, AbbVie extended the period during which it may exercise the Option (the Exercise Period Extension) by paying us a non-refundable payment of $5 million (the Option Extension Fee). As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to us at any time during the period following the Option Agreement Effective Date until the earlier of (a) the tenth (10th) business day after the date, if any, that we receive approval from the U.S. Food and Drug Administration of the NDA for reproxalap in dry eye disease (the FDA Decision) and (b) the date that is eighteen (18) months after the Option Agreement Effective Date. If the Collaboration Agreement is entered into, the Option Payment and the Option Extension Fee will be credited against the upfront cash payment payable by AbbVie.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AbbVie may exercise the Option by delivering the Option Exercise Notice to us at any time during the period following the Option Agreement Effective Date until the earlier of (a) the tenth (10th) business day after the FDA Decision Date and (b) the date that is eighteen (18) months after the Option Agreement Effective Date.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon AbbVie&#8217;s delivery of the agreement execution notice and the parties entering into the Collaboration Agreement, AbbVie would pay us a $100 million upfront cash payment, less the Option Payment and the Option Extension Fee. In addition, we would be eligible to receive up to approximately $300 million in regulatory, and commercial milestone payments, inclusive of a $100 million milestone payment payable if the FDA Decision is received prior to or after the execution of the Collaboration Agreement. In the United States, we would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of 60% for AbbVie and 40% for us. Outside of the United States, we would be eligible to receive tiered royalties on net sales of reproxalap.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan and excluding any potential licensing and product revenue, we believe that our cash, cash equivalents and marketable securities as of June 30, 2024, will be sufficient to fund our currently projected operating expenses and debt obligations through 2026, including continued early and late-stage development of our product candidates. We base our projections of operating capital requirements on our current operating plan, which includes several assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization (as applicable) of product candidates, we are unable to estimate the exact amount of our working capital requirements. We will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources in order to carry out all of our planned research and development activities and regulatory activities; commence or continue ongoing commercialization, including manufacturing, sales, marketing and distribution for our product candidates; or conduct any substantial additional development requirements requested by the FDA. At this time, due to the risks inherent in the drug development process, we are unable to estimate with any certainty the costs we will incur in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the continued clinical development of reproxalap, and our other product candidates. Subsequent trials initiated at a later date will cost considerably more, depending on the results of our prior clinical trials, and feedback from the FDA or other third parties. Accordingly, we will continue to require substantial additional capital to continue our clinical development and potential commercialization activities. The amount and timing of our future funding requirements will depend on many factors, including but not limited to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing, and outcome of regulatory review of reproxalap, including any additional trials the FDA or other regulatory agencies may require for approval or label expansion;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs, and results of any clinical activities for regulatory review of reproxalap outside of the United States;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the exercise, if any, of the Option;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of process development and manufacturing scale&#8209;up activities associated with reproxalap;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of commercialization activities for reproxalap if we receive marketing approval and pre&#8209;commercialization costs for reproxalap incurred prior to receiving, any such marketing approval, including the costs and timing of establishing product sales, marketing, distribution and outsourced manufacturing capabilities;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assuming receipt of marketing approval, the amount of revenue received from commercial sales of reproxalap or any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of establishing collaborations, license agreements, and other partnerships on terms favorable to us;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type, number, scope, progress, expansion costs, results, and timing of our clinical trials of any product candidates that we are pursuing or may choose to pursue in the future;
</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs associated with any other product candidates that we may develop, in-license, or acquire, including potential milestone or royalty payments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs incurred in defending ourselves in any legal proceedings that we may be subject to; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs of obtaining, maintaining, and enforcing our patents and other intellectual property rights.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may need or desire to obtain additional capital to finance our operations through debt, equity, or alternative financing arrangements. We may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant additional liens on certain of our assets that may limit our flexibility. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may significantly dilute the ownership of our existing stockholders. We are in a period of economic uncertainty, inflation, and capital markets disruption, which has been significantly impacted by adverse developments affecting the financial services industry, including geopolitical instability due to, among other things, the continued hostilities in Ukraine and Israel and the surrounding areas. In addition, the disruption in the capital markets could make any financing more challenging, and there can be no assurance that we will be able to obtain such financing on commercially reasonable terms or at all. If we are unable to obtain additional financing, we may be required to reduce the scope of our future activities, which could harm our business, financial condition, and operating results. There can be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will continue to incur costs as a public company, including, but not limited to, costs and expenses for directors' fees; increased directors' and officers' insurance; investor relations fees; expenses for compliance with the Sarbanes-Oxley Act of 2002 and related to rules implemented by the SEC and Nasdaq, on which our common stock is listed; and various other costs. The Sarbanes-Oxley Act of 2002 requires that we maintain effective disclosure controls and procedures and internal controls.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the six months ended June 30, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Six Months<br/>Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,196,985</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,801,654</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(48,614,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,000,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,191</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,851</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(71,793,293</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,256,197</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Net cash used in operating activities was $23.2 million for the six months ended June 30, 2024, compared to net cash used in operating activities of $22.8 million for the same period in 2023. The primary use of cash was to fund our operations. The increase in the amount of cash used in operating activities for the six months ended June 30, 2024 as compared to 2023 was principally due to an increase in net loss, primarily from research and development activities; changes in accrued expenses, due to the amount and timing of payments for research and development activities; and changes in prepayments, due to timing of payment and collection of a receivable; in addition to a decrease in stock compensation for the six months ended June 30, 2024 compared to the same period in 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Net cash used in investing activities was $48.6 million for the six months ended June 30, 2024, and $30.0 million provided by investing activities for the six months ended June 30, 2023. Net cash used in investing activities related to purchases of marketable securities for the six months ended June 30, 2024. Net cash provided by investing activities related to maturities of marketable securities for the six months ended June 30, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Net cash provided by financing activities was $18.2 thousand for the six months ended June 30, 2024, compared to $57.9 thousand for the six months ended June 30, 2023. The net cash provided by financing activities for the six months ended June 30, 2024 and 2023 consisted of stock purchases under the employee stock purchase plan.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-11.276%;padding-left:10.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3.	Quantitative and Qualitati</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures about Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we are allowed to comply with the disclosure obligations applicable to a "smaller reporting company," as defined by Rule 12b-2 of the Exchange Act, with respect to this Quarterly Report on Form 10-Q, we are not required to provide the information required by this Item.</span></p>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4.	Controls </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our Disclosure Committee and management, including our Chief Executive Officer and Interim Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of the end of the period covered by this report. Based on our management&#8217;s evaluation (with the participation of our Chief Executive Officer and our Interim Chief Financial Officer), as of the end of the period covered by this report, our Chief Executive Officer and our Interim Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II &#8211; OTHER INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 31, 2023, a purported stockholder filed a putative class action lawsuit (the Securities Class Action) in the U.S. District Court for the District of Massachusetts, against us and certain current and former officers, captioned Juliana Paice v. Aldeyra Therapeutics, Inc., et al. (No. 23-cv-11737). On January 2, 2024, the lead plaintiff filed an amended complaint. The lawsuit alleges violations by the defendants of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The plaintiff alleges that the defendants made false or misleading statements or failed to disclose certain information concerning (i) the NDA for and the prospects of ADX-2191 for the treatment of primary vitreoretinal lymphoma and (ii) the NDA for and the prospects of reproxalap for the treatment of dry eye disease. The lawsuit seeks, among other things, compensatory damages on behalf of herself and all persons and entities that purchased or otherwise acquired our securities between January 7, 2021, and October 16, 2023, as well as attorneys&#8217; fees and costs. On March 4, 2024, defendants filed a motion to dismiss the amended complaint, the plaintiff filed its opposition to the motion on April 18, 2024, and defendants filed a reply to plaintiff&#8217;s opposition on May 20, 2024. Oral argument on the motion to dismiss was heard on July 24, 2024. We dispute the plaintiff's claims and intend to vigorously defend the suit. At this time, we cannot reasonably predict the outcome or estimate potential losses, if any, that could result from this matter.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2024, a purported stockholder of the Company filed a derivative complaint in the U.S. District Court for the District of Massachusetts, captioned Fawaz Al-Jaljouli v. Todd C. Brady, et al. (No. 24-cv-10585), against certain of the Company&#8217;s executive officers and directors, and naming the Company as a nominal defendant. The derivative complaint alleges, purportedly on behalf of the Company, breach of fiduciary duty and violations of Section 14(a) of the Securities Exchange Act of 1934. The claims are based on substantially identical allegations as the complaint in the Securities Class Action. The lawsuit seeks, among other things, an award of damages and restitution in favor of us, certain changes to our corporate governance, and attorneys&#8217; fees and costs. On June 24, 2024, the plaintiff voluntarily dismissed all claims without prejudice.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, from time to time, we are subject to litigation and claims arising in the ordinary course of business but, except as stated above, we are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors_2"><span id="item_1a_riskfactors"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM </span><span id="item_1a_risk_factors_1"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1A. Risk Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is subject to numerous risks. You should carefully consider the risks described below together with the other information set forth in this quarterly report on Form 10-Q, which could materially affect our business, financial condition, and future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, prospects, financial condition, and operating results.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Risks Related to our Business</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered, together with other information in this quarterly report on Form 10-Q and our other filings with the Securities and Exchange Commission before making investment decisions regarding our common stock.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is dependent in large part on the successful commercialization of reproxalap. If we are unable to successfully obtain marketing approval for reproxalap, or experience significant delays in doing so, or if, after obtaining marketing approval, we or our strategic partners fail to successfully commercialize reproxalap, our business will be materially harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To generate revenue, we will depend on FDA approval and successful commercialization of reproxalap. Our success in obtaining regulatory approval of reproxalap from the FDA depends on our ability to address the issues raised by the FDA in the reproxalap Complete Response Letter, and address any issues the FDA may raise in the future. If we are unable to successfully obtain FDA approval, or FDA approval is delayed or limited, our ability to generate revenue will be significantly delayed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we remain responsible for funding further development and commercialization of reproxalap, we may be unable to raise the additional capital required to further develop and commercialize reproxalap or enter into a collaboration agreement with another pharmaceutical company with equivalent or comparable terms, or at all.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to develop and commercialize other product candidates, we may be unable to grow our business.</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reproxalap and our other product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays, or prevent the receipt of the required approvals to commercialize our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our competitors develop treatments for the target indications of our product candidates that are approved more quickly than ours, marketed more successfully, or demonstrated to be safer or more effective than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since inception and we expect to incur significant losses over the next several years. We may never become profitable or, if achieved, be able to sustain profitability.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require substantial additional financing, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our product development, other operations or commercialization efforts.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to conduct our clinical trials. If any third party does not meet our deadlines or otherwise conduct the trials as required and in accordance with regulations, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates when expected, or at all.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public health emergencies, epidemics or pandemics may impact our business. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse developments affecting the financial services industry, which could adversely affect our current and projected business operations and our financial condition and results of operations. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Potential Development and Commercialization of Reproxalap and our Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is dependent in large part on the successful commercialization of reproxalap, if approved. If we are unable to successfully obtain marketing approval for reproxalap or experience significant delays in doing so, or if, after obtaining marketing approvals, we or our strategic partners fail to successfully commercialize these product candidates, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent in large part on regulatory approval and successful commercialization of reproxalap for our future business success. There is a significant risk that we will fail to successfully obtain marketing approval and/or we or our partners will fail to successfully commercialize reproxalap. Of the large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of an NDA to the FDA, and even fewer are approved for commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to and following potential NDA approval, we will invest a significant portion of our time and financial resources on the commercialization of reproxalap. We cannot accurately predict when or if reproxalap will receive marketing approval. Our ability to generate product revenues will depend on our obtaining marketing approval for, and commercializing reproxalap alone or with others. The future regulatory and commercial success of reproxalap and our other product candidates is subject to a number of risks, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining marketing approval for reproxalap or any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to negotiate and enter into a collaboration agreement with a suitable third party on acceptable terms for the commercialization of reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing at commercial scale, marketing, selling and distributing those products for which we obtain marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hiring and building a full commercial organization required for the marketing, selling and distributing for those products which we obtain marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving an adequate level of market acceptance of and obtaining and maintaining coverage and adequate reimbursement from third&#8209;party payors for any products we commercialize; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining and protecting our intellectual property rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to provide sufficient evidence of safety and efficacy to obtain regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, or comparable foreign regulatory bodies, may implement new standards, or change the interpretation of existing standards or requirements for the regulatory approval, in general or with respect to the indications for which we seek approval; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, or comparable foreign bodies, may require additional clinical data, as was the case with the reproxalap Complete Response Letter;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not have sufficient financial and other resources to pursue our business plans, complete necessary clinical trials of our product candidates and commercialize our approved products, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if approved, reproxalap and our other product candidates will compete with well-established and other products or therapeutic options already approved for marketing by the FDA, or comparable foreign regulatory bodies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitive products may be more effectively or comprehensively marketed to physicians or patients, or contracted with payors more successfully;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our clinical trials may not meet the endpoints, or level of statistical or clinical significance required by the FDA, or comparable foreign regulatory bodies, for marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the safety and efficacy results of our later phase or larger clinical trials may not confirm the results of our earlier trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients in our clinical trials may demonstrate greater response rates or improvements from vehicle or in the non-treatment arm then was expected when designing and powering our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be variability in patients, adjustments to clinical trial procedures, and inclusion of additional clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initial parts of adaptive clinical trials are not designed to be pivotal or definitive, and as such we may not satisfy the designated endpoints and also may need to revise the design or endpoints to achieve success in later parts of the trial or potentially abandon the trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to timely or adequately finalize the design or formulation of any product candidate or demonstrate that a formulation of our product candidate will be stable for commercially reasonable time periods;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be adversely affected by legislative or regulatory reform of the health care system in the United States or other jurisdictions in which we may do business; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to obtain, maintain, or enforce our patents and other intellectual property rights. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, even if we do receive regulatory approval to market reproxalap or any of our other product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to commercialize our product candidates or continue to fund our development programs, we cannot assure that reproxalap will be successfully commercialized, or our other product candidates will be successfully developed or commercialized. If we are unable to obtain regulatory approval for or, if approved, we or any of our future partners are unable to successfully commercialize reproxalap, and our other product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">To generate revenue, we will depend on FDA approval and successful commercialization of reproxalap. Our success in obtaining regulatory approval of reproxalap from the FDA depends on our ability to address the issues raised by the FDA in the reproxalap Complete Response Letter, and address any issues the FDA may raise in the future. If we are unable to successfully obtain FDA approval, or FDA approval is delayed or limited, our ability to generate revenue will be significantly delayed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue will depend on the successful development, regulatory approval and commercialization of reproxalap. We submitted an NDA for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022. In February 2023, the FDA accepted the reproxalap NDA for filing and set a PDUFA date of November 23, 2023. On November 27, 2023, we announced that we had received a Complete Response Letter from the FDA (the reproxalap Complete Response Letter). In the reproxalap Complete Response Letter, the FDA stated that the NDA did not demonstrate &#8220;efficacy in treating ocular symptoms associated with dry eyes&#8221; and that &#8220;at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye&#8221; should be conducted. On November 16, 2023, prior to receiving the reproxalap Complete Response Letter, we submitted to the FDA a Special Protocol Assessment (SPA) for a dry eye disease chamber crossover clinical trial (the proposed trial), which could potentially result in data acceptable for FDA review towards a potential NDA resubmission for reproxalap for the treatment of the signs and symptoms of dry eye disease. A SPA is an advanced declaration from the FDA that a planned trial&#8217;s design, clinical endpoints, and statistical analyses could potentially result in data acceptable for FDA review towards approval for the proposed indication. Based on SPA feedback received from the FDA in December 2023, we have amended the design and protocol of the proposed trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that the design, conduct, and analysis of the results of the proposed trial will be sufficient to establish the effectiveness of reproxalap for treatment of dry eye disease to the FDA&#8217;s satisfaction, and therefore allow us to resubmit or receive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval of an NDA for reproxalap. As part of the potential NDA resubmission, the FDA could require additional studies or clinical trials, and the submission of the results of those studies or clinical trials before a potential NDA resubmission will be reconsidered, which would require us to expend more resources than we planned or that are available to us, and could substantially delay acceptance and/or approval, if any, of a potential NDA resubmission. Any such requirement would increase our costs and delay approval and commercialization of reproxalap for the treatment of dry eye disease and would have a material adverse effect on our business and financial condition. Additionally, the FDA has substantial discretion in the approval process and may disagree with our interpretation of or the sufficiency of the data from our clinical trials. Clinical trial results frequently are susceptible to varying interpretations and regulatory authorities may disagree on what are appropriate methods for analyzing data, which may delay, limit or prevent regulatory approvals. There can be no assurance that a potential NDA resubmission to the FDA will be accepted or approved in a timely manner or at all. If marketing approval for reproxalap is delayed, limited or denied, our ability to market reproxalap, and our ability to generate product sales, would be adversely affected. Even if reproxalap is approved for the treatment of dry eye disease, the FDA may limit use to certain patient populations, include extensive warnings on the product labeling, or require costly ongoing requirements for post-marketing clinical studies and surveillance or other risk management measures to monitor the safety or efficacy of reproxalap.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approval of reproxalap, once obtained, may be withdrawn. Ultimately, the failure to obtain and maintain regulatory approvals would prevent reproxalap from being marketed and would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the Option is not exercised by AbbVie and we remain responsible for funding further development and commercialization of reproxalap, we may be unable to raise the additional capital required to further develop and commercialize reproxalap or enter into a collaboration agreement with another pharmaceutical company with equivalent or comparable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the exclusive option (the Option) to enter into the Co-Development, Co-Commercialization and License Agreement (the Collaboration Agreement) is not exercised by AbbVie Inc. (AbbVie), pursuant to the exclusive option agreement with AbbVie, we will be responsible for funding further development and commercialization of reproxalap, and may be unable to raise the additional capital required to further develop and commercialize reproxalap or enter into a collaboration agreement with another pharmaceutical company with equivalent or comparable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs and reproxalap commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to continue the development and commercialization of reproxalap on our own, we may need to build its marketing, sales, distribution, managerial and other non-technical capabilities to commercialize reproxalap or make arrangements with third parties to perform these services. The establishment and development of our own sales force or the establishment of a contract sales force to market reproxalap would be expensive and time-consuming and could delay any commercial launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We would have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. We would also face competition in its search for third parties to assist it with the sales and marketing efforts of reproxalap.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the Option is exercised and the Collaboration Agreement is executed, then pursuant to the terms of the Collaboration Agreement, we would work closely with AbbVie to execute a commercialization plan for reproxalap in the United States, and this commercialization plan may never achieve its desired outcomes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Collaboration Agreement, we would work with AbbVie to execute a joint commercialization plan for reproxalap in the United States, and execute upon the commercialization plan with the intention to optimize the commercial potential of reproxalap. If this collaboration is not successful, then our business, financial condition, and results of operations could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to develop and commercialize other product candidates, we may be unable to grow our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our growth strategy, we plan to evaluate the development and commercialization of other therapies related to immune-mediated and metabolic diseases. We will evaluate internal opportunities from our compound libraries, and also may choose to continue to in-license or acquire other product candidates, as well as commercial products, to treat patients suffering from immune-mediated and metabolic disorders with high unmet medical needs and limited treatment options. These other product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials, and approval by the FDA and/or applicable foreign regulatory authorities. In-licensed product candidates may have been unsuccessfully developed by others in indications similar to those that we may pursue. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and/or effective for approval by regulatory authorities. For example, in June 2023, we received a Complete Response Letter from the FDA regarding our NDA for ADX-2191 for the treatment of primary vitreoretinal lymphoma (the ADX-2191 Complete Response Letter). The ADX-2191 Complete Response Letter stated that there was a &#8220;lack of substantial evidence of effectiveness&#8221; due to &#8220;a lack of adequate and well-controlled investigations&#8221; in the literature-based NDA submission. In light of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA&#8217;s ADX-2191 Complete Response Letter, we halted pre-commercial activities related to ADX-2191 for the treatment of primary vitreoretinal lymphoma. In January 2024 we de-prioritized the previously announced programs of ADX-629 in chronic cough and idiopathic nephrotic syndrome due to regulatory and trial feasibility challenges, respectively. Additionally, in the three months ended March 31, 2024, we deprioritized ADX-2191 for the treatment of proliferative vitreoretinopathy and primary vitreoretinal lymphoma due to the requirement from the FDA to run clinical trials that we did not deem to be feasible. If marketing approval for our other product candidates is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected. Such a delay could occur because a competitor product is approved before our product and secures patent protection, market exclusivity, or both, and thereby precludes our product approval for a number of years. It is also possible that additional studies or clinical trials may not suffice to make our application approvable. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, adequately priced, successfully commercialized, or widely accepted in the marketplace or be more effective than other commercially available alternatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any termination or suspension of, or delays in the commencement or completion of, our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue, and adversely affect our commercial prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in the commencement or completion of our ongoing or planned clinical trials for our product candidates could significantly affect our product development costs and timeline. We do not know whether future trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">public health epidemics or pandemics or responses thereto;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, or an institutional review board, or IRB, failing to grant permission to proceed or placing a clinical trial on hold; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjects failing to enroll or remain in our clinical trials at the rate we expect; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue the clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjects experiencing severe, serious, or unexpected drug-related adverse effects, whether drug-related or otherwise; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a facility manufacturing our product candidates, or drug product components being ordered by the FDA or other government or regulatory authorities to temporarily or permanently shut down due to violations of cGMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any changes to our manufacturing process that may be necessary or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to timely manufacture sufficient quantities of the applicable product candidate for a clinical trial or expiration of materials intended for use in a clinical trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, cGMP, or regulatory requirements, or other third parties not performing data collection or analysis in a timely or accurate manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inspections of clinical trial sites by the FDA or the finding of regulatory violations by the FDA or IRB, that require us or others to undertake corrective action, result in suspension or termination of one or more sites or the imposition of a clinical hold in part or on the entire trial, or that prohibit us from using some or all of the data in support of our marketing applications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in shipment of clinical trial material reaching clinical sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one or more IRBs refusing to approve, suspending, or terminating the trial at an investigational site; precluding enrollment of additional subjects; or withdrawing its approval of the trial. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product development costs will increase if we have delays in testing or approval of our product candidates or if we need to perform more, larger, or longer clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur and we or our partners may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing, or successful completion of a clinical trial. If we experience delays in completion of, or if we, the FDA, or other regulatory authorities, the IRB, other reviewing entities, or any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for a product candidate may be harmed and our ability to generate product revenues, if any, will be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, if one or more clinical trials are delayed, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reproxalap and our other product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays, or prevent the receipt of the required approvals to commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing, and distribution of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive and time-consuming, and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indication, and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit, or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval, and subsequent commercial success is uncertain and not guaranteed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reproxalap and our other product candidates, and the activities associated with development and commercialization, including testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ongoing research and development activities and planned clinical development and commercialization for our product candidates may be delayed, modified, or ceased for a variety of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining that a product candidate is ineffective or potentially causes harmful side effects during preclinical studies or clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse events which had initially been considered unrelated to the product candidate may later, even following approval and/or commercialization, be found to be caused by the product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty establishing predictive preclinical models for demonstration of safety and efficacy of a product candidate in one or more potential therapeutic areas for clinical development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patients in our clinical trials may demonstrate greater response rates or improvements from vehicle or standard of care than was expected when designing and powering our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of availability of, or difficulty recruiting and retaining, a sufficient number of patients to adequately power our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in manufacturing a product candidate, including the inability to manufacture a product candidate in a sufficient quantity, suitable form, or in a cost-effective manner, or under processes acceptable to the FDA for marketing approval or commercial sale; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proprietary rights of third parties, which may preclude us from developing or commercializing a product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining that a product candidate may be uneconomical for us to develop or commercialize, or may fail to achieve market acceptance or adequate pricing or reimbursement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining that one or more clinical trials that may be required for approval of a product candidate was or would not be feasible;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our expenses and revenue, the sufficiency or use of our cash resources, and needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a safety concern or signal may arise that triggers a clinical hold;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any negative results or perceived negative results in clinical trials for one indication may have an adverse effect on our ability to develop and potentially commercialize reproxalap or our other product candidates for the treatment of another indication;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to secure strategic partners which may be necessary for advancement of a product candidate into clinical development or commercialization; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our prioritization of other indications or product candidates for advancement. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit, or deny approval of a product candidate for many reasons, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with the design, conduct, or implementation of our or any of our future development partners&#8217; clinical trials, including the endpoints of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may require clinical data in addition to clinical trial programs we expect, or may require changes to the designs and endpoints of subsequent clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a competitor product may have patent protection or another type of market exclusivity that delays approval of our product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a product candidate is safe and effective for any indication; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may not accept clinical data from trials if conducted at clinical facilities or in countries where the standard of care is potentially different from the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials or the design of such trials or require additional trials and data; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the leadership or operation of such authorities, which may result in, among other things, the implementation of new standards, or changes to the interpretation or enforcement of existing regulatory standards and requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we or any of our future development partners contract for clinical and commercial supplies; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies, standards, or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods, and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates. Moreover, we cannot predict healthcare reform initiatives, including potential reductions in federal funding or insurance coverage, that may be adopted in the future and whether or not any such reforms would have an adverse effect on our business and our ability to obtain regulatory approval for our current or future product candidates. There are evolving legal requirements that will continue to affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because the Company has no experience in commercializing pharmaceutical products, there is a limited amount of information about us upon which to evaluate our product candidates and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet demonstrated an ability to successfully overcome many of the pre-commercial and commercial risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan we will need to successfully:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">execute our product candidate development activities, including successfully designing and completing our clinical trial programs and product design and formulation of future product candidates, in a cost- effective manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">file for and obtain required regulatory approvals for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enter into a collaboration agreement with a suitable third party on acceptable terms for the commercialization of reproxalap;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manage our spending as costs and expenses increase due to the performance and completion of clinical trials, attempting to obtain regulatory approvals, manufacturing, and commercialization; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">secure substantial additional funding; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop and maintain successful strategic relationships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">build and maintain a strong intellectual property portfolio; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">build and maintain appropriate clinical, regulatory, quality, manufacturing, compliance, sales, distribution, and marketing capabilities on our own or through third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">implement and maintain operational, financial, and management systems;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">price our product candidates, if approved, at expected levels and obtain and maintain sufficient insurance and reimbursement from insurers and other payors; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gain broad market acceptance for our product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, raise capital, expand our business, or continue our operations. Further, even if we are successful in clinical trials of product candidates, we may choose to place further development or commercialization on hold given perceived marketing challenges or the relative differences in commercial attractiveness within our portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The results of preclinical studies and earlier clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug development has inherent risk. We or any of our future development partners will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in their target indications before we can seek regulatory approvals for their commercial sale. Drug development is a long, expensive, and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials. Any negative results or perceived negative results in clinical trials for one indication may have an adverse effect on our ability to develop and potentially commercialize reproxalap or our other product candidates for the treatment of another indication. In addition, as product candidates proceed through development, the trial designs may often be different and may need to evolve and change from phase to phase or within the same phase or same trial, as is the case for adaptive trials; the vehicles or controls may be modified from trial to trial; and the product formulations or manufacturing process may differ due to the need to test product candidate samples that can be manufactured on a commercial scale. Success in run-in cohorts, earlier clinical trials, or clinical trials focused on a different indication does not mean that later clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through other phases of clinical testing. In addition, discussions with regulatory bodies, such as the FDA, may lead to changes in trial designs or programs. Companies frequently suffer significant setbacks in advanced clinical trials, even after run-in cohorts or earlier clinical trials have shown promising results. For example, the results of the TRANQUILITY Trial of reproxalap in dry eye disease did not reflect the results of the TRANQUILITY run-in cohort. Moreover, only a small percentage of drugs under development result in the submission of an NDA to the FDA and even fewer are approved for commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we are developing novel product candidates for the treatment of diseases in a manner which there is little clinical drug development experience and, in some cases, are designing adaptive trials or using new endpoints or methodologies, the regulatory pathways for approval are not well defined, and, as a result, there is greater risk that our clinical trials will not result in our desired outcomes or require additional trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical focus is on the development of new products for immune-mediated and metabolic diseases. We performed an adaptive trial in proliferative vitreoretinopathy, the GUARD trial, and may do so with other indications in the future. In an adaptive trial, the initial parts of the trial are not designed to be pivotal or definitive. Rather, the initial parts of adaptive trials are expected to provide data to guide subsequent parts of the trial, which could require design changes, including but not limited to, different endpoints. In addition, following the initial parts of adaptive trials, we may, among other things, decide to continue to the subsequent parts of the trial, conclude the trial based on its success or failure in such initial parts, or discuss the trial results and regulatory pathway with regulatory authorities prior to determining next steps with respect to the trial and development program. As such, the likelihood of success in our late-stage clinical programs cannot necessarily be predicted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could also face challenges in designing clinical trials and obtaining regulatory approval of our product candidates due to the lack of historical clinical trial experience for novel classes of therapeutics. Thus, it is difficult to determine whether regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">agencies will be receptive to the approval of our product candidates, and to predict the time and costs associated with obtaining regulatory approvals. The clinical trial requirements of the FDA and other regulatory agencies and the criteria regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and require more time and trial data than for other, better known, or more extensively studied classes of product candidates. In addition, it is possible that, as regulatory bodies gain more familiarity with our type of product candidates by reviewing competitor candidates, those agencies could impose new conditions on our product candidates that we did not expect. Any inability to design clinical trials with protocols, methodology, and endpoints acceptable to applicable regulatory authorities, and to obtain regulatory approvals for our product candidates, would have an adverse impact on our business, prospects, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because some of our product candidates are, to our knowledge, new chemical entities, it is difficult to predict the time and cost of development and our ability to successfully complete clinical development of these product candidates and obtain the necessary regulatory approvals for commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our product candidates are, to our knowledge, new chemical entities, and unexpected problems related to new technologies may arise that can cause us to delay, suspend, or terminate our development efforts. As a result, short and long-term safety, as well as prospects for efficacy, are not fully understood and are difficult to predict. Regulatory approvals of new product candidates can be more expensive and take longer than approvals for well-characterized or more extensively studied pharmaceutical product candidates. Following discussions with the FDA and experts in the field, we may determine that it is not cost effective for us to develop one or more of our products in certain indications or we may decide to cease development in that area or seek a strategic partner.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to qualify for or obtain various designations from regulators that would have the potential to expedite the review process of one or more of our product candidates, and even if we do receive one or more of such designations there is no guarantee that they will ultimately expedite the process, or aid in our obtaining marketing approval or provide market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There exist several designations that we can apply for from the FDA and other regulators that would provide us with various combinations of the potential for expedited regulatory review, certain financial incentives as well as the potential for post-approval exclusivity for a period of time. These designations include but are not limited to orphan drug designation, breakthrough therapy designation, accelerated approval, fast track status, and priority review for our product candidates. We may seek one or more of these designations for our current and future product candidates. For example, ADX-2191 has received orphan designation for the treatment of retinitis pigmentosa. There can be no assurance that any of our other product candidates will qualify for any of these designations. There can also be no assurance that any of our product candidates, that do qualify for these designations, will be granted such designations or that the FDA will not revoke such a designation it grants at a later date. Further, there can be no assurance that any of our product candidates that are granted such designations will ever benefit from such designations or that the FDA would not withdraw such designations once granted. Were we to receive a designation that promised a period of market exclusivity, such as orphan drug exclusivity, such exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Further, with respect to orphan drug status, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">To preserve trial integrity, clinical data from the initial parts of adaptive clinical trials may not be disclosed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive clinical trials are often performed such that the initial parts of the trial are used to determine sample size and endpoints for subsequent, possibly pivotal parts of the trial. Results from the initial parts of adaptive trials are therefore not designed to be pivotal or definitive, and, in some cases, detailed trial data may not be disclosed so as not to positively or negatively bias investigators or patients involved in subsequent parts of the trial. Further, the initial parts of adaptive trials may be performed in part to assess biomarkers or surrogate markers that may require substantial time to generate, analyze, and interpret. Thus, disclosure of clinical results from the initial parts of adaptive trials may also be delayed due to the time required for biomarker or surrogate marker assessment.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may find it difficult to enroll patients in our clinical trials or identify patients during commercialization (if our products are approved by regulatory agencies) for product candidates addressing orphan or rare diseases.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As part of our business strategy, we have and continue to evaluate the development and commercialization of product candidates for the treatment of orphan and other rare diseases, including Sj&#246;gren-Larsson and retinitis pigmentosa. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients willing and able to participate in the clinical trials required by the FDA or other non-United States regulatory agencies. In addition, if others develop</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products for the treatment of similar diseases, we would potentially compete with them for the enrollment in rare patient populations, which may adversely impact the rate of patient enrollment in and the timely completion of our current and planned clinical trials. Any negative results or perceived negative results in clinical trials of our product candidates may make it difficult or impossible to recruit or retain patients in other clinical trials of the same product candidate. Insufficient patient enrollment may be a function of other factors, including the size and nature of the patient population, the nature of the protocol, the proximity of patients to clinical sites, the timing and magnitude of disease symptom presentation, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. Our inability to identify and enroll a sufficient number of eligible patients for any of our current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials or development program. Public health epidemics or pandemics and the response thereto may have an impact on our ability to enroll and retain patients in our clinical trials. For instance, patient enrollment in our GUARD trial of ADX-2191 in proliferative vitreoretinopathy was negatively impacted as a result of limited clinical trial staffing at trial sites and some patients electing to delay surgery. Delays in patient enrollment in the future as a result of these and other factors may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent us from completing these trials and adversely affect our ability to advance the development of our product candidates. For instance, in rare diseases such as proliferative vitreoretinopathy and idiopathic nephrotic syndrome, lack of availability of, or difficulty recruiting or retaining a sufficient number of, patients may make it difficult or cost-prohibitive to sufficiently power our clinical trials, which may not enable us to continue development and seek regulatory approval for the applicable product candidate. Further, if our products are approved by regulatory agencies, we may not be able to identify sufficient number of patients to generate significant revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate we or any of our future development partners advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent its regulatory approval or commercialization or limit its commercial potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unacceptable adverse events caused by any of our product candidates that we or others advance into clinical trials could cause us or regulatory authorities to interrupt, delay, or halt clinical trials, or impose a clinical hold, potentially resulting in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications and markets. This in turn could prevent us from completing development or commercializing the affected product candidate and generating revenue from its sale.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to develop our product candidates for the treatment of the indications for which we intend to seek approval, and we currently do not know the full extent of adverse events that will be observed in subjects that receive any of our product candidates. If any of our product candidates cause unacceptable adverse events in clinical trials, which may be larger or longer than those previously conducted, we may not be able to obtain regulatory approval or commercialize such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain marketing approval for reproxalap or any other product candidate, it could be subject to restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies or clinical trials, post-market surveillance, or other potential additional clinical trials. Following approval, if any, of reproxalap or any other product candidate, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping, and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements, including those relating to quality control, quality assurance, and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated seriousness, severity, or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or the manufacturing facilities for reproxalap or any other product candidate that may receive regulatory approval, if any, fail to comply with applicable regulatory requirements, a regulatory agency may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue warning letters or untitled letters; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any ongoing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve pending applications or supplements or applications filed by us; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain products, refuse to permit the import or export of product, or request us to initiate a product recall. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has the authority to require a risk evaluation and mitigation strategy (REMS) plan as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if reproxalap or any of our other product candidates is approved, its product labeling, advertising, and promotion would be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The government has also entered into consent decrees and Corporate Integrity Agreements under which specified promotional conduct is changed or curtailed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for reproxalap or any other product candidate, we or are partners, if any, still may not be able to successfully commercialize, and the revenue that we generate from its sales, if any, could be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, or the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, is also generally necessary for commercial success. In addition, we or are partners, if any, may not be able to secure advantageous contracts with payors or price our products at the expected level or at levels that make successful commercialization viable. The pricing of our products will be subject to numerous factors, many of which are outside of our control, including the pricing of similar products. The degree of market acceptance of our product candidates will depend on a number of factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstration of clinical efficacy and safety compared to other more-established products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the limitation of our targeted patient populations and other limitations or warnings contained in any FDA-approved labeling; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of a new formulations by health care providers and their patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence, seriousness, and severity of any adverse effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">new procedures or methods of treatment that may be more effective in treating conditions for which our products are intended to treat; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the safety of product candidates seen in a broader patient group, including their use outside the approved indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing and cost-effectiveness, including the cost of treatment in relation to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain sufficient, commercially advantageous, and timely third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of adverse events; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable publicity; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because the active ingredient of ADX-2191 (methotrexate) is a generic drug, a generic manufacturer may be able to develop and market a competitive intravitreal formulation of methotrexate following expiration of commercial exclusivity mandated via certain orphan drug designations. Generic drug competition would have a material and adverse effect on the commercial potential of ADX-2191. Further, our ability to successfully commercialize ADX-2191, if approved, depends on a number of additional factors, including but not limited to, the level of enforcement by the FDA to ensure that compounded copies of commercially available FDA-approved products manufactured by compounding pharmacies, including compounded copies of ADX-2191, that may be in violation of the federal Drug Quality and Security Act (DQSA) and other relevant provisions of the United States Federal Food, Drug, and Cosmetic Act (FDCA), are not produced and dispensed to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect that ongoing initiatives in the United States will increase pressure on drug pricing. Such reforms could have an adverse effect on the pricing of and anticipated revenues from our current or future product candidates for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors, or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our or our partners&#8217; efforts to educate the medical community and third-party payors on the benefits of reproxalap or any of our other product candidates may require significant resources and may never be successful. In addition, our or our partners&#8217; ability to successfully commercialize our product candidate will depend on our ability to manufacture our products, differentiate our products from competing products and defend the intellectual property of our products. Competitors with numerous approved products may be able to negotiate</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing and reimbursement that is substantially more advantageous than that which we will be able to negotiate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if any of our competitors&#8217; products are approved and are unable to gain market acceptance for any reason, there could be a market perception that products such as reproxalap are not able to adequately meet an unmet medical need. If we or our partners, if any, are unable to demonstrate to physicians, hospitals, third-party payors, or patients that our products are better alternatives, we or our partners, if any, may not be able to gain market acceptance for our products at the levels we anticipate and our business may be materially harmed as a result.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for reproxalap and our other product candidates are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenues may be adversely affected and our business may suffer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We focus our research and product development on treatments for immune-mediated and metabolic diseases. Our estimated addressable markets and market opportunities for our product candidates are based on a variety of inputs, including data published by third parties, our own market insights and internal market intelligence, and internally generated data and assumptions. We have not independently verified any third-party information and cannot be assured of its accuracy or completeness. Our projections of both the number of people who have diseases in our target markets, as well as the subset of people with diseases who have the potential to benefit from treatment with our product candidates, are based on estimates that have been derived from a variety of sources, including scientific literature, surveys of clinics, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of diseases in our target markets. The number of patients may turn out to be lower or more difficult to identify than expected. In addition, our product candidates may not achieve commercial success due to market conditions or regulatory challenges.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these factors may negatively affect our ability to generate revenues from sales of our product and our ability to achieve and maintain profitability, and as a consequence, our business may suffer. In addition, these inaccuracies or errors may cause us to misallocate capital and other critical business resources, which could harm our business.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate insurance coverage and reimbursement from third-party payors for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. The reimbursement levels may be significantly less than the currently anticipated pricing of our product candidates. As a result of negative trends in the general economy in the United States or other jurisdictions in which we may do business, government authorities or third-party payors may be unable to satisfy reimbursement obligations or may delay payment. Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#8217;s determination that use of a product candidate is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective, and medically necessary; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective, including cost effectiveness relative to existing contracts with other pharmaceutical companies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical, and cost effectiveness data for the use of the applicable product candidate to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved. In recent years, through legislative and regulatory actions, the federal government has made substantial changes to the United States healthcare system, including changes to the methods for, and amounts of, Medicare reimbursement. Many members of the United States Congress have attempted to repeal and replace the Patient Protection and Affordable Care Act (PPACA), but they have been unsuccessful in doing so as of the date of the filing of this report. We cannot predict the ultimate form or timing of any repeal or replacement of PPACA or the effect such repeal or replacement would have on our business. Regardless of the impact of repeal or replacement of PPACA on us, the government has shown significant interest in pursuing healthcare reform and reducing healthcare costs. These reforms could significantly reduce payments from Medicare and Medicaid over the next ten years. Reforms or other changes to these payment systems, including modifications to the conditions on qualification for payment, bundling of payments, or the imposition of enrollment limitations on new providers, may change the availability, methods, and rates of reimbursements from Medicare, private insurers, and other third-party payers for our current and future product candidates, if any, for which we are able to obtain regulatory approval. Some of these changes and proposed changes could result in reduced reimbursement rates for such product candidates, if approved, which would adversely affect our business strategy, operations, and financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of legislative proposals and the trend toward managed health care in the United States, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. Payors may also refuse to provide coverage of approved product candidates for medical indications other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for use of newly approved drugs, which in turn could lower drug pricing. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, larger companies contracting with payors to diminish reimbursement for competitive products, and additional legislative proposals as well as country, regional, or local healthcare budget limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of manufacturing our products is complex, highly regulated, and subject to several risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing of compounds is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our contract manufacturers must comply with the cGMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance, and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our products, including leading to significant delays in the availability of products for our clinical trials, the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could damage our reputation or impair our ability to develop and commercialize our products. If we are not able to maintain regulatory compliance, we may not be permitted to market our products and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. Quality issues may arise during scale-up activities. Our reliance on a limited number of Contract Manufacturing Organizations (CMOs), the complexity of drug manufacturing and the difficulty of scaling up a manufacturing process could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, and cause us to incur higher costs and prevent us from commercializing our product candidates successfully. Furthermore, if our CMOs fail to deliver the required commercial quality and quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement CMOs capable of production in a timely manner at a substantially equivalent cost, then testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. In addition, failure of CMOs to comply with regulatory and quality requirements could delay manufacturing or the review of our marketing applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any adverse developments affecting manufacturing operations for our products, including public health epidemics or pandemics or responses taken thereto, may result in shipment delays; inventory shortages; lot failures; product withdrawals, recalls, approvals; or other interruptions in the supply of our products. We may also have to account for inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends upon the quality of our products. Quality controls, assurance, and management plays an essential role in meeting customer requirements, preventing defects, improving our product candidates and services, and assuring the safety and efficacy of our product candidates. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in adverse inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations, or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our future products, which may result in difficulty in successfully launching product candidates and the loss of sales, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our competitors develop treatments for the target indications of our product candidates that are approved more quickly than ours, marketed more successfully, or demonstrated to be safer or more effective than our product candidates, our commercial opportunity will be reduced or eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in highly competitive segments of the biotechnology market. We face competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies, and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies (including generic and over-the-counter drugs) as well as with new treatments that may be introduced by our competitors. With the exception of proliferative vitreoretinopathy and retinitis pigmentosa, there are a variety of approved drugs and drug candidates in development for the indications that we intend to test. Current treatments that are used in the United States for dry eye disease include over the counter artificial tears, Restasis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Xiidra</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Cequa</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Eysuvis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Tyrvaya</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Miebo</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and Vevye</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In February 2022, the FDA approved the first generic version of Restasis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which is now available for sale in the U.S. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and commercial and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering subjects for clinical trials, and in identifying and in-licensing new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Other parties may discover and patent treatment approaches and compositions that are similar to or different from ours. Competition in drug development is intense. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success depends on our or our partners&#8217; ability to demonstrate and maintain a competitive advantage with respect to the design, development, and commercialization of reproxalap or our other product candidates. Inflammatory and metabolic diseases may be treated with a variety drugs, some of which are generic. Our potential competitors may be developing novel therapies that may be safer or more effective than our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to enter into agreements with third parties to market, sell, and distribute our product candidates, we may be unable to generate any revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no experience as a Company in the sale, marketing or distribution of biopharmaceutical products. Although we currently plan to commercialize reproxalap through a collaboration with a third party, if reproxalap or any of our other product candidates ultimately receives regulatory approval and we remain responsible for the commercialization of such approved product, we may not be able to effectively market and distribute the product candidate. We will have to invest significant amounts of financial and management resources to develop and maintain internal sales, distribution, and marketing capabilities, some of which will be committed prior to any confirmation that the applicable product candidates will be approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in entering into arrangements with third parties to market and sell our product candidates or may be unable to do so on terms that are acceptable to us. Any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data or market exclusivity before approving generic versions of our product candidates, the sales of our product candidates could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an NDA is approved, the drug covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations.&#8221; Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications (ANDAs) in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials demonstrating safety and efficacy. Rather, the applicant generally must show that its drug is pharmaceutically equivalent to the reference listed drug, in that it has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug, and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic drugs may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic drugs are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">generally able to offer drug products at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity, enforceability or non-infringement. The FDCA also provides three years of marketing exclusivity for a 505(b)(1) NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations other than bioavailability studies (e.g., investigations that support new indications, dosages, or strengths of an existing drug) were conducted or sponsored by the applicant and are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving competitor products for product candidates containing the original active agent for other conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full 505(b)(1) NDA. Manufacturers may seek to launch these generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for our drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU and the UK, innovative medicinal products are authorized based on a full marketing authorization application (as opposed to an application for marketing authorization that relies on data in the marketing authorization dossier for another, previously approved medicinal product). Applications for marketing authorization for innovative medicinal products must contain the results of pharmaceutical tests, preclinical tests, and clinical trials conducted with the medicinal product for which marketing authorization is sought (and where applicable the result of the pediatric studies unless a waiver or a deferral has been obtained - as described further below). In the EU, these applications must be made pursuant to either Directive 2001/83/EC (for the decentralized procedure or the mutual recognition procedure) or Regulation 726/2004 (for the centralized procedure). In the UK, there are various procedures available under the new regulatory legal framework to pharmaceutical products, including the possibility of a recognized assessment conducted by the European authorities under certain circumstance or by applying directly to the UK regulatory authority (MHRA).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where an applicant for a marketing authorization submits a full dossier containing its own pharmaceutical, pre-clinical tests and clinical trials data, and where the application does not fall within the "global marketing authorization" of an existing medicinal product, the applicant is entitled to eight years of regulatory data protection upon grant of the marketing authorization (the period starts to run from the first marketing authorization in the EU/ European Economic Area (EEA)). During this period, applicants for approval of generics or biosimilars cannot rely on data contained in the marketing authorization dossier submitted for the already authorized, or reference, medicinal product to support their application. After the expiration of the eight-year period of regulatory data protection, the reference medicinal product benefits from a further two-year period of marketing protection. During these two years of marketing protection, no generic or biosimilar medicinal product that relies upon the reference medicinal product&#8217;s dossier may be placed on the EU market, but a generic or biosimilar marketing authorization application can be submitted to the competent regulatory authorities in the EU Member States during this time. The two-year period of marketing protection can further be extended by one year if, during the first eight years of the grant of the first marketing authorization, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, even if a compound is considered to be a new active substance and the innovator is able to gain the period of regulatory data protection and marketing protection, provided that no other IP or regulatory exclusivities applied, another unrelated company could also apply for a marketing authorization and market another competing medicinal product for the same therapeutic indication if such company obtained its own marketing authorization based on a separate marketing authorization application based on a full self-standing scientific data package supporting the application. The period of regulatory data protection and marketing protection applies in the UK (running from the date of the first authorization in Great Britain).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, pursuant to Regulation 1901/2006, and in the UK pursuant to the Human Medicines Regulations 2012 (as amended), marketing authorization applications must include pediatric data based on pediatric investigation plans agreed with the EMA if the MAA concerns (i) a new active substance, or (ii) a new indication, pharmacological form, or route of administration (where the product is protected by a supplementary protection certificate or a patent qualifying for a supplementary certificate). Applicants may obtain waivers or deferrals to these requirements in certain circumstances (for example a waiver may be obtained if the condition only occurs in adult populations). Where required, pediatric studies must cover all sub-sets of the pediatric population for both existing and new indications, pharmacological forms and route of administrations. Limited further exclusions apply, including in relation to generic or biosimilar applications. Certain rewards may be available for completion of pediatric studies. For example, where MAAs include the results of all studies conducted in compliance with an agreed pediatric investigation plan, the holder of the patent or supplementary protection certificate may be entitled to a six-month extension to the supplementary protection certificate.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to obtain orphan designation in the EEA, the product must fulfill certain challenging criteria. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; and (2) either the prevalence of such condition must not be more than five in 10,000 persons in the EU when the application is made, or without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Products receiving orphan designation in the EU may receive 10 years of orphan market exclusivity, which can be further extended by two years if pediatric studies have been conducted in accordance with an agreed pediatric investigational plan. Applications must first satisfy the orphan designation criteria and apply for orphan designation before making the application for marketing authorization. The applicant must then successfully maintain the orphan designation at the time of the marketing authorization application in order to qualify for 10 years of orphan market exclusivity. During this 10-year period, the competent authorities of the EU Member States and European Commission may not accept applications or grant marketing authorization for other similar medicinal products for the same orphan therapeutic indication. The protection afforded by orphan market exclusivity in the EU may, in some circumstances, be circumvented by competitor products which are demonstrated not to be "similar" or which are authorized for different therapeutic indications. There may be a risk that products may be prescribed "off-label" for the orphan therapeutic indication by healthcare professions in some EU Member States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are also three exceptions to the orphan market exclusivity principle. Marketing authorization may be granted to a similar medicinal product for the same orphan therapeutic indication if:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective, or otherwise clinically superior;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An orphan product can also obtain an additional two years of orphan market exclusivity in the EU if the marketing authorization application contains the results of all pediatric studies conducted in accordance with and agreed pediatric investigation plan. The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation (e.g., the product is sufficiently profitable not to justify maintenance of market exclusivity).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The UK&#8217;s regulatory legal framework provides for similar periods of protection, namely regulatory data protection, marketing protection and market exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is important to note that the regulatory protection afforded to medicinal product such as data exclusivity, marketing protection, market exclusivity for orphan indications, and pediatric extension are currently under review at EU level. It is expected that the protection currently afforded in the EU will be reduced in the years to come.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition that our product candidates may face from generic versions of our product candidates could materially and adversely impact our future revenue, profitability, and cash flows and could substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability, and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our product candidates, if and when approved, are not afforded the appropriate periods of non-patent exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA&#8217;s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels; ability to hire and retain key personnel; and statutory, regulatory, and policy changes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels; ability to hire and retain key personnel; and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positions could significantly impact the ability of the FDA and other agencies to fulfill their functions, and could greatly impact healthcare and the pharmaceutical industry.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2016, the 21</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Century Cures Act was signed into law, and was designed to advance medical innovation and empower the FDA with the authority to directly hire positions related to drug and device development and review. In the past, the FDA was often unable to offer key leadership candidates (including scientists) competitive compensation packages as compared to those offered by private industry. The 21</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">st</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Century Cures Act was designed to streamline the agency&#8217;s hiring process and enable the FDA to compete for leadership talent by expanding the narrow ranges that are provided in the existing compensation structures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other governmental agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our operating results and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing and commercializing our products abroad and may limit our ability to generate revenue from product sales.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to market and commercialize our product candidates internationally. To market and sell our product candidates in jurisdictions outside the United States, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Failure to obtain foreign regulatory approvals on a timely basis or non-compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our product candidates in certain countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any jurisdiction, which would materially impair our ability to generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The UK's exit from the EU continues to create political and economic uncertainty, particularly in the UK and the EU. The UK is now being treated as a "third country" by the EU and new UK legislation has taken effect. This means that some regulatory activities, such as batch testing and Qualified Person certification conducted in Great Britain is no longer recognized in the EU. However, the UK and EU have concluded a Trade and Cooperation Agreement (TCA), which has been approved by the UK Parliament, European Council and European Parliament and has limited the disruption to the supply of medicines, particularly by enabling tariff and quota-free trade between the UK and the EU (provided that the rules of origin requirements are met), and has streamlined some issues, for example by enabling mutual recognition of cGMP inspections and certificates. The regulatory framework for medicines that existed before the end of the transition period has also effectively been preserved in UK domestic legislation as "retained EU law." By retaining a snapshot of EU legislation at its core, the UK has prevented substantial divergence to the regulation of medicines (although divergence has appeared in some areas). However, some changes to the UK legislation have been immediately necessary, including the implementation of the Northern Ireland Protocol (NIP), pursuant to which, the EU pharmaceutical legal framework acquis continues to apply in Northern Ireland (subject to periodic consent of the Northern Ireland Legislative Assembly), and only products compliant with EU law can be placed in the Northern Ireland market - adding an extra layer of regulatory complexity. As companies now need to comply with a separate UK regulatory legal framework in order to commercialize medicinal products in Great Britain (namely, England, Wales and Scotland, as EU law continues to apply in Northern Ireland). The UK government is currently trying to renegotiate fundamental aspects of the NIP so this is an unpredictable area for companies in the near future. The TCA allows for future deviation from the current regulatory framework and it is not known if and/or when any deviations may occur, which may have an impact on development, manufacture, marketing authorization, commercial sales and distribution of pharmaceutical products. It is also important to note that obtaining a marketing authorization is not sufficient to gain effective access to the market in the EU and in the UK; companies still need to agree to a reimbursement price for the products and in some jurisdictions, such as the UK and Germany, a further positive recommendation from health technology on cost-effectiveness is required for the products to be actually prescribed and reimbursed by the respective national health systems (see below). If we fail to comply with the regulatory requirements in international markets and thus receive applicable marketing approvals, our target market will be reduced, our ability to realize the full market potential of our product candidates will be harmed and our business will be adversely affected. We may not obtain foreign regulatory approvals on a timely basis, if at all. Our failure to obtain approval of any of our product candidates by regulatory authorities in another country may significantly diminish the commercial prospects of that product candidate and our business prospects could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Financial Position and Capital Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant operating losses since inception and we expect to incur significant losses over the next several years. We may never become profitable or, if achieved, be able to sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since we were founded in 2004 and expect to incur significant losses for the next several years as we continue our clinical trial, development programs, and commercial activities for reproxalap and our other product candidates. Net loss for the three months ended June 30, 2024 and 2023 was approximately $16.8 million and $9.0 million, respectively. As of June 30, 2024, we had total stockholders&#8217; equity of $98.3 million and an accumulated deficit of $419.2 million. Losses have resulted principally from costs incurred in our clinical trials, research and development programs and from general and administrative expenses. In the future, we intend to continue to conduct research and development, clinical testing, regulatory compliance activities, pre-commercial activities, and, if reproxalap or any of our other product candidates is approved and we do not enter into collaboration agreements with third parties, commercialization efforts, including sales and marketing activities, that, together with anticipated general and administrative expenses, will likely result in our incurring further significant losses for the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our expenses will increase substantially as compared to prior periods as we prepare for commercializing of reproxalap alone or with others, if approved, and continue development of ADX-2191, ADX-248, ADX-743, ADX-631, and other product candidates, and as a result of increased headcount, including management personnel to support our clinical, manufacturing and commercialization activities, expanded infrastructure, increased legal, compliance, accounting and investor and public relations expenses associated with being a public company, and increased insurance premiums, among other factors. Our license agreement with Massachusetts Eye and Ear Infirmary, or MEEI, under which we license certain of our patent rights and a significant portion of the technology for ADX-2191, imposes royalty and other financial obligations on us, and we may enter into additional licensing and funding arrangements with third parties that may impose milestone payment, royalty, insurance and other obligations on us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenses will also increase if and as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek marketing approval for reproxalap and establish our sales, marketing and distribution capabilities for reproxalap in advance of and upon any such approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are unable to enter into a collaboration agreement with a suitable third party on acceptable terms for the commercialization of reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct any necessary clinical trials and other development activities and/or seek marketing approvals for ADX-2191,  ADX-248, ADX-743, ADX-631 and any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pursue the clinical development of reproxalap for the treatment of other additional indications or for use in other patient populations or, if approved, seek to broaden the label of reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scale up our manufacturing processes and capabilities to support commercialization of reproxalap and any of our other product candidates for which we seek and/or obtain marketing approval and for which we remain responsible for the commercialization of;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">leverage our RASP-modulator discovery platform to advance additional therapeutics into preclinical and clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in&#8209;license or acquire the rights to other products, product candidates or technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, quality control, scientific, manufacturing, commercial and management personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase our product liability insurance coverage as we initiate and expand our commercialization efforts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our sales, marketing and distribution capabilities for our other product candidates, prior to or upon receiving marketing approval;</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase from what we anticipate if:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we are required by the FDA or non&#8209;U.S. regulatory agencies to perform clinical trials or studies in addition to those expected;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are any delays in enrollment of patients in or completing our clinical trials or the development of our product candidates; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there are any third&#8209;party challenges to our intellectual property portfolio, or the need arises to defend against intellectual property&#8209;related claims.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to become and remain profitable depends on our ability to generate revenue. We currently generate no revenue from sales, and we may never be able to commercialize reproxalap or our other product candidates. We do not currently have the required approvals to market any of our product candidates and we may never receive them. We do not expect to generate revenue from sales of our product candidates that is sufficient to achieve profitability, excluding any upfront licensing fees we may receive, unless and until we obtain marketing approval for and commercialize one or more of our product candidates. We do not expect to commercialize reproxalap alone or with others or any of our other product candidates before at least the first half of 2025, if ever. Achieving profitability will require us or our partners, if any, to be successful in a range of challenging activities, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining marketing approval for reproxalap or any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing at commercial scale, marketing, selling and distributing those products for which we obtain marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entering into a collaboration agreement with a suitable third party on acceptable terms for the commercialization of reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hiring and building a full commercial organization required for the marketing, selling and distributing for those products which we obtain marketing approval and for which we remain responsible for the commercialization of;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving an adequate level of market acceptance of and obtaining and maintaining coverage and adequate reimbursement from third&#8209;party payors for any products we commercialize; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining and protecting our intellectual property rights.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may never succeed in these activities and may never generate revenue that is sufficient to achieve profitability. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require substantial additional financing, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of biopharmaceutical products is capital intensive. We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we seek marketing approval and prepare for commercialization of reproxalap alone or with others, and continue the development of our product candidates through preclinical and clinical development, including multiple ongoing and planned clinical trials for our product candidates. We expect our expenses to increase in connection with our ongoing activities, particularly as we prepare for commercializing reproxalap alone or with others, if approved, and we continue the research and development of, and, if successful, seek marketing approval for, our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently plan to commercialize reproxalap through a collaboration with a third party. If we do obtain marketing approval for reproxalap and are not able to establish a suitable collaboration for the commercialization of reproxalap, or any other product candidate that we develop, we expect to incur significant additional commercialization expenses related to product sales, marketing, distribution and manufacturing. We may also need to raise additional funds sooner if we choose to pursue additional indications for our product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed on attractive terms, if at all, we will be forced to delay, reduce, or eliminate certain of our clinical development plans, research and development programs or future commercialization efforts. In addition, there can be no assurance that we will be able to obtain such financing on commercially reasonable terms or at all. The development process for our product candidates is highly uncertain, and we cannot estimate with certainty the actual amounts necessary to successfully complete the development, regulatory approval, and commercialization of our product candidates for which we remain responsible for the commercialization of. Our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than expected, through public or private equity,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">debt financings, or other sources. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of reproxalap, including any additional trials the FDA or other regulatory agencies may require for approval or label expansion;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, costs and results of any clinical activities for regulatory review of reproxalap outside of the United States;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the exercise, if any, of the Option;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of process development and manufacturing scale&#8209;up activities associated with reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of commercialization activities for reproxalap if we receive marketing approval and if we are unable to enter into a collaboration agreement with a suitable third party on acceptable terms for the commercialization of reproxalap, and pre&#8209;commercialization costs for reproxalap or any other product candidates incurred prior to receiving, any such marketing approval, including the costs and timing of establishing product sales, marketing, distribution and outsourced manufacturing capabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assuming receipt of marketing approval, the amount of revenue received from commercial sales of reproxalap or any other product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of establishing collaborations, license agreements, and other partnerships on terms favorable to us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the type, number, scope, progress, expansion costs, results, and timing of our clinical trials of any product candidates that we are pursuing or may choose to pursue in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs associated with any other product candidates that we may develop, in-license, or acquire, including potential milestone or royalty payments; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of obtaining, maintaining, and enforcing our patents and other intellectual property rights. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of these factors are outside of our control. Our existing capital resources are not sufficient to enable us to fund the commercialization of reproxalap and completion of our clinical trials and remaining development through commercial introduction for our product candidates. We expect that we will need to raise substantial additional funds in the near future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings, including debt financings. The state of the global economy and market instability has made the business climate volatile and more costly. Uncertain economic conditions, uncertainty as to the general direction of the macroeconomic environment, and the price of our common stock, are beyond our control and may make any necessary debt or equity financing more difficult, more costly, and more dilutive. For example, the capital and credit markets may be adversely affected by the ongoing conflicts in Ukraine and Israel and the surrounding areas, the possibility of wider regional or global conflicts, and global sanctions imposed in response thereto. A severe or prolonged economic downturn, such as a global financial crisis, could affect our ability to raise additional capital. Additional funding may not be available to us on acceptable terms, or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders or be excessively dilutive. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay, reduce or discontinue our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates or curtail, delay, or discontinue one or more of our preclinical studies, clinical trials or other research or development programs. We may also be unable to expand our operations or otherwise capitalize on our business opportunities, may need to restructure our organization, or may be required to relinquish rights to our product candidates or other technologies, or otherwise agree to terms unfavorable to us. Any of these occurrences could materially affect our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our quarterly operating results may fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments affecting reproxalap and our other product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our establishment and maintenance of a sales, marketing and distribution infrastructure and outsourced manufacturing capabilities to commercialize any product candidate for which we may obtain marketing approval and for which we remain responsible for commercialization of;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in the level of expenses related to our clinical trial and development programs; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addition or termination of clinical trials or development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any intellectual property infringement lawsuit in which we may become involved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the exercise, if any, of the Option; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to negotiate and enter into a collaboration agreement with a suitable third party on acceptable terms for the commercialization of reproxalap;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our execution of any collaborative, licensing, or similar arrangements, and the timing of payments we may make or receive under these arrangements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of administrative, clinical, regulatory, and scientific personnel we engage; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nature and terms of stock-based compensation grants; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derivative instruments recorded at fair value. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to stockholders, restrict our operations, or require us to relinquish rights to its technologies or product candidates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and marketing and distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market on our own.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may allocate our cash, cash equivalents, and marketable securities in ways that you or other stockholders may not approve.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management has broad discretion in the application of our cash, cash equivalents, and marketable securities. Because of the number and variability of factors that will determine our use of our cash, cash equivalents, and marketable securities, management&#8217;s ultimate use of cash, cash equivalents, and marketable securities may vary substantially from the currently intended use. Our management might not apply our cash, cash equivalents, or marketable securities in ways that ultimately increase the value of your investment. We expect to use our cash, cash equivalents, and marketable securities to: fund our planned clinical trials of a number of product candidates; continue to fund the potential NDA resubmission and approval process for reproxalap, including conducting any additional clinical trials or other activities that the FDA may require for approval of reproxalap; develop other molecules that relate to immune-mediated disease; pursue regulatory approval for our product candidates; service our debt obligations; and provide working capital and capital for other general corporate purposes. The failure by our management to apply these funds effectively could harm our business. We may invest our cash, cash equivalents, or marketable securities in short-term, investment-grade, interest-bearing securities, which may not yield a favorable return to our stockholders. If we do not invest or apply our cash, cash equivalents, or marketable securities in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The terms of our secured debt facility require us to meet certain operating covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2019, we entered into a credit facility with Hercules Capital, which was subsequently amended in April 2021, December 2022, and April 2024, that is secured by a lien covering all of our assets, other than our intellectual property. The loan agreement contains customary affirmative and negative covenants and events of default. Affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, and maintain insurance coverage. Negative covenants include, among others: restrictions on transferring any part of our business or intellectual property; incurring additional indebtedness; engaging in mergers or acquisitions; paying dividends or making other distributions; making investments; and creating other liens on our assets, in each case subject to customary exceptions. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility. These restrictions may include, among other things, limitations on borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends, redeem capital stock, or make investments. If we default under the terms of the Hercules Credit Facility or any future debt facility, the lender may accelerate all of our repayment obligations and take control of our pledged assets, potentially requiring us to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated, the lender&#8217;s right to repayment would be senior to the rights of the holders of our common stock. The lender could declare a default upon the occurrence of any event that they interpret as a material adverse effect as defined under the loan agreement. Any declaration by the lender of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be limited as a result of transactions involving our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50 percentage points over such stockholders&#8217; lowest percentage ownership during the testing period (generally three years). Transactions involving our common stock within the testing period, even those outside our control, such as purchases or sales by investors, could result in an ownership change. A limitation on our ability to utilize some or all of our NOLs or credits could have a material adverse effect on our results of operations and cash flows. We believe, prior to December 31, 2021, that four ownership changes occurred since inception. Management believes that its aggregate Section 382 and 383 limitation (including the additional limitation for recognized "built-in gains") is sufficient so that no current impairment of its pre-ownership change tax attributes is required. We believe there were no ownership changes from December 31, 2021 through June 30, 2024, based on a review of our equity history during that period. Any future ownership changes, including those resulting from our recent or future financing activities, may cause our existing tax attributes to have additional limitations. However, subject to annual limitations, Federal NOLs generated in years 2018 and beyond will have an indefinite carryforward period and will not expire. Future changes in federal and state tax laws pertaining to NOL carryforwards may also cause limitations or restrictions from us claiming such NOLs. If the NOL carryforwards become unavailable to us or are fully utilized, our future taxable income will not be shielded from federal and state income taxation absent certain U.S. federal and state tax credits, and the funds otherwise available for general corporate purposes would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governments may impose price controls, which may adversely affect our future profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to seek approval to market our product candidates in both the United States and in foreign jurisdictions. If we obtain approval to market our product candidates in the United States, we will be subject to the Inflation Reduction Act of 2022 (IRA), which, among other things, will allow Department of Health and Human Services (HHS) to negotiate the selling price of certain drugs and biologics that Centers for Medicare &amp; Medicaid Services (CMS) reimburses under Medicare Part B and Part D. If we obtain approval in one or more foreign jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some foreign countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. Furthermore, in some European countries, the authorities conduct a Health Technology Appraisal to assess the cost-effectiveness of the product, which may significantly impact effective access to the market. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations could be subject to business disruptions such as earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, public health epidemics, regional or larger scale conflicts or geo-political actions, war or other military conflict (including an escalation of the conflicts in Ukraine and Israel and the surrounding areas), trade policies, sanctions, treaties and tariffs and other natural or man-made disasters or other business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition, and increase our costs and expenses. We rely on third-party manufacturers to produce reproxalap and our other product candidates. Our ability to obtain clinical and commercial supplies of reproxalap or our other product candidates could be disrupted, if the operations of these suppliers are affected by these or other business disruptions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing conflicts in Ukraine and Israel and the surrounding areas. Our business, financial condition, and results of operations may be materially adversely affected by the negative impact on the global economy and capital markets resulting from the conflicts in Ukraine and Israel or any other geopolitical tensions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the conflicts in Ukraine and Israel and the surrounding areas. In February 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit, and capital markets, as well as supply chain disruptions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, various of Russia&#8217;s actions have led to sanctions and other penalties being levied by the U.S., the European Union, and other countries, as well as other public and private actors and companies, against Russia and certain other geographic areas, including agreement to remove certain Russian financial institutions from the SWIFT payment system and restrictions on imports of Russian oil, liquefied natural gas, and coal. Additional potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could further adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and initiated a military campaign Hamas. Significant clashes between Israel and Hezbollah in Lebanon have also occurred and may escalate in the future into a greater regional conflict.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the above-mentioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military action, sanctions, and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this annual report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems. The majority of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in depository accounts may exceed the $250,000 Federal Deposit Insurance Corporation (FDIC) insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limits. Concerns regarding the U.S. or international financial systems, including bank failures and bailouts, and their potential broader effects and potential systemic risk on the banking sector generally, may adversely affect our access to capital. Any decline in available funding or access to our cash and liquidity resources could, among other risks, limit our ability to meet our capital needs and fund future growth or fulfill our other obligations, or result in breaches of our financial and/or contractual obligations. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. A failure of a depository institution to return these deposits, or if a depository institution is subject to other adverse conditions in the financial or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">credit markets, could further impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we engage in an acquisition, reorganization, or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we have entered into, and we will continue to consider in the future, strategic business initiatives intended to further the development of our business. These initiatives may include acquiring businesses, technologies, or products, or entering into a business combination with another company. For example, in January 2019 we acquired Helio Vision, Inc. and obtained the rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection. Any acquisitions we undertake will likely be accompanied by business risks which may include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of the acquisition on our financial and strategic position and reputation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of an acquisition to result in expected benefits, which may include benefits relating to new product candidates, human resources, costs savings, operating efficiencies, goodwill, and other synergies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the difficulty, cost, and management effort required to integrate the acquired businesses, including costs and delays in implementing common systems and procedures, and costs and delays caused by communication difficulties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the assumption of certain known or unknown liabilities of the acquired business, including litigation-related liabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the reduction of our cash available for operations and other uses, the increase in amortization expense related to identifiable assets acquired, potentially dilutive issuances of equity securities, or the incurrence of debt;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possibility that we will pay more than the value we derive from the acquisition;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impairment of relationships with our partners, consultants, or suppliers, or those of the acquired business; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential loss of key employees of the acquired business.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors could harm our business, results of operations, or financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the risks commonly encountered in the acquisition of a business or assets as described above, we may also experience risks relating to the challenges and costs of closing a transaction. The risks described above may be exacerbated as a result of managing multiple acquisitions at once.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely and will continue to rely on outsourcing arrangements for many of our activities, including clinical development, commercial readiness preparations, and supply of reproxalap and our other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had only 10 full-time employees and, as a result, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including clinical research, data collection and analysis, manufacturing, commercial readiness preparations, financial reporting and accounting, and human resources, as well as for certain functions required of publicly traded companies. We may have limited control over third parties and we cannot guarantee that any third-party will perform its obligations in an effective and timely manner.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, during challenging and uncertain economic environments, in tight credit markets and during public health epidemics, and with the continued hostilities in Ukraine and Israel and the surrounding areas, there may be a disruption or delay in the performance of our third-party contractors, suppliers, or partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our clinical trials. If any third-party does not meet our deadlines or otherwise conduct the trials as required and in accordance with regulations, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates when expected, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. We are dependent on third parties to conduct the clinical trials for our product candidates and, therefore, the timing of the initiation and completion of these trials is controlled by such third parties and may occur on substantially different timing from our estimates. Specifically, we use CROs to conduct our clinical trials and we also rely on medical institutions, clinical investigators, and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators, and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no guarantee that CROs, investigators, or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed, or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time, and may receive cash or equity compensation in connection with such services. Any worsening of the global business and economic environment may have the effect of heightening or exacerbating these risks.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some of our product candidates may be studied in clinical trials co-sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we have minimal or no control over the conduct of such trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently anticipate that part of our strategy for pursuing the wide range of indications potentially addressed by our product candidates will involve investigator-initiated clinical trials. Investigator-initiated clinical trials pose similar risks as those set forth elsewhere in this &#8220;Risk Factor&#8221; section relating to our internal clinical trials. While investigator-initiated trials may provide us with clinical data that can inform our future development strategy, we generally have less control over the conduct and design of the trials. Because we are not the sponsors of investigator-initiated trials, we do not control the protocols, administration, or conduct of the trials, including follow-up with patients and ongoing collection of data after treatment. As a result, we are subject to risks associated with the way investigator-initiated trials are conducted. In particular, we may be named in lawsuits that would lead to increased costs associated with legal defense. Additional risks include difficulties or delays in communicating with investigators or administrators, procedural delays and other timing issues, and difficulties or differences in interpreting data. Third-party investigators may design clinical trials with clinical endpoints that are more difficult to achieve, or in other ways that increase the risk of negative clinical trial results compared to clinical trials that we may design on our own. Negative results in investigator-initiated clinical trials could have a material adverse effect on our prospects and the perception of our product candidates. As a result, our lack of control over the conduct and timing of, and communications with the FDA regarding, investigator-sponsored trials expose us to additional risks and uncertainties, many of which are outside our control, and the occurrence of which could adversely affect the commercial prospects for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely completely on third parties to supply drug substance and manufacture drug product for our clinical trials and preclinical studies. We intend to rely on other third parties to produce commercial supplies of product candidates, and our dependence on third parties could adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are completely dependent on third-party suppliers of the drug substance and drug product for our product candidates. If third-party suppliers do not supply sufficient quantities of materials to us on a timely basis and in accordance with applicable specifications and other regulatory requirements, there could be a significant interruption of our supplies, which would adversely affect clinical development and commercialization. Furthermore, if any of our contract manufacturers cannot successfully manufacture material that conforms to our specifications within regulatory requirements, we will not be able to secure and/or maintain regulatory approval, if any, for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on our contract manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our anticipated clinical trials. We do not have any control over the process or timing of the acquisition of raw materials by our contract manufacturers. Moreover, we currently do not have agreements in place for the commercial production of these raw materials. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial, including as a result of the continued hostilities in Ukraine and Israel and the surrounding areas, could considerably delay completion of that clinical trial, product candidate testing, and potential regulatory approval of that product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to have the resources or capacity to commercially manufacture any of our proposed product candidates if approved and will likely continue to be dependent on third-party manufacturers. Our dependence on third parties to manufacture and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">supply clinical trial materials and any approved product candidates may adversely affect our ability to develop and commercialize our product candidates on a timely basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in establishing and maintaining development, commercial, or other strategic partnerships, which could adversely affect our ability to develop and commercialize product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in the past chosen, and may in the future choose, to enter into development or other strategic partnerships, including collaborations with major biotechnology or pharmaceutical companies. For example, we currently plan to commercialize reproxalap through a collaboration with a third party. We face significant competition in seeking appropriate partners and the negotiation process is time consuming and complex. Moreover, we may not be successful in our efforts to establish other development partnerships or other alternative arrangements for any of our product candidates or programs because our research and development pipeline may be insufficient, our product candidates or programs may be deemed to be at too early a stage of development for collaborative effort, and/or third parties may not view our product candidates or programs as having the requisite commercial or technical potential. Even if we are successful in our efforts to establish development or commercial partnerships, the terms that we agree upon may not be favorable to us and we may not be able to maintain such partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are below expectations. Any delay in entering into development partnership agreements or collaborations related to our product candidates could delay the development and commercialization of our product candidates and reduce competitiveness, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if we fail to maintain partnerships related to our product candidates:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the development and/or commercialization of certain of our current or future product candidates may be terminated or delayed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our cash expenditures related to development and commercialization of certain of our current or future product candidates would increase significantly and we may need to seek additional financing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we will bear all of the risk related to the development and commercialization of any such product candidates. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the benefits of our current or future strategic alliances.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in the past, and may in the future, form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including the continued development or commercialization of reproxalap or our other product candidates. We currently plan to commercialize reproxalap through a collaboration with a third party. Research, development, regulatory and commercialization activities undertaken by our partners, if any, pose similar risks as those set forth elsewhere in this &#8220;Risk Factor&#8221; section relating to our research, development, regulatory and commercialization activities. Strategic alliances may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for reproxalap or our other product candidates because third parties may view the risk of development failure as too significant or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, or those of our development partners, third-party clinical research organizations, or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, and collaborators are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war or other military conflict, including as a result of the continued hostilities in Ukraine and Israel and the surrounding areas, and telecommunication and electrical failures. While to our knowledge we have not experienced any such material system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidate could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on email and other messaging services in connection with our operations. We may be targeted by parties using fraudulent spoofing and phishing emails to misappropriate passwords, payment information, or other personal information, or to introduce viruses through Trojan horse programs or otherwise through our networks, computers, smartphones, tablets, or other devices. Despite our efforts to mitigate the effectiveness of such malicious email campaigns through a variety of control and non-electronic checks, spoofing and phishing may damage our business and increase our costs. These risks may be heightened as a result of remote working arrangements. In addition, due to the political uncertainty involving the continued hostilities in Ukraine and Israel and the surrounding areas, there is an increased likelihood that escalation of tensions could result in cyberattacks that could either directly or indirectly impact our operations. Any of these events or circumstances could materially adversely affect our business, financial condition, and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends on our and our licensors' ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and the use of our product candidates or proprietary technologies as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties. Even issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to these product candidates could have a material adverse effect on our financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Composition-of-matter patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. While we have issued composition-of-matter patents in the United States and other countries for reproxalap, and other product candidates, we cannot be certain that the claims in our patent applications covering composition-of-matter of early stage candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) and courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute. In addition, there are possibly treatment compositions and methods that we have not conceived of or attempted to patent, and other parties may discover and patent approaches and compositions that are similar to or different from ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications may not result in any patents being issued; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential product candidates; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the United States government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we rely on the protection of our trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants, and advisors, third parties may still obtain this information or may come upon this or similar information independently. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of our trade secrets or proprietary know-how may be greatly reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of reproxalap or our other product candidates. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming and could likely:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in costly litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divert the time and attention of our technical personnel and management; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cause development or commercialization delays; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent us from commercializing reproxalap or our other product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to develop non-infringing technology; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to enter into royalty or licensing agreements. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although no third-party has asserted a claim of patent infringement against us, others may hold proprietary rights that could prevent reproxalap or our other product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market reproxalap or our other product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing reproxalap or our other product candidates, which could harm our business, financial condition, and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any such claims against us could also be deemed to constitute an event of default under the loan and security agreement. In the case of a continuing event of default under the loan, Hercules could, among other remedies, elect to declare all amounts outstanding to be immediately due and payable and terminate all commitments to extend further credit. In the event we do not or are not able to repay the obligations at the time a default occurred, Hercules may elect to commence and prosecute bankruptcy and/or other insolvency proceedings, or proceed against the collateral granted to Hercules under the loan.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our issued patents could be found invalid or unenforceable if challenged in court.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or any of our future development partners were to initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, or one of our future product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or acquire rights or technology, which could result in the loss of rights or technology that are material to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to technology licenses, including an in-license agreement for ADX-2191, and we may enter into additional licenses in the future. Such licenses do, and may in the future, impose commercial, contingent payment, royalty, insurance, indemnification, and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we could lose valuable rights under our collaboration agreements and our ability to develop product candidates could be impaired. Additionally, should such a license agreement be terminated for any reason, there may be a limited number of replacement licensors, and a significant amount of time may be required to transition to a replacement licensor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our rights to develop and commercialize our in-license program are each subject in part to the terms and conditions of a third-party license, pursuant to which we have acquired exclusive rights and other intellectual property. Our rights with respect to the intellectual property to develop and commercialize the in-license program may terminate, in whole or in part, if we fail to meet certain milestones contained in each of our license agreements relating to their development and commercialization. We may also lose our rights to develop and commercialize either in-license agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we fail to pay required milestones or royalties. In the event of an early termination of our license agreement, all rights licensed and developed by us under this agreement may be extinguished, which may have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2019, we acquired Helio and thereby acquired rights to ADX-2191 pursuant to the Merger Agreement. We agreed to use commercially reasonably efforts to develop and obtain regulatory approval for ADX-2191. ADX-2191 is currently being developed for the potential treatment of retinitis pigmentosa. In the three months ended March 31, 2024, we deprioritized ADX-2191 for the treatment of proliferative vitreoretinopathy and primary vitreoretinal lymphoma due to the requirement from the FDA to run clinical trials that we did not deem to be feasible.  If we cease to use commercially reasonably efforts to develop and obtain regulatory approval for ADX-2191, subject to the terms and conditions of the Merger Agreement, ADX-2191 and related intellectual property rights may revert back to an entity designated by the representative of the former Helio stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees, consultants, or agents have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industry, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants and our employees were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company or an employee, consultant, or agent inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration, and specifics of FDA marketing approval of reproxalap or other product candidates, one or more of our United States patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest, and our business may be adversely affected. Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources, and could adversely impact our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity. Therefore, obtaining and enforcing biotechnology patents is costly, time consuming, and inherently uncertain. In addition, Congress may pass patent reform legislation. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available or weakening the rights of patent owners. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents, or to enforce our existing patents and patents we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have issued composition-of-matter patents covering reproxalap and certain of our other product candidates in the United States and other countries, filing, prosecuting, and defending patents on reproxalap and our other product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive and of significantly shorter duration than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, the growing use of generative AI presents an increased risk of unintentional and/or unauthorized disclosure or use of our intellectual property rights.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and the third parties with whom we work are increasingly utilizing social media tools as a means of communication both internally and externally, and noncompliance with applicable requirements, policies, or contracts due to social media use or negative posts or comments could have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Social media is increasingly being used to communicate about our product candidates and clinical development programs, and we may intend to utilize appropriate social media in connection with our commercialization efforts following approval of any product candidates. Social media practices in the biopharmaceutical industry continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. In addition, our employees or third parties with whom we contract or may contract, such as CROs, may knowingly or inadvertently make use of social media in ways that may not comply with legal or contractual requirements, which may give rise to liability, lead to the loss of trade secrets or other intellectual property. Additionally, such use of social media by our employees or third parties with whom we contract or may contract may result in public exposure of personal information of our employees, clinical trial patients and others or information regarding any product candidates or clinical trials along with the potential for litigation related to off-label marketing or other prohibited activities. For example, clinical trial patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about any product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, negative posts or comments about us or any of our product candidates on social media could seriously damage our reputation, brand image or goodwill. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to its business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Employee Matters and Managing Growth</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are highly dependent on the services of our senior management team and certain key consultants.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a company with a limited number of personnel, we are highly dependent on the development, regulatory, commercial, and financial expertise of our senior management team comprised of: Todd C. Brady, M.D., Ph.D., our President and Chief Executive Officer, and Stephen G. Machatha, Ph.D., our Chief Development Officer, as well as certain other employees. In addition, we rely on the services of a number of key consultants, including IP, pharmacokinetic, chemistry, toxicology, drug development, and financial and accounting consultants. Leadership transitions can be inherently difficult to manage and may cause disruption within our company. The loss of key individuals or the services of future members of our management team could delay or prevent the further development of our product candidates and, if we are not successful in finding suitable replacements, could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to attract and retain senior management, we may be unable to successfully develop or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on our continued ability to attract, retain, and motivate highly qualified management and scientific personnel, and we may not be able to do so in the future due to intense competition among biotechnology and pharmaceutical companies, universities, and research organizations for qualified personnel. If we are unable to attract and retain the necessary personnel, we may experience significant impediments to our ability to implement our business strategy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2024, we announced that Bruce Greenberg, our Senior Vice President of Finance and Interim Chief Financial Officer, will step down from his positions with the company effective August 31, 2024. Following his departure we expect to outsource the principal financial and principal accounting officer roles through the engagement of a third-party provider of strategic and operational finance and accounting services. Mr. Greenberg has agreed to continue to serve as Interim Chief Financial Officer until such time and we expect to enter into a consulting agreement with Mr. Greenberg pursuant to which Mr. Greenberg is expected to provide consulting services to the company through November 30, 2024 to help support the successful transfer of responsibilities, but we may experience difficulties or delays during the transition. This or other changes in our senior management may be disruptive to our business, and, if we are unable to manage an orderly transition, our business may be adversely affected.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future performance will depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, adversely affecting future regulatory approvals, sales of our product candidates, and results of our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In order to commercialize our product candidates for those we remain responsible for the commercialization of, we will need to substantially grow the size of our organization. We may encounter difficulties in managing our growth and expanding our operations successfully.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we only had 10 full-time employees. We currently plan to commercialize reproxalap through a collaboration with a third party. However, if we are not able to establish a suitable collaboration, we may need to grow our organization to continue development and pursue the potential commercialization of reproxalap. In addition, we expect that we will need to grow our organization to continue development and pursue the potential commercialization of our other product candidates, as well as function as a public company. As we seek to advance reproxalap, alone or with others, and other product candidates towards potential commercialization, increase the number of ongoing product development programs, and advance our future product candidates through preclinical studies and clinical trials, we will need to expand our financial, development, regulatory, manufacturing, marketing, and sales capabilities, or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers, and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train, and integrate additional management, clinical and regulatory, financial, administrative and sales, and marketing personnel. We may not be able to accomplish these tasks, and our failure to so accomplish could prevent us from successfully growing our company.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Other Legal or Regulatory Matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is subject to political, economic, legal, and social risks, which could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are significant regulatory, economic and legal barriers in markets in the United States and outside the United States that we must overcome. We may be subject to the burden of complying with a wide variety of national and local laws, including multiple and possibly overlapping and conflicting laws. We also may experience difficulties adapting to new cultures, business customs, and legal systems. Any sales and operations would be subject to political, economic, and social uncertainties including, among others:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes and limits in import and export controls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increases in custom duties and tariffs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in currency exchange rates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, and political instability, including effects of adverse developments affecting the financial services industry, the ongoing conflicts in Ukraine and Israel and the surrounding areas, and the possibility of a wider regional or global conflict, and global sanctions imposed in response thereto; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact on employees, suppliers, customers, and the global economy related to public health epidemics or pandemics, and actions taken in response to such events; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with multiple complex, potentially conflicting and changing governmental regulations and laws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">absence in some jurisdictions of effective laws to protect our intellectual property rights; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">currency transfer and other restrictions and regulations that may limit our ability to sell certain products or repatriate profits to the United States. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in United States social, political, regulatory, and economic conditions or in laws and policies governing foreign trade, manufacturing, development, and investment, and any negative sentiments towards the United States as a result of such changes, could adversely affect our business. Concerns over economic recession, interest rate increases and inflation, supply chain delays and disruptions, policy priorities of the U.S. presidential administration, trade wars, unemployment, or prolonged government shutdown may contribute to increased volatility and diminished expectations for the economy and markets. Recent and upcoming presidential and congressional elections in the United States could also result in significant changes in, and uncertainty with respect to, legislation, regulation, and government policy that may impact the biopharmaceutical industry in the United States. Any such impacts may have a negative impact on the United States economies and on our business, financial condition, and results of operations. Additionally, concern over geopolitical issues may also contribute to prolonged market volatility and instability. For example, continued hostilities in Ukraine and Israel and the surrounding areas, could lead to disruption, instability, and volatility in global markets and industries. The U.S. government and other governments in jurisdictions have imposed severe economic sanctions and export controls against Russia and Russian interests, have removed Russia from the Society for Worldwide Interbank Financial Telecommunication payment (SWIFT) system, and have threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia, is unknown.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any changes related to these and other factors could adversely affect any business operations that we conduct outside the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security breaches, cyberattacks, loss of data, and other disruptions impacting our information technology systems or those of our third-party collaborators, service providers, contractors or consultants could compromise the privacy, security, integrity or confidentiality of sensitive information related to our business or prevent us from accessing critical information and expose us to adverse consequences, including but not limited to regulatory investigations or actions, litigation, and significant fines and penalties, which could adversely affect our business, financial condition, and reputation.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we and our current or future third-party collaborators, service providers, contractors, and consultants collect, may store and transmit sensitive data, including legally protected health information, personal data (also referred to as personal information or personally identifiable information under certain data privacy laws) about patients and employees, intellectual property, and our proprietary business and financial information (collectively, sensitive information). We manage and maintain data, including sensitive information, utilizing a combination of on-site systems, managed data center systems, and cloud-based data center systems. We face a number of risks related to our protection of, and our third-party collaborators&#8217;, service providers&#8217;, contractors&#8217;, and consultants&#8217; protection of, this sensitive information, including loss of access, inappropriate disclosure and inappropriate or unauthorized access, as well as risks associated with our ability to identify and audit such events.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The secure processing, storage, maintenance, and transmission of sensitive information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and those of our third-party collaborators, service providers, contractors, and consultants, may be vulnerable to breakdown or other damage or interruption from service interruptions, system malfunctions, natural disasters, terrorism, war and telecommunications and electrical failures, as well as from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity and availability of information) or viruses or otherwise breached due to employee or third-party error, malfeasance, or other activities. These risks may be heightened as a result of remote working arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we are not aware of any such attack, breach or system failure, we cannot guarantee that our data protection efforts and our investment in information technology, or those of our third-party collaborators, service providers, contractors, and consultants will prevent significant breakdowns, data leakages, and breaches in the relevant systems or other cyber incidents. If such event were to occur and cause interruptions in our operations, our networks could be compromised and the sensitive information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost, or stolen. Any such unauthorized access, disclosure or other loss of information, or the perception that any of these has occurred, could result in legal claims or proceedings, liability under federal, state, and international laws that protect the privacy of personal data, including but not limited to private lawsuits or class actions under the California Consumer Privacy Act, as amended by the California Privacy Rights Act of 2020 (CPRA), and regulatory penalties, which could result in significant legal or financial exposure. In addition, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal data, which is a broader class of information than the health information protected by the Health Insurance Portability and Accountability Act (HIPAA). Unauthorized access, loss, or dissemination of sensitive information could also disrupt our ability to conduct research and development activities; collect, process, and prepare company financial information; provide information about our product candidates and other patient and physician education or outreach efforts through our website; manage the administrative aspects of our business; or prevent damage to our reputation, any of which could adversely affect our business.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies, and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; significant fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data (also referred to as personal information or personally identifiable information under certain data privacy laws) and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, and patient information. Our data processing activities may subject us to numerous data privacy and security obligations, such as various federal, state, and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf. We strive to comply with applicable data privacy and security obligations to the extent possible. However, it is possible that these obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules and/or our practices. Any failure or perceived failure by us to comply with applicable privacy and data security laws and regulations, our privacy policies, or our privacy-related obligations to third parties, or any compromise of security that results in the unauthorized access, release or transfer of personal data or other sensitive information, may result in governmental enforcement actions and fines or orders requiring that we change our practices, private litigation (including class action lawsuits), or public statements against us by consumer advocacy groups or others and could cause a loss of trust in us, which could result in significant legal or financial exposure and reputational damage that could potentially have an adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act). For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. In addition, we may be subject to various state data privacy and security laws and regulations, including the California Consumer Privacy Act, as amended by the CPRA, which, among other things, requires covered &#8220;businesses&#8221; to provide specific disclosures to California consumers concerning the collection, sale, and sharing of their personal data, and gives such consumers the right to opt-out of certain sales of personal information. The CPRA provides for civil penalties for violations, as well as a private right of action for certain security breaches that may increase the likelihood of, and the risks associated with, security breach litigation. Additionally, the CPRA created a new state agency to oversee implementation and enforcement efforts, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. Many of the CPRA&#8217;s provisions became effective on January 1, 2023. Several states in the U.S. have proposed or enacted laws that contain obligations similar to the CPRA that have taken effect or will take effect in coming years. The U.S. federal government also is contemplating federal privacy legislation. The effects of recently proposed or enacted legislation potentially are far-reaching and could increase our potential liability, increase our compliance costs, and adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developments in Europe have created compliance uncertainty regarding the processing of personal data from Europe. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR), the United Kingdom&#8217;s GDPR (UK GDPR), and the Swiss Federal Act on Data Protection extend the geographical scope of European data protection laws to non-European entities and impose strict requirements for processing personal data. For example, under the EU GDPR and/or the UK GDPR, government regulators may impose temporary or definitive bans on data processing, as well as possible fines of up to 4% of global annual turnover for the preceding financial year or &#8364;20 million, whichever is higher, for the most serious infringements. This exposes us to two parallel sets of regulations, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. Further, individuals or consumer protection organizations authorized at law to represent their interests may initiate litigation related to the processing of individuals&#8217; personal data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. The EU GDPR and UK GDPR prohibit the transfer of personal data to countries outside of the EEA, or the UK including the United States, that have not been deemed adequate by the European Commission or by the UK data protection regulator, respectively. Switzerland has adopted similar restrictions. Although there are legal mechanisms that allow for the transfer of personal data from the EEA, UK, and Switzerland to the United States, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. For example, legal developments in the EU have created complexity and uncertainty regarding such transfers and data protection authorities from the different EU Member States may interpret the EU GDPR differently. Additionally, guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data in the EU. These transfer mechanisms have also been subject to various legal challenges. In particular, on July 16, 2020, the Court of Justice of the European Union, in the case of Data Protection Commissioner v. Facebook Ireland Limited, Maximillian Schrems (Case C-311/18) (Schrems II), invalidated the EU-U.S. Privacy Shield Program for transfers of personal data from the EU to the U.S., and added further uncertainty and complexity to the use of standard contractual clauses as a compliance mechanism for transfers of personal data outside the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If there is no lawful manner for us to transfer personal data from the EEA, UK, or Switzerland to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third-parties, which could limit our ability to conduct clinical trial activities in Europe or elsewhere, and injunctions against our processing or transferring of personal data necessary to operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the EU, UK, and Switzerland, a growing number of other global jurisdictions are considering or have passed legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of our business. Some of these laws, such as the General Data Protection Law in Brazil, or the Act on the Protection of Personal Information in Japan, impose similar obligations as those under the EU GDPR and UK GDPR. Others, such as those in Russia, India, and China, could potentially impose more stringent obligations, including data localization requirements. If we are unable to meet these evolving legal requirements or if we violate or are perceived to violate any laws, regulations, or other obligations relating to privacy, data protection, or information security, we may experience harm to our reputation and become subject to investigations, claims, and other remedies, which could expose us to significant fines, penalties, and other damages, all of which would harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us to obtain regulatory and marketing approval of and commercialize our product candidates, alone or with others, and may affect the prices we may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding healthcare systems that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare reform measures that may be adopted in the future, may result in reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies, and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation and regulation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient support programs, reduce the costs of drugs under Medicare, and reform government program reimbursement methodologies for drug products. For example, included in the Consolidated Appropriations Act, 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of the HHS, the Department of Labor, and the Treasury. Additionally, both Congress and the Biden administration have each indicated willingness to continue to seek new legislative and/or administrative measures to address prescription drug costs. For example, on July 9, 2021, President Biden issued an Executive Order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other provisions, the Executive Order stated that the Biden administration will &#8220;support aggressive legislative reforms that would lower prescription drug prices, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and through other related reforms.&#8221; In response to the Executive Order, on September 9, 2021, the HHS issued a Comprehensive Plan for Addressing High Drug Prices that identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to make drug prices more affordable and equitable, improve and promote competition throughout the prescription drug industry, and foster scientific innovation. Congress has also continued to conduct inquiries into the prescription drug industry&#8217;s pricing practices.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These initiatives recently culminated in the enactment of the IRA, in August 2022, which, among other things, will allow HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D, although this will only apply to high-expenditure single-source drugs that have been approved for at least 7 years (11 years for biologics). The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price representing a significant discount from average prices to wholesalers and direct purchasers. The law will also, beginning in October 2023, penalize drug manufacturers that increase prices of Medicare Part B and Part D drugs at a rate greater than the rate of inflation. In addition, the law eliminates the &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. Thus, although it is unclear how the IRA will be implemented, the IRA will likely have a significant impact on our business and the pharmaceutical industry as a whole.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing. These include legislation and regulations regarding price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, legislative action designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the potential approval and marketing approvals of our product candidates, if any, may be. Increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of health care may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for any product candidates for which we may obtain regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify and establish strategic partnerships;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations and relationships with actual and potential customers, providers, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil penalties, exclusions from government programs, contractual damages, and reputational harm, and could diminish our future profits and earnings.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our arrangements with third-party payors, physicians, and other potential customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable U.S. federal and state healthcare laws and regulations include the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, a criminal law, which prohibits, among other things, persons and entities from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, leasing, ordering, or arranging for, referring, or recommending the purchase, lease, or order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations of the federal Anti-Kickback Statute can result in significant civil monetary penalties and criminal fines, as well as imprisonment and exclusion from participation in federal healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal civil False Claims Act, which may be enforced through civil whistleblower or qui tam actions and imposes significant civil penalties, treble damages, and potential exclusion from federal healthcare programs against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Further, a violation of the federal Anti-Kickback Statute can serve as a basis for liability under the federal civil False Claims Act. There is also the federal Criminal False Claims Act, which is similar to the federal Civil False Claims Act and imposes criminal liability on those that make or present a false, fictitious, or fraudulent claim to the federal government;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal criminal statutes created by the Health Insurance Portability and Accountability Act (HIPAA), which impose criminal liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private insurance plans, or, in any matter involving a healthcare benefit program, for knowingly and willfully making materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for health care benefits;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by HITECH, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on certain types of people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDCA which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use or misbranding or adulterating their products, and regulates the distribution of samples;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal and state laws that require pharmaceutical manufacturers to report certain calculated product pricing metrics to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of product coverage and reimbursement under federal healthcare programs</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payment Sunshine Act, which requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, among others, to annually track and report payments and other transfers of value provided to U.S.-licensed physicians and teaching hospitals, and for reports submitted on or after January 1, 2022, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives, as well as certain ownership and investment interests held by physicians and their immediate families;</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, that may apply to our business practices, including sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant compliance guidance promulgated by the federal government;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; require the reporting of certain pricing information, including information pertaining to and justifying price increases, or prohibit prescription drug price gouging; and certain state and local laws that require the registration of pharmaceutical sales representatives; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties; damages; fines; imprisonment; exclusion of product candidates from government-funded healthcare programs, such as Medicare and Medicaid; disgorgement; contractual damages; reputational harm; diminished profits and future earnings; and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may also be subject to criminal, civil, or administrative sanctions, including exclusions from government-funded healthcare programs. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action for an alleged or suspected violation can cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of the business, even if such action is successfully defended.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Providing benefits or advantages to induce or reward improper performance generally to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to induce or reward improper performance is governed by the national anti-bribery laws of EU Member States, and in respect of the U.K., the Bribery Act 2010. Infringement of these laws may result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, provides that, where medicinal products are being promoted to healthcare professionals, no gifts, pecuniary advantages, or benefits in kind may be supplied, offered or promised to such individuals unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision was transposed into the Human Medicines Regulations 2012 and as such remains applicable in the UK.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians in certain EU Member States must be publicly disclosed. In addition, agreements with healthcare professionals must often be the subject of prior notification and approval by the healthcare professional&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of individual EU Member States. These requirements are set out in national laws, industry codes, or professional codes of conduct, applicable in the EU Member States and in the UK. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims statutes and anti-kickback statutes. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce, or in return for, purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">formula managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing, or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Over the past few years, several pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and grants, and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicaid for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Most states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer&#8217;s products from reimbursement under government programs, criminal fines, and imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC, and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels; ability to hire and retain key personnel and accept the payment of user fees; and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC, and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of reproxalap or our other product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if reproxalap or our other product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for reproxalap or our other product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to continue to develop or commercialize reproxalap or our other product candidates; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a decline in our stock price. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain product liability insurance with $5.0 million in coverage. We anticipate that we will need to increase our insurance coverage if we commercialize any product candidate. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of reproxalap or our other product candidates. Although we will maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our development partners, third-party manufacturers, and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials could be time consuming or costly.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our development partners, third-party manufacturers, and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our development partner, third-party manufacturers, and suppliers also produce hazardous waste products. Federal, state, and local laws and regulations govern the use, generation, manufacture, storage, handling, and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we and any of our future development partners are successful in commercializing our products, the FDA and foreign regulatory authorities will require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe or to perform inadequate investigations of their causes. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we and any of our future development partners fail to comply with our reporting obligations, the FDA or a foreign regulatory authority could take enforcement action including the issuance of a Warning Letter, the requirement of a labeling change, the initiation of a criminal prosecution, the imposition of civil monetary penalties, the seizure of our products, or delay in approval or clearance of future products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, or other remedial measures and legal expenses, any of which could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations are subject to anti-corruption laws, including the Foreign Corrupt Practices Act (FCPA), the Bribery Act and other anticorruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and other laws generally prohibit us, our officers, and our employees, and intermediaries from bribing, being bribed, or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also are subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, UK, and authorities in the EU, including applicable export control regulations, economic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sanctions on countries and persons, customs requirements, and currency exchange regulations, which we collectively refer to as Trade Control Laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, legal expenses, disgorgement, and other sanctions and remedial measures, which could have an adverse impact on our business, financial condition, results of operations, or liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA; the Bribery Act; or other anti-corruption laws or Trade Control Laws by U.S., U.K., or other authorities also could have an adverse impact on our reputation, our business, results of operations, or financial condition.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, vendors, principal investigators, contract research organizations (CROs), and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards, regulatory requirements, and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intentional, reckless, or negligent conduct or disclosure to us of unauthorized activities that violate the regulations of the FDA or similar foreign regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">healthcare fraud and abuse in violation of U.S. and foreign laws and regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">violations of U.S. federal securities laws relating to trading in our common stock; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failures to report financial information or data accurately.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations govern a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. While we have adopted a code of conduct and implemented other internal controls applicable to all our employees, it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective. Additionally, we are subject to the risk that a person could allege fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business or cause reputational harm, including the imposition of civil, criminal and administrative penalties, and damages; possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs; and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, during the course of our operations, our directors, executives, employees, consultants, and other third parties may have access to material nonpublic information regarding our business, our results of operations, or potential transactions we are considering. We may not be able to prevent trading in our common stock on the basis of, or while having access to, material nonpublic information. If any such person was to be investigated or an action were to be brought against them for insider trading, it could have a negative impact on our reputation and our stock price. Such a claim, with or without merit, could also result in substantial expenditures of time and money, and divert attention of our management team from other tasks important to the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to litigation risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in various litigation matters and claims, including regulatory proceedings, administrative proceedings, governmental investigations, and contract disputes. We may face potential claims or liability for, among other things, breach of contract, defamation, libel, fraud, or negligence. We may also face employment-related litigation, including claims of age discrimination, sexual harassment, gender discrimination, immigration violations, or other local, state, and federal labor law violations. Because of the uncertain nature of litigation and insurance coverage decisions, the outcome of such actions and proceedings cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows, and the trading price of our securities. In addition, legal fees and costs associated with prosecuting and defending litigation matters could have a material adverse effect on our business, financial condition, results of operations, and the trading price of our securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are, and could in the future be, subject to securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been brought against companies, including us, following a decline in the market price of its securities. The risk of securities class action litigation is especially relevant for us because biotechnology and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pharmaceutical companies have experienced significant stock price volatility in recent years. Such litigation could cause us to incur substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. For further information about specific litigation and proceedings, see the section titled &#8220;Legal Proceedings&#8221; contained in Part II, Item 1, and Note 14 of our Notes to Consolidated Financial Statements (unaudited) of this report.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, product and clinical trial liability, workers&#8217; compensation, and directors&#8217; and officers&#8217; insurance. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant, uninsured liability may require us to pay substantial amounts, which would adversely affect our working capital and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. federal income tax reform could adversely affect us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New legislation or regulation which could affect our tax burden could be enacted by any governmental authority. We cannot predict the timing or extent of such tax-related developments which could have a negative impact on our financial results. Additionally, we use our best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions could have a material adverse effect on our business, results of operations, or financial conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the absence of an active trading market for our common stock, investors may not be able to resell their shares at or above the price at which they purchased them.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the absence of an active trading market for our common stock, investors may not be able to sell their common stock at or above the price they paid or at the time that they would like to sell. In addition, an inactive market may impair our ability to raise capital by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration, which, in turn, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The trading price of the shares of our common stock has been and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price has been and will likely continue to be volatile for the foreseeable future. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price they paid. The market price for our common stock may be influenced by many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of FDA regulatory review processes and other regulatory actions with respect to our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results of clinical trials, and the results of trials of our competitors or those of other companies in our market sector; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results and status of our research and development and regulatory plans for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the exercise, if any, of the Option;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expectations of investors or securities analysts regarding our business and clinical development program, including interim or final top-line results that we may announce;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments in the United States and foreign countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enroll and retain patients in our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems, especially in light of current reforms to the United States healthcare system; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or capital commitments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our stock by insiders and 5% stockholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry, regional or larger scale conflicts or geo-political actions, and market conditions other events or factors, many of which are beyond our control, including frequent and dramatic fluctuations in industry indexes that may contain or influence our stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key personnel; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">intellectual property, product liability, or other litigation against us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concerns over economic recession, interest rate increases and inflation, adverse developments affecting financial services industry, supply chain delays and disruptions, policy priorities of the U.S. presidential administration, upcoming presidential and congressional elections in the United States, trade wars, unemployment, or prolonged government shutdown may contribute to increased volatility and diminished expectations for the economy and markets. Additionally, concern over geopolitical issues may also contribute to prolonged market volatility and instability. For example, the continued hostilities in Ukraine and Israel and the surrounding areas, could lead to disruption, instability and volatility in global markets and industries. In connection with the hostilities between Russia and Ukraine the U.S. government and other governments and jurisdictions have imposed severe economic sanctions and export controls against Russia and Russian interests, have removed Russia from the SWIFT system, and have threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia, is unknown.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market (Nasdaq), such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to de-list our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would expect to take actions to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement, or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because a small number of our existing stockholders own a substantial percentage of our outstanding common stock, your ability to influence corporate matters will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, our executive officers, directors, and greater than 5% stockholders, in the aggregate, own approximately 39% of our outstanding common stock. As a result, such persons, acting together, may have the ability to control our management and business affairs and substantially all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction. This concentration of ownership may have the effect of delaying, deferring, or preventing a change in control, impeding a merger, consolidation, takeover, or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on Nasdaq and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure statement; (ii) a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock, and do not currently intend to do so for the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the Hercules Credit Facility currently prohibits, and any future debt financing arrangements may contain terms prohibiting or limiting the amount of, dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in the value of our common stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A substantial number of shares of our common stock could be sold into the public market in the near future, which could depress our stock price.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of substantial amounts of our common stock in the public market could reduce the prevailing market prices for our common stock. Substantially all of our outstanding common stock is eligible for sale as is common stock issuable under vested and exercisable stock options and upon settlement of vested RSUs. If our existing stockholders sell a large number of shares of our common stock, or the public market perceives that existing stockholders might sell shares of common stock, the market price of our common stock could decline significantly. Existing stockholder sales might also make it more difficult for us to sell additional equity securities at a time and price that we deem appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a smaller reporting company under Rule 12b-2 of the Securities Exchange Act of 1934. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on smaller reporting company exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are incurring significant increased costs and demands upon management as a result of operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, and particularly if and after we cease to be a &#8220;smaller reporting company,&#8221; we incur significant legal, accounting, and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, imposes significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may result in substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect the rules and regulations applicable to public companies to continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If public company rules and regulations divert the attention of our management and personnel from other business concerns, our business, financial condition, and results of operations could be adversely affected. Increased costs associated with public company expenses will increase our net loss. For example, public company rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, the cost of which has continued to rise in recent years, and thus we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements, the impact of which could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. To continue to comply with the requirements of being a reporting company under the Exchange Act, we will be required to continue to upgrade and maintain our systems including information technology; implement and maintain additional financial and management controls, reporting systems, and procedures; and hire additional accounting and finance staff. Furthermore, we rely on third-parties, including software and system providers, for ensuring our reporting obligations and effective internal controls, and to the extent these third parties fail to provide adequate service including as a result of any inability to scale to handle our growth and the imposition of these increased reporting and internal controls and procedures, we could incur material costs for upgrading or switching systems and our business could be materially affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, as a smaller reporting company and a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 for as long as we are not deemed an &#8220;accelerated filer&#8221; or &#8220;large accelerated filer.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish and maintain effective internal controls it could have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we grow, we plan to hire additional personnel and engage in external temporary resources and may implement, document, and modify policies and procedures to maintain effective internal controls. However, we may identify deficiencies and weaknesses or fail to remediate previously identified deficiencies in our internal controls. If material weaknesses or deficiencies in our internal controls exist and go undetected or unremediated, our financial statements could contain material misstatements that, when discovered in the future, could cause us to fail to meet our future reporting obligations and cause the price of our common stock to decline. In addition, we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not continue to publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market, or our competitors. If one or more of the analysts who covers us downgrades our stock or publish unfavorable research or reports about our business, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limiting the removal of directors by the stockholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">creating a staggered board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eliminating the ability of stockholders to call a special meeting of stockholders; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">permitting our board of directors to accelerate the vesting of outstanding option grants and other awards upon certain transactions that result in a change of control; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirors to negotiate with our board of directors, the provisions would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choices of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be negatively affected as a result of the actions of activist stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Proxy contests have been waged against many companies in the biotechnology industry over the last few years. We may be particularly vulnerable to activist stockholders due to fluctuations in our stock price. If faced with a proxy contest or other type of stockholder activism, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. Even if we are successful, our business could be adversely affected by a proxy contest or stockholder dispute involving us or our partners because:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived uncertainties as to future direction may result in the loss of potential acquisitions, collaborations, or in-licensing opportunities, and may make it more difficult to attract and retain qualified personnel and business partners; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if individuals are elected to a board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These actions could cause our stock price to experience periods of volatility.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.276%;padding-left:10.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.	Unregistered Sales of Equit</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y Securities and Use of Proceeds.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3.	Defaults Upon</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Senior Securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4.	Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty Disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.	Other </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim Chief Financial Officer Transition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 1, 2024, we announced that Bruce Greenberg, our Senior Vice President of Finance and Interim Chief Financial Officer, will step down from his positions with the company effective August 31, 2024. Following his departure, we expect to outsource the principal financial and principal accounting officer roles through the engagement of a third-party provider of strategic and operational finance and accounting services. Mr. Greenberg has agreed to continue to serve as Interim Chief Financial Officer until such time and we expect to enter into a consulting agreement with Mr. Greenberg pursuant to which Mr. Greenberg is expected to provide consulting services to the company through November 30, 2024 to help support the successful transfer of responsibilities. Mr. Greenberg&#8217;s separation will be treated as an &#8220;Involuntary Termination&#8221; within the meaning of that certain offer letter, dated November 26, 2019, between the Company and Mr. Greenberg (which agreement has previously been filed with the SEC). Mr. Greenberg&#8217;s departure is not the result of any disagreement with the Company or the Board on any matter relating to the Company&#8217;s operations, policies or practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-11.342%;padding-left:10.187%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6.	Ex</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.34%;"/>
    <td style="width:1%;"/>
    <td style="width:91.66%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1341235/000119312514187708/d721856dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Certificate of Incorporation of Registrant, (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on May 7, 2014, and incorporated herein by reference).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1341235/000119312520131009/d923472dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on May 1, 2020, and incorporated herein by reference).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="aldx-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment</span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:8pt;min-width:fit-content;"> </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;"> to Loan and Security Agreement, dated April 29, 2024, by and among the Registrant, Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="aldx-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Fifth Amendment to Lease between WLC Three VI, L.L.C. and the Registrant, dated as of April 29, 2024.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="aldx-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:2.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="aldx-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Principal Financial and Accounting Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="aldx-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of the Chief Executive Officer and Interim Chief Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:27.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:22.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:22.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The certification attached as Exhibit 32.1 that accompanies this quarterly report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aldeyra Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this quarterly report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.6%;"/>
    <td style="width:1.8%;"/>
    <td style="width:48.6%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aldeyra Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[August 1, 2024]</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/      Todd C. Brady, M.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Todd C. Brady, M.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aldeyra Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[August 1, 2024]</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/      Bruce Greenberg</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bruce Greenberg</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Senior Vice President of Finance, Interim Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer and Principal Accounting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>aldx-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Version</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Amendment&#34;)</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dated as of April 29</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024 (the </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Third</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment Effective Date</font><font style="color:#4b4b4d;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;</font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, is entered into by and among ALDEYRA THERAPEUTICS INC.</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a Delaware corporation </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(&#34;Aldeyra&#34;),</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Helio Vision</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LLC</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a Delaware limited liability company</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and each of Aldeyra</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">'</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s Qualified Subsidiaries (hereinafter collectively referred to as the </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Borrower&#34;),</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (as defined below) (collectively</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">referred to as </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Lender&#34;)</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and HERCULES CAPITAL, INC., a Maryland corporation</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in its capacity as administrative agent and collateral agent for itself and Lender </font><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such capacity</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Agent&#34;)</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower, Lender and Agent are parties to that certain Loan and Security Agreement, dated as of March 25, 2019 (the </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Original Loan Agreement&#34;;</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the Original Loan Agreement, as amended by the First Amendment to Loan and Security Agreement dated April 20, 2021 and the Second Amendment to Loan and Security Agreement dated December 22, 2022, the </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Existing Loan Agreement&#34;;</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Existing Loan Agreement, as amended by this Amendment and as further amended, restated, supplemented or otherwise modified from time to time, the </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Loan Agreement&#34;)</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the Third Amendment Effective Date, the Term Loan principal balance outstanding is Fifteen Million Dollars ($15,000,000). Borrower has requested that Agent and Lender agree to certain amendments to the Loan Agreement. Agent and Lender have agreed to such request</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to the terms and conditions hereof</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, the parties hereto agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 1   Definitions; Interpretation.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Terms Defined in Loan Agreement. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Rules of Construction</font><font style="color:#4b4b4d;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules of construction that appear in </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 1</font><font style="color:#4b4b4d;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:1.12%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 2   Amendments to the Loan Agreement.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon satisfaction of the conditions set forth in </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> hereof</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Existing Loan Agreement is hereby amended as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New Definition. The following definition is added to Section 1.1 in its proper alphabetical order:</font></div></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Third Amendment Effective Date&#34; means April 29</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deleted Definition. The defined term &#34;Amortization Date&#34; is hereby deleted</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 2.2(d). Section 2.2(d) is hereby amended and restated as follows:</font></div></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;(d) Payment. Borrower will pay interest on each Term Loan Advance on the first Business Day of each month, beginning the month after the Advance Date</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and payable on Term Loan Maturity Date</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">'</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations payable to Lender under each Term Advance and (ii) reasonable and documented out-of-pocket legal fees and costs incurred by Agent or Lender in connection with Section 11.11 of this Agreement; provided that, with respect to clause (i) above</font><font style="color:#4b4b4d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the event that Lender or Agent informs Borrower that Lender will not initiate a debit entry to Borrower's account for a certain amount of the periodic obligations due on a specific payment date, Borrower shall pay to </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lender such amou</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t of periodic ob</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">igations in fu</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in immediate</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y availab</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e funds on such payment date; provided, further, that, with respect to clause (i) above, if Lender or Agent informs Borrower that Lender will not initiate a debit entry as described above later than the date that is three (3) Business Days prior to such</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment date, Borrower shall pay to Lender such amount of periodic obligations in full in immediately available funds on the date that is three (3) Business Days after the date on which Lender or Agent notifies Borrower of such; provided, further, that</font><font style="color:#5b5b5d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with respect to clause (ii) above, in the event that Lender or Agent informs Borrower that Lender will not initiate a debit entry to Borrower's account for certain amount of such reasonab</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e and documented out-of</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pocket </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">egal fees a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d costs incurred by Agent or Lender, Borrower sha</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pay to Lender such amount in full in immediately avai</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">able funds within three (3) Business Days after the date on which Lender or Agent notifies Borrower of such.&#34;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 11.2. Sections 11.2(a) and 11.2(b) are hereby amended and restated as follows: </font></div></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;(a)        If to Ag</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nt:</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INC.</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Dep</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rtment</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attention: Chief Legal Officer</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lake McGuire</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Michael Dutra and Mic</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hael </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bowden</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1 North B Street</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 2000</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Mat</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">o</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA 94401</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ma</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">il: legal@htgc.com; lmcguire@htgc.com; mdutra@htgc.com and mbowden@htgc.com</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">phone: 650-289-3060</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;(b)        If to Lender:</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INC.</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Dep</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rtment</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attention: Chief Legal Officer</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lake McGuire</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Michael Dutra and Mic</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hael </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bowden</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l North B Street</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 2000</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Mat</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">o</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA 94401</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">email</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> legal@htgc.com; lmcguire@htgc.com; mdutra@htgc.com and mbowden@htgc.com</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">l</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">phone: 650-289-3060&#34;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#151515;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">References Within Existing Loan Agreement. </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each r</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ference in the Existing Loan Agr</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eement to </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;this Agreement&#34; and the words &#34;h</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reof,</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34; </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;h</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,&#34; </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;her</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">under</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34; or wo</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ds of like import, shall mean </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and be a </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">referenc</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the Existing Loan Agr</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ement as amended by this Am</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ndment.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 3   Conditions of Effectiveness. </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effectiv</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nes</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of </font><font style="color:#151515;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 2</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this Amendment shall be </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">u</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bject to </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sati</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">faction of each of the following conditions precedent:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower sh</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll have paid (i) </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll invoiced costs and expenses then du</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in accordanc</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">wi</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">th Section </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5(e) of this Amendment</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nd (ii) all other fees</font><font style="color:#484646;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nd expenses</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ny</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">due and payable </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s of the date he</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reof under </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Loan Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agent shall have r</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ceiv</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">this Amendment</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">executed by Agent</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">L</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nder and Borrower</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; </font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:13.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such other docum</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e</font><font style="color:#151515;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nts as Agent may reasonably request.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the date hereof and the Third Amendment Effective Date, after giving effect to the amendment of the Existing Loan Agreement contemplated hereby, there exist no Events of Default or events that with the passage of time would result in an Event of Default.</font></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 4   Representations and Warranties. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To induce Agent and Lender to enter into this Amendment, each Borrower hereby confirms, as of the date hereof and the Third Amendment Effective Date, that (a) the representations and warranties made by it in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects; </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however, </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof provided, further, that to the extent such representations and warranties by their terms expressly relate only to a prior date such representations and warranties shall be true and correct as of such prior date; (b) there has not been and there does not exist a Material Adverse Effect;</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) [reserved]; (d) Agent has and shall continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrower to Agent, pursuant to the Loan Documents or otherwise granted to or held by Agent; (e) the agreements and obligations of Borrower contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors' rights or by the application of general principles of equity; (f) the execution, delivery and performance of this Amendment by Borrower will not violate any law, rule, regulation, order, contractual obligation or organizational document of Borrower and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues; and (g) no Event of Default has occurred and is continuing.</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 5   Miscellaneous.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents Otherwise Not Affected; Reaffirmation; No Novation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as </font><font style="color:#464446;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expressly </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amended pursuant hereto or referenced herein, the Existing Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. Lender's and Agent's execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Borrower hereby expressly (1) reaffirms, ratifies and confirms its Secured Obligations under the Existing Loan Agreement and the other Loan Documents, (2) reaffirms, ratifies and confirms the grant of security under Section 3.1 of the Existing Loan Agreement, (3) reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Existing Loan Agreement, including without limitation any Term Loans funded on or after the date hereof, as of the date hereof, and with effect from (and including) the date hereof and the Third Amendment Effective Date, such grant of security in the Collateral: (x) remains in full force and effect notwithstanding the amendments expressly referenced herein; and (y) secures all Secured Obligations under the Existing Loan Agreement, as amended by this Amendment, and the other Loan Documents, and (4) agrees that the Existing Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrower's Secured Obligations under or in connection with the Existing Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent's security interest in, (on behalf of itself and Lender) security titles to or other liens on any Collateral for the Secured Obligations.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#312f2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conditions. </font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of determining compliance with the conditions specified in </font><font style="color:#312f2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3,</font><font style="color:#312f2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to Lender unless Agent shall have received notice from Lender prior to the Third Amendment Effective Date specifying its objection thereto.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Release. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the agreements of Agent and Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Borrower, on behalf of itself and its successors, assigns</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and Lender, and each of their successors and assigns, and their present and former shareholders, affiliates</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subsidiaries</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lender and all such other persons being hereinafter referred to collectively as the </font><font style="color:#312d2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Releasees&#34;</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and individually as a </font><font style="color:#312d2f;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;Releasee&#34;),</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of and from all demands</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the Third Amendment Effective Date for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or the transactions thereunder or related thereto. Each Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or attempted in breach of the provisions of such release. Each Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">asserted </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or which may hereafter be discovered shall affect in </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manner the final, absolute and unconditional nature of the release set forth above. The provisions of this section shall survive payment in full of the Secured Obligations</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">full performance of all the terms of this Amendment and the other Loan Documents.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Reliance. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby acknowledges and confirms to Agent and Lender that each such Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs and Expenses. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees to pay to Agent on the date hereof the reasonable and documented out-of-pocket costs and expenses of Agent and Lender party hereto, and the reasonable and documented fees and disbursements of counsel to Agent and Lender party hereto in connection with the negotiation</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the date hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Binding Effect. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment binds and is for the benefit of the successors and permitted assigns of each party.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governing Law. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complete Agreement; Amendments. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Severability of Provisions. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U)	</font><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Counterparts. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment may be executed in any number of counterparts and by different parties on separate counterparts</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">each of which, when executed </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delivered, is </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">original</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pdf) or other electronic transmission will be as effective as delivery of a manually </font><font style="color:#444244;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">executed </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">counterpart hereof.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment and the documents related thereto shall constitute Loan Documents</font><font style="color:#545456;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:10pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#312d2f;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">Electronic Execution of Certain Other Documents. </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The words </font><font style="color:#413f41;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;execution,&#34; </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34;execute&#34;, &#34;signed,&#34; &#34;signature</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#34; and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assumptions</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">amendments</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">waivers and consents) shall be deemed to include electronic signatures</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the electronic matching of assignment terms and contract formations on electronic platforms approved by Agent</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or the keeping ofrecords in electronic form, each of which shall be of the same legal effect</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">validity or enforceability </font><font style="color:#413f41;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a manually executed signature or the use of a paper-based recordkeeping system, as the case may be</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the extent and as provided for in any applicable law</font><font style="color:#504f52;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including the Federal Electronic Signatures in Global and National Commerce Act or any other similar state laws based on the Uniform Electronic Transactions Act.</font></div></div>
  <p style="font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#312d2f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#5b5b5d;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#312f31;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">the parties hereto have duly executed this Amendment, as of the date first above</font></p>
  <p style="margin-left:1.16%;font-size:10pt;margin-top:0.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:46.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.913%;"></td>
    <td style="width:76.087%;"></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">BORROWER</font><font style="color:#4b494b;white-space:pre-wrap;min-width:fit-content;">:</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">ALDEYRA THERAPEUTICS</font><font style="color:#5b5b5d;white-space:pre-wrap;min-width:fit-content;">, </font><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Signature:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">/S/ Bruce Greenberg</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Print Name</font><font style="color:#4b494b;white-space:pre-wrap;min-width:fit-content;">:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Bruce Greenberg</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">HELIO VISION</font><font style="color:#5b5b5d;white-space:pre-wrap;min-width:fit-content;">, </font><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">LLC</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Signature:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">/S/ Bruce Greenberg</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Print Name</font><font style="color:#4b494b;white-space:pre-wrap;min-width:fit-content;">:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Bruce Greenberg</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#312f31;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#312f31;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">[SIGNATURES CONTINUE ON THE NEXT PAGE]</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#312f31;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to ThirdAmendment to Loan and Security Agreement]</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="min-height:0.44in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:46.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.913%;"></td>
    <td style="width:76.087%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">AGENT:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Signature:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/S/ Prentis Robinson III</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prentis Robinson III</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Associate General Counsel</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LENDER:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:14pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:14.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;min-width:fit-content;">HERCULES CAPITAL, </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">me.</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Signature:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/S/ Prentis Robinson III</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Print Name:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prentis Robinson III</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Associate General Counsel</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.68in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#312f31;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to ThirdAmendment to Loan and Security Agreement]</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>aldx-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.96in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.2</font></p></div>
  <p style="margin-left:2.04%;font-size:10pt;margin-top:3.85pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:center;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">FIFTH AMENDMENT TO LEASE AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.987%;text-indent:7.617%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.046%;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">THIS FIFTH AMENDMENT TO LEASE AGREEMENT is made and entered into on April 29,</font><font style="color:#3d3d3d;white-space:pre-wrap;font-size:19pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#3d3d3d;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">2024, </font><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">by and between 131 Hartwell LLC, a Massachusetts limited</font></p>
  <p style="margin-left:7.92%;text-indent:0.128%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.065%;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">liability company (&#34;Landlord&#34;) and Aldeyra Therapeutics, Inc. a Delaware </font><font style="color:#3d3d3d;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">corporation </font><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(&#34;Tenant&#34;).</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.759%;text-align:center;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">RECITALS:</font></p>
  <p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.87%;text-indent:7.668%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:8.667%;min-width:6.398%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:4.195159014436124%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">The Landlord and the Tenant executed a Lease Agreement dated September 20, 2017, a First Amendment dated November 27, 2017, a Second Amendment dated October 7, 2020, a Third Amendment dated August 12, 2021, and a Fourth Amendment dated November 22, 2023 (the &#34;Lease&#34;) for approximately 9,351 square feet located at 131 Hartwell Ave, Third Floor, Lexington, MA 02421 (the &#34;Leased Premises&#34;).</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.815%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:8.667%;min-width:6.537%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:4.188839155079171%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">The Term of the Lease currently expires December 31, 2024, subject to the option extension contemplated in the Lease. Tenant has requested an extension of such Term as considered in the option.</font></div></div>
  <p style="font-size:10pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.815%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:8.667%;min-width:6.537%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:4.188839155079171%;text-indent:0;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Now, therefore, in consideration of the foregoing premises, the mutual agreements contained herein and, in the Lease, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, Landlord and Tenant hereby agree as follows.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.037%;text-align:center;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT:</font></p>
  <p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.731%;text-indent:7.827%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:8.796%;min-width:6.537%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:4.188839155079171%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#262626;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Term.</font><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> The Term shall be amended such that the Term of the Lease shall be extended to December 3 1, 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.602%;text-indent:7.803%;font-size:0;margin-top:13.1pt;justify-content:flex-start;margin-bottom:0;margin-right:8.667%;min-width:6.537%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:4.322604385376308%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#262626;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Rent.</font><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> The Term Base Rent of the Lease shall be amended with the following addition:</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.139%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.82%;"></td>
    <td style="width:24.48%;"></td>
    <td style="width:27.1%;"></td>
    <td style="width:21.6%;"></td>
   </tr>
   <tr style="height:21.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:7.1pt;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:7.1pt;text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lease Year</font></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:2.2pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:2.2pt;text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Annual Base Rent</font></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:2.8pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:2.8pt;text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Monthly Base Rent</font></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;text-indent:3.15pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:3.15pt;text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Per Sq. Ft.</font></p><p style="margin-left:3.15pt;text-indent:0;font-size:11.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.001388888888888889in;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rent</font></p></td>
   </tr>
   <tr style="height:13.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:7.1pt;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:7.1pt;text-indent:0;font-size:11.5pt;margin-top:0.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.0125in;text-align:left;"><font style="color:#262626;white-space:pre-wrap;min-width:fit-content;">1/1/2025 - 12/31/2025</font></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:2.2pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:2.2pt;text-indent:0;font-size:11.5pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.021527777777777778in;text-align:left;"><font style="color:#262626;white-space:pre-wrap;min-width:fit-content;">$285,205.50</font></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:2.8pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:2.8pt;text-indent:0;font-size:11.5pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.03194444444444444in;text-align:left;"><font style="color:#262626;white-space:pre-wrap;min-width:fit-content;">$23,767.13</font></p></td>
    <td style="border-right:0.75pt solid #000000;text-indent:3.15pt;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:3.15pt;text-indent:0;font-size:11.5pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.030555555555555558in;text-align:left;"><font style="color:#262626;white-space:pre-wrap;min-width:fit-content;">$30.50</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.463%;text-indent:7.79%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:8.667%;min-width:6.537%;text-align:justify;"><font style="color:#262626;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:4.466321579476317%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#262626;white-space:pre-wrap;text-decoration:underline;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Extension Option.</font><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> The Tenant has One (1) remaining option to extend at a rate of $31.50 per Square Foot, (the &#34;Fourth Amendment Second Additional Extended Term&#34;)</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#262626;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">In all other matters and respects the Lease is ratified and affirmed.</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.2%;text-indent:7.432%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.046%;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, </font><font style="color:#2f2f2f;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the parties set their hands and seals to this Fifth Amendment to Lease Agreement to be executed the day and year first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:1.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">LANDLORD</font></p>
  <p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">131 Hartwell LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.55pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#2f2f2f;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Charles P. Minasian</font></p>
  <p style="margin-left:5.16%;font-size:10pt;margin-top:5.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Its: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Charles P. Minasian Managing Member</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TENANT</font></p>
  <p style="font-size:10pt;margin-top:0.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.053%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#2f2f2f;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Bruce M. Greenberg</font></p>
  <p style="margin-left:5.16%;font-size:10pt;margin-top:5.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2f2f2f;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Its: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Bruce Greenberg Senior Vice President of Finance, Interim Chief Financial Officer</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>aldx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Todd C. Brady, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Aldeyra Therapeutics, Inc.; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.98%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:45.52%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 1, 2024</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/    Todd C. Brady, M.D., Ph.D.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">     </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Todd C. Brady, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>aldx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Bruce Greenberg, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this quarterly report on Form 10-Q of Aldeyra Therapeutics, Inc.; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.98%;"></td>
    <td style="width:1.5%;"></td>
    <td style="width:45.52%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 1, 2024</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/    Bruce Greenberg</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">    </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Bruce Greenberg</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Senior Vice President of Finance, Interim Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>aldx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Aldeyra Therapeutics, Inc. (the &#x201c;Company&#x201d;), does hereby certify, to the best of such officer&#x2019;s knowledge, that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the &#x201c;Form 10-Q&#x201d;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"></td>
    <td style="width:1%;"></td>
    <td style="width:59%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 1, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/    Todd C. Brady, M.D., Ph.D.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">         </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Todd C. Brady, M.D., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 1, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/    Bruce Greenberg</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">        </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Bruce Greenberg</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Senior Vice President of Finance, Interim Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification &#x201c;accompanies&#x201d; the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img130887665_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img130887665_0.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M(S-S\6.#LR1TM#8WPD,U=24GA,1%_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
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M_#F_FS<//]GT _2CNNO^'-_-FX>?[/H!^E'==?\ #F_FS<//]GT _2CNNO\
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MZ ?I1W77_#F_FS<//]GT _2CNNO^'-_-FX>?[/H!^E'==?\ #F_FS<//]GT
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MY_L^@'Z4=UU_PYOYLW#S_9] /TH[KK_AS?S9N'G^SZ ?I1W77_#F_FS<//\
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MZ ?I1W77_#F_FS<//]GT _2CNNO^'-_-FX>?[/H!^E'==?\ #F_FS<//]GT
M_2CNNO\ AS?S9N'G^SZ ?I1W77_#F_FS<//]GT _2CNNO^'-_-FX>?[/H!^E
M'==?\.;^;-P\_P!GT _2CNNO^'-_-FX>?[/H#HI_#Z\M>07-_I::+Y'<H;_[
M3MS7*T[HCK)<O*M)I?K%G4]NW*KU]'R]KRMU.JL_5\%%-T.\@Q2.KX??4R=0
MQCYL[@FG$
M
M
M
M
M
M                  !3,^-E_-\<6/QR8S^)+;XO]/EWTW7,Z$4
M                                                         '3%
M^":_-\<I_P <F3_B2U +_3Y=Y-U<S$4  '"<YG?YX7*_\97>O\:-I&J_O3XT
MI^['B:U#*@
M              #?_I._G3>FG^/_ ,-_Z16N0';Y   !1G^.!_S?.!/[LFX_
M\":B+_3Y=]-USGQ%
M                      !U7_@^/S/C'\9O=_\ \@I8LYH\7\4A:9$4  '
M'
M        !,I\/=^>>Z?G[M2W^ ]O&J<_DGZDG-Y8^MV9!E0  <\WXXW_ !C]
M.7^\GDS_ ,^Z2%_I\N\FZH<B*
M                               #KB?"C_F1>,G]^W(K^/S88LYH\7\4
MA8T$4
M
M
M
M
M
M              4S/C9?S?'%C\<F,_B2V^+_ $^7?3=<SH10
M                                                      =,7X)K
M\WQRG_')D_XDM0"_T^7>3=7,Q%  !PG.9W^>%RO_ !E=Z_QHVD:K^]/C2G[L
M>)K4,J
M           -_P#I._G3>FG^/_PW_I%:Y =OD   %&?XX'_-\X$_NR;C_P "
M:B+_ $^7?3=<Y\10
M                      =5_P"#X_,^,?QF]W__ ""EBSFCQ?Q2%ID10  <
M <
M         $RGP]WYY[I^?NU+?X#V\:IS^2?J2<WECZW9D&5  !SS?CC?\8_3
ME_O)Y,_\^Z2%_I\N\FZH<B*
M                             #KB?"C_ )D7C)_?MR*_C\V&+.:/%_%(
M6-!%
M
M
M
M
M
M             %,SXV7\WQQ8_')C/XDMOB_T^7?3=<SH10
M                                                    =,7X)K\W
MQRG_ !R9/^)+4 O]/EWDW5S,10  <)SF=_GA<K_QE=Z_QHVD:K^]/C2G[L>)
MK4,J
M         -_^D[^=-Z:?X_\ PW_I%:Y =OD   %&?XX'_-\X$_NR;C_P)J(O
M]/EWTW7.?$4
M                 '5?^#X_,^,?QF]W_P#R"EBSFCQ?Q2%ID10  < <
M
M   $RGP]WYY[I^?NU+?X#V\:IS^2?J2<WECZW9D&5  !SS?CC?\ &/TY?[R>
M3/\ S[I(7^GR[R;JAR(H
M                          .N)\*/^9%XR?W[<BOX_-ABSFCQ?Q2%C010
M
M
M
M
M
M
M        !3,^-E_-\<6/QR8S^)+;XO\ 3Y=]-US.A%         '05^%#Z9_
M GF7T[MS;/Y2\5]3;QV! \T=B4*'ME\@U9.7CZ=%Z.XZ6&/KK9=-VWP2-:3=
MHD')"=F<X5=J9[?E%B9C1YDF+4X=LX#?#(TW9LEHF[:_Z8U/W0P=H0\IJ&Q[
M@U=6MJQLC(1:$NTCW5%D-B,;C'R3J'>).T29:D6,W4(L3Z4Q3"VU9K(M\4;Q
M9'TE'9U1?A'.'6SM17[:/3MA[#H+?M?B)ZWUS4Z%KG;MI[;#XC8DD:G(-;O+
M3=@H,K+J-E$XEQ'218EHLY\$[#+?P3-9DG)(IR_#Z<>=4<BNL=Q.X_<C]8PF
MQ]:6ASR%97K6=ZC5U(J2>5'C)NVT1;2;BU#-G!',%;*ZT=%3-W3).6I>]CM+
MG 9I7.Z.^[>E1\/?QHK\5;>1W&O@3Q_JL[,EKL'9MVV2H:JK\S8#,G<D6"BI
MF]VZ!CI&9-',%W&&J*AU\H(*'[O=(;.+PI\'FA+(\/GE@Z\?#Q=!;G5J\UCT
M5J[74'&2C-XC6]W\-=T+N6+)Q*QK1PV?,/4UFNVI+"=!!1LZ;D?13U/!#X,7
M&"+'\1,SNP>)SGNL%TN=B=)CE],\=+98L7^C6"O,]CZ5V<E&*Q6+OK:8DY6*
M:9EV'>6:1EPKLM#.6$JT165(55(CA/.$'*';)\&95L7X4/IG\">9?3NW-L_E
M+Q7U-O'8$#S1V)0H>V7R#5DY>/IT7H[CI88^NMETW;?!(UI-VB0<D)V9SA5V
MIGM^4(F8T>9)BU-;LGA;\+EIJ[S^L]P5SI5:IV15%VS6T:^V3N_3E&N];=/6
M#259MI^J6C9,7/0Z[N,?H.4B.&Z9E$%DU"XR0Y<YO"GP>:"R/#YY5_?B&-4=
M!6E]/"0F.G7*=/!YR*-NC6+-)'C5N;4M]V;Y(7]?GLYT8.H7JQS18,IT6WI:
MY6^$T\9+@Y\8-V96VQ-MGF@LL5:NE7TP]X]5GE%#<>]0Y3KM=BV2=MW'M>48
MN'=<U9KM"0:L7LT[32RD64L4HNYPVAXHJJ:LB[SGM,DW1<N$)$>972-HO10Z
M"'2NT>QN/)'6W'Z<C8@T:C8]Z\YI6K79:UV+"31L5)G7KWV:_:KR+HO>2B(6
M&)XGB9+E-;/:;-RSDC-]-U/&^G2>(_PR_4B;3M T?JGIR;%GEHU=B\@>.3:@
M:>V?'-3IK'Q+QD5J977]Y:&0\(YR/TD,D[4\XR<Q<9*&6-%GDDR3E<P[J0T#
MC7JCG9RDU;Q!5M*_'76VV[#0==.+E.XLLVY3I^4*]:7))WU5#*R,"YNL=)'B
M3JHF<8B3-BK+.5<'<*R<DD9G0UZGOPZW1PX\=.WFKO73O#WR?M34G&S;5_U[
M:?>"Y2V#R_;:S49*4@Y;U):-W3=<E?0GS<A_ ?,W+93L[JB9RYSC*,L^0ER\
M!% '4/X9?#K='#:_3,XI<@[_ ,/?7^W]E<%-%[DNMN]X+E+%^NMD7'0%6NUD
ML?J"%W='5B.]8V>16=>AM&2#!'O^&D@1+!4\6,LQ'A2<D2YU_3VU;1-X\^N#
MVE-I07FC66X.7_&G5NQ:UZSF(3S%1-@;HI53MT%ZYKLA$6"(];U^7<-_2F+M
MJ\;^)WT54U"E/B*ZFCKX6SH6.&KE!+A(NQ570612>M>2_+H[IFHJF8A'38CW
M?3QF9=N8V#DPLBJEDV,=XAB]I<AS#>I]P%V!TTN:6WN*-ZR[D6-3E"SNLK>Z
M*VQ[0-1V11P\H5S)EGV-<.GT:F9L_3)@N&THT=(=W&4LX%F+/$0D]^%_X%<3
MNHESZV[I3F+JGVP:RJ_$"_;2@JUYYV3K_P!!O<)NC0%3C)WUSJVXTFP.?1J_
M=I1OZ*L[49G]*[YTC*)I'3@?% <"N)W3MY]:BTIPZU3[']96CB!0=I3M:\\[
M)V!Z=>YO=&_ZG)SOKG:5QNU@;>DU^DQ;?T5%VFS)Z+WR)%445.H$OWPO_1GZ
M;/42X"[=W7S%XX>V#9M7Y?W[5L%9?;!OK7_H-$A-+Z MD9!>IM6[1I-?<^C6
M"[2CCTI9HH\/Z5W#JF332(F%9;K;\;M+\1.J5RXXY<>*9[/=,ZPME)C*-3O,
M5KMGJ-E+ZFH%FD4/,-XG;+:I+TB;FW2_>>/G!R>+W"Y*F4A"V<D^1(2-?#__
M  ^MCZJLS);\WU*V;6O"V@6,]>=2=>\*.NV[+E&89.Y.F41_(L7C2+K,0@Z(
M29G,)+9254]#:%RZPNJR69+9/!"[7?.'_P -3TRXJIZ_W[IKIXZTE)*'*A!L
M.3$!0MO[,L+!EAN5>><DVVWOMV>$56[OB2&2$1\13)"G+@W<%RSHL\D&2&M7
M,'IS_#<\B^$._.6]#UMQQ5USI36UVV9)[-X+7JOT>=AGT) R:[.OEC-:*R=-
M0G)B41(S9QLW .TDWIR8]&QV9P+ES3&3Z:,Z>+.Y7@PTO8?" ]+_ $3R(H7*
MOEERIX_:EWQ2#6*M:)U#6]XZDI^SJJUF81HE=MF6N%C;_#3D06323FH&/2>-
MFY54B^F(^+V'4)B[GA3=3S]7_HZ<"M]],#E-)<0.('%76FXZ%3;/LK6=\X^Z
M"TQK>W2=ET7,OY*U45M::G2X>3=Q]F;U>4AEFQ')$7#DZ><&SW"YS8C+9.<M
MR6PY- RJW[\*5TN."?4H]_/WU=&>VCV+^ZY[-/\ U3=Q:Z\M>T7WBO.7^*?8
M-$]<>N/(D5_YP]*]']%_4/"\5;Q T4^)>X.\7.GYU$J_HKB)J_V2:K?<;-:W
M]U5O.NQ+[XMML%NV9%R\MZ[V;;;I8R>EL:^S)X!7F&R?@]XB93'/DUG-'B2-
MU7M$4          '3%^":_-\<I_QR9/^)+4 O]/EWDW5S,10  <)SF=_GA<K
M_P 97>O\:-I&J_O3XTI^['B:U#*@                #H*_"A],_@3S+Z=V
MYMG\I>*^IMX[ @>:.Q*%#VR^0:LG+Q].B]'<=+#'UULNF[;X)&M)NT2#DA.S
M.<*NU,]ORBQ,QH\R3%J<.V<!OAD:;LV2T3=M?],:G[H8.T(>4U#8]P:NK6U8
MV1D(M"7:1[JBR&Q&-QCY)U#O$G:),M2+&;J$6)]*8IA;:LUD6^*-XLCZ2CLZ
MHOPCG#K9VHK]M'IVP]AT%OVOQ$];ZYJ="USMVT]MA\1L22-3D&MWEINP4&5E
MU&RB<2XCI(L2T6<^"=AEOX)FLR3DD4 N 6H:AN#J#<*=";BK#F9H6T>9''#4
M.TZ6]>3M:>2M0NV[*;3+Q6'<A"/H6S0#E]#2;IHHLT<M'[4QLF2525*4Q8J\
M1\0;T*.E7P?Z6N[^1O%WBS[,-S4^V:8C*[<?;?R-NOJYE;-LU&LV!#R]L/;U
MMJKOT^$E%T.\NQ5.EW^^GDBA2GQ8S3XDG<<Z\171\Z"O05Z3W-'I/<4^2_)?
MBG[2MV[*]N?G6Z^W/DE3O77D[DEN*@5S^YR@;BJM2CO5U2JK!I^M&"'C>!XJ
MO?6.HH<*"W,V@5+5','E;JV@1/J"B:UY)[TH%*@O3Y.4]2U*G;0M-=K<3ZSF
MGLC,R/JZ&CD4?'=N%W*W<[ZJASY,;-G),QX4C+$)7_AL."]=YU]4O5%:V328
M2_:1TG7;3O;;]7MM68VVEV2&JS9"#J54M$1,H.H"1C)_8=EBL+LWJ2Z3QDBX
M)E(Y>_W4:2733F.E1TD;CB[:U0Z?/ QC.$JZ"5@\K\3^/D1;*O&W=M/1D-,Q
M\JQUT5U!3"V8AXJQ<)FPNBJWPJ7&/I,Y98R[AGR..5S"XYV;B)RGY!<8[<FY
M+.:.VU=M='<N_ RM+1E>G';6OV$IFW8@9O9:_AK((F+@N#).2Y[I>WLPF+)\
M"PR/TZ^$E_ZB?,K1_$/7;Y."D]K695&P6]RP=2+"C4.NQCVS7RY/&K4OZX-!
M56(=*-&ZBC=)[(9;M<K(Y7PH5 Z=E9Z/O0$Z3VAX&P\D]6\9G4,V>,8F4W?S
MC\H;'F[]<UH=)!9)C%[$;/JJG(R3>*5=IPE>B&[9'L663;8SXBF;GR1F^FZF
M;.^2EP0^&6ZD5-M[?4- X$S^&,8[?3DGQ:L5-TI?*4T@&'K)Q83PFIY&F2T(
MRCV#,SA95[&FCW"::F5RK$\7 9<UD3]-,)DSN<-QDUYQHV5UBN-VI==5N5MW
M$6]]1[2.MJM5]F2;:SR=RT+9.2=5JK6-N;YA#5EO(8ME(>=UTF5HADJ;G*63
M',7*IY.2<C3J';7Z/G08T-2)/9F\N(W"G3&MX5>.:S&P=KNX'75(B74P_;Q4
M2VD[7;[-#P+!>4DW:39L15P0RZZI$R8,<V,9O"GP>:$LCP^>6H_N]_"4?/\
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M5KD!V^0   49_C@?\WS@3^[)N/\ P)J(O]/EWTW7.?$4
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M?J2<WECZW9D&5  !SS?CC?\ &/TY?[R>3/\ S[I(7^GR[R;JAR(H
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M63^/VE[=R.WIIW0%!;+.KGNC9E)UA6DT&:S[*4M=K%'UYJ\6:M\E4.SCSO\
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M_F1>,G]^W(K^/S88LYH\7\4A8T$4
M
M
M
M
M
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M7\92,\^/^"IX(H          .F+\$U^;XY3_ (Y,G_$EJ 7^GR[R;JYF(H
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M_#?^D5KD!V^0   49_C@?\WS@3^[)N/_  )J(O\ 3Y=]-USGQ%
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MX@72:BZGH\83N3/'A@S3X&#?@8_^]$_U)O\ M<"*@!^*._/K\YO]6;^AYQ]
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M\7\4A8T$4
M
M
M
M
M
M                  4S/C9?S?'%C\<F,_B2V^+_ $^7?3=<SH10
M!T^_@J?S66_/Q_\ :?\ 1UXJ@))>476MZ(?#GDAL?7?(#;%*J7*C5LG%)7=F
MQXL;GM-Y834G7(:<BBH[(K>E92OR3M6M2[,Y5D9M0B:9L)&.4Y#)EU;5FMR)
M9&>S*KQ]6KXO?6EWTW?>/_32K.P/,^PJ^^J4[R8V-!I4UO48"?9.6,ZOJBH'
MD'5E<6T\>X\%K*RJ4=B-6.99%LLHFBKADCPR9_$K\_"X_GU^#/\ K,_T/.00
MRKIB]4;JL\>>DGI_7^[.1U-W/=:KL?926K8./TE7J/8[ UL"U7L-M*\E6M[V
M)K>.0AL1U:7)E1%VNOXYT\>%W<F.6V9+3=L9(L/(*]\K.GS*\D>FQ:*'/;%V
MYHY?8/&*9VC"/W%2?65TQR[CZ_<(-&3B'43-X=MG$2L1PME**F"]KI)=)!5!
M199.5-QQ9>2^S-];@W]MO8G**PVVT<A9^[S*>W9:]-RLK86ZPB_E^5B9B+3:
ML&\(M73118Y..1;MV\<BU(V12222(F5-MN7.L>!TBO@J?S66_/Q_]I_T=>*H
M@P5U1/BM]Y]/_GIR)X?5;B1J?8D!I2PUB&C;G/[!N$-,3B5@U]4;HHL^C(Z*
M<LFJC9>RG0+A,YL&(E@V>S.<XQK^6,]OG^QG+.A5OZQW7LV=UB*#I2A[!X]T
M/3".E;A:+=%R5-N-@LJLVK:86/AG3)^VFXUF1NFV)'$43.F?.<YR;&<9^3.)
M,Q99"Y=U>;^$?N$=9NC#JN%8KM57.O=T[\I\PFW7\95M(O;TO?TD'R?<+Z*Z
M-$7AJIA/M-VHJ)G[?I^S"<T>+^,D9Y<[WK@:LF=/=7GJ+5*=.JH^E^5^V=IH
M&68GCSXAMYV%?=E<(5N==P91).O;!:E37[V,.D\86P4F%,$*F+%18"  [7_6
MF_-)=1S\3K>_^ ,P+3G\D_4DYO+'UN* (H [7_3N_,S<&/\ [&-QE_HJTD6G
M[T>-*ONSXG(_Z3OYTWII_C_\-_Z16N1%7_/C5OS66@_Q_P#5G]'7E4 ]?\*/
MU6"\SN([CAON6T%E>1G$:%91,(K-/W3^<V5QT,=M&4ZQK*OD_P!?/M=NW)*W
M(8*HJ8C,D8LKG*CHW99RQ;NIX'R^"'3 3Z9OQ'N\;1K6I+QW%?F-P?WA;]+F
MB&#E.NZ\N2.\N-MEV5J59VNLLBB2OR$:=_%H)Y+@D/+-$$R9PU6,6S%O\Q;9
MD5YOC5OSIN@_Q -6?TBN50RJ?[X*G\UEOS\?_:?]'7BJ ID?$D_GN.>W]_6M
M_P"(C58M6?R1]21F\L_6ZCFX:XORUZ2.TJE1'2:KKDUTY[O7*:]BD#SJ*B^Y
M^,\G&5YU&MDU&*DRF=2R(G1(4Z)G&.S&,DR;MQ9RUV;EI&2GR.(^,J )DN@1
MPUSS@ZJW%C6$DW.O1*%<$]^[0R54B2>:/I55M<\Q3GOH.3J,[=:FD7!*E3*5
M3PY3.2G2SCQ26-.A)T.JAU5."EJZDO"S8_#RL[^=<;T-I2]+4M6P6>OU-E+.
MZK5+/'6MY4C5Q&^ZW4RUL4C#-2.%?6>"^CD.D=)4BIBA"HQ^B3\/W:NC9N7<
M.QF/-E'D%3-T:WC:79-=*<<%-4JH6"N61M-U*XH6HN_-D)JYA&3N79F9&C/U
M<LIW\+IY1[JJW)8>%!O\;!PP(SG.+'/RM192$F6KWC!M9ZV;/NP[^-Q/;$U*
M_>JIF/&$678*V5H94Y4W"A&S9/OJD33*DW/$FZ^U\#'_ -Z)_J3?]K@148WQ
ME'YVVJ?B=:<_P^W*+.:/%_&4C//C_@J>"*          #IB_!-?F^.4_XY,G
M_$EJ 7^GR[R;JYF(H  .$YS._P \+E?^,KO7^-&TC5?WI\:4_=CQ-:AE0
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MT_Q_^&_](K7(#M\@   HS_' _P";YP)_=DW'_@341?Z?+OINN<^(H
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M^%'_ #(O&3^_;D5_'YL,6<T>+^*0L:"*
M
M
M
M
M
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MC-I,5G"<<HH@D[48X3,<I39+@W;C&>SL%C@S-EDY?#]B3PHBW)]/*YV(PT
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M<1B+6OMV[(D>T:U1 Q,F[ZAE%#YR;L[I2R;,EA%NZAJ$4
M  =5_P"#X_,^,?QF]W__ ""EBSFCQ?Q2%ID10  < <
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MUJK5+*R1<Y<):^JLWWA5>4MK2']3QS!R4SURD\7<81*DCA47-%IG<O494
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M=/ Y) RH          .N)\*/^9%XR?W[<BOX_-ABSFCQ?Q2%C010
M
M
M
M
M
M
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M%ALMEL,PY>2\[8)V7>+.GKUTLJY=.53JJG,<QC9#SX
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M2,5,/JU(6&BS4%+O*^\EX)BZ59*+&;*.6:"IB9.BF8H;/_E8NJ;_ .N6<_\
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M>1_7?DKVZ;DV+MOR?YF]4>8_*WG^QV#R_P"8/+[#T[T3P?2_06_B][P4^Z&
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M;**AB=[NFSC(:U            ZXGPH_YD7C)_?MR*_C\V&+.:/%_%(6-!%
M
M
M
M
M
M
M        %,SXV7\WQQ8_')C/XDMOB_T^7?3=<SH10
M                                               =,7X)K\WQRG_'
M)D_XDM0"_P!/EWDW5S,10  <)SF=_GA<K_QE=Z_QHVD:K^]/C2G[L>)K4,J
M
M    -_\ I._G3>FG^/\ \-_Z16N0';Y   !1G^.!_P WS@3^[)N/_ FHB_T^
M7?3=<Y\10
M               =5_X/C\SXQ_&;W?\ _(*6+.:/%_%(6F1%  !P!P
M
M 3*?#W?GGNGY^[4M_@/;QJG/Y)^I)S>6/K=F094  '/-^.-_QC].7^\GDS_S
M[I(7^GR[R;JAR(H
M                     .N)\*/^9%XR?W[<BOX_-ABSFCQ?Q2%C010
M
M
M
M
M
M
M   !3,^-E_-\<6/QR8S^)+;XO]/EWTW7,Z$4
M                                          '3%^":_-\<I_QR9/\
MB2U +_3Y=Y-U<S$4  '"<YG?YX7*_P#&5WK_ !HVD:K^]/C2G[L>)K4,J
M
M  -_^D[^=-Z:?X__  W_ *16N0';Y   !1G^.!_S?.!/[LFX_P# FHB_T^7?
M3=<Y\10
M             =5_X/C\SXQ_&;W?_P#(*6+.:/%_%(6F1%  !P!P
M                                                           3
M*?#W?GGNGY^[4M_@/;QJG/Y)^I)S>6/K=F094  '/-^.-_QC].7^\GDS_P ^
MZ2%_I\N\FZH<B*
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M \9+ZZG]67Z(!XR7UU/ZLOT0#QDOKJ?U9?H@'C)?74_JR_1 /&2^NI_5E^B
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M >,E]=3^K+]$ \9+ZZG]67Z(!XR7UU/ZLOT0#QDOKJ?U9?H@'C)?74_JR_1
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MZ.5FKI-)=+"J*A3E[Q<=XIL9Q\F<!.YXDA8E$4   !KZ*XP
M
M
M
M
M
M
M
M
M
M
M
M                                                          &<
MHC_S5&?_  /9?^\R8C<9GT 4 :^BN,
M
M
M
M
M
M
M
M
M
M
M
M                                         !G*(_\ -49_\#V7_O,F
M(W&9] % &OHKC
M
M
M
M
M
M
M
M
M
M
M
M                         9RB/_-49_\  ]E_[S)B-QF?0!0!KZ*XP
M
M
M
M
M
M
M
M
M
M
M
M
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M*YA1+06[T>FW0C(T:2WU2O6@L<9QAT9@6?B&<J5D9UA%OAR9KAWW,J>&3O\
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MF+M92PJ03%S*S!:U;*@ZME(D_0X=DN]\)9^T>Y9H*K9;E*BKW+XDF)A.8(@
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M@Y2FQC/RXQGY S9$?3$
M
M
M
M
M
M
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M'??%W=-BK)K'5'ZGI%8V;J*Y/X&0>0SY9LCER@RL,$K@GC(8(NECNJI9*8Q
MS2T[-/#C>9N3G$OC/R*5:IL'>\-#ZHVG)QR29TTHN9N](A+!-Q293E)VIQ<N
M^6;X,7M(?"?>)DQ<X-FRXW+&^(H_//<Y?[\];?Q%ZM$JSMQF:Z<>[A>>E;U-
M=,WBU/6^9+C;N^B3]HD:Z;,DQMFI+(WC74^_@#)X,LO&;&TK;EE&GTN%L(2)
M.TN%,9+BV<&JR3/#LE,'[*58LI2-=MW\=)-&S^/?-%2+M7K)XB1PU=MET\F3
M6;N$%"G(<N<E,7.,X^01A6J^*NY:FX\],:6U'!2:K&[\N+]!:B:%:*HIO4=?
M01BWO9K_  57/>/'/(^$903K!"F-X<]C'R=O>Q=Q8SN:)8-/V.MZ4UANZ3*Y
M;5_:]^V]1JRV<QKIIAYC4$1J:0F9Y@_6,5"5C'C_ &GAC@R)<D1=1C@ACF/@
MQ$Y9DM;=$_X.#\V/O3\>_9W]'[C $,59ULT$ ')F^)D_/<\U_P#5O_HD:%$;
MC,FBZ0/PU'!7J =.OCSRYW)M?EG6MD;:]K7F.$UG>M/0U(9>0]Y;,UG$>I(V
MTZ(N<\V])@:8U6<^/).>^[45,3PTS$2)4F;)25?H<'3'^_ISO_?.X_?[, 6)
MPI3.]7?GLTZ;W W<G)5LDS?;!:M6-"TQ"ODT%VLOMV\G6C*GEVT<.&Q'\76D
MTW,Y((8/A1:-BG!28R?.,9I&67)KUM0N374GY?UZC14I-;BY-<G=C+%<V*WR
MZJCJ8GY)-S*S]HL\N=-?,=7*Q L'+YX=)+*4?%,3X11\-(B0F>6\R^7QQ^#P
MX04^FQA^36Y]Z;FV4XBT23^:'-U[6&MH^34,FLXS7(C-7G[BY*U,7*!%WLMD
MBZ><J9:I',4J=R,\)$]UB?A;V7#O0]YY7<*MHWS9NN=5QCJU;8U'M@M??7RM
MT5CA5S/WFHW6L1%8BK'$U)IG#A]&NHILZ;QB"SHKQR=/*)I81.E%[T!NJ+>>
MG?S2H%;G+;(I\6>0-PK^OMZ4YX]2\MQ"]B=(U^L[>;HOW*#*&F*!)O$%G[Q/
M)5'$$5T@<JIL(831H68M=6G8W^+V^?WF6C_F1\+&>/&PX7@RY'2&M?P:W3U>
M0KE"C\D.9==L1_\ W#E+79-(W*%0SX:F,>DP,1I&B/G?ZKDN?I9)'Z7&<?U<
MX,6Y-UGA2H;<WN)^Q.GSS"W'Q9NEC:2EXT7<8UJSN59].B49F+EH2#O5"N$8
MDJIZ?".IFIV&.D/ \50[)=7*95E?#PJ9F:C*ZLG1+Y66_FCTO^*&^-C2;F;V
M3)4V;HNPIIZ0I7\]:]47.R:R>V>0.D@W:K2%N;51&67,B7P_&>F+V%,4Q"WP
ML3G2JB(C=ZP_YJSJ%_BA[U_P FA8_A)&=RFNEI^<XZ<WX]_$/^D#KT9;G,[*
MFQO\7M\_O,M'_,CX:C/'C8<1S0VE;7R(VG7]/412/Q<[:PMJE8:23C#5&:FZ
MW3+!;(ZL-ES=B9)>V.8(L8PP?)4S/G:6#F*7.38D1;-CD6,OA*N5/L2ZDTIH
M:9D_1*GRWU58*:W:*=A&JNS=:(N]D49\X<9^E2.6M1UECD"FSC"SF43)CM/D
MF,HT)5F=.0&'/ ^,<Y:FNG)'CQPTK\FJ>$TA07VW;^S051RT6V#M=<L?66#]
M+&3+XD:Q1*WATCG."EPA9,]G>[?I4YFJ52+=NG['HJ]I:\MI7*-A+0=07F18
MO8UU#OXC.V]1T?;+:!DHUZ;+MI)U]G=TV+DJF"'RNW/G)"=O<*F+)L:=BWI:
M?FQ^G-^(AQ#_ */VO0<<YW)KY<4AQLWJ?<G-;M):+@76P>>>Z*0VG)M4Z,+"
MN+7R$LL"C+2ZR13J)1<<H_PLX,4N3%2(;.,9R+,6U6>%N,S=GH6;VLG 7K):
M-@]AF4JJ,_LRS\0=T1*YTCD9N;_**Z]0823M(ZB"#*L[@8PKYRO@V4BIQQC9
M-W.TPD9)LDG+#K5 PI7_ !D7+4U3T1QKX7UZ351D]OW.4W7L5JU51QGR-K-$
MT#38N32-G*QF%CNMB7>H]TN,>D5SY38[.Z:[C5*AGLS3]CU97=(S]B*Y;YW?
MJ4VX(./>1KJ,=,*XMM'9^M(HQRNC=]ZVFRZT/*-7)2D279OT3$P8O8H>3%C3
MJ??#-_F1N%'^LA_2WWT#$YU0#XO?\ZG4?Q0]1_X?[C%G<\2TYEA#X.#\V/O3
M\>_9W]'[C )"59ULT$<F;XF3\]SS7_U;_P"B1H41N,R\1\+G^9AXW_WY\@OX
M]+\-;D,SG5,_B]_SJ=1_%#U'_A_N,)W/$M.97)OVK-L\>IC5<W96<G39.^:[
MU_O[4UFB))1NO)4ZU^,^JEQK<Q'+).FCR,G8=VS.=,R:[.5C5T\9P9+O9F6&
MG6,Z'G4GC^IEP9I.SYUXP3WOK-9/5/(:"9^E$RC?8)B@>/N#=)X0BAHK9%;4
M;3"9D\JMT'BSMD54ZC-7LOA8F+&NOQ1GYF'DA_?GQ]_CTH(;DD9U6;X.#\YQ
MO3\1#9W]('C )"U9EIGXHS\S#R0_OSX^_P >E!%W)2,[GB=('AOK'J =13CS
MQ&W).WRM:WVU[6O,<WK.3K\-=V7D/1NS-F1'J22M-7N<"V])GJ8U1<^/&N>^
MT45*3PU#$5)EJ<D+O_Z'!TQ_OZ<[_P!\[C]_LP"V,\*4L_2[Z-_&/I*^W+W<
MKUO>Z^W_ -F?G+VV6?7UC]6^RKV@^7O+/D36&M_0_3/:0^]-]*]-\3PD/"\'
MNJ>*)FU+," #F1?%[_G4ZC^*'J/_  _W&+.YXFJ<ROM/5#:7$/8_'_9D=*L6
MEDD*?I?E-IZUQ"I7C7"4@LVLU?>%(;L.22I]YKSR*>I'P7NR$4M@O:GW#&ED
MQ+6=V?.-^[JQR5X^Z3Y"4P^#5?=>JZ)M"%2[W>49L[M6HZP8C'6,]ATGT4H^
M,V<)FQ@Z2Z1R&Q@Q<XQ7&CVZZ7+4W#3I=\I=G14FK%WJW4P^E-9+M544I%*\
M[B/FE-I2+,OG!/3ZG R$A.%^0V<%BS9P4V<=F4:5C.Y*T=I^QR&B;COWNN6]
M1J6VM;:?P=6-=8:3%CV'3MKW0Q6$P8Q&1W-;C-88R[;%PHJ4LJV.;*93$\26
M9+6UV'X)[_O,/]33_M6!#-3;SXRW_,)XQ_C>1O\ $SM@7^GRI3G52.@7TT]%
M=4_F'LGCYR#MFVJ=3*=QJN.Y(R3TW.T^O6=>SU[:.G*2R8/WMVH>PHI6!5BM
MA/5%4DV23@SA) Q5RD*HFIEJ9L6Z?T.#IC_?TYW_ +YW'[_9@%L9X4IP.FGT
MT]%=+#15LX^<?+9MJXTRX[:G=R2<GN2=I]ALZ%GL-/H=)>L&#VDT/7L4E I1
M6O62B22C)5P5PJN8RYB&333$S:YH/Q%'YY[G+_?GK;^(O5H59VHS)U.D#\-1
MP5Z@'3KX\\N=R;7Y9UK9&VO:UYCA-9WK3T-2&7D/>6S-9Q'J2-M.B+G/-O28
M&F-5G/CR3GONU%3$\-,Q$B$F;)>0ZD?PCEDT?J>T[HX';CN.[$Z'"2-BLVC=
MKQ<+C9<S!Q#55[(N]=6RF1D-!VJPH-4S')"+Q$>JZ(F;#9TLY,DT566YB*M*
M!;H_]53;?2VY-U^_0<K-3>@KK*Q,'R&U&1XLI#VVF*.TD7%FB(M0^6+;8M,;
M*'=1#TI2*G[JC)13#5TOC*)TYEF+77UKEAA;=7H&UUN01EJ[9X:+L,!*ML*8
M;R<+-,4)*+D&^%2)JX1>L7*:A.\4INZ;';C&?D%8<5_J"_Y^W-W\;SDI_'-=
M!*OO3XVXS.N7TM/S8_3F_$0XA_T?M>@Q.=Y_JO\ +@O!SIZ<I.1[.3;1=NJ.
MM).#UBLY*[5P?;-]50HVM.XV89*]=$97"P-':Y4S)]UJW54.HDF0ZI+!&5RR
M^E)P#G^I5RFL&@XUVJ@=AH#D#L]U)Y])77;6"NZ[EHK63M0B3IGEVB?=EGK1
M72:KA%-9J=4IC9[V"FD1;.5N9L9JZ!_+1QPIZJ?'.US[Y:!I>R;&ZXX[81=-
MS)^'6MM.&E=8'E2J8(NQ:U?9#>#EG1NSOIIQIL9QG':7*,]A.9UV085L.4_P
MMG3^Y=<B-O\ )C9.X.8L)>]U764OEJB:/L#2D;4F$O+Y3RY;5]A/<?++,M8T
MF4\=PCE^[5Q_PJ9"<JVRJ&_$*=(7C7TF[3Q:@^.EWWC=&F[J_MJ5M:FZK+0K
M&XCW%#D=?LX@E>/1=::X3:(N4[6XRYPY([,<Q$^YE/&#8.F,EK43:]!\/%T;
M^,?5J][[WC;UO>E>P#V >3?8G9]?5SUE[5?;9YA\S>>]8;(],]#]F['T+T7T
M+P_%7\7QN\GX4)FQ;FX@_#!\!^%7)/4O*75FW>7T_L#3=A<66L0]_OVF)6G/
MWSF&E(,Z4]'UW0-5FW33#264-@K>0:G\0I<][)<9+FQD9ME5=^+W_.IU'\4/
M4?\ A_N,6=SQ+3F91Z!?0+X>=4_AYLGD'R#V3R5IUSIW)6XZ;C(S3=QU=7JP
MO6*]J[3EV9/W[*[:<V%*JSRLKL)ZFJJF]2;F;I(%*@4Y5%%(3-B;_P#0X.F/
M]_3G?^^=Q^_V8 L3A2L@4G3=8XZ<2*CQ\I+^>E*9HKCG Z;J,G:74>]L\C6-
M8:S:4F ?V-[$Q<'%.YYW%0:2CQ5LR9MU'!CF302)G"9;&>$<189<CI0/?@W>
MFH=JN2/WYSE:O3$[&SA[L+0;]JDIVX[#+LT.-T<JX)V=OTI5TL_^U%L8X4JQ
MW66^'GW+TNJVGONA7XN_N*KV>CZ](6]6#S7=@:MF)M?+>"9;&@FB\A#NH&7>
M&(S:3K)=-%9^<J"[1D=9KAPLT-1-K?SX6'J[;!USO&K]-G=MED[/I;;JDPEQ
M[?S+QU(.=3;-:Q[J<\DQJRWCK-J!L!LP<$19%SA!A.F242(0KUV<(RY$JC==
M$L&0  <SCXM_EZ;=W4'JO&J!ET7M+XA:W9P\BT;^F9(CMW;:$5=[PH=90Q6#
MGT>FH59GG"!#90<MG":BN5.\DBEJE$-S:Z>]BXE<5>FSR,DLN#-^:N@[CL*8
M2\!V=I'V2)V%(S==RD\77,1,DQI&_P!/5P@5% GI*+E0F5L&,?"8R+$N@Y\,
M%R\]Y_I9ZVI,Y*^GW[BC.RG'FPD5)A)QY2@DFT[J9T1,N<D-'M-=S;.'24QV
M945AENW';C.<W<M9G.GQV-_B]OG]YEH_YD?!&>/&CB(:4TOL7D+LNO:@U+ J
M6K8MM0L!JM66ZR2+VP/J[69FU+0L7XV2D<3,FQ@U462';C+EV=-+&<9/C(D1
M;D<B13HN=2*;Z97-^@[B?/'JFD[LHUUGR(KZ2DLNW=ZOGY1GZ9;6T/%X7-*6
M76[Q,DQ'$PW666P@NS3[F'AS!'H28M=?J$FHBR0T18H"293,%/1C":A)>-<)
MNXZ5B)1JD^C9)@Z1,=%RR?,UR*I*$SDIR&QG&>S(K#F;?%[_ )U.H_BAZC_P
M_P!QA.YXFJ<RW_\ #-_F1N%'^LA_2WWT(DYU0#XO?\ZG4?Q0]1_X?[C%G<\2
MTYF4>@7T"^'G5/X>;)Y!\@]D\E:=<Z=R5N.FXR,TW<=75ZL+UBO:NTY=F3]^
MRNVG-A2JL\K*[">IJJIO4FYFZ2!2H%.5112$S8W>YG_!P5J(UW-VG@7R+OM@
MO\$T=2#+5/([R@[;W@C=,RV(>&V51JU2F5:GEDT\IM</H99BY<'*59RR2[RY
M5D'"TJE/"[F7R=Z67+%GM76;B;IU^UQ9Y"E[=U/85'\7#W6)A9=6,NNJME06
M<?3%(\:+)8RJD9S$R2*;I#N.$"&PS2N=V#^,7(.B\KN/6FN2.M%'1J/NG7M:
MV! MWY/#D8Q&>CTG+N"E28Q@A9>OR.5F+O!.\GZ2W/W#&+V&S6&=1!&[UA_S
M5G4+_%#WK_@!-"Q_"2,[D%ZDTK:]SM]L&IZD>=_J33]IW5*Q3MQAN\F:I1Y2
MO)6].%P?L37D(&MS+F:53-G&3,(MSW>T^"E-(BUR+D/P9W*GU3L/EAPMG)/N
MM;C7*_R+UU'*]B:"<W47;+7^SRH*Y[,+R$U#3]:5*EV]_P "(5.7&2E/G",S
M-6E?U!ERW_BB>44KRHZJTYIBFFDK%7>,5:JN@*K!Q")I+,QLN95):]@J0\>P
M*X>NIUQ:+*WKZJ."Y546@TR%)V]G>3H;C,KZ[JUG(Z5W)MK3<N^2DY;4NS+Y
MK.4DD$#-4)"1H=IE:L]?(M3JKG;).W,490J>5#Y)@W9DV>SM"8LFQ7<J!QN*
M+U!?\_;F[^-YR4_CFN@5?>GQMQF76.&'PHG3NY%\/.*'(.[;FYHQ=SWKQJT5
MN2W1E6V)HYE6(ZS[/U=5KM/L*XREN.DY*M(%I*SBJ;-)R]>.$VY2%475/C*A
MB6RWOT'\*)T[N.F]=+<@Z3N;FC*7/16VM<[DJ,9:=B:.>UB1L^L+A#7: 86-
ME$\=(.5=P+N5@TDWB39ZS<*-S'*FND?.%"DMENOU-NAIQ,ZK6QM;[.Y#[#Y$
MTV>U?2GM#@&FF+;K6NQ#R(?SKFP+.9AO>-2;%>N)(KUV8I3HN&Z6$L8QE/)N
MTV1$V*PG67^&]X.].[I^[:Y6Z5VIRMM&Q*'8-714/#;1O&HINEN6]VV36*=*
MGDHZIZ,I,XLLWC)I51OE*11*1<I#'PH3&2&69%B9M5RND#PWUCU .HIQYXC;
MDG;Y6M;[:]K7F.;UG)U^&N[+R'HW9FS(CU))6FKW.!;>DSU,:HN?'C7/?:**
ME)X:AB*DBSDA=_\ T.#IC_?TYW_OG<?O]F 6QGA2M5U&M,:95*Q3XM5VO&52
MO0M:CEWZB*KY9C!1K:+:*O56Z#5NH[4;M2Y4,FDF3)\YR4I<=F,69MFU'-:^
M+?Y>FW=U!ZKQJ@9=%[2^(6MV</(M&_IF2([=VVA%7>\*'64,5@Y]'IJ%69YP
M@0V4'+9PFHKE3O)(R6J40W-KI[V+B5Q5Z;/(R2RX,WYJZ#N.PIA+P'9VD?9(
MG84C-UW*3Q=<Q$R3&D;_ $]7"!44">DHN5"96P8Q\)C(L2Z#GPP7+SWG^EGK
M:DSDKZ??N*,[*<>;"14F$G'E*"2;3NIG1$RYR0T>TUW-LX=)3'9E16&6[<=N
M,YS=RUF<Z?'8W^+V^?WF6C_F1\$9X\:.%X,N1THG?P;O32.V7(QWUSG;O#)'
MPV7=[$T$];(K9Q^IJ+M$>-;!5PD4WRY(59+)L?)WL?U1;&.%*ESUD^F8OTIN
M8>>.3;8RVTZA:=:5S<FNK:_AVT#/*4NT6.XU5"*LT:R?R#(L[#3]%D&RBZ)D
MDGB2:;@J"&%?!(EJ)M77_A"=Z[ V=TZ]E:RNDL]FX30/(&:J6MW#Y==PI#4N
MV5*LW52J-U%CG[(^)M,I).D"8[,)%D/#QC!"$QB[C-6=\GXJ?JCWCB)HB@\0
M="VR2I^XN4$9/2]^MM?=$9S].T-%+9@G[&+?I.$Y*%E=H3ZJS!%ZW+WR1T7)
M)E425.D?#-XR(4M.DATGMQ]6/?LOK"A3S'7>M-<1499MU[=EHY:8:4J#F';I
ME 1,/!H.&1I^Z6US'NBQK,[AJAE%DZ756*1ODIY$-3-B[; ?!_\ 3$CZ0I79
M[87+*PVQPB?QM@DV/08>29NU$T2Y/#U]MJM>LMV2*B1C)I/&S]7&%#8.LIV$
MR6Y&>%*I-UM>AGL/I+6*EWBNWMQN7B_M6;>5JF;!D8EO VZH75NS>S*>O-@1
MC-PXC'4D]K[%=U'2C+*2$F1D[[S5F9#!%),-1-J<KX2;JBWF?LUCZ:.Z;;(V
M.#9T^4V#Q:?3KU)RZK:%7.1Q?M0L';MSZQ=0YX9WF<AV9"*)QZ,?)%P8B1D4
MR6,L)5&ZV_\ C+?\PGC'^-Y&_P 3.V _I\J4YT*GP<'YSC>GXB&SOZ0/& 2%
MJS.E4#( YD7Q>_YU.H_BAZC_ ,/]QBSN>)JG,L(?!P?FQ]Z?CW[._H_<8!(2
MK.U<^+(ZK%ZU0TK/3=T19)2J2>QJ6WO_ "7MD&Z5823K7M@7E(FJZ=:/DBE<
M-F%M+'.)&P81,F=Q'89-,G.V=OD#W-"TQNJZO1.Z(6Q>K3=+C99JY.=0<9-3
M2<=#[ V.QC$)>S62UOT$9)+7FO8YZHG&YG20BA7;^0=>*VBD7#8QD'!W":69
M$;LK,V+<%H^#YZ9LI2FT#6-G<LZK;F21>Y?%M@:\GW,HYP10F36"NNM5M()=
MH;*G>RG'DBU.\0O8KW>^4[(SPI>NZ,GP\,ETMN8NYN0=YV_4MYPJFLV]"X_3
M<9!S%3M$/FV3SMUL61N=1=*R\1%R[6"@(IDP<,IA^FX1DI#!TD.ZGW[DC,3-
MJT8(@ Y&GQ%'YY[G+_?GK;^(O5H59VXS)U.D#\-1P5Z@'3KX\\N=R;7Y9UK9
M&VO:UYCA-9WK3T-2&7D/>6S-9Q'J2-M.B+G/-O28&F-5G/CR3GONU%3$\-,Q
M$B$F;)>0ZD?PCEDT?J>T[HX';CN.[$Z'"2-BLVC=KQ<+C9<S!Q#55[(N]=6R
MF1D-!VJPH-4S')"+Q$>JZ(F;#9TLY,DT566YB*M*!;H_]53;?2VY-U^_0<K-
M3>@KK*Q,'R&U&1XLI#VVF*.TD7%FB(M0^6+;8M,;*'=1#TI2*G[JC)13#5TO
MC*)TYEF+77UKEAA;=7H&UUN01EJ[9X:+L,!*ML*8;R<+-,4)*+D&^%2)JX1>
ML7*:A.\4INZ;';C&?D%8<5_J"_Y^W-W\;SDI_'-=!*OO3XVXS.N7TM/S8_3F
M_$0XA_T?M>@Q.=R&.:G)>V\Q.5V_>2USEY27E-N[-M%HCC2YR9=1%25DEFU'
MJZ2:?ZDV85*G-F,:V2)]*F@U*7MSG&393EER+]FB/@_N T1IR#CM^[/Y#WS<
MDS6&)[=;J1=:C3*Q7;.\BBED/9[7ST:QIYCHN06,9LI,.)?T@R13G)A,YD!<
MC/"EA=+X.K4E+Y)Z1V!1>3<W>./=5V-5[)MG4.YZ;#/K;::G7YM.8?UR-N-6
M:L:Q*M[,U:IQ[ML[@6A,-U%CX6SDQ4RLAPDH'Q1)2DZ+_(\A"E(0EQX^%*4N
M,%*4I=YT#!2E+CLQ@N,8[,8P&Y*1G<\7I \-]8]0#J*<>>(VY)V^5K6^VO:U
MYCF]9R=?AKNR\AZ-V9LR(]225IJ]S@6WI,]3&J+GQXUSWVBBI2>&H8BI,M3D
MA=__ $.#IC_?TYW_ +YW'[_9@%L9X4I9^EWT;^,?25]N7NY7K>]U]O\ [,_.
M7MLL^OK'ZM]E7M!\O>6?(FL-;^A^F>TA]Z;Z5Z;XGA(>%X/=4\43-J68$<DG
MXB/EZ;E_U5.0DK%2Z,M0-$/6O&G7)VWIGHY(K4[F0:7-9([HV$G2<CMF3L3E
M%P@FFW6:JHY)E4N,+JI;C,UUZJ?3WL73DW?J+54]EP?.R.*G'S<ZQE$'946E
MRLM(;5_;D0W=NUUU':3#<%4G3HXR5 R+-= F42%P7)DQ81-KJ%='3EY[\'3?
MXM[YDI7UM>'6O65"VJY4)A%TIM/6*BE&NS]X@7.2('LDG">MTBESW?1I!+.,
M8QGLQ9TLSG:$_%(\E[;QRZ4%WC*3+RD!.<CMJT3CBM,PYR).FU:M,1<;Y=F"
MBYOIT&-FI>MI"(<Y)].="0,3&<=[)L",ZA;T3.FA7^JGS2]WBZ[!G-;Z\J.J
M[7N78,U5$(I:XR%9K%@IU13@*DK.-WT.PF9*PWUAVN7#1ZFW:IK']'5SC&!(
M:F;%T#8OP?/34LL"R9T#9_*K6EA8-U$L3A;S0[BQF%5"-2E=6"#G-;I9550R
MW.8A8YW%I]Y=3OE.7"6$[D9X4MDNB-T&VG24V5R+V;;-L5K>EQV7%5Z@ZTN$
M73G%1E*OK%F_5L%HCI2,?NYU2.E;=8FL4HZ3:2;IJ=.';FSGO?(43-J#WXU/
M_&%T]_[S.1__ #WID)S>7>6E&9\/%T;^,?5J][[WC;UO>E>P#V >3?8G9]?5
MSUE[5?;9YA\S>>]8;(],]#]F['T+T7T+P_%7\7QN\GX65F;%E3]#@Z8_W].=
M_P"^=Q^_V8!;&>%*PUP:X;ZQZ?\ Q:U=Q&TW.WRRZWU+YV\N3>S).OS-W>^?
M-B6[9DOZ[DJM5Z9 N?1IZYND6W@1K;N-$TBG\10IU3DSN.YS4Y+VWF)RNW[R
M6N<O*2\IMW9MHM$<:7.3+J(J2LDLVH]7233_ %)LPJ5.;,8ULD3Z5-!J4O;G
M.,FRG++D7[-$?!_<!HC3D'';]V?R'OFY)FL,3VZW4BZU&F5BNV=Y%%+(>SVO
MGHUC3S'1<@L8S928<2_I!DBG.3"9S("Y&>%+"Z7P=6I*7R3TCL"B\FYN\<>Z
MKL:KV3;.H=STV&?6VTU.OS:<P_KD;<:LU8UB5;V9JU3CW;9W M"8;J+'PMG)
MBIE9#A+J!2E(4I"%*0A"X*4I<8*4I2X["E*7'9C!<8QV8Q@1E_T
M
M
M
M
M
M
M
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MTZ-I2+E7Q#Y[%UCX+V%P7&(DY)<T?XBC\\]SE_OSUM_$7JT*L[49E^WX9O\
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M3F7*_C+?\PGC'^-Y&_Q,[8%_I\K-.="I\'!^<XWI^(AL[^D#Q@$A:LSI5 R
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M;I287P^$_4/X@=0N@K[ XI[D@-AMXLC;S945<+P&QZ&X=+.F[=O=Z#,IM+)
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MABN1JZ.@9@_PB8[1PNGCOBLYFZX@
M
M
M
M
M
M
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MG;Y@I)Q>K86751>J9R9O*P>KFRS55(B2+AD9%4F#8/XJEW&9SK'XB(W>L/\
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MU2YP8OR9P*PR,(
M
M
M
M
M
M
M                         SE$?^:HS_X'LO\ WF3$;C,^@"@#7T5Q@
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M6.HXQ1%5XX1/'ZWI,)361TEY ZC]9,S:&+DIUS&6-CY3YR;.<B^+,PS((
M
M
M
M
M
M
M
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MJ]CJ.UFRE4;X;9;':%(4ZG?PIG)<DG@6)L?3Z7?1OXQ])7VY>[E>M[W7V_\
MLS\Y>VRSZ^L?JWV5>T'R]Y9\B:PUOZ'Z9[2'WIOI7IOB>$AX7@]U3Q1,VI9@
M0   !5YW%\)=TYMV[<VGN>U[IYKQ]HVYL:[[/LC"O;&T4T@&4_?K-)VN8:0;
M62XX2TBVB&TC+*$;)KNG*Q$2EP=50V,GRG+-JVRL6:#TW6..FBM+<?*2_GI2
MF:*U+KG3=1D[2ZCWMGD:QK"GPU)@']C>Q,7!Q3N>=Q4&DH\5;,F;=1P8YDT$
MB9PF4C+0  KI<S_ADN!O.?DWM;E;MK;7+FN[$W!)PDK98;75\TW$TMBX@*G
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M;GIB_P N:76=6EP590KXJ)DR)X*D3.#&.G*L38T%_0X.F/\ ?TYW_OG<?O\
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M=KA9\W@8R);O%>[XI#$21(D29F4J B
M
M
M
M
M
M
M                                          ,Y1'_FJ,_^![+_ -YD
MQ&XS/H H U]%<8
M
M
M
M
M
M
M
M
M
M
M
M                         #.41_YJC/\ X'LO_>9,1N,SZ * -?17&
M
M
M
M
M
M
M
M
M
M
M
M
M         SE$?^:HS_X'LO\ WF3$;C,^@"@#7T5Q@
M
M
M
M
M
M
M
M
M
M
M
M                                                    ,Y1'_FJ,
M_P#@>R_]YDQ&XS/H H U]%<8
M
M
M
M
M
M
M
M
M
M
M
M                                   #.41_YJC/_@>R_P#>9,1N,SZ
M* /A>6H/YO3^R+_;02R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7
M^V@60>6H/YO3^R+_ &T"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]
MD7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?
MV1?[:!9!Y:@_F]/[(O\ ;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-
MZ?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\
MWI_9%_MH%D'EJ#^;T_LB_P!M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4
M'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M
M0?S>G]D7^V@60>6H/YO3^R+_ &T"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@
M\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R
M#RU!_-Z?V1?[:!9!Y:@_F]/[(O\ ;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT
M"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;
M0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_P!M L@\M0?S>G]D7^V@60>6H/YO3^R+
M_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(
MO]M L@\M0?S>G]D7^V@60>6H/YO3^R+_ &T"R#RU!_-Z?V1?[:!9!Y:@_F]/
M[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T
M_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O\ ;0+(/+4'\WI_9%_MH%D'EJ#^
M;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/
MYO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_P!M L@\M0?S>G]D7^V@60>6
MH/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y
M:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_ &T"R#RU!_-Z?V1?[:!9
M!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%
MD'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O\ ;0+(/+4'\WI_9%_M
MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^
MV@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_P!M L@\M0?S>G]D
M7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V
M1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_ &T"R#RU!_-Z
M?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\W
MI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O\ ;0+(/+4'
M\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0
M?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_P!M L@\
MM0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#
MRU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_ &T"
MR#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0
M+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O\
M;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O
M]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB
M_P!M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_
MLB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3
M^R+_ &T"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/Y
MO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_
MF]/[(O\ ;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:
M@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'E
MJ#^;T_LB_P!M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D
M'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@6
M0>6H/YO3^R+_ &T"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V
M@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[
M:!9!Y:@_F]/[(O\ ;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1
M?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9
M%_MH%D'EJ#^;T_LB_P!M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI
M_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>
MG]D7^V@60>6H/YO3^R+_ &T"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?
MS>G]D7^V@60>6H/YO3^R+_;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!
M_-Z?V1?[:!9!Y:@_F]/[(O\ ;0+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#R
MU!_-Z?V1?[:!9!Y:@_F]/[(O]M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+(/
M+4'\WI_9%_MH%D'EJ#^;T_LB_P!M L@\M0?S>G]D7^V@60>6H/YO3^R+_;0+
M(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O]M
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M+(/+4'\WI_9%_MH%D'EJ#^;T_LB_VT"R#RU!_-Z?V1?[:!9!Y:@_F]/[(O\
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MX*1,N"$+C.<YSG!2X[/E!7]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M !CG<.SH#26H]I;FM327D*OJ/7-WV=9&%?;LG<^]@*%69.U3#2$:R4A$QSF7
M<QT2H1LFNZ;(G6,7!U4RYR? 52/TU;I9?>#Y_P#[UG'7_:J 6_0
M
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MBU1;:7B7*\>_1;R$:]]%=%*X:N$TW#9<ITE2%4(8N RB
M
M
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M]<=DP_%],[Y^7[ZMWX67\!'&C^1H-DOR^]W]/B>N.R8?B^F=\_+]]6[\++^
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M953)4TDDDRY,8QLXP7&.W/R"Q$S-D9Q_40
M                      < <!LW$\.N9:U:A-E07%CDVK3Y",A;97+_ !.C
M]J'K3Z&EDFDC7K+"6IG6,Q;F,DD'2"[)Z@N9)8BB9TCYP8N<AG7C%U6NH]PM
MM#.7T-RZWG3B13UOEY0Y^Y3%TUO(GCE\=K&P:OO2T]2GW=*4Z.3*,,.44SG*
MFHGG.<@.H9T$>LG$]7GC/8YVXP,#1N3NBY&!K.^:76LOBUF0)9&D@O3MFTUO
M(K/'D?6;OZCD4LQZSETXC7\>X2,JHB9LLL$[@
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MNC7=*V=%UG6\?.6B0[C^>-?JV]6[R$GE5T_63P]8^ T0<IF"W"
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M(O5/(G16S9-18S9..U[MR@7-^=P1,BIT"-*Y8))P98B2I39)@O>P4V,]G9G
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MT.VUF[5QTHLBVL%1GHJR0CA9N;N+I(2L,[>L%E$39[#E*IG)<_U>P!Z8
M
M
M      :9\]>:VM. _&^X;^V-GUBNP\. H%,;N"-Y/8&PY5NZ/7JJP4-@WHZ*
MGHJKI\Y[I_0XYLNM@JAB%3/[)W4[LXWO9KF[U3@\D3_->5[EW=Q9PJY\\13&
M[5,1DMMCDNKJJ]KBBES+N5W+/>'-#<=AW;OJWN[/:9E51"*C$U'*-7I%<(X6
M7CJ;1X-5PX1K]8BO'-X:)#&576.HY<J+NEEEU/VUJ#N_JONUJZC5FJKN*+BG
M/.3A5U;M==7]54Z<T1933$4Q$1YN[NZ;JG@T9FM@\TV
M
M
M
M
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MWKO_ !?T7^\ZL?\ ,C$>A8S_ !=[_P RK_:EP3GE[$=9
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M--$13$TQ$3;P8LBV)FRV(RVY;;(=+4]_?WO#IO9FJF+,LY<NBU<.'S!YP
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M6A;,J/I3^)CYJXR"A&<3*17H3,SY1%HLR+E;THH6SNH'_F%\W/Q1.2?\35T
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M^AM+/ZB7>MY)S5;(Q>OJY>:8[D&I2-WSVEWB$D8E98I4\**LS&[A,Y[F VR
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MD8E98I4\**LS&[A,Y[F VR
M
M                               <^;XD#EO);RYPJ:&B)(ZFN>+$&VJ;
M9F@J?+)_LRW1\59-A39BY*GG+E@DI'0>2FQG"2D2L9//8L;.?US\F>[]&J^Z
M_P"ZWE/_ (S'U37,[L7=$S3=T^*?YJ_#%<6YGEL'=\&ZX<_>J^I7H'U]W
M
M
M
M
M                                             '1Q^'^Y<R?*/@'5
MH"X2SB7V/QSG7.E;&]D'/I,G+UF+8,I?6TZX,;)EC)8J$DE$>*J8RKAS"KJG
MSG)NW/XV^;?=ZC47>V\O</3%.#QE$7U,1&2*IF8O*>7$UV1DB*XAX?%W? O;
M8S59=]-^/F#J@"'/K]_FD>67_P XC^DOIH?1OE+_ /(.K_\ M_\ TU\[&$_Q
M%/E^J4K>N_\ %_1?[SJQ_P R,1Z%C/\ %WO_ #*O]J7!.>7L1UD
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MXZZO+J\W.%$Q;XIS3'AB9AW[J^NKZGA75451X&?!TG(CHZN_YK[GO^*QN+_
M^2'G.[/_ +@P?_F:/]J'5QW^#O/\R5//X07_ #V^3'XJZ_\ &WK@?3_F;_\
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MYK'W-Y=5SFX461/BG-/DF7=NKZZOHX5U5%4>!L,.BY6D'4U_-N=0;\2#E?\
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M]=U%Y<TYYNYX5D:>#DJLC=FRR-W(Z-SK/"7U7!BK@U3IR>G-Z4VH]3>0
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MX+G ];QVK-8:LO.:Q]S7=5SFX49)\4YI\DR[MU?W-_'"NJHJCP?QT-C1T7*
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M.^,F=)%) ^/EQC*GB'.%FP
M
M                              !R6N8%LD[YRRY.W6:4.K*VOD%N.P/L
MG/A3N.)78=A>&1(8J:*>$6_C>&F4A"$(0N"E*4N,%Q^_^[N'HPFH,#AKO_AW
M>$N:8\EW3#S]W%EW3$;D0UT'F6P
M
M
M
M
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M'8;&1^=L1<58;$7F&K^_=UU4SXZ9F)^I[A15%=$5QFF(GSO>CA:
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M)_J3?]K@!?\  '._VA_OQ,9^Z)J'_P!AI4H!T0 %+[XVG_,+XF_C=D_B:V6
MLA=)W\UETT_Q .&_]'77("E]\-9_O(/58_<[YS?T[]$@,Q?'*>O?+'32]'\3
MRSZ^Y;>M^SP/!]>^K^.'EWO][]=>)ZO]:=WN?J?9WN_\O< 74.'1H4_$7BP>
MMX:8KI^..CS0.&!,)L<0IM95C,7AFG@I<$:>@Y3\/&,8["=F.P!L<   #1SG
MSTZ.)_4LTU[$N5^NRV^!CGZDU3+7#/35_8FM[$JB5NI/T*W-T5G4.[<H$*1T
MV5(YCI!,A".VRY"$*4*9FSOAM>KATP;=-[QZ,W-FUWJ'1<K2;G5.;(UU-L^4
M9(8PNVBK!59YV_X];U;,TF9,JXE\17I"Y4L(19S8QW0WHZ,OQ*.X]X\G8CIQ
M=4/42.FN4KZ7<Z^J&Q4*O*ZX6G]HQA%CXUON#5DVDEFAWFP)H938.V'H\>]D
M#)M,,&IED3G#5/XY-A8%*GTU91MZ3Y59V+EBPF>ZKV-/,$E&\=G%9\='M[%'
M/JV*EO"-V9[A?$Q\G>^4+IG#I["R?$7BQ(UL[12NR'''1[V!48(X;L5(5WK*
ML+Q9V:&$TL(M#L5$\IDP0O=)V8[,=G8 V. <XC:JJ<_\;9%GHIO$*AOO3:3[
M,7@T;V*5K@U1D-BE5P?#/*GA*Q4IAYGY<.^Q3./%PICOA8U^+#_,F\A_W1./
M'\=5- 9$^%Q_,4<&?]9G^F'R" 5BN.?^^W6']W?E+_04V\ Z.8"GU\:P\:$Z
M7O'Q@=TV(_<\]];/&S(RZ17;AHQX]<GD7KI!MDV%E6S-:0;D5.4N2IF73P;.
M,G+VA.%T3?S1O3F_%$TK_@=' *@6T/\ ?B8S]T34/_L-*E .B  YW_6__P!Z
M_P"EK^Z)TT?Z7<F LR?$S,+!)=#KG>WK/I/K).NZ5?N?15?!5\OQ7)?3$I;>
M\?M+VMO*K-[XQ?\ PT>\7Y>WL :G_"!/85WT=:^A%G:'?1G([>3*R%;HX363
MFE'-:D4"/SX3)Z0[S79!@;!\Y/V(&3+V_2]TH6C '/I^.5D(12P],^*0.VS8
MV<+R[D)4A6YBNRPDF^XU-J^==WE$I5VQW\3)X23PH;*1BJ&R4OB8R<+./4J:
MR['H&\IF-@PYQ/,^G%.M9O#Q?TIWB7;Z9:HR6'3GQ%O2'.'A#]]3OG[YNW/;
MGM[0$4_P5/YK+?GX_P#M/^CKQ5 6_0'._P"M_P#[U_TM?W1.FC_2[DP'1  <
MY#XV#Q)OF%P.JD&?TJT+:,N/HL8@J5)WXEAVBC&P1RJ*&222]/D8Q=-,V3EQ
M@R1LYSC&.T!T;P                         !2+^-W_S3>$OXQ%Y_BU5
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MZ8;$=1\E'NTL]ADU4C]AB&P55)3!DU"E.4Q<![L
M
M                                                  '*,Y_ZS?Z=
MYP<L];OVRS;RWR"VJ2+PX(HFJYK<I<)6;J<EDBJJZA22U8DF;HG:=3/<6Q],
M;^KG][=TL;1K'NQJ_&T3$\/"75O@JBB*:X\E43'D>>NJN%=4U>"&H0]B<@
M
M
M
M
M                                             "XM\*)K-[@W,C<;
MMJ8D<<NI=9P+WL/DKEZGFYVFVM<&[Y4RF9(*PA\X[ILY](Q\I<8[#_G/Y]XV
MG_\ C=6TS_/_ +V\JC1'\E-$^7^?S/'8^K[M/CE<:'YS>. $.?7[_-(\LO\
MYQ'])?30^C?*7_Y!U?\ ]O\ ^FOG8PG^(I\OU2E;UW_B_HO]YU8_YD8CT+&?
MXN]_YE7^U+@G/+V(ZR       TVZAG(9WQ0X/<I>0T6LDWL.L-,7.9IZJYD2
MH%OCV-/!T'"V''ZDHD>YRK IB=AC*8SDI2F-G&,^4U)@8UEK?#X*K[EY>TQ5
M_FVVU?ZL2X,3>\SAZ[V,\4S9X]STN?%\.#P\@N9O4@977;<?YRH_'6L2G("R
M-+"HI)-;9L-.?BX?7K.?RYPX5E5"VR;//*$7-X3LT,9-QE1-0Z2OVOOUK2O5
M6HINL-/ OK^J+N+,EE-DS59HR1P?!PLFF/6=5W$7^*X5>6FF.%XYW/3E\CIS
M#X ]M    :*]23A?3N>_#C<_':S0\:_GY^JR<SJB9>I-<.:?N"!CW;S7UECG
M[C&#QOAS>"-'QDU$LN(IVZ;'/A)<_;YC4.M;W4VM+K'7<S%%-417'&HF?YHF
M-W)EC1,1.>'7Q5Q3B;BJZG/,9/!.XY_GPU7*>5XW=3S7VNY)^>/HO)^'GM%W
M%@\,LF@G9E&KBR:R?E9=I"YG"7V#;PZ)SX[46\TZQCY39P/L_?S5U./[OUW]
M,6WV'F+RF?!FKCQ<&9J\=,/6M57TW6+BF?NUY)_AZ<GE7UNKO^:^Y[_BL;B_
MP/DA\<[L_P#N#!_^9H_VH>QX[_!WG^9+GO?#X\)J?S=ZC5(KNS8AM8=4Z0J$
M]R OM;?HX5C;8G3Y6O5^GU>0*JDLT=1[Z_VZ+</F:I3%?1;-VAG&"G,8OVOO
MKK:]U3J.N\P\\'$WU47=,QGCA1,U3'AX-,Q$[DS$O6M68>G$8J(KRT4Q;/DS
M>F74V*4I"E(0I2$(7!2$+C!2E*7'84I2X[,%*7&.S&,?U!^>'M[_ *   !YZ
MW5*LWVJV6CW2"C+13[C RU7M-;FFB3^'GZ[/,%XN9AI1DN4R+N/DH]THBLF;
M&2G3/G&?ZHW=7MY<WE-]=3--[3,3$QDF)C+$QX8E*J8JIFFJ+:9ARM799/I!
M=:U=I39EW'USC+RN;LVSES(=QQ*:"M4DWR[A)R14.H3*E@TA;S,WRQ\YP518
MZF<8R7Y/T3'![S=U+;V(FO$8;1FO(C/$>"\IMAZ?EP./_ES45^B?LETC.IK^
M;<Z@WXD'*_\ B&OH^%:@_P#SN"_\W<_]Y2]IQ?\ A;W_ )=7U2YN'0DX55;G
M1U&M4:WV)&H3>JM<14YO3:%?=)&7:V2L:]7BD8NLOTN[E-6'L=[GH9E(D/DN
M%8Y=<F,]\Q>W[KWPUK>:HU%>7]Q-F)O)B[HG1-5ML^.*8JF/#8]6U=<1B,53
M15]R,L^3[;'5I000:H(MFR*3=LW230;MT$R(H(((DPFDBBDG@J:2229<%*4N
M,8+C'9CY!^=)F9FV<[W%_40  !\J=@H6T0DS6;)$QT_7;%%2$%/P4PR;R41-
M0LNT6CY2)E8YVFJT?QTBQ<*(KHJD,FJD<Q38SC.<#5%==W7%Y=S--=,Q,3&2
M8F,L3$Z828BJ+)RQ+E2;_A)#H[]:*TIZM=R$?#\7>2E<N]-9)O5UWJ^F+HR@
M[ZPHDG(&5<.I!*9TU>O44BJ8V%722ZV<X(8^<%_1>"KI[T=U:>T1$U8BXFFK
M_/IMIFJ(W+*Z>%&C(]/O8G X^>!FHKMCQ3EL\TV.HUM_4FK>26G[MI_:=>B+
M_JC;%3=UZRPK@Y7$?-0,PW(HB\8/FI_$:O&RGA/(]\V4(NT=)).$%"*ID/C\
M]X7$XC 8JC%8>J:,3=U6Q.[$QI^J8G/%L2]NKHHO;N:*XMHJARQ.=7$'D7T5
M>>\.UJEGGXU:EV9CMSB]N]FEAN6XU!C+&/$.GG@)DC59^'.F:*LT0<G@*&RH
M4R2D>];G7_0^I]9X'O7J:9O*:9BNG@7MWQ:K,OALG/15Z>%$V>GXBXO<!B<D
MSDFVF=,?3/'\'1UZ6W42UUU*^*=2WG531\+?XPJ-3WAK=!UXKS7NS&#5,TDT
M(FKG+A:KV-')9*$=Y[Q5V"^$SFPZ0=(H_#.\.H[_ %#K&K!WELW,_P UW5QJ
M)S>6,U4:8T3$S[3@\53B[F+RG[V:8T3],R1P>"=H 0F]<3JIPG32XPN24N0C
MWO*7=;.7K&B:ZJ1%YY=PFFBVLFVYYFIDR>(6BMWY#,DE2*$D9I5LAE,[;#PZ
M'MG='N[7K[6'^]B8U==3$WDZ=%$>&JS+HIMG/9;T-88R,)<_R_\ &JS;_D^M
M3)Z%72SLO4^Y0S>Z]]HST]QIU/:_-NYK-/.'KIUNC9\F[)8FVL#SCM4SR5>S
MZKOUI9W)5%%T8U0I%#I+R+54?4^]_>*[[OZOC"8/@QC[RG@T1']%$9.'9N69
MJ(TZ8IF'@=78.<7?3>7ELW43;,Z9T;_VNFZP8,8MBSC(QFTCHV.:-V$?'L&Z
M+1BP8M$2-VC-FT;D30:M&J"92)ID*4A"%QC&,8QC ^ S,U3-54S-4SEE[;FR
M1F0*?$S_ )H'??\ ?QHC^.*GCW+N#_[GN?\ ,O/]BIXW6W^"J\<?6BQ^#F_Q
M;\\/[]]!?\P[4'L/S0_Q&#_S+SZZ'3U']V\\=/\ $^,!Y%S,/K_B3Q5AGB[>
M)O%CO&[KZBF=5##LE%:1E/UZR.=(^"O6*KRW3KA=!3'<(X9M%<8R<I<D?+'
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M_$QG[HFH?_8:5* =$ !2^^-I_P POB;^-V3^)K98"R%TG?S6733_ ! .&_\
M1UUR I??#6?[R#U6/W.^<W]._1("P3\3]TZ[QS]Z<,D_TY7W]JW?Q;N)-\4N
MJPZ2[N<N]48P$M![/I,%&H)KJRDX\K+\LLQ:()F>/GT*BS;]Y1SX:@1M_#P_
M$1\0"</M0\*N;6X*[QWW/QSK+#5M(N^T7JM>U=L7558,C$:_3S?910\!3;-2
MJYZ-#NV4NX8MU6S!)RU4.4RZ#0)]-R]=KI :,@7-@MO4(XT69!NT]*)'::V'
M&;^GG>3Y<%1:MH326;](^EJJ-LE[JA$\)=XAE<D(<ILA*#2K;$7ZFU*]U\SD
MT#=:S VV$,\0]&=FB+'%-)B-,Z;=X_H[G+-X3OD[V>X;MQVY[ 'I@$0'*?KD
M]/KA#R[1X<<L=B6;2MWD==TW9$%?YVES,[JB4B[I)V6(8Q;BQ4Y.Q3%=E6+R
MKK9<JR<:SC$TEDC>EY_5,)AE97K*=)M&IFNA^I!PJ-#E98?Y9I<C=6.+9E R
MF$L)EH2%E4O1WO>SVY;8CLN,%^FR3NX[0%&ODON#6O6H^)NX>W'I^P,Y.T#4
M=HXV^T?=$57']<1MT1QQVK+;1V'O4YGC-C+QT9%4U=E7(9W+)M7#Y>(8HIEP
M5=J7(6T/B-.FI:.I7T[+/4M2PWKSD-H>S,]Y:5A$<D3>W.0@XN3AKGK=FX44
M(F5[<:;+NC1Z1OI'$VR8)G,FF8RI A\^'G^(7XP5/B[0. _/W8\=QGW5QCCO
M911KMMO+^M42[:\JR[F/K=<L%GE$2QNN+OK*-;D@G+&:48-EFC)L=NJ=<SAN
M@$VG,KXAKI4<1-3V*^L>6>E^2-V;1#M:D:AXU;+J>XK-=;%E!WF*@W<UKY]:
M*U1&#ITU['4C,N&R+1#/?*194Z""P5N_A?\ B=O_ )G]03D7UP^2U=>PT)8Y
M[;J^H9)XP79QMSVWN"1E(B]2% S(&.Z4U_J:BO']:25)C*!EI K1)8QX]XD0
M)OOBP_S)O(?]T3CQ_'530&1/A<?S%'!G_69_IA\@@%4#J<7&Q='7XI"L\\[Y
M3+!*:5OMMK^[(A]#,RN7=CUKLW3B^AM](UT\HH>*>W&HR4I8%$XXSE ^<98F
M,=FF[04(%WRI]:[I(7.AM-BQ747XA,()XP+(DB[9O&BT>^(HF236RB[UC<I>
M"V.T?E*KC&6RD45?OXR7!,Y+G& H5_$R=5>#ZJ$S6*]P]AK7=N$G"Z>:$O\
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M1FXGA&QEO0Y-[7:K>I KPALD.=:-RT4SCP<=T.D:
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MDV0>.>Q1[E/^E/).8G#,I*7G9$IG<C(*=JB[M59?./%/W3'R0H;<@
M
M
M *2'Q.?!V5JVU:;SJI,*=>H;+CX76^YUV+4Q_4NPZVP,QI-GEU$B=I&=MIS)
M&**J?L31<0J29C]]TB3/Z;^2'>B[O\!>=UL559B+B:KRYMG[UW5-M=,>&BN9
MJLSS%<S993+R>"O;:9NISQEA4^'WUWP
M
M
M
M
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M /IKYV,)_B*?+]4I6]=_XOZ+_>=6/^9&(]"QG^+O?^95_M2X)SR]B.L@
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M,?BYMO:Y\D1N4QX(C)'GG+:]MN+FC#W475W]V/3X6R@Z#E0$_$S_ )H'??\
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MGK'[)B./1Z=X_1!>;?X3'%?[/MO^3@-INJ?9\1_J>L?LF(X]'IWGZ6?P@?-
M[IN1_P G^,#9D94F'3AF3:SYTBADV/$4;LUJ)'I.52E^4I#+I8-GY,FQ_5$G
MYFZJLR8?$6_Z'K2O[)?[M=%GEWD\G2_^'%XV<!;]7]][0O$AR:Y!U57$A29F
M4KJ5/UIK:9[%"I3U5I!9:?>3%LCTEC$;R<J_<)MSX*Y:LVCHB:I/3N\'?K'Z
MYN:L'AZ(P^"JR51$\*NJ-$U619$[L1$6YIF8R/(X35=UAJHO*YX=Y&;<B/)I
M6-AZ,\H                @!_1<>A1^ S_.9YA_[00";[4^K:)H[5FM-*:M
M@O*^LM/Z_INK==5KUG,3?EVB:_KD;4ZC!>N;%(2]@E_5%?B&[?TI\[=/''A]
M]9510QCY#_K:FKM?[NUK?-/;7JL9>-:;.J4]1KW4)DJQHVQ56S1KB)FHET9L
MLW=H%=L71RE6052<(G[%$CD4*4V @_\ T7'H4?@,_P YGF'_ +00"<G6^O:O
MJ;7U*U?2$)=K3=>U>#IE5:S]IM5XFFE>KD<WB8=K)6^\35CN%D=MF#5-,SR3
M?O'J_=[RJIS9R;(:L\P>F_P8Y]1<?&<O.,^M=TKQ#1:/A+/,L'\!L. CG&3G
M<1E>V?3)"M[%@(QPL?Q%&S.400.L4JABY.0AL!#TZ^$EZ+KB7S)(ZAW$Q9Y<
MH+^7VN_MAGB,)(^'XC/"SY^\GO1G7<SXF?3?&QW\]PY/I>Z&_P#Q2Z&_2GX7
M3\/<M$<-=9,;_ N4Y"&V)L)6R[DN\-+IIHIXFJ[/;:G;FO497&$?I58?##PN
M^?">"84/@P8F^(^_,F\^/W.Z)_'5K(!RT>D3+2$+U5NFP\C7'HSA;G=Q.B5%
M/"06[T?/;THT'+-^XX353QZ7%2*R7?QC!T^_WB9*?!38#IM\S/AB^DWS0O%A
MV?-:HNN@MCV]^\EK9:^-%Q::^1L$R_7RZ>S3RCV.NWG6#67>NE%%G+EI!ME7
MBZIU7&553=\!Y7B)\*_TE.)-]@=F>S_9_)&X51^26K*_)V[PEWKL1+H.4W+*
M25H5)IFMZ!8EH_N=U!.7BY%N3.<*^'E<B:I L:D(1,A4TRE(F0I2$(0N"D(0
MN,%*4I2XP4I2EQV8QCY,8 1*<L>A7TK><6[;%R+Y1\6_:AN2UQU=B9^X^V[D
M92O3X^J0C*NP#?R]KO;M2JK7T"&CT4>^BQ3.KW.^IDY\F-D-KN%7 KB=T[=6
M3^E.'6J?8_K*T; E=I3M:\\[)V!Z=>YNN56IR<[ZYVE<;M8&WI-?I,6W]%1=
MILR>B]\B15%%3J!M^ _!*Q49.QDC"3<<PF(:88/(J7B)5FWD(R5C)!NHT?QT
MBP=IK-'S!\T6.DLBJ0R:J9LE-C.,YP KH<H_A4^D#R9M$M<X[5>Q.-%AGG!W
MLN?C%>V=)KJ[U1=195Q':_NE9V-KFL)J%/@GHT1$,&92EQDJ)3Y,<P8YTC\(
M;T?M0S\9/VF!Y#<A<Q;]*11AMW;?98@'*S<YE6Z,G&:=I>H"2C!-;)#';+F4
M0<%3PFL11(RA#A9/USK;7NGZ/6=9:HH]2UKKJF1B4+4:+1:]%56I5J)1.=1.
M/@Z_"-647&-,*JG/DB*1,&4.8V>TQLYR$-^SOAO>C-N?8EWVUM3B)+WG9&R+
M1-W2\W"?Y0\PW4Q9+18GZ\G,R[];'(!-/QGCUP<W<3*1),N<$(4I"E+@)$^&
MW!CBET_-4.](\/\ 3\5IK6DC:Y2\2D&PG[C;7\Q;)EK','\Y-VK8%BMEOFGI
MHZ(:MDLNGZQ6[5LDBC@B1"DP&=]HZQH&ZM<7K4.U:K%7C6NRZI.4B]5"<2.M
M%6.K62.7BIF)>E241<)INV+DY<*)'362-G!TSD.4IL!!Y^BX]"C\!G^<SS#_
M -H(!,67C5HY;CZSXK3VOXZ]Z!9Z_C=6GUSM.0G-MQ\M1(=@VC(R"LTMLV4M
MMCMOH;1DC@CJ4>/'G?2(IE7*A"FP$&ER^%$Z*UMM;BT-./VP*6W=O</G-2IN
M]MJ-*H=4RI5G2+=I-6*=E8QD[4[W:@T>-T4"'R1N5$A2%($H?"CI=<">G>QD
M$.(7&VD:HFIJ.]4V"]^+.7/9M@C#.B2"T9+;+ODM9KNO"KR*9'&8XCY..(JF
MGX:!,))X(&KF_OAZ^CYR@W+L+D!O#AZTN&V]JV!:U7ZTL]X\E:8C8+$Y00;N
MY8];H>Y*Q4XYV]PV*=?+1BWPNODZRF#*J*',$M^P:'5-IT*[ZQOD5Z]H^QJA
M9:'<X3TZ2C/7-4M\,]K]BBO64,\CI>.]8Q$BLCX[1P@Y1[_?24(?!38"##]%
MQZ%'X#/\YGF'_M! )_@$-O,_H$]*WGA?)?;6\>-#!AMZQ.\OK)M#5=MMVK+/
M:'ATRI.']K9U&88U.V2[K"2?B2$E&.Y'/AXQA?!<GP8,9\<_AJNCAQJMD7?*
M[Q/8;)N$(LFXB93>EUNNVXEDX2>8>HN/(5HFUM:/';=9)+PEW$*LLEA+'<.7
M)E<J!O[S;Z;O"KJ,U.B4?F7I!EN.M:SGG]EHK/SMLK7KNNR\I&EB))1I,ZKN
M='FUF3]@DF55HLY59J&124REE1),Q ]%PJX%<3NG;JR?TIPZU3[']96C8$KM
M*=K7GG9.P/3KW-URJU.3G?7.TKC=K V])K])BV_HJ+M-F3T7OD2*HHJ=0.81
M\6'^>RY#_N=\>/XE:: L.?"[\,^,74)Z*^YM(<P]/53=6O:WS[VUBHLYQ%U$
MS])=.-!\;)):5I5TK+F%N-5FE'<Z[[[MB^17506R@H8[?]2 ;H/O@T>DL[MQ
M;(WNO,R+ABN<+YH#'<.N%*B=+&#]K,SV3TC(WS#8W>QVYQ-X6^EQV'Q\O:$_
MG"3I\<0NG;K!34_$;3-?U97I%9L^M4PDM(3]XODPU0RBG,WF\V%W)6>R.T_$
M4R@BLY]"886.FS0;HY\/ ;G  #Q6RM>U+;FNK]JB_12,]1=G4JU:]ND&Y*4S
M>9J5T@G];L<4N4Y3D,C(P\DLB?&2YQDI\]N,@.?'T#KG<>B_UM.3?2?Y$2SB
M.H_(:5:TO6MFF4UV$5:;]5'$G8N.=XBS.?#8MF6Y=<V5_&F(W+DZ\\ZCV1C]
M]MDF Z*("-'G=T@NGKU(?19/E7QXKMLOD:R0CH?;=7?R^O\ ;,:P:^)AG'*W
MFGO8F4L4,Q*NKX$=,>L8U RICIMRJ9P? 1?:[^$;Z-E&L:4_-Z]WCM1J@_3?
M)5C8F\)].N8PD90Y&*J>O6% F';#OG+DQ%WBF5,)X*<QBY.4X6(]/:8U+Q\U
MU6M1Z.UQ3-3ZRI[+#"MT:@U^-K-<BD.WOK*(1L6W;HJ/7JV3*N7*F#N'2YS*
MK'.H<Q\A 3\6'^9-Y#_NB<>/XZJ: UUZ)?3VX==1/X>_@;0.86CJON&.AB\G
M?*L_(J2<)?J2J?EQR 9^)3-A5I_$7*N(Y222\1JW>E8NO 2*X06(F0N RK4_
MA$^C96[:6R2M$WS>HHKM%R6B6S>D^A4NXD;O99F<4V/J-S4:+=G8?O3&5,X_
MJ'P L2:6TAJ#CEK6LZ=T1K:G:EU=3FAV=:HU$@V5?KT6FLJ=PZ639,4DRKOY
M!VJ==TZ5RHY=N%#JK*'4.8V0\%RQXC<>N<6DK%QTY1Z^]J&F[7(UV6GZ=YKN
M]*]/D*I-LK% ./,.N[+4K4U] F8]%;N(ODR*]SN*8.3)BY#Z/%SBYHGA=HFC
M<:.-%&]FNDM:^9O)5*\S7&X^I?.-QL-_L?\ ='?[#:K;(^L;;:G[O]=OU_!\
M?PDNXB1-,@9_ 1WQ?2BX"0O.)7J11NA?1N:*TC,2RFYO:ENA;O2$]K1[IZ6<
M>SMQL575&/2]<R*T=W,06")]_P!()@KK!5L!(@ @%Y$?#(]'7D?L*<VA/<;)
M'6ULM$BXE[)C2NQ+AKBL2TH[566=O24:.D7-)@5'2RW?4+%1[!-0^.^8N3&.
M8P;X:4Z6/!OC]PWV%P&UIIUW&\6]LHW1'9>OW^QMG2K^X9V'%,(.XK/+L[N!
MKO$K3$3%MT.V,D&.&Y4L90PD;)C9#)?"K@5Q.Z=NK)_2G#K5/L?UE:-@2NTI
MVM>>=D[ ].O<W7*K4Y.=]<[2N-VL#;TFOTF+;^BHNTV9/1>^1(JBBIU V_ 1
MW[PZ47 3D?RPU;SAW/H7SERBTK(ZSEM9[/\ :ENBN^6I#3UO5OFN7'DJJ;%@
MM>3/EVUK&=]R0B79'?;X3K"R/8F WWL=<KUPK\W4[= PMIJUEBG\%8ZU8XMC
M-U^P0<JU58RD--PTF@ZCI6*DF2YT7#==-1%9(YB'+DN<X 5Z=F?"J=%S9%N?
M6]#CO<=<*R;M9\_KNL]R[&@*BHZ<K>.L9C7I&;G&E?:9-G)2-(ST)F@3/=21
M(7!<8"3;ACTON!W3\IUAIG%#CE2M:-[E&9A[U9ESS%RV#>XP^#F5C+;L.[R=
MAN4O!G7545)&&>EBVRBAO1VR)<]W >IX2]/3A_TYZ%;-8\-=0^QVCWFWYOEI
MA//^T-A>M+7F&C*_F5]9;3NMXEV7]J(=LCX#=PBV_4^_X??,8Q@Q_P XNE%P
M$ZD4MKN<YHZ%]LTKJB.L430'7M2W1KOU#'VQS$O+ W\#5&Q:*WE/3W,$U-WW
MI')TO"[$\DP8^#!O_,1,?/1,I!RS?TN*FHY[$R37Q5T/28^1;*LWC?QVRB+A
M'QFRQB]],Y#E[>TN<9[,@-$>#'2XX)]-?VH^Y5HSV+^VCR3[2_\ U3=Q;%\R
M^SKS=Y-_QL;!O?J?U/Y[E?\ S?Z+Z1Z5^K^+X2/AAO\ @([Y3I1<!)KG$EU(
MI+0OI/-%&1AY9/<WM2W0CW9"!UHRT]$N/9VWV*EJC/HFN8Y&.[F8+)%.YZ0?
M!G63+9"1 !I?S:Z>G#_J,4*IZQYE:A]L5'HUOQ?*M">?]H:]]5VO$-)U_$KZ
MRU9=:/+O?[43#E'P'#A9M^J=_P /OE*8H;(:GU;1-':LUII35L%Y7UEI_7]-
MU;KJM>LYB;\NT37]<C:G48+US8I"7L$OZHK\0W;^E/G;IXX\/OK*J*&,?(:7
M\:NE%P$X@\D-K<N>.VA?9YR%W='7F)V?L'VI;HMOF>/V5?('9MU;^5+SL6S4
MB%]=7>LL7O?CXUH=MX'@H92;G42.$B "$[FA\/1TJ.=-ZG-K;9X[^3]M6AZ\
MD[1LG2MJF]73MHE7Z6".YFRP\*LK1[!/.'!<.%9!Y$K/G#C&3K+*=]3!PU0U
M+\)5T:]8V!C8)W5^XMTYCGI'[:%VUNFQ*U\RZ/@G;)OHS7#77&)5DW71\3+9
MV==NX[QDW!%D<^& LEP4'$5B#AJU7X]M$P->BHZ#A(IF3PVD;$1+-%A&Q[5/
MMSW&S-FW(F3';GL*7& 'U0$=O-?I.]/3J'NF$QRYXR4K9]OB8@L#$[$:OK/0
MMEQ\.@NL\8Q9=@:[G:I:W\1&/G*J[=B\=.6"2BRO8CV++8.$6+7X27HNMY?$
MDMJ'<3YGARNOY?=;^V&2(RDMXGAL\K,7[.>]&:]_'AY]-\;/<QWSG^F[P3/\
M0. /#7@-49&D\0N/=!TC#31FAK ]KS:1EK=:,QZ)4&&+9L"UR,_?+65B3!LH
M8D9)UA(ZBAR8P=50Q@W! 0_<Y^A#TQ.H7:7>Q]^<=F$=MV0-@\KN#4T[+:MO
M\^?P4T/'MSBLKH5^]/RH())INYR.D7B*214TE2)]I,AIQI/X4'HV:=L<=9Y;
M3NRMX/(IWEZRCMV;:GYNN>D%,D9#$C6:6A0X.>:-\IY_6T@@[:JX4-A9-3'=
MP4+%%4J=5HE:@Z91ZU7Z;3ZQ&-(2M52J0T=7:U7H:/2*W81,'!1#9G%Q,8R0
M)@B+=NDFDF3&,%+C&.P!@_ECQ&X]<XM)6+CIRCU][4--VN1KLM/T[S7=Z5Z?
M(52;96* <>8==V6I6IKZ!,QZ*W<1?)D5[G<4P<F3%R'T>+G%S1/"[1-&XT<:
M*-[-=):U\S>2J5YFN-Q]2^<;C8;_ &/^Z._V&U6V1]8VVU/W?Z[?K^#X_A)=
MQ$B:9 \9S#X+\3N?>LB:AY<:5JFY:4T>JRD&E-^LHNPU.97;&9JS5,N5<?P]
MNJ$JJU-X:BT<];F72QX:O?3^E 05M/A!^CBWM25A6JW(A_$)J(G-17>])$E5
M6*GE/)T57C&!9W?";C!,X/DDR0^,'SW3%^E[H2RS/2'Z;\WQ#4X'K<5:1%<5
M'%BAKA(:PJ<W?*0O,VZ >HOXNUV'8%-MD#LZQ69)9LF160?33AVY;IE06440
M+A/ ;H:3TQK3CIJ/7.B--UOR=JK4M0A*'KZJ^N)^P^7ZI76:<?#Q7KRTRLY8
MY7T-HD4GCO7CERIV=IU#&[<@,&<T. ?$/J$ZW9:KY>Z2K.X*M#O74I5W,BO+
MP5LI<L]03;NY.EWBK2,);ZNX>IMTL.B,WJ2#TJ*9'*:Q"%+@(U.,WPTW28XH
M;QHO(?6&G-A.]F:OML3>=</[;NO9,Q%T^U03L[Z'EF<.TG(MG+F8.<D,5&4P
M_;FRD7OD-]-W@W?WATHN G(_EAJWG#N?0OG+E%I61UG+:SV?[4MT5WRU(:>M
MZM\URX\E538L%KR9\NVM8SON2$2[([[?"=861[$P$B #2#FOTW^$_40J#&G\
MO= T[;24*BY1JMI<^LJWL6EX=G(NOBG['JCZ$NL T<.D4U7#-%[A@\.D3#E!
M8F.Z A:@OA".CA$64\[(5/D-:8LRR:N*9.[TE&]:3(15)0S8CJL0E<N&45B)
MY3-DTL93!#FR4Q3=TQ0G^XR\3>-O#363#3O%W3-&TGKE@L9YFOTJ)*T/*R2A
M"IJS5FFW2CNPVZP+(D*F>0E';Q\=,A"&5R4A<8#VN[-,:TY%ZCV-HC<E;\XZ
MJVU4)NA[!JOKB?KWF"J6)FI'S$5Z\JTK!V.*],:*F)X[)XV<I]O:10INS(#"
M/"K@5Q.Z=NK)_2G#K5/L?UE:-@2NTIVM>>=D[ ].O<W7*K4Y.=]<[2N-VL#;
MTFOTF+;^BHNTV9/1>^1(JBBIU V_ 1W[PZ47 3D?RPU;SAW/H7SERBTK(ZSE
MM9[/]J6Z*[Y:D-/6]6^:Y<>2JIL6"UY,^7;6L9WW)")=D=]OA.L+(]B8#8[E
M;R4UMP\XX;GY/;=D2QNO=)T&<O,_G"R:+J4/&H>'#5F)RK](K8+?/KM8J-2S
M\J[]XBGCY38 4>/A2^,.S.9'.+ESUI>0T<HN\=7/9<+K.2<ME?5\MN[=KQY.
M;:FJHH]RLY:PNMJ!.8K[8B9_ *WL9FR9OUHH0H= D
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MFWFJ-76\1F/U9K"8+A--RE)U>!>NI%^V7_5F$O./6IOE1 6*P
M
M
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M+*JO+W&(IOHLG)7HWD/P^B.R
M
M
M
M
M        ^A%14I.R<?"PD:_F9F6>-HZ*B8IFXD).3D'BQ&[-A'L&B:SIX\=+
MJ%(FDF0QSG-C!<9SGL&+R\N[JB;V]JBF[IB9F9FR(B,\S,Y(B-V9,V65VSHA
M]#R6T9,UKF)S'K>&>W8XR<MI;2\GA!S[-%5VV<-K_?VY<K(&V&FFODT7&&SG
MU ;L<K_VSPD2._,GS.^:%WK2[K[N=W*[=73DOKZ,G.9<MW=_]7QJO_N?=C^2
MV:_&8G%<..;N_N[LZ5K0?!70  !#GU^_S2/++_YQ'])?30^C?*7_ .0=7_\
M;_\ IKYV,)_B*?+]4I6]=_XOZ+_>=6/^9&(]"QG^+O?^95_M2X)SR]B.L@
M    /)7^C5G9U$NNM;I')S%.V'4K)1K9$*Y[J4I6;9#/8">CE,XQG.$WT7(*
MI9S_ .R,.6YOKS#WU&(NILO:*HJB=$TS;$^>&:J8KIFBK[LQ9/E<I"[5CDST
M+NIP@LQ170OO'V^+6*A2\LU5;UK=6EK'B4B6<C@Z9#(NJQLNBNW<;(9;&.K&
M/\NF^#IOF1O"_1EU>8#O?W?LJ_X-_195$9[N\BR;/'159,6YXLG-+TZJ+[5^
M+_RJ9R>&-Z8='?IZ]53B1U'M?0T_IJ_P\-M#$4@XO.@;3+L&.TZ/*IM$UY9
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M8=*&$Z:W&Q&:OD:P?<K=XQD-8-TSV,(NE:7'X2].@=-0#TO?(G&5'+K)I95
MQB2<UE13*BS9NPPC\U[W]XZ]?8_@7,S&K;F9B[CC3NUSX:MRW-3HF:K?-:OP
M<86ZMJ_XU6?P>#R;OA\B<<>HO( " GXF?\T#OO\ OXT1_'%3Q[GW!_\ <]S_
M )EY_L5/&ZV_P57CCZT6/P<W^+?GA_?OH+_F':@]A^:'^(P?^9>?70Z>H_NW
MGCI_BWM^)]X*V/E1PA@]Y:XA%Y[8_#V<L%_=Q3%NHYDY/3-JCH]GMHD<@D8O
MB+USR]$3ZV3=[NQT.[P3&5#%*;Q'R_UQ1J[6TX._FRXQ413;N17$SP+?';-/
MCJAV=;X>;[#\Y1EKHR^3=_A/D0@_#@=9[5W$B.G.%/+*UH4?3MMMKJXZ>VS,
MF4\LZ[M\^FT;6.GW9X7!_4%*LSIHD]:R1BX9QDBHY.\.FW<F<-O;>_7=7$:S
MJC6VK:>'BJ:>#71&>JF,U5.FJ,TQGF++,L63X_5>/HN([/?39=S-L3HG1/@=
M "#G82SPT78JU,Q5AK\VQ;2<+.P<@TEH:7C7B15V<A%R;!9PR?L72)\'362.
M=-0N<9+G.,CXO717=U31>1--<39,3%DQ.B8G,]DB8F+8RP^J,J
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M_+M'S7TANGZ0S=)+$[R:A#9";X
M                                     $;'4YZ86I.JOIRJZ$WMN3D5
MK/5U=N*=YE*[H&TZYJA;[.L69VE?Q>G-\U5LM>3C*N9PNX9-&N62&7:_CKE7
M40:F;AM9Q>XSZ>X=:!U=QGT'5TZAJ?459;UFJQ&%,.7JQ<++OY:=G'_AI&EK
M-:)QZYDI1X8I3NY!TLMG&,G[,!GL
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M#)52>LZI.;CN%_D:O*E27.0KJ/4;."IGR3!\%SG "50
M
M
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M7VO>X^MZ>'C*L/759_\ <NYBJ/!;-,3YI>.IPNM,/-EW%<1X)R?6SG_]M?\
M^G!_U.'3_P#ZX_2?ZSE__F?^L]!_]M?_ .G!_P!3@_\ ZX_2?ZQ__,_]9Z#_
M .VO_P#3@_ZG!_\ UQ^D_P!8_P#YG_K/0V0XF;=^* TGOG7EUVUJ3E'O#4K>
MRP[7:&MM@0%+F6$_1',@@E9,0KM%1M+0%H9Q9U%XYXU6+W'B:>%TW#?*K=7H
MZRPWR^Q>#KNL->X>YQ/!G@54S5$Q59DMW)BW/$[F:R<KEN:];W=Y%5=-=5%N
M6)LS+Y8^.O8@
M
M
M
M
M
M
M
M
M
M
M                      0Y]?O\TCRR_P#G$?TE]-#Z-\I?_D'5_P#V_P#Z
M:^=C"?XBGR_5*5O7?^+^B_WG5C_F1B/0L9_B[W_F5?[4N"<\O8CK(
M
M
M
M
M
M
M
M
M
M
M
M
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MC)<XS\F1ZLXG_0
M
M
M
M
M
M
M
M
M
M
M
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M*8CG+JXJIO:;*HJ_DKF\JLS63DG),Z7%7B*KRG@S31Y(R_6EP'SYUP
M
M
M
M
M
M
M
M
M
M
M
M
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M$Q+((ZB
M
M
M
M
M
M
M
M
M
M
M        "'/K]_FD>67_ ,XC^DOIH?1OE+_\@ZO_ .W_ /37SL83_$4^7ZI2
MMZ[_ ,7]%_O.K'_,C$>A8S_%WO\ S*O]J7!.>7L1UD %(+XC[J0;'G=URO K
M5UHD:OK#7417W>[S0+]9FOL>Z6N"8V9C4YEXU*FHZI]5K4RS,JP*J9NZDW*N
M'29E&:&$OT[\FNYF"NM64]Z\==TWF.OJJHN.%%O-T4533-<1.:NJJ)LJLMBF
M(X,V53;Y/!W-,4\[5]Z<W@53!][=\
M                                  ;P< ^>&Y.G_OFO[<UA,/EJVY?1
ML?M77"KI3%;V91R/"GDH239'-EJC--FJBJD3)8+X\:\-@Y<F2.NBMZOWL[JZ
MM[VZJKU?CJ8B^B)FZO+/YKNNS)5$Y^#,V<.G-5'AB)CBO;JF]HX-6?<\#H3?
ME;^"GWW?_P"B2'_Z _(>S[O5[/Z8>(YB]T)*AZ6X0
M
M
M
M
M
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M4RSA<ZBRIBD)@N,FSGLQC&![G31313%%$1%,;D9(<V9^0:
M
M
M
M
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M4V*NL17=6<**9RQ$YILF(F8FS/%L>%BB\HO+>!,38U>'G6P
M                                   !^SU@_P#_ '>>?URM_P#IC' H
MT1YDLAV)!_.IZ\
M
M
M           ([^<75=X"=-V6UW!\T=]>QF5VO'6*6H#7V6[HV)Z^CZFYB6=@
M<>/JC75Z;Q?H#F=:E[CT[8ZOB]J>#X*?)0D0 1W\:NJ[P$Y?<D-K<1N.V^O:
M'R%TC'7F6V?K[V6[HJ7EB/UK?('65U<>:[SKJLTB:]2W>S,67<CY)V=SX_C(
M85;D45($B             #P=UVGK'6JU;;[&V-0Z O<IE&N5!"ZV^OU5:UV
M%P9(C>!K:<[(,#SDRN=<F"-6N%5S9.7&"Y[< />
M #\4E)1T-'/Y>7?LHJ)BF3J2E)22=(,8Z-CF*"CIZ_?O72B39FR9MDC**JJ&
M*1,A<F-G&,9R \W0]B:_VG6F5TUC>:=L:G29EB1ULH=FA;?6I [93*+@K*=K
M[V1BW9FZI<E/A-4V2&QV9[,@/8@                /%7_96NM45U2W;2OU
M*UK4T7;5@M9[_:H*G5U)\^,8C)FI-6)_'1I';PY<X23RK@ZF<9P7&0'KVSEN
M\;H/&:Z+IHZ12<M7394B[=RW7(55!=!=(QDED5DC8,0Y<Y*8N<9QGL ?V
M!X.;VGK&LW*KZZL>QJ'7]@W=-TM2Z+-V^OQ5RMZ+(JIWBM7K#^00FY]-H1 ^
M53-$%<)X(;)NSLR ]X   #P=>VGK&W6JV46J;&H=GN]"4;(WJG5ZWU^:M5+6
M>94PT2ME>C9!S+UQ1UE$^$RO$4<GR7/=[>S(#W@
M
M                               "$[K?=2QSP"XYLJ]K*1;)<D-[>N*[
MK-0Q".CT6O1R+8EOV>X:GP9$SJ$))(-(A-?Z1:4=%6[BZ+-REGZ;\L.Y5/>W
M7,WV.B?V7"V57FYPZIMX%U$Z*K)FN8S4Q9;$U4R[.%N>=KMJ^Y&?><Y"5E92
M>E)*<G))_,S4R_>2LQ,2KQQ(RDK*2+A1Y(24E(/%%G;Y^^=K'5665.=150^3
M&SDV<Y'[(N[N[NKNFZNJ8INJ8B(B(LB(C)$1$9(B(R1$9GF<V2,SYXV
M
M
M
M
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MCZ]J[O=W:UOBHP6K,;<7^+JB9BBBJV9B(MF?)#MTWMW5-E-43/C:?CV-R
M .Q@/YSO70
M
M
M  !3/^,/Y<ST1QYXX].'5+ES(;/YD[1A+!;:Y&+K%>R&N:%8(QI2JT\;ERDD
MHG?-RR,8NSR8QRY4K*V,DQVE-@/+_!X\J+/&:^Y<=+W;JY6&R.)>SYZ]TN!=
MJ]K]G5I^S.Z;MZL,DLG(;,90]MQ2;M4QD2G]*MAL9-G'<(F%U@!SO_CB?\;/
M3P_<[Y$_X2ZE =$ !SO_ (:S_>0>JQ^YWSF_IWZ) =$             !5W^
M(.Z$&_>KYLOBE?-)[WUAJ]IIF,ME-N\-M!"Z=QO 6R?@9EQ<Z,:I1,\E,6AJ
ME%Y2/&.RQ"+K"*';(IXQV$"S55H12M5BN5Q65D9Y6 @8B$5G)A4JTM,J14>W
M8GE918N"E5D9$R&5ES8QC!E3FR ^\     _!*RL9!1DC-S<BPAX:'8/)67EY
M5XWCXR*C(]NH[?R,B_=J(M&+!BT1.JLLJ<J:29<F-G&,9R Y]G/;X@SJ =33
ME:YZ?70WAK7#U=Y*RE=QNJDM6+/:NU&,0N@VG;[&W*>PC%: TS&.?IT)K*S&
M55;F176>LLN?5^ _1 ?!R<V.0[)"Z<W>J&R)LQ\GF0>H(4O9G*ARUD'V2J.D
M7MXV5M?43]P]P7LPNJDV6(=4N<%.H3!5#!YVT_#+=;O@X]97+IT]11SL',&]
M28L*]6-G[&XR6MU#IX9(L\+4^8M%IU/*0I&[!,KR.?S^4,)HI$(FY+CL3"_Q
MJ&N7>G:HUE4MF7ISM#8]8U_3J_?]E.XV(A7.P+K#UZ/C[3=%X> C(6#BE+/.
M-UWN6S1HV;(>-W$TB%Q@N R(         T@ZDO$Z?YT<%N2_$NK7LNM+)N_7
M+FJ0=T73>JQ\5)HRL7.,V\VC'&P_6K<VM$X829$<'4-'NEL%(?.>X8- /A^.
ME+N7I(<1]AZ2WKM6C;+O6R=V2VV'+35J]G>Z[J#5S3:=4$(V&D[? 52<EY.0
MQ5?27KD\8Q3[#(I%3-X)EE0G>              $ _6/ZO&PNGCR"Z;7'73-
M;U9;;GS-Y#0M,V,ELF)MDR>HZ;5NVOJ-(S592JUTIGJZVS$K>CXC73W,@R+F
M,<84:*?)V!/P @!^(3Z1NZNKMQMTYJ_1&UM=ZWNNH]O*["] VN>V,J-:HZ2J
MTG6'974S3H.VRT5-0J;[*C//JAX18JRR>3H8-WS!*MP<X[R_$CAUQEXQ6"[+
M;'G-#:3UYJV6NZJ*S9*PR%.K;"'=/(YHY57=,8--5ME*/0544508II)G,8Q<
MFR&U    *K/4CZ O('FMUB>+_41HG(V@T/4^K'^@Y"^5R6+<F^V:[G15X7N"
M3;5)8N(EJM+&M9NSL7?/X;$6Z<*K>"][.XH%I&=G(BL0<S9;!(-HF!KT5(SD
MW*O#^&TC8B)9K/Y*0=*=F>XV9LVYU#Y[,]A2YR @RZ"?5<VSU;-,<G-R[.IF
MM:3%:TY-V#6&JX_7<-;(APZUD6J5NU5IW>36FZ7'UE=?1I_N/'#'$<R4,7Z1
MHG\O:$\0"JSTI>@+R!X =5;E9SMV'R-H-[U?MEAN>/H%8II;DWOUHQN/9L/?
MUG.WV,]$(0$06LEB<9(@PDYO+Z0RFXRLW*CE-8+4P
M
M                                 #F?=<+DA(\C^I%O]UF05=5;34\?
M0%*:&45.A'1VK7+N'LV&W>542RE)[%4FGN#IX*4Y')?DSV=[/[7^6&IJ-3=S
M,)399?XFCGZYTS>Q$TV^*[X%/D>:PM' N8TSE\Z) ?078
M
M
M
M
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M2^OZ=2X2JFKFZ)LBN]O(F+;9B8BRF[B*IBGA3'!BV'4PMS%];%<SP(W/#/\
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M?SNK_D7JV^U-1>8W%XBG7-=U%4\'@<U15,6\'@S1PZHIG),\.F9LMB(S.2G
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MALWD+@^E.R    [& _G.]=
M
M
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MK.Q9-T[:U51(U5=.2-5RH8(8+=0
M
M               #D=\EGCJ1Y&[_ )!\L=R]?;LVJ\>.%,XRHX=.KU/+N%E,
MXQC&3JJGR;/_ +7(_H+J6FFC4V$HIBRF,-=1$>"**7L%'W(\4,)CR;0
M
M
M
M
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M);5%4S]V:9MB8FR8F+)RO*TUTU4<.)_DLSN@5S"=XX<]#*XZ_P!B+,6MAIO
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MY]U9=F[ GW$Q:I-V@5GW79$TF+6+9QR9$T8J*@H]HBR9LTRE3:-6Z:1<8*3
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MR+FYMGQ19/FETL3DQ,S.:V/JASNG-7LS-2P(NZ[.M5JDKA"U).8B004K*^9
MD3A&P$5;E-#*YE5"MNZYPGGT@V$_^/G&!^P*<1<511--=$Q>1;19,?S9+?Y<
MO\V3+DMR97F'PAS    #L8#^<[UT
M
M
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M0
M                                                  .7-U:='27'
MWJ+<L:,\8K,HZ8VU8]FU;OX.9NO4MM.<['@L,7!C*>EMHUM9?03'[YS%7:*)
MJ9\4A\8_<WR_UI1K?N=J_%4S$UTX>FZJ_P ^ZCFZK=$S-/"\4Q,9)AYS#U<.
MYIGP6>9'0/<G,
M
M
M
M
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M/W9RQ9X7'<X2;JN+R:K9C<L5>A]R=X   !V,!_.=ZZ
M
M
M                                  YXOQ3&W;GU ^J%PLZ0^BWBSR2I
M<Y4FMP2:E2>-&FYN1J]?,P=S;(CI#&6&K].D9S"BRJS8J+6<>]_)"$\0!)V3
MX*GI:X(7"F_N?IE,%+@YB;0X[$(8_9CO&*0W%A0Q"Y-_4QDQLXQ_PY_J@/\
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MR;>#<R*3AX[*=:.0F7)"&+W<]U;.,]O9CL"C?J__ 'XF3_=$V]_[#2NH#H@
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M78E&BDI1-1)ZYM_'3<[*)L%843RDU43ES0SZ1?'*=ND7"<4MV^&;!4SAT@@
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M;]8[VO4GK2H;FBM?O)29)K;9]%OD8[+*)L5ESODHMRV\9VW<-U<!TN0
M
M                                           %8GXCWIT3&_M40?,O
M4D&XE]FZ K;J%VA!QS=5Q(6?1Z+M].9G&B")53KOM6RK]X^5(4A<GB'[U4Y\
M^AHIF^W_ ":[XW>J=85=V]8513@<77%5U5.:F_LBG@SX+V(BF/\ +IIB(_FF
M7>P=]%%7-U?=G-X_M411^J7E
M
M
M
M
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MPSPZ=+KYC^>3U\
M
M
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MF;?6CPGLF[6<H))J9<*Y9!?4
M
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MQ,Q;IC/#R--5-46TS;#P@[:@
M
M
M
M
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M8>2?G&@
M          !+)TP^E)O7J ;7J;M>H66H<98J<8O-G[CDX]Q$PSN 9./'DZK0
M'STB)+/<II%#+1/T+#E**,N5R[[A,$(KZ!WX[^ZJ[I8"\IB\HO-=U43%U<Q-
MLQ5.:J\B/NT4Y_YK)JLX-.6V8Z]_?T75,Y?Y]R'0W]SGBS]X;6OW-L_H#\@?
M$6O?:[_E2\1SEYIELJ/"L
M
M
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MGVA39^Q=@(S"?<([ICYSX-4CY%8V$Y<_HI&IE4G;/Q Z1
M        _FLLBW15<.%4T$$$SK+KK'*DBBBD7)U%55#Y*1--,A<Y,;.<8QC'
M;D!#]U]MJ4#5/2"YXO+]:(BN%NV@KIK"H-Y*09,WEEO.P6&:Q6*Y!-'3A!:6
MDW;^0PJ9%OA14C1%9;)?#2/G 19?!E4Z9K/2;V#-2:/ALMB<U=OW&NG[JA?2
M(9EJS0^OUUNTY2E/W;!1GR?:3)B_2=G;WL9Q@+:0
M
M
M      QGL_2VGMV0N*YN/56N=K0)<*X3A]C4JN72.1RO@N%3MVECC9%%LJ?N
M%SWT\%-C)<9QGMQ@=W ZSUCJR]Y[5M_?8>]TW==5$^6:9BUJFJJF;:9F):'S
M_1BZ7ME<8=2/#?5[93"SI?NP#BWU1OWWAR*+%RTJUFAVF42&)CPD^YX:!>TJ
M928SG&?:[GYD]^;B.#1K*_F+(^]%%>;PU4S/CG=W7+VF_C^J7P/R'O2L_ _I
MWW9[7_;^.7:AW\]XWG(NNK.TW_&D_(>]*S\#^G?=GM?]OX;4._GO&\Y%UU9V
MF_XTGY#WI6?@?T[[L]K_ +?PVH=_/>-YR+KJSM-_QI/R'O2L_ _IWW9[7_;^
M&U#OY[QO.1==6=IO^-)^0]Z5GX'].^[/:_[?PVH=_/>-YR+KJSM-_P :3\A[
MTK/P/Z=]V>U_V_AM0[^>\;SD775G:;_C2?D/>E9^!_3ONSVO^W\-J'?SWC><
MBZZL[3?\:3\A[TK/P/Z=]V>U_P!OX;4._GO&\Y%UU9VF_P"-)^0]Z5GX'].^
M[/:_[?PVH=_/>-YR+KJSM-_QI/R'O2L_ _IWW9[7_;^&U#OY[QO.1==6=IO^
M-)^0]Z5GX'].^[/:_P"W\-J'?SWC><BZZL[3?\:3\A[TK/P/Z=]V>U_V_AM0
M[^>\;SD775G:;_C2?D/>E9^!_3ONSVO^W\-J'?SWC><BZZL[3?\ &D_(>]*S
M\#^G?=GM?]OX;4._GO&\Y%UU9VF_XTGY#WI6?@?T[[L]K_M_#:AW\]XWG(NN
MK.TW_&D_(>]*S\#^G?=GM?\ ;^&U#OY[QO.1==6=IO\ C2?D/>E9^!_3ONSV
MO^W\-J'?SWC><BZZL[3?\:3\A[TK/P/Z=]V>U_V_AM0[^>\;SD775G:;_C2?
MD/>E9^!_3ONSVO\ M_#:AW\]XWG(NNK.TW_&D_(>]*S\#^G?=GM?]OX;4._G
MO&\Y%UU9VF_XTGY#WI6?@?T[[L]K_M_#:AW\]XWG(NNK.TW_ !I/R'O2L_ _
MIWW9[7_;^&U#OY[QO.1==6=IO^-)^0]Z5GX'].^[/:_[?PVH=_/>-YR+KJSM
M-_QI/R'O2L_ _IWW9[7_ &_AM0[^>\;SD775G:;_ (TGY#WI6?@?T[[L]K_M
M_#:AW\]XWG(NNK.TW_&D_(>]*S\#^G?=GM?]OX;4._GO&\Y%UU9VF_XTGY#W
MI6?@?T[[L]K_ +?PVH=_/>-YR+KJSM-_QI/R'O2L_ _IWW9[7_;^&U#OY[QO
M.1==6=IO^-)^0]Z5GX'].^[/:_[?PVH=_/>-YR+KJSM-_P :3\A[TK/P/Z=]
MV>U_V_AM0[^>\;SD775G:;_C2?D/>E9^!_3ONSVO^W\-J'?SWC><BZZL[3?\
M:3\A[TK/P/Z=]V>U_P!OX;4._GO&\Y%UU9VF_P"-)^0]Z5GX'].^[/:_[?PV
MH=_/>-YR+KJSM-_QI/R'O2L_ _IWW9[7_;^&U#OY[QO.1==6=IO^-)^0]Z5G
MX'].^[/:_P"W\-J'?SWC><BZZL[3?\:3\A[TK/P/Z=]V>U_V_AM0[^>\;SD7
M75G:;_C2?D/>E9^!_3ONSVO^W\-J'?SWC><BZZL[3?\ &D_(>]*S\#^G?=GM
M?]OX;4._GO&\Y%UU9VF_XTGY#WI6?@?T[[L]K_M_#:AW\]XWG(NNK.TW_&D_
M(>]*S\#^G?=GM?\ ;^&U#OY[QO.1==6=IO\ C2?D/>E9^!_3ONSVO^W\-J'?
MSWC><BZZL[3?\:3\A[TK/P/Z=]V>U_V_AM0[^>\;SD775G:;_C2?D/>E9^!_
M3ONSVO\ M_#:AW\]XWG(NNK.TW_&D_(>]*S\#^G?=GM?]OX;4._GO&\Y%UU9
MVF_XTGY#WI6?@?T[[L]K_M_#:AW\]XWG(NNK.TW_ !I/R'O2L_ _IWW9[7_;
M^&U#OY[QO.1==6=IO^-)^0]Z5GX'].^[/:_[?PVH=_/>-YR+KJSM-_QI/R'O
M2L_ _IWW9[7_ &_AM0[^>\;SD775G:;_ (TGY#WI6?@?T[[L]K_M_#:AW\]X
MWG(NNK.TW_&D_(>]*S\#^G?=GM?]OX;4._GO&\Y%UU9VF_XTGY#WI6?@?T[[
ML]K_ +?PVH=_/>-YR+KJSM-_QI/R'O2L_ _IWW9[7_;^&U#OY[QO.1==6=IO
M^-)^0]Z5GX'].^[/:_[?PVH=_/>-YR+KJSM-_P :3\A[TK/P/Z=]V>U_V_AM
M0[^>\;SD775G:;_C2?D/>E9^!_3ONSVO^W\-J'?SWC><BZZL[3?\:3\A[TK/
MP/Z=]V>U_P!OX;4._GO&\Y%UU9VF_P"-)^0]Z5GX'].^[/:_[?PVH=_/>-YR
M+KJSM-_QI/R'O2L_ _IWW9[7_;^&U#OY[QO.1==6=IO^-)^0]Z5GX'].^[/:
M_P"W\-J'?SWC><BZZL[3?\:3\A[TK/P/Z=]V>U_V_AM0[^>\;SD775G:;_C2
M?D/>E9^!_3ONSVO^W\-J'?SWC><BZZL[3?\ &D_(>]*S\#^G?=GM?]OX;4._
MGO&\Y%UU9VF_XTGY#WI6?@?T[[L]K_M_#:AW\]XWG(NNK.TW_&D_(>]*S\#^
MG?=GM?\ ;^&U#OY[QO.1==6=IO\ C2?D/>E9^!_3ONSVO^W\-J'?SWC><BZZ
ML[3?\:3\A[TK/P/Z=]V>U_V_AM0[^>\;SD775G:;_C2?D/>E9^!_3ONSVO\
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M9VF_XTGY#WI6?@?T[[L]K_M_#:AW\]XWG(NNK.TW_&D_(>]*S\#^G?=GM?\
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M<8QC&,=F!X^9FJ;9RS++^H@
M
M
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MONT;2_5MNVM@Y9',=DC:+H_337)$,3&R9O%1R,?#MUC'63:%75644"1(
M                  81Y,Z0B>37&_D%QNGYN1K,%R"TAM?2$U9(=!LZEJ_$
M[7H<]0Y&;BVSW&6;B1BF<^==!-7]2.JF7!OI<Y 4V:Y\$_07MMAU-R]2C<FR
M-8P:R*<;2H+2D14+.PB.\T(]C(RZV7;>S8.,,Z:,R)%41KI2$[A,Y2/@F"@+
ME''#CMJ#B9HW6G''0E0:4346I*VA5Z566B[EYEFQ*X</WSU_(OE7#^7G)V8?
M.7\B]<**.7K]TLNJ8RBAC9#-@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTRA0&3Z1:=@SNEJA=K;K[REM68U? 6FS:I]=-9+RSL&0JC26FM?>8D"X9/\
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M^K[_ &G6>JO736M^TW8-?JDM+4S7WF)Z4[*!\YV-HVC?35L92:^D^*?&2ER
M\OQAOVXMHZ!U9L'D#IWW?MSVNKH2FP],>9V-S]G=@4<N4EJ_YIC")L)OP4$D
MU/&2+@N?$[/^ !ASAYO'EGN2:Y&LN3_$SW7XK6^Y)JF:,E?:/"W_ -N>KF3N
M31BMH^CPZ21ZEZU;-6ZGJ]QWED_2.S.?I<@$?O'EFXYXSF@WO$ST+AVQTVC<
MXCF+[1X57UOM$[B'35U=[,2I>O6WA(O'1_6!C^#GT7L[/I\ '*W>/+/4VSN)
M=7XY<3/>-U_MS<D;3.2>P/:/"T?W;-7.;!2XY_M'U-*I*.KUZ!"S<J]]7M,E
M6/ZJ\/&>U8H#WG,S:7(+2W&S9&S.+''WWI]\5KR?Y$T/YTC->^>_7-]JT!9_
M[L)E-6-B/+%-E9&9_5"Y](]7> 7Z90H#)](M.P9W2U0NUMU]Y2VK,:O@+39M
M4^NFLEY9V#(51I+36OO,2!<,G_J6QK*1OII,825\+Q<8[N0&".">Y^4>^= Q
M^P>8'%SW/MS.+198I[ICV@P^S/0J]&.44H&P^:8-)%@KZ^0.=3P<%[R/<[,_
MU0'R] [QY9[!Y,<J=8[GXF>QC0>J)2M->.V_/:/"VGWBH^3-*XGI#R<P2))4
MGU"5HWSW'1C96](^3_BY -B;QY9USG%H'1='XF>>.(^P:';9_<_+GVCPL3[&
M+C$06PG]:IWLV<)&F[3YEEZ[",_2FYRIH>N^^;Y$#]H.>&\>6>A-8T&T</.)
MGOB; L&Y*M3+GK_VCPNL?)FKI6OW"1L6T?7,ZDLUE/+LU#QC+U>GC"R_K/Q"
MY[$C ,[\AKGM'76C-L7O26K?;=MZI4.QS^M]0^8&=4]I%QC8Y9S!T[S+(%.Q
M@O7KXA$/2E<931[_ 'L_)@!\OC#?MQ;1T#JS8/('3ON_;GM=70E-AZ8\SL;G
M[.[ HY<I+5_S3&$383?@H))J>,D7!<^)V?\   QAQ!W/RCW%[??>;XN>[)[/
M]\7&A:9_]4&'OOMFT]#>C>5]Q?VH22\K^:/%4_M8X[R[?P_IL_* 0&Y^4<AS
MFN^B9KBYZEXAP6AVE]J7+SV@P[KS;N%:Q5"-<Z=]FJ:6)R-]&@YB3?>LSGR@
M;U9X?9VJE ?YR6W/RCUEMGBC4="\7/;UK;;6T'-6Y';)]H,/3O=QU\DO6B-]
M@^HI))1W>/2$I-^?T)IDJI?0.SM_5"@/4\S-I<@M+<;-D;,XL<??>GWQ6O)_
MD30_G2,U[Y[]<WVK0%G_ +L)E-6-B/+%-E9&9_5"Y](]7> 7Z90H#)](M.P9
MW2U0NUMU]Y2VK,:O@+39M4^NFLEY9V#(51I+36OO,2!<,G_J6QK*1OII,825
M\+Q<8[N0&".">Y^4>^= Q^P>8'%SW/MS.+198I[ICV@P^S/0J]&.44H&P^:8
M-)%@KZ^0.=3P<%[R/<[,_P!4!\O0.\>6>P>3'*G6.Y^)GL8T'JB4K37CMOSV
MCPMI]XJ/DS2N)Z0\G,$B25)]0E:-\]QT8V5O2/D_XN0#8F\>6=<YQ:!T71^)
MGGCB/L&AVV?W/RY]H\+$^QBXQ$%L)_6J=[-G"1INT^99>NPC/TIN<J:'KOOF
M^1 _:#GAO'EGH36-!M'#SB9[XFP+!N2K4RYZ_P#:/"ZQ\F:NE:_<)&Q;1]<S
MJ2S64\NS4/&,O5Z>,++^L_$+GL2, SOR&N>T==:,VQ>]):M]MVWJE0['/ZWU
M#Y@9U3VD7&-CEG,'3O,L@4[&"]>OB$0]*5QE-'O][/R8 ?+XPW[<6T= ZLV#
MR!T[[OVY[75T)38>F/,[&Y^SNP*.7*2U?\TQA$V$WX*"2:GC)%P7/B=G_  P
MYPFWCRSWA"[E>\L>)GNFRM+W)8J9JR*]H\+L;VIZNCFC%:$VCZ1"I)$KWKMR
MNLGZO6[5DO![<Y^FP 5#>/+.8YX[3T'9N)GECAW5--QUSUWS%]H\*_\ :)M%
MRXUPF^U=[,44L3L)Z"C9)T_K!4^43^HNS&/UP3L!R;WCRSU?O/B#1- <3/;_
M *AW%?+# <F]O>T>%IONR4Z.D=?MH2X^6I-)1]??7;&PS2_HK3)5$O4O=S\J
MY.P/><S-I<@M+<;-D;,XL<??>GWQ6O)_D30_G2,U[Y[]<WVK0%G_ +L)E-6-
MB/+%-E9&9_5"Y](]7> 7Z90H#,<'/W%]K&'M$O3O5&P'E#CY^3U_ZS0<^K+B
MXKZ,B]IWKDF,-7'H4T<S+TK&/#/W?$Q\F0&".$>W.26\>.U3V-RSXV>Z7N^7
ME+4ULFC_ #U$['\MQ\38Y&-KDAYLA$TH]]YC@VR#[N$+C*'C^&;Y2Y >7T#O
M'EGL'DQRIUCN?B9[&-!ZHE*TUX[;\]H\+:?>*CY,TKB>D/)S!(DE2?4)6C?/
M<=&-E;TCY/\ BY -B;QY9USG%H'1='XF>>.(^P:';9_<_+GVCPL3[&+C$06P
MG]:IWLV<)&F[3YEEZ[",_2FYRIH>N^^;Y$#]H.>&\>6>A-8T&T</.)GOB; L
M&Y*M3+GK_P!H\+K'R9JZ5K]PD;%M'US.I+-93R[-0\8R]7IXPLOZS\0N>Q(P
M#._(:Y[1UUHS;%[TEJWVW;>J5#L<_K?4/F!G5/:1<8V.6<P=.\RR!3L8+UZ^
M(1#TI7&4T>_WL_)@!\OC#?MQ;1T#JS8/('3ON_;GM=70E-AZ8\SL;G[.[ HY
M<I+5_P TQA$V$WX*"2:GC)%P7/B=G_  PYPFWCRSWA"[E>\L>)GNFRM+W)8J
M9JR*]H\+L;VIZNCFC%:$VCZ1"I)$KWKMRNLGZO6[5DO![<Y^FP 5#>/+.8YX
M[3T'9N)GECAW5--QUSUWS%]H\*_]HFT7+C7";[5WLQ12Q.PGH*-DG3^L%3Y1
M/ZB[,8_7!.P')O>/+/5^\^(-$T!Q,]O^H=Q7RPP')O;WM'A:;[LE.CI'7[:$
MN/EJ324?7WUVQL,TOZ*TR51+U+W<_*N3L#U'-S;G)+1W':V;&XF<;/>TW?$2
ME5:UO1_GJ)UQYDCY:QQT;8Y#S9-IJQ['RY!N5WW<.7.5_ \,ORFP S'YIV#[
M%O.WL^_]57V7^:?93ZZ:_P",'RIZV]GWF+N^A?\ I'_:WTWL\+_RO9W0&'.$
M>W.26\>.U3V-RSXV>Z7N^7E+4ULFC_/43L?RW'Q-CD8VN2'FR$32CWWF.#;(
M/NX0N,H>/X9OE+D!\OCWN?E'L3?W+C7VZ^+GL3TSJ"T4.*XT[G]H,/:_>7KT
M^VN"MQL/E:/2(_H?DY>&BT_!=F,9UZT[2_\ BC /\NNY^4<)S7TYI"J<7/-?
M%"YZOM%IVCRP]H,/'>R[8,62UYK^OO9RLEF:L'F T3&X]-1/A)'UE]-C]2,
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M\38Y&-KDAYLA$TH]]YC@VR#[N$+C*'C^&;Y2Y >7XR;QY9[0WGR^HF_^)GL
MU#IV^5Z XR;>]H\+<O>;ITC([ ;3=Q\M1B2;ZA>I&->A5_17>3**^NN[CY4#
M]H+?O'EG#\\=6:#K/$SS/P[M>FY&Y[$YB^T>%8>SO:+9QL=-CJ[V8K)9G9OT
MY&MP1_6"1\(D]>]F<?K<_:#FSO'EGH^%TT]XG<3/>RE;IN2NTS:<5[1X77/L
MLU=(M'RTWM'TB:25)8?4CE!%/U>CV+*^-VXS]+D!G?D-<]HZZT9MB]Z2U;[;
MMO5*AV.?UOJ'S SJGM(N,;'+.8.G>99 IV,%Z]?$(AZ4KC*:/?[V?DP <>;G
MM'8NC-3WO=NK?8CMZVT.N3^R-0^8&=K]F]QDHY%S.4[S+'E(QG?43XYT/2DL
M836[G>Q\F0&'.%>Y^4>[:7M:;Y6\7/=2M=3WQ>:%KFJ>T&'V+[1M/04357=0
MW%ZQA4DD8/S?)2TBV]6*XRNV]7=XV>Q4H#Y=0WCRSF.>.T]!V;B9Y8X=U33<
M=<]=\Q?:/"O_ &B;1<N-<)OM7>S%%+$[">@HV2=/ZP5/E$_J+LQC]<$[ <F]
MX\L]7[SX@T30'$SV_P"H=Q7RPP')O;WM'A:;[LE.CI'7[:$N/EJ324?7WUVQ
ML,TOZ*TR51+U+W<_*N3L#U'-S;G)+1W':V;&XF<;/>TW?$2E5:UO1_GJ)UQY
MDCY:QQT;8Y#S9-IJQ['RY!N5WW<.7.5_ \,ORFP S'YIV#[%O.WL^_\ 55]E
M_FGV4^NFO^,'RIZV]GWF+N^A?^D?]K?3>SPO_*]G= 8<X1[<Y);QX[5/8W+/
MC9[I>[Y>4M36R:/\]1.Q_+<?$V.1C:Y(>;(1-*/?>8X-L@^[A"XRAX_AF^4N
M0'E^,F\>6>T-Y\OJ)O\ XF>P#4.G;Y7H#C)M[VCPMR]YNG2,CL!M-W'RU&))
MOJ%ZD8UZ%7]%=Y,HKZZ[N/E0/V@M^\>6</SQU9H.L\3/,_#NUZ;D;GL3F+[1
MX5A[.]HMG&QTV.KO9BLEF=F_3D:W!']8)'PB3U[V9Q^MS]H.;.\>6>CX733W
MB=Q,][*5NFY*[3-IQ7M'A=<^RS5TBT?+3>T?2)I)4EA]2.4$4_5Z/8LKXW;C
M/TN0&8^3U^W%J[0.T]@\?M.^\#N>J5=>4UYICS.QIGM$L";ELDC7_-,F11A"
M>,@JHIXRI<EQX?9_P@/J<>;GM'8NC-3WO=NK?8CMZVT.N3^R-0^8&=K]F]QD
MHY%S.4[S+'E(QG?43XYT/2DL836[G>Q\F0&".!^\>6>^]8WZT<P^)GN=[ K^
MY+33*9K_ -H\+L[SGJZ*K]/D:[M'US!)(M8OS%-3$FR]7J8RLAZL\0V>Q4H#
MZ=*W/RCF^:^X](6OBYY4XH4S5]7M.KN6'M!AY'VH[!E"53-@U][.44L35?\
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M>4C&=]1/CG0]*2QA-;N=['R9 8(X'[QY9[[UC?K1S#XF>YWL"O[DM-,IFO\
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M%HB*=ZWV SH<A/QFO_6:#;UG<6]?6D65.]<GQEJW]-FB%9>E9QX9.]XF?DP
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M9AQEUG%U9UH?DU[1X6?]O$A*LHA>PQ_D)FD67I_EYV\<I=]R8V%_1NTOR&P
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M ]L_*/WYO83[KG_T(?L'\^^]Y[08?_'#YB]6^QWV:^%Z\_\ ,?Z^]9]_P/\
MR?9V@/E\P]X\L]-S7')EQ@XF>]!%;(W)"TS><K[1X6@>PS5SUW&(RNT?1YA)
M4]M]5-G3A3U>W[JRGH_9C/TV &3^6NR-Y:BX[;-V-QKT;[RF[ZO%Q3J@:/\
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MZ/\ (3Q(TO</,+MFV2[[8Q<(>D]IOD+D Y^;QY9\?M&-+WPRXF>^=MY:^0$
MYU#[1X75WHU.D(Z><S5Q\RSR2S%3U*^8,T/1<8\17TSO8^0F0&[8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M      UWH_+WB;LW;%IT+K;E!QWV%O.C.;,SNVF*/NO6MLVQ3W=+ERU^XM;3
MKJ!LK^X5]S4Y\Y6,F1VS1,P>9PBO@BF>Z V(                      &I
M]VYQ<7=<\MM-\%[ELXT-RGY 4ZQW[46K\TC8L@2W5.I1-VG;#*%O4747VMX,
MT;%:ZF5<MI*89NE,-,%32.9=N54-L
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M>E8K!XK WTW&+HJN[V-R8],3FF/#%L.":9IFR<[V0ZR
M
M
M
M
M
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M,CR2896=IF\1)4+*X            #G?]$#_ 'K_ *I7[HG4N_I=Q@#H@
M                  -+^>J?.M30#G\G4OI!#DDE<Z@X8>\)F6]FKBEMY ZU
MP92.(-JZE,O7S$A$4?!RBH7!S&*JF;!<@*4W)#J9<Y*;UD.+5TWMQDX?8Y9<
M8:#+\3YZQ4?DE;F?%*K;<YBQ]E=Z>@MM7-S1+!)ZWLB\'5I]1.'?2[MLHA(I
M++O8WT1V<!;]Z=COJJR:>ZIGJ>17%>M.Y:7I;O1=2XO/;1(QM7@C,+!YTBK@
M_MF7D@^DTG>8SP5BOG::A\.,D\-/N8R$E@
M                                                      #Q]^O=
M8UE3YZ]7&1)%UVNL3OI!R;&#JG[,E3;LV:/>*9R_?N5"(MTBY[RJRA2X_JCL
M83"W^.Q-&%PT<*^KFR(_C.B(C+,[D+$35-D9U;+DKRDOG(VRK+RCEQ"T6/>*
M*5:CMG&?5\>EC&4DG\IE/"99>>52[<G<*8SA+OG(CA-/.<9^TZDU%A-37%E$
M15BYC^:N<\^"-%/@C/GFV7>HNXHC)G:Q#SCD
M
M
M                          !EK3>[-@:+MS6W4*859+%.B26AUS**PEBC
MTU<**1DTPP<I'+=3&,X*<N2KH9SWTCD/V&'C]9:LPFM</.'Q=-L;D_U4SIIG
M<^J=V)9JIBN+)64] [UJ?(/7S&\5CO,URJ>K['7G*R:S^N3B*9#N8]P=/!<+
MME"J85;.,%)A= Q39*0_?3)\5UOJK$:HQDX6_P L9Z:MRJG<GQ[DQN3ISNC7
M1-%5DLVCQC
M
M
M
M
M
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MG_:NS?3?0O9DP]!]$]"\/QG'B^-WD_""6_J9=2_CMTL>-TIR&Y /G\B=V_\
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M4%B$53.7 1-=:#KEZ*Z/].IT5-4R3W9R.VQ&2DGJ_2T)--J\W+#1SG$8>Z;
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M;[R8Y+W1I4];:R@V[ZPRC-@JI(3TT[40CX>LT^O9>.7<G9+7..$VD<QPN?\
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M3U_ANF1(JF4<KF13)E=5=?Q%U S8
M                                                 @WZG.['4Y>(
M?2,.\,6#IK9E8+4BD?.,/+9+-3+QK5R4ILE.E#0#I-5/^I^J/CXSCM(7(^H]
MQ]64W6%JUI>1_O;R9II\%$3EF/'5$Q_HQI=NXILCASGE%:/?'8
M
M
M                                           &Z'!/=KG4&\X&/>/#
M)4_8[EE3;(W.IW6J3I^YPC6YH^#9PDFI%2ZY2G5-V83:.%__ &8]:[U:LIUC
MJNNNF/\ Q-S$UTSNV1]ZGRQN:8AQ7M'"H\,+)0^+NB
M
M
M
M
M
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M.JE7*YG;5K]!;7-DG7_I"#;.9.9FJDNY=&3(5N9PJ?*/:CDF<A)@
M
M               "J!ORRN+?NW;-C<'.?,GL&UJ-_$R8QDF"$R[:1C;M-]-W
M6L<@DEC^IV8)CY,?U!]]U3<1A]5X>YI_IN://9$S/EFV7D:(LHB/ Q(/(-
M
M
M                                                   #^B2JJ"J2
MZ"JB*Z*A%45DCF35253-@Z:J2A,X.FHF?&,E-C.,XSCMP),1,63EB1;KHDZK
M:*/3;,OC.%K%5*].K8R0B><*R\0SD%,933,9-/.#N,_2ESG&/ZF,]@_/>*NH
MN,5>7$9J+RJGS3,/&S%DS#U8ZZ
M
M
M
M
M
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MBIC=JF(Z0;D7[.Q4IR_( ID<[_A3MS\-3S_,CHW<F=P1-XU8TDKHSTO,61U
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M]A/NESG/9VY#8H
M                                     %2S<42Y@=M[0A'A3%<Q6PKE
M'K=\F"9,=K8I%'Q,%*=4O=5P3O%R4QBY+G&<9SCLSG] ZNO*;W5]Q>T_=JN:
M)\],/(TY:8\3' [C0
M
M
M           +<.L(MU":TUY"OB>&^B*-4HMXG\OTCJ/@(]HX)\N,9^E62S@?
MGS'7E-[C;Z]H^[5>US'BFJ9>-JRU3/A>Y'50
M
M
M
M
M
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MU;-(VLQ36G3CO6FJ[*8B)VY#3^O=G[OJ,R8J"ACJ(%S(Q"G80V<F+CY,YSG
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MA!J4YB(%R I/=;__ 'K_ *6O[HG31_I=R8#H@ (O.ME^:-ZC/XHFZO\  Z1
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M_JZ0B/45GEZ_'R$_#>J999Q*QGJR5<*H>CN5#N$>YW%#&.7.<A[L
M
M               %?'J0ZC<T;>)KZS;&+7-IL4I9-8A<X0;V:(;M8VPLLY[3
M=BK@A6[[.<YQWS.SX+CL)GL^N]S-84XK5?9*I_WUQ-G^C-LTS]=/DC2[EQ5;
M19NPCS'N#G
M
M
M   &Q/%34;G=&\J14O1%7$$UDDK';E2$[R+6KP2R3R0*Y/V&PB635PDQ3-G&
M<>.Z)\@\/K[6%.K=5WN(MLO9IX-'AJJR1YLM7BB7'>5<&B9W5I$?"G0
M
M
M
M
M
M
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M $GU)'L?'[_HJ7;WNWM\,O\ ^#CL#W8  PCL;C-QOW#*I3NV^/ND-I3C?P/
MF=C:HH=WE4?1D\(MO"D;- R;Q/T=+&"D[#X[A<=F.S #)U8J=5I,.WKU,K5?
MJ, T,J=I!UB&CH"':G7/E18S>,BFS1DB993.3&R4F,F-GMS\H#T
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MWPL9QA!1"LQ,6D='#@V5.YG&2]_.3=G;\H#)X
M
M #"N_P#2-;W_ *UF*!8<X:+JYQ)5N<(EA9Q7;(T16)'2R*63$\=(N%SHN$N\
M7QFJJA,&(8Q3E\GJC6=]JC&TXNYRQ&2JGC4SGC^,3N3$3X&J*YHJX4*RVUM4
MW33-TE*)>XLT=,1QO$163[ZD=,1RASE9S,,\,1,KV,>E3SDA\8*8ABF34*14
MAR%^VX#'X;66&IQ6%JMNY\\3NQ,;DQ]L6Q,2[]-451;&9C@=UH
M
M
M                                        'V:]7IVV34;7*S$R$[/3
M#DC.,B8MLJ\?/7)\9-A-!NB4QS=TA<F-G_BD(7)C9P7&<XX[Z^NL/=57U_5%
M%U3%LS,V1"3,1%LYEC[ASQ@9\<Z$H:8PV>;)MR;1Y<9%+)%DHXB)3'95>-7*
M8Q#,HHRY\K*DSV.G)C'[<IE1*3XQWCUY5KG%_P"[MC!7=L41ITU3X9W(W(R9
M[;>E>WG#G)]V&X8]=<0
M
M
M
M
M
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M<14*33:TQ2C8&M5J!9(QT1#Q;)'&"(-&3- I"_U3&[.\;.39SG(>U
M                                              >*V5 3]KUU?JO5
M9Y:K6BR4JU0%;L[9R]9.*Y/S$$_CH>>0>1ITY%HM$2+E-P15 Q5DS)X,3.#8
MQD!16V-\-EUZ.4J+;4G+SK!P-_X[X>QCA[&RFX.3NV%GQVI6JV).6U':*O1J
M?996'>(=K$[^>44QGO*%50.JIC(6SNF9TS..?2NXXL>/7'QG*R>9"54MFR]F
MVSU>M>]IWETU09N)^PN8YHS9LXZ/9MR-(J,;D*VCF9,%[57"CETX"1
M
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M1^TW?IWCG;O2>YWR=^\Q<?ZV:?V8'Q'J/VF[].\<[=Z3W.^3OWF+C_6S3^S
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M1^TW?IWCG;O2>YWR=^\Q<?ZV:?V8'Q'J/VF[].\<[=Z3W.^3OWF+C_6S3^S
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M\,P
M
M
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M:SD9E++Y"HREP5I]"S+6")CUD2212Q39)K(>,W3,N1(KA4,T
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M3-!VFXI;YPH]4K;FX5]E+.HQK)*M&"DO%(N'!LLGN4$/36>4E_#)XG=P&T0
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MR41I3R;D*)96WE6LW"+DX1:P&<23"59,[)AM(,CN77AY(BYPH4KHJ"(3E@
M       "NEQIZ_S*]=4?8W2EY=\5E.'F[H":E*SJZW&W=G;5(V_8VS0ECK3!
MBN\T_J9S66^S* X1F:RX6]*))^*1D;"#U5NBN%BT
M
M
M
M
M
M
M
M
M
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M
M
M
M
M
M
M
M
M
M
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MH]NC.;9Y(QNL47QD<^G.JOIC7<!/,#$7SVE]79L&X)-,I2]F<K(*9-C.,$R
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M/U15TKC&<]SLP%R4
M
M
M
M
M
M
M
M
M
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M+GOX)A'O?)DO:%^L
M
M
M
M
M
M
M
M
M
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MM>[<GL:YQV) [R'JJ!F,49K5Z5!)$1PG%L3%0<.DO2W&5G!L'*$M?Z;WR;_
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M]I<2A\)QB%<DT7AV4VM(J9P5 C8ZIEC9["8SD!S[/CB?\;/3P_<[Y$_X2ZE
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MKR[)V5!ZR57;+&;/&ZB2F"FSDBJ9BY[#%SC 0L?!4_FLM^?C_P"T_P"CKQ5
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M_CT56,+9;[)LDSDSW\N6;@I\=A"=H7-@
M
M
M
M
M
M
M
M
M
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M38SC.< *EUC^"_Z5,]89Z<9;>YS51G-3,I+-*O7-IZ+\O5MM(OEWB$! ^O\
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MDG'?3M9K:UO?/;IM"5;N3&.L[8+7FP/B,CJ&R8C!-!/'=(0I2AOZ
M
M
M
M
M
M
M
M
M
M
M                                               "#CK2=#W4W6$J
M>IG;O:+WCIOO2DRY4HV]8.BIW]WFFRZB3N=HMAJY+CKYS,QQI5FW?Q;@LN@M
M#OB*G1P8CITFJ$K_ !THFT]7Z,U;KG=FWT=_;3H].B:O<=TI4E77:VS)&&2R
MQ0MTI3U;A?<Q-@EH]%$\D8LJY2=2'C.$RH$5*W2#-
M                                                         *YW
M'#X?YM3.J1?NJSR_Y6J<QMSR\U*V?5M+5T=C5-'U#9%T"0-3?1R,AN#;;BP,
MM74=%.+K#8^&F(Q5)-^8ZSQ)%5(+&(
M
M
M
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M9G[3 ^$N\/L_27?KG,WFCZCW_N)'WV?^H>S/VF!\)=X?9^DN_7.9O-'U'O\
MW$C[[/\ U#V9^TP/A+O#[/TEWZYS-YH^H]_[B1]]G_J'LS]I@?"7>'V?I+OU
MSF;S1]1[_P!Q(^^S_P!0]F?M,#X2[P^S])=^N<S>:/J/?^XD??9_ZA[,_:8'
MPEWA]GZ2[]<YF\T?4>_]Q(^^S_U#V9^TP/A+O#[/TEWZYS-YH^H]_P"XD??9
M_P"H>S/VF!\)=X?9^DN_7.9O-'U'O_<2/OL_]0]F?M,#X2[P^S])=^N<S>:/
MJ/?^XD??9_ZA[,_:8'PEWA]GZ2[]<YF\T?4>_P#<2/OL_P#4/9G[3 ^$N\/L
M_27?KG,WFCZCW_N)'WV?^H>S/VF!\)=X?9^DN_7.9O-'U'O_ '$C[[/_ %#V
M9^TP/A+O#[/TEWZYS-YH^H]_[B1]]G_J'LS]I@?"7>'V?I+OUSF;S1]1[_W$
MC[[/_4/9G[3 ^$N\/L_27?KG,WFCZCW_ +B1]]G_ *A[,_:8'PEWA]GZ2[]<
MYF\T?4>_]Q(^^S_U#V9^TP/A+O#[/TEWZYS-YH^H]_[B1]]G_J'LS]I@?"7>
M'V?I+OUSF;S1]3^J//GB4NJ1$FVTBG4-W2Y6I6QFZ6,_^WKN*@DBD7_VIC8P
M)/=/O!$6SA_]>[G_ .LYF\T?4SO1MRZHV9])0MAU&U.<%,<\?$S;):623+C.
M3*+PYE22C=/L+G/>.B7&<8SV?U!XK%:MQ^"_Q=S>7<:9IFSSYO2Q--5.>)9+
M'29
M
M
M
M
M
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M'W7LJIZGN#2Z<I)&OW%K:==0-E84^P-K9 $*QDR.V:Q7[/&$5\'3QW0%[@
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M#%KQ=5R,?88_6C#42EN8;_/LIWW7BC!Q;D4R>,<^81RW<XCT$?3CHK@+<(
M                                        _P SG!<9SG.,8QC.<YSG
MLQC&/ESG.<_)C&, (@^5W426B'\IKO0#IJJZ9J*L)O9ADV[]JFY3SDCAI3&Z
MI5V;O"1L9(:16*=(QL&]'3-CPW&?HFH.YT7E-.,UO$\&<M-UFGQUSGC_ #8R
MZ9SP[-W<6_S5^9#W/V*?M4JZG+/-RUAFGI\J/)6;D'<I(N3YSDW:L\>JK.%.
MS)L]G:;LQV_(/HMS<W.'NXNKBFFBZC-%,1$1Y(=F(B,D9GQAR*
M
M
M                                      _0U=NF+E!XQ<N&;QJJ1=L[
M:K*-W+=9/.#)K(+HF(JDJ0V.W!BYQG&?Z@E5--=,TU1$TSGB<R)->,741M]+
M?QU0W@^>W*EK*)-$K@L4[NW5HI\E3*YD%\=J]FBDLY[RWB8._(7M,0ZO=*B;
MTC7G<_#XFBK$:KB+O$QEX&:BKQ<6='].F(SN"\N8G+1DE.;$RT9/1D?-0L@S
ME8B59MY"-DH]PDZ9/V3I(JS9TU<HF.DL@LD?!BF+G.,XR/EMY=UW5<W5[$TW
ME,V3$Y)B8SQ,.IFR3G?0&
M
M
M
M
M
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M[UG+2]Z]9S4Z_0:HE)7%$?$6+DZI2]N<!:S
M             $9O4;Y&O=<5!AJ&H/U&5LV%'KN["^;'R1U$4?*JS%1%%0IB
MG1<VAVBLWP<O;W6S=QCZ4QR&Q[MW-U-3C<1.L<1%N'N9LIB<TUY_]6+)\<QX
M7/<4<*>%.:$"X^KNX
M
M
M          )9>FIR+>Q5A4X_VE_E6"G2OY77RKI7.<Q4^B0[Z5KZ)U,]B;";
M:)JN4B=[!2/$C8(4QW6>SY_WUU-3>7/[O<1_O:+(O+-VG-%7CIFR)\$Z*76O
MZ,G#C/NIM1\R=4
M
M
M
M
M
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ME?\ RMYC]46#R_Y@\O\ HGIWH#[T3QO%]'6[OAF#??\ 3G/_ (UW_/9_^)'
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M,YR/N?=W"TX/4V'NH^]5=Q7/CK_FGS6V>1W[N.#1$-;1YIR
M
M
M                                        #T%2LLG3+37+=#*F0EJQ
M.14_&JE-DO=>Q+U!\W[V<8SVD,JAC!L9QG&2YSC.,X^0<.(N*,3<5X>]RW==
M,TSXIBR4F+8LG,MT0TJTG8B*FV!LG8S$:QE61\X[,G:2#5)VW-G'_!DR*V,C
M\]WEW5=7E5U7]ZFJ8GQQ-CQLY)L?2&
M
M
M
M
M
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M !5.X7Q"Y3QVF[G84([^DND:/^+TYO-[GE-2<=;SZCZM6-*+(R3LI7E\MTI
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MZM!MVVNKEK6>>*D[EHKB3!HDR4P]QA^AWU2A>Z
M                %1O9::J.Q]@)+D.FNE=K6FL13&<*$5).ORJ$4P;Y<'*?
M&<9[?E[1^@\#,3@KF8S<U1_LP\C3]V/$\2.TT
M
M
M                               "VEILAT]0ZJ34(9-1/6]&(HF<N2'(
M<E8BRF(<IL8,4Q38[,XS\N,C\_ZRF)UC?S&;GJ_]J7CJOO3XV2!TF0
M
M
M
M
M
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MQHXL&M>2&S:9HJ_4Z8401/(5^08;'FJ_'3RT8X4REE[#.9&-<=W)T7"A>W.
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M% 0D(H_=RJD/$1L4>4?GRH^DCQ[)%H9^\4,8YCNWAD?$4SG.<Y.;.>W(#ZX
M                                   "LSS?UTXUSR3V(WR@9*,M\CF_
MPJO9W2.6MK.H_D3)%[<X*1K8?36_9_\ P>W&,8S@?;>Z^,IQFI;F;?Y[NGFZ
MO!-&2//3P9\KO757"HCP-2Q[ Y0
M
M
M                   ![G65&D=F;"IE BBJY>6RQ1<+A1(O?,T;.W1"OY V
M.S.,(QK#"KA3.<9P5-(V?^ =7'8JC X.]Q=Y]V[HFKQS$9(\LV1Y6:IX-,S.
MXML,F;6.9M(]BB1LR8MD&;1NGC.$V[5JD1!NBGC.<YP1)(F"X_\ :8'Y^JJJ
MKJFNJ;:IFV?'+QS](R
M
M
M
M
M
M                      - .<_2XX)]2CV7>^KHSVT>Q?SM[-/_ %3=Q:Z\
MM>T7RCYR_P 4^P:)ZX]<>1(K_P X>E>C^B_J'A>*MX@;W0\3'P,3%P<2W]$B
MH6.91,:U\5=?T:/CFR3-FW\=RHLX6\%LB4O?4.<YNSM-G.>W(#4;FOT^^'_4
M4UW6=5<R=,L-RT>FW%&_5>-5MM_HDE"6E&&EH#TYE:-8VREVHC1Q%3:Z;AEE
M[EBY-A)19$ZC=N=(,\Z3TMK#CEJ/7.B-*U%E0]3ZEJ$)1-?U!@ZDY!""K-?9
MIL8UFI*3CZ4G9E[E)/ON7S]TZ?OG!SKN5E5U%%#!Y'E'Q<T3S1T3>>-')>C>
MTK26RO+/G6E>9KC3O77DZXUZ_P!<_NCH%AJMMCO5UMJK!W^M'Z'C>!X2O?1.
MHF</@\1.&O&[@AIF/X^\4M<>RO4,5/3UF85'S??+QX$W9W17LX]]?['M%PLZ
MOISDF#>&=Z9%+L[$R$Q\@#.5YHE)V=4+'K[9%0K-^H=OBG4%:Z7<X*,LU5LL
M*^)X;R)GH"9;/8J6CG2?R'172.F;']7 "NCN#X3'HW;6MKZV0^K=MZ7S)OU)
M%[6]/[@FHZI&<+F,HY38PEY87XD&P66/DQ6L>=HU;X["()I)8*3 ;Z<&^A_T
MSNGC9$[_ ,<>-\*VVJBFY1:[<V--SVT-B123K&4UL5B7N3^38TA15J;*"BL&
MUC5ET#&(L=0IS]X)90&+-TZ0U!R-UK9M.[WUM3MM:NN+0C.RT:]P;*P5Z431
M5(X:K*,GR2A4'\>[2(NU=)93<M'"9%45"*$*; 5V;7\(CT;;';U+-%T??=&B
M%')W&:!5-Z3J]0*4YSG]&3<7&,MMW(V)@^"EQB9[^"EQ]-_5SD)4M/=(/IRZ
M'XP[2X?:PXP4ZNZ-WE6UJKNF+2EK<I==J1*[7+4Q;EM<UAQM%ZLV[YU61D9A
M#$6LJ<[##;)L@-E^)W$;CUP=TE7>.G%S7WLOTW5)&Q2T!3O-=WNOH$A:YM[8
MI]QYAV)9;;:G7I\S(++=Q9\H1+O]Q/!"8*7 >SWEH'27)G7,UJ+D'JJA[DUG
M8.X>4I6Q*U&6>"6=($5(TDV[63;K^KIJ.\<YFKYME)XT4SWT52'[# *\.P_A
M$>CA=YYS,P-,W[JAJY=NG7ES7F\)1S H8=8;]UJVQLF%V),(M&ATCF2+Z9G.
M/&/@V3%PF5,-F^+OPUW2!XI6V!V%5>,ZFS-@5:1B9BNVO>=YM>S,1$M"N6S]
MC*-:<_D&6MS2*4DS3<%74A3JI*E_4C)DSDF0G/F(F/GHF4@Y9OZ7%34<]B9)
MKXJZ'I,?(ME6;QOX[91%PCXS98Q>^F<AR]O:7.,]F0&B/!CI<<$^FO[4?<JT
M9[%_;1Y)]I?_ *INXMB^9?9UYN\F_P"-C8-[]3^I_/<K_P";_1?2/2OU?Q?"
M1\,-_P !K[R:XJ<=>96J9C2'*#4-.W1J^;61>.:Q;V*BOH,HV(LDTG:[,L%V
M-AJ=D9(N52(2<6[9OT"*J%36*4Y\9"#)K\)ET5&]FQ/*Z)VB^BL/<.LTIUR#
MVT2LF0P<ILQN73*QL[EZ%G!<E[V);#CLSG]5[>S. E?M_3%X%7;B"]X$RW&:
M@Q?$B1=P4B^TW1E;'K.+<S%<L<1;8Z?4L>N9VJW;-D6L,$V</9+UGA_)Y*<C
MQ5=-54APV?TGIC6G'34>N=$:;K?D[56I:A"4/7U5]<3]A\OU2NLTX^'BO7EI
ME9RQROH;1(I/'>O'+E3L[3J&-VY 8,YH< ^(?4)UNRU7R]TE6=P5:'>NI2KN
M9%>7@K92Y9Z@FW=R=+O%6D82WU=P]3;I8=$9O4D'I44R.4UB$*7 1J<9OAIN
MDQQ0WC1>0^L-.;"=[,U?;8F\ZX?VW=>R9B+I]J@G9WT/+,X=I.1;.7,P<Y(8
MJ,IA^W-E(O?(;Z;O!.!?M?T3:M-L.N]G4NJ;$H%NCE(BU4F\5^*M53LD4L8A
MU(Z<KTXT?1,JR.HF4V4UTCD[Q<9[.W&,@*[>YOA-^C;MNR2%FA]3[5TDO*/2
MOWD1IG;\[&5LJ^<.?24X^ O338$=",G:K@I\MF)&S='*)"H$13[Y#AZK17PK
MW1FTC,L+ ]X^VO=\O&?3,S[UVE;;9#>/XAS>._IU?<U"CS?:D?P_"?QKIOW<
M8-X?B8[X"PU%149!1D="0D<PAX:'8,XJ(B(IFWCXR*C(]NFT81T<P:)HM&+!
MBT1(DBBD0J:29<%+C&,8P _> C@XF](_IZ\'MTW_ )%<9./A:!N[:,1.P5[V
M/,;4W9L^PSL9:++'W"R(Y4VULB]-8U:>LL4W=O%V:3==PHB7"AS$QW0$CX
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MDCY(JDJD?!3IJIG+G!BYQC.,X[,C[%$Q5$54S;$N\_F*
M
M
M                                    )L>G!QC>UMJ;?UXCC-92;C3,
M];QSQ')'+.#D4NQ_;#IJ8[Z2DZT/A!EGZ7.61E5/IB.$\X^9=\]>4WU7[3A:
MK;NFJV\F-VJ,U'^C.6K_ "K(SQ+J7]Y;_)'E2TCY^ZX
M
M
M
M
M
M
M
M                                                          "
M7XFO3>WM]](/>VM-&:JV1NC8\O?-$O(G7^IZ-9]BW:4:1&W:G)2SJ.JE/BYB
M=>MHN.;*.'!TD#%003,<^2E+G. ]Y\.'J?:>CNC'PVU;NO6FP-/[-J_O#>9=
M=;2IMCU_>Z[Z[Y5[RL4-Z]J-LC8BP1'K>OR[1\U](;I^D,W22Q.\FH0V0F^
M
M1Y\J^!E:W<\?7O7[QA2]EN<&6DL.4U2UBWKX+C&%I<C1)9Q%2YN[CO/4$E?%
M^7QDE#Y\0OM^H>]=_JNF,+BXF]P49K/O4>*W/'^3,Q9N3&9S7=]-&2K+2A/V
M?H7;NG'RS/8-%G(1!)7*:4T5J9_7'N.WZ0[&P,/2(EQXA<XSW/%PJ3M[#D*;
MMQCZ;@=;:NUE3%6#O::IXMME4>.F;)]%FAVJ:Z:ONRQ"/(M@
M
M
M                                   /<T;66PMF2)8J@4RQ6QYE4J2F
M(6+=.VS0Q^SL-(/RDPPC4<8SC.5'"J29<9^4V!U<5CL'@:.<Q=[1=T_Y4Q$S
MXHSSY(EF:J:<LS8EXXQ].!K6WL=>-_&C9N4:F1>1VMV9DI&#9N29PHF>V/\
M'?:3JB1_ZK)#!F6<E_5%7!#93Q\\UYWSJOJ:L+JGA4W<Y)O)R53_ )D9Z?\
M.G^;1$3E=:\O[<E'G2SD(1,A$TR%333*4B:9"X(0A"8P4I"%+C!2E*7'9C&/
MDQ@?/YF9FV<[KO\ H
M
M
M
M
M
M
M
M
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M9/8QI[[U&M?N%J_[%A^Y:Q]HO^75OG"JTR>QC3WWJ-:_<+5_V+#]RUC[1?\
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M[LY99?I&0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7"[6&(JE6A&[AVW8-UY>P3KQA$QJ*[YTDB0RRQ"F54(3&<F-C&0^E7K# 6Z
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M>8I->V)L[7M"G]ESR55UQ!W2Z5NK3&P+.X=1[%"N4F-G))B]M4\L]EFJ)&;
MB[@RKE(F"9,H3&0^Q=KU2-9U:7O.Q[C5=?TFOHHN)ZX7:PQ%4JT(W<.V[!NO
M+V"=>,(F-17?.DD2&66(4RJA"8SDQL8R'V(:9A['#Q5AKTK&SL!.QK&9@YR&
M?-92'F8>4:I/HV5BI)BJNRD8V19+D6071.=)9(Y3D-DN<9 >5UQM/6.XJRE=
M=1;'H>TZ<N\=QR-MUQ;Z_>*RM(,#E3?L4IZLR,I%J/&2A\%62PKDZ><XP;&
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M3:.SM>K;?9P);4[U4E=*VILAK6#&0(6QN*,22S9T($QW26,/#-<-\Y4+CO\
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M*%<I,;.23%[:IY9[+-42,V!%W!E7*1,$R90F,A]*_;#H&JJG+7[:%XI^MZ+
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MUC28U9DWD;AL*U05+JT>XDG:3".0>V"R/XV):K/WRY$42J+%,JJ<I"XR;.,
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M8X&WU*RQK29KEIJ\Q'V"N3\._2*NQE82;B7#N,E8UX@?!TET%5$E"9QDILX
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M1=&Z3J+.A:IUI!I5NC4Z/>2L@SK\(@LNX28-WLX_E)9RF19R<W>7<*J?3?\
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M074K)(8DX6J':F5E7!O%,P,Y_5<_JG9C'8#D3PXXT\L9+3LQR&U5$[,DN/\
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M*7>.WP4_>3R8A@]Q6-;4BFZVKVH*S -XG6]4H\3K:OU9%P^6:QM(@H%O6(F
M2=NG2\DJW9P+5-N511<ZYBE[3'R?M, Q7Q:XE<=N%.IVFC>+NLHO4FJ6$Y-6
M1I3HB5L<PS1F[$LFXF9 KVU3,]+&4?+(E,8N7&4R]GTI2X ?AU/PXXTZ,W5O
M;D5JG5433MT<F7T+);SO;*7L[U_L%]7LOC0SB1CY:<D(2.,QS)K]W#!JT*;Q
M,][!NS'8"X<..--^Y/:GYFV_543-<F]&56P4G5.UUY>SH2U.JUIB[="S\0SB
M&<XVJ[U&1B[Y+HF.[8N%2X>FR0Y3%3R0'*CAQQIYM4BIZXY2:JB=NTFC[&@M
MM52!F)>SPS>'V)68BPP4'9D7%5G(%\NZCXFUR")4EE5&QBN39,F8Q29*&5-O
M:DUWOK5U^TOMRL-;IK#:%5F*3?*D]=23%I8JM8&:C"8B'+R'>QTHV1>LUC$,
M=NNBJ7&>TI\9^4!^'2.DM6\<-3T71NDZBSH6J=:0:5;HU.CWDK(,Z_"(++N$
MF#=[./Y26<ID6<G-WEW"JGTW_&[.P!CGC/PXXT\.HW8\/QJU5$ZKC=N;&F-M
M;%:Q,O9Y8EGV)/MVK67LSH]FG)M5HZ>H,DBF2;&1;%P3Z5/&<Y[0_=$\2N.T
M%RAL_-&)UE%L^3URU6WTE9MLDE;&>7EM6M9BO3[>HK0ZTRI5D6:<O5(]?"R3
M CO)FQ<95[ICX,#=/$KCMR(OVA=H[GUE%WJ^\8;POLC1%B?REC8.=>7=PK"K
M+3\<VA9F,CY)PHK7F6?#?HNT/U#'83Y3=X/N<C^-VDN76F+EQYY&4&/V?IK8
M/EWSC1I20G(IA.>4[7!7>O>._K<I"S2'JRU5IB\+X+E+O';X*?O)Y,0P9&C*
M35H:D1^N(R(1:4F*JK2DQ\"19V=NVJS&(3@FD05PJX.^,BC$I%1P<RN5<EQV
MY/DWR@,.\6N)7';A3J=IHWB[K*+U)JEA.35D:4Z(E;',,T9NQ+)N)F0*]M4S
M/2QE'RR)3&+EQE,O9]*4N 'X=3\..-.C-U;VY%:IU5$T[=')E]"R6\[VRE[.
M]?[!?5[+XT,XD8^6G)"$CC,<R:_=PP:M"F\3/>P;LQV N'#CC3?N3VI^9MOU
M5$S7)O1E5L%)U3M=>7LZ$M3JM:8NW0L_$,XAG.-JN]1D8N^2Z)CNV+A4N'IL
MD.4Q4\D!RHX<<:>;5(J>N.4FJHG;M)H^QH+;54@9B7L\,WA]B5F(L,%!V9%Q
M59R!?+NH^)M<@B5)951L8KDV3)F,4F2AE3;VI-=[ZU=?M+[<K#6Z:PVA59BD
MWRI/74DQ:6*K6!FHPF(AR\AWL=*-D7K-8Q#';KHJEQGM*?&?E ?ATCI+5O'#
M4]%T;I.HLZ%JG6D&E6Z-3H]Y*R#.OPB"R[A)@W>SC^4EG*9%G)S=Y=PJI]-_
MQNSL 8YXS\..-/#J-V/#\:M51.JXW;FQIC;6Q6L3+V>6)9]B3[=JUE[,Z/9I
MR;5:.GJ#)(IDFQD6Q<$^E3QG.>T%>X<<::IRIO7-NOZJB8WE+LS7+/4MYVZE
M+V=68L&NV"U.7:5EQ#.)Q:J-VJ*NOX<V%4&"3G/H)>U3.#*=\&[>''&GD;M'
MCUNC=6JHF^;/XIVJ7NW'VV/Y>SQ[O6UIGGE2D):7C&<).1<7*+/7E%B3F)(H
M/$BY9EP4F,&4P</N<FN+FA.9&GY_0?)?74;M74-H?0,E/4J6D[!$,I%]6)AG
M8()PH^K$O!S"1H^8CT5RX3<D*8Q,8/@Q<YQD,J1E)JT-2(_7$9$(M*3%55I2
M8^!(L[.W;59C$)P32(*X5<'?&11B4BHX.97*N2X[<GR;Y0&*^,O%S0G#?3\!
MH/C1KJ-U5J&KOIZ2@:5$R=@EV4<^L\P\L$ZX3?6>7G)A4TA,2"RYL*.3E*8^
M<$P4N,8P'X=1\2N.VA]L<@=Y:EUE%TS:W*><JMDW]<64K8WSS8\W2$;$WJTA
M),I>9D8F,4B$;9(E(6/;LTS^DF\0I\E)W0_#<.''&F_<GM3\S;?JJ)FN3>C*
MK8*3JG:Z\O9T):G5:TQ=NA9^(9Q#.<;5=ZC(Q=\ET3'=L7"I</39(<IBIY(#
ME1PXXT\VJ14]<<I-51.W:31]C06VJI S$O9X9O#[$K,188*#LR+BJSD"^7=1
M\3:Y!$J2RJC8Q7)LF3,8I,E#*FWM2:[WUJZ_:7VY6&MTUAM"JS%)OE2>NI)B
MTL56L#-1A,1#EY#O8Z4;(O6:QB&.W715+C/:4^,_* _#I'26K>.&IZ+HW2=1
M9T+5.M(-*MT:G1[R5D&=?A$%EW"3!N]G'\I+.4R+.3F[R[A53Z;_ (W9V ,<
M\9^''&GAU&['A^-6JHG5<;MS8TQMK8K6)E[/+$L^Q)]NU:R]F='LTY-JM'3U
M!DD4R38R+8N"?2IXSG/:"O<..--4Y4WKFW7]51,;REV9KEGJ6\[=2E[.K,6#
M7;!:G+M*RXAG$XM5&[5%77\.;"J#!)SGT$O:IG!E.^#=O#CC3R-VCQZW1NK5
M43?-G\4[5+W;C[;'\O9X]WK:TSSRI2$M+QC.$G(N+E%GKRBQ)S$D4'B1<LRX
M*3&#*8.'W.37%S0G,C3\_H/DOKJ-VKJ&T/H&2GJ5+2=@B&4B^K$PSL$$X4?5
MB7@YA(T?,1Z*Y<)N2%,8F,'P8N<XR&1O9M2/9M[(/4#?V;^1_9MY6](?>B^2
M/4/ECU!Z7Z5ZR]']0_K?Q/'\?N_+W^_], QSQEXN:$X;Z?@-!\:-=1NJM0U=
M]/24#2HF3L$NRCGUGF'E@G7";ZSR\Y,*FD)B067-A1R<I3'S@F"EQC& ^'I+
MAQQIXY;1Y"[HTKJJ)H>S^5EJB+MR"MC"7L\@[V3:8%Y;9")EY-G-SDI%Q:S)
MY>I8Y21R#-(V7AL&)G!4\$#]UEXE<=KAR7UUS#LFLHN4Y)ZEH\YK?7>TU92Q
MI2M9I%D+/%FX!K$MIE"LNF[\MG?X,HY8K+E](SW3E["]T')3B5QVY@5JAU#D
MCK*+VE6]8[4J^[:)%RLK8XE*O;2I;"=BZQ;FZM:F81RY>1+"S/DR(N#JM#X<
M9R=(V<%R4,C;>U)KO?6KK]I?;E8:W36&T*K,4F^5)ZZDF+2Q5:P,U&$Q$.7D
M.]CI1LB]9K&(8[==%4N,]I3XS\H!J'4FN]"ZNH.E]1UAK2]8:OJL/2:'4F3J
M2?-*[5J^S380\0V>3#V1E'*+)FB4A3N%UE38QVF/G/R@,5\9^''&GAU&['A^
M-6JHG5<;MS8TQMK8K6)E[/+$L^Q)]NU:R]F='LTY-JM'3U!DD4R38R+8N"?2
MIXSG/:"O<..--4Y4WKFW7]51,;REV9KEGJ6\[=2E[.K,6#7;!:G+M*RXAG$X
MM5&[5%77\.;"J#!)SGT$O:IG!E.^#=O#CC3R-VCQZW1NK543?-G\4[5+W;C[
M;'\O9X]WK:TSSRI2$M+QC.$G(N+E%GKRBQ)S$D4'B1<LRX*3&#*8.'W.37%S
M0G,C3\_H/DOKJ-VKJ&T/H&2GJ5+2=@B&4B^K$PSL$$X4?5B7@YA(T?,1Z*Y<
M)N2%,8F,'P8N<XR&1O9M2/9M[(/4#?V;^1_9MY6](?>B^2/4/ECU!Z7Z5ZR]
M']0_K?Q/'\?N_+W^_P#3 ,<\9>+FA.&^GX#0?&C74;JK4-7?3TE TJ)D[!+L
MHY]9YAY8)UPF^L\O.3"II"8D%ES84<G*4Q\X)@I<8Q@/AZ2X<<:>.6T>0NZ-
M*ZJB:'L_E9:HB[<@K8PE[/(.]DVF!>6V0B9>39S<Y*1<6LR>7J6.4D<@S2-E
MX;!B9P5/! 6'AQQIM?*FB\V[!JJ)DN4NL]<O-2T;;JLO9TIBOZ[?K7%=W66\
M,WG$:HX:K*[ F#9578*N<>G&[%,8*GW <F.''&GF+&ZXA^2NJHG:D;J/8T/M
MK7366E[/$DK&Q(!NZ:Q%F:GK,Y"*NW3)!ZJ4J3DRS8V#_3)YSC'8&1MW:2U;
MR/U/>M&[LJ+.^ZIV7!JUN\TZ0>2L>SL$(NL@X58.'L&_BY9LF=9L0W>0<)*?
M2_\ &[.T!^[4.I-=Z%U=0=+ZCK#6EZPU?58>DT.I,G4D^:5VK5]FFPAXAL\F
M'LC*.463-$I"G<+K*FQCM,?.?E 8YXU\2N.W#^M7RH<;M91>K:WL[:EHW;>X
MN*E;'+)6':5T80479[<X5LLS-N6SR685EBF=%N=)H3#?&2)%SDV3 K7$KCM3
M^2^Q>8=;UE%Q?)/;5'@];[$VFE*6-65LU(K98$L) .HES,KUEJW8%K##!5&S
M%%<WH^.\<W:;O!^'=O#CC3R-VCQZW1NK543?-G\4[5+W;C[;'\O9X]WK:TSS
MRI2$M+QC.$G(N+E%GKRBQ)S$D4'B1<LRX*3&#*8.'W.37%S0G,C3\_H/DOKJ
M-VKJ&T/H&2GJ5+2=@B&4B^K$PSL$$X4?5B7@YA(T?,1Z*Y<)N2%,8F,'P8N<
MXR&1O9M2/9M[(/4#?V;^1_9MY6](?>B^2/4/ECU!Z7Z5ZR]']0_K?Q/'\?N_
M+W^_], QSQEXN:$X;Z?@-!\:-=1NJM0U=]/24#2HF3L$NRCGUGF'E@G7";ZS
MR\Y,*FD)B067-A1R<I3'S@F"EQC& ^'I+AQQIXY;1Y"[HTKJJ)H>S^5EJB+M
MR"MC"7L\@[V3:8%Y;9")EY-G-SDI%Q:S)Y>I8Y21R#-(V7AL&)G!4\$!8>''
M&FU\J:+S;L&JHF2Y2ZSUR\U+1MNJR]G2F*_KM^M<5W=9;PS><1JCAJLKL"8-
ME5=@JYQZ<;L4Q@J?<!R8X<<:>8L;KB'Y*ZJB=J1NH]C0^VM=-9:7L\22L;$@
M&[IK$69J>LSD(J[=,D'JI2I.3+-C8/\ 3)YSC'8&1MW:2U;R/U/>M&[LJ+.^
MZIV7!JUN\TZ0>2L>SL$(NL@X58.'L&_BY9LF=9L0W>0<)*?2_P#&[.T!^[4.
MI-=Z%U=0=+ZCK#6EZPU?58>DT.I,G4D^:5VK5]FFPAXAL\F'LC*.463-$I"G
M<+K*FQCM,?.?E 8KXK\..-/"6D6S7'%O543J*DWC8T[MJUP,/+V>9;S&Q+-$
M5Z"G+,LXM4Y//D'4A$U2/1,DBJFV*5L7)4RF,?)@4_AQQIH/)[;',VH:JB87
MDWO.JU^D[6VNA+V=>6N-6JT7486 B'D0\G'-79(QT70XA$IVC%NJ;#(N3G,8
MRF3A^[;G$KCMOC;''[>6VM91=SVMQ8G+59- W%[*V-B\UQ-W=&NM[3(1K*(F
M8Z)DU)=&IQQ3ED&[Q,GHQ?#*3)C]X/W<FN+FA.9&GY_0?)?74;M74-H?0,E/
M4J6D[!$,I%]6)AG8()PH^K$O!S"1H^8CT5RX3<D*8Q,8/@Q<YQD,J2=)JTS2
M)#7$G$(NZ3*U5W29"!.L[(W<U9]$*03N(,X2<$?%16B53(Y.57"N"Y[<'P;Y
M0&.>.'&[27$73%-X\\<Z#'ZPTUK[S%Y.HT7(3DJP@_-EKG;O8? ?V24FII?U
MG:K*^>&\9RKW3N,E)W4\%(4/*Z2X<<:>.6T>0NZ-*ZJB:'L_E9:HB[<@K8PE
M[/(.]DVF!>6V0B9>39S<Y*1<6LR>7J6.4D<@S2-EX;!B9P5/! 6'AQQIM?*F
MB\V[!JJ)DN4NL]<O-2T;;JLO9TIBOZ[?K7%=W66\,WG$:HX:K*[ F#9578*N
M<>G&[%,8*GW <F.''&GF+&ZXA^2NJHG:D;J/8T/MK7366E[/$DK&Q(!NZ:Q%
MF:GK,Y"*NW3)!ZJ4J3DRS8V#_3)YSC'8&1MW:2U;R/U/>M&[LJ+.^ZIV7!JU
MN\TZ0>2L>SL$(NL@X58.'L&_BY9LF=9L0W>0<)*?2_\ &[.T!^[4.I-=Z%U=
M0=+ZCK#6EZPU?58>DT.I,G4D^:5VK5]FFPAXAL\F'LC*.463-$I"G<+K*FQC
MM,?.?E 8KXK\..-/"6D6S7'%O543J*DWC8T[MJUP,/+V>9;S&Q+-$5Z"G+,L
MXM4Y//D'4A$U2/1,DBJFV*5L7)4RF,?)@4_AQQIH/)[;',VH:JB87DWO.JU^
MD[6VNA+V=>6N-6JT7486 B'D0\G'-79(QT70XA$IVC%NJ;#(N3G,8RF3@VQP
MXXT[SW5HGD5M;543<=T<9GTU):,O;V7L[)_KY]8<L33+B.CXF<CX21,^S&(=
M[#]J[*7P\=W!>W/:'[N4O$KCMS6U.[T;RBUE%[;U2_G(6R.Z=+RMCAV:TW75
ME'$-(&>U69@98JC%98QBEPXPF;M^F*; #*EGUM2+EK:PZ@LT WEM;VNCRVMK
M!5EG#Y%K)4B=@7%8EH!5VU=(223=Y NE&YE$UR+E*;M*?!^PP#P_'#C=I+B+
MIBF\>>.=!C]8::U]YB\G4:+D)R580?FRUSMWL/@/[)*34TOZSM5E?/#>,Y5[
MIW&2D[J>"D*'P]+<2N.W'>_;ZVCIC6471;[R>O"&R-[V)A*6-^YV'=VZLTLC
M/R+::F9./C7":MA>Y\-@BT0_5\]I/D+W02W$KCM.\H:QS1EM91;SD]3=5N-)
M5G;)Y6QDEXG5KJ8L,^XJ*,.C,IU99FI+VN07RLJP.[P9R;&%>Z4F"@Y"\2N.
MW*SV4>\%K*+V3[#MJ5S=NJO6<K8XOR?M*I>-Y=MS/R],P_IKR,](/W47?I#0
M_>^G2-\@#W&[M):MY'ZGO6C=V5%G?=4[+@U:W>:=(/)6/9V"$760<*L'#V#?
MQ<LV3.LV(;O(.$E/I?\ C=G: _=J'4FN]"ZNH.E]1UAK2]8:OJL/2:'4F3J2
M?-*[5J^S380\0V>3#V1E'*+)FB4A3N%UE38QVF/G/R@,5\5^''&GA+2+9KCB
MWJJ)U%2;QL:=VU:X&'E[/,MYC8EFB*]!3EF6<6J<GGR#J0B:I'HF2153;%*V
M+DJ93&/DP*?PXXTT'D]MCF;4-51,+R;WG5:_2=K;70E[.O+7&K5:+J,+ 1#R
M(>3CFKLD8Z+H<0B4[1BW5-AD7)SF,93)P;8X<<:=Y[JT3R*VMJJ)N.Z.,SZ:
MDM&7M[+V=D_U\^L.6)IEQ'1\3.1\)(F?9C$.]A^U=E+X>.[@O;GM#]W*7B5Q
MVYK:G=Z-Y1:RB]MZI?SD+9'=.EY6QP[-:;KJRCB&D#/:K,P,L51BLL8Q2X<8
M3-V_3%-@!E2SZVI%RUM8=06: ;RVM[71Y;6U@JRSA\BUDJ1.P+BL2T J[:ND
M)))N\@72C<RB:Y%RE-VE/@_88!X?CAQNTEQ%TQ3>//'.@Q^L--:^\Q>3J-%R
M$Y*L(/S9:YV[V'P']DE)J:7]9VJROGAO&<J]T[C)2=U/!2%#RNAN''&GC%=]
M_;'T1JJ)UY=N4>QGNVM]ST=+V>2<;&V)(2]EG7EFDF\_.2S&,=+RUODELI1Z
M31M@SHV,)X*4F"@=\..-+[E3&<VW>JHE;E+#:Y4U+&;=-+V<LPTUVJM(+J5D
MD,2<+5#M3*RK@WBF8&<_JN?U3LQCL!R)X<<:>6,EIV8Y#:JB=F27'_8T;MK3
M[J3E[/%GI.Q(=PR=1MF8DKLY#)/W35>.1-A)X5RVSE/'>3SC.>T,C;NTEJWD
M?J>]:-W946=]U3LN#5K=YIT@\E8]G8(1=9!PJP</8-_%RS9,ZS8AN\@X24^E
M_P"-V=H#[FL=;TC3>MM>Z@UG -ZIKC55'J>M]?U=HX?.VM;I%&@6%8JD V=R
MCI]).F\/ Q;=N11PNLN<J>,J'.?.39#%?&+B5QVX:4&8U=QEUE%ZHH4_>+#L
MB8KL3*6.7;/;O:THY&P3YW-GF9R03<2242WP9,BQ4"^%CN$+VY[0_#3^''&F
M@\GML<S:AJJ)A>3>\ZK7Z3M;:Z$O9UY:XU:K1=1A8"(>1#R<<U=DC'1=#B$2
MG:,6ZIL,BY.<QC*9.#;'#CC3O/=6B>16UM51-QW1QF?34EHR]O9>SLG^OGUA
MRQ-,N(Z/B9R/A)$S[,8AWL/VKLI?#QW<%[<]H?NY2\2N.W-;4[O1O*+647MO
M5+^<A;([ITO*V.'9K3==64<0T@9[59F!EBJ,5EC&*7#C"9NWZ8IL ,J6?6U(
MN6MK#J"S0#>6UO:Z/+:VL%66</D6LE2)V!<5B6@%7;5TA))-WD"Z4;F437(N
M4INTI\'[# /#\<.-VDN(NF*;QYXYT&/UAIK7WF+R=1HN0G)5A!^;+7.W>P^
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MROE(V%LY,3.<%S@-F@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW*U),667L?Z?V',7?A9WU[U5K BX1;[4UG$R#,QL%7E:"\=Q;QNGC/RJ%@[
M[E&\@KDO]4OI[0O;\N.S'R#Q6,[A7,Q,X"_JBK1>1$Q/^E3$6<F6*L/'],I0
M]/[]U7O2)/)ZZM#647;)X4DH)UC+"R1&,GPGWI*&<9PZ20RH;!2KDPHV4SGL
M(H8>C:QU3C]57G-XR[FF)S51EIGQ59O)G\#KU454394S(/&L@
M
M
M
M
M
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M,L^<HPD%3%XC:UJNLA-2T0S5E<(/(1@9E'X)E[Z*NNW06"78
M!7V^(AZKO(CI)<9M(;FXX4S2]UM&RMZEUC.L-VUV\6. :0&:!;[5Z7$M:)L7
M6TBA+^L8!$GB+.ET?!,?'A=[)3E"6KA%NNU<E.%_$3D7>H^OQ-VW]Q@T%NNX
MQ=3:R+&JQMJVIJFIWJPQ]:8S$K.R[.OLY>=639).GSQRFV*0JJZQ\&4,&SX
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MR'(;!B'(;&#%,4Q<Y*8IBY[<9Q\F< /^@
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MRI+K!+.
M
M                C]YL\Q":&C"42A+-7FUY]AESZ2H1%VTHT2OVD0EWK98B
MC=U-/NPV6+50IB%*7QURY3\)-Q[=W9[N3K6OM>+MC5]$V69IKG1$[E,?U3Y(
MRVS'-=77#RS]U7[FYR9LLM(3UAE)";FY5RH\DY:4=KOI!^Z5SVJ.'3MR=199
M4W_LS9S\F,8_J8'URZNKNYNXNKFF*;JF+(B(LB(\$0[D1$19&9\L;4
M                                                   >DJ-PM%"L
M,;:Z;.2%=L,0N5PPE8Q?*+A$^,_3)GQV&2<M5R_2*H*E.BLGG)%"F+G.,\.(
MPUQB[FK#XFB*[FJ,L3],DZ)C+&XDQ$Q9.98LX>\KHOD=5%V,N1I$;/JS9#S1
M#(9[C:59FR1!*TPB1S9/B.<N#8(X1[3&9N#8(;.2*(F/\<[Q:@O-38B*KNVK
M WD_RU:)XM7AC<G=C+GB;.E>W? G)]UN4/6W$
M
M
M
M
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M"\>(R8:*%;7CD$Q3:NU[ZU1<)^$_@=,LG13M5\%RF:SN6YT5?&B7*> Z50
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M-.JVV4D+95(_6YM&PMN7CFIW35OK>5IQKY8Z_&RN5DR*YMD8X>(=P^2-S=I
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M54V5'2U:57-G)E#9 68
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M*MAHO+524E63=Z5(V,F14.54G_A%QD!ED
M
M                                    'AMF7R*UAK^W[!F^TT=4H&0F
M54"F[BCU9LB;T*-0/G!BE<R;XR;=+.?I<**X[>S';D=K!82\QV+N\)=??O*X
MCQ6YY\41;,^):8FJ8IC=52;S=)_8EOL5XM+PS^?L\JZEI)P;MP3"SD_:1LV)
MG.<(,F2&"(MTL?2I()D(7L*7&!]\PN&N<'AZ,+<19=7=,1'DW?'.>9W9RO(Q
M$4Q9&9Y0<Z@
M          ,I:6VI.Z6V95=BP*BN5X&13-(L2*=Q.9@G.?1YJ&<8SVIF2D8\
MYR%R;&?"5[BI>PY"YQT-9X"ZUG@KS!WN:N,DZ*H^[5Y)\\6QFEFNF*Z>#*UE
M S<;9H.%L<,X*[A[!$QTW%.RXS@KJ-E6:+]BX+C/RX*NU7*;&/\ VH^"WMU7
M<7M5S>19>4533,:)B;)]+Q\Q9-DYWUAQH
M
M
M
M
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M<SSUQ)/8766U&MT9/*%&NE_$52K=)L5"RNR;J'[&R<WX"&,((E32#]_QM/\
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M?*.5<F(@_32I3NQ83<=S)E/2RG(;!#F[P=&L
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MEUHZDL)FM0M=8/F3J;GG+QTX(P:*.LD:D6*IEJF<!,X
M
M                                              ".CJ<VIQ"<>HZ
M;&,7SI?H*+?E[>PIXR*9REC/C/R]IC8E8EGG&.SL^3.>WMQCM]R[CW$7NN*K
MVK_[5S5,>.9BGZIESW$6UVZ(5_!];=P
M                                 %DO@!:5[1Q<H17:IEG5:<V&K**G
M/@V<H1DT\6C$L8[<Y(5K#O&Z)<9_\%/'_!G ^+][;B+C7M[P<E-<4U>>F+?/
M,3+HWT67DMSQZTX@
M
M
M
M
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M55$%'5F9D<&R3)>SY28["9[H#HW@
M               J@?%Z<Y2<;NG''<9:Q)F:;)YLW$E*5*V<X;O6&F-<.86X
M;3D4C)J^/DLQ*+0$ JD9/*3AA,N\9/C),%.%7;H_?$M4SI)\0&G%^M=/SVO6
M"2V)=-G[$VN;E(77A[Q:+.JQC(Q8E/\ =SO1X-M7J-7HB**GF6=X749*.<>%
MEQE%,/L=6_XG"F]5[AK9.*%JZ>QM4RJ]UI&Q:!M,G*A*_GH-RI\BLDK*EIZG
M&RF^NRS-,F9B&.0LJR,DG*&5P<WA^$H%D;X/+G%G?W3^MW$ZW3Y7^P>&EY5C
M:XS=N2*22^C-IKR=KI:Q<JE(Z>HU^ZHV*,^3*I&+%)@CWB$,BG@([?CG/^Z[
M_P!=G_LC@+W&H?\ %-J_]SNE?X-1@"C?\<C:)=I2NFU2D<F]06"T<J;1)8P9
M;N9EZA$\?XF$R8I3X;Y-AE>)#LR<N3XQG/<SC&3XR%SGA14X2A\-N)E(K30K
M&NU#C1HJLP;,I4BX;1,'J^K1K!'.$4T4N\1JV+C.2D+C.>W/9@!LV YQ5_+C
M47QM3-*D9-&)S.^=9&D"E.=/"^=U<':B[OV#^B&:=\LFYO,@?L-WL9RICQ,*
M?3=X+&?Q8?YDWD/^Z)QX_CJIH#U_PL,'%1/0SX;OXYDFU>6:5Y)SDZN0RF32
M4JWY3[IK:+U;!SF*50D'7F;?&"8*7N(%SV=[)LY"PF YQ75232U9\7]PUM5.
M2+'S&Q=\].Q2TK%,HAA\K<;'2],SBN<L%&2QC.:,Q2;YPH=0JF2YPIA1+.4L
MA)I\;3_F%\3?QNR?Q-;+ 60ND[^:RZ:?X@'#?^CKKD!2+^#82:;=ZBW/;D1:
M6_I-]=Z5>O47*YDG.6JVY-U1EKMJY%<H(_KU9Y56Z>%B$3SE(ZI>S!3Y* Z.
M8    #G&?"S?G_\ J.?N$<OOZ:G'L!T<P !S/^3;YOR\^,IUY$4@S:8C]8\Q
M.,['QHE4YE<..(>NZ'>=GE?K-_61#N:[9]93B#@A2(E(BS\)7PCE45P$^7QF
M-TEZMTF:)!QI^XSV1S0T_2[ 7O=GBQ#'66\]B(D[.Z;O=D]0F1NSM+_Q>WM^
M3LR$,'2]YU_$@\>^!G'35'"WI<:.VEQC@JO-RNJ=D6#5^S)2<O$3<;I9KI*V
M65DX/E)2(M^[DK'8'AO%2BF6,E[.TF<XR8P;\_E5/BY/_6?>._[T&XO]LX!I
M]T,^!/54H77,D><'+#AG<>/],WE)\K[SM>690$9&:SKE@W1&V^])5BN,G-HM
MD[!5LEZ=MF\8FHZ<N$D4TD57*O>.90/R?'$_XV>GA^YWR)_PEU* Z#U0JL'1
M*G5Z16&*<96J;782JUZ-1P4J,?!UZ-;1$2Q2*0I"%3:,&::9<8QC&,%^3& '
MH@'.J^&]@XJ6^)-ZG;^19)NGE9J'.R<@ESF4P:-E7'-345;6>HX(<I3*'@["
M\;YP?!B]Q<V>SO8+G =%4!SMOB7FC:0^(VZ6+!Z@FZ9O=9<(&CMLL7!T7#9S
MSKWPBN@J3/R&352/DIL?\.,@.B2 K>_%A_F3>0_[HG'C^.JF@,B?"X_F*.#/
M^LS_ $P^00#4WJ'?%$:NX^<A9?A=P/XW7?GURDAK,O1IIK2WK]'7<5=67B%E
MZG62T^"NEVVK:ZX\;J-9)G',6#)JN10N)!15!9$H:W,N;WQB.W"M[%1.F)Q9
MUI6UG!T&\=:G-.J4VD@JM@R:\W%;:YD1MI44:I&[#*(1C4A\8SV(Y-\@"$'B
MU+\R9[XMG2TMU JMK^E<NG>Q*U[6JSJUPQ=T2,\#@VDVH?J)Q&V.VLE/3-9(
MPKAUW)!QV/%5<9\,V,ID#H =6+\UEU+/Q .9']'78P"M[\$M_F%\LOQNS_Q-
M:T 700'._P#AK/\ >0>JQ^YWSF_IWZ) 2A_&K?FLM!_C_P"K/Z.O*H!-UT3?
MS1O3F_%$TK_@=' '6R_-&]1G\43=7^!TB A%^"I_-9;\_'_VG_1UXJ@/)=8;
MX;7=6V.4LQU)NE7N0ND^5+^<-L2W:Z7M$EKL\_LXB)4)"_:CV?$&(6F6VWH9
M4-*QTKX47(O'"ZYWS8CA9$X:+:W^)2ZMW3&ND+H[K-<);)=8S"R3!MM%&MM-
M1;.EF+7";9_-5NR0+5_QZWFT:%;&[GJ7U215QE7QI+.<8*0+F7 ;J*<4>I9I
M?&\>*.PO-U>8R)8*XU>:8'KVP=<V7*&'6*]>ZFX56<1#U9MGQ&SA)1S'/TRF
M.T<KD*8V WA
M
M              !%KU58Y575&M9?&3>"QV&M'*8[G:7*LI6Y5RCG*G?QDIL$
MAS]F.[GO?+GMQV?+[WW"KB-87]WNS<V^:J(_B[&'^]/B07CZD[8
M                                                     +#/32CU
M67&=NY4[W<EKW:Y!OVDR7'A)XC8K/=-G.<*%\>,/]-CLQV]N/^ ?(.^M<5:[
MFF,]-U1'US_%TK__ (GD2 CU%P@
M
M
M
M
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M#W'2:K8+YJ:M,*I"^K=.7VWSDG*KQ^SGSL_H5<K;Q1!$A,>DN2IHY42*?*I
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M%0,7*N$SJIEPBF<I0Z00
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MV^KKW^.@T+-(4=&P1*MP8UMRZ*Q;6!Y62.S336#</381([.@5 ZN<$P?)OD
M<^?XXG_&ST\/W.^1/^$NI0'1   '._\ AK/]Y!ZK'[G?.;^G?HD!T0 '._\
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MA9G]3DW*K)8V,&59/I Y"=F39*'1O
M
M                                !JIS5UFYVGQSOL-&-U'4Y MFUS@D
M$B>*JL]K"OISQLBCCL.LY?0?I;=(I<][*JI>S!O^+GSW=G'4X#7-U>US9=5S
M-%7BJR1/DJLF?!#DNJN#7$[BL@/M[O@
M                               #^B22JZJ2""2BRZRA$D44B&45554-
M@B:229,9.HHH?.,%+C&<YSGLP),Q$6SDB!:OX[ZY5U+I+6VOW1"IR,!6VV9E
M,F<933GY99><L":9RY-A1-.;DG&"G_\ #QCM[,=O8/@NN,;&L-9WV,I^Y77D
M_P V/Y:?]6(>.KJX54U,SCQK(
M
M
M
M
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MG\R;_P"*X /T&/\ ^.B?S)O_ (K@!O\ ]+CX4K\FOSLT9S5]_/VT>Q?VF_\
MJ:>ZY[.O,OM%T[L'4_\ Z9>\5>_4_J?SWZP_\U.O2/1? _4O%\9,+?H  H!_
MH,?_ ,=$_F3?_%< +_@"I9U5?A.N,?.;9MOY%<:-FN>).\+[*REHV+!9JOGG
M2NQ;=*N3OI*SFK2$S7YO7EFGW[A1:3=QKEW'NEL^-ZL*Y4<.%PK[O/@H.I(2
M>*WC^2O"!U6,K(%/+O+;OEC/%;FP7TE4M<0T%(QYUDLYSW$\RI2J=F.TY.WY
M FEZ;OP>7';CAL"N[CYN[=1Y8V6K/VLS7M.5VJN*;H]M,,E$UV;FZ*2<I)VC
M9[1F[3*LFR4)"QJN2^&\;/4,F2,%S0A")D*FF4I$R%*0A"%P4A"%Q@I2E*7&
M"E*4N.S&,?)C #_H!S_?C >,NQ=#<FN%G5GTNV68OJQ)TW6MMGV:*QF]6V[I
M^V/]L:+M4GZ+X+GQK$S-(LLK>.F4A:\U2+DBBI<F"[QQ&Y*T/F+QCT7RBUHN
M56F;QUK6-@1C7TA)RY@W<S'IFG:I)JH9,CB<IUA3=13\A<YPF]9JD[?I0&'^
MH/TYN+G4UT0\T%RCIKF;@T7IYRE72N/$878NK[;Z*JS2M=!LBC1^G'2.&ZN4
MUVSIN[C7Z78F[;+DP4N J5H_"M]3_C-)2]:Z?O63OVJM12<NYD$*\C>.0G'R
M2;-WBGC&++QFE+?8:Q9)=#ND(J\PE'E>&)XO@H=N$BAM'PH^$=UC2-X1_)3J
M.<H;7SLV#&S3"Q)T63B)=E0K!-PRC;$2XVM9;M9;E=ML12"+-/MC%?5+-7!"
MH.BO&OB(*!<5;-F[-N@S9H(M6C5%)LU:MDB(-VS= A4D$$$$BE21112+@I"%
MQ@I2XQC&.P!7EYO]!+WRNK!Q:ZG_ +UOLX]VJQ<:)_V'^POS?YT]W;;SK:OH
MGM+]L57\N></2?0/$\OO_5_=\?NN>WP<!8@ 8UW)I[6O('5.PM([BJ49>]7;
M4J4U2+U4I<JOH,Y7)]DJQD&N5FRJ#U@[(FKXC9VV51=LW)$UT%$UDR'*%+F<
M^$:Y$\>]K6J]=,_JL[;XR5JV+*(^IU#;&HNP(B!(=RHQ@);:6D]@5;-_:,LN
MU"I&<0\;W"'SWBG/DQSAO)P;^&'J6LN0-6Y==1WE[M7J1;\H\BSFZ/'[14LK
MG7==G(QV5_$2ME<7^Z;$NNT'L')I%>LDW3R+B4USYPXCG62$4 ;M]*?HF0'2
MVY)\Y-Z53?9=E5;E_;4)RM:O)J0E!)IF C[[L.X0U7+:4]DV].]%C8Z\IQV'
M)8N$*;#'QL(EPKX*0>QZVG2&_+%Z%U-I#WA?=T]E^WB[5\S^R;VN^O.RF6:H
M^H?4OM+UAZL_](O2/2O2W'_B?#\'Z?OE"2'B=HOW7^+'&GC1YI\\>[OQ_P!-
MZ+\Z^I/+/G#V2:ZKE \T^7/6]@\O^8/+_I?H/I[[T3QO"](6[OB&#/X"/'J8
M=,SC=U4..SGC[R)CY=D2,ERVW6NR:@LT97O5UX08.XY"P5UV]:O&+U@]8O%&
MTE&.TE64@V-CO%(X2:N6X59J-\*UU-] ,WVL^,G7 VKJ?1KMZ[6S6J,ZY ZC
M9K(R:KE205?:XU_N\U0=/7&'1\K&],QAR90^3=WO9P DET)\+9Q-TUQ9Y8ZN
MM6V+?O3E7RWU%:]9VOF-M>JMIR5HLC/^CRC&Q:]UBK:55(YNVN44PEI CNR/
M)J4.U]'S+H('[I EAZ3W3Y_)?\)M=\.O:Y[</(5BV'/^T7R%[-/6WGVZS-P]
M$\H^=-@>@^JO6_H_B>M%O'\/Q.ZGWNX4/F=47I1\7^K%I!AJ/D(PEX2PTY^]
MG=3;@I9F+;8&L)^100;R9XE>0:NV$M6["BS03EHAVF=J^(@DH7*+INU<H!5F
MJ/PN75_X\'-K;BCUJ+?K/0^'KI5&,J.P^3^C3E1<N'2RC@VJ];W:;IN7J^7!
MCJXQ+XP914^<FSVYR8) ]+?"A<>Z=QZY/0>[.0]SY$\S^3VKI;7KGEMLVIJ6
MAMJ%Q*^IW>)Z@ZWG+J[E)B>3D(5!)W+25DS*NXY+T9HM%I+NB+!-3TGNGS^2
M_P"$VN^'7M<]N'D*Q;#G_:+Y"]FGK;S[=9FX>B>4?.FP/0?57K?T?Q/6BWC^
M'XG=3[W<*&@%7Z"7EOKBN>LU[UOIOI%BM\_[M_L+]&[GFOC1-\=O1/;![8E^
M]Z!ZX]<>)Y6QXOA^B=TG>])*%B ! #USNAC^6C]UW_Z*+W;/=L]MG_S$_;%Y
MT]L7LC_^NYJSR[Y=]EG_ ,O^F>G_ /D/ _5@G<J$!Y4J=7J_I?I_ENNPD!Z=
MX'HOIOJ>-;1WI?HWC.?1O2/1^_X?B*=SM[.\;L[<A@#FSQM]\3B-R-XK^<_9
MU[?]0W757GOR[YN\I><(9Q$^OO+'KVL>OO5WI'B>B^L67C=G=\8G;VX#2+HJ
M=*3\CYQ8OW&CV]>\1YXY 6G>GG7V7>R3U7YFUUJJ@>5O+GM%V;Z;Z%[,O2_3
MO3T?$]-\+T<O@^(J&KO7%Z"7Y9JV<=[1[UONW^P2N[$@/0?87[8/-?GZ2J4C
MZ7Z3[8M6^HO5/E;N>'X;SQ_'[>\GW.PX3_6^ \UU.T5?TOT#S)79N ].\#TK
MT+UQ&N8[TOT;QFWI/H_I'?\ #\1/O]G9WB]O;@((^ACT,?R+GO1?_11>\G[R
M?L3_ /F)^QWR7['?:Y_]=S:?F+S%[4__ )0]#] _\OX_ZB$_P"N_UQ>@E^6:
MMG'>T>];[M_L$KNQ(#T'V%^V#S7Y^DJE(^E^D^V+5OJ+U3Y6[GA^&\\?Q^WO
M)]SL.$_UO@/-=3M%7]+] \R5V;@/3O ]*]"]<1KF.]+]&\9MZ3Z/Z1W_  _$
M3[_9V=XO;VX""/H8]#'\BY[T7_T47O)^\G[$_P#YB?L=\E^QWVN?_7<VGYB\
MQ>U/_P"4/0_0/_+^/^HAISU*_A>8_F5R]V%SGX[\Y]I\6=[;,?Q$S:6QZCYL
M@B2T76(FFF/3+'3;GJRXTIH[@X1N98BRTUDZ^%<8R1-4I40TX>?#)]7S9D27
M7^[>O9O&<U:NB@V?5UY;^3VSXGT=$A6::!:-;=Z5NNNT4(Y54I"'<)EQCL3Q
MC!3Y,4)X.DGT*^(?2-C+!8-6KV3:^_;O$'KUUWYL-*/0L"U:,_;2.:A2Z[%$
MQ%4>I+O6#9=RB11V]>N$"&<NU2)-TD0DAY9\5]+\V>/&T>+_ ""K1K3JG;5?
M]1V)BV<88RT<Y:O&LO7[/7)+*3CU5:*E8H]K)1KG*:I$7K5,QTU4^^F8*<E9
M^$VYV<:;/9HS@UUF-KZ&U1;9<SR3C:R7<6I;.NQ4]&03)9FVH-MQ-;O,NR8(
ME2RZ4)&D<^"3L20+GNIA.3N_HRW+D#T;JSTJ]A<R+%.7>.4JC^S\L;9K:5OM
MAM<M7MPK[;<NY*D3FW6DN\4>Y7]6$5<6A55-),JV>]_XC ;N]+C@Q^37X)Z,
MX5>U'VT>Q?VF_P#JE^2?9UYE]HNXM@[8_P#0WS=>_4_J?SWZO_\ .KKTCT7Q
M_P!2\7P4PW_ 5=^K9\,9H_J'[R<<N=#[LG.(/*&5=Q$O=+!#U8]NH>P+)7&[
M-O W):%C;+3)^C;"0)'-L+S48^43<F;D748G>F6=*AHS$?"T\_=X'B:+SRZV
MW([</'U@LT/*:KB+1NF^GFV+7+<I(R)/N3:<U2:<LD1 ADGBD!-D2RB0OHN>
MW!DPD,Y%?#,<9K[L#IMV;C'L%AQ4JG3VL$;*K5-#5.=IR^]FD3M*G;6:FM=X
M<[*HLG$VAW8(:8,[E7+>;RJ>;[4T$4FA$%0LQ *B_4>^%<J_(_E58.;/!KE5
M8N$^\;E9I"_6^)CH&:>UM79,UARI8;_0;;3+93[IK.:M+YTLZE$TO6:+AX[<
M*H^C%/E$P;S=(CI.<WN"VXMC[MYE=37;/.:5N>KC:SK](OLUMRVPU*[UOA+,
M>SQMHVIM.W.3/56\$5KZ,A$M.Z5R?/CFP7NG#X-7Z"7EOKBN>LU[UOIOI%BM
M\_[M_L+]&[GFOC1-\=O1/;![8E^]Z!ZX]<>)Y6QXOA^B=TG>])*%A&5BHR=C
M)&$FXYA,0TPP>14O$2K-O(1DK&2#=1H_CI%@[36:/F#YHL=)9%4ADU4S9*;&
M<9S@!38Y:_"-5C&Z'W(CI<<O;SP7NCY_(R): 56W*UBLN97.#NT-8;,HEFKV
MR-?U_*A<Y]6."3I,>+DJ*S9NDDWP&O./A1>HMR?EZZTZC/6$V!MZ@P$B1[B
MQ9]Y\@Y?"+?Q"I)UV0WI<(6%JDBLF_=%P[]7/\-O$SG"*V%#XP%O3@KP+XT]
M.;0,!QRXNTGRI2(ERO+3<S*+H2MYV#:WI$DY*Z["LR;-BI8K-()H)I>)X2+9
MJV22:M$6[5%%!,,3=6'I\_E0.$VQ.'7M<]A_GVQ:\G_:+Y"]I?JGR%=8:X>B
M>4?.FO\ T[UKZH]'\3UHCX'B>)W5.[W#!Z+I<<&/R:_!/1G"KVH^VCV+^TW_
M -4OR3[.O,OM%W%L';'_ *&^;KWZG]3^>_5__G5UZ1Z+X_ZEXO@IAO\ @*[]
M7Z"7EOKBN>LU[UOIOI%BM\_[M_L+]&[GFOC1-\=O1/;![8E^]Z!ZX]<>)Y6Q
MXOA^B=TG>])*&Z76EYNQ_3]Z:_)SD"G+%C+^>C/]9:43(OX+]YN?9[9Q4Z*X
MCB87;*NC5-T^5L#M-)0BOJV'<F)G!BX 0%?!D\'9;47$K=?-NZ12S&9Y66V-
MIFK\.\'*?V0Z;>ST?(6%FGE-/*:-OV5+238^#Y/WTZ\W53[I%.TX70P
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M\/KIBN=5#BCU&-$;)@=$T'B[JZI:U9\5ZUIHDA#VC%-H]_UU$3+?9^-F1"\
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MJX8M&$7#5V$-(N<1L2Q01:M"N%#'RNY57<JA)L
M
M                                         #_,XP;&<9QC.,XSC.,X
M[<9QGY,XSC/R9QG "N?SBXP/]'; =VVN1ZAM67B2</85=NCGT6L3+O*KM[4G
M1B8[C=-,Q5%8_O=W"C3Z3&3'05,/LG=?7E&M,)&'OI_\?=4V5::J8R17'U5>
M'+NP[MU><.FR?O0T6'M+F
M                     28]/7B^]V!<&.Z+A&Y)0J8_RO64'B.?#M=N9*=C
M=9NFH7L6B:TY)XJJO_%.](FD7O\ <7P3TGO?KRG"8:=68:K_ ,7>1_-9_31/
M\:HR1'%MG1;P7UYP8X,9Y3TCY0Z8
M
M
M
M
M
M               #5GFMQ#U)SOXO[@XI[MC?3:)MRJ.H-6100;K3%0L*!B/Z
ME?*T9T0Z*%FI-D:MI)B8^,I&7;835*=$ZA#!$7T".F[U".E?KK;G&#DUMCCK
MN+C.K:'UYX^2&L;9LUWL*CSTO(Y2M4+,56Y:GJ\'%U*YM"I2YF[.>?>JILKK
M"9719!5RD%AH
M                           %7WK8]''G7U@.3G'&IO=VZ(U)TY=,2L7-
M6:M,[5L1]R M=CG/#3V'=6]/)J,VN?,3*OD]1UI-W9%D&"*KI\?/>>K,2A9"
MU1JR@:/UE0-.:JK$=2]:ZOJ%?HE%JD20Y(^ JU8C&T1#1C?*IU7"WHS%J3!U
M53J++'[5%#G.8QLAD
M                  !6]^+#_,F\A_W1./'\=5- 9$^%Q_,4<&?]9G^F'R"
M3_
M
M
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MN1-%!(A?ZF"XQ@?,KV]O+Z\F]OJIJO:IMF9FV9G3,NK,S,VSG?3&
M
M
M
M
M
M
M
M
M   &-]L:;U#ONDR.M-YZJUONC7$NYCGDMK_;%&K&Q:3*.XAZC)1+J1JEPBYB
M">N8N1;)N&YU4#&073*<F2F+C. _1JW4^K-'42"U;I36FO\ 3^LJOZS\M:ZU
M;3:YK^B5WUW,2%BF?451J<;$5^(];V"7=OG7H[=/TAXZ56/WE%#FR&0
M
M
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M:;SSQO'.7FF3W.^,?WF*;_6KO^RP^(]>>TWGGC>.<O-,GN=\8_O,4W^M7?\
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MO-XMJU1-W,9^3MQ\@\9?8G$8FKAXB\KO*M-54U3Z9EF9F<\VO2#A0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MG(GV?>5./-]M4M*Z>X\^28=6+D?8[77<P]C:[YU64PZD_1FK7QURX,;OY^4
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MY5W![%UM(3L<LQ;7&E3#!Y'O(VR02BN%VJR2Z1TU28S@V,_* ^7QATU/\>]
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MB83E)OC5=4X[>T'S7QYH5JEHK3W(;SM#I1<=[8JZTF&4;8O)2R>749Z2U=>
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M<?;#L6KKUZ)W/J&9>U[9>NW2SELX+8:;-1S^,?1TPB5OE,JB;A(V"*&QWOE
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MZK-'.2YR7&<!NX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M #Q5^V+2-75QU;+_ &2,K$"T^E,\D5LX.X7R4QR,X]FD55[)R"I29R1NW356
M/C&>PN>S([.$P>*QU]&'PE%5=[.Y'US.:(\,V0L4S5-D9T6NSNJBR;.7##4&
MN_6:21CD1LE[=*M&ZYBY,7!T:S#*E=F;*=F#%,I((*Y+GL,D7/\ 4][P/<.J
MJF*]8WW!GBT1;/*G);XJ9CPNQ3A^-+65WU+.3#A=19%Q16"9\]I6K2I]]!+Y
M/ZB9GTD\=9QG_P!N4-D>;I[E:DB+)B]F=,U[T1'H;YBCPOS?E)N3GSI3?N1:
M?V0-?!>H^+><N=Y>8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI
M3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N
M3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"
M?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.
M8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG
M+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J
M/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0
M'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1
M:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI
M3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N
M3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"
M?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.
M8N_"?E)N3GSI3?N1:?V0'P7J/BWG+G>.8N_"_P"B]2?DX4Q39DJ8?&#8SDAJ
MDVP4V,9[<E-DCHI^Z;^IGLSC/_LLA\%:CXM[R_L.8N_"S50>JI<FCA!#9NMJ
M]-,<F*1>1I;M_ R**?R=KCU=,.9ME(+?)_XO"[,F<Y^0Q>SLSXS%]P\-5$S@
M;ZNFK17$51YXX,QYI8JP\?TRE%TOR,U+ON-.\U[94G,BV1*O*5>4(6,M,.3.
M2%R=[$J*'RLV*=4I<N6IW#3)\]W"N38SC'HNLM3:PU37P<9191,Y*HRTSXIT
M^";)\#@JHJH^\SB/%L
M
M
M
M
M                                                     T/E>J;T
MQ8*3D82;ZC7 ^'F8=^\BI>(E>7O'V/DXJ3CW"C1_'2+!WL)%VQ?L7:)TED52
M%424+DIL8SC. &S.F]\Z-Y%U%38''S<VJ-[4-*7>U]6[:;V)4-GU%.?C46CF
M1A%+)29B<AB2[!O((*+-LK862(NF8Q<8.7.0RN PWM/D7Q]T8XAF>[-ZZ;TZ
M[L2+QS7VNT]G4G7SB=;QQVZ4@O#(6V<B%9-%@J[2*L=#!RI&5)@V<9-CM#%'
MY0/@7^&YQ$_^&3TU^W0!E/7?)#COM]VBPU-OK2^T'SDKL[=GKO:5'NSM<C N
M#OS(MZU.R:RI61,]JV2XSA/'RF[ &: 'P;3::Q1JU8+I=;' T^G5.%D[':K9
M:9>/K]:K->A6:TC,SU@G99PTBX:%B8]NHNY=.54T$$2&.<Q2ESG :/?E8NEE
M_P"N6< /_AR..O\ *, W[161<(I.&ZJ:Z"Z9%D%T3E51615+@Z:J2A,F(HFH
M0V,E-C.<9QGMP _Z.<B9#**&*1,A3'.<YL%(0A<9,8QC&S@I2E+CMSG/R8P
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MIUOL.ZTUO&2R4#)+VJK5&RS$[7D8^=7(R7.[01*D[.5$V<*9P4!L,
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M=@%H\DY<K5M]+%?GAEW+=\S8KN8:<Q%._0))N5:.?9:K8074RBI@H;=@
M             #3MEU ^%LCRP=\&6/)#6;KEHRCEY)SHY&84/;DR-8 ML=1V
M#X;>IE+$UJIO6:L41T:33CRG<F0PB0YRAN(          ->9CEUQ0KNZ8_C;
M8.3O'F#Y$RRT:VBM!S&Z=;QFZ9-Q,QI9F'0C]6/;*A>7BTM#FP[;$38F,NVS
MA4F#$^F ;#
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M0VO0]KQ-?EG3;#UM%S<C0YZ?9Q4BX9Y\5-!<Z:ITOIL%R7Y0&;@
M                       $8_5'ZKO'?I):CUYN;D?3-T76K[*V-C6,$PTE
M7:/8Y]I/YK,Y:O2Y9K>]BZVCD(CU= +$\1%TNMXQB8\+NY,<H;L<>MUU7DIH
M+1_(NBQ]@B:3O[3^M-UTZ+MC6.8VJ-JNU*7"WJO1]E8P\K.Q#.P,XB=13>I-
M7SQLFY*<J2ZQ,%4,&8                87Y!<BM'\4]3V?>?(K9E7U'J:G
M%89L5WMST[2*8JRL@VBHIDDF@DY?2,G*2;Q)!LT:HK.7"I\%33-GY '[=$[Y
MT[R<U/3=YZ!V'6]JZDV P<2-0O53>&>0TRW9R#N)D$R9530=,W\5+Q[AF\:N
M$T73-V@HBLF15,Y,!EL  :@<]>:NK.G;Q.VMS%W7 ; M&LM/^1O,L%JV*KDW
M>WWM V33M6PWJ*,MEJI-?<^C6"[-%G7I$HU[C--4Y/$4*1)0/B]/;GEJ'J4<
M7*9RVT97-D537%YFKE!Q,+MB'K$%=F[NCVB3J<LI(QM/N%[@DFSB1BE#M\I2
M2QCH&+DY4S9R3 ;L@            -.]*=0/A;R-WAM;C9HWDAK/9N\](^LL
M[.UQ5YA1W.UHD)-I5J>6*=1LC'SC:NV-PDPDE8U=XG'/%DT7)DE%"%,&X@
M
M                 ,3[LW%5-%:\FM@VU;M;1Y,-HJ*25*F^L,ZY(IZM@X[O
M%4SZ0\43SDY^Z8J"!%%CX[B9AY#5FKL1K7&4X/#Q_-.>=RFG=JGQ>F;(C++5
M%,UU60K/[MWG?M]W%U;;Q)J*EPHL2#K[954L%68Y0V,DCH=F<^2)X[A"^,L;
M&5W)R]]0QL]G9]LU9JO":IPT8?"T_P"=5/WJITS/U1FC<=ZBBFB+(8='D6P
M                                  'H*K:[)1Y^,M-1FG]?L,.XPYCI
M:,7,W=-E<8R4V,&QVD5163-DBB1\&353-DARF+G.,\.(P]SBKFJXQ%,5W-46
M3$YI^FY.>-Q)B)BR<RQGP]Y51O(^H.&TN1I$[,JB+8EJAV^<D;2;53&$F]HA
M4CYR;$<\7QDBZ.,G,S<=A#9[BB)U/C?>+4->IL1%5W;5@;R?Y)W8GBU>&-R=
MV/#$Q'2O;O@3D^ZW''KCB
M
M
M
M
M                                                     1J]8#F2
MWX$]-_E;R40DO5MPK.LI*JZJ.FX.@[/M_9"B- UFNS*C^NG'J6V6)M)N2I9*
M<K%BNIWTRD,H0.+W1]3[!V=!;<M5/@7\_%Z4UZCMC9CQLDX<G@J2ZV+0=79G
MG/A)JF,B2X[-B4E3&R7!$UCJ&S@I# +K_P %%S))6]M<I>"-EDS)Q^S:W%<B
M]6-%U<)M$[C1#,Z9L^.:)Y/VKR]FJ,O"/,%*7Y&M;6-G/R8P Z)X#G?_ !Q/
M^-GIX?N=\B?\)=2@*HW!CI<<[.I1[4?<JT9[:/8OY)]I?_JFZ=UUY:]HOF[R
M;_C8V#1/7'KCR)*_^;_2O1_1?U?PO%1\0,R<D^B/U:>%%4=[9WEPTVO2Z;4B
MISDML&BS-(VS"TMNQ,DZ)8+!8=(W&_-Z@P8*]PV7SU5JB@IV8RH4WR )$.D7
M\39S,X(WRG:\Y,7NZ\K.(+I_'0UFK.P9=U;=M:NKZBOHZMBU#?IUV>>=F@&Q
MR')6Y=VYAW+1MZ(T]5J*^F)AU.]9;*UER$U-2]JZVGX/8FI=NTJ)ME3GV92/
MH.U4ZVQ23UDL=LZ2QG*+V/=]Q=LX3*HD;OHK)E.4Y,!R4?B)^DZ\Z87-N9=:
M]@5FO%'D@[G]D\?GC=L8D545#/4'%[TOE4B*:"*VM9:62Q')=ISFKKV.,=0Z
M^''="YM\*-U5_?/X@&X?;9G_ $WD5PTKL+!13N0<=^4V)QVPJ6&H%D[Q\X.]
MD=;GPC69,Y2YR5L6*76.HX>J&R'I?BINJACA!PM5XPZJLA6')'F3$3=.05C7
MIT9O7NB,D-&;+O!#-C8<1S^U)+YKD2KG*1\F=OG+<_BQ^>P*6_PY'2;6ZF_-
MJ+FMF5U1_P 3>,[F!V1O51\R,K!WR3+(&6H>CSJFQX2WM!D8Y9:53QV9Q7H]
M\7!TEUFQC!UX4446Z*3=NDF@@@F1%!!$A4D444BX(FDDF3!2)IID+C!2XQC&
M,8[, /Z .?3\1UT0.J%STZE4_O\ XG\8O:MJ-[IG5%3;6WVT\>J-XL_6F4LC
M-L/4.R=LTZS$]"4=$QXIF6$%.]^IG-C&>P(&_P!%QZZ_X#/\YGAY_M! -0.:
M/1HZD'3RUE"[AYB\?([36OK';V5#@)=SO+CK=9"9M;^,E9E"*C:OK?;5QMCS
MN1<*Y76738F;-B)X\50G?)W@D6^$RTO?-E=:#1FPZO%F<U3CQKW?&RME2BA5
M2-HNOVK35WTG!)$7PD9 \G(W3:D<5)N8Q3J-TW"A>W")^P.M& J7_%1]83'"
M7C7[F&BK45GRDY4U>1:665A),[6?TQH!\HO$6"TD5:&PZC+1LU5!U!0BA<D5
M0:IR3U-1%PV:&4#EK@._/,-7SZ)E&47**0DD\CGK6.FD6K5\M$/G#95)I*),
M7R:K%XI'N#E5*DL4R2F2=T^,ESG #D0\].$?6\Y:=2C='%7<C'D-S<Y ZQL"
M[MC/-$GB6IVNMK$Y,>E;&J3=\YAM0Z0UK>H["2S=N4\0Q;O3*M5?UXDN4!ZR
M_?"G]:"@ZWD=B9T!2+FXB(X\K(Z[H.XZ#9-D)M&Z"SEZ6.@RR;2-LDBT11SW
M6,4^?/G:ABIM47"IL$ 1U].SJ=\O>EEO>&V-HN[V9A QMB1)M;0-AEI=#66T
M8EHZ(WG:S=:>OE1BPGLM4E6[683:EEX=?.3H*%_5$U [3.JMC0&X=7:WVW5,
M.\5;:5!I^QJUA^D1%]B N]>CK-#8>(IJ+)I.\1TFGXA2G.4I^W&,YQ\H#WP"
MM1\4'U/YGI\\##:WU//J07(SF$YL>J:%+QSY1E.4773&,;9V_LB'7:.6\@SF
MHR)G&4/&.D3)JLI&;2>)G[[3NF#VOPT733B>G_T[:-<K5!%:\B.6\97-Y;=D
M7K0B$U!5V:B</-3ZO/GOF6;-*94I3TMTW4P59*<EY I_I2ID3"Q$
M     I??&T_YA?$W\;LG\36RP%D+I._FLNFG^(!PW_HZZY ;_@        (
M?BCOS%'.;_5F_IA\?0&._A//S)O'C]T3D/\ QU7(!9"       !7]ZT'0+UQ
MUC+[QWV!:.1%ST3*:093E7FFL!186]M+M1+#,QDV_C([$C8*TI4+6BX9*E;R
MBF9=H0JV._'JY)],$\U9KT;4:W7ZI"D63AZQ!Q->B4W+A5VX3C85@WC6!%W:
MYCKNEBM6Q,'4/G)SF[<YSG.0'W    >5O=/BMAT>Y4"=4>HPEYJEAI\PM&JI
M-Y%**LT0\A9!1@NN@Z01>D:/3Y2.=)0A3XQG)38^3(0;=%?H-:[Z-T_R+M5=
MY VW?D_ODU3AF3B<I##7S&E4:F/;!(Q<*I'1MIM*=HLCU[8,F>2QC,DC$;IE
M;LFV#+95"?,   $/G7?YU73IW=,G?G(75-A3J^[%%*;KC2DVK#0%@+&;"OMI
MC8PLQB%M,;,UR34K=43E94B#UFZ;+'8X(HD<ILX ;(]+K<^R^1?3JX6;WW)9
M/..U=M<<]7WS8-J]3P%>\P6NQ5IE(3$KZCJT5!UR*],=JF/X#)FV;)]O81,I
M>S #?(        !6*Z*?52W]U#^HUU<*-:]C)V3C#H"^5B$XO4Q*G4&%+5ZJ
MC>MG4I>;S9:_68ZY612Z,:6UD3EF9*1PV.ODB'AD^E 6=0%>&*^'JU-&=9EU
MU>#<A;R[=+6B3V2AQ]4IL4@Q0V=*T)>B*2RFSVEB0>N*<V3=*/DH?U(1QES@
MA%9!5OA1)4+#P          I[_%N]/9ULGC=1>IAI$LG6>1?"67KRMIM%047
MC;3)Z:?VQ@M$SS>5CUT)1K.:3V&];S,<Z;Y*HR8OY-<YNQ)(R03(=#OJ.)]3
MWI[:JW]/.6&=RUA9YJ'D+'1Z"3-NVV_2&<8>4F6S%$YDF3"]5V5C; @BGV)-
MBRF6Y?\ Q&0$O
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M $=>*H"WZ T ZL7YK+J6?B <R/Z.NQ@%8KX(C_--YM?C$4;^+5(!=T
M            %8KHI]5+?W4/ZC75PHUKV,G9.,.@+Y6(3B]3$J=084M7JJ-Z
MV=2EYO-EK]9CKE9%+HQI;61.69DI'#8Z^2(>&3Z4!9U             4OOC
M:?\ ,+XF_C=D_B:V6 LA=)W\UETT_P 0#AO_ $==<@-_P
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M##./SB*A44$53G52<+8242"P\
M                                            "OKU'MSNK]N8VNH]
MT;-6U6EZMR@FH;*#VW2"*#F??JDQW2G4CT\I,"8-@V4CH+9+G&%38'UWN9JV
MG":M[97'^_O\OBHC)3'ERU>&V-#N7%-E/"W91WCW!S@
M                     S-Q_P!N2>D-M5#83!5?#2,DD6MC9(9[?6U5?J$;
MS\:9,WZFHHJP,8Z'>QG";I-)3&.\3 \;K?5]&M-7WF#KLX55-M,Z*H^[/GS^
M"V-UBNGATS2M6M7+=ZV;O&BR;AJ[02<MG"1L'27;KIE5162/CY#IJIGP8N<?
MU<9'P6JF::IIJBRJ)LEX]_<0
M
M
M
M
M                                                      !04^-C
MYF+-H[BAP%K,MW,2:DIRBVVP;KF(JHT9'F=;Z;9.? /CQ63AX:VNEVZV,ERL
MU9+8+WB$-@/!_"G],RN\D.GIU.+WLADFWC^859G>%M*EWS1-52 @X:D.YVTW
M"*P8IU5?"O%]@UT%,8[$W]9QDG:<F>P*H'3XY%W+II]2G06[+(@_K<KQUWZG
M6MQP>%%2/4J;ZV?ZWWC5E?1"N.^[5IDE,-"]A%BE<=TW</W<8R';7BI2-G(R
M.FH9\TE(B88,Y2*DV"Z;IC(QL@W3=L7S-RB8Z3AH[:K%434+G)3D-C.,]F0'
M/.^.)_QL]/#]SOD3_A+J4!D3X&/_ +T3_4F_[7 "_P!'(10ADU"E.F<IB'(<
MN#$.0V,E,4Q38R4Q3%SV9QGY,X <B_XGO@-K[@=U.;(TTW7(RGZ?Y'Z]@>0U
M0IT$B@T@:7,V&=LM5V!5X2-;IHI1$06Y5)U*-&:)"M&3252;-\%21*FF%LCX
M,GE!8-L=/K<?'.RR#B24XL;O,6FF77=+%B];[IBG-PC()$KA15-)-KL"&L[K
M&$LD3P5[C'AXSC)U G8ZM_3AH75&X3[-XSV?$5$WD[?-TT5?I%J58VN]S5UF
M\-4IPS@K5V\;0,OZ2M$396Y,K*PL@Z*GCQ?#,4.2CP^Y)\B^CUU#*OM0U:E:
MMMOC9LV=H>Y-4SAC,C6"OMWKFI[6UA/%*8[8Z<Q%8<IM77ZLDV>D:OT.^9%$
MP#TO.KE1OWK,=1^T;0A:O8+'>=^[&@M6<=]1,<$=R-;HV97%:U'K9BFDN>/2
M?HM'9'$JX(=-JO+NWSTV2%6/G =8_I*].6@]+KA+K#C#5,QDO<VZ*EUWC?X]
MKZ.?9&Y[*V9FMUC,8Z:3A2(BTFC:&ABJE*JE"1C0BO>6PH<X26     .5]\6
M]U"<\JNH,WXNTB<,]U!PAC)*@O$6JY%(Z8W]9E&;_;TKDS=;)5S51!A%UG"2
MZ?BLI"(D>YGNN3=H6AOA&> 2?%[IYN^4-PAC,]L\W9QG>$5'::6'45HJEGE(
M;4<6G@JCCPRV5R_E[)E4AT_26<NQ(JG@[4N<A/\ <\.:>H>GQQ4VYRQW6\-B
MH:OKYW;"O,W35M/7ZXR*A8ZG:]JQ76>XK8+?/KHM4C9*9-JD91TOW6R"RA Y
MC_3)XP[\^(FZOMJWYR:-(V#5L;<V.[N4UA02QFM0="BW'HVL>/M:*^\1%O'6
M1&":UJ.:=X[I&NLGSW.556JACA7*NLO'3]RML[$-E&43-V:>EXMFLB@W6:1T
ME*NWC)LJW:J+-D%$&RQ2F(F<Y"YQV%SG&,9 =](!B;<>]M%<<ZH78G(+<FIM
M$T9>585PEZW'L.GZPJBTX^2?.HN!+9[M+P<.I*O$&CE1NUPOE90B2IB%S@I\
MX"-7D1U\>D5QPI$Y<I[G5Q_V<ZBX5Q*1M+X^[!KN^[E9WI?&285^(CM5O[0R
M9RLH]3*B4\DY8,VV%,+.EV[;!EBARA]6:#WQU7.>]HIW&_6#MY>^2>[+WL12
M%8).%ZMJJL7J\R-EF['<IM!MZ/!T:A,IO]=/5"E[Y4R)(D4<K(H*!VG>/NGH
M/CSH72.@*PZ4>UK1NH=;:>KSU9N5HL[@]9TR%I<2Z5:D6<$;*.&$(F<R>%#X
M)G/9@V>SMR&7@'-_ZR?>ZFGQ0_&G@[(N?6^K-/6+C_I>?AO#4>Q#NNX8)<D-
M]N",?$60/*O:M874.[5,0A?[4)$5QE-#O9#H_$(1,A4TRE(F0I2$(0N"D(0N
M,%*4I2XP4I2EQV8QCY,8 5._B,.NMMC@=.Z[X+\%H].<YL[PBH>3=VAO7&UZ
MD=4UZX3*];HL32Z:LA*,+)N+84VU5+'M'S)X@S9835RT<*/6AD@C:H7PM75,
MY;UMAMCGWU9]@:]VW;4\624H64MB\FG]3?263*^HY:PN]YZOJ<9(QC57"*C:
M"*]BFF2^ T75;D(?(:V;@D>N5\,%LO7>S;ER$D^</!2]W$E<E&5JM%XM&OY)
M^YQZUD*A+QMY5G;'Q\V?.Q<>[=P\A$/'T:\.V.9;+_"3IB OX<1.4NJ>:_&O
M3W*72<L:6UON6G,;5"^/W"R4*]RHM'6.I3R21CI-K)3+,Q>1,DD0QTR/F:N"
M'.3NG,%/7JW]27:'";XDCB(E=>5&[-7\,(+3>K;5N;5L1LS82.F).-F5-W1,
MW,V+4<1.$J-DDW.46>>^I'KN3K-6YB]Y1%+L#Q%AN'Q)_7ADGV[N'5P6Z:G
M^:6D#: <6/:EBT59[_54U%DFEPF[CJBL7+>=IDYY-F0Y7+1JSJB7BE3CC+X(
MX>K!93Z*_%'GKP_XL7/6G47Y(R?*+>\AO&UV* V"]W!LS=32/U2K5*+$UBMQ
MMLVK'0MJ\%.PQ,S(&379HJES(8*;)L$)@@0N<N.FY\1]SSY>[_@)'J%LN)'"
M&O[-FV6D'>M+=*:_F+9JMUV255,2C:(786NV/8YE(X9RYKI9F*BTDV54;(^B
MX;$3#1SE!\/'U<."&FKOREXB]8'?.[KQIBKRFQYS7K5WM[2UHFZ]4X]W*61O
M4E";WVO!7>3:02;E4D/(HM$Y1+"C8F%%E4T%@F\^&DZNFS>J9Q1V+%<AW45+
M\D^,%FJE3V';X>,8P:6Q:?>XN9?:[O\ +0<4V9PL/9I1Q4IIC(),$4&2JT;A
MPDDCA?**8:"?&T_YA?$W\;LG\36RP%D+I._FLNFG^(!PW_HZZY ;_@,5;U;;
M:>:5VVUT)*P,)O!?6]U)I^6M,8E-5IALW-=D?([BP12[V-1?PQ;)AMZ2F==(
MN4<F[38P I5UCH7?$)\\DB[ ZA75NN/')2PE3D/9-KFT6R]>755%#O,MI;5V
MF;?H_0$&_;.>Y@OJ>2DBX(4N,JX\,I,!HKSRXD=:KX=*/H'+K2_4JV5R9X_K
MWZ'IMO;6=S>#5B/G'_I\E!16T]"7^^;1J3NI7!%J]9)3#"2R^8NULI$69.7#
M194+WG3EYC0?4!X0\<N8,#$HU]+==!+,3E=:N%7C.MWBO3,M2MBUQB\7*1=X
MPK]^K,DS054Q@ZJ*!3&Q@V<X 5R/B2^NCN_B)>J%TZ^ 2KU/EOMB.KDA>]@P
M4.VLMIUY%WV1Q#Z\USK2"7:R2+K;.Q5L^,9PJW44BXU=IEFFH[?IN& :/:G^
M%.ZF.^*O#;IY?]6_9&L.0TVV+8'-901VCR+L%8D9-#+M2.L.V9'D!KK*=B:J
MG*D]S%H23(BN#^ Z<$*4YPT5ZKE@ZNO2^X@;FZ;/4(V4IS;XB<N*K66W'+DL
MK.6*>L]!V)I_:FM-GM*W*6^VHFN31,K&G)%=5F:7DD#-U$UX5_X;:21,%I?X
M3S\R;QX_=$Y#_P =5R 5O^;?6CYK]/\ ^(#YPQ=+O>\=^44C!?4FE.)L]M#8
MUBTM';1V+I;6.=;RL+J+S O (&B=CN47BC:(9MY&0*X<M4%D5'IUBANR]^&Z
MZN_4%B2;SZBG5OM&N-OVXOF1+2M8JEMVM2M<G>E=.&58:,(';VF=;T1:,3?'
M379UN(=Q[=55;PUW.3&54"-.(Y4]4GX83G_KO2?+/>5WY2<.[XR96)[7,VNS
MWZI7343V<=PDO;-/L-CR3=SK'<5*<MC+.8E%XU9.5_!0>+.&CAN[*&_^N>+O
M7 ^(SA7/*[:?,J5Z<W!?8$K)FT#I&@JW&4>35"8OW3:-GWU$IECU7C8S)1=%
M0F)^USB3J0<E56CV#:,,T* T:Y\]'WJQ=!_6Z'-OBKU&]H[>U5KJS5]39$A4
ME[QJN9J'F*0B(*,GKOI^7V+LZB; U_(6-9G%OB.';[L,LV,X99;^*HW"[/T7
M>H0XZFO3UTQR>L+&.B=FN/7FNMSQ$04B46SVI0'N(J>?QK8ASX81ULC5&4XW
M:YSG+1"4(CVF\/OF"LW\8QR]Y9<8MG<$F'&OE!R(X],+?0]\/+8RT=NO96IF
MEH=P]@U@C$NK$VH5E@$9MS%HR"Y&QW)53(%74P3)<'-VA=]VF\=Q^L=C/V#I
MRQ?L:';WC)ZS75;.V;MM7Y!9LZ:N43$6;N6ZQ"G(<AL&(;&,XSC. '+[Z6G6
M<ZR.U-;7SIZ<7;SN;DKS(Y+[5@I:A\@=[;$LFXI#CSJ9A5'49LR2CYS:4M:6
M]3CD'*$>\]8/2JQL23TLZ#5>2>-<D"8N5^$PZ@&YV1]C\B^M3>Y[?#OQ91VB
M>G;@VM!)3AVS,Y4V>S[9OZDV5)D5VV*B59.M(Y2;H)&(ACLPB0-,>+?-_JA]
M 'JB:KX!]0'=]DWYQ5VI8*FP(\L]LGMCP".M]HV)]4*IO#3EJNV372EM*C;V
MJYYZO&-AF<K.21PU4<*-) !T1]IO'<?K'8S]@Z<L7[&AV]XR>LUU6SMF[;5^
M06;.FKE$Q%F[ENL0IR'(;!B&QC.,XS@!2^^#6Y8\I^4'Y1SWE^2W(#D1Y']T
M'R5[=-R;%VWY/\S>]#YC\K>?['8/+_F#R^P].]$\'TOT%OXO>\%/NA^;K2=3
M_J&<F.J/5>A[TP-@IZ,M+U2!K^SMO1,TI6;9/6F;UF;<EH;H[$8,I2?U]KO5
MFL#8?22U?1+873YH\0(=0I"-5@\@O\(=S-G&K.]V;K5;(>;F29&4.JOK+:LV
MU:2*[ETJX:L]GR')UI:E&2GIRZF5\PJ1SJ+'QE''?,;(2A]%SIS=97@YR2V7
M#\W.>4CR/XA1NLUF>K:Y[1['M7S'?9*?CRQ3EV;<-<5V%K)E3JVT?'6CXA\5
M@[=OFV,.5TFZJ9PKU?%<<*>H-K^ ?<PN2_.TV\^-UYYC/==\?.+L7%3=5K>E
M*Y;JWNF[ZW64KT?F.H<O:*=KJDF@GTZ9DK-R2C@RBSM7!U.\&6^!70ZZS>\N
M%W&#<.E^M_O/1VIME:5H=QUYI^"W1RJA(;6U3G(-J]AJ=&1%4V9&5J.90;10
MJ":3%NBV(4O80A2]F $N'5PC^9?3N^'&=UB9YC[DMG+#4U@U+ V7EA2]K;4K
M^TK:>S<C6SE5S[1G5E+LG)5JC.HQ3@KB0/D[9'*&<F1[I0$8FH^LIU.N:W$#
MAIT_NDTSN.Z>933CC5Y;FUS+V%(,I]SJ!PM+3582B9._[3</X)&_2L?&D?2%
MAE%)"26(L1**07E,+J,@D!Z7_2MZ_G'SG9IK?7.[J0/=[\;V3+8,AM'341RX
MY*[&9OY:7UI9(JDQDAKJ^4>G:\3;0E]EF#X_JQ=9 IH[)>Q1$_TX28=:S6G6
M1VS5-!4/I*[7J6I2VZVVJO\ (NUS*].KLW6*VK%1TA3;2QO-B86*R0-?:/V#
MYK()UB)=6!5=RTRD8K<KDIP@T2^%FZG%[BS7?<'7;W0KN=1%)PHW:(;^V+"X
MDD\^DD1)LVQ\BZ=9BM$'JA\IK8KY3%_XV$BYSDN U\Z:'49ZF72TZN=5Z074
MFW).<AM9[*NM0U12;A=[-+[ DX&:V:V;):+O^KMEV9'SO,4:\RK^/AG<)++*
MIQ2BQR))LW3)RDL%HKJ_\*>H-SBU_K/6?"+G:;A+5VYK[[=E(N*FT+3L]O*I
MTY*@L(B]T_+"[U*,KB;*>+(-F$@T1E22B97)5BH$P0.=9\/]P$YR<[[ER:B.
M$W/C8'!.6UO6=8R6P9>AWG;U(6V/'625N;6OQTDMJ6U5=S()UMS#NE4BO3+$
M3R\-E/!<F/VA?/Z0O3!ZDG!G=FS-@<T.ISL_G'0;?JP].JU!O>R]\W1C4+?Y
MMKDTG;V4;M:Y6>%;.\PL8[997;II.L$<Y+WLIG/@!"IKGE[RR??&,2'&)[R@
MY$/.-9+YM-F3CTZW7LIQHXC2/Z>]ONC!J74RME/0BMF-Q;)RR),1_=2DTRNB
MXPN7!\!;DZAG.+5W3GXA[?Y;[:2<R<#K2%;E@JG'.6[:9OU[L#U"#I%'AU7'
M>*DYG[ ]1(NXP17#%B5P[.F=-N? "BYQLTKUU?B7GMNY*W[F),\-N&+>USM:
MHD-4'MVK>O'[UBY12DX#6NHZ38*L^VHRJ!%C-7MGM4T=3+[*S)L[6.D\;LPS
M5M_X;#J_=/\ J3[?73JZH&S=W7G7S*0MK[6$(AL/1%RM!&C;Q).+I]7SM?<%
M$V9*OV4<ACU1,*,DY/">$"E65*@BJ$U/P[/7.E^J90;SHSDBQ@:MS4T)%-9:
MUEAF/J",W%K[,B2"6V/&5;"9$JQ8JU.N&L?98Y'NLTG;YJY:$12=&9L@S5\3
M7N3;VA.D'O;9>C-J[(TOL>(OFB6<3L#4]YL^NKM%M)?;M3C99K'6NGRD/.LF
MTI'.5&[@B2Y2KH*&(?!BFSC(5D>%_,+KC]<?1FD>&'$#<5QXX:QXYZLA*QS$
MYV7"Z7%/86T+^>2E_5K-;;<8:7V1)V![3,,\DBXITWDI)TFY>3,BBT<-BD#8
MC8'PBG/&J5^1V-I;J_VVZ[Y0C#/6D9:*GM?4[64F$([!RQA-O0N_-CV%N55X
MW3;I.E80I?#P50Y4\%[F SE\-5U?>95ZY2[HZ4'4;LMHO&Z=6L+L76]VV$LW
MD]GPMMTS-'@-KZ@V%:TE5WE_=HMBJ2<;+O%'+TN(Q\5=XZ379X0"Y-N35E4W
MGJ+:6E+XR3DJ1M[7=TUE;V"J*3A-Y6;W7)*KSC<R*Y3(J>+&RBN,8-C..T!0
M-^#UVA:N/'/'J!].N[R9LJ&K\K:4V*WI"+)#9?&G9JNJ[>2(9N%2F9O[#$7W
M*SDN4\J*MX-+OF+X&,&#H=
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MV)FT338).7#1PV(BF]]$:AE?X@CK2-ND?QVJ[36<5 V_EAO]2PP^F8&?-AW
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M^;39DX].MU[*<:.(TC^GO;[HP:EU,K93T(K9C<6R<LB3$?W4I-,KHN,+EP?
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MVLJ'M>G.%L8*LXJNQ*M%6^O+*EQ\F%%8B81,;&/D[<@,F
M                                                           "
MHA>["M;;O<;4Y6RX<66TV"?67SG)O%4EY9W('4[3%(;.#F<=N.TI?D_X,?U!
M^A<)<QA\+=W%,611=TT^:(AY*(LB(>4'84
M             !:2XEV!>S<;-,RCE8RZY:-%1"BQ^WQ%#5WQ:]WE#&P4RBG9
M%_3'SVY/GZ;.<]O;GX5W@N8N-=8F[C)'.S/*_F_B\?>197/C;$#P[
M
M
M
M
M
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MI>66<D(<RB>#XR<I<'3R8+W5IM%=I%8L=TM\U'5NIU"!E[1:+%,.DV43 UV
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M.3860/VD4*4V,XP%4KXU;\UEH/\ '_U9_1UY5 )NNB;^:-Z<WXHFE?\  Z.
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M) 0$8PA82&BFJ+&,B(B+:I,8V,CF+8B;=FP8,D")(I)E*1-,F"EQC&,8 ?3
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M.)VWWJS2>D:):YA#!G<S9+/*Q^VN0=M1\;NERYD91]76J;U%/&.\>1;X4_\
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M<V.(6DB8R8V39P1.EQJ:9<9SG.>Z1,N"XQ_4QC&,8^0!*"
M
M*A=U@5:M<K;6%T<MUZY9IZ!60SDQLH*Q$JZCU$<Y.=0^<IG;Y+VY-G/R?+G(
M_0V&O8O\-=W\98KHIJ\\1+R43;$2\R.=0
M            %H[B- +UKC3IF,<D.FLI28Z8,FI_XPF+&=>Q$*;&2ER3)22N
M/I<X[2_U,_+@?"^\-[%]KO$UQFYV8Y/\O\'C[R;;R?&V,'AF
M
M
M
M
M
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M@4U_@SN)U]O.X.8'4RV>PD5D9R.?Z.H%EDVIDD;G=+Y:XS9V[[%'=])--12
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MJ&</%6ZN$E,>C+%R%B;HF_FC>G-^*)I7_ Z. 2A@
M                                                     "O-U%M.
MNM>[Q=7ADSR2K;51S/M7"1"X00L[1-NUM,>?)?IL.5W&4I#)C8Q@_IV<%SG)
M#]WZ_P!S=8TXS5<86J?]_A_Y9_S9RTSXL]/^CX7=N*N%19NPC^'MSF
M                                !EK1FJY7=&U:=KN+26R2<ED,S+M$
MN>R*KC,V'4]***=TQ$O1(Q)3*?>[,*+Y33QGO'+C/C]:X^[U9@+S&5V6TT_R
MQIJG)3'EG/X+9W&*ZN#3-2UJP8M(MBRC(] C5A'-&[%DV3[?#;M&B)&[9!/O
M9,;N(HIE+CMSG/9@?!*ZZKRN:ZYMKF9F9TS.=X]^L9
M
M
M
M
M
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M<Y53PKA5UXY<Y3RCDIPOR@
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MRV4[.TBAB]F0&^0
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M8]%,3FC1,S#I7MYPYLC[L-W1ZPX@
M
M
M
M
M
M                                    !$UUI^FE ]4W@EL;CV0T=&;<
MKZA-G\>;5(>"BW@MPU:.DDX..DWYT5E6-9N\<_=0<HH7!\MVK_+HI%%6R10$
M=?PQ6VN:U>XK37!'G-Q9Y,Z0NO$QRXB=/[(W!IC9%/HNP]..IAPW9TZ"V%/U
MII3;!/:OFE5&C,C.16(^K:[$[(JJ+)RM@+/(
M                                                   *;WQ-K;J!
M\[KQQ^Z5G#'BWR&L&L+A=:=>.07(SV1[+CN.WKITOG%!J$[N8U5\@I4[7J"Z
MMDL;@KYPF60)'MDL9?LEFQ@LP<!N&6MNGWQ$TCQ'U68SVMZBJ2<9(6-PT392
M-WN<J[<SU[O<JW347P@_M]NDWC[*'B*E:)+$;)FRDBGC ;@@
M
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MN6Q4D9)'.3$41R<.CR K>_%A_F3>0_[HG'C^.JF@,B?"X_F*.#/^LS_3#Y!
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MZ[SAFM;W$W)6,Q">'A9A(Q^%B^*ACNA:S
M
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M[SU#GKO3]9[@/+?[TW_7S6?[<P^+>[WM'1WGJ'/7>GZSW >6_P!Z;_KYK/\
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M?#,S.BQUZ[RJO/F;#CP[
M
M
M
M
M
M
M
M
M      AKZH_0UX<=6^Q:VMW):R[WJ=FU369BI5*8TO=:A654HB<FV,Z_*_97
M/7FPHIZY,Y8^&4^6Y>ZBJ?'9W^X<@?TZ=O0=Z<G3)LZVQ^/^K)JT[D49+1K7
M=>ZI]#8>QH*.=(.6KUK4%B1,'5:,I(LWBS=VZA8I@]>M5#(.%E$,^& F0
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MY-WM][0-DW':4SZ]DZG5:37W/HU@NSM%KZ/%M>XS32(?Q%"G54#;\
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MR%33*4B9"E(0A"X*0A"XP4I2E+C!2E*7'9C&/DQ@!_T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>-WOE[H#8O=_M<]B^WO=_P#)_MX]E]_]B?M"].\@^USRI+>S?SQZL_MEY/\
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MI=->X)[O?K[VR5WVZ^\%YF]7^PST1]YG\A>6OU3SYZ9Z/Z+Z3^M^YW^]\O8
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MW^3I]C<C[8/7GF;WD/;GZ1L?U9Y-]'_N6\A^C>5O%\?]<=[T[L_\F <V??\
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M^9/8/^3V]@[3V?\ JSS%[Q7O%>8JAZ;YA\7^YCV;^6/7?<\+]=>E>C=OTO?
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M7D./]=^KO2O*'M%\OH^LO0?%_7OEOS+W_"[WZKZ+V=OTP#!'"/WS_=VJ?O\
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M %7/8M_]1_MY]E__ ,O>0/:YY4_Y2\G^<O\ Z?Z%_P"W ,.<(_?/]W:I^_\
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M>O7?LG_]/:MYW\U^7/[<_P"+GUOZ#X/_ +\O1^_])W@&3Z1[7/8M4/:!Y/\
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M 9WY#>W/V&;8]V3R'[POD.Q^QGVH>L?9U[1?5RWE?SKZH_MIY;]:>'Z5Z/\
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M9O:+[.O6.P/,OMR]=_VK\R>J_+7HOJ_]2\7TWO?)X8!;_?\ ??QU9Y)]WO\
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MV2^8O.OLC\>R^E^VCUU^L/.'H_JKN>@?J'>\?M_\$!_L_P"_-[\U(\M^P?\
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M\+VF>9O:WZH[T5Y5]C7JG^TOIG=],]+].^E[?#[O_" W;
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                !^=X\:1[1T_?NFS%@Q;+O'KUXNDV
M:,VC9(RSETZ<K&(BW;-T2&.<YS8*0N,YSG&, ,$:+Y8\6.4'FGW:.2W'_D1Y
M']2>=?87N376V_)_F;UOY<\T^0+'8/+_ )@\OO\ T'TOP?2_07'A=[P5.Z&?
MP               :[[*Y>\3=,;(JFF]P\H..^J-O7QM!/*/JK96Z]:T79%S
M:6B>?U:LNJI1K198NSV)M8K/%NHUB=FU6*[?ME6Z63JIG)@-B
M              &N[7E[Q-?;Q-QB9<H..[SDH1R\9GX]-=UZU<;Q([CZRO='
M[4VIDK*>^E<L:<V4EEB9C^\E&)F=&QA N3X#8@
M
M
M
M
M
M
M
M
M
M
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MWS)4I3F+C!LALB   #'>WO\ %-M#]SNZ_P"#4F HC_ Q_P#>B?ZDW_:X 7_
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MOV#IL^8/FR#QD]9KI.6CQHY2*LV=-7*)CHN&SA$Y3D.0V2G+G&<9SC(#]
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MG+5.L)T6)=UR,A<MF9S,V$J[:HJI$*J14+J0
M
M
M
M
M
M
M
M
M
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M=CGW&&57-MFBV:0GH].I7%ZN0B%NA)!"$:]I%56OH1EWS4+K    .<9UE_\
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MP7!"A)L
M
M
M
M
M
M
M
M
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M)F*=\?!PM6=,K?-AY,=%KC+N:WR9IRW63AKB%MLZJ5<KF=M6OZG,ZYLDZ_\
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M]-J=?Y=\;XV"K-6K<:VAX&!AX]OL0B#*,B8MFD@@D3&"D33QC']0!7E^*5Y
M=,[F5TO['*ZOYF<+]Q\A./VS=;7_ %#6=8\D-+W_ &G*M;;<H'66QJ_5J]3[
ME+V65BEZI:\S,JV11.AA& 3=K8QZ&0Y RGT8N3>U-A?"X;GGX"46E]M<9../
M.;5.OY'L<ED,26MM>7>Z:AC%#&]7HG-7(2SP\:URW4P3#1FA@ROCX5S@-7?@
MAZGK9/CCS?O3-I&*;?=[LU_4[(^R5-29::VCJ(I,4IH4YD_&9QDC:)2?/G!#
MX*Y5:X[^,Y0)G 7B'C-I(-'3!^U;/F#YLNS>LGB"3EH\:.4C(N6KILL4Z+AL
MX1.8AR'+DIRYSC.,XR YZ7PH#A>E]8WJD:GU"8I.,R-&VXXCT6*G>C,KZ\Y2
M5^MZ+,ECQ$/$*E0+98\(&\#/8F8WRI]O=.'L_C6N1UGEKQP<X.PMD:0=6E6%
MCY!7EG(ROJN$?SDQ/*:JU=-6)TMDC)C&51O'VK/CJ9,4A7ZIS8+A/&<A9WXC
M<Q>C-PRXTZ7XOZAZB?3SA:%IFAPM/C",^7W'!HI,R+5#TBR6Z5*CL7&'-BNM
ME<NY>3<&[3N7[U94V<F/G(#2CKC<K.E)S0Z67,/4://+@?L*^0>I+/MW35?K
M_*G0UFNKG<.H8IY>J1'4"(A+V^GGUQMKF(5@&[9BD=S()2ZK/!3D<G(8-,_@
MKM\V&\\#>1NAIR3-),="<AD)JGH+%7\6!JNXZDVEE8)N?P$V>8S-SJ,S(IE*
M=1QAS(N,J=U/*& $&W)'BW4N9WQ@-GX[7^&;6.@V_DS2K+>JT]RV]7V6EZFX
MS5G<-KK<F1WG"2\58("A.&;I+'ZHLW6.1/\ 5#% =.J-C8Z&CF$1$,&45$Q3
M)K&Q<7&M4&,=&QS%!-JR8,&35-)LS9,VR14TDDRE(F0N"EQC&,8 5C/B[M:4
MZZ=':\72?AVCVRZ@W9I.W427.GC#Z%E;%;4M<36&[DN2JX:259N;M-9'.3)*
M'*D<Q<G22,0-I/AF;3,W#H=<$):=<>E/6E=W55D%/U3Z6&HW)?<])KK?]444
M-^M*_7VJ7R9P7Z3Z7!2]A<!3MZ8&]N+O,SXB?DUSWY_;\T1KG7>LK-M3;ND7
M?(C:M&U]4Y*UUBZP.LN-M8@7.R)J"CIESJW6W=E8\J)\KMGT"T=83QDN3%"_
M?^5BZ67_ *Y9P _^'(XZ_P HP"A'\6)M?B/9>8W#'FKP4Y,\>=J;@DZO/L-D
M6;C=M[6VTI6IW#C_ &BB3^F[Q=?(4[8FD78'K2Y+,XQS(%PJ\:ULJ)>^DQP4
M@70^IYLE+<W0>Y:[@12;(H[6Z=]GV2DBS*[(T22O6H$+0FDU(_(D_(V3+*8P
M3"Y2K8+C'?Q@W;@!5U^#5Z?>L=L1^ZN?6X:TRV#+Z7V0AH_C<PM"7KB!UI;R
MUB&O^TKQ!0\AEQ&MK>XC;G -V+U-(BS$BCLQ#>(O@Y Z$0#_ ),0A\8*<I3E
MP8A\8,7!L8.F<JB9L8SC..\10N#8S_5QG&,X^4!I!M7J:=.G1\F[@MN<ZN)%
M L;!1-)[5;'R#U8SMS4RN<E)EQ4\6@]C23QG'TQ\M<$)_P"%G "@M\7GRCX3
M\I]E\#MN\0>0>I-X7^!J6]J3M"?U!=X.T/JO 5V?U39]1MIIW!**/8LRDU;;
M6NPRHKW3'*N9+!3%4R8.DSKN7?V'7]&GY14J\G.4ZLR\BL1)-$BS^2A63UVJ
M5%(I$DBJ.%C9P4N,%+C/9C'8 Y^'1 _WK_JE?NB=2[^EW& .B  YW_6__P!Z
M_P"EK^Z)TT?Z7<F L*_%-\F[/QJZ/>ZF]-E30EBY#W&C<:DY1%?P'B==OYIB
M?V!'L_U9(RAK%KBE2\8L7&%,X:/53=W'=[Y0\%\*#PYIG''I2ZWW0C7F37;7
M+^:LFV=A60[0N)EY5H.U62F:EK7K!1)-TI78JHQ699JW_P#%)/9YZH3M\;)C
M!9H <V3E[5(CH]?%::$O.EF9=>:BY'7[3%]EZ?")HPE;9:[Y26&4TONR+:L,
M9:PYZVC>8R=G&33!4F;!RDW31PEZ(D<@76.ME^:-ZC/XHFZO\#I$!6"^"<XE
M4%35'*WF_-U>*EMB*;59<;=?VB0;1[N2IT'6:/6M@[":UU0Y#OXE2WGV1"D?
M*ER7#A&/22+GLPL4P7P '.CZL5=A]'?%S\"+?K>/:5V9W'N#@#8KVHS3.@C+
M3%]VTCHZV2!T4%4DR.YFB0B22YBX*5=?)U52G.HIDX=%P!SI;-G/6Z^*\80!
M#>:>,_!FQ%:.L(IO9*$SKWB-+Y>SOI&,)IL7<-LSE)-Y89<8\)!>)EDL$4<=
MQ/*P=%H
M
M
M
M
M
M
M                           !YM"Y5!S.*5AM:JVXLJ)E2*UY"<BU9Q(Z
M"65ERJ1*;HS\AD4<9.?&4\9*7Y<_( ](
M
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M.7I]5Z=?232>EV;]<GI&?-VV)25;/\=]3"JE;;GSGO%SC 710
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MQ51DGZXW7!5351-E3*@Z#(
M
M
M
M
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MIER@]8KZP;UNV6%U;V]MTZ]:J9P2:=UYG"LW1"+>)+1A3FP_65]*:]P+5P
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MXZJVU4(2^:^M7J>?KWF"J6)FG(0\KZCM,5!V.*],:*E/X#UFV<I]O8=,INW
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M36^S:E WFC6R&6\>-L%7LL:WEH:3:FS@JA"N63HF3)J%(JD?M(<I3E,7 >^
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M40W0L%F7PJ8Q\/;38<NI)Q_4QX[H_84N.PN V1
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M'2O+N:)\#:T> <8
M
M
M
M
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M(_<8.N336Y%)F0- 1Q5%3N7+2G;(@I=94_9@C=*?:(E["X)C 7-@
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M1ZPU8S61]&5::XH-4H[95OA8SC""B%9B8M(Z.'!LJ=S.,E[^<F[.WY0&3P
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M?6>Y6K*<+J^<?>1_O[_-X*(FR(_TIMF=,<'0[EQ393PMV4;8]T<X
M                              ,[<;=Q2&C-P5*]MUUB1"3Y**MK1+)L
MED:G)JI(3+<Z6,XPLJV1['3?&?DPZ;IF_P" >*UUJVC6FKKS"S$<Y9;1.BN,
MWGS3X)EBNGATS&ZM/HK).44G#=0BR"Z2:R*R9L'3525)@Z:B9\=N#$.0V,XS
MCY,XR/A$Q-,S3.28>/?U$
M
M
M
M
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MD[30VI07V&34F6;)ZUJM'QA/.>PB";I9$AOI\8,'1S
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M$&D>S03(@S:MFQ"(E#=<
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MS,@5%4Q&IVOBNLN L7@
M                                   *B^Q+&O<+_=[8Y6\=>RVVQ3JB
MN%,JE/F5EW;W'<4_\)(I5L8)V?)W<8[/D'Z$P=S&&PEUAZ<D47=-/FB(>1IB
MRF(\#QH[+0                                       "TUQ5LBULXY
M:;FG*N5W)J+#1CA8QC&.LO7TC0"RJAC$)DRJBD9DQ\]G_&SGY<_U<_"=?7,8
M?7.)NJ<E/.S,?Z7\W\7C[R+*YCPM@!XA@
M
M
M
M
M
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M9,G+@I>UWFQ%=>/G_P )?OY[<]O: F-  '._^!V_QL]0_P#<[X[?X2[: =$
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M9,ROHEH62:F*7!LX6[,]G=+DV Z-X
M                                            -=]X\O>)O&)W76')
M3E!QWX]/[>VD7E39;QW7K74SNT-(=5HC+.JZVOME@%IMM%K2"!')VQ52H&73
MP?)<G+VAL0                                  ,;[8W)J'0E)D=E[S
MVKK?2^N(AS',Y;8&V+S6-=4F+=R[U&-B6LC:[A*0\$R<RDBY3;MR*KE,NNH4
MA,&,;&,A^C5NV-6;QHD%M+2FR]?[@UE:/6?EK8NK;E7-@42Q>I)B0KLSZBMU
M3DI>OR_JBP1#MBZ]'<*>CO&JJ)^ZHF<N R
M
M                                    J"VV#6K%KLU;<)F1<5ZPS4&N
MD;)\F26B9)RP53-DY2'R8AV^<9[2XS\GRXP/T/A[V+_#T7].6*Z*:O/$2\E$
MVQ:\^.90                                       %HGB!"K0'&73#
M!<JA%%J6RF.ZK_Q\)V)=S84<_P#BT^PN490N2X[/D+V?*;^KGX9WBO8OM=XF
MN,W.S')LI_@\?>3;>3XVR(\*P
M
M
M
M
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ME@J8I#*,I.+>)+I&SC&<D/C/9@!9DZ3OYK+II_B <-_Z.NN0&_X#F(].K?\
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M<.8OZK\F0%HCXL/\R;R'_=$X\?QU4T!D3X7'\Q1P9_UF?Z8?((!/\  .=_\
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MMEDWC4GCM;7R5W(@E3(4K=93*D252D.K!DGA][#=)AAM@N"'[2AT?@
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MK++)S]CCX&(96"=1:E8HS4VUCVZ$K+),B9R5FG(OTU%BI8SG">#]W_@ ?>
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MXZJ: R)\+C^8HX,_ZS/],/D$ G^
M
M                            5U>H9J!SK??4I:6S<Q:UM0JMLC7&,?J1
M)W&44;:P,?NEP9R634*\SCL[,)OB8[<YQD?8NY^L:<;JFFXJG_?W'\D_YO\
M1/FR?Z,N[<U<*BS=AH>/:W,
M #)>G=:2^W]F4[74,FOE>RS35H\=()^+F+AB'PO-S"F,XR7P8J*257SV_P#&
M[G=QVYSC&>EK'&W>KL#>8R\LLHIF8C3/],>6;(9JJBFF:I6P8R-90T;'Q$:W
M(TCHIBTC8]JG\B;9DQ;IM6K=/&>W."(H)%+C_P!I@? :ZZKRN;RN;:ZIF9G3
M,Y9>.G+E?N&0
M
M
M
M
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M/V#[4MT6WS/'[*OD#LVZM_*EYV+9J1"^NKO66+WOQ\:T.V\#P4,I-SJ)'"1
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M+[/.0N[HZ\Q.S]@^U+=%M\SQ^RKY [-NK?RI>=BV:D0OKJ[UEB][\?&M#MO
M\%#*3<ZB1PCO^)OZ@4=P=Z8FT:G SJ<?NWEVRE^.NK&*#@Z4JW@+/'80W+<V
MQ4%47C9O5];/7+1)ZD8IF<U+QN>WZ?&,AC7X5;IY2G"?IPL-K;#@EH/='-*7
MBMUV5@_:8:2\%JUC'.([1]8D2F3(X[QZY)/;'A-7L4;'LQT#E(HF? "S4
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MIOKMY:75J.NPHUME:2M:$EY&L5&7B&DW.0+WP6+QGXZ*:6#8672436.$BP
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MERSR<LLC"/Y))PD[;-SQ3MG@K?!L'55"5\
M
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M9SV1T[V\X<V1]V&^X]3<(
M
M
M
M
M
M                                  C$ZG_22XE]6K65'UOR=;7R#>:S
MLSJS:_V;J69K=;V;4S2S9!G9H*-F;74+S!*UFVH,FOK%FYC5R*JL6RQ,IK()
MJ%#=/CII=OQTT9JW1++8NRML1NIZ=$T:'V!N&4K<YLRP04 EEE!9M\W4ZK28
M.9DXR(309X=DC4%W*3<BCDRSDRRZH9H
M                     $4O6#Y,<_N)_&BC[6Z=/&9ARPVYC>M7K^P]6O*3
M=;\Y3TM(439;ZPV2'@=?6FK6C$NPNL57FR:Z&7Q4B/#]]HJ7.3IA3&Y%Z8^(
M%^(UW-H+6W)GAQ)\(^.&L+(]D7DO<=2; TK5*8A,DC&%RO\ *L=S2R^R-GW7
M,4T,UA8V,13:=JN"9(W2.]D<!T7-9:^KNI=;Z^U54$G*-3UG2*IKZKHO%4UG
M:5=ID"PKD(DZ611;(JN4XV-2P<Q$TRF-C.<%+CY,![<
M      $+W-+H6\1>H'S#U7S"Y47[D1L9UIQM6(^E\=E[?KEIQH3AZW(9FW$+
M*TY/4Y[U*QUNL!LO9O"EE\62SW6QSX8))-$PF?(0B9"IIE*1,A2D(0A<%(0A
M<8*4I2EQ@I2E+CLQC'R8P _Z
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MA=D94J-7X^LUYCG**2"1C-8F,2)DQ2$P;.,Y[,=O8 R$
M
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MW)13DC_2G/5/CR;L1#KUWM5>?,VH'@7&
M
M
M
M
M
M
M
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MOGQ[GJ?:<+1+[%N,1Q7GK)Z5G->D%;87-E))FNICQ"D,<@7'_P!$4Z-'WO\
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M!,E.@VFF&2G[F,E.'0K
M
M
M
M
M
M
M
M
M
M
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M@X3E:=KMK!0;DBQE3D<1JF,&[G=*4)M@
M
M
M
M
M
M
M
M
M
M
M                             !\Z7AXF?C'T+/1<=-PTFV49R43+LFTE
M&2#1;'=5:OF#Q)9J[;*E^0Q%"&*;']7 #2^R=,?ILW&56G;?T]N#UJFW/>](
MF+)Q.T+.2J_>557-XTA)T%T[5[RZYSY[Q\]ISFS_ %<Y 9UUOQIXXZ<>^LM0
MZ TGJN1P9T?#_6^JJ)1WO??-T6CTWI58@8M?O/&K=--7/>[5$R%*;MQC&,!F
MP  :^WWB7Q6VK,*6':'&?C[LB?667<K3E]TSKFX3"KAT1LFY74D[#6Y%Z=9P
MFS1*H?)\F.5(F,YS@I>P,ET366M]711H+66OJ1KJ$/X'>AZ)5(&HQ1O14O ;
M=Z/K["/:9]'0^D3^D^D)\F.S #VX#Y$_7X"U0[^O6B$B+) 2J/HTI!S\:RF(
M>2;]\BG@/XR11<,GB/B)E-W%"&+WBXSV=N &'Z)Q:XR:MFSV767'/1&N;&HY
MR\/8*)J+7]1FSN\E6)ET>5K]>CWYG.2N%,9/E3O=BAOE^FSVAG<!SV/BY;W*
MVOJ;]-#CGNRPO:YPQ\J:^O=N<N))6(K!96^\@9^B[KL,HX2,1(SVH:JJ<29-
MRK@YXYO(+Y1R3#E;OAT :57:A4*?5:IK^'@:]1*W78:"ID%5FC)A6H>K14<W
M90$97V4:0D>UA646BDFV30QA(J)2X)]+V /O/'C2/:.G[]TV8L&+9=X]>O%T
MFS1FT;)&6<NG3E8Q$6[9NB0QSG.;!2%QG.<XQ@!SENF0YH_(OXN[=6[N'6&$
MCQQJUDY.; M,_2&)R4R;K;_2LMJF>M+5PU3PQ/7[GR#M[629NB]B#XSE-9'M
M*H3(#HX@   \'=-6:QV1Z'[0]<T.^^KN_P"K_.E0K]I]!\3M[_H?KR/?>B]_
MMSV]SN]O: ]/!P4'68IE!5N&BJ]!QJ9D8Z&@XYG$Q3!$RAUC),HY@BW9M4S*
MJ&-DI"%QDQLY_JYR ^J I??&T_YA?$W\;LG\36RP%BOI>5^ M72:Z<5>M$)$
M62 E>GUPW;2D'/QK*8AY)O[O&ME/ ?QDBBX9/$?$3*;N*$,7O%QGL[< -JM>
M<:>..HIAQ8=4: TGK"?=F<'=3FO-542E3#D[PADW9G$G6X&->K&=)FR53)CY
MR<N<XSVX 9L         ?.EX>)GXQ]"ST7'3<-)ME&<E$R[)M)1D@T6QW56K
MY@\26:NVRI?D,10ABFQ_5P U]BN&G#^!L)[=!\4^-D-:U%C.5+/%:,UA'6%1
MP==-T=<\TSJZ,D98SE$BF3Y5[V5"X-V]N,9 ;)@        //V:IU6ZQ*T#<
MJU7[;!N#8.O"V:&CIZ)7.4IR%,M'2K9VS4,4BAL8R8F<XP;./^'(#\M1HE'U
M_'&AZ'3:I28@RAEC1=1KT16XXRQCG4,J9C#,V3;*ACJF-DW=[<Y-G/\ PY >
MJ   !Y6YT2C[&@UZQL*FU2^5IRH19S7KG7HBT0;A9(JA$U5XF;9OF"JB9%38
M*8R><XP;.,?U<@/"ZUXZ<?=,KJ.=/Z*TWJARL5<BKC6NL:315U2.O"PY*HK5
MX.+4.5QA G?QG.<'[A>WM[, ,R *WOQ8?YDWD/\ NB<>/XZJ: ]Y\+ZS:2'0
M=X1L'[5L^8/FW*!F]9/$$G+1XT<\ON0J+EJZ;+%.BX;.$3F(<ARY*<N<XSC.
M,@)BZMQ4XO4:U9O5)XW:$I]WRY3>9N-6T]KROVK+M'/:BZS88FNM)?TE+/RE
M/XW>+G^ID!GL      ?\G.1,AE%#%(F0ICG.<V"D(0N,F,8QC9P4I2EQVYSG
MY,8 <W#E5.1WQ"'Q*.K-(:[>J;$X<<87$+5K%.QA4)"GR.H-,RJEVWI:L>*1
M6-4CMI[(D35%A(8(X(_;K1:O8='NE*'2/(0B9"IIE*1,A2D(0A<%(0A<8*4I
M2EQ@I2E+CLQC'R8P _Z
M
M
M
M
M
M
M
M
M
M
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MDB64/)6/U*FKF.JM+KS59_Y(UW&/'*SE*/,]?NW+I;*KMVX\-L1L$R@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O\
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M8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O]J
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M>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_L:_P!J M@\RP?S@G]C7^U
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M+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O\
M:@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O
M]J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_L:
M_P!J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_
ML:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?S@G]C7^U 6P>98/YP3
M^QK_ &H"V#S+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?S@G]C7^U 6P>98/Y
MP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_
MG!/[&O\ :@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE
M@_G!/[&O]J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F
M6#^<$_L:_P!J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)_8U_M0%L
M'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?S@G]C7^U 6
MP>98/YP3^QK_ &H"V#S+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?S@G]C7^U
M 6P>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[
M4!;!YE@_G!/[&O\ :@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-
M?[4!;!YE@_G!/[&O]J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)_8
MU_M0%L'F6#^<$_L:_P!J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)
M_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?S@
MG]C7^U 6P>98/YP3^QK_ &H"V#S+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?
MS@G]C7^U 6P>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!
M_."?V-?[4!;!YE@_G!/[&O\ :@+8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S
M+!_."?V-?[4!;!YE@_G!/[&O]J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+8/
M,L'\X)_8U_M0%L'F6#^<$_L:_P!J M@\RP?S@G]C7^U 6P>98/YP3^QK_:@+
M8/,L'\X)_8U_M0%L'F6#^<$_L:_VH"V#S+!_."?V-?[4!;!YE@_G!/[&O]J
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M>98/YP3^QK_:@+8/,L'\X)_8U_M0%L'F6#^<$_L:_P!J M@\RP?S@G]C7^U
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M*XP
M
M
M
M
M
M
M
M
M
M
M
M              &<HC_S5&?_  /9?^\R8C<9GT 4 :^BN,
M
M
M
M
M
M
M
M
M
M
M
M                                                         !G*
M(_\ -49_\#V7_O,F(W&9] % &OHKC
M
M
M
M
M
M
M
M
M
M
M
M                                         9RB/_-49_\  ]E_[S)B
M-QF?0!0!KZ*XP
M
M
M
M
M
M
M
M
M
M
M
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MA',(YQ1;C;/6C-:O/&CDSTCFL$2[I\F3RFJ;/]7&!<EELK$6RJW_ *9URZ_
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MO!/TSKEU^!_QQ^Z/9O[,A;!P5J[H:=3;8W5:XF;#Y#[.UO2M7SU-Y$VW3#2
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MT39R9)4IBY^7 3DR,OJB
M
M
M
M
M
M                        #.41_P":HS_X'LO_ 'F3$;C,^@"@#7T5Q@
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M_&I_XPNGO_>9R/\ ^>],BSF\N\U2U#^%VZ9O"+J*^_)[Y&E/;#['O=G]G/\
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MVI&R4S>->:4V!NYG3TT7;J<O$-K%*,EK;7*DR8HN'4E:DJFL]D6C--,ZKW+
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MO4U'+%7R7.31)<D)@N>^I+,EK>ZZ$?P<'YL?>GX]^SOZ/W& (8JSHWOC4_\
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M+75W4J,VG8HF*7D;8=>_0Z*DDV0*YR:7>HKM4?"RA@QSJ&9,Y;*S&(@
M
M
M
M
M
M
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M;AFRUBKSDB3AXB1[6["5TP7*194A5FQL8.?&,&S6%*/XU/\ QA=/?^\SD?\
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MAM3:2:YDSLW)G132>M6R7AD.W-C*F#^)DI#)*MQ:<ZJ5\*WKFOWSK :KF)U
MCE75FJ-T;&KZ*I#J)>8"U/-$:KF(5=)/OLF=Z<+I&.54I%DB&P7!\$4(C=\3
M569U0@8 ''0ZV.NH#5G5BYZU*L()-(8_(:X6]%HW1RW;-'6Q\,]BRK1JW\58
MB#1K*VI=-(A,E2(F7&$R)DP5,JK.W&9TD_AZ;\[V3T:N"UB>)*HK1VO;I02$
M5415-EIJG<&QM7,%<&0;MB8278TY,Y"Y+DY"&P4YSGP8YKG9G.Y</4%_S]N;
MOXWG)3^.:Z"5?>GQM1F6O^-WQ<>M^,_#?CKQZA.%%WO5ZT%QWTII4DS*[E@:
MG4[-+:PU]5J'(V RC2A6B8C(Y]ZD5>(M\-UE3=I$#*)][*Q&1."K0\S.6O*G
MK&\V,[.FJ,M;-M[&]3ZWU'IK4]>?RWEVGPJLF\KE%K3-!-U.SQV1Y%](/W[L
MQSJN'#IP;T=M@B*#.N:'3CZ(/3RE>FEP UWHJZJ1R^X;=-S.Y=X*11B*Q[/9
M5Y90[16M-G:3EXA(%HU3@(J#4=HJ9;O7$<HY2P5-8I<5F9ME(_O72NO>1VF]
MFZ'VO")6+7.VJ7/46X1"AC)F<PU@8*L5U6C@F<*LY)D90J[5PGG"C=RD14F<
M&)C."..MO/5?(#I-=06PT@LF\KNZ.)FZ(JQT2W$278MK(P@Y%E:]<W=NV:/N
M^K6K_5%V3U1GZ1GO,WJC5?.#85)B9I;SP^EQXTYR"ZNG4-@:0K(O[!MOE-N*
M7N&SKME%R\9U&!EY5S9]DWIV1TNX]#KM(K>'*K1J97NY(@W8H=JAT4S,\F:'
M8=TEIR@<>M0:ST7JN&Q7]<ZDI%;U_2XCQ,KJM*_5XMM$Q_ICLQ2J/I%PBVPJ
MZ<GQXCEP<ZI\Y,?.16&41  <R+XO?\ZG4?Q0]1_X?[C%G<\35.980^#@_-C[
MT_'OV=_1^XP"0E6=;-!'*\^*BUM7:!U?]J2]?;)-%-J:JTSLFP(()&11\Q*U
M7R.]<E)E91+Q7[6CH.%C$*EA1=4YS%RH8ZAT[GB;C,M9_"'W^4N/2FL-=?D,
M5IJCEEMZ@0ALK^-A2+D:;J?:2IR)^"EZ*7$ULIV7P^\IVY+D_>QW^X4S.=3$
M^(H_//<Y?[\];?Q%ZM"K.U&9?M^&;_,C<*/]9#^EOOH&9SJ4GQ!_1QV]P3Y*
M[-Y'4"IS-IX<[PO<Q>J_>(=D\DF6HK3=Y?UE+ZRV&N@@<E<13LTLJE77;D_@
M2; Z*.%3O4G"94Y<K43:QWTU?B+N=W3OAZKJMU(1/)/C75VR$5$Z9VFZ7:2U
M0@F_IITHO66TH]H\LE2;)*.$R(M)!"=B&;5#"+5BAC/>PMTDQ$N@1TRNM7PL
MZH\:XA]-V24HF\(2'4F[9Q\V8FRB=@QT6W<Y9NIZM.&3IY 7ZL(K]PRCN*<K
M+LDW"&7[=DHNFGF^)F8L93ZP_P":LZA?XH>]?\ )H(_A*1G<?/3FUKCHC;VJ
M]X:\=,V.P--;(H^UJ,]D6"$I'L[CKNSQ=OK+I]&.L&;2+-O-0Z!U4%,936)C
M)#?)G(RY$^WZ5?UA?OHZ?_>*HW]C"V^!+(6G/AHNJQS"ZF_OJ^]A::?9?8E[
MN/D'RG18.E>A>TGV\^:?3_4J:?K/TGR#&^%XO;X/AG[O_C#!;:S,6);^L%R[
MQP>Z<7*7?[![AE<XS7CRD:P.7M,OC:.S5T*#1WR"13IG7+7IF?)*KDP8N?1&
M"N>W'8+&DC.YGG03XN*<LNJQQ-H[R+-)T_7]X]O.P#95(FT:5G2K<]Y8DD2Y
M-A9PQG[K&Q$.=)(IS'S)8P;N)>(H21GM:G,N&_&"<6D]G<%-2\H(EBV4L7%W
M;R$5//5/2$UD=7[Q38528PF9 JB+A8FR86J%3(N4I2)+KF(H0V<IKMQFG.B^
M^#@Y>GJF\^1G"6PR!R0VVJ@UWEKELJDWPV2O6NSM*[=X]!?"Q'9I"R4J99N\
M)^&HEA"NJ&[R9OD61F6K2O2\J>.U+Y;<<-U\:-AK/6E/W9KJRZ_F)*-[F9.%
M]>L%$&%AC"J9PBI)UV4P@^;E4[4CK-RX/C),FQFPRX_7-W@MRLZ7?) ^LMRP
MMAI%JK4]YCU'M^JGFHNLWUC7I!F]A=B:GNB!&*QUXUR=JLIA!5.1A7V2I."H
MKEQ@2RQO.L%]/+XM[DYI'U-K_GA3/>FUPV\-K[4ZDG"5'?\ !LR^F'\60:]D
M5K_9_@ERW023<E@'V2E.LYD72N>S*W2DTZ%\CAOS?XQ\^=0M-V\6=GQ.R*6=
MZ>'FD$D743::98D4B+N:S=ZG*HM9RL3B**I52)N42INFYR.&QUFRB2QZRK8_
M&6_YA/&/\;R-_B9VP']/E6G.HO\  _J!<DNF_MZQ[PXN3];KNP+5K>7U3,/;
M14XJXQZM.G+/3[?(-48R8(HV0>'FJ-'G*N7'B%(0Y,?(<PD9&[+4L_Z5?UA?
MOHZ?_>*HW]C!;X$LA?JZ*?*S</-SIE<:>3^_92'FMM;-]LGFR3@()C6HESY+
MY ;5U[!>B0D:4C)EX-:J;--3N8_5%2&4S],;(,SG4%/B#^CCM[@GR5V;R.H%
M3F;3PYWA>YB]5^\0[)Y),M16F[R_K*7UEL-=! Y*XBG9I95*NNW)_ DV!T4<
M*G>I.$RIRY6HFUCOIJ_$7<[NG?#U75;J0B>2?&NKMD(J)TSM-TNTEJA!-_33
MI1>LMI1[1Y9*DV24<)D1:2"$[$,VJ&$6K%#&>]A;I)B)= CIE=:OA9U1XUQ#
MZ;LDI1-X0D.I-VSCYLQ-E$[!CHMNYRS=3U:<,G3R OU817[AE'<4Y679)N$,
MOV[)1=-/-\3,Q8EU$0
M
M
M
M
M
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M
M
M
M
M
M
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M/HR+9E*OE)9ZY:H7-XV9FUO9\49^9AY(?WY\??X]*"&Y)&=1W^&;_/<\*/\
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M<@E 4.LQE6ATT(]K^M6*)(Z*3P5%/]32+C!2_)C K#(P@
M
M
M
M
M
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M3X4#I"Q4CZ<^I&]+*V^9YO>%@0CO_'I+?^-KC& E_P#Q:>4O_<K_ ,6H;/\
MQ^Z<K)H+931<4^#'$7@]57=.XI:!U]I:)DTF",X\K4<N[M=F)%H%;1V;=>[
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M9R)MWJ?S=49ZB6'^YZ][;L]5D/6%5L[YK^NF*_A>/XJ7<6(FH2+;*68$:?\
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M(CO6,O(K+> T;H-D>_W$DR$P4N&=;9>0_1F^B-^!1_.0Y;_R] 6R?HS?1&_
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MQY6HY=W:[,2+0*VCLVZ]V!U,7BWJ,TRYRF>3D79RJ***=O?44,8C:\0
M
M
M
M
M
M
M&<HC_P U1G_P/9?^\R8C<9GT 4 :^BN,
M
M
M
M
M
M
M
M
M
M
M
M                                           !G*(_\U1G_P #V7_O
M,F(W&9] % &OHKC
M
M
M
M
M
M
M
M
M
M
M
M                           9RB/_ #5&?_ ]E_[S)B-QF?0!0!KZ*XP
M
M
M
M
M
M
M
M
M
M
M
M
M          &<HC_S5&?_  /9?^\R8C<9GT 4 :^BN,
M
M
M
M
M
M
M
M
M
M
M
M                                                     !G*(_\
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M /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H
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M '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT
M#P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !
MX*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \
M%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"
ME]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2
M^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?
M6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK
M2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI
M/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG
M]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^
MH+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4
M%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"
M_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?
MH '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT
M #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z
M!X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]
M\%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >
M"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!
M2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I
M?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4O
MK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7U
MI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZT
MG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3
M^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_
M4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J
M"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!
M?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@O
MT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z
M !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]
M \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@
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M >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0
M/!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '
M@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P
M4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*
M7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+
MZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]
M:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M
M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D
M_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?
MU!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z
M@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]0
M7Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+
M]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^
M@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0
M /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H
M'@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #
MP4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X
M*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%
M+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E
M]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^
MM)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6
MD_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2
M?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/
MZ@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]
M07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H
M+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%
M^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_
M0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H
M '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT
M#P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !
MX*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \
M%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"
ME]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2
M^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?
M6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK
M2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI
M/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG
M]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4%^@ >"E]:3^
MH+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"_0 /!2^M)_4
M%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT #P4OK2?U!?H '@I?6D_J"
M_0 /!2^M)_4%^@ >"E]:3^H+]  \%+ZTG]07Z !X*7UI/Z@OT '],8QC&,8Q
MV8Q\F,8^3&,8_J8Q@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQY<2#0ZK=4R2AFK]AH-RP?-C&)G)%D%%$52]AB&,7.,Y"970.^=7<G]-:]Y
M:3G9.T:FVK7T;70+-+4V[4%U8JTZ770CYQ*K;%KE3N#&,EB-\KLEG4>@1\S4
M2=(94;+(JG#,   TMY<=1;@_P0B6<MRVY,:PTL>216<Q%=GY9Q+7R<:MR8.X
M=P&N*JSG[_/-$.\7!U6<8NF4YR%SG!CEQD(>I#XM3HL,YP\2WW5MF68$<^ 6
MSQ_'[9R<&JEWLE],(WE(:-LN&W9CM[#1Q5NS/_$[?D 3!\.^HOPAY^P4A/\
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M\B2O_F_TKT?T7]7\+Q4?$#?\
M          >7NUXI6M*C8]@;'M]7U_0Z=$/;!;KM=K!$U2HU: C43.9&;L=D
MG7;"&@XB/;DRHNY=+)(I$QDQC8QCM >'TIR%T%R4JLA>N.F\-/[^I,38'53E
M+CI39=+VI58VU,8Z*F'U:D+#19J=B&=@9Q$ZQ=*LE%BN4VSQ!4Q,$63,8,P
M
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M957AKI1KC KF<1-BK-@8HR,3*,SJ$273*X:KER9)4B:Z)^\FJ0BA3%P'O@
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M,7 >^
M
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MD9#91^OZ#\XVH_H>F_*/T@'_ $2_X>/\C(;*/U_0?G&U']#TWY1^D _Z)?\
M#Q_D9#91^OZ#\XVH_H>F_*/T@'_1+_AX_P C(;*/U_0?G&U']#TWY1^D _Z)
M?\/'^1D-E'Z_H/SC:C^AZ;\H_2 ?]$O^'C_(R&RC]?T'YQM1_0]-^4?I /\
MHE_P\?Y&0V4?K^@_.-J/Z'IORC](!_T2_P"'C_(R&RC]?T'YQM1_0]-^4?I
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M-2:XF+O"7T1B)_HK_EK\41.2K_1FIN</7'L
M
M
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M$O8YXWHZ[_*\H[R8IS,D'B!2-DLE2:-S(IIIII83+@+V7P,?_>B?ZDW_ &N
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MOM+]4^0KK,T_TOS=Y+U_Z=ZU]4>D>'ZK1\#Q/#[RG=[Y@DA
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M3AE5[K'2#6;BDU#J&0:O\-C***ME3 )8P
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M7Z;I$!K^D1#AZXDGC:"KS%-DV5D9-V8[J3E7IB&7=N5<Y4<.53J&^4V0&8@
M                   %>[XC7JH\A>E)Q(U;M/C77M:RU_VWN@FJ%);9L)-6
M.-JD2I0[=:EIR%A(FP5U!Y8".H!)-'+U1RR(4QLJ-U?DQ@)6.G_M>[[XX&\)
MMX[-E$9S9&YN(W&[:^P9IM'1\.WE[OL33=,M]LE$(B);,XJ+1D)Z8<*D;-D4
MFZ!3X(F0I"X+@-N0
M
M                         !^5\^91C)Y)23QK'QT>U</G[]\X2:,F+)HD
M=PZ>/'3@Z:#9JV03,=10YBD(0N<YSC&!JFFJNJ**(F:YFR(C+,S.:(C=F6:J
MJ:*9KKF(HB+9F<D1$9YF="JCU"NJ]<=Q2L[J'CG-2=+U R<.XF9N\6Y586G:
M!4S90<*-':14GM;I;C)38202.5V_0SWW)B)JF:$^Z=TNXF'U==TZPUQ33>:P
MF(F*)RTW7CC-57IF<E,YLL<)\3[U=]\1K"NK :IJF[P$3,37&2J\\4YZ:-$1
MEJC/DG@Q"4/I;YT
M
M
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MV,&+G!BFQ@Q3%SC.,XSCMQG&<?)G&<#XN^P/]
M
M
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MQ8YA\Z=/['.2RU:1<.'[LRCUPX54,JJ?&2%3"1_X&/\ [T3_ %)O^UP O^
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MY7."F7=X.@N8!/B%>MQTN-KT>G]9OA)$3.IK@_08J7FGU^O5.VK)HHI$E7E
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M@A)>G7RO1UIK,H4F#'P4LA"RJ"N,=N>S!_ZN0'O@
M
M                                    $"76SY:R%&J%=XNT>568S>QX
MS-HV>[9*F2<-Z 5VX80U8\9/Z8I+=+,G"CPF#$/Z&Q*D?!D79L9^J?+74%&*
MQ%>O,33;=7-7!NXG^Y9;-7^A$Q9X:K<]+YC\Q=>5X:XHU+AJK+R^IX5Y,<2V
MR*?]*8FWP19FJ5?Q]M?&@
M
M
M
M        %N3H[<MW^]=*2&G[Q*9?[$T<C%QS%\[6[\C8M;/2J-ZT]7R<V%'C
MRLKM3QCA3&,]C?#(RIC*K&,;X#\P]04:KUE&L,+39@\5;,Q&:F\C[T>"*K>%
M'AX5F2'W7N#KVK66KIP&)JMQ>&LB)G/5=S]V?#--G!GP<&W+*8D?/'OP
M
M
M                   #D&_$V<S3<PNK5OAM!S:DMK;C-Z#QAH"9'"AV";G6
MB[WVH/6R.#>B&4>[?E)U,KE/&?2F39KG)S%(3NA8K^%QYM=,'@#T^;&IR!YD
M:.UER Y ;HME\NE0LTT^9VJKU"HIM]>:]K<TW1CET"%.6"DIYMG!C&RWL!<Y
MS_4*4(V/BT=_<!>9.Q>*?)GA]R:U-NV_Q=0MVDMOP-%DEW<RRJ\/+%NVL)Y<
MBD>TRJR0DK+9&JZAS9R0RK8I<=F<]@;'?!3\SL5/=G)O@A9Y58D3MVKQ_(#5
M3)=0_H"%\UWAO5]D1K)(IC8];VZCRT8\,;)<%]%JIL9/@W<*<.C  X X#M\]
M)W\UETT_Q .&_P#1UUR W_ <:?XB":BI[K2\_P!]#JIK-$-O0\*L=+*62XE:
MYK:C5Z=2SX)SD\1";BW!#]N>_P!\N>]C!NW& N[_  7]>DH7I1[6DGR92-;;
MSCVW888Q?$[58UMIGCM5%5#]],A>]B7K+HOTF3E["X^7O=XI0M*[GW#KGCYJ
M;8F[]NVB.IFLM55"<O%VLTHL1%I%0%?8JOWJI<',4SIZN5+"39LGWEW3E1-%
M(IE%"%R'$!YU<@JARNYC<E>25 UI':?IF[-Q7;8E<UU&X)@E>C+',+O4/6/@
M++L\V*7[^7TKEKDK/,FZ7RW(FAX:90WLZ G*OCCPVZI''?<_*2JQ$QK0CN;I
M36ZS6%EVND+C>6.*_6MT98%-Z*]1J2[I1!V=<BOJY@_7D&Y,O&C;. [+2*R+
MA%)PW537073(L@NB<JJ*R*I<'3524)DQ%$U"&QDIL9SC.,]N $(_5RZZ/'WH
M^632%9W9J#<FSW>](.\3M?<:L+2<MX=O1']:CY!&9\VVBO*^,\5LR1D? *J7
MNIG[V2Y[.T(>OTVG@7^";R[^HTU_*6 L$]*+JCZCZMO'>Y\C],Z\V-K6KTK=
M%BTD_@MG8K.)]W/URCZZO;J6:>59R?CO5"\=LEJBGWUBK>,@KVDP7N&,$F3E
MRW9MUWCQ=%JT:HJN73IRJ1!NV;H$,JNNNNJ8J2***1<F.<V<%*7&<YSV .:E
M\2M\0VVY9.;+P$X/W%R;C5"2JD=OG<]?>X3;<A)F)=$SBCTQX@7"RNF8*2;8
M4</B*8):':9<I8S%I$4D0QS\,GT(+7R_VS1^>W)ZI.X7B1J&T-+-JJMV"/*7
M/)#9M3E2+1F$(Y\3.'FGZ5.,L*RKM1,[69?ML1:6%D\266P=/D  <TCXVG_/
MTXF_BB$_CEV6 V[^!C_[T3_4F_[7 "[+S+XT5CF3Q2Y!\6+@^6B8'>^J+CKA
M6<;$\5U6Y&?B'"$#:6B&3$(Y=U>?PVD$DC]J2JC;!#XR0QL9#B>\EN-7(W@#
MR3M&D-VUJP:GW?IZT-G;9TU6>L_%5C'^'M6V%0+&DFT-+UN7,T3?P\LTS@JI
M.Z<N2*%,4@3Y-_B_>K^WTX75I9'C8I:DX-.&3WZXTY)N-QD639IM,3IFRU[/
MIIQ.&R3QC'5J"B!EC9SE+..PN @CYAZ@Y.:XOE+V+RW/8%-O\L-<H<K7:UW?
MR#O9,A![-OE_B(RR;':RC=!_$62[K4Y>=;H*9.92&DV+C.297\),.AS\%=2W
MD+TT-^7-X1RB6[<T+JA%IJE2]'<Q%6TWI-D62;'(8RF?&FG[YL?!\%[#-.W&
M.S/;D+A0#FD?&T_Y^G$W\40G\<NRP&W?P,?_ 'HG^I-_VN %_P   &L7-K8J
M^H.&7+G;35YZN<ZNXQ;\V*WD.^L3T%>DZJM=E1>=]L15P3T92,P?M3*8^.[]
M+C.>S "F-\#QK%HWIO4(W,X:IJ/Y:S: UC$/C92RLR:5Z*V=:K$U0P53QB)R
M:UGBSJY.7NFRT3[F>TI\ +ZP#G?_  UG^\@]5C]SOG-_3OT2 W_^-I_S"^)O
MXW9/XFME@)?_ (=;B50>*?25XC'K%7BHJY<@=553DEL^SMVT?Z\NDYN6+2O5
M9=3LFS)XKU.NT2=C8MBDH;.6C5J4F<85RKDP3;OV#&48O(R39M)&-D6CAA(1
M[]NB\8OV+Q$[=VS>-'!%&[IHZ;J&(HF<IB'(;)38SC.< .=S\*Y&-=0==+J;
M\>J03U;K*L:JY+1D3"^(Y5\!KI_F#JJD4<GBK.%3*^K*_:'B7>4\13/B=O?^
M4W>"53XU;\UEH/\ '_U9_1UY5 )NNB;^:-Z<WXHFE?\  Z. : ?%A_F3>0_[
MHG'C^.JF@-'OA!NGWK&H\+674*O5:97#?.\K->Z;JV[61+UP_P!9Z.UE9)'7
M1JS1#R.7/EQ2P7RNSBDBNS\$[EJFU;Y[$TC84"Y& _(]<L6+5>1DEVC-E&HK
MOW+YZJBW:L&[=!4[EXNZ7,1)JB@U[^5%#&*4J?>[<XQV@-"=@]5[IC:KE%X*
M_=0/AS7I]F[48OZ^MR)U6]GXQVCCM41EH.+L[Z5B3%_J?KE%+&3?)C/;\@"A
M;U@>0G&3;/Q(O3MY&<)]RZYVRPL=DX)2]_V#JFRPUJ@S;<JW)F?IBD5+2$-W
MT%9-MJ^M5I)PU<F5.=BHD4_:B<A,!<[Z_?"4O/#I8<F-6Q$0G+;+UY7<<@=,
MD\--1Z78^G6SZPXBXCQCI()RMWI1YJM)'4,4A/763&,7&.W 14_!T<TL;SZ>
MUVXI6.6,[N_#;8SAE"-G+@Z[H^FMRNYN[4U7"B^/&6+%WEK:&."%,H1HS19I
MX[A#)DP$@?Q*/-(_"[I-\@)& F31&R^0R+3C%K51L]RRDDWVUFDDWO<I'KHF
MP]:NX/4T9/N6[E'NG0?%;YP<AC%-@-3?A'.$^>,_3)2WU98@K#8W-6ZN=J.5
M5DB)R2.I:::0INGXMV8J>,J-':99FQ,\]\^/1K(7_BFR8N A<U?_ +\3)_NB
M;>_]AI74!9"^*._,4<YO]6;^F'Q] 8[^$\_,F\>/W1.0_P#'5<@$_P!M[_%-
MM#]SNZ_X-28#F2?".=/[6G,SE]MS;F]JZTV)JKAU6Z1=:_K:QIYDZ3(;TV9*
M3T;KRT6*NNS*P\T6KUZA3KA!!P@<N7Y&JN>W#?N&#J.D(1,A4TRE(F0I2$(0
MN"D(0N,%*4I2XP4I2EQV8QCY,8 <_P#^-:Y'6>6O'!S@["V1I!U:586/D%>6
M<C*^JX1_.3$\IJK5TU8G2V2,F,95&\?:L^.IDQ2%?JG-@N$\9R%G?B-S%Z,W
M#+C3I?B_J'J)]/.%H6F:'"T^,(SY?<<&BDS(M4/2+);I4J.Q<8<V*ZV5R[EY
M-P;M.Y?O5E39R8^<@-*.N-RLZ4G-#I9<P]1H\\N!^PKY!ZDL^W=-5^O\J=#6
M:ZN=PZABGEZI$=0(B$O;Z>?7&VN8A6 ;MF*1W,@E+JL\%.1R<A@TS^"NWS8;
MSP-Y&Z&G),TDQT)R&0FJ>@L5?Q8&J[CJ3:65@FY_ 39YC,W.HS,BF4IU'&',
MBXRIW4\H8 7%9^=KU5BGMEM,S"UR#B&QEI*P3\BQAXJ+:**(D.J]E9%9NS9-
MCJX3QDRBA2Y-W?\ A[ $?MLZP'2KI$D:'L?45X8MI-,RR;ADPY%ZMGEV2S=3
MPEFTB6 LLGB-=IJ8[,I+^&K_ ,/=[ %'#2&SM)3_ ,95";*XA;"J%[TQM7;T
MS/,+MKR8C)^FW"1VIPC?RNY5&<C$EQ&2?C;/G9S#C/8<Z4BD8QC9<)>( NS]
M;+\T;U&?Q1-U?X'2("$7X*G\UEOS\?\ VG_1UXJ@+?H  YW^K_\ ?B9/]T3;
MW_L-*Z@)_OBP_P R;R'_ '1./'\=5- 8 ^#^XE4'4G3!8<H$:O%>U/E?LC94
MG*7A1M'K6%376KKM+ZHK5,0D$B9?,Z['6BDS$AZ*<Q?$>/CJFP8O@Y*%L$!S
MH^)5=A]!_&G;#UKK"/:5FFWC97)-6;A&"9T&/AWWAW<]^SS9FV25*@U:*;&2
M(Z31*7P$2%P1-,A2DP0+#7Q8?YDWD/\ NB<>/XZJ: R)\+C^8HX,_P"LS_3#
MY! *A_3 WMQ=YF?$3\FN>_/[?FB-<Z[UE9MJ;=TB[Y$;5HVOJG)6NL76!UEQ
MMK$"YV1-04=,N=6ZV[LK'E1/E=L^@6CK">,ER8H7[_RL72R_]<LX ?\ PY''
M7^48!0C^+$VOQ'LO,;ACS5X*<F>/.U-P2=7GV&R+-QNV]K;:4K4[AQ_M%$G]
M-WBZ^0IVQ-(NP/6ER69QCF0+A5XUK942]])C@I N[<\N=$[IGHV;DYYT95E%
M7)]Q KVR]>/$4G_H$+>MT5>MQ=!DF[=TFE(G;0MKOC)PFDOA-0V$<%4R3M-G
M 5QO@RN#%$6TYO;J-[$KK:S;DN&U9W2>J;19$C2DE5:=6H.NV#85HKSEYXO@
MS6P;5:O5[U_VF>X1@SHD4(DZ=%7"\\  .=_\#M_C9ZA_[G?';_"7;0#H@ .=
M_J__ 'XF3_=$V]_[#2NH"1;XT;DW9]8\%^/O&RM2IHMIR?W1*REY307\-Q/4
M71<5#V$U>62PL4RL8I?;?7Y!7/AFP5:.0QDQ<&[#A.#T..'-,X2],#B;K*MU
MYE#6NZZJI^[MQR"30J$I8]O[<K,/;K:\G')DD7,@YKQ'K:!9G6+@Z47$-4>P
MI4L%P$JTW"0UEAI:N6.)C)^O3\8_A)V"FV#65AIJ&E6JK&4B9:+?)+L9*,DF
M*YT7#=8ATEDCF(<N2YS@!SBNE_'FZ4GQ4^YN$%(=2,)HW;]OV;J)K5UW:A6;
M.C7O7..2''QLNC(+8+)R-9,:'B6KTQO25&SUP9/.?2#I*!9&^+#_ #)O(?\
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M7"&,EQC)C9,&9/C:?\POB;^-V3^)K98"R%TG?S6733_$ X;_ -'77("DC\1
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M (<X+CMSG/;D!+6
M
M            HM=079KW;',KD'9G:YUVT;L2:H\-C/;A)."UXMY)B\MDNPN$
M4GC>"])SCLP8RBYC&QWS&R/T_P!T\%3@.[N$N:8LFJYBN?\ .O/YY\W"L\C\
MV=Z<95CN\&*OJIR1>S1'BN_Y(\_!M\K3<>Q/7P
M
M
M
M                         $D_26V:[UOS@U<V(Y.A$[(:V/6L\D4^2X=M
MIV)7D81 ^,?2GP6WPL:?LS_^!\GRCTWO[@J<9W9OZIBV\N9IO*?!-,V3_J34
M]O[C8RK"=X[F+;*+Z*KNKP\*+8_UXI71A^<'Z$
M
M
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ME-QRT_OAE!F,: 7V11X2PS%=RH?Q%\5RPN6OK^O%=&_\=ADY0PL7Y#X-C.<
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M7IYYG<(%P_.0]->4C>D@51N@<BC0OE212R?)\]J2>?&SC).S&0Z.(
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MZ?B[US_G&7 2[
M
M          .>]NI!9KN/;35RD=!PVV9?$%T52Y(HBLC:95-5)0F?E*=,Y<XS
MC/\ 4S@?K35LQ5J[#U1EB;BC_9A^6-8Q-.L+^FK),7U?^U+&8[KI@
M
M
M
M                                        -M.!R2BO,[C&5),ZIL;G
MHJN2ID,<V$T9MLLLIG!<9S@B2*9CFS_4*4N<Y^3 \!WIF([N8VWV:OZGG>[,
M3/>'!V>T4?6O<C\NOTL
M
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M*'@O&K=AWL/0Z,P  YI'QM/^?IQ-_%$)_'+LL!MW\#'_ -Z)_J3?]K@!?\
M'RIV#BK-!S-;G62<E!V&*D8.9CEC*%1?Q4LS682+)4R)TU2INF;@Y#9*8IL8
M-\F<9^4!SEOA?YJ0Z?O6WYH]./93Q9I(W.(VMJ*#6?X] 6L^Q.,]WDK'5I!N
MS5411<L+)J@EEEFJJ6%,J(&2.EVHJ&. Z/P#G?\ PUG^\@]5C]SOG-_3OT2
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MXZ$K#U==-KFT/ZAJ&^[1E;/!PWI":CHSN2KK!J4V5G3U-%(W?"$GAOPFY/\
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M4D9-U$V&+F6R"2BF#YB5<$*=LDIG =),
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MKTA88"K3;N.,1T7!3N8YHKG.,]J>/D[0WJ
M
M                               4A^IIJ)WI[FINN-.V51B;S85=K5Y<
MY#II/8[8AU9^14:8-\F6S"TK2+''=^DP9H;&.S&.S'Z7[EZPIUAW;PU=MMY=
M4<U5X)N_Y8M\,T\&KROSGWQP%6 [PXBB8_DO*^=I\,7G\TV>*KA1Y&A0]J>L
M
M
M
M                                                )5.CEJ1UL?F?
M6+2HU\:!T]7+)?I555/.6WI[B/5J=;:^)W#%P]Q,V$CU$O:4V2L5#8_XF<#T
M7YB8^G!]W*[B)_WN(KIHC39;PJI\5E-D_P"=#W;N!@:L7WAHOIC_ '6'HJKG
MQV<&GRVU6QXI7&1^>'WT
M
M
M                 :;[!Z=73ZVU99.Z;4X*<-]F7&;D9*8F;9L'C%I.YV67
MEIAXK(R\I)SMCI$E*/Y&5D%CKN5U53JKK',<YC&SG(#+VJN-G'31),I:0T%I
M73:9D\(F3U5JRBZ\(9$K=%H5+)*C!1!<IX:MDTL%_J>&F4O]0N,8#-0
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M LS
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M<1-ULZ6U[3';!VEOV<B'R3=[!-[C(H)L($JI$UG;)>0<>$5HLP6<!=P
M
M
M                         $/?5[X:R/(34D;MS7L4:0VEIAI(KN(UFCXD
MC;==..U[-1#8B9?&>2E==)>L&*6,YR8AW:293*KIX'T+Y?\ >*C5.L)U?BZK
M,#B9C+.:B\S4S.B*H_EJG_-F<D2]"[^=WZ]:X",?A:;<;AXG)&>J[SS'AFF?
MYHC_ #HC+*HL/O[X2
M
M
M
M   #^S9LY>N6[-FW7=NW:Z39JU;)*+N7+E=0J2#=N@D4ZJRZRI\%(0N,F,;.
M,8QVB5513$U53$4Q%LS.XL1-4Q33$S5,Y(70^F#P_<\4- IGM[$K7;FU5V%M
MV B<N/2:^W1:J)UBD*J%.8BBE;9NUE7.<8["R#UR0ICID3-G\X]]N\,:^UK9
MAYMU?<1-%W_E9?YJ_P#2F(L_R8B<DS+]"=S=0SJ/5=N(BS'W\Q57_DY/Y:/]
M&)F9_P J9C+$0DD'IKVX
M
M
M                              'CM@:[U_MFF6'7&U*-3MEZ]MK#,5:Z
M'L"LPMRIEGC#*I+FCK#5[&RDH.:8&61(?*+E!5/)B%SV=N, /,Z;T-HWCI45
M-?\ 'S3.J-$T-67>V!6DZ;UW4-85%2?DD6C:1FU*W28>#ACR[]O'H)K.<HY6
M5(@F4QLX(7& RN
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M5)T<RI<84SDP#8@
M                              $:>YNC?TL.0$Y)V?:O OC1.V>:171F
M;+#ZUAJ/8I<[A(Z*CZ4G*$G6)20ERI'[I'RRIWB6"$[BI?#)W0_3HKH]]+WC
M58XFY:8X,<=:I<8 J'J&WO:!'W*UP:[8R9D9"&LEYS99J+ERY2Q^O4%TW9L9
M-C*F<&-VA)&
M
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MES5&2JF8JB?%,9'R*_N+_#7LW&(HJN[ZF<M-43$QXXG*\\.9Q
M
M
M
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MIUCK7@UX^,M-$9:;N=,SFJKC<_IIG+%LV3$VP^:OHH
M
M
M
M
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MU2R6Y9TP:)0"]XCZ\^I=<D3J221\$E7[']0[ZW;X*2IR!M<
M
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MXCET^H?D0.&?SINO[N(#]I0;3.\?%PW(J]<V<]W].(Y=/J'Y$#AG\Z;K^[B
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MW(J]<V<]W].(Y=/J'Y$#AG\Z;K^[B _:4&TSO'Q<-R*O7-G/=_3B.73ZA^1
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MK W5W=7?^33$6^.<\SX9MEDH=)W
M
M
M
M
M                                        !5N^)NY5;<0U=QIZ6G%N
M3*UY%]3K9[74LDX:.5BO8#2&):$K]J(_,T15<PT1>IZRM&3QZ;."9@&$TGW3
M8[YT@VQYR\3M5<&_A[^6G%?3$4WC:+I_@CM>MH/$V2+%]:Y_%*D7=MOL^F@=
M0BEFOEG<NY:1/@QBY=NSX)V$P4N P[\)Y^9-X\?NB<A_XZKD LA *1>E/]]E
MY>_B[UG^A5Q? 7= %#;XA%U8N<O79Z:_2NVC=IZI<2YF.U9<K-7(.54C,VNV
M[)NNQ&%HFUE.\V:*3SFG4AM78%54CI2(7>O56V<F?+(9"T56NBGTDJK06>MX
M[IS\0'L RBB0Z<I9=&4.W7Y9L1$B'I#S:5IAY?93R5.4G>R]4EC.\GSDWB=[
M.<@-E^'W##C[P/U,[T7QCJ#N@ZF5O-NO\935YZ8L;.NRUU>(R$VPA']@=R,T
MG!X>I94;MW#EQEO@^2$/A/!"$#:@  4.OC4(YE+[(Z/43)MDWD;*7?E;'2#-
M;&<HNF3V>X<-G;97&,XSE-=!4Q3=F<?)D!9/_((]''_UO3CO]SDC^RX#<;BQ
MP6XB<(V-SC.)V@Z#HF/V&[A'UV9T-B[8-[&\K:,FW@W,BDX>.RG6CD)ER0AB
M]W/=6SC/;V8[ HO=)CAKQ=YI_$*];VB<JM)4C>50JFYN9=MKE?O3%=_'1%D]
M]UQ#^N6:3=TU,1[ZKDET.]G.<=Q4V.SY0%I79OPXW1>VE77%?D>#6O:B91%=
M-I/:RL6P==6*.66,W/AVW?U:VQZ+Q9$[8O<(]2=H8QDY<IY*HH4P5/>57&[E
MG\)QRQU'RBXG;=OVYNG3O+81*K?]476602+)R"+1U)O=7[+C6#=C5'M^=4>.
M>/Z==8Y@S>)K1CM%PV3;)K(20=#[4^SZ9NW5NM]RZXEDY[7VV*'4MDT>;2[N
M$Y>HWB 866NR)2E.I@GID1)HJ9+WL]W)NS_@ 4\?B@=CV/F'RJZ;714U+,*>
MN]][>K.W=WECGJ1<PE7=RTA2J.O*>!A93#> KJ-PL3QLL7M*DP8N"I*9,EG
M>7^&LOT[P+ZBO4OZ)NRWIF4=4-GVK=7'I&1<N2&DFD O%0\HJP([7<G<K;'T
MG*4^QM4NTJR32+=J*94R;.4PN[  "@MU5MU\FNN[U<%>BQQ2V;)ZSXG<>).8
M2Y3W&&4>*1$Y/Z\D(Q+;5HO;",DFN;;$:NMCAK5:[7W)D&JUOR=PY-@IF[AB
M%E?C)T >D=Q?U_%4>%X2Z.W$_:,$&\UL#DK0*IO^]6F1(FB5U-2#W94-.PT(
M[?*(8.9O",8J/1R8V$6Z93&QD(].J[\,KQ!Y"ZFM&V.!6KJWQ$YFZ[15OFJG
M.E3'UMKF[V:NFS,QU/EJ9 80K5,?R#IOC$3,P3:+<QLEX"BIU6Q#I ,C?#/=
M5W8O42XL7G4?)B3</N7/$&>B*+LB5G$L1UJV%19A.10I%[LT4N@R=)W-@^K\
MC"3^?",<[R/1=N#%<2!B%">*N\HN,UOVI>-%5/D3HJT;NUE$2-@V3IRN[<H$
MUM37L!$.8=G+3=XU[&V!S;JG$1;RPQZ3AR_9MT4%'S<IS%,LG@P>"TISRX5\
MDME6C3G'SE5H3=FT:5"R5CM-'U9M"HWJ?A:_#3$17I>;=M*Y*2/]JHN>GV3)
MPX)DR2+IVDD<V#G+C(>UUQRNXM[C/LY/47)/06U%-)F*3<Q-<;CUW>#ZC.?-
M@*0NSBUBQRAJ$8QJG*XQB5]$SG,8[_\ ==;N!J%']:7I-2E])K5AU#.*+FV+
M2OJ1N0NWZL6O.I3)L)IM6=V4>$I+SQULX32.E(G365S@A#&-G& $F3-XTD&C
M5^P=-GS!\V0>,GK-=)RT>-'*15FSIJY1,=%PV<(G*<AR&R4Y<XSC.<9 4?OA
M/)V#J_)CK]62S3,57:[ [WT[,3L_.R+.(A86)CMA<X7<A*2TK(+-V,=',6J1
ME%EUE")))ER8QL8QG("RS4NLOTIKUL1EJNI]0/BO,W:3D\PL2P0VW6$8J9EN
M]X:$?"VMT\;U*8=R"V<)M"-GRN7BIBIH>(<Q2Y"3 !J)R0Y^<)>("B#7D[RK
MT1I&7=IIKLJS?MDUF&N4@V5*4Q'<=2COU+9(LL%.7)ED&2B1,&+DQL=[':'\
M>,O4#X1\S'$O'\6N4VD]XS, CZ7-UJAWR%D[=$L,G\(DI(T]1PWM#2(56^D(
M\.T*U4/C)2J9SC.,!G+;N[=,<?:8XV/OK;FL-(Z]:/V$4[OFW;]5-;4QM)RJ
MN4(N.<6BYRT+!HOY)8N2-T3+X46-CL)C.0&'MS<[^%W'G5](W3NOE/H;76J=
MG1$;8-7WNP;/J:4!M&"F(ME.14QK%TVDW.=B1DC!R3=\BO"E?)J,EB+ESE(V
M#Y!QCYV\-N9[:;<<5>3&F][K5DI%;+$:\N\-,V6NMEEO1VS^>JA7"5EAHQZX
M[2-W3EHDW<'*;"1SY+GL#;   <W_ .$;Z>_"OFWK?F]+<L...M][R6OKOH^.
MI3R^1KJ06K;*PP.RG,VVC<MWK7"2<DO%-C*]N,]N42_^R 6E]Y?#.=&3>%9>
MP7NBQ6H9A9D9I&WC1MRN>O[-!*Y([*F_9,,34K1I1ZB=X8^/6T-(HGR1/"B9
MRID+@*Q%#L7*[X4GJ6:AT#L?<]@W+TL>54NJI%N+$X4:PD' .IZ)A;C?6%:7
M=NH^A;@TI)3[![8O5><1MG@7:!E<8<+-RQ8= _;6\-*Z"I*VRM[;?U=I77+=
M['1J]_VU?ZGKBDH2,NIE*)8+6JXRT-!)O917'=;I&7P=<WR$P;(##VW.>?";
M0E%U]LW<O+/COK?7VVH6,LFJ;C:MO4:-@-GUJ:CFDQ$V37<@I-Y0N]=D8=^@
M[1?QF730[5=-7"GAG*;(?=:<S>(3VUZBH2'*;COY^Y 4BJ[+T705]SZZ:7O<
M>O+RW?NZ9>-8TQW8D;->:I:F\2[-'OXUJY;.\-5O#.;*2G=#94!@Z#Y.<;+/
MN6Q\=*UR$T=8>0=/8*RMMT3![8H4MN6K1B"$4Z7D;'K!A/N+M",$6TZQ4.LY
M8I)E3>(&SGL53R8,P2\Q$U^*D9V>E(Z$A(ADYDI:8EWK:-BHN.9I&7=OY&0>
MJHM&3)J@0QU%53E(0F,Y-G&, (TV76HZ3,C?$];,>H7Q3<VM:7) MTTMN5G-
M?=2JBI$$FS2ZY=XI;LJZY\$353D#)*'SW2FSGY &XTIREXR0FW*KQ_F>1FB(
MC?%[BFL[2-)RFW=?L-N7*#?-)-^QF:KK=W84KE88IXQA7BR3AHR6142:+'*;
M)4CY*&=P$ /Q1WYBCG-_JS?TP^/H#1[H5='SIC\BNDYPTW3O#A=I79>U;Y2+
MC(W"\V>$?.IVP/6.U[_#-',@X3DD4U%&\5&H(%["X[$TBX_X &8>:GPF_2VY
M'4F?]@5%FN'6X5&[IS6KMK*Q6>Q48TN91PN@VMVJ[G/S,$[KIU7&2G2A%8)V
MF4J>$W'AI^"<-#?AZ>H+R\XU\X=P="/J-VV1N6Q]8>8TN.UVLMB=6>:;K4JO
M-[FMKF,M$MW9JUZWN.HE,6VH*/<$>QD8W4:&(1!5LU8A=CDI*.AHY_+R[]E%
M1,4R=24I*23I!C'1L<Q04=/7[]ZZ42;,V3-LD91550Q2)D+DQLXQC.0$9*O6
MPZ22%W-KQ7J(<4260DKB%.?VN5K-8)(9[,9(>]E=9HQ&Q#Y[IG&9'#<A\9*8
M^#8S@!)I%2L9.QD=-PDBPF(:88,Y6(EXIXWD(R5C)!NF[82,<_:*+-'S!\T6
M(JBLD<R:J9L&+G.,XR U<Y.<\.&?#%&%4Y4\FM,Z)<V1/+BN0NPKS"PUHL#,
MJYVJTC!5++E6SS$4U<IY37=MVBC9 _850Y<YQC(?VXR<Y^'7,YE-/>*O);3>
M^#5HJ2EEB]=7F%G+'6F[APJU9O+'54W)++ L)!PW4*U<.VB*+K)#>$8_9D!B
MK4]3Z8A>;>Z;3I,O#5WU"%ZV[QOHFNK!J>3Y01E88O:U'S3W8-:@9-SL"M,%
MY&3A491VZ:-?2UU6!':BA_1< -TKYL&A:KJ,Y?\ 9]WJ&N*'6&1Y*R7:^66&
MJ%1KT<EG&%'\Y9+"]CH:)9)YSCO*N%DR8[?ER T)U;UB.EONK847JG6'/#C5
M:]@SLCF'K]:;;)AF#FQRV53(HQ=<=2ZD?'6"1>*E[&R#-9=5UVX\(I^W':&V
MD'R<XV6?<MCXZ5KD)HZP\@Z>P5E;;HF#VQ0I;<M6C$$(ITO(V/6#"?<7:$8(
MMIUBH=9RQ23*F\0-G/8JGDP?][#Y,\;]17W7NJML<@M(:PVAMR180^J-;[#V
MO0Z5?=G2TK,M*Y%Q>O:?9)Z,L-TD9*POT&#="-;N55GJZ:!"Y5.4N0U_Y&]3
M[IZ<1K@77G)'F+H34FP?1F[QQ0K+?H@UVCF3Q$KAB]FJG%JR$_!LI! W?;+/
M&Z";DO;E(Q^S/8&S>FMXZ9Y%4&)VIH3:NO=S:WG#+)15YUE;X*[5=VY:]S#U
M@69KSY^R2DXY0^$W34YRN&JO:14A#XR7 ?BW3R#T/QOJ2E\Y![GU9I"ED,HG
MBT;8OM7U_!KN$BE-EFTD;3*1;9Z_-WRX(W1,=90QRE*7)C8QD-0M-]7SI@\@
M+[&:NU!SIXWW+84XX*RK]10V/#1,S99 YLE3C*PVL"D3YEE5>[DQ&K'+AP<A
M<F*3)<9R V]W7R%T%QKJL?>N1>\-/Z!I,M8&M3B[CNO9=+U759*U/HZ5F&-:
MC[#>IJ"B'E@>1$$^=),DUC.5&S-=4I,D14,4*8'0OZLE/F.HSU=+1S=ZBNOV
M^LE=@,:]QDE.1/**G5[6BVOX3<F[2Q3#1?GFYQM.6KJ565C%C&@"Y2706074
MR?Q2J&"UGR2N/3=Y#\2_-_*?8_$+9G":^OXA1IL;:FS-5ON/=@F&LTY80+R!
MV9+6).E'G&U@CUV[1PQD2NB.DE4DS8/@Y0&T&EX[3T5J+6++CVVUVUT22AU5
M?3J>HL5WV6J:U>0K-[2W>NU*CDU7<TQ_7W""\<M'F,S7:*$42,8AL&R& ^2G
M4-X,\/'[6&Y/<L-$:3L;]L@]8U"\[%KL;=WD>Y/A-&3:TA-XO;7$48^<8RZ(
MRRW+_P )\ /^N-?4*X.<Q'CR*XP<KM%;MGXY%1U(5.B[$K\E=&+)(RA3R+RE
M*/$+8VC,Y1-W7)V96Y\%SDI\XP V7OVP:%JFFV'8NT;O4-;:^J,<I,6R]7ZR
MPU/IM8B43$(M*6&SV%['0D+')'4+@R[E=)(N38QDWRX 8,L/-WAM5=#Q_*.>
MY5\=V/&Z9</6,#O<NX]?O-2V22CI:5@'L35[ZQGW-:L\TWGX)ZPRR8.7+K+Y
MHLWPGE9(Y,!X+C5U*N G,2RO:3QDY<Z*W)=X]HM(+T>I7R(4NRD8U3PJ\EF-
M/?JL;)*1# AB^D.VS59LWR8N%#ER;&,AYWJ@<"]>]27A1N?BO>V3#UG::^ZG
M=46AXD8RVO=T5UB^<ZXO#)5)1!PD6-F5O1WZ::B?IL0[>-#F\)PIC(1O?#4\
M\[YR^X(/=,[[4DR\HN"-U7XQ;F2GU4U;%)QE:2<-M;6.=,5=RNK+^I(IS 2#
MA=0Z[Z6KKQT<QLK]N0L1
M
M
M
M
M
M
M
M
M
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M#V>GN[16EMSI,/526W=3:YV>E%]XQ_5J=^I\-:R,.\;)C&]#++83[<YSG/=
M5.>FHB3C1\5-U@N-<.W4B*/OS3L5R-;M6S=^TC)>]3"FCMKKO46O<]"<^$]W
MU;BG=YSW".R+)$S@RAB@+CX
M
M
M
M
M
M
M
M
M
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M2B6'!TG$JSJG$BNR,6=3"9DD95K:9B00P3.2E,C&*FQG)L=F0N+@
M
M
M
M
M
M
M
M
M
M
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MT^==@-+/>6S1Y6X[8?KB-(G$I%P?.8S*SA)NIDI5 L. *UGQ _1QY-]5N\<
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M9)>NO;W:',&V,=/O81J2>4L$3/\ J@6UP
M
M
M
M
M
M
M
M
M
M
M8*Y,\;M0\O=#;0XV;YJR-QU1MRKO*K;890_H[HJ"YDW,?,PK_!#JQ%DKDLV0
MD(QZGCQ63]LBL3Z8F &JO2WX/[6Z=W%^'XJ7WE ;E+2-<R\BVTC89;4Y]9W"
MA:T>.5GL?K:Q2!-G;"9WAI6W*YRQKQ-"(RU:&PU*AE!)N1$)'P
M                       !3Z^%[XS<D./_ ";ZU$_OCC[N_2<%M3>^GYC6
M$UMS5%\UO$['B8S8',)[)2E"D;E PS.X1T>SLT:JNO'G<)))2#8QC8*NEDX7
M!0                         !!'U9>:_51X2[=TK>N%_ ^5YV\9Y>D3K7
M>%+I<9-2.RH*],[&U4@EJDK0B6B]QWK&N+*$555JT[&=I"]F$E2GP<(NK!\2
M;U)MEPBM.XT= GEZGN6;:&0A)'8\;MR<H=9=J)83]<3D=$:%ICB8B&+U4A3X
M7F(%')#8,=RE\A<AL-T'^D3RETAOOD!U2^IL_BI/G;R=3F6,;3&DK$6 ^I:G
M:)*-D[,XG'4 =Y4F%OFR0,?&Q[&'=.VT#7&N&F''?=N6K8+38
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MKD<A%P\6R1+_ %$VK-L4N3&R8ZANTY\F,;.<A[L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      &$=N<F
M>-_'^6H4!OCD%I#2<[M21?0^L(7;FUZ'K>6V/+1CF#92470HZY3T,\N$C'O+
M-&I+H1Y'"J2L@V*8N#+I8.&;@
M                              !A?5G)#COO.?V)5=);ZTON*T:AEVU?
MVS6]6;2H^P9_5\^\>SL:TA-B0]2G9>1I4NZD:M)H)MI)-LL=:.=$*7)FZN"!
MF@
M
M
M
M
M
M
M
M
M
M
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MZQP,ZO$J)HRJ$-+Q\HM&+*F7(DE()LG"YV:BIVJN"E4P7)LIFQC_ (N>P/O
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MFL-M1C Q"/I'6=^JE\8,CJ*+I)E=NZM+2K=L915LH4N#F+G)DS8Q\I<]@9/
M  !A.Z\EN..MK*SI>Q=_Z3H-QD#&(PJ=UVK1*K97QRIHK&*S@IV>82CDQ4G"
M9LX(D;."J%S_ %#8[0S,V<MWC=!XS71=-'2*3EJZ;*D7;N6ZY"JH+H+I&,DL
MBLD;!B'+G)3%SC.,]@#\4U-PU;B9">L,M&0,'$-%G\K-33]K%Q,8Q;DR=P\D
M)%\J@S9-$"8[3J*'*0N/ESG #&&M^1''_<C^1BM0[ST[M64B/'];1NM]FTJ\
M/XOT8Z*;GUBSK$W*.&7HZCA,I_%*7N94+C/9DV.T*D'PLW^?I\1!^-WKG^.7
MG8 N@@
M
M
M
M
M
M
M
M
M
M
M           #Q6P(BA2=5F'.R:]7['4X6,E)B6:V.N-K2Q1CF4<Z4DU\0[AA
M)G=F]6X5*9-)%154ALD*4W>[N0YVS'B&C\2IO#J;\G-,:JK^BM'<6=/O=,<!
M:]4*77]3/MA<@&,H6Y5J?V<M"Q;,[^<LU;JZC6;;2)%C03*UQ2")_$C_ !3A
M8S^'(YI:=Y[<23)6'C=K?4G*OBK*U_4V]L5W2E:H4=-3L,@L:IWR$/%5:(90
MTS*)1:II2(2RFXAIANMDJ*+99IDP:$_$4?GIOAQ/QNZ!_2OXO@,G_&COGD7T
MP..TG'.5F4A'=0K4CYB\;*&2<-'C3CWRG<-7*"I,X,FL@NF4Y#8^7!L8R ]W
MP\^'MX]<QM44WFAU@7VRN;/,/DS3H+;5O3LVWMJZ_H6FHK8$='VVM:DU[ :I
MNM,7CXS7L3(X8&1P\5B4ES+$9-DFY$,X"-:\<7X+X?CKW=.B!X87C84!Q.ZB
MUD@M.;!T+9;9,6R#:R]EN\)J5=NHN^=>L)N,@9V_U^=AGDD=U)QSY-XEZ4HS
M5,W ;%;+:&Z2_P 5#K?:"7]H.-/6"ICBD6$^,J$A&6Z[+(04+((I$70P@I/.
M=\P-9E7;C*F<M6MZ<]BA4S&0R%M_E#O^F\5..6\.26P%TT*?H_5UTV9-D45,
MB=^C4X)Y*MX9J9-)=4\C//6Z3)J0B:BBCEP0A2F,;&,A3DZ$5@EN'72]ZFW7
MNY$QZ=HW#R=L6W=N02<PNY1);(K7]@M+:O1",NZ<N'\:WVKR3M<G%+]A3&PV
MCV*V#+=A"E#[G24Z)NM^J]IA+JF]8V:V-RNW#RR?V*S:\UQ*;+V!0*7K35D;
M9)N#K!6.-:VJL3[9&6-'J/(B*9R+:&BH11HEAIE<R^<!AOEYQW8_#+]1WA%R
M0X67'8D%P-Y=[(SJ;DCQQLMXL-KJT,=F[KT5,R+1>:55=2RC:HVH\W75I-T]
ME&<M".DCN\L7/@%#83XB"Z1VZ.K1TR>GKR_W79M!=,/;-,5V5MVPQ-H0HU:O
MVU4;'M"*CZM>;,Y,DP:0K!_5*E&>FO3X;P*-N</RF25*59,)";K\*-T0]AT9
M&*INA;]K1W(QB!V&S=9\C=QS=C62<M$S-IEBGLZY;/UZY,X(;"Y#>I5&Q\G[
M<$RGV%P$;WQ,O2KXUZ>Z54#O2*GMV678O$.@\9^.FIUK?MJR353)5T+["5"=
MM<S1UE,5QUL*YM9]VYEI5)%%5TZ4*;.,%33*4-E^D[\.?TSO=_Z:?/3R?MGW
MA?8[PWY=^M?:U/>6/;-Y*USN7UAY8\#T+U#YW_5/0.]X7H_ZEV]T!A7C9_OI
M/4#_ !1*7_1MX1@/[<^)#8W5H^( ;]'VY[FV?JS@]QHT5&;<WOKC5EDDZ3(;
MWL,K1:?L#T"PS;/NEE(Q4NU:Y'D363<MV+1H_.V*D^7\=$/+]:#X9GIF:=Z>
M?(3D1Q+UI:] ;:XY:WEMKMG;7:VT=BUV_15/33D++7[;#;6N-U]%4D8%-R9H
MXB58TR#XJ1CE51[Z)@D%^&%X<\.=>=/;1G-C0VGY/7VZ^4&J/+&\+%(7O8]A
M1LDOJC85KHDTM$UNUV)_7J]$2]PJ#N4;X9,TSX2=X(591#"> &2]O?#5=/[D
MYRTW/RTY<3_(CDG,;6M[BQ0^J[GNFWP.LM:Q+MJWRM5*FI37T'L1"%2EO'6;
M-B3Z$>Q;'1:MFB2:/>4"!#K0=.K2GP_-WX8]4;IHN]C:&8QO)>L:>VWIQKL>
MWW>L7& F:Q9M@'B6SJ_STY:G4';:QK:<BYN/DI5\R<>EM5&^&:J&3J!^;XR?
M@MI/6U-U?SEAY#9\OO7=O(*,UM:%K;LBPV>E0E+C-1V1ZU@:)3)196*I;##V
MHM%C),L$3,KE4^2]Y4^<A8SX:_#G],[@AR1UQRMX^T_;,5M[5?F_RB_LVVIZ
MSPB'GBAVC7$_Z;!O4"-GWBUBX/2)][./"6,13'RDP @9TSI2?^)]ZD/,'8?*
M#9NRHKID\&=C8U3HG0=#M)ZQ&;$M&9"=B65AD%V69!%L_G(2KK3=AD28];E3
MFHZ-8/$VJ!LI!N=U!_AA>'FMM"7/D7TN8C:/#_F)QUK,WMO4<I0=V[?LS2Y3
MM(C7\ZYJKEQL6W7BSP<]9(I!9E&.XF0CDTWQT<.2JMCKE,&5^.O48LG4Z^&8
MYQ[ZV,=@KNJE\).=FC]YNHMLW91\MLFA<:[9(XLR#!FV9LHY:YT>T0LTY:MT
MDVS5W(*HH%PBF0!#QT8.%W+7K/=./2.E=R\DMK\3>G'Q7-<]0,*7QZ>LJ]L;
ME_L)_LJU;)M-FM]EEVS^+CZ#KJM7B+@&+-W%S<<ZFFCEUA'#A%3"87".F+TR
MM%]*30%DXX<?+;M6Z4:Q[5G]M+2^XYVN6*XH3=CJ],K+Z,+(5.ITB 3A6Z5,
M25;HMXQM@BBZIC^(J=150)& '/;Z+W$7AMUP=V\W=W]7JSV3>7.Z&WS/UAKQ
M6M6YKKK5'66HX.+:F:N:3 :\MU*M\C7ZU;WDI *,F3K,9!)0;7*J15'^3K!9
M$XY?#D]-/B#R[U?S%XRU;;VI;?JWS-AAK9GN"U6_5-@\R5N3KY5+(QV I:[V
M_4@7#]-^Q3Q/D:%>MDE%D%LD3R0*^W7X:\F)_P")*Z?>M^(VT7^EMV[LX24+
M145M.,02</Z%4MP;DYAT/9%O9$.9-PD_JNOIN2DFRS51%^W=-$U6BJ3DB2A0
MF6COA.^CLIK9]5KMK+<VQ]I3+=RM/<D;1R$VH7;\K99$Q',I;EHV*L,?J%:9
M?2&57!O2:LZ2,=<^5"J9[,X"/SH@7;?W3"ZM_)?H1[@V;:]M<?L5"2V[P[G[
M:J=T[@(MM$1M_8LX#*IDDXJ%M.NY=\6=8-"YC&MIKBYV**.'3Q18/@\MX[:G
M7]ZV&V^F:_VWL#5?3>X UU"9W] ZZF4(62W%LZ*=0D?),Y%3))1@ZGE;S8%(
MF+S(-GC.(B:](/$44I!WW3!O5R(^$OZ7%NU!(1?%BE[ XM<AZ]%8D]8;QKV[
M=QVMPVV'"H(.ZQ+W*$OEON<3B*/.LDU7AH)I$/D2JG.S41.1+! ]_P##3=13
M>7,OC/NSCURTDGL[RNX#[1:Z0V=9)=;#FR6FK/,6".H\U<W94DL/KFPF:'8(
M1\[-E1:0Q#)O'"BCIPN?(58/ALNGC>.JQJ':VD.2&[MHPO3=XX;5\_2'';7E
MI?4Y'>7(';E8AF1L6Z<B5,.U:AKFN:S9/2MU"^,B_E^\P40,X?G,$RW60^&^
MZ?7''@ONOEWP-I]^XH\@.*E7SO"MSU2W7N&U,)YC17:<K8F#U395ZN4Y RZ<
M!X[F+?PSZ.<MI)JWR;Q$\JIJ!M9+=27E=?OA5''4 UK.RJ_*K'&]*LRNP(YN
M1&Q-IFF[_3XV;=W$VR?"B32S1E4@9JT>E)E*1!\EXZ1"8*0I0U;Z/70EZ)G.
M+@3I;D3L>(E^9._=FTJ'LW(K8$UR.W)$VRC;SL;165V%0YNLZRV94F\._J5C
M=KM&ZDTT</I5JU1D#J+$==\X3><(>E9PDZ*\#RRW7H>3V\PU_<:@VV#>Z[L"
M\(W:&UY6]0P5KGYLNO2+QL(\;IS,:MA1Z>5=R#Q<\>W+EV5),I"A7$Z8? 9;
MXCV];HZI?50M&QKMH]/<%GUEQ6XH5Z_6"H:^K--KN6$E,-#O*P[CI^-J4427
M:Q),P[R)E9B88R#Y^X4,9+*@9?ZK_0KU;TP]*R_5"Z.DWLWBAO;B+ZKOMLHD
M1LN\[ I=[U4WE8EO>"+I;+E[G87?JAMW9.3C)"3<P$I#MGC=9F8^4.Z$QU\Y
MB1O/[X<GDKR^CHUI"N-T=+KE_+6>#CU57$= [!KFBMM4C9D!&.'!2N'$9![#
MK,HT;**8PH=!$IC8P;.0%;WHP<+N6O6>Z<>D=*[EY);7XF]./BN:YZ@84OCT
M]95[8W+_ &$_V5:MDVFS6^RR[9_%Q]!UU6KQ%P#%F[BYN.=331RZPCAPBIA,
M-X^HM6H_X;WI6,.&?3;O^XIS=O.SE4^K>K+GLJT5B6VU2UK?2JA";"G*;+UB
MKT2O-)%H2JP\3$';QS+,8^LV7^%,ND?&5#:CCQ\)GTS(#247&<N:ML+E!R<L
MT9B9VQOZ6W7N&K/U]@S1#/;(ZIT'4[G!0*D0VE7"F&JLZSF'[DI,*N53G.8N
M U*Z-UIV_P!++K,<BNAI=-IW/;O&&R:_7W!P^D+U+KRLQ24&E;:;':P<:4Z#
M".CV4K2'LRTG4F#=!@I.UPCEJW1(X7[P8DY9U78_Q!777VET[;5LK86O>G7T
M\H-64VU6J))^JC;%V% .H"'G5'QSIOXC-UG;]8E8>+<O4'>(JNP3]PS31=N7
M&5 E#VS\+'TWH^D%GN$D/M?A;RMHC!Q-Z8Y%:[W_ +LEYF%V1'1^<5R3M3"\
M7*[,,U]W)IX+*$A&T4\.T<+E;J)]I"E",#X.&P;'MN]^MA:MQD:)[=LVV^-U
M@VHFPCHB'8I['F;CS1D;P1G$0"#:"BVA;.Y=83;,DTVB!.PB)2IE+C 7H0
M
M
M
M
M
M
M
M
M
M
M
M     >;KU-J%16LCBIU6MUAQ<K([N5O7KT'%PJUJM\@QCHQ_:K(K&M6QYRR/
M8V':-UGSK*KI1!JBF8^2)$P4/^JS4*G2F#J+IM7KM2C'TU-V-['5F$C8%@\L
M-FE'4Y9)YTSBFS1NXFK!-/5GCYT<N5W;I8ZJICJ',;(4X/B*/STWPXGXW= _
MI7\7P&1/C5OS66@_Q_\ 5G]'7E4 M<ZA_P 4VK_W.Z5_@U& *@7Q%'YZ;X<3
M\;N@?TK^+X#>CXJ'A]+<A.FI)<@M=(NVN[N!UUBN25&L$.H=M88VF1RS2.VP
MG&/R8[[)&(@"M;.J<IB&PI5TLE-WL8*8(R.M!U'[/U!NDGTMN/.@5F"^]NL3
M<=3U^R5V,?\ @M8USKJS5FO;/K3@C##I5C7T.33F.8X<K&3(9A$/<'3SW%RH
MA*_UK.(S+3WPX?(OB;HA@X-7N/W'/1$;$89-<H/7M)X^;5U!=KW8I-)!8QCO
M92IT:3DY18ZBAE5%5U53*9,?)@B2Z070GXE<[>G/QBY)1O4$ZG]5EK92%82\
MT34W*BB5RAZ_V!2IB1J5MJ%=JKS2$W)56%8241E5@R=.EU<1SANKA11)5-0X
M;W7OX1/@MM)HP8;-YK=4S8S"*<J/(ME>^1^GK>TC7:R7@K.F#:P<:Y!%FY51
MQW#'3*4QB_)G/8 G@YQ=/GB3U&-4):=Y;ZEBMEUF,>N9>IRY7<A7[M09YRU]
M$5G:/<H-RRG8!ZJD4F'")%3,GQ4DR.T'"9,$ 50>1'2SZG_0;U=L#E?TH^>N
MP-O\6M*1TWLW9W#7D>U;V:*A=8UMN^F;=/1K!%=K0[,G$0)%7DTXA(^CSF&+
M,ZS=PNJFFD4,S]9?FE%=0[X65+F/%5OR?G=,CH9]/50CE1ZUKMWJ').,UYL*
M&C'RR:+A_"QU[J,BDQ74(15=F5(YRE,;)<!8HZ3OYK+II_B <-_Z.NN0%;WC
M9_OI/4#_ !1*7_1MX1@/W]=_3=LU=U7NGQR,Z;6RK!6.KER",_U=#Z=S6XJ<
MU/M#2]+@Y@MJV1MR<GI)E'5&OU:H^D,))'P)-25BV)%VB+)U$F=K!L)O[@U\
M0UU+M>2'%GFOOWIX\5.+5K?PC+<DEP]K>ZK;MK:U4BI5O*KP#5+:+U[&1L9)
MNHU%1?PI*$RIG!$UD'#4SAHH$W4PWT7TENG+9U=?U:33T=P>XV6RPP%5P]4?
M6&Q1VMJK*6'+-[+^BFPXM%[G$#F=OCHD0R_?J+G*FEVX*%:SIW:-ZJ/78TR3
MGERIZH7(+B#QVVS9+K%:1XY<"Y5/3+TE4I%QG:+.O)J]L3FDTV"5LKLFQ20E
MT['(R":/CK.T4/ ;9",3XFSI;ZJZ?7#32%I@N;_4*Y'778W)N$@(W7G+SDK$
M[?HK&K0FJ]IR-FN=<J4?KZEJM;;#RSN'8DD<J+E;LY1='NERYQG(2@_&T_YA
M?$W\;LG\36RP%T$!3"^#<43U[J'J.<9+8Z\'=&E>7Z2FQ85YWBRS5-[6%M?H
MNG153**J=ZUZKFTC_3J9353SWLXR?&3!<$VA?ZMJC6FP]I7AXC'TK6M&MM_N
M#]SE,K=C5J= 2%BL#Q<RN<)%1;1,<L<^3?2X*7/;\@"ACT%*198#X83K17"7
M1=M(._4;GTO4T7!%2(OV%;X.0T'*3[#)C915:.IQ-=ADY<8-X\8H4W;W2]@3
MB_">?F3>/'[HG(?^.JY +(0  @#ZC7PYO!;G[?I3D%!+WGB;RU?2:%B/R#T#
M(EB',[:6GAX:V"]49P=*#G9<F2954DHQ6"GG+C!%%Y%3!>X8(M-!\L.J[T9>
MHWQ&Z>'43W@PYQ<1^;%Q:ZKXX<DII!\?;$7:W<O6*/#)2$S+.7EL=/XJXW&
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M[J*RP$FS7;NFDC"SNU><<I%/VKIHJNU<MGC%TFH11,YTSE-C)39QG&0%U\
M
M
M
M
M
M
M
M
M
M
M
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MTBMLK6>'V?%IX-#.)-LX7;N3&,B7"6%0L6@
M
M
M
M
M
M
M
M
M
M
M
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M&2V1OC$A UF28&,FZ+A;)F+W#<+;(
M
M
M
M
M
M
M
M
M
M
M                                                        /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>aldx-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-01T13:56:47.6965+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.aldeyra.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:aldx="http://www.aldeyra.com/20240630" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited" id="Role_StatementConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail2" id="DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical" id="Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>100040 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" id="Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>100050 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited" id="Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusiness" id="Role_DisclosureNatureOfBusiness">
        <link:definition>100080 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>100090 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisition" id="Role_DisclosureHelioVisionAcquisition">
        <link:definition>100100 - Disclosure - Helio Vision Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities" id="Role_DisclosureCashCashEquivalentsAndMarketableSecurities">
        <link:definition>100120 - Disclosure - Cash, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100140 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100150 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1" id="DisclosureCreditFacility1">
        <link:definition>100160 - Disclosure - Credit Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100170 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100190 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100200 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLegalProceedings" id="Role_DisclosureLegalProceedings">
        <link:definition>100210 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100220 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements" id="DisclosureSignificantAgreements">
        <link:definition>100230 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies" id="Role_DisclosureBasisOfPresentationPolicies">
        <link:definition>100250 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100260 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" id="Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>100270 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100300 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables" id="Role_DisclosureCreditFacilityTables">
        <link:definition>100310 - Disclosure - Credit Facility (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100320 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100330 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails" id="DisclosureBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - BASIS OF PRESENTATION (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail" id="Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Helio Vision Acquisition - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail" id="Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail">
        <link:definition>100360 - Disclosure - Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail" id="Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail">
        <link:definition>100370 - Disclosure - Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail" id="Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail">
        <link:definition>100380 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100420 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>100430 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail" id="DisclosureCreditFacilityAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Credit Facility - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail" id="Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail">
        <link:definition>100450 - Disclosure - Credit Facility - Schedule of Long-Term Debt (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail" id="Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail">
        <link:definition>100460 - Disclosure - Credit Facility - Schedule of Principal Payments Incuding End of Term Charges (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100480 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
        <link:definition>100500 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail">
        <link:definition>100510 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail">
        <link:definition>100520 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" id="Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail">
        <link:definition>100530 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail">
        <link:definition>100540 - Disclosure - Stock-Based Compensation - Summary of Employee Stock Purchase Plan Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail" id="Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail">
        <link:definition>100560 - Disclosure - Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail" id="Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail">
        <link:definition>100570 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails" id="DisclosureSignificantAgreementsAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Significant Agreements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - SUBSEQUENT EVENTS (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="aldx-20240630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:href="aldx-20240630.xsd#Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="aldx-20240630.xsd#Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" xlink:href="aldx-20240630.xsd#Role_StatementConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="aldx-20240630.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="aldx-20240630.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="aldx-20240630.xsd#Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:href="aldx-20240630.xsd#Role_DisclosureNatureOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:href="aldx-20240630.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisition" xlink:href="aldx-20240630.xsd#Role_DisclosureHelioVisionAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="aldx-20240630.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities" xlink:href="aldx-20240630.xsd#Role_DisclosureCashCashEquivalentsAndMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="aldx-20240630.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="aldx-20240630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="aldx-20240630.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1" xlink:href="aldx-20240630.xsd#DisclosureCreditFacility1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:href="aldx-20240630.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="aldx-20240630.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases" xlink:href="aldx-20240630.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLegalProceedings" xlink:href="aldx-20240630.xsd#Role_DisclosureLegalProceedings" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="aldx-20240630.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements" xlink:href="aldx-20240630.xsd#DisclosureSignificantAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEvents" xlink:href="aldx-20240630.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies" xlink:href="aldx-20240630.xsd#Role_DisclosureBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="aldx-20240630.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xlink:href="aldx-20240630.xsd#Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="aldx-20240630.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="aldx-20240630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="aldx-20240630.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables" xlink:href="aldx-20240630.xsd#Role_DisclosureCreditFacilityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="aldx-20240630.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:href="aldx-20240630.xsd#DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aldx-20240630.xsd#DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="aldx-20240630.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#DisclosureCreditFacilityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail" xlink:href="aldx-20240630.xsd#Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="aldx-20240630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:href="aldx-20240630.xsd#DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="aldx-20240630.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail2" xlink:href="aldx-20240630.xsd#DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" xlink:label="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SupplementalEndOfTermCharge" xlink:label="aldx_SupplementalEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HerculesCreditFacilityMember" xlink:label="aldx_HerculesCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AbbvieOptionAgreementMember" xlink:label="aldx_AbbvieOptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NetLoss" xlink:label="aldx_NetLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" xlink:label="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SecondAndThirdAnniversaryMember" xlink:label="aldx_SecondAndThirdAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_VolumeWeightedAveragePrice" xlink:label="aldx_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityTransactionCosts" xlink:label="aldx_LineOfCreditFacilityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="aldx_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FourthAndFifthAnniversaryMember" xlink:label="aldx_FourthAndFifthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonCreditableNonRefundableLicenseMaintenanceFees" xlink:label="aldx_NonCreditableNonRefundableLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="aldx_DeferredTaxAssetsValuationAllowancePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock" xlink:label="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_StateAndFederalMember" xlink:label="aldx_StateAndFederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FoundersMember" xlink:label="aldx_FoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ReverseRepurchaseAgreementsMember" xlink:label="aldx_ReverseRepurchaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_EquityIncentivePlanMember" xlink:label="aldx_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IncomeTaxLineItems" xlink:label="aldx_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonFoundersMember" xlink:label="aldx_NonFoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityInterestPaymentPeriod" xlink:label="aldx_LineOfCreditFacilityInterestPaymentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LoanFundedPriorToTheDateOfAmendment" xlink:label="aldx_LoanFundedPriorToTheDateOfAmendment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SixthAndSubsequentAnniversaryMember" xlink:label="aldx_SixthAndSubsequentAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonRefundablePayment" xlink:label="aldx_NonRefundablePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" xlink:label="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:label="aldx_AccruedGeneralAndAdministrativeExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" xlink:label="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SplitProfitsAndLossesPercentage" xlink:label="aldx_SplitProfitsAndLossesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IncomeTaxTable" xlink:label="aldx_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceFiveMember" xlink:label="aldx_TermLoanAdvanceFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_DirectorOfficerPrepaidExpenses" xlink:label="aldx_DirectorOfficerPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CsbuMember" xlink:label="aldx_CsbuMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" xlink:label="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:label="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MilestonePayments" xlink:label="aldx_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" xlink:label="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashReserveForIndemnitiesAndGuarantees" xlink:label="aldx_CashReserveForIndemnitiesAndGuarantees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceFourMember" xlink:label="aldx_TermLoanAdvanceFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SupplementalEndOfTermCharges" xlink:label="aldx_SupplementalEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreements" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashAndMoneyMarketFunds" xlink:label="aldx_CashAndMoneyMarketFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" xlink:label="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceTwoMember" xlink:label="aldx_TermLoanAdvanceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_JefferiesLimitedLiabilityCompanyMember" xlink:label="aldx_JefferiesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_UpfrontCashPayment" xlink:label="aldx_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedContingentConsiderationPayableInStockCurrent" xlink:label="aldx_AccruedContingentConsiderationPayableInStockCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IndemnificationObligationsClaimsOutstanding" xlink:label="aldx_IndemnificationObligationsClaimsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_JefferiesSalesAgreementMember" xlink:label="aldx_JefferiesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" xlink:label="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceOneMember" xlink:label="aldx_TermLoanAdvanceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ExistingEndOfTermCharge" xlink:label="aldx_ExistingEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceThreeMember" xlink:label="aldx_TermLoanAdvanceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MEEIAgreementMember" xlink:label="aldx_MEEIAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LegalProceedingsAbstract" xlink:label="aldx_LegalProceedingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonvestedFounderSharesMember" xlink:label="aldx_NonvestedFounderSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ServiceBasedAwardsMember" xlink:label="aldx_ServiceBasedAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_UnderwrittenPublicOfferingMember" xlink:label="aldx_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" xlink:label="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MilestoneMember" xlink:label="aldx_MilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommitmentsAndContingenciesLineItems" xlink:label="aldx_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityCommitmentCharge" xlink:label="aldx_LineOfCreditFacilityCommitmentCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityPrepaymentFeePercentage" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreement" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredLongTermLiabilityCharges" xlink:label="us-gaap_DeferredLongTermLiabilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease obligations, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised/Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sales estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available for sale carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available-for-Sale Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SupplementalEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SupplementalEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SupplementalEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities measured at fair value on a recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant-date fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_HerculesCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_HerculesCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules Credit Facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_HerculesCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AbbvieOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AbbVie Option Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AbbvieOptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AbbVie Option Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_HelioVisionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Helio Vision Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_HelioVisionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Helio Vision Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_HelioVisionIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Helio Vision Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Helio Vision Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reclassification of losses to net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Miscellaneous prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Miscellaneous, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Examination for the tax years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CREDIT FACILITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NetLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NetLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NetLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Proceedings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Matters and Contingencies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement right to purchase aggregate amount of equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement Right To Purchase Aggregate Amount Of Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement right to purchase aggregate amount of equity securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SecondAndThirdAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second and Third Anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SecondAndThirdAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second And Third Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SecondAndThirdAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second and Third Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Long-term lines of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining recognition period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_VolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volume-weighted average price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_VolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Volume Weighted Average Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_VolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Volume weighted average price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility, transaction costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional equity consideration issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expense current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_FourthAndFifthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth and Fifth Anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_FourthAndFifthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fourth And Fifth Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_FourthAndFifthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth and Fifth Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonCreditableNonRefundableLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-creditable non-refundable license maintenance fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonCreditableNonRefundableLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Creditable Non Refundable License Maintenance Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonCreditableNonRefundableLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-creditable non-refundable license maintenance fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line Of Credit Facility [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding at June 30, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets valuation allowance percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash, and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Relating to Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock Option Exercise Activity Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of stock option exercise activity table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_StateAndFederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_StateAndFederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_StateAndFederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State and Federal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_FoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founders member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument variable annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ReverseRepurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Repurchase Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ReverseRepurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Repurchase Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ReverseRepurchaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse repurchase agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of commissions and other offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued in connection with Helio Vision, Inc. acquisition milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,414,489 and 59,195,951 shares issued and outstanding, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Principal Payments Including the Supplemental End of Term Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs not yet paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Exercised/Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restrictions on Helio founders' shares, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IncomeTaxLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonFoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Founders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonFoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Founders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonFoundersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Founders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocated Share Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, vested restricted stock units, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSU granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityInterestPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payment period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityInterestPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Payment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityInterestPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility interest payment period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the period for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LoanFundedPriorToTheDateOfAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan funded prior to the date of amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LoanFundedPriorToTheDateOfAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Funded Prior To The Date Of Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LoanFundedPriorToTheDateOfAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan funded prior to the date of amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Employee Stock Purchase Plan Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled in common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation arrangement by Share based Payment Award Equity Instruments other than Options settled in Common Stock in period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation arrangement by Share based Payment Award Equity Instruments other than Options settled in Common Stock in period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SixthAndSubsequentAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sixth and Subsequent Anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SixthAndSubsequentAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sixth And Subsequent Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SixthAndSubsequentAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sixth and Subsequent Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonRefundablePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Refundable Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonRefundablePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonRefundablePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non refundable payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares issued and outstanding subject of vesting shares based on service requirements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Shares Issued And Outstanding Subject Of Vesting Shares Based On Service Requirements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock shares issued and outstanding subject of vesting shares based on service requirements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedGeneralAndAdministrativeExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedGeneralAndAdministrativeExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedGeneralAndAdministrativeExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative expense, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Notes 3, 9, &amp; 14)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Commitments and Contingencies, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected aggregate gross proceeds from issuance of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Stock To Be Issued Per Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Proceeds From Stock To Be Issued Per Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SplitProfitsAndLossesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Split Profits and Losses Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SplitProfitsAndLossesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Split Profits and Losses Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SplitProfitsAndLossesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Split Profits and Losses Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IncomeTaxTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance five member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_DirectorOfficerPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director &amp; Officer prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_DirectorOfficerPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director &amp; Officer Prepaid Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_DirectorOfficerPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Director &amp; Officer prepaid expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Exercisable, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Settled in common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Settled in Common Stock, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Settled in Common Stock, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, increase amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Increase (Decrease), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Increase (Decrease), Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CsbuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CSBU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CsbuMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CSBU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility prepayment fee percentage, thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Prepayment Fee Percentage Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit Facility Prepayment Fee Percentage Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with acquisition milestone shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock in Connection With Acquisition Milestone Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with Helio Vision, Inc. acquisition milestone, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring and Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restrictions on Helio founders shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Release of restrictions on Helio founders' shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: effect of discounting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, contingent consideration stock to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Equity Interests Issuable Number Of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, contingent consideration, equity interest issuable, number of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Exercisable, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payment extension period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Interest Payment Extension Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility interest payment extension period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashReserveForIndemnitiesAndGuarantees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Reserve For Indemnities And Guarantees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashReserveForIndemnitiesAndGuarantees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Reserve For Indemnities And Guarantees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashReserveForIndemnitiesAndGuarantees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserve for indemnification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Security Category [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Cash Equivalents And Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Cash Equivalents And Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average recognition period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance four member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SupplementalEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental End of Term Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SupplementalEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental End of Term Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_SupplementalEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Diluted Weighted-Average Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Equity Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalent - Reverse Repurchase Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalent - Reverse Repurchase Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalent - reverse repurchase agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Relating to Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">2024 remaining total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, 2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale fair value disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total of common stock equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premium on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashAndMoneyMarketFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashAndMoneyMarketFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashAndMoneyMarketFunds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock value in connection with acquisition milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Value in Connection With Acquisition Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with Helio Vision, Inc. acquisition milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance two member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, forfeitures, intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate at Period End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Commitment Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, vested restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies Limited Liability Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies limited liability company.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">upfront cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_UpfrontCashPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Cash Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedContingentConsiderationPayableInStockCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable in stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedContingentConsiderationPayableInStockCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contingent Consideration Payable In Stock Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_AccruedContingentConsiderationPayableInStockCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contingent consideration payable in stock current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 employee stock purchase plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Cash and cash equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IndemnificationObligationsClaimsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indemnification Obligations Claims Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IndemnificationObligationsClaimsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Obligations Claims Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_IndemnificationObligationsClaimsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding material claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_JefferiesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_JefferiesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_JefferiesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Jefferies Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Jefferies Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four Jefferies Sales Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock after FDA Approval prior to 10th Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock After F D A Approval Prior To Tenth Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock after FDA approval prior to tenth anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance one member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ExistingEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Existing End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ExistingEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Existing End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan Advance Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Advance Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TermLoanAdvanceThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan advance three member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Closing market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MEEIAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MEEI Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MEEIAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M E E I Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MEEIAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MEEI Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LegalProceedingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Proceedings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LegalProceedingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal Proceedings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonvestedFounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Founder Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonvestedFounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Founder Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_NonvestedFounderSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested Founder Shares [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available for sale unrecognized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale unrecognized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ServiceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Based Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ServiceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Based Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_ServiceBasedAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service based awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Cash Equivalents And Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Cash Equivalents And Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermLoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred research and development expenses, and deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Gross-up Payment in Event of Change of Control or Divesture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Gross Up Payment Change Of Control Or Divesture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax gross-up payment, change of control or divesture.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_MilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Expenses And Other Current Assets [Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityCommitmentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityCommitmentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Commitment Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityCommitmentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility, commitment charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale unrecognized gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit facility prepayment fee percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Prepayment Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of fee if the term loan is prepaid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reverse repurchase agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalent - reverse repurchase agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalent Reverse Repurchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalent reverse repurchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, weighted average remaining lease term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock after FDA Approval Prior to 12th Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock After F D A Approval Prior To Twelfth Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock after FDA approval prior to twelfth anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredLongTermLiabilityCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Long-Term Liability Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredLongTermLiabilityCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred collaboration revenue, long term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisitions of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" xlink:to="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_SupplementalEndOfTermCharge" xlink:to="aldx_SupplementalEndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_HerculesCreditFacilityMember" xlink:to="aldx_HerculesCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_AbbvieOptionAgreementMember" xlink:to="aldx_AbbvieOptionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_HelioVisionIncMember" xlink:to="aldx_HelioVisionIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_NetLoss" xlink:to="aldx_NetLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" xlink:to="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_SecondAndThirdAnniversaryMember" xlink:to="aldx_SecondAndThirdAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_VolumeWeightedAveragePrice" xlink:to="aldx_VolumeWeightedAveragePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LineOfCreditFacilityTransactionCosts" xlink:to="aldx_LineOfCreditFacilityTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="aldx_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_FourthAndFifthAnniversaryMember" xlink:to="aldx_FourthAndFifthAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_NonCreditableNonRefundableLicenseMaintenanceFees" xlink:to="aldx_NonCreditableNonRefundableLicenseMaintenanceFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_DeferredTaxAssetsValuationAllowancePercentage" xlink:to="aldx_DeferredTaxAssetsValuationAllowancePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock" xlink:to="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_StateAndFederalMember" xlink:to="aldx_StateAndFederalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_FoundersMember" xlink:to="aldx_FoundersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ReverseRepurchaseAgreementsMember" xlink:to="aldx_ReverseRepurchaseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_EquityIncentivePlanMember" xlink:to="aldx_EquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_IncomeTaxLineItems" xlink:to="aldx_IncomeTaxLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_NonFoundersMember" xlink:to="aldx_NonFoundersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LineOfCreditFacilityInterestPaymentPeriod" xlink:to="aldx_LineOfCreditFacilityInterestPaymentPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LoanFundedPriorToTheDateOfAmendment" xlink:to="aldx_LoanFundedPriorToTheDateOfAmendment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_SixthAndSubsequentAnniversaryMember" xlink:to="aldx_SixthAndSubsequentAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_NonRefundablePayment" xlink:to="aldx_NonRefundablePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" xlink:to="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:to="aldx_AccruedGeneralAndAdministrativeExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" xlink:to="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_SplitProfitsAndLossesPercentage" xlink:to="aldx_SplitProfitsAndLossesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_IncomeTaxTable" xlink:to="aldx_IncomeTaxTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TermLoanAdvanceFiveMember" xlink:to="aldx_TermLoanAdvanceFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_DirectorOfficerPrepaidExpenses" xlink:to="aldx_DirectorOfficerPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CsbuMember" xlink:to="aldx_CsbuMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" xlink:to="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" xlink:to="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:to="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_MilestonePayments" xlink:to="aldx_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" xlink:to="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CashReserveForIndemnitiesAndGuarantees" xlink:to="aldx_CashReserveForIndemnitiesAndGuarantees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TermLoanAdvanceFourMember" xlink:to="aldx_TermLoanAdvanceFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_SupplementalEndOfTermCharges" xlink:to="aldx_SupplementalEndOfTermCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CashEquivalentReverseRepurchaseAgreements" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CashAndMoneyMarketFunds" xlink:to="aldx_CashAndMoneyMarketFunds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" xlink:to="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TermLoanAdvanceTwoMember" xlink:to="aldx_TermLoanAdvanceTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_JefferiesLimitedLiabilityCompanyMember" xlink:to="aldx_JefferiesLimitedLiabilityCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_UpfrontCashPayment" xlink:to="aldx_UpfrontCashPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_AccruedContingentConsiderationPayableInStockCurrent" xlink:to="aldx_AccruedContingentConsiderationPayableInStockCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_IndemnificationObligationsClaimsOutstanding" xlink:to="aldx_IndemnificationObligationsClaimsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_JefferiesSalesAgreementMember" xlink:to="aldx_JefferiesSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" xlink:to="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" xlink:to="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TermLoanAdvanceOneMember" xlink:to="aldx_TermLoanAdvanceOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ExistingEndOfTermCharge" xlink:to="aldx_ExistingEndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TermLoanAdvanceThreeMember" xlink:to="aldx_TermLoanAdvanceThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_MEEIAgreementMember" xlink:to="aldx_MEEIAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LegalProceedingsAbstract" xlink:to="aldx_LegalProceedingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_NonvestedFounderSharesMember" xlink:to="aldx_NonvestedFounderSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_ServiceBasedAwardsMember" xlink:to="aldx_ServiceBasedAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="aldx_CashCashEquivalentsAndMarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_UnderwrittenPublicOfferingMember" xlink:to="aldx_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" xlink:to="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_MilestoneMember" xlink:to="aldx_MilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_CommitmentsAndContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LineOfCreditFacilityCommitmentCharge" xlink:to="aldx_LineOfCreditFacilityCommitmentCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_LineOfCreditFacilityPrepaymentFeePercentage" xlink:to="aldx_LineOfCreditFacilityPrepaymentFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CashEquivalentReverseRepurchaseAgreement" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" xlink:to="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredLongTermLiabilityCharges" xlink:to="us-gaap_DeferredLongTermLiabilityCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashAndMoneyMarketFunds" xlink:label="aldx_CashAndMoneyMarketFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreements" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredLongTermLiabilityCharges" xlink:label="us-gaap_DeferredLongTermLiabilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="aldx_CashAndMoneyMarketFunds" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredLongTermLiabilityCharges" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FoundersMember" xlink:label="aldx_FoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" xlink:label="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" xlink:label="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NetLoss" xlink:label="aldx_NetLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_18"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_FoundersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aldx_HelioVisionIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="aldx_NetLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aldx_HelioVisionIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLegalProceedings" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LegalProceedingsAbstract" xlink:label="aldx_LegalProceedingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_LegalProceedingsAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock" xlink:label="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FoundersMember" xlink:label="aldx_FoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonFoundersMember" xlink:label="aldx_NonFoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MilestoneMember" xlink:label="aldx_MilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:label="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" xlink:label="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ServiceBasedAwardsMember" xlink:label="aldx_ServiceBasedAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_FoundersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aldx_HelioVisionIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_NonFoundersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_MilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="aldx_ServiceBasedAwardsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonvestedFounderSharesMember" xlink:label="aldx_NonvestedFounderSharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="aldx_NonvestedFounderSharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" xlink:label="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreement" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ReverseRepurchaseAgreementsMember" xlink:label="aldx_ReverseRepurchaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_Cash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="aldx_ReverseRepurchaseAgreementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_MarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ReverseRepurchaseAgreementsMember" xlink:label="aldx_ReverseRepurchaseAgreementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="aldx_ReverseRepurchaseAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_DirectorOfficerPrepaidExpenses" xlink:label="aldx_DirectorOfficerPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="aldx_DirectorOfficerPrepaidExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedContingentConsiderationPayableInStockCurrent" xlink:label="aldx_AccruedContingentConsiderationPayableInStockCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="aldx_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:label="aldx_AccruedGeneralAndAdministrativeExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="aldx_AccruedContingentConsiderationPayableInStockCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="aldx_AccruedResearchAndDevelopmentExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="aldx_AccruedGeneralAndAdministrativeExpenseCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceOneMember" xlink:label="aldx_TermLoanAdvanceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HerculesCreditFacilityMember" xlink:label="aldx_HerculesCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceTwoMember" xlink:label="aldx_TermLoanAdvanceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceThreeMember" xlink:label="aldx_TermLoanAdvanceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityInterestPaymentPeriod" xlink:label="aldx_LineOfCreditFacilityInterestPaymentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceFourMember" xlink:label="aldx_TermLoanAdvanceFourMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" xlink:label="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceFiveMember" xlink:label="aldx_TermLoanAdvanceFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityCommitmentCharge" xlink:label="aldx_LineOfCreditFacilityCommitmentCharge"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityTransactionCosts" xlink:label="aldx_LineOfCreditFacilityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredLongTermLiabilityCharges" xlink:label="us-gaap_DeferredLongTermLiabilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityPrepaymentFeePercentage" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LoanFundedPriorToTheDateOfAmendment" xlink:label="aldx_LoanFundedPriorToTheDateOfAmendment"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" xlink:label="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SupplementalEndOfTermCharge" xlink:label="aldx_SupplementalEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ExistingEndOfTermCharge" xlink:label="aldx_ExistingEndOfTermCharge"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aldx_HerculesCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityInterestPaymentPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityCommitmentCharge" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityTransactionCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredLongTermLiabilityCharges" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityPrepaymentFeePercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LoanFundedPriorToTheDateOfAmendment" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_SupplementalEndOfTermCharge" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_ExistingEndOfTermCharge" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SupplementalEndOfTermCharges" xlink:label="aldx_SupplementalEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="aldx_SupplementalEndOfTermCharges" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="us-gaap_LineOfCreditFacilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LongTermDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" xlink:label="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_JefferiesLimitedLiabilityCompanyMember" xlink:label="aldx_JefferiesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_JefferiesSalesAgreementMember" xlink:label="aldx_JefferiesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_VolumeWeightedAveragePrice" xlink:label="aldx_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_UnderwrittenPublicOfferingMember" xlink:label="aldx_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="aldx_JefferiesLimitedLiabilityCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aldx_JefferiesSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aldx_VolumeWeightedAveragePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aldx_UnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IncomeTaxLineItems" xlink:label="aldx_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IncomeTaxTable" xlink:label="aldx_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_StateAndFederalMember" xlink:label="aldx_StateAndFederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="aldx_DeferredTaxAssetsValuationAllowancePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="aldx_StateAndFederalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="aldx_IncomeTaxTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxLineItems" xlink:to="aldx_DeferredTaxAssetsValuationAllowancePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxTable" xlink:to="aldx_IncomeTaxLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_EquityIncentivePlanMember" xlink:label="aldx_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_5.0"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CsbuMember" xlink:label="aldx_CsbuMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_EquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember_5.0" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="aldx_CsbuMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" xlink:label="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MEEIAgreementMember" xlink:label="aldx_MEEIAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SecondAndThirdAnniversaryMember" xlink:label="aldx_SecondAndThirdAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommitmentsAndContingenciesLineItems" xlink:label="aldx_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonCreditableNonRefundableLicenseMaintenanceFees" xlink:label="aldx_NonCreditableNonRefundableLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FourthAndFifthAnniversaryMember" xlink:label="aldx_FourthAndFifthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IndemnificationObligationsClaimsOutstanding" xlink:label="aldx_IndemnificationObligationsClaimsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SixthAndSubsequentAnniversaryMember" xlink:label="aldx_SixthAndSubsequentAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashReserveForIndemnitiesAndGuarantees" xlink:label="aldx_CashReserveForIndemnitiesAndGuarantees"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aldx_MEEIAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="aldx_SecondAndThirdAnniversaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_NonCreditableNonRefundableLicenseMaintenanceFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="aldx_FourthAndFifthAnniversaryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_IndemnificationObligationsClaimsOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="aldx_SixthAndSubsequentAnniversaryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="aldx_CommitmentsAndContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_CashReserveForIndemnitiesAndGuarantees" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AbbvieOptionAgreementMember" xlink:label="aldx_AbbvieOptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonRefundablePayment" xlink:label="aldx_NonRefundablePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_UpfrontCashPayment" xlink:label="aldx_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MilestonePayments" xlink:label="aldx_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SplitProfitsAndLossesPercentage" xlink:label="aldx_SplitProfitsAndLossesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aldx_AbbvieOptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_NonRefundablePayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_UpfrontCashPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_MilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_SplitProfitsAndLossesPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" xlink:label="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FoundersMember" xlink:label="aldx_FoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" xlink:label="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" xlink:label="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NetLoss" xlink:label="aldx_NetLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_FoundersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aldx_HelioVisionIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="aldx_NetLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aldx_HelioVisionIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FoundersMember" xlink:label="aldx_FoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ServiceBasedAwardsMember" xlink:label="aldx_ServiceBasedAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HelioVisionIncMember" xlink:label="aldx_HelioVisionIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonFoundersMember" xlink:label="aldx_NonFoundersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" xlink:label="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MilestoneMember" xlink:label="aldx_MilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" xlink:label="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" xlink:label="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_FoundersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="aldx_ServiceBasedAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="aldx_HelioVisionIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_NonFoundersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aldx_MilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonvestedFounderSharesMember" xlink:label="aldx_NonvestedFounderSharesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="aldx_NonvestedFounderSharesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" xlink:label="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail">
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:label="aldx_CashCashEquivalentsAndMarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:label="us-gaap_AvailableforsaleSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreement" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ReverseRepurchaseAgreementsMember" xlink:label="aldx_ReverseRepurchaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="aldx_ReverseRepurchaseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ReverseRepurchaseAgreementsMember" xlink:label="aldx_ReverseRepurchaseAgreementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="aldx_ReverseRepurchaseAgreementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceOneMember" xlink:label="aldx_TermLoanAdvanceOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_HerculesCreditFacilityMember" xlink:label="aldx_HerculesCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceTwoMember" xlink:label="aldx_TermLoanAdvanceTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceThreeMember" xlink:label="aldx_TermLoanAdvanceThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityInterestPaymentPeriod" xlink:label="aldx_LineOfCreditFacilityInterestPaymentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceFourMember" xlink:label="aldx_TermLoanAdvanceFourMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" xlink:label="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TermLoanAdvanceFiveMember" xlink:label="aldx_TermLoanAdvanceFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityCommitmentCharge" xlink:label="aldx_LineOfCreditFacilityCommitmentCharge"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityTransactionCosts" xlink:label="aldx_LineOfCreditFacilityTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredLongTermLiabilityCharges" xlink:label="us-gaap_DeferredLongTermLiabilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityPrepaymentFeePercentage" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" xlink:label="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LoanFundedPriorToTheDateOfAmendment" xlink:label="aldx_LoanFundedPriorToTheDateOfAmendment"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" xlink:label="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SupplementalEndOfTermCharge" xlink:label="aldx_SupplementalEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ExistingEndOfTermCharge" xlink:label="aldx_ExistingEndOfTermCharge"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="aldx_HerculesCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityInterestPaymentPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="aldx_TermLoanAdvanceFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityCommitmentCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredLongTermLiabilityCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityPrepaymentFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LoanFundedPriorToTheDateOfAmendment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_SupplementalEndOfTermCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="aldx_ExistingEndOfTermCharge" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" xlink:label="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_JefferiesLimitedLiabilityCompanyMember" xlink:label="aldx_JefferiesLimitedLiabilityCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_JefferiesSalesAgreementMember" xlink:label="aldx_JefferiesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_VolumeWeightedAveragePrice" xlink:label="aldx_VolumeWeightedAveragePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_UnderwrittenPublicOfferingMember" xlink:label="aldx_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="aldx_JefferiesLimitedLiabilityCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aldx_JefferiesSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aldx_VolumeWeightedAveragePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="aldx_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IncomeTaxLineItems" xlink:label="aldx_IncomeTaxLineItems"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IncomeTaxTable" xlink:label="aldx_IncomeTaxTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_StateAndFederalMember" xlink:label="aldx_StateAndFederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="aldx_DeferredTaxAssetsValuationAllowancePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="aldx_IncomeTaxLineItems" xlink:to="aldx_IncomeTaxTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="aldx_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="aldx_StateAndFederalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_IncomeTaxLineItems" xlink:to="aldx_DeferredTaxAssetsValuationAllowancePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="aldx_IncomeTaxTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_EquityIncentivePlanMember" xlink:label="aldx_EquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CsbuMember" xlink:label="aldx_CsbuMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_EquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="aldx_CsbuMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" xlink:label="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:label="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CommitmentsAndContingenciesLineItems" xlink:label="aldx_CommitmentsAndContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MEEIAgreementMember" xlink:label="aldx_MEEIAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SecondAndThirdAnniversaryMember" xlink:label="aldx_SecondAndThirdAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonCreditableNonRefundableLicenseMaintenanceFees" xlink:label="aldx_NonCreditableNonRefundableLicenseMaintenanceFees"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_FourthAndFifthAnniversaryMember" xlink:label="aldx_FourthAndFifthAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_IndemnificationObligationsClaimsOutstanding" xlink:label="aldx_IndemnificationObligationsClaimsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SixthAndSubsequentAnniversaryMember" xlink:label="aldx_SixthAndSubsequentAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashReserveForIndemnitiesAndGuarantees" xlink:label="aldx_CashReserveForIndemnitiesAndGuarantees"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aldx_MEEIAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="aldx_SecondAndThirdAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_NonCreditableNonRefundableLicenseMaintenanceFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="aldx_FourthAndFifthAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_IndemnificationObligationsClaimsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="aldx_SixthAndSubsequentAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="aldx_CommitmentsAndContingenciesLineItems" xlink:to="aldx_CashReserveForIndemnitiesAndGuarantees" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AbbvieOptionAgreementMember" xlink:label="aldx_AbbvieOptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_NonRefundablePayment" xlink:label="aldx_NonRefundablePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_UpfrontCashPayment" xlink:label="aldx_UpfrontCashPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_MilestonePayments" xlink:label="aldx_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_SplitProfitsAndLossesPercentage" xlink:label="aldx_SplitProfitsAndLossesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aldx_AbbvieOptionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_NonRefundablePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_UpfrontCashPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="aldx_SplitProfitsAndLossesPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" xlink:label="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="aldx_CashAndMoneyMarketFunds" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredLongTermLiabilityCharges" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreements" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashAndMoneyMarketFunds" xlink:label="aldx_CashAndMoneyMarketFunds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredLongTermLiabilityCharges" xlink:label="us-gaap_DeferredLongTermLiabilityCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreements" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_Cash" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="aldx_CashEquivalentReverseRepurchaseAgreement" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_CashEquivalentReverseRepurchaseAgreement" xlink:label="aldx_CashEquivalentReverseRepurchaseAgreement"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="us-gaap_OtherAssetsMiscellaneousCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aldx_AccruedContingentConsiderationPayableInStockCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aldx_AccruedResearchAndDevelopmentExpenseCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="aldx_AccruedGeneralAndAdministrativeExpenseCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedContingentConsiderationPayableInStockCurrent" xlink:label="aldx_AccruedContingentConsiderationPayableInStockCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="aldx_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="aldx-20240630.xsd#aldx_AccruedGeneralAndAdministrativeExpenseCurrent" xlink:label="aldx_AccruedGeneralAndAdministrativeExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermLoansPayable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LinesOfCreditCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="aldx_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_LineOfCreditFacilityInterestPaymentPeriod" name="LineOfCreditFacilityInterestPaymentPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_CashReserveForIndemnitiesAndGuarantees" name="CashReserveForIndemnitiesAndGuarantees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" name="IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_IndemnificationObligationsClaimsOutstanding" name="IndemnificationObligationsClaimsOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" name="IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" name="LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_SplitProfitsAndLossesPercentage" name="SplitProfitsAndLossesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="aldx_SupplementalEndOfTermCharge" name="SupplementalEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" name="NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="aldx_DirectorOfficerPrepaidExpenses" name="DirectorOfficerPrepaidExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_ServiceBasedAwardsMember" name="ServiceBasedAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_FourthAndFifthAnniversaryMember" name="FourthAndFifthAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_LoanFundedPriorToTheDateOfAmendment" name="LoanFundedPriorToTheDateOfAmendment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_TermLoanAdvanceTwoMember" name="TermLoanAdvanceTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_NetLoss" name="NetLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_SecondAndThirdAnniversaryMember" name="SecondAndThirdAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_NonCreditableNonRefundableLicenseMaintenanceFees" name="NonCreditableNonRefundableLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_ReverseRepurchaseAgreementsMember" name="ReverseRepurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod" name="LineOfCreditFacilityInterestPaymentExtensionPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_LineOfCreditFacilityTransactionCosts" name="LineOfCreditFacilityTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" name="CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_UpfrontCashPayment" name="UpfrontCashPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_NonRefundablePayment" name="NonRefundablePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_SupplementalEndOfTermCharges" name="SupplementalEndOfTermCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_MEEIAgreementMember" name="MEEIAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember" name="TaxGrossUpPaymentChangeOfControlOrDivestureMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_CashEquivalentReverseRepurchaseAgreement" name="CashEquivalentReverseRepurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_CsbuMember" name="CsbuMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_LineOfCreditFacilityPrepaymentFeePercentage" name="LineOfCreditFacilityPrepaymentFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_LegalProceedingsAbstract" name="LegalProceedingsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_CashEquivalentReverseRepurchaseAgreements" name="CashEquivalentReverseRepurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_LineOfCreditFacilityCommitmentCharge" name="LineOfCreditFacilityCommitmentCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_AccruedGeneralAndAdministrativeExpenseCurrent" name="AccruedGeneralAndAdministrativeExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_TermLoanAdvanceThreeMember" name="TermLoanAdvanceThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_CashAndMoneyMarketFunds" name="CashAndMoneyMarketFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter" name="LineOfCreditFacilityPrepaymentFeePercentageThereafter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_VolumeWeightedAveragePrice" name="VolumeWeightedAveragePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems" name="CashCashEquivalentsAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_SixthAndSubsequentAnniversaryMember" name="SixthAndSubsequentAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_JefferiesSalesAgreementMember" name="JefferiesSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_AccruedContingentConsiderationPayableInStockCurrent" name="AccruedContingentConsiderationPayableInStockCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_FoundersMember" name="FoundersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_DeferredTaxAssetsValuationAllowancePercentage" name="DeferredTaxAssetsValuationAllowancePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_NonFoundersMember" name="NonFoundersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock" name="ScheduleOfStockOptionExerciseActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="aldx_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_StateAndFederalMember" name="StateAndFederalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_HerculesCreditFacilityMember" name="HerculesCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" name="TwoThousandTwentyThreeEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" name="CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_ExistingEndOfTermCharge" name="ExistingEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_MilestoneMember" name="MilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_NonvestedFounderSharesMember" name="NonvestedFounderSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_TermLoanAdvanceOneMember" name="TermLoanAdvanceOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_HelioVisionIncMember" name="HelioVisionIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" name="GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember" name="TwoThousandTwentyFourJefferiesSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_TermLoanAdvanceFiveMember" name="TermLoanAdvanceFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_JefferiesLimitedLiabilityCompanyMember" name="JefferiesLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_TermLoanAdvanceFourMember" name="TermLoanAdvanceFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" name="BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" name="Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="aldx_AbbvieOptionAgreementMember" name="AbbvieOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="aldx_CashCashEquivalentsAndMarketableSecuritiesTable" name="CashCashEquivalentsAndMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210095184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALDEYRA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001341235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,421,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1968197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Hartwell Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lexington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">761-4904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208772080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashAndMoneyMarketFunds', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,029,723<span></span>
</td>
<td class="nump">$ 142,823,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashEquivalentReverseRepurchaseAgreements', window );">Cash equivalent - reverse repurchase agreements</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,317,836<span></span>
</td>
<td class="nump">4,987,317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">125,649,519<span></span>
</td>
<td class="nump">147,810,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">391,595<span></span>
</td>
<td class="nump">510,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">126,043,834<span></span>
</td>
<td class="nump">148,326,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">254,434<span></span>
</td>
<td class="nump">1,338,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,842,802<span></span>
</td>
<td class="nump">5,536,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of debt</a></td>
<td class="nump">15,242,327<span></span>
</td>
<td class="nump">15,146,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">255,039<span></span>
</td>
<td class="nump">239,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,594,602<span></span>
</td>
<td class="nump">22,260,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredLongTermLiabilityCharges', window );">Deferred collaboration revenue, long term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="nump">138,893<span></span>
</td>
<td class="nump">271,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,733,495<span></span>
</td>
<td class="nump">28,531,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 3, 9, &amp; 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,414,489 and 59,195,951 shares issued and outstanding, respectively</a></td>
<td class="nump">59,415<span></span>
</td>
<td class="nump">59,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">517,449,424<span></span>
</td>
<td class="nump">513,994,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9,658)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(419,188,842)<span></span>
</td>
<td class="num">(394,259,148)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">98,310,339<span></span>
</td>
<td class="nump">119,795,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 126,043,834<span></span>
</td>
<td class="nump">$ 148,326,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_CashAndMoneyMarketFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_CashAndMoneyMarketFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_CashEquivalentReverseRepurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalent - Reverse Repurchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_CashEquivalentReverseRepurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredLongTermLiabilityCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of long-term liability charges that are being deferred beyond one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredLongTermLiabilityCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210977984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">59,414,489<span></span>
</td>
<td class="nump">59,195,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">59,414,489<span></span>
</td>
<td class="nump">59,195,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209005120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 14,969,743<span></span>
</td>
<td class="nump">$ 6,962,907<span></span>
</td>
<td class="nump">$ 21,153,251<span></span>
</td>
<td class="nump">$ 18,198,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,038,064<span></span>
</td>
<td class="nump">3,379,750<span></span>
</td>
<td class="nump">6,248,420<span></span>
</td>
<td class="nump">8,947,167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,007,807)<span></span>
</td>
<td class="num">(10,342,657)<span></span>
</td>
<td class="num">(27,401,671)<span></span>
</td>
<td class="num">(27,145,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,637,836<span></span>
</td>
<td class="nump">1,882,800<span></span>
</td>
<td class="nump">3,448,105<span></span>
</td>
<td class="nump">3,561,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(477,601)<span></span>
</td>
<td class="num">(527,141)<span></span>
</td>
<td class="num">(976,128)<span></span>
</td>
<td class="num">(1,018,428)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,160,235<span></span>
</td>
<td class="nump">1,355,659<span></span>
</td>
<td class="nump">2,471,977<span></span>
</td>
<td class="nump">2,543,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,847,572)<span></span>
</td>
<td class="num">$ (8,986,998)<span></span>
</td>
<td class="num">$ (24,929,694)<span></span>
</td>
<td class="num">$ (24,602,677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">59,414,489<span></span>
</td>
<td class="nump">58,791,920<span></span>
</td>
<td class="nump">59,414,489<span></span>
</td>
<td class="nump">58,791,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">59,414,489<span></span>
</td>
<td class="nump">58,791,920<span></span>
</td>
<td class="nump">59,414,489<span></span>
</td>
<td class="nump">58,791,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077205189232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,847,572)<span></span>
</td>
<td class="num">$ (8,986,998)<span></span>
</td>
<td class="num">$ (24,929,694)<span></span>
</td>
<td class="num">$ (24,602,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) on marketable securities</a></td>
<td class="num">(6,629)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,658)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Reclassification of losses to net loss</a></td>
<td class="num">(6,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,658)<span></span>
</td>
<td class="nump">103,938<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(6,629)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,658)<span></span>
</td>
<td class="nump">103,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (16,854,201)<span></span>
</td>
<td class="num">$ (8,986,998)<span></span>
</td>
<td class="num">$ (24,939,352)<span></span>
</td>
<td class="num">$ (24,498,739)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077211611824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss), Net of Tax [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 151,008,029<span></span>
</td>
<td class="nump">$ 58,560<span></span>
</td>
<td class="nump">$ 507,770,045<span></span>
</td>
<td class="num">$ (103,938)<span></span>
</td>
<td class="num">$ (356,716,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,560,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,316,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,316,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, exercise of stock options</a></td>
<td class="nump">5,292<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">5,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock, employee stock purchase plan</a></td>
<td class="nump">52,559<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">52,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock, employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock, vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock, vested restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">103,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NetLoss', window );">Net loss</a></td>
<td class="num">(24,602,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,602,677)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">129,883,199<span></span>
</td>
<td class="nump">$ 58,801<span></span>
</td>
<td class="nump">511,143,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,319,315)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,801,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2023</a></td>
<td class="nump">137,243,213<span></span>
</td>
<td class="nump">$ 58,792<span></span>
</td>
<td class="nump">509,516,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372,332,317)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,791,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,621,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,621,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock, exercise of stock options</a></td>
<td class="nump">5,292<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">5,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock, exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NetLoss', window );">Net loss</a></td>
<td class="num">(8,986,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,986,998)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="nump">129,883,199<span></span>
</td>
<td class="nump">$ 58,801<span></span>
</td>
<td class="nump">511,143,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,319,315)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,801,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="nump">119,795,030<span></span>
</td>
<td class="nump">$ 59,196<span></span>
</td>
<td class="nump">513,994,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(394,259,148)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,195,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,436,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,436,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock, employee stock purchase plan</a></td>
<td class="nump">18,191<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">18,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock, employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock, vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock, vested restricted stock units, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(9,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NetLoss', window );">Net loss</a></td>
<td class="num">(24,929,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,929,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2024</a></td>
<td class="nump">98,310,339<span></span>
</td>
<td class="nump">$ 59,415<span></span>
</td>
<td class="nump">517,449,424<span></span>
</td>
<td class="num">(9,658)<span></span>
</td>
<td class="num">(419,188,842)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,414,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2024</a></td>
<td class="nump">113,419,441<span></span>
</td>
<td class="nump">$ 59,415<span></span>
</td>
<td class="nump">515,704,325<span></span>
</td>
<td class="num">(3,029)<span></span>
</td>
<td class="num">(402,341,270)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,414,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,745,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(6,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NetLoss', window );">Net loss</a></td>
<td class="num">(16,847,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,847,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 98,310,339<span></span>
</td>
<td class="nump">$ 59,415<span></span>
</td>
<td class="nump">$ 517,449,424<span></span>
</td>
<td class="num">$ (9,658)<span></span>
</td>
<td class="num">$ (419,188,842)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,414,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_NetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_NetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208603136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (24,929,694)<span></span>
</td>
<td class="num">$ (24,602,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,484,366<span></span>
</td>
<td class="nump">5,763,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense</a></td>
<td class="nump">95,781<span></span>
</td>
<td class="nump">187,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premium on marketable securities</a></td>
<td class="num">(697,119)<span></span>
</td>
<td class="num">(14,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="nump">122,263<span></span>
</td>
<td class="nump">131,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(330,519)<span></span>
</td>
<td class="nump">2,918,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,083,623)<span></span>
</td>
<td class="nump">137,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">141,560<span></span>
</td>
<td class="num">(7,323,007)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,196,985)<span></span>
</td>
<td class="num">(22,801,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(60,614,499)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(48,614,499)<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">18,191<span></span>
</td>
<td class="nump">52,559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,191<span></span>
</td>
<td class="nump">57,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(71,793,293)<span></span>
</td>
<td class="nump">7,256,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">142,823,016<span></span>
</td>
<td class="nump">144,419,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">71,029,723<span></span>
</td>
<td class="nump">151,675,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 884,500<span></span>
</td>
<td class="nump">$ 823,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209816672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NATURE OF BUSINESS </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the &#8220;Company&#8221; or &#8220;Aldeyra&#8221;), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s principal activities to date include research and development activities along with related general business planning, including raising capital.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209129648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BASIS OF PRESENTATION </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 7, 2024 (2023 Annual Report).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial information as of June 30, 2024, and the three and six months ended June 30, 2024 and 2023, respectively, is unaudited. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for the fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented, have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company&#8217;s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its current operating plan, and excluding any potential licensing and product revenue, the Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund the Company's currently projected operating expenses and debt obligations for at least the next 12 months from the date the financial statements are issued. The Company has based its projections of operating capital requirements on its current operating plan, which includes several assumptions that may prove to be incorrect, and the Company may use all of its available capital resources sooner than the Company expects. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company&#8217;s planned research and development activities and regulatory activities; commence or continue ongoing commercialization activities, including manufacturing, sales, marketing and distribution, for any of its product candidates for which the Company may receive marketing approval; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional funding, it could be forced to delay, reduce, or eliminate its research and development programs and its reproxalap commercialization efforts, whether alone or with others.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Curtailment of operations would cause significant delays in the Company&#8217;s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company&#8217;s management evaluates its estimates and assumptions on an ongoing basis. Management&#8217;s most significant estimates in the Company&#8217;s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes to significant accounting policies during the six months ended June 30, 2024, as compared to those identified in the 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Annual Report.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to this new standard. However, given the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment, this policy is not expected to have a material impact on the Company's consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to this new standard.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208415200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Helio Vision Acquisition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Helio Vision Acquisition</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Helio Vision Acquisition</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 28, 2019 (Closing Date), the Company acquired Helio Vision, Inc. (Helio) and thereby obtained rights to ADX-2191 pursuant to an Agreement and Plan of Merger dated as of January 24, 2019 (the Merger Agreement). As a result of the acquisition, the Company issued an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,407,006</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to the former securityholders and an advisor of Helio, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">246,562</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued in January 2021, pursuant to the terms of the acquisition agreement. In addition, the Company, subject to the conditions of the acquisition agreement, is contingently obligated to make additional payments to the former securityholders of Helio as follows: (a) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of common stock following approval by the FDA of a new drug application (NDA) for the prevention and/or treatment of proliferative vitreoretinopathy or a substantially similar label prior to the 10th anniversary of the Closing Date; and (b) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of common stock following FDA approval of an NDA for an indication (other than proliferative vitreoretinopathy or a substantially similar label) prior to the 12th anniversary of the Closing Date (the shares of common stock issuable pursuant to the preceding clauses (a) and (b) are referred to herein as the Milestone Shares), provided that in no event shall the Company be obligated to issue more than an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,248,885</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in connection with the Helio acquisition. If the Company ceases to use commercially reasonably efforts to develop and obtain regulatory approval for ADX-2191, subject to the terms and conditions of the Merger Agreement, ADX-2191 and related intellectual property rights may revert back to an entity designated by the representative of the former Helio stockholders. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, in the event of certain change of control or divestitures by the Company, certain former convertible noteholders of Helio will be entitled to a tax gross-up payment in an amount not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that liability accounting is not required for the Milestone Shares under FASB ASC Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (ASC 480). The Company also determined that the Milestone Shares meet the scope exception as a derivative under FASB ASC Topic 815, Derivatives and Hedging (ASC 815), from inception of the Milestone Shares through June 30, 2024. Accordingly, the Milestone Shares are evaluated under FASB ASC Topic 450, Contingencies (ASC 450) and the Company will record a liability related to the Milestone Shares if the milestones are achieved, and the obligation to issue the Milestone Shares becomes probable. At such time, the Company will record the cost of the Milestone Shares issued to the Helio founders as a compensation expense and to the other former securityholders of Helio as an in-process research and development expense if there is no alternative future use. No milestones related to the remaining Milestone Shares are considered probable of being achieved as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209138208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NET LOSS PER SHARE </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three and six months ended June 30, 2024 and 2023, diluted weighted average common shares outstanding is equal to basic weighted average common shares due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Three and Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,033,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,567,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,208,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total of common stock equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,765,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,775,253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208467008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, cash, cash equivalents, and marketable securities were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.4399999999999995%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized<br/>Gain</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized<br/>Loss</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and Cash<br/>Equivalents</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current<br/>Marketable<br/>Securities</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,434,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,434,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,434,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse repurchase agreements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,311,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Available for sale marketable securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,311,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and current marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.</span></div></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contractual maturities of all available for sale securities were less than one year at June 30, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, cash, and cash equivalents were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.689%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.598%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.598%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.598%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and Cash<br/>Equivalents</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,510,451</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,510,451</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,510,451</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,823,016</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,823,016</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,823,016</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> marketable securities held at December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210624896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FAIR VALUE MEASUREMENTS </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Quoted prices in active markets that are accessible at the market date for identical unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s assets measured at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.429%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities (b)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse repurchase agreements (c)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,897,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,897,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.429%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. government agency securities are valued based on observable market prices in active markets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. </span></div></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> liabilities measured at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 or December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments including clinical trial prepayments to contract research organizations and accounts payable are carried in the condensed consolidated financial statements at amounts that approximate their fair value based on the short maturities of those instruments. The carrying amount of the Company&#8217;s term loan under the Hercules Credit Facility (as defined in Note 9) approximates market rates currently available to the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210571344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PREPAID EXPENSES AND OTHER CURRENT ASSETS </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.52%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred research and development expenses, and deposits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,859,927</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,463,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,036,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">340,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Miscellaneous prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">421,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">183,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,317,836</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,987,317</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077212289904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACCRUED EXPENSES </span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 were:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.457%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,571,463</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,087,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,411,867</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,687,327</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">859,472</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,842,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,536,464</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208007424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CREDIT FACILITY</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CREDIT FACILITY</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s current and long-term debt obligation consists of amounts the Company is obligated to repay under its credit facility with Hercules Capital, Inc. (Hercules). In March 2019, the Company entered into a Loan and Security Agreement (Loan and Security Agreement or Hercules Credit Facility) with Hercules and several banks and other financial institutions or entities, from time-to-time parties thereto (collectively, referred to herein as Lender), providing for a term loan of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, subject to the satisfaction of certain conditions contained therein, that is secured by a lien covering all of the Company&#8217;s assets, other than the Company&#8217;s intellectual property. The Loan and Security Agreement provided for (i) an initial term loan advance of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at the Company&#8217;s option, which expired unutilized on April 15, 2019; (ii) three additional term loan advances of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million each, at the Company&#8217;s option, available to the Company upon the occurrence of certain pre-specified funding conditions prior to September 30, 2019 (2019 Tranche), March 31, 2020 (2020 Tranche), and March 31, 2021 (2021 Tranche); and (iii) a final additional term loan advance (Fourth Loan Tranche) of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million prior to December 31, 2021, at the Company&#8217;s option, subject to approval by the Lender&#8217;s investment committee. The 2019 Tranche was drawn down in full by the Company in September 2019 and the 2020 Tranche and 2021 Tranche expired unutilized prior to the Company satisfying the funding conditions for such tranche. On April 20, 2021, the Company entered into the First Amendment to the Loan and Security Agreement (First Amendment). The First Amendment, among other things, (i) increased the Fourth Loan Tranche from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and extended the deadline for drawing down the Fourth Loan Tranche to July 1, 2022; (ii) lowered the variable per annum rate of interest on borrowings under the Loan and Security Agreement from the greater of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (b) the prime rate (as reported in the Wall Street Journal or any successor publication thereto) plus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to the greater of (x) the Prime Rate (as defined therein) plus 3.10% or (y) 8.60%; (iii) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are required from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 1, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to July 1, 2022; and (iv) following the satisfaction of certain conditions, which conditions were satisfied in April 2021, further extended the expiration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC Topic 470, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and did not result in extinguishment.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 22, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (Second Amendment), which became effective as of December 31, 2022 (Second Amendment Effective Date). The Second Amendment, among other things, (i) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2023 to May 1, 2024; (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extended the Maturity Date from October 1, 2023 to October 1, 2024; (iii) extended the availability of the Fourth Loan Tranche commitment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which remained conditioned on approval by the Lenders&#8217; investment committee,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from May 1, 2023 to May 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">; and (iv) amended the Prepayment Charge (as defined therein) to equal </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the amount prepaid during the 12-month period following the Second Amendment Effective Date, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% thereafter. In addition, a supplemental end of term charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">292,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Supplemental End of Term Charge) shall be due on the earlier of (A) the Maturity Date, as amended, or (B) repayment of the aggregate amount of advances under the Loan and Security Agreement. The initial end of term charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,042,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (End </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of Term Charge) was paid</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2, 2023. The Second and Third Amendments were determined to be modifications in accordance with FASB ASC Topic 470, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and did not result in extinguishment.
</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 29, 2024, the Company entered into the Third Amendment to the Loan and Security Agreement (Third Amendment). The Third Amendment, among other things, extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2024 to October 1, 2024. On May 1, 2024, the Fourth Loan Tranche commitment expired unutilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Hercules Credit Facility, the Company incurred a commitment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, transaction costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">273,186</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">375,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon closing, the End of Term Charge, which was paid in October 2023, and the Company will be required to pay the Supplemental End of Term Charge. The fees and transaction costs are amortized to interest expense from 2019 through the Maturity Date using the effective interest method. The End of Term Charge was amortized to interest expense from 2019 through October 2023, and the Supplemental End of Term Charge is amortized to interest expense from December 2022 through the Maturity Date, both using the effective interest method. The effective interest rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024. At the Company&#8217;s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus all fees and other amounts due under the Loan and Security Agreement as of the date of such prepayment.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been funded under the Loan and Security Agreement and no additional amounts were available to the Company for borrowing.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term debt consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.05%;"></td>
        <td style="width:1.333%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.809%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.613%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.196%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental end of term charge</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,242,327</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,146,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future principal payments, including the Supplemental End of Term Charge, are as follows for the years ending December 31:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,292,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,292,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan and Security Agreement also contains certain events of default, representations, warranties and non-financial covenants of the Company. As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company was in compliance with all covenants of the Hercules Credit Facility in all material respects. In addition, subject to the terms of the Loan and Security Agreement, the Company granted the Lender the right to purchase up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s equity securities, or instruments exercisable for or convertible into equity securities, sold to investors in financings upon the same terms and conditions afforded to such other investors.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077303192608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders Equity</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, the Company entered into an Open Market Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> SM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with Jefferies LLC (Jefferies), as sales agent (2021 Jefferies Sales Agreement), under which the Company had the ability to offer and sell, from time to time through Jefferies, shares of common stock providing for aggregate sales proceeds of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock may be sold under the 2021 Jefferies Sales Agreement, and no sales had previously been made pursuant to the 2021 Jefferies Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208430480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INCOME TAXES </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> current or deferred tax provision expenses for federal and state income taxes have been recorded as the Company has incurred losses since inception for tax purposes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In assessing the realizability of net deferred taxes in accordance with Accounting Standards Codification (ASC) 740, Income Taxes (ASC 740), the Company considers whether it is more likely than not that some portion or all the deferred tax assets will not be realized. Based on the weight of available evidence, primarily the incurrence of net losses since inception, anticipated net losses in the near future, reversals of existing temporary differences, and expiration of various federal and state attributes, the Company does not consider it more likely than not that some or all of the net deferred taxes will be realized. Accordingly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% valuation allowance has been applied against net deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended (Section 382 and 383), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> percentage points over such stockholders&#8217; lowest percentage ownership during the testing period (generally three years). Transactions involving the Company&#8217;s common stock, within the testing period, even those outside the Company&#8217;s control, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#8217;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#8217;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Section 382 and 383 limitation (including the additional limitation for recognized &#8220;built-in-gains&#8221;) is sufficient so that no current impairment of its pre-ownership change tax attributes is required. The Company does not believe an ownership change has occurred from December 31, 2021, through June 30, 2024, based on a review of its equity history during that period. Any future ownership changes, including those resulting from the Company&#8217;s future financing activities, may cause its existing tax attributes to incur additional limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the Company is subject to tax in the U.S. (Federal and Massachusetts). The Company is open to examination for the tax years ended December 31, 2023, 2022, 2021, and 2020. In addition, any loss years remain open to the extent that losses are available for carryover to future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertain tax positions pursuant to ASC 740-10 which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. Accordingly, in the provision for income taxes, the Company recognizes interest accrued related to unrecognized tax benefits and penalties; however, management is currently unaware of any uncertain tax positions. As a result, the Company does not have any liabilities recorded including interest or penalties for uncertain tax positions.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inflation Reduction Act (IRA) was enacted on August 16, 2022. Based on review of the IRA, the Company does not expect any impact to its tax provision. In particular, the Company does not expect to pay Corporate Alternative Minimum Tax (CAMT) in the next few years based on its projected losses. The IRA introduces a 15% CAMT for corporations whose average annual adjusted financial statement income for any consecutive three-tax-year period preceding the tax year exceeds $1 billion starting in 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077317787360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCK-BASED COMPENSATION</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company approved the 2013 Equity Incentive Plan in October 2013, which was amended in June 2016 and June 2018, (Amended 2013 Plan). The Amended 2013 Plan provided for the granting of stock options, restricted stock units (RSU), stock appreciation rights, and stock units to certain employees, members of the board of directors and consultants of the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company's Board of Directors approved the 2023 Equity Incentive Plan (2023 Equity Plan) to replace the Amended 2013 Plan. On June 30, 2023, the Company's stockholders approved the 2023 Equity Plan at the Company's 2023 annual meeting of stockholders. Pursuant to the 2023 Equity Plan, the Company will not make any further grants under the Amended 2013 Plan following June 30, 2023, though awards previously granted under the Amended 2013 Plan will remain outstanding. The 2023 Equity Plan is effective for a period of ten years after June 30, 2023, and a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,450,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, in addition to shares of the Company&#8217;s common stock that are subject to awards granted under the Amended 2013 Plan that are outstanding as of such date and that are subsequently forfeited, cancelled, or expire before being exercised or settled in full, are authorized for issuance under the 2023 Equity Plan. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,542,805</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock available for grant under the 2023 Equity Plan.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022 the Company granted cash awards under its Management Cash Incentive Plan, as amended (the Management Cash Incentive Plan). The Management Cash Incentive Plan provides its participants with the opportunity to earn cash incentive awards for the achievement of goals relating to the performance of the Company and was adopted in 2016. The cash awards vest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in four annual installments from the date of grant based on continued service and entitle the employees to receive a cash payment, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value to the amount by which the then value of the Company&#8217;s common stock exceeds the base value. As of June 30, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was accrued as compensation expense for vested cash awards. There was no unrecognized expense as of June 30, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the Company granted performance cash settled bonus awards (CSBUs) under its Management Cash Incentive Plan. As the performance criteria had been met, the awards will vest in four annual installments from the date of grant based on continued service, and entitle the employees to receive a cash payment for each vested CSBU, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value of the closing price per share of the Company's common stock on the Nasdaq Capital Market (Nasdaq) on the payment date. As of June 30, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was accrued as compensation expense for CSBUs as the Performance Criteria was met in February 2023. There was no unrecognized expense as of June 30, 2024.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes stock-based compensation expense over the requisite service period. The Company's share-based awards are accounted for as equity instruments, except for cash awards and CSBUs, which are accounted for as liabilities. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amounts included in the consolidated statements of operations relating to stock-based compensation associated with the two equity incentive plans, cash awards, and CSBUs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are as follows: </span></span><span style=""></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.53%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.142000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">862,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,898,358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,053,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">901,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711,170</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,586,008</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,710,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,935,529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,573,540</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,484,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,763,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes activity relating to stock options under the incentive plans for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Term<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value(a)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,868,816</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.44</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,376,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">179,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,033,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.19</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,829,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.86</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#8217;s common stock on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the per share exercise price of the underlying options.</span></div></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, unamortized stock-based compensation for stock options outstanding was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.66</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. Total unrecognized compensation cost will be adjusted for future forfeitures, if necessary.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes activity relating to restricted stock units (RSUs) for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.746%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.658%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.277000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number<br/>of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">944,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settled in common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.29</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs granted during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The total grant date fair value of RSUs vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024. As of June 30, 2024, the outstanding RSUs had unamortized stock-based compensation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with a weighted-average remaining recognition period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.07</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and an aggregate intrinsic value of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,928,226</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2016 Employee Stock Purchase Plan (2016 ESPP). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the weighted-average grant-date fair value, and total stock-based compensation expense recognized related to the 2016 ESPP are as follows:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.389%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.676%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.676%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average grant-date fair value per share</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,505</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209837440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LEASES</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company currently leases an office used to conduct business. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise, the Company includes the renewal period in its lease term. As the Company&#8217;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. In November 2023, the Company entered into a lease amendment that extended the lease by 12 months through December 31, 2024 and contained two options to extend the term of the lease for an additional 12 months each. Each option shall be exercisable, if at all, by giving a nine month written notice to the landlord. In April 2024, the Company extended the option to extend the term of the lease for an additional 12 months into December 2025, which will have no impact on the balance sheet as the option to extend the term of the lease for an additional 12 months was accounted for as of December 31, 2023.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the Company maintained an unamortized Right-Of-Use asset with a corresponding operating lease liability of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> based on the present value of the minimum rental payments in accordance with ASC Topic 842, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The weighted average discount rate used for leases as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The weighted average remaining lease term as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.50</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The operating lease expense for the six months ended June 30, 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">140.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities and balance sheet presentation of the Company&#8217;s lease liabilities for all operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 is as follows:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 remaining total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,132</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: effect of discounting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255,039</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s gross future minimum payments under all non-cancelable operating leases as of June 30, 2024, are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.829%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:23.05pt;vertical-align:bottom;padding-right:0.01in;"><p style="margin-left:23.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease obligations</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,132</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,928</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">285,204</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077214552240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">COMMITMENTS AND CONTINGENCIES </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime. Through June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company had not experienced any losses related to these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">indemnification </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obligations and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related reserves were established.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-License Agreements</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MEEI Agreement</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is developing ADX-2191 pursuant to an Exclusive License Agreement with Massachusetts Eye and Ear Infirmary (MEEI) originally entered into in July 2016 between MEEI and Helio Vision, Inc., as amended, (MEEI Agreement). The Company assumed the MEEI Agreement in connection with its 2019 acquisition of Helio Vision.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant and subject to the MEEI Agreement, the Company obtained an exclusive, worldwide license from MEEI to develop and commercialize ADX-2191 under certain patents and patent applications, and other licenses to intellectual property (MEEI Patent Rights). The Company has agreed to use commercially reasonable efforts, to develop ADX-2191, and to meet certain specified effort and achievement benchmarks by certain dates.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration for the rights licensed under the MEEI Agreement, Helio Vision issued MEEI a number of shares of its preferred stock and Helio Vision agreed to pay non-creditable non-refundable license maintenance fees to MEEI of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on each of the second and third anniversary of the MEEI Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on each of the fourth and fifth anniversary of the MEEI Agreement and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the sixth and each subsequent anniversary of the MEEI Agreement during the term of such agreement. In addition, Helio Vision was obligated to make future sales-dependent milestone payments to MEEI of up to the low seven figures in the aggregate, as well as royalty payments to MEEI at a rate which, as a percentage of net sales, is in the low single digits for products that incorporate or use the MEEI Patent Rights in the United States and as a percentage in the low single digits for products that incorporate or use the MEEI Patent Rights outside the United States. The Company is also obligated under the MEEI Agreement to pay MEEI a percentage of certain sublicense revenue that it receives in connection with entering into any sublicensing arrangements with any third parties, at a percentage rate which tiers downward from low-double digits to mid-single digits based on the date of the sublicense. Following the Company&#8217;s acquisition of Helio Vision, the Company became obligated to make any future payments owed under the MEEI Agreement. There is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional equity consideration issuable under the MEEI Agreement.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MEEI Agreement will remain in effect until the expiration date of the last to expire patent licensed under the MEEI Agreement. The Company may terminate the MEEI Agreement with timely written notice to MEEI. MEEI has the right to terminate the MEEI Agreement if it, subject to certain specified cure periods, ceases all business operations with respect to licensed products, fails to pay amounts due under the MEEI Agreement, fail to comply with certain due diligence obligations, defaults in the Company's obligation to maintain insurance, one of the Company's officers is convicted of a felony relating to the manufacture, use, sale or importation of licensed products, the Company materially breaches any provisions of the MEEI Agreement or in the event of its insolvency or bankruptcy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of an early termination of the MEEI Agreement, all rights licensed and developed by the Company under the MEEI Agreement may revert back to MEEI. The Company has agreed to indemnify MEEI for certain claims that may arise under the MEEI Agreement.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 31, 2023, a purported stockholder filed a putative class action lawsuit (the Securities Class Action) in the U.S. District Court for the District of Massachusetts, against the Company and certain current and former officers, captioned Juliana Paice v. Aldeyra Therapeutics, Inc., et al. (No. 23-cv-11737). On January 2, 2024, the lead plaintiff filed an amended complaint. The lawsuit alleges violations by the defendants of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The plaintiff alleges that the defendants made false or misleading statements or failed to disclose certain information concerning (i) the New Drug Application (NDA) for and the prospects of ADX-2191 for the treatment of primary vitreoretinal lymphoma and (ii) the NDA for and the prospects of reproxalap for the treatment of dry eye disease. The lawsuit seeks, among other things, compensatory damages on behalf of herself and all persons and entities that purchased or otherwise acquired the Company's securities between January 7, 2021, and October 16, 2023, as well as attorneys&#8217; fees and costs. On March 4, 2024, defendants filed a motion to dismiss the amended complaint, the plaintiff filed its opposition to the motion on April 18, 2024, and defendants filed a reply to plaintiff's opposition on May 20, 2024. Oral argument on the motion to dismiss was heard on July 24, 2024. The Company disputes the plaintiff's claims and intends to vigorously defend the suit. At this time, the Company cannot reasonably predict the outcome or estimate potential losses, if any, that could result from this matter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2024, a purported stockholder of the Company filed a derivative complaint in the U.S. District Court for the District of Massachusetts, captioned Fawaz Al-Jaljouli v. Todd C. Brady, et al. (No. 24-cv-10585), against certain of the Company&#8217;s executive officers and directors, and naming the Company as a nominal defendant. The derivative complaint alleges, purportedly on behalf of the Company, breach of fiduciary duty and violations of Section 14(a) of the Securities Exchange Act of 1934. The claims are based on substantially identical allegations as the complaint in the Securities Class Action. The lawsuit seeks, among other things, an award of damages, certain changes to the Company&#8217;s corporate governance, and attorneys&#8217; fees and costs. On June 24, 2024, the plaintiff voluntarily dismissed all claims without prejudice.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, from time to time, the Company is subject to litigation and claims arising in the ordinary course of business but, except as stated above, the Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceedings against them that the Company believes could have a material adverse effect on the Company's business, operating results, cash flows, or financial condition.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077318141424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Agreements</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNIFICANT AGREEMENTS</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">AbbVie Option Agreement</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 31, 2023 (the Option Agreement Effective Date), the Company entered into an exclusive option agreement (the Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which the Company granted AbbVie an exclusive option (the Option) to obtain (a) a co-exclusive license in the United States to facilitate a collaboration with the Company to develop, manufacture and commercialize reproxalap in the United States, (b) an exclusive license to develop, manufacture and commercialize reproxalap outside the United States, (c) a right of first negotiation for compounds that are owned or otherwise controlled by the Company in the field of ophthalmology relating to treating conditions of the ocular surface, and (d) a right to review data for any other compounds that are owned or otherwise controlled by the Company in the fields of ophthalmology and immunology before such data is shared with any other third party (the Collaboration Agreement). AbbVie has paid the Company a non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in consideration of the Option (the Option Payment).</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 21, 2023, pursuant to the Option Agreement, AbbVie extended the period during which it may exercise the Option (the Exercise Period Extension) by paying the Company a non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Option Extension Fee). As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to the Company at any time during the period following the Option Agreement Effective Date until the earlier of (a) the tenth (10th) business day after the date, if any, that the Company receives approval from the U.S. Food and Drug Administration of the NDA for reproxalap in dry eye disease (the FDA Decision) and (b) the date that is eighteen (18) months after the Option Agreement Effective Date. If the Collaboration Agreement is entered into, the Option Payment and the Option Extension Fee will be credited against the upfront cash payment payable by AbbVie.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon AbbVie&#8217;s delivery of the agreement execution notice and the parties entering into the Collaboration Agreement, AbbVie would pay the Company a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront cash payment, less the Option Payment and the Option Extension Fee. In addition, the Company would be eligible to receive up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in regulatory and commercial milestone payments, inclusive of a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment payable if the FDA Decision is received prior to or after the execution of the Collaboration Agreement. In the United States, the Company would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for AbbVie and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for the Company. Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap. As of August 1, 2024, AbbVie has not exercised the Option.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had recognized </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> collaboration revenue and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of deferred collaboration revenue, long-term, related to the Option Agreement and Exercise Period Extension. During th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e three months ended  June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the deferred collaboration revenue was moved from a long-term liability to a current liability on the Company&#8217;s balance sheet as a result of the Option expiring pursuant to the terms of the Option Agreement in less than one year if not exercised. The Company concluded, using ASC 606 by analogy for recognition considerations as the Option Agreement was not considered to be a vendor-customer relationship, that the transaction price is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the Transaction Price), and all other amounts are excluded from the Transaction Price as they relate to fees that can only be achieved subsequent to the exercise of the Option. The Transaction Price was allocated to the single unit of account, the Option to enter into a future Collaboration Agreement which is a material right, as the Option Extension Fee and the Option Payment are creditable against the upfront payments payable by AbbVie if the Collaboration Agreement is entered into. The Company concluded that all other performance obligations were immaterial promises in the context of the Option Agreement and did not represent additional units of account. The Company will begin to recognize revenue, if and, when the Option is exercised or when the Option expires.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208888032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company&#8217;s management evaluates its estimates and assumptions on an ongoing basis. Management&#8217;s most significant estimates in the Company&#8217;s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes to significant accounting policies during the six months ended June 30, 2024, as compared to those identified in the 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Annual Report.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to this new standard. However, given the Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment, this policy is not expected to have a material impact on the Company's consolidated financial statements.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to this new standard.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077301947280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Weighted-Average Shares Outstanding</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:21.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:20.38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Three and Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,033,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,567,153</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,208,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total of common stock equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,765,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,775,253</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077302051424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, and Cash Equivalents</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024, cash, cash equivalents, and marketable securities were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:6.4399999999999995%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized<br/>Gain</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized<br/>Loss</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and Cash<br/>Equivalents</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current<br/>Marketable<br/>Securities</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,434,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,434,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,434,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse repurchase agreements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,311,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Available for sale marketable securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,311,618</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">486</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents, and current marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,029,723</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.</span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, cash, and cash equivalents were comprised of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.689%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.598%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.598%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.598%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.38%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and Cash<br/>Equivalents</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,510,451</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,510,451</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128,510,451</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,823,016</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,823,016</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,823,016</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210372864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about the Company&#8217;s assets measured at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.429%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,595,519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government agency securities (b)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reverse repurchase agreements (c)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,897,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,897,479</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.429%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.339%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.554%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds (a)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets at fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,312,565</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. government agency securities are valued based on observable market prices in active markets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208424832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 were:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.52%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.440000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred research and development expenses, and deposits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,859,927</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,463,783</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,036,223</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">340,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Miscellaneous prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">421,686</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">183,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,317,836</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,987,317</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209113152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023 were:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.457%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,571,463</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,087,937</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,411,867</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,687,327</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">859,472</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">761,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,842,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,536,464</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209820064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-term debt consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.05%;"></td>
        <td style="width:1.333%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.809%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.613%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.196%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Term loan payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,000,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Supplemental end of term charge</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">173,646</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unamortized debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,316</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,242,327</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,146,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Principal Payments Including the Supplemental End of Term Charges</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future principal payments, including the Supplemental End of Term Charge, are as follows for the years ending December 31:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,292,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,292,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209654176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amounts included in the consolidated statements of operations relating to stock-based compensation associated with the two equity incentive plans, cash awards, and CSBUs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> are as follows: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.53%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.222000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.142000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.222000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,034,174</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">862,370</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,898,358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,053,738</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">901,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">711,170</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,586,008</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,710,157</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,935,529</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,573,540</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,484,366</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,763,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock', window );">Summary of Activity Relating to Stock Options</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes activity relating to stock options under the incentive plans for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Term<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value(a)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,868,816</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.44</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,376,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.67</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">179,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,033,741</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.19</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,829,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.86</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#8217;s common stock on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the per share exercise price of the underlying options.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Activity Relating to Restricted Stock Units</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes activity relating to restricted stock units (RSUs) for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.746%;"></td>
        <td style="width:1.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.658%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.277000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number<br/>of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">944,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settled in common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">732,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.29</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Summary of Employee Stock Purchase Plan Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the weighted-average grant-date fair value, and total stock-based compensation expense recognized related to the 2016 ESPP are as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.389%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.676%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.676%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average grant-date fair value per share</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.44</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,505</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of stock option exercise activity table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077214550944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities and balance sheet presentation of the Company&#8217;s lease liabilities for all operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 is as follows:</span><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024 remaining total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,132</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: effect of discounting</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">255,039</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s gross future minimum payments under all non-cancelable operating leases as of June 30, 2024, are:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.829%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:7.902%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="padding-top:0.01in;text-indent:23.05pt;vertical-align:bottom;padding-right:0.01in;"><p style="margin-left:23.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease obligations</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">423,132</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,928</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">285,204</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210354432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210935440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Helio Vision Acquisition - Additional Information (Detail) - Helio Vision Inc [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 28, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination, stock issued | shares</a></td>
<td class="nump">1,407,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember', window );">Common Stock after FDA Approval prior to 10th Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration liability | $</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember', window );">Common Stock after FDA Approval Prior to 12th Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration liability | $</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember', window );">Common Stock after FDA Approval Prior to 12th Anniversary [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares', window );">Business combination, contingent consideration stock to be issued | shares</a></td>
<td class="nump">5,248,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember', window );">Tax Gross-up Payment in Event of Change of Control or Divesture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, contingent consideration liability | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember', window );">Founders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination, stock issued | shares</a></td>
<td class="nump">246,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, contingent consideration, equity interest issuable, number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=aldx_HelioVisionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aldx_FoundersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aldx_FoundersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077212396800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total of common stock equivalents</a></td>
<td class="nump">8,765,797<span></span>
</td>
<td class="nump">7,775,253<span></span>
</td>
<td class="nump">8,765,797<span></span>
</td>
<td class="nump">7,775,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total of common stock equivalents</a></td>
<td class="nump">8,033,741<span></span>
</td>
<td class="nump">6,567,153<span></span>
</td>
<td class="nump">8,033,741<span></span>
</td>
<td class="nump">6,567,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total of common stock equivalents</a></td>
<td class="nump">732,056<span></span>
</td>
<td class="nump">1,208,100<span></span>
</td>
<td class="nump">732,056<span></span>
</td>
<td class="nump">1,208,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208000896">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, and Cash Equivalents (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 71,029,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale carrying Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,311,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Available for sale unrecognized loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Available for sale unrecognized gain</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Available for sale fair value disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,434,204<span></span>
</td>
<td class="nump">128,510,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,434,204<span></span>
</td>
<td class="nump">128,510,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,434,204<span></span>
</td>
<td class="nump">128,510,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,595,519<span></span>
</td>
<td class="nump">14,312,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,595,519<span></span>
</td>
<td class="nump">14,312,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,595,519<span></span>
</td>
<td class="nump">14,312,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=aldx_ReverseRepurchaseAgreementsMember', window );">Reverse Repurchase Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashEquivalentReverseRepurchaseAgreement', window );">Reverse repurchase agreements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Total Cash and cash equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,029,723<span></span>
</td>
<td class="nump">142,823,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,029,723<span></span>
</td>
<td class="nump">142,823,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,029,723<span></span>
</td>
<td class="nump">$ 142,823,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available for sale [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems', window );"><strong>Cash Cash Equivalents And Marketable Securities [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available for sale carrying Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49,311,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Available for sale unrecognized loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(10,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Available for sale unrecognized gain</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Available for sale fair value disclosure</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Cash Equivalents And Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_CashEquivalentReverseRepurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalent reverse repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_CashEquivalentReverseRepurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=aldx_ReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=aldx_ReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209124960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210812544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value on a recurring basis</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077211393744">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 116,897,479<span></span>
</td>
<td class="nump">$ 14,312,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">27,595,519<span></span>
</td>
<td class="nump">14,312,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=aldx_ReverseRepurchaseAgreementsMember', window );">Reverse Repurchase Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,897,479<span></span>
</td>
<td class="nump">14,312,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | U.S. government agency securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">49,301,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">27,595,519<span></span>
</td>
<td class="nump">14,312,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Reverse Repurchase Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | U.S. government agency securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Reverse Repurchase Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | U.S. government agency securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Reverse Repurchase Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. government agency securities are valued based on observable market prices in active markets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. </span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=aldx_ReverseRepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=aldx_ReverseRepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210583520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Deferred research and development expenses, and deposits</a></td>
<td class="nump">$ 3,859,927<span></span>
</td>
<td class="nump">$ 4,463,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">1,036,223<span></span>
</td>
<td class="nump">340,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Miscellaneous prepaid expenses and other current assets</a></td>
<td class="nump">421,686<span></span>
</td>
<td class="nump">183,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 5,317,836<span></span>
</td>
<td class="nump">$ 4,987,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077214610048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 2,571,463<span></span>
</td>
<td class="nump">$ 3,087,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">2,411,867<span></span>
</td>
<td class="nump">1,687,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued other expenses</a></td>
<td class="nump">859,472<span></span>
</td>
<td class="nump">761,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 5,842,802<span></span>
</td>
<td class="nump">$ 5,536,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210154352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Apr. 20, 2021</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredLongTermLiabilityCharges', window );">Deferred collaboration revenue, long term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,292,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember', window );">Hercules Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Debt instrument annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_LineOfCreditFacilityInterestPaymentPeriod', window );">Interest payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod', window );">Interest payment extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-Term Debt, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">extended the Maturity Date from October 1, 2023 to October 1, 2024; (iii) extended the availability of the Fourth Loan Tranche commitment of $20 million, which remained conditioned on approval by the Lenders&#8217; investment committee, from May 1, 2023 to May 1, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_LineOfCreditFacilityCommitmentCharge', window );">Commitment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_LineOfCreditFacilityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Credit facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_LineOfCreditFacilityPrepaymentFeePercentage', window );">Credit facility prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_SupplementalEndOfTermCharge', window );">Supplemental End Of Term Charge</a></td>
<td class="nump">$ 292,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_ExistingEndOfTermCharge', window );">Existing End Of Term Charge</a></td>
<td class="nump">1,042,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember', window );">Hercules Credit Facility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities', window );">Loan agreement right to purchase aggregate amount of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember', window );">Hercules Credit Facility [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument variable annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember', window );">Hercules Credit Facility [Member] | Term Loan Advance One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember', window );">Hercules Credit Facility [Member] | Term Loan Advance Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember', window );">Hercules Credit Facility [Member] | Term Loan Advance Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line Of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt instrument, increase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_ExistingEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Existing End Of Term Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_ExistingEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_LineOfCreditFacilityCommitmentCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility, commitment charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_LineOfCreditFacilityCommitmentCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility interest payment extension period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_LineOfCreditFacilityInterestPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility interest payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_LineOfCreditFacilityInterestPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_LineOfCreditFacilityPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of fee if the term loan is prepaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_LineOfCreditFacilityPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_LineOfCreditFacilityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility, transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_LineOfCreditFacilityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan agreement right to purchase aggregate amount of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_SupplementalEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental End Of Term Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_SupplementalEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredLongTermLiabilityCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of long-term liability charges that are being deferred beyond one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredLongTermLiabilityCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=aldx_HerculesCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=aldx_TermLoanAdvanceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=aldx_TermLoanAdvanceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=aldx_TermLoanAdvanceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=aldx_TermLoanAdvanceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=aldx_TermLoanAdvanceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=aldx_TermLoanAdvanceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077205265504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility - Schedule of Long-Term Debt (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Term loan payable</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_SupplementalEndOfTermCharges', window );">Supplemental end of term charge</a></td>
<td class="nump">251,643<span></span>
</td>
<td class="nump">173,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(9,316)<span></span>
</td>
<td class="num">(27,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: current portion</a></td>
<td class="num">(15,242,327)<span></span>
</td>
<td class="num">(15,146,546)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_SupplementalEndOfTermCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental End of Term Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_SupplementalEndOfTermCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077213802864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility - Schedule of Principal Payments Incuding End of Term Charges (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Facility [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 15,292,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 15,292,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210990928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - Jefferies Sales Agreement [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aldx_JefferiesSalesAgreementMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of commissions and other offering costs</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aldx_JefferiesSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aldx_JefferiesSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208755280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_DeferredTaxAssetsValuationAllowancePercentage', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=aldx_StateAndFederalMember', window );">State and Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_DeferredTaxAssetsValuationAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_DeferredTaxAssetsValuationAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=aldx_StateAndFederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=aldx_StateAndFederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077212517872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation</a></td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average recognition period</a></td>
<td class="text">2 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">RSU granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining recognition period</a></td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=aldx_CsbuMember', window );">CSBU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
<td class="nump">2,928,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for issuance</a></td>
<td class="nump">3,542,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Additional shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=aldx_CsbuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=aldx_CsbuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210711456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share Based Compensation Expense</a></td>
<td class="nump">$ 1,935,529<span></span>
</td>
<td class="nump">$ 1,573,540<span></span>
</td>
<td class="nump">$ 3,484,366<span></span>
</td>
<td class="nump">$ 5,763,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share Based Compensation Expense</a></td>
<td class="nump">1,034,174<span></span>
</td>
<td class="nump">862,370<span></span>
</td>
<td class="nump">1,898,358<span></span>
</td>
<td class="nump">3,053,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share Based Compensation Expense</a></td>
<td class="nump">$ 901,355<span></span>
</td>
<td class="nump">$ 711,170<span></span>
</td>
<td class="nump">$ 1,586,008<span></span>
</td>
<td class="nump">$ 2,710,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208646432">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,868,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,376,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares, Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(179,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,033,741<span></span>
</td>
<td class="nump">5,868,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Exercisable, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,829,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.57<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Term, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 2 months 8 days<span></span>
</td>
<td class="text">6 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Term, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,996<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#8217;s common stock on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the per share exercise price of the underlying options.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077214612784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing market value of common stock</a></td>
<td class="nump">$ 3.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077211582784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at December 31, 2023 | shares</a></td>
<td class="nump">944,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod', window );">Settled in common stock | shares</a></td>
<td class="num">(212,441)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at June 30, 2024 | shares</a></td>
<td class="nump">732,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Settled in common stock | $ / shares</a></td>
<td class="nump">5.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 5.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation arrangement by Share based Payment Award Equity Instruments other than Options settled in Common Stock in period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Settled in Common Stock, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077210581472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Employee Stock Purchase Plan Activity (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share Based Compensation Expense</a></td>
<td class="nump">$ 1,935,529<span></span>
</td>
<td class="nump">$ 1,573,540<span></span>
</td>
<td class="nump">$ 3,484,366<span></span>
</td>
<td class="nump">$ 5,763,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share Based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,505<span></span>
</td>
<td class="nump">$ 26,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077208735440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 391,595<span></span>
</td>
<td class="nump">$ 510,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, weighted average remaining lease term (years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, weighted average discount rate</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 140,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077301993376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">2024 remaining total lease payments</a></td>
<td class="nump">$ 423,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: effect of discounting</a></td>
<td class="num">(29,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">393,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">255,039<span></span>
</td>
<td class="nump">$ 239,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">138,893<span></span>
</td>
<td class="nump">$ 271,631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 393,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077211162096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">2024 remaining total lease payments</a></td>
<td class="nump">$ 423,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating lease obligations, 2024</a></td>
<td class="nump">137,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating lease obligations, 2025</a></td>
<td class="nump">285,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating lease obligations, 2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating lease obligations, 2027</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209482768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_IndemnificationObligationsClaimsOutstanding', window );">Outstanding material claims</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CashReserveForIndemnitiesAndGuarantees', window );">Reserve for indemnification</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aldx_MEEIAgreementMember', window );">M E E I Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Additional equity consideration issuable</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_SecondAndThirdAnniversaryMember', window );">Second And Third Anniversary [Member] | M E E I Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NonCreditableNonRefundableLicenseMaintenanceFees', window );">Non-creditable non-refundable license maintenance fees</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_FourthAndFifthAnniversaryMember', window );">Fourth And Fifth Anniversary [Member] | M E E I Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NonCreditableNonRefundableLicenseMaintenanceFees', window );">Non-creditable non-refundable license maintenance fees</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_SixthAndSubsequentAnniversaryMember', window );">Sixth And Subsequent Anniversary [Member] | M E E I Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NonCreditableNonRefundableLicenseMaintenanceFees', window );">Non-creditable non-refundable license maintenance fees</a></td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_CashReserveForIndemnitiesAndGuarantees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Reserve For Indemnities And Guarantees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_CashReserveForIndemnitiesAndGuarantees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_IndemnificationObligationsClaimsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification Obligations Claims Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_IndemnificationObligationsClaimsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_NonCreditableNonRefundableLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-creditable non-refundable license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_NonCreditableNonRefundableLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aldx_MEEIAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aldx_MEEIAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_SecondAndThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_SecondAndThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_FourthAndFifthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_FourthAndFifthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_SixthAndSubsequentAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=aldx_SixthAndSubsequentAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140077209319904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Agreements (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_SplitProfitsAndLossesPercentage', window );">Split Profits and Losses Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aldx_AbbvieOptionAgreementMember', window );">AbbVie Option Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_NonRefundablePayment', window );">Non refundable payment</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_UpfrontCashPayment', window );">upfront cash payment</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_MilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_SplitProfitsAndLossesPercentage', window );">Split Profits and Losses Percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aldx_AbbvieOptionAgreementMember', window );">AbbVie Option Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_aldx_MilestonePayments', window );">Milestone payment</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_NonRefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Refundable Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_NonRefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_SplitProfitsAndLossesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Split Profits and Losses Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_SplitProfitsAndLossesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aldx_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aldx_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aldx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aldx_AbbvieOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aldx_AbbvieOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4A.[R/>0\Q/)XVP;=L&EY&%VN&;48T+?H'Y?<B[W)_H!Y4[^\#]02P,$%
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M&PDZQ#YY!,:H6*Q1E,=0]790SC?ELC2%HV9B%5/Y5=A-, U9Z%-(B=VQJ[M
M%C(2.OXI;M;%$8P]EWCX%#@WC!S@,/#9@?%$O=>J]P;5_\1S2,2T$A_%4/,2
MJ<K$W'&3_IK+.YJ%Z[B!PZ@FWX!S_=#W'$U^%\<(#2C1</,N+@BIC_O$LU8\
M&Q3_JY 2+0N1(=&67Y-LUAG^!@>.XP=Z/*<FI.-2PCP]\@8D\:D#FO30&Y&8
M>J%+S?+]5KX_7(/4FA<HR1<BX^BJJ4/7QCKD7[(.79)L=DFR^87(3J(1M-$(
M!I/Q<ZXXL*HF(*8H!)U,P,SU Y=I66C !0&!C-5RL(MS*0VPXVD9:,!Y#+/
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M)0#^7PJAWA[* =H3MLD_4$L#!!0    ( &V  5E6AT/@DP,  )\-   8
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MP54N']CA'6GK\11?PG)1_Z)#@_4!G%1"LJ(-AA$4M&R>^$NKPU$ \.@#[#;
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M-P%,%&^N TU#LEU]WETS":?G^C6#&Q3A"@#_;QB3+PV5H+N3Q7\#4$L#!!0
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MU?I5[KQTY@%S,F'Q#QJ)S?G &X"(K/$N%BOV_)V4#MG*7LABGO\%SX6LZPQ
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M_XF0#0'LWQJ^J>$0"AS^EA8_ 5!+ P04    " !M@ %9NER%>9P*  !?'
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M/M6]B+?W"-Y)X_'%>W%JJTP9R6EZ\=<R\\&A.?[>EG)"G&]'Y(%YZ6N9T]$
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M;K#QL22)7'@!?E]9Z&3[P@[Z_X0X_A=02P,$%     @ ;8 !6308CEY) P
M(0<  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULC55=<]HZ$'WG5^RX
M,WURL;$!<U-@)DGIM)TV94+:/G3Z(.P%:R)+KB1#\N_O2@9?>IO0/H#UL7OV
MK(YV-=TK?6]*1 L/E9!F%I36UA=19/(2*V;ZJD9).QNE*V9IJK>1J36RPCM5
M(DKB>!Q5C,M@/O5K2SV?JL8*+G&IP315Q?3C%0JUGP6#X+APR[>E=0O1?%JS
M+:[0?JF7FF91AU+P"J7A2H+&S2RX'%Q<#9V]-_C*<6].QN R62MU[R;OBUD0
M.T(H,+<.@=%GA]<HA ,B&C\/F$$7TCF>CH_H;WWNE,N:&;Q6XALO;#D+)@$4
MN&&-L+=J_PX/^8P<7JZ$\?^P;VW3.("\,595!V=B4''9?MG#X1Q.'";/.20'
MA\3S;@-YEF^89?.I5GO0SIK0W,"GZKV)')=.E)75M,O)S\YO2/>/RAA8HH95
MR31.(TNX;C?*#QA7+4;R#,88/BEI2P,+66#QJW]$?#I2R9'457(6\$,C^Y#&
M(21Q,CR#EW9)IAXO?09OP;3D<GN2)'R_7!NKZ4[\>"K?%F[X-)RKDPM3LQQG
M 16"0;W#8/[RQ6 <OSY#=MB1'9Y#_TM%SF(\S7#8AYO%'7S\O%K!<G$+JW>7
MMPN@NPVV1/II1&"R ,,?H&H%12<HD!S8R>%-:)"&4'#16-K?^ZM/ [9#394,
MN:H( (PC;X!:@;'D10H )\R?#1-@E2LFGO_)N6C0V3J&UZJJF7Q\^6*2#++7
M!B0=E' '52O#78GWX8[,-DI0IW'!:F516LZ$>&RY4OV#P;S19/X_8B6%AS6B
M!'S(1>/2WFA5^<#$J&XL\UU$;7Y+^]61^>_YA@29L\;07I.7I[%+1AE34R)^
M'35.^>7VHG>4Y*Z39$62G-98)TG/2^+DZ'VN'4'C3JMN=%Y2J^K.TJK\'B9A
MG*9A-AS .!R-LW P2GLW2N[0N&R(N=4\=\/6O)'<&LC2)(Q'8QB$23P)!W'<
MNU.6]*-S^ 6<5.4[)NB\#07*QJ,P^R>#+,RR49B,4GBJ,**3ME6AWOKF; BW
MD;;M8-UJU_\OV[;WGWG[>'QB>LLI>8$;<HW[V2@ W3;D=F)5[9O@6EEJJ7Y8
MTAN&VAG0_D;193E,7(#N59S_"U!+ P04    " !M@ %9ST*\.!<$  !I"@
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MLSK<.)W[3]FI=O@P]I>)X$@%">#]3"/*\H8,U/_;N/@74$L#!!0    ( &V
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M<$5SP(09#5X4&D#G6\[5<:$3=*-\^@=02P,$%     @ ;8 !6?#O=/<*"P
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MO<GX<:[0)%H:@.\S8WS]@Q9H_E^#B_\ 4$L#!!0    ( &V  5D"\9)-# ,
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M9J!*&%F^D@&J@)"9[%8"%<CD86L?VG+;[HFL=KI;&.;7[W=.2[(,QB%36_L
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MQX."E^^EEQ=GUJR$96N@\2*$&G;#.:4Y*7-O\:W"/G]Q*9URPBS%M25'VLO
MU<MK4ZA$D=L[&WN<PK;CI$&\C(C3)Q"/Q6>C?>[$!YU2NKE_#.\Z%Z>MBY?3
MG8"_UGHD#B9#,9U,#W?@'70A'P2\@R?P9DEB:NV5SD0;IOASMG#>HD3^VA9P
MQ#O<CL>R.7653.A\4#&)]IX&%R]^VC^>O-WA[6'G[>$N](M;1YR>#\XKU""Y
M;?X]#T%\R4G TTK:F&U\F1@D2SM*>>7 2@K+5"R5ECI1LA .E4$0HW=":3;B
M?J#\(\K5Y^*7V>P:$OU:*Q" \M30,QL+;W!U1X*ZPZ5.A73H 16?[8: 2XHZ
MY6PLI;+B7A9UWQ[GP.0>-^+I/I=>R.42JL::<&IE+/LJ2\YJJ&7@DX]'%4HN
M5*$\DCP,-WA/JEQ2&%=;:F+G8F!WMV\4,A[%G/ &7C^#L/6YVWREAXIQG$AK
MRR2L[?BJ(JM,ZD8A9^],64G]^.*GD^G^Z[<;/!/3%OA2@'V2;<%]$ G7F6'T
M!8M_)#YW.&MHX[QP*M-JJ1+)!W202+_?XLSS*HA33D.QJ,$YLJ"-!^&H)^SP
M9LAME:QEHMC_)+$UUJPM:9,\W$SI'@.E"L$G<!8LHU<F=Z^X1;,/)=,:ZGO8
MHK2JCR4%$Q)>/C0L62J"PY'(,# *3"PX3R,Q*WQNZBSGR-V.:@[!1 _,=IKN
MM%D5E&:Q\FH$&;(7:(EN1B#ED=Y'48-4ZUE!#>W+VJ-LAVQ7@U1P@O'CHFT1
MO2H>!7]8D(YEJJ 5*Y;6E-_S?K2C71UU[>IH9[.9Q^'.T<U[Y;.EYVYK9#\*
MF^6"3*PHU)9(<@E].^Y&_9KNE435;NRIT*D'Z"",,N)1)C"(J!M$2($+929M
M*%IL,2!7000>!^!>DS$8'XB9UIRNFR#L73P?=SP?[^3BAA+Z)G9K--9)U-@V
M=O\?HKC2XC=S3^4"Y<1!#4-X'SN!]W;./4I+VM2)2X,/\?+C;'ZY)Q1J#<1L
M-;RM0GM].9O?[N&<43CBU>3U4,PI"S*_Z;KBRR^F4HF8GDSV3L5565EV*TX'
MTYC)14'=SO==OW?A@!9[#\I>7\$]Y,S'7 -(1>"F&P= UP#V!D@S]9I.7UE(
MRRKHSN<V= R9IHK5!8+2GAMR@2?DC6ILL=N!L#$9T;$<%L56;[CB>$[%*>$:
M2CD<"G,2C[T!88GSX<8CNJ@3"\J4U@PNEV@6XCW2'U*[?S1LTLOM@0E!3.T@
M"N,>A?TL*&@E/"7 &,3(U(1VPY#H^.BYT6^)6-*818=F6Z3 %;*J"A5ZO[?&
M53$89M=P>V:Z$5?K6Q4?8=?2VS9\-D9IX*CI^(WJGTAM-Q^"TK%-XX6CI7HD
M/ID5FK@=B@S^;71^D4L>N]L2-XQ(H?<$5W@,<OJ3YJ!<(G.RZ^9<D>C[WXR6
MG]WW)^Z(Q=NEI2=>R+)3)92PUMV;X;^$=15'YA?Y\)2@WFP(ZDWOB=" SI2\
M5$7(3CM[^Y*(B<EJA(&6L][;5C>[T)B'+,DLLY3)F.[X=AJF=A 6@L.SY+K\
M^2S+_<42R$KP8-=8HZ+Q1LB?(%X&Z??1\+?QI%!)A;I\%']C3+A4A6$='7^J
M;E8*\+U*YD-1J5TQQX>P1B&<DT8=7.'8PHV$RF_K_X<J_;_)\P<K9ML('/=>
M8TNR67A9Y^K&L(AOM-W=[O> 67P-7IO''Q,^2XN@G2AHB:V3T6L\6=CX@AXO
MO*G"2_'">+QBAV5.$@];;(#OE\;X]H(/Z'XEN?@'4$L#!!0    ( &V  5G)
M?N&1#@,  &\&   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U5WV_;
M. Q^SU]!>,#A#O!JQX[CKI<$:+L-N\-^%&NW/1SN0;&96*@LN1*==/_]*-OU
M4B#-BRU*Y,?ODTEZL3?VWE6(!(^UTFX95$3-112YHL):N#/3H.:3C;&U(#;M
M-G*-15%V0;6*DCB>1[60.E@MNKT;NUJ8EI34>&/!M74M[,\K5&:_#*;!T\97
MN:W(;T2K12.V>(OTK;FQ;$4C2BEKU$X:#18WR^!R>G$U\_Z=PW>)>W>P!J]D
M;<R]-_XIET'L":'"@CR"X-<.KU$I#\0T'@;,8$SI P_73^CO.^VL92T<7AOU
M0Y94+8/S $K<B%;15[/_@(.>S.,51KGN"?O>-WL30-$Z,O40S QJJ?NW>!SN
MX2#@/'XA(!D"DHYWGZAC^5:06"VLV8/UWHSF%YW4+IK)2>T_RBU9/I4<1ZO/
M_-T_&N?@!BW<5L(B_'DGU@K=7XN(.(%WBXH![*H'2UX F\,GHZER\$Z76#Z/
MCYC8R"YY8G>5G 3\M]5GD,8A)'$R.X&7CFK3#B]] >^=L%KJ[:':_R[7CBP7
MQ__']/9PL^-POF$N7",*7 ;<$0[M#H/5'Z^F\_CO$V1G(]G9*?35M:F;ED17
MO&8#;Z5J"4OXT14:EJ\O=VBY;WH=#KZTY$CHDO4=4W(RUW$E=Q7"QBCN6\:$
MQA!JDD*IGU!Z+MQ-X+!HK23)^<WO_% )/ELC:L#'0K5<#+"QI@9BQ.*YK'*0
MM7^2)099KI=U !LR9"%:QV=M41WFKD0)@EN<^8W49,UZZ&+"S=OEO:LL(KN4
M<"L?GQ4J<)FA+[.)+S-?:^GD2^,).B #36N+BAO?,Z^9-/=D<0_G89RF83Z;
MPCS,YGDXS=+)9Z-WZ+P:9DY6%G[9N[=:DH,\3<(XF\,T3.+S<!K'DSM#0OE[
M> :.#ZW<"<7W[3A1/L_"_$T.>9CG69AD*1RKKNA@"-1HM]VH<XS;:NKGP;@[
M3M/+?HC\=N]'\2=AMY+%*]QP:'R69P'8?KSU!IFF&REK0SR@NF7%?P2TWH'/
M-X:+93!\@O$?L_H%4$L#!!0    ( &V  5E5:DS!OP,  (H)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;)U6WV_B.!!^YZ^PLJ=5*T7D)Q2Z@$39
MKNY66JDJV[V'TSV89$BL)C9K.]#>7W]C!T*Z#='I'@@>>^:;;\8SMF<'(9]5
M#J#)2UEP-7=RK7>WGJ>2'$JJAF(''%>V0I94HR@S3^TDT-0:E847^O[8*RGC
MSF)FYQ[D8B8J73 .#Y*HJBRI?+V#0ASF3N"<)AY9EFLSX2UF.YK!&O33[D&B
MY#4H*2N!*R8XD;"=.\O@]BXV^E;A!X.#:HV)B60CQ+,1_DCGCF\(00&)-@@4
M__:P@J(P0$CCYQ'3:5P:P_;XA/[%QHZQ;*B"E2C^9*G.Y\[$(2EL:57H1W'X
M'8[QC Q>(@IEO^10ZXY0.:F4%N71&!F4C-?_].68AY;!Q+]@$!X-0LN[=F19
M?J::+F92'(@TVHAF!C94:XWD&#>;LM825QG:Z<6*JMPEYDON?U9L3PO@6A'*
M4_*-RF?0=%, 64-22:89*'+UW<RHZYFGT;T!\9*CJ[O:57C!U9A\$USGBMSS
M%-*W]A[2;KB')^YW82_@UXH/2>2[)/3#N <O:G(16;RH)Q<V\G?I^&NY45IB
M!?W=%7:-&G>CFJZZ53N:P-S!ME$@]^ L/GX(QOZG'LYQPSGN0U^LL4O3"K=(
M;$F]EUT!=+'NQUUJ@NF%)KTN22RZ^1(X(]?^RG.IJ'.I'$ "242YDTQ!B@QO
M!RLJY2OC&7GB$A*1<?8/KKP1[I5FV&UPC*()9U5)B1X'5OB-1&X<Q6[HQSC^
M^&$2!N&G-Z/V>H?N &L17H_$R;;BJ2+AC3N:CMQ1,&UP3O^MI?=:@T?8@U2
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MY*:L%7!<$]4_'PT=D-T8Z1(M&MNZ*Z%I$-BPH,F+T@!H?RV$WB?F@'Z6I_\
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M:? CPBXW^-4&B@3P_4I*LW^@ [KOP.F_4$L#!!0    ( &V  5F9\/ -( ,
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MB!PA%)A:A\#H=8\7*(0#(AJ_&\R@+>D2M\<;]/=>.VE9,(,72OS@F5U-@V$
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M*$O>ZH<KNLQ0NP#ZGBME-Q-7H+T>9W\!4$L#!!0    ( &V  5D+J_$;-P(
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M3T 8!WV?<ZZ.A@G0OU#Q7U!+ P04    " !M@ %9YW6>UIH#  !-#P  &0
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MBRN2\!#'Z#,%+(DB2%]O4$A>KD?V:'?C :_67-X8+ZXV<(4>$?^R^4S%U;A
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MI1_>N9'S><CN?R)[8][OS?NGV/O\9[S2&:;Z;@T9;EDBPZ(KPR;UPM@-(DS
M9M?+89SO)/&U'_=Q;V0&O<S@+)EZ ZC("I.K'#98A1JL*8I =T"'M+?4X:[V
MP'63*-[3?ACG1DGL>T>TA[WV\"SM7!4@3@H-#P0DX740>WLZ#\/BR,6R/2PS
MZF5&9\D\)3 ZR&Z8!%[B["L<B O]*(B"/8GV3N'2C\8/*E9E+0F#)2*=JQA-
MBK80MQW%&U/+%EQA933- M\N$#H YY><J]>.+H_]:YC^ U!+ P04    " !M
M@ %9L1LL@B\(  !/1@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RU
MG&MOFT@4AO_*R%M5K93&,/B2M(FEQ QJ5HD:-6WWPVH_C/'81N7B#H.32/OC
M=P:P\6 \-MOC?F@,YCP'>.?Z,N;J.>$_TP5C KU$89Q>=Q9"+#]VNZF_8!%-
MSY,EB^4WLX1'5,A-/N^F2\[H- ^*PBZVK$$WHD'<&5WE^Q[YZ"K)1!C$[)&C
M-(LBRE]O69@\7W?LSGK'UV"^$&I'=W2UI'/VQ,3WY2.76]T-91I$+$Z#)$:<
MS:X[-_9'SQFJ@/R('P%[3K<^(W4IDR3YJ3;NIM<=2YT1"YDO%(+*/RLV9F&H
M2/(\?I70SB:G"MS^O*9[^<7+BYG0E(V3\*]@*A;7G8L.FK(9S4+Q-7G^S,H+
MZBN>GX1I_C]Z+HX=RHQ^EHHD*H/E=A3$Q5_Z4MZ(K0"[MR< EP'XV "G#'#J
M ?T] ;TRH%<+N+#V!/3+@/ZQIS0H P;YO2]N5GZG72KHZ(HGSXBKHR5-?<CE
MRJ/E#0YB5;*>!)??!C).C,:<30.!/.H'82!>T0=T,Y4[I.@T1'=Q4715$7CG
M,D&#\+T\XON3B]Z]>7_5%?($%*;KE\G<(AG>D\Q&#TDL%BDB\91-&^*).7Y@
MB._*"]]</5Y?_2TV EWFGR.,SQ"V,&XXG[$Y_&;)9;B5A]M-M^/WLA-S^)]9
M?(Z<(GNO(=P[(KMCY^&.X5XZFY+DY#QG#^]>;J,O,U0O47_G7]P)%J7_-)SE
M;4'M-5-5P_HQ75*?77=DRYDROF*=T=L_[('UJ4DO2)@+"2.0, \(ING<V^C<
M,]%EN9DQ+C5&LND)Z23A1?O V8K%&3M#81+/D6 \:A+;B&XK-B3,A821 C;(
M8:IO7XVLJ^YJ6\'=(P96_F]SG"9.?R-.WRC.O;SY'[[)FX]<-A%-"ACCVRH
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M2*+\XX+1*>/J /G]+$G$>D,EV+Q#9O0?4$L#!!0    ( &V  5G(TD:4T (
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M'S'*H: --_>R_0J]GZGCRR37_HG:/C? *&NTD54/M@HJ)KHW?>Z_PQ$@#,\
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MC#F6SHS>@/'6Q.8;(38!36JX\KNX<H9F.>%<NG(ZNRFUR-'8M_#Y;\W=/7R
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MW/?6"=4+)@WA,+?0J-&S1:E]N_(35*NB1<P4VH93#)>VQ8-V!^S^7"G<3UR
M\D]#\@=02P,$%     @ ;8 !6?I?M3(!!0  S1H  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&ULQ5EK;^(X%/TK5]G1JB.U)#'/=@$):$?;U5:+BNA\
M&.T'DY@0-8D9VT#97[^VDR8\4G>*@MH/)0_?XWM.[.N3N+NA[)DO"!'P$D<)
M[UD+(98WMLV]!8DQK]$E2>2=.64Q%O*4!39?,H)]'11'-G*<EAWC,+'Z77UM
MS/I=NA)1F) Q [Z*8\RV0Q+13<]RK=<+CV&P$.J"W>\N<4 F1$R78R;/[!S%
M#V.2\) FP,B\9PW<FQ%JJ@#=XBDD&[YS#(K*C-)G=7+O]RQ'940BX@D%@>7/
MFHQ(%"DDF<?/#-3*^U2!N\>OZ-\T>4EFACD9T>A[Z(M%S^I8X),Y7D7BD6[^
M)!DAG:!'(Z[_PR9KZUC@K;B@<18L,XC#)/W%+YD0.P&2:'D R@+008#;>".@
MG@74-=$T,TWK%@O<[S*Z :9:2S1UH+71T9)-F*C'.!%,W@UEG.A/!/6>KX92
M"!]&-):C@V.M[Q4,?#]4ASB"^R0=,.K&Q2T1.(R^RA;3R2U<?/D*7R!,X"&,
M(GF?=VTA\U+HMI?E,$QS0&_DT(('FH@%A[O$)_Y^O"WYY*30*ZDA,@+^M4IJ
M4'<N 3FH49+/Z-?#ZX9TZKG&=8U7?TOC!6;D:G:L\8 QG 1$S@H!LRWLMAOC
MK;X\V&#FPX^_)23<"Q+S?\OT3?MOE/>O*L$-7V*/]"PYU3EA:V+U?__-;3E_
ME(E3$=B>5(U<JH8)/94*4@F\7:G(BSHF9>13Q&N-J*K6NN_44-=>[W(R]GHB
MIV;.J6GD],]2,> @*(Q7S%M(<FH8Q)*5GGWPXX'$,\)*GZP1^J-/MB*P/15:
MN0JM3YX$K2JEJ@AL3ZIV+E7;.&"F"8XI$^%_4@*NZ_/QA"@3H'TT$=SCF6#L
M^D1BG9Q8QTCLNUY4)1.\)DR:!.D#/!HD>I6!)6$A]<MXF4$1; EF'-H0IZL(
MZH"/MV7KT,B(="+YZYS\M3'/1\(%"SU%/YWV4TF<P\7C9,J_&FN $?>C [LB
ML#T)7*=P&\XG5X$L@8K4J@IM7ZX=<^:^OQR6N;-2N8;'<EU"MOI<PI,<?_*V
M=&IC/=,NX1L.&3SA:%6ZK&:I[963FGM03<SYGZH/*O1!9ZF4&>PN-U3K''(S
M]GTJM\(TND:CU9=U 0+YE,6A)<XHI-'-7=MS2. <3LXMK)QK]G(EU5Z]5X9)
M\(MU_QW\U\*/FF_6>S/"J0H4QL\U.[]!$# 28$'DK).U7[[[>K!6\PWH'&AF
M"^6[-1<X\:4NI2(T2X9JX_!)G\/9N86U<XUVJ#^:#*?&%<P<_^&B? YSYA;N
MS&U_]AI6D4G+Y#J'Y7,+S^>:_=DIKW09Y/[:TSX<].=P<VYAYURSGT..VX*[
M>!G1+2&9I<O?[\813LPSHE)35Q7:_M>6PM6ASW9UJ%)75Q7:OER%JT-F5Y>]
M_&O#(A=''$9X%A&84P8AYRN<>*63(D/=7?'1->H@U#J8&.;N3Z57F#)D-F7J
MJQG<_5R%8JOG02F7BKQ51O@<3@T53@U]]O<]5.D'OJK0]N4J?"$R^[93AW_C
M:/C7FPW4<9J'P_\<I@\5I@^]8_J*S^9</7!N<O%FK \_V.:11,U&TY%_N40I
M*7MGPR F+-#[*%PNSZM$I'L'^=5\KV:@=RCLHGFZT?. 62"=+41D+D.=6EOV
MSM*]D_1$T*7>?IA1(6BL#Q<$^X2I!O+^G%+Q>J(ZR'>P^O\#4$L#!!0    (
M &V  5F&PY(/M0,  %H1   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;,U8;8_B-A#^*U9:57?2[>;%>6,+D8"D[55=:;7HV@^G?C#) -$F,;4-[/[[
MVDXV1R"@O38GW1>PG7D>CV>&!T_&!\J>^ 9 H.>RJ/C$V BQO3--GFZ@)/R6
M;J&23U:4E43(*5N;?,N 9!I4%J9C6;Y9DKPRHK%>>V#1F.Y$D5?PP!#?E25A
M+S,HZ&%BV,;KPF.^W@BU8$;C+5G# L2G[0.3,[-ER?(2*I[3"C%838RI?9?8
ME@)HBS]S./"C,5)'65+ZI"8?LXEA*8^@@%0H"B*_]C"'HE!,TH]_&E*CW5,!
MC\>O[+_HP\O#+ F'.2W^RC.QF1BA@3)8D5TA'NGA-V@.Y"F^E!9<?Z)#8VL9
M*-UQ0<L&+#TH\ZK^)L]-((X DJ<?X#0 YQ3@7@#@!H#?NH/; -RW[N U 'UT
MLSZ[#EQ,!(G&C!X04]:230UT]#5:QBNO5*$L!)-/<XD3T4+0].EF)D.=H3DM
M9?UQHC-X@Q:R*+-= 8BNT$6SY%F- ;V+09"\>"]QGQ8Q>O?C^[$II']J%S-M
M?)G5OC@7?,'HGE9BPU%299#UX./K>/\*WI1Q:8/CO 9GYEPE_'U7W2)L?4".
MY;@]_LS?#L=]Q_E_NR?_>?=.,'!;*5CSX4N5LB$,;I;G)3!EC%1KD.HAT/(%
M'=L]D!>]/#T0EGWHPN:4"_3Y#[D+^BB@Y'_W%4SMDMOODA+1.[XE*4P,J9(<
MV!Z,Z*<?;-_ZN2];0Y+%0Y(E Y%U\NJV>76OL4?3HJ I$3);.G/H\H^\+T$U
MMZ^YU9_2/K)'V/.<T=C<'\>^Q\X+L.=:7;OXW Z[H8M]OVN7G-MY@8_#D=?:
M=8+AM<'PK@;C48:7L'2#2)6A&/;RCW2K*[@) 4>?[Z%< NNMUJO<7UNM0Y+%
M0Y(E Y%U$N2W"?*_/Q7RA\SKD&3QD&3)0&2=O 9M7H-OJ$(UMW>L+A9V[< ]
M4:%SN]!W<' J0CUTX2C$7G@B0N=VV/)P@,-^$0K;6(178_$K5,!(H35HFLE+
M7\X%(^I"_389NLK^M>4Z)%D\)%DR$%DG1:,V1:/O3X9&0^9U2+)X2+)D(+).
M7FWK2S]D?4,A:LB/[R4CRY87HA,AZK$+;-L^4Z(>.]L+?<LZE:(>0R>P+7G)
M.M$B\ZA7+(&M=9/.44IWE:B;@7:U?1$PU>WOR?K,OIO;/>NQ>G&@>],O]/5;
MAWO"UGG%40$KN95U&TCE9'4C7T\$W>I.=4F%['OU< ,D Z8,Y/,5I>)UHC9H
M7Z=$_P)02P,$%     @ ;8 !6=?(@8("!0  ?!0  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&ULM5C;;MLX$/T5PBV*%D@M43?+J6,@L;.[7:#;H.GE
MH=@'6AK;1"71):DX_OLE*5F^R73C;%]L4>1<S@PY.IS!DO$?8@X@T6.>%>*J
M,Y=R<>DX(IE#3D27+:!0,U/&<R+5D,\<L>! 4B.49X[GNI&3$UITA@/S[HX/
M!ZR4&2W@CB-1YCGAJQO(V/*J@SOK%Y_H;"[U"V<X6) 9W(/\LKCC:N0T6E*:
M0R$H*Q"'Z57G&E^./5<+F!5?*2S%UC/24":,_="#]^E5Q]4>00:)U"J(^GN
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MIXHKKUI=U4"RA6G^3)B4+#>/<R *FEZ@YJ>,R?5 &V@:CL/_ %!+ P04
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MT:SI$0 7 FA_;2V>G-"8_;-2_@-02P,$%     @ ;8 !6?!-7/0H P  =@@
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MJ)+HM4N8[3A2!4[)Q"E,"N6&.,F[-W[D?6CC^T=BSVC#AC;L4D],SF&+FD.
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M=(D6YKB+F@$2:W1;ZUH"NJ.<EG6)YN3)'(-6:,D+D.B[X)?7A.? R,K$_ZA
M$DWY!K5:%S>@"67O4U\;0+N,G[<PLP8&OP#SM>8#% 8?$ [P""T7-^CB[3,9
MW_CK3.+.)':ZX7F3OZ]62DOS'?SI0VLD1OT2]FY,5$5RF'KFXU<@=^!E[]X,
MX^#3&<"P PS/J6?.KP1[B>Q&:J$)0\Q2HZK=_#[D1C1VHO;V[;(1#H<A3OU=
M#\RH@QF=A?E_H V!6#&Z(?8.J>9D^E :R>@(91@F'_&X'R7J4*)7H41]*-$)
M"AY'.!CUH\0=2OPJE+@/)3Y!"?HIDHXB>15%TD>1G'PFSRG\HP)B:_$=D1O*
ME5ED;7*"06(LR*:^-1TM*E=35D*;"N6:6_-+ &D#S/Q:"'WHV#+5_62R?U!+
M P04    " !M@ %9"<,@I7L#  #:#0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U-2YX;6RU5VUOVS80_BN$.@P)L$4O?DLS6X#SAF58VB!>VP]!/]#2V2(B
MDBY)Q2FP'[\CI<@>HK!I8"- S)-X]SR\>\0CQVNI[G4!8,@C+X6>!(4QJY,P
MU%D!G.HCN0*!;Q92<6K05,M0KQ30W#GQ,DRB:!ARRD20CMVS&Y6.965*)N!&
M$5UQ3M7W4RCE>A+$P=.#6[8LC'T0IN,57<(,S*?5C4(K;*/DC(/03 JB8#$)
MIO'):3RR#F[&9P9KO34F=BES*>^M<95/@L@R@A(R8T-0_'F ,RA+&PEY?&N"
M!BVF==P>/T6_=(O'Q<RIAC-9?F&Y*2;!<4!R6-"J-+=R_2<T"QK8>)DLM?M/
MUO7<$2)FE3:2-\YH<R;J7_K8)&++(4E><$@:A\3QKH$<RW-J:#I6<DV4G8W1
M[, MU7DC.29L569&X5N&?B8]DYPS@VDVFE"1DS,I#!-+$!D#30ZF><YL]FA)
MKD2M ;0.R<$Y&,I*?3@.#;*PL<*L03RM$9,7$(?D&C$*32Y$#OG__4-DWRXA
M>5K":>(-^%<ECD@O^HTD4=(GGV;GY."70T_<7IN:GHO;>T5JIL]2<_<W3B=7
M!KC^VI6$.G:_.[;]UD[TBF8P"?!CTJ >($A_?1</HS\\S/LM\[XO>OJQ,MI@
M-9$M:L6 8EB_K*2,ZRZJ=;"A"V:_XH<T&H</'?B#%G_@Q;^M5T10,(1AE;E@
M"Y8YZ73AU\$&/\8?MOA#+_XUN<"_*S)=*@!;0')W#7P.JK-2WEAOK-2H93K:
MH\9&>V!^W#(_]N9X:V> ;Q4SWTDF<:_.0;DZ$Z9U1><E=/$^?FW!W[=DWGO)
MS #!<Y?!?PJF[$C@9J\T-IJV]N1?\G/"\&*^,;UQM-F8HSU*HPF^8_);727V
M%N2#%+]G"E B5@-$H(G=MA*Y,TN685\'8D\-!@05&>X5 )V;4P.T+99X$$4O
M""9.-@P3+\-+62E3N,Q>LH4;[4 R?M"WIGW3L>)]MJQX'STKWC2MV-^U=JB9
M_C/-)![-;-I:[.]K,_;82&96S35N>U8.N]&-%_BMJ=_TRWBX3]WLHX/&FQ8:
M>_O<+G4S>G82ZG7H)MPZ;G-02W>IT-C_*F'JDW?[M+VX3.OC^F9Z?>NYIFK)
MA"8E+- U.AJA#E1]D:@-(U?N\#Z7!J\";EC@Y0N4G8#O%U*:)\,"M->Y]#]0
M2P,$%     @ ;8 !6>&E 7AB!   PQ<  !D   !X;"]W;W)K<VAE971S+W-H
M965T-38N>&ULQ5AM;]LV$/XKA%8,*9!%HOR2-+,-.%&*!6B:($ZV#\4^T-+9
M)BJ1&DG'*; ?/Y)29,NQB1ACT"^V*/&>XST\'1_=8,7%=[D 4.BYR)D<!@NE
MRO,PE.D""B)/> E,/YEQ41"EAV(>RE( R:Q1D8=Q%/7#@E 6C ;VWIT8#?A2
MY93!G4!R611$_+B G*^& 0Y>;MS3^4*9&^%H4)(Y3$ ]EG="C\(&):,%,$DY
M0P)FPV",SQ-\9@SLC#\IK.3&-3*A3#G_;@;7V3"(S(H@AU09"*+_GN 2\MP@
MZ77\4X,&C4]CN'G]@O[9!J^#F1()ESS_BV9J,0S. I3!C"QS=<]7?T =4,_@
MI3R7]A>MZKE1@-*E5+RHC?4*"LJJ?_)<$[%A@+M[#.+:(-XVZ.\QZ-0&G;=Z
MZ-8&7<M,%8KE(2&*C :"KY PLS6:N;!D6FL=/F5FWR=*Z*=4VZG1A,X9G=&4
M,(7&<P&@]U1)=#3.,FHVAN3HFE7II4<?T5$"BM!<?D2_H<=)@HX^?$0?$&7H
MAN:YGB$'H=++,N!A6B_ALEI"O&<).$8WG*F%1%<L@ZP-$.IXFJ#BEZ N8B=B
M ND)BO$QBJ.XLVM!;S#O[#=/W.:WJ=IGWHJFTVQ1Q^)U]^ ]?KU^N$K0Y&'\
M<#79L9P+I[DI'.>R)"D, UT9)(@G"$:__H+[T>^[J/$)EG@":]'6;6CK6O3.
M'MIT)<C)E MB"@L:"T'8W&8W(BQKC6_5 @12"\)0V^C;%XV)KA44\N]=Q'=]
M$N\3+/$$UB*^UQ#?<^;KI,RI0G>"SZBN)(;L+UQ*D.@.1*KYUL?)+C(K4%P5
M*G-</8VBD^X@?-HDR>GY4)(\@;5(ZC<D]9TDC:=3?8:AV]*>?DWE1=]NH)B"
MV)EN3L1#T\TG6.()K,7D:</DZ<]^ST]]$N\3+/$$UB+^K"'^S)G"7ROEMV09
MF>: 2O+#L+R+OPJGO_%F][;>:Z>G0TEY[0XW[EJ1?FHB_>2,=%G.A%8H*"5R
MX8JS0NEM.HZBK4B=G@Z-U!-8BQ0<K:5CY*1%2S[0 I4Y][[&Z#M)<3LZE!5?
M:&U:-A0U=M)R#T_ EG",[L%\>%$V-R>?U= LU25_FM.Y5=/':%SPY1[:G#X.
MK3DUVN8F]-M;D/ARV"8M7I,6OX=HJ%&W5$-_.[V<O@].+T]H;:;67P/8_3E0
MI]>N#ZT+M^G!6=-Y5<^B[:QY#X6/UQ(?.X6L_E*;@1"0H71]GMM3R5*TDR&O
MFKU&Z[G>J_>0XGBMQ;%;C#]H^2-)U6,I!4UWD^)35E_6:,YB\Q[2&Z^U-_Y_
MXAO]BV[(,RV6A5./N[T<3)M71>X+K<WP6I/CGR[*L5=5[A4M\8769G\MS+%;
MF;]-F+V6R9W7PLRK,/>%5M$2;G0]"Q!SVSV6^BC0DJIJ@#9WFP[UV/9EP_7T
MJKU]0\2<,HERF&G3Z.14UR=1=8RK@>*E[:%.N5*\L)<+(!D(,T$_GW&N7@;&
M0=.W'_T'4$L#!!0    ( &V  5G48>/T0@,  ,H4   -    >&PO<W1Y;&5S
M+GAM;-U876_:,!3]*Y&[3JTT-4#:0%9 VI J3=JF2NW#WBI#'+#DV)EC.NBO
MGV\<PD=]$>O#!@LJL>_Q.??8OFG<]DNS%.QAQI@)%KF0Y8#,C"D^AF$YF;&<
MEE>J8-(BF=(Y-;:KIV%9:$;3$DBY"#NM5ASFE$LR[,MY?I>;,IBHN30#TFU"
M@;M]20>D'5^3P,F-5,H&Y.GB_<^Y,K?O G<_^W!VUGJZO-V-7U3 )0F]HC<'
MB%ZU6K@P@)AX?)CX/FU,NGN0]!YE3+BW+;SR<6ZE&E/G&#GQD-=,C-9M>7-N
M9*R(85TFPWZFY+I:(N("5IGF+'BF8D!&5/"QYL#*:,[%TH4[$)@HH71@;)G:
M5&V(E"\.;KL>5'"MDW.I=)7;97#?XWKX#K#J@4$N1&.P0UQ@V"^H,4S+.]NI
M!E?!5U!0MQ^7A74XU739[MR0-:&ZV21CI5.FFS1ML@H-^X)E8$?SZ0SN1A4A
M@,:HW#923J=*TLK#BE$WK.R$"?$ C_>/;$M[D6WL6;5CLFE:0W73R;@.Z&^J
M.>U-V>LWZ08%?U;F\]Q.1U9]*&QVKUG&%U5_D34&,/4VKDZ+0BP_"3Z5.7.3
M/SCAL$]7O&"F-'^QV:!4)C; - F>F39\LAGYI6GQR!9F54Z+#/?<.4'/?W>=
MITPR3<6F:5O[Q[S*;W8<=?^5Y>JWRJYAK\?ZG7WL)F].P61\"B9/HB9[IV R
M.7Z3T0EXK,^61V<RK$]"&\>MK<-6$PW@4#L@W^%X+-9)@_&<"\-EW9OQ-&7R
MU9G+RALZMG^H;>G;\2G+Z%R8QP8<D'7[&TOY/$^:4?>P$/6H=?LK3*\=-R=J
MFXO+E"U8.JJ[>CJNFH%MV*SU!81=Y*ZZ_ C&<9@? 0S+@SG .(Z%Y?F?YM-#
MY^,PS%O/B_103@_E.)8/&54?+(^?D]C+/],DB:(XQE9T-/(Z&&'K%L?PXU?#
MO $#RP.9_FRM\=W&*V1_'6![NJ]"L)GBE8C-%%]K0/SK!HPD\>\VE@<8V"Y@
MM0/Y_7F@IOR<*()=Q;QA3S".) F&0"WZ:S2.D=6)X>/?'^PIB:(D\2. ^1U$
M$8; TX@CF /P@"%15+T'=]Y'X>H]%:[_>SG\#5!+ P04    " !M@ %9EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M &V  5DYD8.LJP0  %$E   /    >&PO=V]R:V)O;VLN>&ULQ9I;3^,X%(#_
MBM67[4K+MLV%F4'3D0I#=RH!K:8LKRN3N-3"L;NV \S\^CUQ*>/T<K0OAS[1
M7'"^G#C^SK'S^=G8QWMC'ME+I;0;=I;>K\YZ/5<L1<7=GV8E-!Q9&%MQ#YOV
MH>=65O#2+87PE>HE_?YIK^)2=[Y\WK0UL[UXPWA1>&DT[&QVW$GQ['X=;S;9
MDW3R7BKI?PP[X;<2'59)+2OY4Y3#3K_#W-(\?S-6_C3:<S4OK%%JV!FL#]P)
MZV6QLWO>0-[R>Q?V>'[_G0/(L'/:AP87TCH?S@CM<V!\$G#R>JOV9BR5%_8K
M]^(O:^J5U ]-,W 7O>@V0APV?]=!/+/_)XQFL9"%^&J*NA+:K^-HA6H M5O*
ME>LPS2LQ[&Q.82-=LDOM(4ALHM=-P;G-G<*E)^7ZKCW@1C&T9Q(.V$D9P.D@
M+V#;*%G"U4MVSA77A6 AN(YU_XXA$P0R.2+D/TD$F2*0Z3M"SAN(YA\<,PLV
M70D;068(9'8TR M3K2+('(',CP8Y]Z:(($\1R-/C19*[903Y 8'\0 MYPWUM
M1<-T7CNIA7,1UT>$ZR,MUSEW,H1J9H6#4[<'Q$\(VB=:M&]"2</NX+)&LU'Q
M;PV_MH?K/C9>]XD?*;1[99QC,V%A#.16Q&2H2:A5 MW^C]#YV26$[8FK\$)P
ML-\UMX\Q)N:2 ;%,QEQ:=L=5+=BUX [>C_#BQGB810;$&H$W8L4E) POT(@3
MZ_A-_1*>]D5M8XT,,(\,B$4R*@I;BU^8,1>FC@&U.ZPHI6=C7H2L-,;"9#$@
MMD7CK<>E4:6P[K?P>K39,$<,B"4QT86I!+OE+^W'B/EA0"R($*\3T 1TL28Q
M@3ZVDS1CDA@06^(*1HY6M!+,"0FQ$R!"E?35VW +N8F'JD?H0K8A,3TDQ'J8
MRP<MX5S>5$0/5NP,NPE:81!;86]&PKHS2/&V@XC9(2&VPZ[]61=*7R7<[S$B
M9H:$NL3 TH!6L99@HDB(17$@#=B$,\;$Q)$0BP--!]K1Q!R2$#MD.QW8VRLQ
MH23$0MG*"_;R84))B(5R2'BOH/$4!V::E-@T:^_MBUZ*N24E=LOY:#Z9L^F8
MS;Y?SB]O;D>WD^D-ZX[*<KMV2S')I,22.51;LA/6H,:8Z$36^TOF)'3*.F@Q
MQL1$DQY5-&F,B8DFI:Y(4,PLQL1$DQ*+YI /UUW3QYB8:%)BT1S&G$/K98R)
MZ28EU@VN[5;?Q*R3$EMG1]NO8:Q5F#2,YZPQZV34]<V6O%_[))S&%9O$PWN&
M62BCG@#;P8R#>15C8A;*J%=34,Q9C(E9*".VT+XID^C)QYCH@@JQA>+9D^V.
M"0W&F)B%,F(+'<PO=U*/#+-0]A[S9/LQFTX:8V(6RH@MA&'6515C8A;*CC2+
M%C!;Q6.&62@[5NT3,&-9YIB%<F(+X9AQ(I=C%LJ)+?1:HNT.13N?'>28A7)B
M"[UAQO*Y;M8K ;HU_Y)C%LJ)+;07<UR'9=5KV8HF9J&<?%T?F0%FW1@37=BG
MMM#>.>"W0CW&Q"R4!POU-I_PE&(AM2AOX!(.]A=<%3/+FC_KQ<8L;]8*%K52
M%[!OJJ\,+S=?!&V^9OKR'U!+ P04    " !M@ %9##^0_.4!  !_(0  &@
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M72]_67[O'-WC%YP#_&_Q^ 502P,$%     @ ;8 !68_AMVG3 0  -B$  !,
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M<',O87!P+GAM;%!+ 0(4 Q0    ( &V  5F(RC]^[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    " !M@ %9=2)U0? "  #M"0  &
M    @(&7%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M;8 !6=<SDYC#!   ;1,  !@              ("!O1<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &V  5E6AT/@DP,  )\-   8
M          " @;8<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " !M@ %9%3 #4KD(  # 0P  &               @(%_(   >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ;8 !61"%:QDL!@  *!@
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &V  5G/0KPX%P0  &D*   9
M      " @7](  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ ;8 !694S1?.<!@  YQ   !D              ("!S4P  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !M@ %9XRX]M]\"  ";!@
M&0              @(&@4P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( &V  5ER'O),HP(  -8%   9              " @;96  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ;8 !6?#O=/<*
M"P  =R   !D              ("!D%D  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " !M@ %9 O&230P#  "S!@  &0
M@('19   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &V
M 5EFPA7<_P@  -45   9              " @11H  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ ;8 !63_+4ZLM"@  $!P  !D
M         ("!2G$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " !M@ %9P6GF)&H%   -#0  &0              @(&N>P  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &V  5GK9"(6L P  &8@
M   9              " @4^!  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ ;8 !65T!%5A "   "Q8  !D              ("!-HX
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !M@ %9^_.4
MKV &   Q$0  &0              @(&ME@  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( &V  5G)?N&1#@,  &\&   9
M  " @42=  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M;8 !655J3,&_ P  B@D  !D              ("!B:   'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " !M@ %9<WT6-OT#  # "0  &0
M            @(%_I   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( &V  5GAZRF(R@(  (,&   9              " @;.H  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ;8 !6;?58VVB @
MUP4  !D              ("!M*L  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " !M@ %9RT?_RS4#  !=!P  &0              @(&-
MK@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &V  5F0
MU*R5F04  !,.   9              " @?FQ  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ ;8 !69GP\ T@ P  *@<  !D
M     ("!R;<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &V  5ER0"@$"0(  $4$   9              "
M@<3+  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ;8 !
M6;KO'"$] @  + 4  !D              ("!!,X  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " !M@ %9 M/]YT,'  !6.@  &0
M        @(%XT   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( &V  5DW4.R-T (  +0'   9              " @?+7  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ;8 !6:M?)9"; @  &0<
M !D              ("!^=H  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " !M@ %9L1LL@B\(  !/1@  &0              @('+W0
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &V  5G(TD:4
MT (  +<'   9              " @3'F  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ ;8 !62G,*](J @  K@0  !D
M ("!..D  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !M
M@ %9HLC-^@ #  ! "0  &0              @(&9ZP  >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( &V  5F+1XX<L0(  $ (   9
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M970T.2YX;6Q02P$"% ,4    " !M@ %9\$U<]"@#  !V"   &0
M    @(%Z @$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M &V  5GF+ ;0> ,  $<.   9              " @=D% 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ ;8 !63\P<6?. @  0P@  !D
M             ("!B D! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " !M@ %987C,]/$"  !+"0  &0              @(&-# $ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( &V  5DKQ<-9=P(
M ' &   9              " @;4/ 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ ;8 !60G#(*5[ P  V@T  !D              ("!
M8Q(! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !M@ %9
MX:4!>&($  ##%P  &0              @($5%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    ( &V  5G48>/T0@,  ,H4   -
M      "  :X: 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ;8 !69>*NQS
M    $P(   L              ( !&QX! %]R96QS+RYR96QS4$L! A0#%
M  @ ;8 !63F1@ZRK!   424   \              ( !!!\! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( &V  5D,/Y#\Y0$  '\A   :
M  "  =PC 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M &V  5F/X;=ITP$  #8A   3              "  ?DE 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !  $  =Q$  /TG 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>236</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Helio Vision Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisition</Role>
      <ShortName>Helio Vision Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Cash, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1</Role>
      <ShortName>Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Credit Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables</Role>
      <ShortName>Credit Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - BASIS OF PRESENTATION (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Helio Vision Acquisition - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail</Role>
      <ShortName>Helio Vision Acquisition - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Credit Facility - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail</Role>
      <ShortName>Credit Facility - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Credit Facility - Schedule of Long-Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail</Role>
      <ShortName>Credit Facility - Schedule of Long-Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Credit Facility - Schedule of Principal Payments Incuding End of Term Charges (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail</Role>
      <ShortName>Credit Facility - Schedule of Principal Payments Incuding End of Term Charges (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stock-Based Compensation - Summary of Employee Stock Purchase Plan Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Employee Stock Purchase Plan Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="aldx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Significant Agreements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails</Role>
      <ShortName>Significant Agreements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="aldx-20240630.htm">aldx-20240630.htm</File>
    <File>aldx-20240630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img130887665_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="455">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aldx-20240630.htm": {
   "nsprefix": "aldx",
   "nsuri": "http://www.aldeyra.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "aldx-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "aldx-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 208,
   "keyCustom": 28,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 20,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 142,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 429,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 455,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited",
     "longName": "100010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "aldx:CashAndMoneyMarketFunds",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "aldx:CashAndMoneyMarketFunds",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited",
     "longName": "100040 - Statement - Consolidated Statements of Operations (Unaudited)",
     "shortName": "Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited",
     "longName": "100050 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_26f21088-fd82-4099-b10a-e221c702905e",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_26f21088-fd82-4099-b10a-e221c702905e",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusiness",
     "longName": "100080 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentation",
     "longName": "100090 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisition",
     "longName": "100100 - Disclosure - Helio Vision Acquisition",
     "shortName": "Helio Vision Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "100110 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities",
     "longName": "100120 - Disclosure - Cash, Cash Equivalents and Marketable Securities",
     "shortName": "Cash, Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "100140 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses",
     "longName": "100150 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1",
     "longName": "100160 - Disclosure - Credit Facility",
     "shortName": "Credit Facility",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity",
     "longName": "100170 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100180 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "longName": "100190 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases",
     "longName": "100200 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100220 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements",
     "longName": "100230 - Disclosure - Significant Agreements",
     "shortName": "Significant Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies",
     "longName": "100250 - Disclosure - Basis of Presentation (Policies)",
     "shortName": "Basis of Presentation (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "100260 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables",
     "longName": "100270 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "100290 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "longName": "100300 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables",
     "longName": "100310 - Disclosure - Credit Facility (Tables)",
     "shortName": "Credit Facility (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "longName": "100320 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "100330 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails",
     "longName": "100340 - Disclosure - BASIS OF PRESENTATION (Additional Information) (Details)",
     "shortName": "BASIS OF PRESENTATION (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
     "longName": "100350 - Disclosure - Helio Vision Acquisition - Additional Information (Detail)",
     "shortName": "Helio Vision Acquisition - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_ebf661ea-8dd4-4850-bc1d-1fc69b508bcd",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ebf661ea-8dd4-4850-bc1d-1fc69b508bcd",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
     "longName": "100360 - Disclosure - Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Detail)",
     "shortName": "Net Loss Per Share - Computation of Diluted Weighted-Average Shares Outstanding (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail",
     "longName": "100380 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, and Cash Equivalents (Detail)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Schedule of Cash, and Cash Equivalents (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
     "longName": "100390 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_2168d68b-67be-44e7-815f-cebd869819ec",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2168d68b-67be-44e7-815f-cebd869819ec",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "longName": "100400 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "100410 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "100420 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
     "longName": "100430 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
     "longName": "100440 - Disclosure - Credit Facility - Additional Information (Detail)",
     "shortName": "Credit Facility - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:DeferredLongTermLiabilityCharges",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_96d3e115-830a-4157-ac6e-d8edcdd92568",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail",
     "longName": "100450 - Disclosure - Credit Facility - Schedule of Long-Term Debt (Detail)",
     "shortName": "Credit Facility - Schedule of Long-Term Debt (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LongTermLoansPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LongTermLoansPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail",
     "longName": "100460 - Disclosure - Credit Facility - Schedule of Principal Payments Incuding End of Term Charges (Detail)",
     "shortName": "Credit Facility - Schedule of Principal Payments Incuding End of Term Charges (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
     "longName": "100470 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_ce9c8181-658b-4601-b349-c64cda3f969b",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ce9c8181-658b-4601-b349-c64cda3f969b",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "100480 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "aldx:DeferredTaxAssetsValuationAllowancePercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "aldx:DeferredTaxAssetsValuationAllowancePercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
     "longName": "100490 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail",
     "longName": "100500 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)",
     "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6b7f665d-724a-4e0d-8cda-8a1d42dfea6c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
     "longName": "100510 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_2168d68b-67be-44e7-815f-cebd869819ec",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0f7c50b-70af-4297-b9aa-41adb3adb312",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail",
     "longName": "100520 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
     "longName": "100530 - Disclosure - Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Activity Relating to Restricted Stock Units (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_d3f16ce7-5180-4c42-a5f4-7353119a3125",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d3f16ce7-5180-4c42-a5f4-7353119a3125",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail",
     "longName": "100540 - Disclosure - Stock-Based Compensation - Summary of Employee Stock Purchase Plan Activity (Detail)",
     "shortName": "Stock-Based Compensation - Summary of Employee Stock Purchase Plan Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_faf7cb0d-6157-4f20-a7ac-312439f84084",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "longName": "100550 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail",
     "longName": "100560 - Disclosure - Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail)",
     "shortName": "Leases - Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail",
     "longName": "100570 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)",
     "shortName": "Leases - Schedule of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "100580 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "aldx:IndemnificationObligationsClaimsOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6",
      "name": "aldx:IndemnificationObligationsClaimsOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails",
     "longName": "100590 - Disclosure - Significant Agreements (Additional Information) (Details)",
     "shortName": "Significant Agreements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_d16b308a-5d1b-46ab-9b7e-ef142ccd89bb",
      "name": "aldx:SplitProfitsAndLossesPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d16b308a-5d1b-46ab-9b7e-ef142ccd89bb",
      "name": "aldx:SplitProfitsAndLossesPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aldx-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "aldx_AbbvieOptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "AbbvieOptionAgreementMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie Option Agreement [Member]",
        "label": "AbbVie Option Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r642"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net amortization of premium on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "aldx_AccruedContingentConsiderationPayableInStockCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "AccruedContingentConsiderationPayableInStockCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration payable in stock",
        "label": "Accrued Contingent Consideration Payable In Stock Current",
        "documentation": "Accrued contingent consideration payable in stock current."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_AccruedGeneralAndAdministrativeExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "AccruedGeneralAndAdministrativeExpenseCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued general and administrative",
        "label": "Accrued General And Administrative Expense Current",
        "documentation": "Accrued general and administrative expense, current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "aldx_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r77",
      "r132",
      "r489",
      "r505",
      "r506"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13",
      "r30",
      "r396",
      "r399",
      "r428",
      "r501",
      "r502",
      "r674",
      "r675",
      "r676",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r515",
      "r681",
      "r682",
      "r683",
      "r733",
      "r752"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r330"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated Share Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r367"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r83",
      "r296"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total of common stock equivalents",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r126",
      "r159",
      "r189",
      "r197",
      "r201",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r389",
      "r393",
      "r411",
      "r484",
      "r549",
      "r642",
      "r654",
      "r699",
      "r700",
      "r738"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r134",
      "r159",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r389",
      "r393",
      "r411",
      "r642",
      "r699",
      "r700",
      "r738"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Available for sale unrecognized gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Available for sale unrecognized loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "terseLabel": "Available for sale unrecognized loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available for sales estimated fair value",
        "verboseLabel": "Available for sale carrying Amount",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r247",
      "r478",
      "r686"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and Cash Equivalents",
        "label": "Debt Securities, Available-for-Sale, Current",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r247"
     ]
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableforsaleSecuritiesMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-Sale Securities [Member]",
        "terseLabel": "Available for sale [Member]",
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r634",
      "r635"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r384",
      "r634",
      "r635"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, stock issued",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional equity consideration issuable",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1"
     ]
    },
    "aldx_BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, contingent consideration stock to be issued",
        "label": "Business Combination Contingent Consideration Equity Interests Issuable Number Of Shares",
        "documentation": "Business combination, contingent consideration, equity interest issuable, number of shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination, contingent consideration liability",
        "label": "Business Combination, Contingent Consideration, Liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r56",
      "r386"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Helio Vision Acquisition",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r385"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "periodStartLabel": "Cash, Beginning Balance",
        "periodEndLabel": "Cash, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r486",
      "r516",
      "r544",
      "r642",
      "r654",
      "r669"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r125",
      "r615"
     ]
    },
    "aldx_CashAndMoneyMarketFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CashAndMoneyMarketFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash And Money Market Funds",
        "documentation": "Cash and money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_CashCashEquivalentsAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Cash Equivalents And Marketable Securities [Line Items]",
        "label": "Cash Cash Equivalents And Marketable Securities [Line Items]",
        "documentation": "Cash Cash Equivalents And Marketable Securities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_CashCashEquivalentsAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Cash Equivalents And Marketable Securities [Table]",
        "label": "Cash Cash Equivalents And Marketable Securities [Table]",
        "documentation": "Cash Cash Equivalents And Marketable Securities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r85",
      "r155"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r85"
     ]
    },
    "aldx_CashEquivalentReverseRepurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CashEquivalentReverseRepurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reverse repurchase agreements",
        "terseLabel": "Cash equivalent - reverse repurchase agreements",
        "label": "Cash Equivalent Reverse Repurchase Agreement",
        "documentation": "Cash equivalent reverse repurchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_CashEquivalentReverseRepurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CashEquivalentReverseRepurchaseAgreements",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalent - Reverse Repurchase Agreements",
        "label": "Cash Equivalent - Reverse Repurchase Agreements",
        "terseLabel": "Cash equivalent - reverse repurchase agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Cash and cash equivalents [Member]",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash [Member]",
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "aldx_CashReserveForIndemnitiesAndGuarantees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CashReserveForIndemnitiesAndGuarantees",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reserve For Indemnities And Guarantees",
        "label": "Cash Reserve For Indemnities And Guarantees",
        "terseLabel": "Reserve for indemnification"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r188",
      "r303",
      "r304",
      "r305",
      "r307",
      "r310",
      "r315",
      "r317",
      "r508",
      "r509",
      "r510",
      "r511",
      "r629",
      "r661",
      "r677"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Significant Agreements",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r113",
      "r120"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Notes 3, 9, &amp; 14)",
        "label": "Commitments and Contingencies",
        "totalLabel": "Commitments and Contingencies, Total",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r64",
      "r485",
      "r535"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r259",
      "r260",
      "r602",
      "r698"
     ]
    },
    "aldx_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock after FDA Approval prior to 10th Anniversary [Member]",
        "label": "Common Stock After F D A Approval Prior To Tenth Anniversary [Member]",
        "documentation": "Common stock after FDA approval prior to tenth anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock after FDA Approval Prior to 12th Anniversary [Member]",
        "label": "Common Stock After F D A Approval Prior To Twelfth Anniversary [Member]",
        "documentation": "Common stock after FDA approval prior to twelfth anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r648",
      "r649",
      "r650",
      "r651",
      "r681",
      "r682",
      "r733",
      "r750",
      "r752"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r536"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r71",
      "r536",
      "r555",
      "r752",
      "r753"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued in connection with Helio Vision, Inc. acquisition milestone",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "terseLabel": "Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,414,489 and 59,195,951 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r488",
      "r642"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r139",
      "r141",
      "r148",
      "r480",
      "r497"
     ]
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration by Type",
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Type",
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_CsbuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "CsbuMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CSBU [Member]",
        "label": "CSBU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacility1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CREDIT FACILITY",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r157",
      "r274",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r290",
      "r297",
      "r298",
      "r300"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r68",
      "r69",
      "r102",
      "r103",
      "r161",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r421",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r678"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument variable annual interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Fair Value Disclosure, Total",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Available for sale fair value disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r410",
      "r625",
      "r626"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, increase amount",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "totalLabel": "Debt Instrument, Increase (Decrease), Net, Total",
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r161",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r421",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r678"
     ]
    },
    "us-gaap_DeferredLongTermLiabilityCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredLongTermLiabilityCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Long-Term Liability Charges",
        "verboseLabel": "Deferred collaboration revenue, long term",
        "documentation": "The total amount of long-term liability charges that are being deferred beyond one year."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Offering costs not yet paid",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Total",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred collaboration revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred collaboration revenue",
        "label": "Deferred Revenue, Current",
        "totalLabel": "Deferred Revenue, Current, Total",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "aldx_DeferredTaxAssetsValuationAllowancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "DeferredTaxAssetsValuationAllowancePercentage",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets valuation allowance",
        "label": "Deferred Tax Assets Valuation Allowance Percentage",
        "documentation": "Deferred tax assets valuation allowance percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred research and development expenses, and deposits",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r732"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r37"
     ]
    },
    "aldx_DirectorOfficerPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "DirectorOfficerPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director &amp; Officer prepaid expenses",
        "label": "Director &amp; Officer Prepaid Expenses",
        "documentation": "Director &amp; Officer prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r332",
      "r360",
      "r361",
      "r363",
      "r637"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net loss per share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r176",
      "r178",
      "r180",
      "r181",
      "r182",
      "r186",
      "r404",
      "r405",
      "r481",
      "r498",
      "r618"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Net loss per share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r178",
      "r180",
      "r181",
      "r182",
      "r186",
      "r404",
      "r405",
      "r481",
      "r498",
      "r618"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r183",
      "r184",
      "r185"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r372",
      "r380"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized stock-based compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to Purchase Common Stock [Member]",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r121",
      "r142",
      "r143",
      "r144",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r187",
      "r240",
      "r241",
      "r318",
      "r364",
      "r365",
      "r366",
      "r376",
      "r377",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r428",
      "r501",
      "r502",
      "r503",
      "r515",
      "r576"
     ]
    },
    "aldx_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plan [Member]",
        "label": "Equity Incentive Plan [Member]",
        "documentation": "Equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_ExistingEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ExistingEndOfTermCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing End Of Term Charge",
        "documentation": "Existing End Of Term Charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r408",
      "r437",
      "r438",
      "r439",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r320",
      "r325",
      "r408",
      "r437",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r320",
      "r325",
      "r408",
      "r438",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r408",
      "r439",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r437",
      "r438",
      "r439",
      "r625",
      "r626",
      "r631",
      "r632",
      "r633"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r299",
      "r315",
      "r401",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r496",
      "r622",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r690",
      "r691",
      "r692",
      "r693"
     ]
    },
    "aldx_FoundersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "FoundersMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founders [Member]",
        "label": "Founders [Member]",
        "documentation": "Founders member."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_FourthAndFifthAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "FourthAndFifthAnniversaryMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth and Fifth Anniversary.",
        "label": "Fourth And Fifth Anniversary [Member]",
        "terseLabel": "Fourth and Fifth Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r559"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "aldx_GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "GrossProceedsFromStockToBeIssuedPerStockPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected aggregate gross proceeds from issuance of stock",
        "label": "Gross Proceeds From Stock To Be Issued Per Stock Purchase Agreement",
        "documentation": "Gross Proceeds From Stock To Be Issued Per Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_HelioVisionIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "HelioVisionIncMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Helio Vision Inc [Member]",
        "label": "Helio Vision Inc [Member]",
        "documentation": "Helio Vision Inc."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_HerculesCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "HerculesCreditFacilityMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hercules Credit Facility [Member]",
        "documentation": "Hercules Credit Facility.",
        "terseLabel": "Hercules Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r254",
      "r560"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r560"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r370",
      "r373",
      "r374",
      "r375",
      "r378",
      "r381",
      "r382",
      "r383",
      "r513"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Examination for the tax years",
        "label": "Income Tax Examination, Description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r118",
      "r173",
      "r174",
      "r194",
      "r371",
      "r379",
      "r499"
     ]
    },
    "aldx_IncomeTaxLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "IncomeTaxLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "documentation": "Income tax."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_IncomeTaxTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "IncomeTaxTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "documentation": "Income tax table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "aldx_IndemnificationObligationsClaimsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "IndemnificationObligationsClaimsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification Obligations Claims Outstanding",
        "label": "Indemnification Obligations Claims Outstanding",
        "terseLabel": "Outstanding material claims"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Security Category [Axis]",
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r106",
      "r145",
      "r193",
      "r420",
      "r561",
      "r652",
      "r751"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the period for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r153",
      "r154"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r192"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520",
      "r521",
      "r523",
      "r525",
      "r582",
      "r584",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r646"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520",
      "r521",
      "r523",
      "r525",
      "r582",
      "r584",
      "r586",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r646"
     ]
    },
    "aldx_IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "IssuanceOfCommonStockInConnectionWithAcquisitionMilestoneShares",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in connection with acquisition milestone shares.",
        "label": "Issuance of Common Stock in Connection With Acquisition Milestone Shares",
        "terseLabel": "Issuance of common stock in connection with Helio Vision, Inc. acquisition milestone, shares"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "IssuanceOfCommonStockValueInConnectionWithAcquisitionMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock value in connection with acquisition milestone.",
        "label": "Issuance of Common Stock Value in Connection With Acquisition Milestone",
        "terseLabel": "Issuance of common stock in connection with Helio Vision, Inc. acquisition milestone"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_JefferiesLimitedLiabilityCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "JefferiesLimitedLiabilityCompanyMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC [Member]",
        "label": "Jefferies Limited Liability Company [Member]",
        "documentation": "Jefferies limited liability company."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_JefferiesSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "JefferiesSalesAgreementMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies Sales Agreement [Member]",
        "label": "Jefferies Sales Agreement [Member]",
        "documentation": "Jefferies sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Proceedings",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "aldx_LegalProceedingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LegalProceedingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Proceedings [Abstract]",
        "documentation": "Legal Proceedings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities and Balance Sheet Presentation of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "2024 remaining total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "Operating lease obligations, 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Operating lease obligations, 2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Operating lease obligations, 2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Operating lease obligations, 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: effect of discounting",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r159",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r390",
      "r393",
      "r394",
      "r411",
      "r534",
      "r619",
      "r654",
      "r699",
      "r738",
      "r739"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r104",
      "r491",
      "r642",
      "r679",
      "r694",
      "r734"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r124",
      "r159",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r390",
      "r393",
      "r394",
      "r411",
      "r642",
      "r699",
      "r738",
      "r739"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Fair Value Disclosure, Total",
        "terseLabel": "Liabilities measured at fair value on a recurring basis",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_LineOfCreditFacilityCommitmentCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LineOfCreditFacilityCommitmentCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment charge",
        "label": "Line Of Credit Facility Commitment Charge",
        "documentation": "Line of credit facility, commitment charge."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility fee",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "aldx_LineOfCreditFacilityInterestPaymentExtensionPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LineOfCreditFacilityInterestPaymentExtensionPeriod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payment extension period",
        "label": "Line Of Credit Facility Interest Payment Extension Period",
        "documentation": "Line of credit facility interest payment extension period."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_LineOfCreditFacilityInterestPaymentPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LineOfCreditFacilityInterestPaymentPeriod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payment period",
        "label": "Line Of Credit Facility Interest Payment Period",
        "documentation": "Line of credit facility interest payment period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility, interest rate",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "documentation": "The effective interest rate at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument annual interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line Of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility amount",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "aldx_LineOfCreditFacilityPrepaymentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LineOfCreditFacilityPrepaymentFeePercentage",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility prepayment fee percentage",
        "label": "Line Of Credit Facility Prepayment Fee Percentage",
        "documentation": "The percentage of fee if the term loan is prepaid."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_LineOfCreditFacilityPrepaymentFeePercentageThereafter": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LineOfCreditFacilityPrepaymentFeePercentageThereafter",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit facility prepayment fee percentage, thereafter",
        "label": "Line Of Credit Facility Prepayment Fee Percentage Thereafter",
        "documentation": "Line Of Credit Facility Prepayment Fee Percentage Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line Of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r678"
     ]
    },
    "aldx_LineOfCreditFacilityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LineOfCreditFacilityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Line Of Credit Facility Transaction Costs",
        "documentation": "Line of credit facility, transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion",
        "label": "Line of Credit, Current",
        "terseLabel": "Current portion of long-term debt",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r102"
     ]
    },
    "aldx_LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan agreement right to purchase aggregate amount of equity securities",
        "label": "Loan Agreement Right To Purchase Aggregate Amount Of Equity Securities",
        "documentation": "Loan agreement right to purchase aggregate amount of equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_LoanFundedPriorToTheDateOfAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "LoanFundedPriorToTheDateOfAmendment",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan funded prior to the date of amendment",
        "label": "Loan Funded Prior To The Date Of Amendment",
        "documentation": "Loan funded prior to the date of amendment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from Long-term lines of credit",
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r103",
      "r287",
      "r301",
      "r625",
      "r626",
      "r748"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "terseLabel": "Current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LongTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtDescription",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Description",
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r42"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r161",
      "r292"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfPrincipalPaymentsIncudingEndOfTermChargesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan payable",
        "label": "Loans Payable, Noncurrent",
        "totalLabel": "Loans Payable, Noncurrent, Total",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r38"
     ]
    },
    "aldx_MEEIAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "MEEIAgreementMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MEEI Agreement [Member]",
        "label": "M E E I Agreement [Member]",
        "terseLabel": "MEEI Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities",
        "totalLabel": "Marketable Securities, Total",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r670"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable Securities, Current, Total",
        "label": "Current Marketable Securities",
        "terseLabel": "Current Marketable Securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r327",
      "r464",
      "r500",
      "r526",
      "r527",
      "r583",
      "r585",
      "r587",
      "r588",
      "r593",
      "r612",
      "r613",
      "r621",
      "r629",
      "r636",
      "r643",
      "r701",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "aldx_MilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "MilestoneMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Member]",
        "label": "Milestone [Member]",
        "documentation": "Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone payments",
        "documentation": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r327",
      "r464",
      "r500",
      "r526",
      "r527",
      "r583",
      "r585",
      "r587",
      "r588",
      "r593",
      "r612",
      "r613",
      "r621",
      "r629",
      "r636",
      "r643",
      "r701",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r87",
      "r105",
      "r122",
      "r137",
      "r140",
      "r144",
      "r159",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r179",
      "r189",
      "r196",
      "r200",
      "r202",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r405",
      "r411",
      "r494",
      "r557",
      "r574",
      "r575",
      "r620",
      "r652",
      "r699"
     ]
    },
    "aldx_NetLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "NetLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Loss",
        "documentation": "Net loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_NonCreditableNonRefundableLicenseMaintenanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "NonCreditableNonRefundableLicenseMaintenanceFees",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-creditable non-refundable license maintenance fees.",
        "label": "Non Creditable Non Refundable License Maintenance Fees",
        "terseLabel": "Non-creditable non-refundable license maintenance fees"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_NonFoundersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "NonFoundersMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Founders [Member]",
        "label": "Non Founders [Member]",
        "documentation": "Non Founders."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_NonRefundablePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "NonRefundablePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Payment",
        "label": "Non Refundable Payment",
        "terseLabel": "Non refundable payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_NonvestedFounderSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "NonvestedFounderSharesMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Founder Shares [Member]",
        "label": "Nonvested Founder Shares [Member]",
        "documentation": "Nonvested Founder Shares [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "NumberOfCommonStockSharesIssuedAndOutstandingSubjectOfVestingSharesBasedOnServiceRequirements",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares issued and outstanding subject of vesting shares based on service requirements",
        "label": "Number Of Common Stock Shares Issued And Outstanding Subject Of Vesting Shares Based On Service Requirements",
        "documentation": "Number of common stock shares issued and outstanding subject of vesting shares based on service requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r196",
      "r200",
      "r202",
      "r620"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liabilities",
        "terseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesAndBalanceSheetPresentationOfLeaseLiabilitiesDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r641"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r641"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities",
        "terseLabel": "Accrued other expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current receivables",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r642"
     ]
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsMiscellaneousCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Miscellaneous prepaid expenses and other current assets",
        "label": "Other Assets, Miscellaneous, Current",
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Other comprehensive loss",
        "verboseLabel": "Reclassification of losses to net loss",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r17",
      "r138",
      "r141",
      "r147",
      "r412",
      "r413",
      "r418",
      "r479",
      "r495",
      "r674",
      "r675"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r100",
      "r138",
      "r141"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized (loss) on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r238"
     ]
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisitions of fixed assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r303"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r536"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r303"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r536",
      "r555",
      "r752",
      "r753"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r487",
      "r642"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "documentation": "Prepaid Expenses And Other Current Assets [Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance expenses",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r623",
      "r695"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate [Member]",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of common stock, net of commissions and other offering costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock",
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r508"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r15"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r137",
      "r140",
      "r151",
      "r159",
      "r165",
      "r173",
      "r174",
      "r189",
      "r196",
      "r200",
      "r202",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r388",
      "r391",
      "r392",
      "r405",
      "r411",
      "r482",
      "r493",
      "r514",
      "r557",
      "r574",
      "r575",
      "r620",
      "r639",
      "r640",
      "r653",
      "r676",
      "r699"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r483",
      "r492",
      "r642"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r319",
      "r327",
      "r355",
      "r356",
      "r357",
      "r440",
      "r464",
      "r500",
      "r526",
      "r527",
      "r583",
      "r585",
      "r587",
      "r588",
      "r593",
      "r612",
      "r613",
      "r621",
      "r629",
      "r636",
      "r643",
      "r646",
      "r697",
      "r701",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r319",
      "r327",
      "r355",
      "r356",
      "r357",
      "r440",
      "r464",
      "r500",
      "r526",
      "r527",
      "r583",
      "r585",
      "r587",
      "r588",
      "r593",
      "r612",
      "r613",
      "r621",
      "r629",
      "r636",
      "r643",
      "r646",
      "r697",
      "r701",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r429",
      "r430",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r554",
      "r556",
      "r581"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r429",
      "r430",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r554",
      "r556",
      "r581",
      "r737"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r731"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r731"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r368",
      "r746"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost And Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r96",
      "r490",
      "r504",
      "r506",
      "r512",
      "r537",
      "r642"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r240",
      "r241",
      "r364",
      "r365",
      "r366",
      "r376",
      "r377",
      "r395",
      "r397",
      "r398",
      "r400",
      "r403",
      "r501",
      "r503",
      "r515",
      "r752"
     ]
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "milestone payments",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenues, Total",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r159",
      "r190",
      "r191",
      "r195",
      "r198",
      "r199",
      "r203",
      "r204",
      "r206",
      "r239",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r411",
      "r482",
      "r699"
     ]
    },
    "aldx_ReverseRepurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ReverseRepurchaseAgreementsMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Repurchase Agreements [Member]",
        "label": "Reverse Repurchase Agreements [Member]",
        "documentation": "Reverse repurchase agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares sold",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareComputationOfDilutedWeightedAverageSharesOutstandingParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computation of Diluted Weighted-Average Shares Outstanding",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r384"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, and Cash Equivalents",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r42",
      "r45",
      "r58",
      "r59",
      "r61",
      "r66",
      "r94",
      "r95",
      "r625",
      "r627",
      "r680"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408"
     ]
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Principal Payments Including the Supplemental End of Term Charges",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "aldx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Employee Stock Purchase Plan Activity",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of employee stock purchase plan activity."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Relating to Restricted Stock Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r94",
      "r95",
      "r96",
      "r129",
      "r130",
      "r131",
      "r188",
      "r303",
      "r304",
      "r305",
      "r307",
      "r310",
      "r315",
      "r317",
      "r508",
      "r509",
      "r510",
      "r511",
      "r629",
      "r661",
      "r677"
     ]
    },
    "aldx_ScheduleOfStockOptionExerciseActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ScheduleOfStockOptionExerciseActivityTableTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Relating to Stock Options",
        "label": "Schedule Of Stock Option Exercise Activity Table [Text Block]",
        "documentation": "Schedule of stock option exercise activity table."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_SecondAndThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "SecondAndThirdAnniversaryMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second and Third Anniversary.",
        "label": "Second And Third Anniversary [Member]",
        "terseLabel": "Second and Third Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r519",
      "r522",
      "r524",
      "r584",
      "r586",
      "r590",
      "r594",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r630",
      "r646",
      "r702",
      "r749"
     ]
    },
    "aldx_ServiceBasedAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ServiceBasedAwardsMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Based Awards [Member]",
        "label": "Service Based Awards [Member]",
        "documentation": "Service based awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at June 30, 2024",
        "periodStartLabel": "Outstanding at December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining recognition period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Released, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Exercised/Released"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled in common stock",
        "label": "Share Based Compensation arrangement by Share based Payment Award Equity Instruments other than Options settled in Common Stock in period",
        "documentation": "Share Based Compensation arrangement by Share based Payment Award Equity Instruments other than Options settled in Common Stock in period"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value, Settled in common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Settled in Common Stock, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Settled in Common Stock, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Additional shares granted",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Shares Exercisable, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Exercisable, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Number of Shares, Expired",
        "negatedLabel": "Number of Shares, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "aldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Forfeitures",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Intrinsic Value",
        "documentation": "Share-based compensation arrangement by share-based payment award, options, forfeitures, intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant-date fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeitures",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Closing market value of common stock",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Contractual Term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "aldx_Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsreleasedinperiod",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfActivityRelatingToRestrictedStockUnitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
        "terseLabel": "Exercised/Released"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, Shares",
        "periodEndLabel": "Ending Balance, Shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r156"
     ]
    },
    "aldx_SixthAndSubsequentAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "SixthAndSubsequentAnniversaryMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth and Subsequent Anniversary.",
        "label": "Sixth And Subsequent Anniversary [Member]",
        "terseLabel": "Sixth and Subsequent Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_SplitProfitsAndLossesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "SplitProfitsAndLossesPercentage",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Split Profits and Losses Percentage",
        "label": "Split Profits and Losses Percentage",
        "documentation": "Split Profits and Losses Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_StateAndFederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "StateAndFederalMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Federal [Member]",
        "label": "State And Federal [Member]",
        "documentation": "State and Federal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r121",
      "r142",
      "r143",
      "r144",
      "r162",
      "r163",
      "r164",
      "r166",
      "r172",
      "r174",
      "r187",
      "r240",
      "r241",
      "r318",
      "r364",
      "r365",
      "r366",
      "r376",
      "r377",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r428",
      "r501",
      "r502",
      "r503",
      "r515",
      "r576"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r519",
      "r522",
      "r524",
      "r584",
      "r586",
      "r590",
      "r594",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r614",
      "r630",
      "r646",
      "r702",
      "r749"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r187",
      "r465",
      "r507",
      "r517",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r647"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r187",
      "r465",
      "r507",
      "r517",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r558",
      "r559",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r647"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Release of restrictions on Helio founders' shares, Shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, employee stock purchase plan, Shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r71",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, employee stock purchase plan, Shares",
        "verboseLabel": "Issuance of common stock, net of issuance costs, Shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r71",
      "r96",
      "r508",
      "r576",
      "r599"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, vested restricted stock units, Shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "verboseLabel": "RSU granted",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, exercise of stock options, Shares",
        "negatedLabel": "Number of Shares, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r71",
      "r96",
      "r341"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Release of restrictions on Helio founders shares",
        "negatedLabel": "Release of restrictions on Helio founders' shares",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r71",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, employee stock purchase plan",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r71",
      "r96",
      "r515",
      "r576",
      "r599",
      "r653"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, vested restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70",
      "r71",
      "r96"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r96"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r74",
      "r75",
      "r89",
      "r538",
      "r555",
      "r577",
      "r578",
      "r642",
      "r654",
      "r679",
      "r694",
      "r734",
      "r752"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r158",
      "r302",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r318",
      "r402",
      "r579",
      "r580",
      "r600"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r432"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r433"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_SupplementalEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "SupplementalEndOfTermCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental End Of Term Charge",
        "documentation": "Supplemental End Of Term Charge",
        "terseLabel": "Supplemental end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_SupplementalEndOfTermCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "SupplementalEndOfTermCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental End of Term Charges",
        "label": "Supplemental End of Term Charges",
        "terseLabel": "Supplemental end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TaxGrossUpPaymentChangeOfControlOrDivestureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TaxGrossUpPaymentChangeOfControlOrDivestureMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureHelioVisionAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Gross-up Payment in Event of Change of Control or Divesture [Member]",
        "label": "Tax Gross Up Payment Change Of Control Or Divesture [Member]",
        "documentation": "Tax gross-up payment, change of control or divesture."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TermLoanAdvanceFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TermLoanAdvanceFiveMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Advance Five [Member]",
        "label": "Term Loan Advance Five [Member]",
        "documentation": "Term loan advance five member."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TermLoanAdvanceFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TermLoanAdvanceFourMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Advance Four [Member]",
        "label": "Term Loan Advance Four [Member]",
        "documentation": "Term loan advance four member."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TermLoanAdvanceOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TermLoanAdvanceOneMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Advance One [Member]",
        "label": "Term Loan Advance One [Member]",
        "documentation": "Term loan advance one member."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TermLoanAdvanceThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TermLoanAdvanceThreeMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Advance Three [Member]",
        "label": "Term Loan Advance Three [Member]",
        "documentation": "Term loan advance three member."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TermLoanAdvanceTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TermLoanAdvanceTwoMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Advance Two [Member]",
        "label": "Term Loan Advance Two [Member]",
        "documentation": "Term loan advance two member."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r299",
      "r315",
      "r401",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r496",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r690",
      "r691",
      "r692",
      "r693"
     ]
    },
    "aldx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfEmployeeStockPurchasePlanActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "documentation": "2016 employee stock purchase plan member."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TwoThousandTwentyFourJefferiesSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TwoThousandTwentyFourJefferiesSalesAgreementMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Jefferies Sales Agreement [Member]",
        "label": "Two Thousand Twenty Four Jefferies Sales Agreement [Member]",
        "documentation": "Two Thousand Twenty Four Jefferies Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "aldx_TwoThousandTwentyThreeEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "TwoThousandTwentyThreeEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Three Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Twenty Three Employee Stock Purchase Plan [Member]",
        "terseLabel": "2023 Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCashCashEquivalentsAndMarketableSecuritiesScheduleOfCashAndCashEquivalentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agency securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r631",
      "r747"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureCreditFacilityScheduleOfLongTermDebtDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten public offering."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "UpfrontCashPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureSignificantAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "upfront cash payment",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r112",
      "r114",
      "r115",
      "r116"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/DisclosureCreditFacilityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "aldx_VolumeWeightedAveragePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.aldeyra.com/20240630",
     "localname": "VolumeWeightedAveragePrice",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume-weighted average price",
        "label": "Volume Weighted Average Price",
        "documentation": "Volume weighted average price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "terseLabel": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r182"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.aldeyra.com/20240630/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8B"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0000950170-24-089238-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-089238-xbrl.zip
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M:2+1#TY(,;F\Y[AX7J[-!C77$;;!SDD^)?C(2V,Z?<4YQ9]/QWXXR:/Q8?V
MLB%485AQ\3G7+\;W'E)6AQ.F3Q\R&4^O4@P_O$S:Z?A&2KGG>/79;_]2_7(
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M#1A/;FK2!_OV.N5GT5DMK68 O?[0MG>3,MONF=]P1E+L>".0UY@O[5DS(]9
M(E9FIX526;*&C/QZV?XTF_2',)DT7J_]80UCG@A8+R]/I9M8:^!J^WI[NMWS
MOD&M$$D:+RUA-AHB2V]T&P"(2,$RK96FJJ%DV--%^W.]9B_G2[9<T&JZ<\1=
M[/E52KFZK__B:9T)Y^^X"4O2P;6^S7Z^[LBE/FA!)7<XJL])9I.YBQ&G.>_
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MSNM5^9MI<F>9<RUF+U*]J^5'@YM4+!T,;E_;U8L^NE;TK0F3!S] )H*/DP.
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M$&8A$QFX)#9;E!=1&:U]%#&))K39-Z/AIWT8'Y;^0$TX/%2/HR(K^%/W>'3
M]-1)N:; %)SA(L>(P!3HO$)7T#&1%-#"UB$EZ1_4LW=QP,2D[BFYP#8Q*[&;
M.U?L4G38LP)SU:!4F+L8,M>)B[5FL$Y<7"K(Q2T'*H%X[Q)"?T2=5'M)=**,
M4U \P96SNX<7G#UU?QPW$F6@>E1T;1 Z@'K:I%Q3@/)@713&$<TU A1(1;R4
MC 0NHA<>4<I=Z8+X\(JSC0*4<#UFNYX(G6]V"7KM*\B .[8.,1_X,"I[&GEI
M#)]A..LB:+M2C5VIQA^J=RZTU4I1DGG0*$E*O?/(([%&99>RTR)?.1:\CWI\
MRK:[<SYM0.KH'BY!^;\KU-@ISQT$=A!X[[@MF9FGH(A3G!&) $,<-8)8BO^
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MM28T:2/G3D==9C+FK"1\UQ^4D1V.1H..&S<YUV?]=W:0Q[\-.9<;*BNAQ00
M. #XQI@>ABICF!)(>V41IR7[G>"(/!7>:6YQ-&25":#+ =QG"]EO*,@^#3P
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M7< K2.)49M24P?"L(%N";$9B)!QGTFDEA9#+\+JO&GC+D27,U$RL\"0\0%Y
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M]-KWK=Q1]%)2*NRD1U2DK-OZ#$+:!HFBXLE33S439-6!ON\#KT?JPQFW +,
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MB!R(? _W=*\F"P2\>WNZ0Y,%2QU@886PL'^6>EN$"S8Z< EPR5>,H(LL4T;
M)< EP"5?X9(0.B7%S';_RPU^_LL[VPFHTZM>V<O.*'\&W /< ]SS]5/M&\:Y
M=<A/\TE[TL_//Y;V7#_5S4>].*KZJ1K9+\!8P%C 6-_GP2Z<\SJFCN^ -@=L
M VSS%;8YZX\FBMRMO*+F$\@M@@/E%BEU6ZREX^]VX,\K1IJ>CARJ(;\R8>A%
MO,^]B!\H@.0I"$PC8DY;Q+TPR%!I$;.!)QEY,MK=+8#DP1&B9$2*!(HX$1%I
M&S$2@CHIN9&"Z37T<S0U)[SF>FTUD!O31!AZ<.P1!CYW/?@>@:$P@B7#&>(9
MU! /W",;K$.6<AJB4B;PL!0P7&[[L@*$:^N0 2 (( @@N,,@Z),0+!**6#8T
M$5<F(BLQ+7A#I*3)&D/G3I/@64TD1B-N+<Y:)!9(*QY1Q$H$0HS!\>E-@[[1
MPU'4"O.:44!"0$) 0D#"S6O'IBP/TF&-1%8:LZI($K*)2>0MD5PHQ@R;L[63
M4\92$E$*6&65U!*D<09:3X)CB@FGL%]7.[8:T_VSM:$-&Z LH.P6H:R,#KN0
M;7%-8T;90!ER-'"$%7;4:YV2]_/ZJ[=:$(,2#5GGI8DCS9-"RH>LURI&B'UZ
M2[?O0UF.:<TXJ:G"@+6 M8"U@+5+M.V9-H%*CZ)E&1NIQZC$>9#"%BO"@B!J
M[J1(JY7 @5!DJ"*(9QT5&:4XLM8)1Y@12:05M[LDK.;$U)RO[;R:C8'$=>04
MP#&1,RURD+/#6')_+BYC;V@+D8&\692IMH)A%MS*K1<1RSZR8I<W&_AV9[82
M^':/-AOX=F>V<NOY]GZ3#%O%@R<"I6@YX@1;Y!S/BKB,6G./I69SX5;O9-(V
M)>2$I8BS;,8Y[A4B4OO$C:)*L;LFV6$H'=HO\E"&9_V;8KQ2AW?<FU3A-4EZ
MC?[[:D;]?1^S!3?,$SV-@T\=']_%0:<?WD??_]AKGO)WVQW')QEXM>*BQJL\
MS6"7.0- ;F>V<NM!#I03X-O-F2[P+? M\"ULY>[R[0/G<#-ORZ':*)+ $%<J
MVQ-$,T2(,R9Z0YB<BX%S%92B22%F=,GAI %IRRPRSGMK$F'6"S JMH\SH,9T
M4=YJFFXTD:#KAAM5MS_\9D.TS5X0$"4@2D %!+Z%K02^W;O-!K[=F:T$OMVC
MS0:^W9FMW'J^75.Q&,$AD!B1BS8@'H-!EF**G+(F$,W=/;T(C,36>A=1<M8A
M[B5#5HMLUU.JA?52>A;ONG :(_=64\FVGV3I)ODVCD[2F?VRE,(&6<M5EH\]
MNVL!RA4 !O<)!D%] ;[=G.D"WVZ6^J*UPK)DM'DI>%9%F$":<HP"-UHZ'ZW@
M<1D1*%!?GD-]@1JC1;DETR3$D':OAA4:E6ZN8KDSE9V #X /@ ^ #X /@ ^
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MW?X0XG&[54 ,C4XW5P?<F;):P ? !\ 'P ? !\ 'P ? !\ 'P ? !\ 'P ?
M!\"'+>L1&6EB@8F$I,$6<:H3,H12%+DB1(F@G&9W?>.:,^]QH(A+81 7T92,
MFUC.*C#""!8%-E/?N.V&+R_>QM&;_G"XE*Z0NC9:UL;L7W]NZ D)D J0NOF0
M*HED3(>(J T:\6 5TCPPE*0UF@1EI$M/"3<"I&X"I$(QX9//7/S;N!<KAN'(
MQ67R%CV@A;E"?^RZ<0\%U_WSWWK1]4!FB\TW\R219#8BGK*\L:HDLTOGE \&
M9U"?Z_"N(S4L"YC$1+['E(IX2Q+*XD8KS*.Q#J_EV$6-24WQVGJ[WR$,\(D
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MOWH%GJFTB5$$9SE!7M4@.8BMD0TTH! =#@)[Y?U:&4IE J=,1<1%= BL=HG
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M3'#2ZWH;ZG(.EN^BY%?8O(^?OY-;A9*!4.)^Q=#M#T&?#Y,49"S(^'*04:J
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M.D;:1'[M#M,?T=)XT+Z1%1[T\=H0,'T]1X((!U8OD82NTU\03 =0_JGF-5@
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MJ<5\.GA+8-S.0]6!C(;-?\V])P","6&7143()Q'&)9P_.PC<A[\!_])3#J>
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M=CU+BAPMU)X_8\@^FOS]\E-20-$%PYJ:?X3L\$HG-F[:Q?O:T'^>5)!\PR0
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M+9O(WL4]Y8MLND0V952<1\/]L01U[^90EYX$*)=X^WVPDUG*X\RA*$6&W?J
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M>DYD^H[OFIYGI6:4> GPVS2UN6]9+.1/X@T)L<'.HSJ,)XXY<<R)8[XJCAG
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M\[Q9%NSJ;5:(K^/E^&?;K/+L2K^=KC";%:M7W]/$37Q?\Q9E<I&78F.)^CG
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M^A.?;'YCHO[IP^GG#Y\[HAZ@01S9L;TQO7K"'MC6#%@G5*=M7<.WQ951$(?
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MNVE0ACP*N .7<^ZFH#V[B9E8\ @G$IXE0I8&?*/69JPWTYY^RF!'3W%##U1
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M0#9T[=%13A!D49;Z OA&:@'#$8G)6!"8=N9$3FHQW[7#=<I)@S") QZ;&0_
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MFT[9 CX,M'21I\C5X3)F9**HRBL9RB'!(54@H,$V T8!:SA#Z3XC)05%?;X
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M6(ZSB>"I3JAJ1;QQ#JC3T%)Y",=M:G9RH[_D%]+>)4C P4\SXZIJ#;EL=#:
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MQ 837I<GLUYPX0VZXGT[)HJ2=M*I@/1F)$P*#,SK!>I>7:E*)%U$*3WO"):
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M:XJ PY.2\TB+<BT)J$>Y4*)#^I24;K1#SG0:Q&75%FA*7$DU!E,U.W5EF[1
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MD& NX LORL5I,G.H5G(ZN_-C=3H[OW^RN#PY.WMT_]'=TQD^L+3L$)=SKDU
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M.DQ5+)%X,A 22_&H5R:#C0BVE"G\FE;,\2NF=HR+!Y.O,Z:H<1+HEV2'%+;
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MU9\++E0P#I60VHV&%CC:%ARK&? =J)TEU/"3#XRH.GJR]E(*%LA9+!T^$57
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MD;ZE8C<^-8>K&F^\<"MZ.$:#B&Z:E!S0!>5E1W6=5"[77.MM)/8\X/N_5BV
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MY42(OM/L&GRITU3V9&Y':BW5^6(,VI#@$"HGMB3@W09AI *#R,:6X7OAI =
M!B02H^$-JSM#J.@#Q!3KQZ:VZ:ZJP6GB;R9+GBSY*$M>H>'-ZRK5C=J*#(RW
M@290+ISRQ1+!$8BEZTJ3"N;4MJ#0B%4&874BT3B)<C,Z\<KY"5^$%?JY2<XQ
M!U7J4R2)A@@*,4H)NA1%"2I:@R=Q%*Y'L97N?O"Z?NAJ=!*BRIG[*X^O>V^D
M;3EX,7+YBW55-73E8,9H+GR.:TD?,?9#5NO9*L>+"=3$)E1<IY#OT%"1-'PX
MK;YT?@A_P:@8"[=I::8"#XKH%6PMB1:>SY0FO.*M0-*]C:??AP8LJ12=UD7N
M]B<MT7 )9DM=(:OB&> 4<G@&/P](4=QD6D=8(WO<IKU1?4*1+=/+JA;@M&?7
M)CW< ;HV9+#>R3@&K8"ATO@$B9P@D9_94SVONU6T$!!*G)=KICY!%./I[)>;
MK!_"#UJQF#V2 ,[^O:(10>I=4=!%U15L!=FP"LT8NKAV Z1$B:(-PBH5JH$3
MO"D\$$)E$E%J<H*AS&$#@M?DVHAC=H[(?B>#";/&N7?C4!H^2$\2[W2V]YP9
M;EUA:86[<'31$6!4QQ3YUSS40?.*>8&/'Z^E6BQP>$"F$%KJ]BWM>2S(C=KK
M?&F6V#F\U]YC9W_Z[2H,]$:4TF;H6/2.T,S%KJ-GSR?)B1R;N0WQQBMX#R6N
MD< QI-,_"KQU,H:%G5$>QF-V@G4J01C] _65./#A^:B-"W^@G^C<=.5YPU :
M_"N3(Z=;>F]*$(I_%>G?1J-+6(V>\F-3P=7F*/[D*9BH48S_X#S4"K<;V&/#
MK(\#X[="SX#/P/:=]1G@P-G ;MX0D%E\ JZ!N9WNY0FL-%J "UJ!;SCZI>FM
M#C)4#"?7$"O"\AJ)/9(AYH=EM>@:/4MX@<:VL\HU%"5L7%KR90Y&!=Y5FKA\
M+L,= X:FP<4)+_.AT$2EY*R_-86& 4(A,$O(,@@6+R]F5>-@=+!G641H5CWV
M(IX'["T2R'/A^33TWJ]XD-$[RGF5\7@J3: V.GV7T+4CJP&QB!JR@VCE,&TC
M@6U/9?"E!ZC'6W5U-#?7N':>+MXU/ 5)D=W>[B)Y$GO'V#3H68T$IN2^FC46
MM>&Z-CRWZ"/1&',?A\#XX]O7%S_^X^<7?W_Q]O_,WM)]1I@VO-X,'IG;H9=H
M&)J1LY!:[98%C88>/FIT)W:^KBKA6:6S9@-.E#UYZ3<.&F1D/5B[686A1%;6
MFL/M-@($ 1O_\?F%58JEC1@?Z=*AJ#)NT%HCXQGX?I(X96JW(L#7R3(I%QAA
MU1+>77'T3BH&VT0#Y#(MIJ-FL+>WA244[L='9I9-QY@;','!'0PCHMI9G'Z\
MF['>FT[G&BIAV(A<NZXR>.(K<D6\AKR'VJ;MFM+,2.%04U",4HE<HJ1B+UY5
MBE$<KPXS1[?"IX'.!"--'[L.NG]>T+JZ\&-X5[2-=2W.'!VF$_J#9HPWRJJN
M3>QN8U[URKYPBAG0,*I2:*-,T8Q)=G0:DRPOWVRZTIUL7);+:%J&AIO.D>'!
M+R]*S 2D)_-KT3*8<091Y$LGH_J7.:Q3V =@WZ[0U'>\ /[V\\7KYSY6E$@T
MJV"]"6?6GNA&-!3-$4#_[,(H1'/:!:6'?I?BJ]-5Q:N80SX(AK;Y9=6RKC@M
MM1P/>3I[G7))<_"@_>5/(\_:B,%H&=9QGCDFGX"?5QW^9%C%]R]/F9,6-,RM
MZT\&>R1&.:QHD9CHT+N@7K2TA'2WN@KZ[X?O2XNQPP1.F5O@76$(584Y;MFO
M#]TH*A62HG9X-Y[*@,CX)' VJ2?CH=;Q%;,T",=_YE@:HG!SJ^]J]X)$2[1
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M,AQ:8&$7BCL0,LN%1X%*3D6"6[IM->RE)!OP:@12<]Q1N50:AED$;/2B(WU
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MDS?1T;>AZ^QH;VDADZ.D_L$1#T5_PZ0+\:(>L;V_W)X4?-(:FK2&>B)ML*?
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M\_K[EV_NT@@70?)E'EITU3!29U8=WT\(."79A52,NX\?V>]*N:CGRMTGL>&
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M\V+7R<P.).X?),M'=/=]F/?KB(H7F<>%6NW]8MH\#NYU<0C^KA4E_5G;3'^
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MM#GN0?AH#(5;L3Z46N\J$.H19S42MK-PWRC.XODDBC_))0K1+&!@)?FGP$K
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M!O"?*^K-ZE.Y.VJ5@#GTZ/*F_<Q'+:?Y-4JMI8>;'CJCT,'_H6Z-6$&D^8Y
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MV6_R)H[M[!&9 #NEW[1%=6 I<-PPX\8!WGLJAOKLL,,PR0K7M*: ,PB XD]
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M&_]!4Y.'X0T69L;WG/K;U&3S%,TS$4Z43%>9#$H:6#Y:=<4;%_V :$W6(]^
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M,WA.2X"J-1M_UH)0Y7&9!UN96DE4;/ 10PU.RXTW'$)#DMP2YVW"/H&TCYR
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M$FAK-+2KB(A*I=#\7_V?,]@VQ1O,1YV08=^U?BP%8EGFEW5C>S:DG[:Z+.K
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M?Z0'\CYK/%6V/$K@?/+.]N#OC^;M0"$4$.03:V!H544;X^_SU2N(MJH^J#F
MJCE>^QR%;E/A3WC.*L-1'I-]0,V6$CA_1,&97!'LO5F]=>X@-%%A[ R1;5YA
MK)*H=-L -N MQA_'G(,E@J;V&CGSH-+<3H+J[\,_.Q%8SZM%/L38^A$405Z
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M26(<+ V+J3I.5BT70UL,[5Z&)B&_,LB%TC=>/T\8;?2/,8'.;%$Y"T7@3$O
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MTBKBAD6F0\& JJW%2O)IM Y_T+K?O7*(.\MS#S&%>&W?.1$Q&[OE@(Q& 84
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MN/Y.X6JK7%U,.*ZA-^E?FG[&.@Z63B=-$AYI\'WMAE)4V3"VC=M#".-7A&T
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M]51;J#*VG*4-I_?)'!$XC.,_U;,V)-QBBLGW(;IQ-3 P0XIV[D,U%8-C95*
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MU_%+(YXAU1RY;P0"119<6LQ7!R(6N]:_ .]D.YV(G3.@(J77.' [4HYMT-7
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M+6*1)H ]!R#'=&:8FQ/') &BF/HH<S/'AK1O>1K]!1X\!'3GSDZ2=L@3X53
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M7&5?W6MC&#I^I!0WC: :'*3M=*SE; O'"F@C^Z9+_NSS2T&/:$W7D0(E;G(
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M/Q+>[\@&D M<V+W/@?L"0RF$IP7O:(DM>5A\Q?)OUF Z$'.3F.JT6T6$ _8
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M2O5>4GT-^[95MLX#!RG$($ W$(TE5:/D1<G;3_+"Z Z%2^C'5/"),J:G@R1
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MK"$G1#&'U(\A?J'&Y$1&)%P)TO) @F\U:8?=S)K*A3LM)!T>-GH3KB<G\QG
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M>3,8^0;[7UFM#V3? RR?O;9L1Q89[1LV'^-M0:W[Q#+/!\G\%;E<-.SF8;L
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M=OJM8C;EB&!1Z0@3.$U=55@WQ;(!9YO<Y=>+F@JI+=@.8,?!A(6>L_S(!SS
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M7R;=]0O%,T*D%-@[!EZO@P2ZT=C1#QUN$)!EY+TU8%BNS\FLL3$CVPU226!
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M=5@WGA10ND[B3_7K\JGH .'OO:U"IU5X<,AU&+@80]I[U7KD'FI8F:+#@U%
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MLY*GKVP95KL\!Y/1+0GD8X(KG.?:UB2VESXX8.77WW=RMP8R<1B B-("_&4
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M J9RALH"W65/6(48N0%-JA)@1/WK<*F'.&Y9]5N5DMB>@.:UAWI_UC9N]<2
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M.Z%'VD.Y5ZCV^>GIU,);2HV#-?8 3#VJP#(RR6D$>O7<C[T5Y-W3_9::IO2
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M5F^1MWDV-\_JZ97TP'PO)\?\G0*"N3'S\D$5!N])@L.GU)_>1Z(,?00,$.6
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MZ'8Y7Y[=VD5R80A%B_5=A-D<]3(W@=11L#[: =*0G3XJ.F41BU$ I4GDN@.
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MU'LM-TVGV&7["/WXD4V5\4:XHYVJ$O>*65229+PSP_5*+,9Z*NH*E\X+#S-
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M-Y(#1S!RQ(=N>B%$(2]\S7/7#7<.Z1O;EA39K$B:%H/5G[&/0X> 0*N-YWO
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M9KD<:[)=>C[X$.D0O/C<<5G1)35",'TMAK8K\_A:INCUBE@P!F@M.# 3@O%
M(64R82'%)@4.S%W,Y3Q/Y)1L> \;)Y;%XI35X*T)*IN[5O<FR&&1B7P9?!UZ
M;B_=OP"_)BDC1GI<+1T&GC?5;]*K<VY3PX<9:EB6 0!UV3]#K"&%H@Q:=X8D
M_<F)1MI(9<4O<(D?H.$-Y. <@MVOKA$CA3BM$0^9%$=KJ6& @)US2%I4VT.
MA)I2*&Q)D+(K&B*;'DNT.\<:ZF-S.@A:F__*#4G5I'2D+!#E8:FDE2G'W((Y
MW4'G27Z),$<V^ULV ;B?XEP5A)XA+&\H^A<>EQ8^[,G++^]])A1GA#BGY+X6
MH23^B R+) S-)W.>;7#X0 ?T.0R>XT?02AQ_KR%-5=)%G# 2E"<B$!E2%EV-
MRN0N2E1:YO2Q$ADUOH''/$<=M/V.50Y95=]2P!0^K3D=U8I=@,3IUWQ&$D)
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M(EKER'WC!7F,6R]7F#>D"(,G;X57Q_N["'(T^<:@(YA33?*)Q]H.%#&3\P>
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M("LZ+BB9B[L'F@I'?J30_%__]H=/'W__[P@SVN.7I@A&8!UI0)<0*;Z 7?"
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M9*>_@=AH[=&4BJZ8O_C-+)N23@(!VK.+56 2;\1RSJ;F("'WP'.E=2!J,T$
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MOGE4/;Y /MJR@_*<H2# *-U9=^U$)FE(074R"%#S$.EZB_^;O>3*%"[,@2!
M$!IHPHQRV33S@F&X4/]3]AAQIT<WH.P)!-T]D$ZPF,&S:Y>3[]<>!6+SPNR
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M#W)(BP(">9([TYJE-(K-%W5]Q7AL[Y+XEK!X9L6GJ[^!.&7VRU(5ZB5A5B*
M-P'&-/&I87JE#D1LI=&"3VZIN8:%0:!(O>)9=+=U7P4$\+U[V$GK7%9O;R%Z
MP_I*_1F*2A,BKK0UM!\0!W+1?D:2Z3E5&6]>X]A\!)M=D$08P9L/?"K'S2Y$
MB-MQEV?,]UD%Q&E*%,,>NB0(L!HQ_KK7L\)1W*95G18  ?()]YWX/0\M"X-
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MQ%AY%N4>#\G^%85$JST$899^]U8KH&V6$_ GP&#8CJG= OCGS*.-"Y7]8IN
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MH$CFUL<(15%,.3 A>1./"-M#3@<2XBXQK-:P^0B4M89R[+C7<ZH,\J_GVN]
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M_J$R,@VZM#G>]A*2 7O]:>_(PV)/5HRNMUO$U:E&WH0Q9%^A0XAL5V3"UX9
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M?R+X$"GM.A$R$8FL1"C*89!:UK1<)$T$,R*2&08U$R$>I=I>>4RP;L8HQ'!
M(^7<;\:<*ZZ+"0T9:7I<)(P0XT2!EGD$ZG'*B0(YED= $C:=./;Z&I"=(K 3
MQ]$@UB(WM NY.'_4VTEH7D#&DI[KJ!5&GSC(JI)FF C^Q)'7703UR " 7. ]
MJN1I1",AUW&/BA<%ZWT(7.EZF'X47#5"$).MUL[>G']$(16A1+=.XJ+!E9?@
MV^N?R'W;X?^NL 9CO:%4U*Z3.(HMG_1V,5S%O<+$ZI"=8CE7=O&Y_B2=9Y!#
MVO[4@+JV0A]ONH"X=3DUZW!U+0^@.OQ$6-1JQ[5\Q%QI]FF[QT*#N8"HT'O
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M!>RZBF8K]O[Z^G;U%B+Z.;Z=RAIF#/$D)K?>5A G,$G98Y=%,^8?F&(7UU3
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M/813]UCRY)IDGKG.%QSG(Q,.SF X1,>V--7HC3D7!*EQO%924F//,U>K)7=
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M2*%@?9Y^N>C>L-/.Y_/;SD6#;- &X^P3#R<>7I*QQZI)5M)G,E+,X?!DU*Q
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M 1O8KI[6L^HBA8\J-@+T58,B3$[>ATG-GJA?3P>K5@QS# _S("!Q0FL)A;2
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M=,^>%+UX[W@OF[RKF,,-[_&^=J_\_$P]T?O3+^=G^EG@_P=02P,$%     @
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ML^27/(5!>(?MIZ1TIF.FY%=092ES3K[R\%EZ/-[^'"2]7YVEN0&\O'^=Q;]
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M<KP:Z@ (D#PI0(T6 !%6N1X'M-&9<O0?Z-$]K!TAO=-SHM@,.0XNM_)T/8!
MK8@C@#&H!HLX# )F@W0VN%&(5,' '!X78&$:6 0R@4J4L" @)Q9ET'.4: $#
M8@)CPH00KI,,)0$P0#% &\)W.&327K-1T81V*0=F#27(>&B9">S9*AZO):2C
M,#*36B*60@0DGAKID8(!8-!$,AV 16>"=4B0%F;E6OE*F4N.L!,D=BD6*>H!
MA/-XA'"='"3F*\D, , )Q @!?!I3JA99-"[KOXJ;6HC=++,;S2Q(F)$EXDAM
MJ-X@981J0&PW!6-6Z@4@J(B&MRDH:*G)8QA*I$@,$$K"X4Z9'(F5F$-A>)I-
MYR"9V707S.(VTM@8*\L28N= '2:=F@JW]@#2H#29F$[%RYUZD-((E&@D3*S8
M92<P[1R32"\W,BE0"E1G1]@,'#?5*.906#R[2:GV;' %V<21N$ ,G!C) ,E"
M>)K>G0*F<K!8G-0!"G,"952@ &-VR5E6LI5.8Z.L.+@$K#03P"0V1(UR\%%6
MFYOBIF!-#!D$3J2'$DF6, =01&#S/"X RNT-HVJZ6.^RFL0,!I%(XC-TX:'A
MX1H>F8=UL05JBYE,#27@,%RS'41V\H@0A\4<RD;8J&(7V*31J#A4.HY(-UMH
M+@[;2$;T *I<$K*5I5%S0X J!HF'5JM,$C) &/KY9H4 I!)<8E6("P.2(HU.
MA49EDN&,'J-EX2T. MN.@\G@#HI+@S :G9Z)]=HAQ4B$L"@*ALL4B@!R/*&6
MS8:J:&HB.A1ADKKM (W0#<307&Z G894$>5$.,W,!_(,=H!9;+(#)2PU$.')
M,^1Z(IS:ZQSL)I  R+."!4 ;R?EYCS*(:A0,2!9+T7R59\/83$"T,Y0!Q%#^
M@X[.(.'1>A$$#+-8)&@-7XIEF*T>E]8;Z(5 H=$! R&18@!#R=+1P3:LPF(&
MLF4Z(,HJ\0!A:0* C4N2 C1H.A N@LE1&(W0CI;P_OX$T.M_H#V ?W!+?)5>
MJ1/H<22+BF=T,95* 5Q-X $H-B</\L^^U'8] J*Q]1HV5:.U$XT6G9D -V#%
M6#)4&0[ NQ@N-#^,C3>1  P&4N#DPM HGDR,$!OH0+'9"&=H;)XPSC2*#0R6
M7:R#T4@L@[UWAD*NVX)C*T,D7 "!A6)[W >6K@2YD#@PT*$UL^4VK4 C!L!(
M ) 3!@*RR5!/YJ:WL:$0FYG"9>'"H4(PE$-V&D)M3%FO<PA3 FP"NELBP'.E
M(0 H5@Q P#UKAR&$0!$\*$^F9,B@\A 3FT?',;%N&X:#9E ]UJ^BLJQ,&ILO
M 6J)?)XJG(17*GL Q5RQ$2G"@4)X<HXG$7&365P"QPD54CPI"L6S1T/ <JY9
M!++0>40MT4UDR T4)P3IXK@!6JJ;SM/@=08+GV\PNVCAO6<]OI89IJ-8]'H4
M!"#6V-Q$(EQL)XME=KP HU8*Y#*U!"<!P\18.Y+_V5O#3'JKW41'4\5.ERL$
M*85R:2"\5D\3,#6\7L.V".%$M@%!5#F)=@6/2X=+\5RTP QT8&P\-]#-\]BZ
MRN,M3&Y.& O."5?PR3B9E6ZW@Z$R6[C!I09(T6H*1"(3,*B],]0CJ&2TV *#
M6I$F$8E,4RILGK@($IIM:!Q3;>;09#*N"T+!<H$>7<L!0(\=&ETV!D!D,3&1
M"+@4B$1[3$Y/@0%[4Q&3QR#!+H]'I@. Z#">TS,SL,>#_C(2(3&K@1Z+$L@%
M5$\@(WX>]WF09^(F,Q8-I&&Y.B87@4**>!Z=]SH'B0IF\D18DP  [-D%;*AG
MA7F?#1SOX&O<%"0883 RN0!6.! ,,]G_A7E#?G4.<+?>(J1CM#( .!0),D'0
M;*)>!O%PE)OD/*[)P, *PB$&M1P'"J/8J5HPT(4QXQU '</L9H,)!A6';2<I
M=!I);Z"G4BQX,<%M,YC #%LH@8L@ZJ$NL81*E^#<<).:R<"R7>80,<EDY +Q
M1KZ3IR7!+!0%&(CS', 4*!B &PXS>[P:RD7O7641*4PH= @-<L[GE$5D\@1U
M@\*S-\0:LTF*4"B !)692I*[54"JP^%4TL/Q:IJ&Q68ZV7H]PLH*!6,49A=%
M;U3PX+UG/1,>HG!"Z28JP^W$$8@2D RAT0AX6A%+++'(.?S0,"1>8#3Q=1I8
MJ(**9K*4/!O0)J>P(6((BN$Y;]E(<#$8)S)*^;TZ-.O"L,*0,#;5:2=R8%"U
M9R=!U';/(4KK,2,YG";06+16J@D-)'IX(APVDMG-XVK9$CH"HU.1-<(0!0C&
ME4I-4B:M5V0>5> F CB>U%#%1(!-$JC9"C1X<FP;$ZS526%J!(M$],1AMC9,
M#Q.:=&@[0*J'L_D\G0;/M[(<$+!!0V-3A' 3Q4SJ >3@K7R^T:02$EAF&1<>
M'DI3 <+I0JQ-QE9P=%J<'4)R>6Q3*'<S=1 >$\KE2B@LC8M-(& !!C36S250
M+"R.!,[F4H&]%T$4- %&!Q#1$JP-8&?)<'(E4/#9D WV$+L#Z,FX[6:00 &%
MR3_[9#""ZA"C& A/0H_XE8XG1<M4J% @#M #:*.8+%R3B^KB&P@B\7]BN10C
M!V[4:-0@OHC-X(GEGD0?II*R;2"U1J46],9E IS"T\CH#*@"@,%;K0("/\0I
M4DMY!(:;#9*%&T0R8RA5S@'C\!881J@*]^0[%*J% 6&'&4V?\V:.3(0T@=@.
M1#B\-P2 L&B;P6#C0L$B%\!BM6'U="#'KB4PN$0NR4 F4' >$PLE&_1P)87'
M1*"-9H_1:=P,HY@&TF(Y)*P*RA5RZ18,D].;VR"16A[#' :QP]!D%1M!HT&,
M9AS;HV*G6B10@R&A#C-2SE*9W>%B.5!/LM&8%BB & [&,-TLD%8ET81@$4H;
M3874:WI38AB 0."A+79@&(O+@XNM4CY4:_-L 9+21H+I;"25T $6<,-<=F>X
MED 0>P[3"#V!SX=X BA":S? D&X7U(BV"BUH<F^@5]+9(CZ+"\<3E 0TETF3
M,9P8B1.%XH53$30!2@64T'@B42A-H: 8Z'2U,\23YG%D/*";#">JX28%%@P!
M@K!0A!R%ZTU%6$Z/9[1#K,00#5 O%X*!2CG*Y<D@3")/]J[!0CW.4R21,8A
M.@ LPY&!80 G%$  NJE A,Z38QLQ5B#@UP&]Z=P71F$H3*H<J-,3U1Y7*K<*
M%"ZYVVZ1?N:%H7EVT7] .7"]@QP8*)('H_4 ZE%())YEA&K=;C1.[F!#[3IV
M*-R*]YSFQ"J7DFM3(,PN+H4E<)H56@:1#Y);.:%X)%2+5E.!GEQ#(T JM3@)
M$B2T]X8  L"S17O^[?D%,9D,!@.&J*!;>.+?&[4="&$N6/#WJ_+>>_ _W/X#
M>Z___Z%8 /QCM:"W]/#%\D*0T3.:839(;1*9^9=*"@-'F*95B<TBLVL:&!X
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MPJ5+6RG+_O:V/=/RP>\)J?)!_.&Z33(/Y*NEJ-OM\=5)'RON7^W\N'=5U\Z
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MM$UH"DW2T3+BI5;"W$;.7>^GTZSM%+)R<52GIX!*#5)$X3Y%0Q9EXPQ\Q+2
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MWGBZ,SZ=H#6C1K"NY<:C=7&\,27X8N#; *7KH7I&?JA>_M3R.LX992].6PF
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M!)-T4P:' 0)/0%_M;[,L* >K-X>08D T^S];UK&H?(E3^!];UI5JL@V:9R,
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M!K-6YN9'2<K_?:POQ3X]9&]B18R?DU,QA$6."V1DWCN==J]%7<Y- !W.-3(
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MC/^013X%1[4%%JTAFSZCWFQ 7JK;><"ZE;Z@RSN\_?CT&O(\(F(U5-[Q23S
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M)48J+U<H2X:BI1FU48$P]>-("C).;=PEB!!=^",R,5V;X>6FQ=\=&>&J8K&
MP-'>Q!'O\G9E%#D77^;N&6#'N0]5949GMG<@OR>K,.G8',*U3_1'>7;+KNF>
M_&#TKUHW HELCX"I/(K=6)8N/YOTG39@)BE",/T$.&FG,%?-:1(6=1'>)=4>
MNE]KB+&H'%I4ZBN:$_75EP:,=[IPM9ME7KB#C:%J!6J2T!(NX7C>92%G [I-
M+G(UQ2%Y)GPR&N9,.^.<9O/:%&FQ&9DWDG%>VS&+:7Y7IC,W_^1<6V>0_%#:
M@^'!0#$'M\%D7553EPMQRF6PC(9+?"&CZ%A(<5QZ 6T42VF\!+/_O\<82D2
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M59H;5@FPUH4";&GG64*XG42Y@GP@=O-:)MX"\\6RQ >/%)P'Q?=O&J^(@Y?
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MLL\43ZO ](2""$@:. '7$0PUX6]J(W6Z(0)0QGLY!7U^I/W\L"YMX@XG9YZ
MCE^@;8[_0(YGV3&IWAHB]5TGVX3DLAK8ZAYMOSM09E.HLP90;?!@.(6#+^S3
M0JKMEZHD2"ZX*G3B1</_9F^(K[$*N</YZ\4&8Z::2T6$"F85^,4J')_\"+.N
M3(_ M/_0\L_Z$&>-]"X>F*Y:[9.M>^?9]<<,DJ.1(M^WR\KAD(5%WUPR&L/Y
M,21JZ0Z'/O1(>] PMSRA=+@0-S9Q D)6N+R[F.(:,3)PQ*=2U;G<LX"F+3PY
M)E0MB")_+,L%UB<H>),8C!HH OUUG=8XJ8(=])?52-I=.6D70:K8F>&/&RN#
M(OC]K%)DIF:M5M26M\ER'^/,'[#SK-WPE)YXV$G&1EH=((VTA1L .TJ7%GN9
MGP+#VLE)T<9YO;4Y&QGKU-_M[+VO-%JFOX\K/[57APQM%5'>*UAK5(ZLM&U7
M\&CRH#_)0;*75J<"/71/D>N&GS9=N^??G8A5\#0:X;<L7JH*-26W.Y?#Z#L#
MBU_C4'0W_\W7Z,^K>[3P39&GGL:^C#":-C=?"0S(EWN5#TBW@D]XQ6SD2I@R
M"+S07R-%.Z"@I'AXB+I>IWNCQ"E($24WZJ*JKQW%3?'#V/).GCS MV[7G#*R
MR_4P#L%YMNYT-\EUUF+V?FRQT@:60X(IQ=XL%&4NP$BG&H?OMO_)@9$<@KS2
MCHT^D$+H+6+*A:5TL7$ 0?".U["NX*AU]DO"KHP5UR($OJDB'/^AIG!W#2]<
M@:3IF %L?8X1Z]\+: FIG#@P,".^]"R[EM,;V5?VF3.^S4X]+<1[BG0[B+O#
M25 FN<,A[YY?A-H\NQ'5R!%,-WA]F:PAJ *O> \';.7;(+U9UKKZ#./L] HF
MT[> S\W8(-0:AFK)NM<53Q[V5MA@]?-GNF,2!,*6_5K+/J^11BY8F8QE^BA2
M_W%[S^/+V736[?B#G@6EI^TB ,%?WUMR@-GH3M+**[=ZG&^Q5;8!)2R0"N(8
M>',IWB U01P+5?7!:Q,I5YBIGNSA8P$ E-2K!<IM?DZB&0,!; CGOS-[5!/9
M9MF:&6W!(UV?R$#^XZ+,-@:))J/WIP6<X%\G3Y*VV1;C=[K*>(.!:52W3?07
M@20\]9D#ZB2]R[UO3.,I_5HE:!4@[+J;\@?B1R^3D]H&TDZ<FPL=..7G:>E9
MK_ $BZ >9;SFBS4L00,,5FH> .G?,X=9\M@ZE1\LOK8OI!*29Z&MR*C2U5J%
MI)F0A*?)2 YDC,8[CYYF#^4.C/-+%&_C DYQYS0+<JL]?#N>%[_-3I^ :;1Q
M  :Y3Z**+)83U]@7IK+KGM?;A8W1I?-!N4#0T#&O#.E"LFJ3S@IGA40^J0Q>
MV]>*%5JA$( &I-IF%B^2@/Q;X%OQ5PFM<OJF)&BNC\:=?/^&:$.N)N*S%F3:
M:=*J^QW3A[0;.!6; 99-&@OI-G'><6@LRCUM)"U+A^9-OBV181;5S?+"OB=K
M"!U)MB>#AS#=Y##&#;&V(=-QVCB[2=TIRML/5!-/=9GF&FZ@S,/36484K#^?
MMV$/:]6,,,B;O%Q$:KOV\%$!A EGHOE;!V85AD%5 LE"/F^@,B7?A93O< P,
M?6S;I@?*PXOS9W^[],X9&8EU_E5SB486UNP\TI*WQ?6 9KN5W01JZ[4ZQT_U
M=MAX^OI)-:P16S5Y'0O@[RME:WCJYX3C/WB^K#"=SB>]:UC0]B)37W_.C@&7
M%(QN-2VN+L,</%3 +7 ./WMI[\7DHLNJ2:8YK1!E\U6E)WK8%(_/2SC^$5O(
MCA+4-#TAAUE)@F!9P-XDH:XUR 1)F<6E&#9C5H?V<$#=>_KDVLIGZ5E.RUEB
M]QW.Q9Y"L$!CP\ _>PGF_<'_L ?D48*NK8<?/+1^$4.A/DGA7'_0=E&S O/\
M4K4;=ZK7M-BD&VY*;3)!EAX2@]?/D+9,D7]0D0PO^,*F_M./+HKX 5H>M2J%
M+."R,FGYQ^,S4=_EV'4HXT=V%LGU5IGE +(7PB/R)^'>^>M77V<Q2ZN$JSY^
MQD$L_1=H"2U$*;:^ "#^6B(GFJ 6[? QY&#)0A^,U@^^F1;EGM7Z2C?&[/ED
M$J]:=.,9U?!0$VO$JT2!P<_)T'(NP=7>.YP'L!2X)[UT7>\4)Z)#_N'!,SBH
M58LX7UEOU]!)*\;?%PMC3=J2'EG#-<E8]W(-KMP<.NK\<,K3E#_&QU00N-74
M^CAGBY<NYY%4M!I;35J%Y5+)8K9GWVN3_M3G8I*4H?G%D<DR DXRT1DZ= M9
M2[7M>45E6]+3&0.FH5I4U@C(-\/7?*4L!3@7,X[/B#,5QV4W7-:DA$U$3+%L
M!YF8Q4-:(,Y*ZX$:_+@Q?--.(.\; Y&;Y"(#"ZMBI=W7*>//2#)%"7WGF *>
M'YHNUARHKP4D?/P0Y@6>;Z#/]$;9FF;K,!"@?0&]7M N<C'2)A:EW[XTH(R8
MX7,>:I+;ZM)^R54N8J<]/,=0HE-J$J)Q[$!\4M1;P7N,>9'HJ4$D\:#+,4%5
M/@D/RN+YU_!NM8)P^+2\7L/AN</!N?2M+]E@$23 ?5!W8D[WP9JE0T[M4?&X
M ?>[SJ<G.L$1D8X7[3E/]%CD%-@2QX&A(R@9R@2%GM,>*\ DA'/AZ^IO%P^&
M$<8?D 0U.8:N'P]/2O"E^L9WS33'M'7 UM75$;IL9L78<K.#F5$Z-50=#40<
MH,:<TA\I(NUZ4/$+BKO_C7IDA1"2"&K[Y$/,J1 USDZHE"T8=^])ZRQ%Z^:N
M4GG(A\\?9+!#MGYD?98-B@6>K%%Z=$B3%J8-TP6@$)1 WSE__V( 56:M@5F,
M"M_&CRK[H8H'/P1RQ?J%TVW9& D;C'P@V7C"%VUG:CRLO\;FB$C,^_4[LU2+
M LX;3@W-M+T)%Y;CC_Y2FOB:(/)_^\>\.@XU.#A$O?A\G)*)/Z>4?\=IR??(
MKG?FXI'U+/MVE4>G>P456K2SF$>*E(DA05ZB6T!S"2JXHOU0)Z?UN0P]Q[.0
M>('^8#XMDW&=->+.B3Z1&^G2+4,6R]ZSUR;;8+' R"DY ^)II&=IF)S%%(^2
MIEX5;YEXC/>/M0-]1FK 161X2+GKYQY"C-8Z!D4@Y)BQP==MF ]99,E3#$@I
M6N]F7M:<0WWTH"JVYDXPLY\65Z,"@#> F*X*"]UZA<@#V17SH(S,64$6A:#\
M%4G8+MM 6+U>L*8JMV'AA)ZISCL:W0F]_'C(Q''"0[1@8*>6522[L?%TLA/0
M?+:6#F#6VU<0S59?!PPBZ>(*36JG??QOZ(D_W,_N:&;_3Q9KNO0E*0S!GG'@
M[O >"<TY;5[.E+2DT'4MJ%[22/"6UM7M\S*J*V\+-Y$?5J.)A879[>3G0UM0
M#+,T#1ZXLSL-(2/)&)[9>>,9JV-*C4V8>Z=.EOP4X03WC&OYX]:^;;Z(G'*^
M8B"8AY(0PA;R"^S7>RWF_DQ>Q'_*Y)GB2NX,V:CJU-('_,PAX4=_T0K-JO++
M*ZEJH(RZ_^[1%4>;E"U25.,K<S@J3OF]4@^'?D(7G_T*6C&E-<\!XT*]^^$.
M)X61S8?4=N?ZP[3X+\3#1U>#$\;WK\+W['4=J<$>L@<-09[F2Y4UN*=9Z=KB
M#D<*EI:L;,Z#N5U=DYD\L-JBH12ELO>K]?^]:T3:)IN+2 8R?TZ8PH BNE%$
M9PX%BW/#PI'+%O^+O;<.:_/MTD6I0H52K#@4=R@6K-!?<0ON6DCPX 27%HH'
M* 0I!&EQMQ!<BA.TN+L&;7%G_S[9Y]K?S'?FS,R9?<VY]N'^,U=RY[G?]\EZ
MUWK6REJ?5BI5_N0PUO'=:]3)SH14B(IGTM(8?9G6R2/G$Y[HH]!1_>M?#H=K
MM(@&)/.D#M019 .\7)(!U1]AA7/_TGOMA%+=_$/M6'[?-B_["T,:8F9NQ>Z;
MG,/DY/MJEG'*=.H9E3,R9\ $4M;RK%&!+FL%I-$C';<*3+=">:!+4$4:H?X#
M(3KI"W-MY> 57H@XI7UX ]]"ZEOZ<\8^\;>CIV)M[G84HR4-4,=#"OKQ8U_.
M9?WCB,<L'2JR^/[ZLX5\#DJ+F,2.]^ WAN[R042UWYF<<[L.'KMZ73VHO,4Z
M'MLXF7V57;%Q^9O:\8')+[P\@X*;V,SO?_PT2-=6!P17%$EEO_;:-1^1HE0M
MU0JM?4*BDB+B&)^1E=6*3@6QS FW.TU][DN')&38!57<D"I_H/EBQ QX%5:N
MZ 7=",7CUO_-;]AHORYMI 7]G%!O:_THME-AMYY)A:I?0H"U-Y:XDLZ<+FD'
M33AJ&4TA8.DB3FKW4WZ_$YXIUS^U<L:*FGM';][7@9Q#JW[H;VO-@E2]GUEE
MC67G@U1,LFIJ1D[PF@\ /P^FN+L4P7YIJ6TMC;4Y'T-FCZ[#RC#01IT_QK[P
M0ON!!=O.7$6Z197EI:07$YSO'/UZ6/L+T&;^!#-/2Q"DZV'\%E,,TW&K>NX$
M%@L$[;K5&ZTD+4:1F377C9Z^E87(>$9/H9M$W=$RC3XMF#=M(6J>.;UV\B%X
M-<LS%(%*& #3#^03_D9(7JCKBKK+%7C7]/7R^:@W<G)3_ESIH(FK>YI-[S3O
MHV\M/H]6*JULZZ7^,80,D5'WQ)%YPN ^4D4%?3/("_M*YT#LIKS:$VY;Q^>J
M/$A-P-1!XZ4.U9IK9'%?39L=?ZEF\#3>,\A.=Z8NH(7EX 7YG\]AZC7WLA(*
MY7);ND;G"7TO#*BS^X)^^+4.%Z%:';K(.8P0I/&JQ)/B=_S1M7:-N_J5S3H[
MA1N^*KJEL\5:7G\IY4-0CSSUZ+9SFWP,8;IP2UP[#\P01-:".S,5+./!6V"B
M=U,]8UMH7I)NR$F+R]=YK<''S5<*]=(0+AM4UEW(J=1S>]R62B^TKL+A\5$8
M@00//></E1^)"RW,Y,@,(A2-E-(M,VG5&A[^K>1KOJ53OZ4ND%#EY3*-]\J,
M.=DTZ_.8<X_;EM$IVW-*QI!BVK7,:0+J1P/.Z;E(%[I:.;>"2B--BU]9 RM6
M_Z0'J:9BQCN-@A"%%]J0%U)S4"#<H</P[-QVN'];RYO(R.(]+"@"M!71HU'X
M+L'T]93V7]JN&201P+%Y9K], MX8KO"^Y532KXS^A]BP]BUKBQ*-G'VMUV5A
MY(K+\.;%_;6<P1R;>%NIN,@2S!-+CB$[YP,U(!F/+3XN3<*ZW=?L%QGAK.E;
MB8^XO%UB*_0@#!WAOO]Z-FY"2B^.#R4-@L;+3^Q2].*=TT<Y!62E[/(LQM^W
M7(_M6N%H3%^]_P&9(FSB[;>HSS:R]C;][.PE^J]FW/J1/MV<.%G@8%,+JJ\;
M"F( GBX>N9@)S2KGUA'14(;-T@EV:]>$<@-,K&8T9!8TS0?;2?2U@%4(;'/:
M+,-US\RKJ.X[N:DD>V$ZO,1>E6:F$>*"1ZPFFT0ELX,^A^E%:!?$GO6(>&0_
MEUX66NL[':>,>9M/PJ@S]%NU0X,!H,7*G+POG-A%2]3Y1L."OY;')67CT8!H
M+?B KR7!8_/Z-[:^2,6A/]AICR_R"[FHIEK-ML\L?L7@_K#@=8@8C^&TEW,D
M#GR#<_N8?);(ML8WX+BMRKK2+Y\R_C[3(8.\)!<3A][/E_>Z1Y99K@YGUVZN
MCJM_DQ1*%.UV@I&N%6>I*&85ZH=6 S2Z9]GE;N81JH16:V,]A*!QVS)DN$DU
M=?LT1\]G[XLC^#K#A_$MN( 2B!W.\BG*T(WBT?,P'@C*,I^[XUF?N)OM,T#(
MV/1%>7LCMT_HE](=N2U4ZE[[5&+X; $[?WR^_$X2Z5.X7$$6DO@M2:AT:YG'
M+D=>^$#4F+E!DGU0J)EX$!4A(%K=:$9C&B&3*:B[]**^C!\Q*>BI79(QM4?R
MDK>F-3G"J%8#IP;Q=F1< 86(M4RI#K%(7N7%-(EJ1H7.I;3WIPEJG422E]E,
M1;SJG^(%S[V"355* _KU!2!):O932%<%*57[ (86' G0(U8GV)]QV[T0HOE_
M-N>E[9>"C3IJJ#YX7$A6!B1P;X0OFD\-+SR9G2PE2^>5#=Y7$38N#;VZ'/O=
M^S2/5$-HZT5Q82O5]T?2R.8TW4/3R9@6"\K-#=:[R-D1'T(]PM(MK= !V[UJ
M0RUR8#SN4HAY4KZR7*I2.K967-PSY]S9'0<X4>?;*I* &(KH3J,?)ZX3@U:4
M9FN-T1]BPD,BBV=!1VM<R<LJ0_&\P'2C[VZH$SL$97T+CCF\M"2'D"?Z<X79
M8C!8^7F>"?MN81XSSRZ!EH+3KNA&XNS'ZIF9D0*E1#Y+P;D.CX0J14"T)#5/
MYB(]F&E"2VM<,  =P*P'BN<?\.'KU?L^%+A\;]3IRO_,??V(__V(.K/\2(U)
MW@J1M$X4_EN_ZF8;?5OZK(9/HWX5%G;/#>.VO_92T+ >PBV%28!)3>,@D8^I
M[+79]T9ZT[R8OVJ'\W>B _Z:DXV_Q]'S5-]V\,+6=.MD/HR=;FP%T%3BZ0:<
M3CWJ7Y!_0$@5#."#M6G$.ZG\0TJV*(UH,:<Z<T)?!%MGT".=WFHF^.NIUXG\
MM@K P-1.''R"W!7\V?A@]'=,4^"6OX6M1Q.S?\=1AKNW:/ N>%8^@G+C8OG@
MJ&%\"XK>+2=DJ4Q]C'0X$2A\[CJ%7\[B%<G-+.A+[F93\WN%TXV)5R,OKR!$
M<S+^W#%--"^7650MEL1X<_^GR4>-.<$:5)FP3D>=^/2\J(M)9DWQJT(W.Z5L
M@I"I02.#34=2$!78(E#J&_0JR\!EA8$MQ%%+DT<>?@:N34I"J)N?/Q 1\[LW
M[7^Q=7AI_TS1O.^RR!WOJR,HGX2EYEH_2/N9D<S\H<=HD6-$@"QJK!X@EGJ0
MCO=B;3B"G9Y*Q?*M%4=I/!%/BG2!!J*=]7<8IXRNOL301%?L!7M&-?"%RF92
MN$"T38O=DQ)F9W(4DA;M'(PJSF7E0A-E!\F%R3U[:SB6EDW\A-\=U[@<.L.2
M@QNO&)MGYP]L!HXBV;G_DT4'+2VREOK[8?XJT(?+ M4AAJ9#WOKYFM-P5_=Z
MY@_[]X>7F(8#OLVRS[S@O5^JFCG-W?]F3V9%]P,TBR11I=5B%$-<$0R%5QL\
ME-%^?29W%N(V/2=)Y=QHTWNP-<"Q?3GTQ-51_G'Y4SO?;"W_DN\%3B4$/9"U
MG+<A-@@OS -SS:EJ-@46=99Z23)RA5RGNN9_T@J&U@O_./.;:^!I[N% 9(V]
MOX>)Z4WA06K5J^*U9O#\Q+7@R+43&2-FON;D:W30TNE;;NEWWM5-QNA7]D4=
MA8]ODL4_73T^Q=Y'*5X7/8.WIA!_$8H?Z/39Q+10#0 ]59/'GBP<SY\D%VLS
M@S,Y7(B3@#IV4_K'),HFU68P@T/AQ._F!^8]5*TYY1KBN+$(U"NES@CUOBJV
M9^TJ,+BCEFY%\2$HDKB_3.JMU""R$MP"7<O;7,SBQ4Z<J.+M&\UE4,Y1"2SH
M47A4J['G)H@.!U$;/&N1B^Q:X5KT%K'=J'S!XSS?52;7(=DYOL=SX9P(=&+>
M[$EB&BSY6:]_">B/,EK\S(N>F-!X\K6K58_'49*7^;$F=_S)V"CAUY,PMFRA
MD]3#WKT_#'9W,6-,BDE(Q-YR@Z(!(T+V>S3IT"_\"D+;@H)MBA9P"V%1>4^R
MI3C96M'/G:4N(UF:KAOQS6+<EZZC8<->#KI;0AWX6BN?56B*,6_BQF7E/1_D
M78/[IDEK62=X$@#B&AM, \[<$7S/NU__=Y=@_1^ ?Z/[5I( T;P;N3[NTC@P
MJP]TEJL X,%9 AQP:EG4_A3)+TK29K.U9$2'FBW.I=8,B+\',:EIFOSC/'*"
MCB6%J6^AZ"WS8=OP5&V6NHO$[ENL=]JK4&C,<7!\.8HR7J*Y?)FB[\T1!:XF
M//&I](G0,079%ZNE[;<5NVJC+EH*SF3<.?4)',#0N>'F9^G/SH[:'*6VC+6A
M#PHD]XNE[8;J;:A*AE?.,_:\IC=GB]=-&?4H8,9/PTEJ ZM-2%N[*9A:@+-J
MZE1DSXPU@#Z,C0#7G/FQ^B@*&Q>Z"9X" ",?N%W;?H90OBE7I6=H1VU<=S-"
M@Y3K[82%\406M0P^<RC*KQ]J\'6-#KTA!*"%%#_&P2K5$?8CM[_GL@T7?1"/
MD#E%7SSNG$*/1SJ%CY(4&SU1^@(OTC:S 5KBA]5AO*\0K/(X5H :]R5Q=FB"
M"KLI74%&CHAS$1!6JG+F5X.-WUKC]Q@"L2^^S+*A4.^M$4#.%9=ETI=>M$Y
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M1AE:/+!4^I7*VJ=7F^^""'/=J01+$E:IF%U<9-0W,JK&:V?C27N5VX<&;0D
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M7Z*C0J;4M4<ZV=<?;Q>?=H_8=FH!YQ9+&;>THNK5<+E]DSUO&:2PH^(62V2
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M81O"W2^^IS[T0K<?>ZZ(1;FM/'@@L[H7$?.I:#_9R)8[0N\+8TQ6P-$N NA
MA^R*.48TYZVJ]WD-& E%^E,OT;-E,$$J6D0__M_($B#,HSD/.G3Y+;6:_EO
M]5X;#K;___I>8I.ME@GXEV3"O!<?,;XCDEK61K][BC^)Z89,E[K34Z1&14K$
M-R_5'8M8Z]GV!Y:N@2R^VSZUZ ?'>.WLF+W6_&.>($0TD/^9A+9Z!:U!Z7=G
M?VQV!YD7C.R:V1:,5X_L%;H1CU=3_$T"XA$5/1(M#7&M!?Q6ZS+OW;I)P_+6
M7!+9OHHO_FTA.(_.DD^9YG^FOCZMZAU"Z("M?:/Q?88XEMT>YS9,'8]-<V8U
MS>5W]@I$H4;6:#?T '%1SIGN#^6=XUV)>/ "B:8Z)>=]A+Q!UOO4,!_ M$&I
M^0YN"]*.^M>\^62]PAIHDJ2>)%]8IZ&P;+ZQVH A>X?@)J^TG=]L8IB2=7-G
M.BM,-#]'8I'I# N[I7)JD54@@FI@@F6>H%3M4R)RBBG-(RT,_]X]ZF5M,[6)
MS]+$1V[X_42:U\-?YX8MD62#W0\>_Q9-?.NU\2JVY( [ H$]'8Q =4]F?. 2
MUZP?;A27R ><U(LO],X0H-11 D=/OA['[!=U\++/[N?"X8P 22.1QGFNNI'L
M!;&JQS75TP+7!ZD=C?4?\N;R 4]LLNN*WU%H^JV+V->" ]Q:+5X8B[6\R7BA
M7Q2+IB'E <)6*A^*7]&E!"TTQ&&JZQT,(^8I OV-,CR;*VR<W*DF*O80ZF,4
M6J#O-1-O.E$TIHU Y5YD*3(QU0?#)%^DC:[UJ,MF>E$1_$;?]:\WXA'^#4^4
M\4$OS$ T0$EHHN>%E!,FJ"FDB=J S&IWH@+%IRA9X_VX3(9Q+ SUM!<+-O.U
M$DQ"#ZIER_FC,#\ 7"-<+W'Z]\W%)C9,6%BMWF1\_'&]ZZ4G<V$F7>6K[];5
M*1UEY@6K5@=U G/LEM+CT :?M0S)FAN/B:V9L?IN^34=E7$5/-TSW)?.20&S
MK_^7W?J:9-EV%N$MX1HX/\,M8V<4DWWR5OI0"ADV29YV:#FA8U45>^F62\$Q
M+C*A$A>2"IY6%^Z)G,5G[-'ZJ=HN_ES#D@S/\]?2;F1N@Q?/KQEK^\;$,L''
M_97>;9Z)9KOL\=$?C'?^?)09'Y2T>9W,06(3RQ0O,II?#D68R#GF9B)M8AGV
M<I*>?43\9<N29R+/6SH:^=!B>.U4<)3!A"<9.D&;E8JY6%&SL5^TIJQ P.?$
M:?GDZ;&Q?J:F_5R#04J69S[.CB@?%"<DW)FT!K?DGMI>[IQ17?QO]^(%W#.-
M;RA7\\#(2_/Y2#MF$VC!JD6..SOP$]03NW*5UHV@,>DS5UU@2QS;[R[Y(HFB
M@7653CMXEFHUSM\O#8[SMF]OFKOCN^#8*^02+J$DY&"+S)6A>HP/JG["6;Y,
M7J$F4Y[FE<U:ZM94Z3@Y&A8_K&V.S=K,FF'(=H@-2?&:%S)OBFU4."[5XJ)0
M$^96@/2@G.G"AZO]*J1/J&O'#>R?(#4F7X=_CW+G8D?BSM&RXZPI=U!*B4NR
M+48IU,D_3/IGYB?+I'/_QKJ!\<J,^UU'P3? 0FYU6\A0M,<ODL"94FO'F7X*
M04>G!Y&BBF93ODNU.D_6V>=_#!\5FM>YCX[-K>&;A!XW!ABU14N;#14";IB=
MB.!*V4P/AIT)EQYA:%#?LBDPFU1#';UL>? W%1>W6!!] "4%=CZ@AZ$/Y>[6
M.!F]3D]B<*R#0\_4TA)YP+!$X,OR=$)5L%H].H@0$3<OOF_@6G*Z:(&.T7:*
M=PJ<V#MN:IL(@5L-#)4=54*V0Y0% %M9K Q)ZZ:$>DR#AF1$:4DSLO@502\2
M10YNL92GC\B5AR;@?9R:G)'J)?/6VE8HQP:[@'S;4&M1DR2S$E'178:,=(8*
MSW.^.7%1)]C'D[]O93KF4O=UIRV2L_K)6ZP-TH_$PF<F%WQ'4UN,/XSJZ\XC
MNO @%(#2WLN3XH"*RP\+^K=8/ZV^))O\84#_NA%8Z!;)U+0Q5$1B+4L=AY2F
MIAFN#]%$Y\00/J/QBXB6B/YA>=YWB'?][>-?ZY8,'55RFO]2MT2V8S(C^[>Z
M)41-%7>2;ZKG7^N6/LQ?JVSYB_7\M6Y)^BA:X=JDXU?,K[:_UBV97B=U&SW*
M5IX2ZVK@O\E16](0Y87T)RI^3QTB[LF6ZX^P3@[G75/M3G^$]G9*^3*7/MJ-
M!U6K&W%[2/=*GZH*Z58BH@8VT&7C&]*6DWTF*.CD^B4^V.TXH(<.<D*9K2',
MY5\X^6 $"RLTK7$AJ2O/9'D?=(N58H:EN;'DOSDX8IF7>,]M;WN=FU*L##+=
MS+T_7?6T=S?0U_86ZWV&A+7O/0@LX!A0/,V??)DN4V:43>FEWD_DX:^P1Z7!
ME"REQ'P(NF*>(]A_&1)>]'O"U'IB0WI9&FD;);DW)5\9M4;'%!$K.)-HE&O0
M,[3!I1SU/XAURZ XF/=+E/=-B)  (;@']R% < L$=QO<W65P3PCN,#@#!)=A
M<!\DN.O@, 09W-WAYO>ONG5W[]T/MVIW:Y\/7=U5_:'[D=/G5#^8%.8C9E:]
MS(4'@']AD./=P&G2M>P%'+*#W=/!=[#QJ#'[>&="XK<O/RJB"(Q$Q%K97H,S
M#B/B"PY\,*O/(75Q$,>%A@\)&L',JLJC9&N_#8<+"56S_&=H0A8WDBZ:KBZC
M7@;%V63Z&M)01=#L^S=KR^9D[-UX0G"L.)14 V;5F"SD)%/#$FSS"JB+^#$H
M^TL[Y"H EZ;3&DC1P=X&#2'']I;U:X4&6SL-!]T-=$"Y69H-SR"+286^'?8&
MO9G^C2.N)\'JYM&'@2S<#?H!1\T?DRT;T2WR0)=CE6XFHUD!RS#=.0VO5&R"
M!*_%-LUH)X+?9YQ*("O.Q(J!L.C#J>:A"OT2=^6+_@%L.X=6M1*<@-:VI;V+
M$B-BGI6FAGEJ.Y> ^ 9GC?C+X.$&12$+Q>PN<,<*3V#I=Z)AP[.HZ"6'6^I+
M96HWS5&PJAF/DJ#AX1#ZZ.TR#B>SVYNI9N-$9XOPQ$(>V:#K*G4SX:STW^_W
MT%X8'9!5K_?*S:#TM.B:GM%TX#=1-*C]5Z@YE=E*XG;-[N#6-CHS!_9UJI0]
MX\T37_E$TL;:6N$?V9G\CJ<MV,05446Q";+#6HK)U(?+C?HA0/0) QIBN@0=
M&N,>?M?$M.8^E^S?E/.ONZMUH.YO4KEFAU^2&V(F@#S!FDR6'Q+8W@81W7*E
M$S-@IO_2_Q Z!G+=($\;"US]9VL7;J9I;P%IG(.S&ZW,6::G>(7P;.K7L<Y\
M)/Z77(NI2U9$X&W\46*?@KT9T5!(_Q.!X+=/:,]H8$A$_!"C:0(G7C__F#U>
M,)4+F*B/HS8HJ1 @Z IY2/N-Z9ZX1?F1JEQ6@YY?OI\/:OK$\%,K$;DX&A/A
MA"XM UL3%Z@MI"T.KL4?<.RI17(R] 6HD59Q'>B7FR_[REKK$'P\57N3//R6
MKS$&1;/2*/H@N2ALG0>#Y 6,QZ,XHG(>T[!77F ?C(GOL#%[#!X)KQ5?<L9A
MI"^ +>U;#-X?A5< F:7L]12F55.90R5N /)+T:C0@Z>BK[YE,;.9550?:B8.
MZS/K7::BJ!<[5;,C:\3Y=)KA407!Y5R-Y02JN%95F\SI@ZZ/AK\ITO[_$.K_
M*7N5?CZ7L8CX_N#4Y'08DZ-=T=W]_9<Z:1.-M_"/JDV]%F&?LLYOQBNQD=F1
MT.(QW^(+OJUA6%")*3[7/8.[8&W,L64S?(9/*$%TU-MP$[FLTU7A=XK7=ZB.
MD[ADEKBW!UU<C]0?;C88%EX;Q>PW0<+W5H[&;=*!$M3YN*I#W#Z2SK$$A@*9
MTC^!W<%VE^&59"LDM!S)!F8EFT-1+3H6TX_U)8(=9??UT)*9C+(CQJ9B(=2:
MEN:A^\PC4 DR2:"N(,F!0^%X=)19YO7%TL[X7/'[_W:/_9\P5M%)RG+AXK#[
M5XU]C\]H=OX</4NM>2XXV);Z90=W&,.<SVC\XOT8:V994HM_2?]"+3]YW'0F
ML<) 0R<^2T'V0^"6YS T]M2$94ZWZ(AI[EICB0/'2E1!&@E51$D$TNELC:'K
M\'$I*^.&10VL33ZC?10&_!@LR1@LJF'&T4BFTI#5&%$ORK,"O)?$_5OQD#"
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MC'XL?K0%)%BFS;/OB%FIN&)[HT;B2$#.=IP[S[R0CM9.6D -1\D(D%]<%9?
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MBPRV/?U:#0IDE(7U,9JC)#+>4>B@!376_)[XX9WM_?3FU*^5.-9YNX7Q*=N
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M2O<7E>+[;-9(=7UG;@/=(&\JNOQBK,FH_S1D]%&6)=9JCH946I]KQS MF3#
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M40J+^;B<DZX%+MQ!(8^BWH)5@ =0P\$KMR@_],'WOS3HA?&G42)-*'3#FG5
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M2GG\X$#+W%V^[GRMM)Q(Q+[4/@TF"U<5E$N)UH((%<6O2 ]3 -U1#1G_Z8@
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M*P3"=M=\1SF\ IQ;VV9C*_@H0N<.R'#9J4URD%_C4XCJU:953"JRWS4N98K
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M;NZY0V+'?4#9$^#P"7 ^,]J'?R\M;@A5;?CK'WL?B.]&R_V&(V5R321ZEYX
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M5! +-I!;JYQA"(*#\-D7%L0;<SX)H"NFB3"$7PWKK<QB_[A'7TMR",CD7G?
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M<_FO4Z;>O-R62TNK![?U/OR-Q*F973&)QC%XM&%2_<HSMBJJ;]6.U=YDP*6
MGX=^Z8BK,F@(S5O_\J.DZ>T*K0POX+8N !/,CO)D8JGHNT%Z-Q='^":YN+CB
MC4U8%952Y4*AK)DU[.H9CWB2^1TZ+/*>=8N!WA+$'DQZ+9/:#!>0I:HB]LB?
M1^4?XIW10=VE_Q2Y(/:G5)E39T$3"A69*\'BCH;C[LR[1S(0JT-<? V:-:NR
M^UN[(NO015BSNTH^[>21L:/@S8IY7HM)KY#M&3 Z7]=/U7I)SNJN/F<>LA/Q
M6+) * #99V4)2.KQGGK3[?PAH@\G/:?'^@26C3]P-9)(<TA)EQ!(0%,:>WU_
M%=2SQDD"Y=+R+(H$(C5Z4#U].5!C<&\-AWUE.(?]5OC:/',(JQ+$Z66<#Z''
M$?9TJ45.E$Z*N4F#8%O+7&'P9N,4R1#)"7:V.T8\G_8UN,BRC/<3?.6#;8D:
M78'7]+;AN7CQM#O5Q9Y5QJ!5:F4VVN$R41GWM6WF.6AW56IN]SHB8A&=D6Y4
MKCYMDEKQY)Z2TE,7@C>C+W]=K+H$49/I6E['C%)VMW&A=*_B0PU_0_#(\=)8
M;[,3E<V.PTUS*;=;0;,<@:.VPI\F/MSSM I'/P&^[I-5NR6/##\!^)!ZUHP"
MR3P@,A.IGK%?*R?J:RCCTYRV=!.I!QXZ1W=&RV<8;4["I5TN$^NOXU4W:)=.
M4R"U*>66Z7L%TMLICNF6]3"[IBUK4_@:43CRY@V<7C:7SCS)-EA-Q%94F&H.
M286:J:H+N9M-1<RHX7L(NZA0D94/Y658B"6?\P5S<Z9(##T!R,H7'I4K%+.#
M]%D/VI2;) 6:K^9Y)A>MIBX[^%$VO&<AE5GV43D,!\D,\[_/HA$\<,W:O9:+
MPBRXNHJ+B3H3@;#"0)VZCW+;PUH+ZK$JD@$G@.1NT)U7RD\:-R'$?#.M)$K8
M."WD!V)6J'<9N+E9"\&W'4T;[[ALMJ_^UL<6(3C09T>;;Y(N8$1-U=G,1E)M
M/(XG8#F2\64#B%Y!]C---MV42?8S,4D?5Z3)BQ4>'O41D.*(FI#981/LBRFF
MM^(3(/VESQ/ CXSV>JTXQAF%\[C=] 3@/GL(SQ;0]?,OZZ?68?7%=CAQ&,,Y
M6O[D-RSRU0MG!.>$1.*,0[R94DSFRD'4Y0F O_YL0V]8O&--F= HFWV)X<2D
MU7Y_CRE+G?,@42,N\<%S8%OVFF6:N;5!J5$?C6N1-MB.L(_;.87.N^;W).B1
M46N&>D2:%SGYF%0'>ASA6DOC0Q[T\NKU6:6EG9K&5!KBK%;/B_$)&O7:L&\C
M,Z'KA2\3R1]'!$<[<3QFDU)%*EZ")A@I.T%,$5_D6EEVG+7-32AG]4A2%?#8
MLOHV/V=@O>476!X6;Y]N[LMDP,?R,ZAJ*F)-MTHK@NY%F)>9B,5Q*5JFEBD6
M0:LPG, "*4F3Q BE@\W0J+'U+6W&TY;S]GNQZYJ[$[4G@&E(GC?/$HY)SRGS
MDH<!,N!QDPK\[R\$K&8?>U$QQFF<+%3[+>:/^FKZIBR'=!!)^#+['<3^[\XB
MKCAWB1[+1-W3NH4^QN\WIE)$KC<V,P@2M4UM9J8U=L%QO*.EU://2^1*Y]"<
MU<_\BY"P8J$63#W3N3Z>9I&*)9;!O'!'M\O1='>N[0P:45A"3&>/KD#BS>*M
M\/)990*"O(1 ?S\Z:8BBCJ:VRK(5C&"GD)*PLIA7D%E$N4H=8$&'$KCCH%IV
M&?1#@GWRL3&$Y@'@\G!L0I5F0VM4<G$;ZK(P(Q.BWGL!0G@9Z"7J KG,FHH&
MBA@L^.KG>'!MINN":3+-&8,@^)VAX2;=R6ZBE>G>^@AV7AG2QL/\)=(:Y&X%
M8<F%0GZMBEDZ95_K3\T]EC3H**%^5T5D@;BSY(?<4>-+T[Y1+V=QM'(NKLC^
MY;5UOL,+R"DTO2-B@=UR"U7:LC:)NQ5!.N6R^/T_PDELP(J(]WG6_;3^7\)^
MBTW^!)#1=WZ>+4$B(*<* Q,B-+],3])J#FKR;7.\IR%C2,;S]<Y_4>$6X8_?
MLN;IMR_?.G=RNJK:PZP^DD15_C6\(_A%N3Q2XN9C"HD I/2+GN0F6[HPUUV8
M@"4M1G&#=YC)"M1+:JB5"S>B<C;.=IYHH#@T7LHF.":)7XY\4=!PO2(%.(U4
M%42#76\2M;JXS@7&12SHH+MJZPE$12R<%\&BUDCEFN# X!I-LHW%@A=)9P%&
M>:I-8"17'),S1?0'-R6#\U];HD 86U!'#$7%.A!IW!CXJ]M3-%$TW2[9A.FE
M!.9]N,PLE&COW#^46<_,\L8]I9V&^8,_O"RVH0YG/7SNY)?[]6'&)"S*:7:G
MFELU>5Z9KAB"Y#M/^>%?=%'XW$'A )ZZE1T7F7DX8N)H0BRVR*SWP(EE#KO7
M]?G29-+QRQ>*J*N0ZQ4S\5A,KR\T58IZN_< VRR[9 MX02Y"M/[-4(R978CX
M>/3-PFNI3ND.&<P/>?:8WL6)_NL2N%=;P.U^E)O4HW!=++8H1+@.MF\453YN
MD\QB5PF4;E,V+.V14]8R)3*?LT)[T,7'1BXFU)'Q6.9M'R?PJ\GQ4(L%L8._
M-_43^/)FRUJUD6M.ZX6N2:LE9.#EZIOH633-HHKG/76&9>OW?YGQ^97CJ]N&
MWBS@C0PN3%)P@M]F%*JJ*+\*T?WU0]L@OTWR:EMM5%F[26* D0MKVY269*I4
MO7D(DCY55]0<"*$Y?1ZG YROI*/@-4=I+S2P9S&7I<0LL=? ]"A*BRA?/^(:
M9,[8TSJ6?7/V<IC61[@J\Q7NNNID$K2HY?(0__Q0X[QG(Z1I*7A@P&07P 1.
M3F&F9Q)C8.2RR6$8E97R+S DHMZ&;4B@W/ICUC32G\](_.<3813'OAS1\>24
M;#79I<V?H8^(*C:09YURTG"N]JU>$OJD4HR92J&=!_HA_GG 1#D(W>E/U>)&
M,)WNSB]L6!KMJ=%;?]\H,>\;\O'S&4]I^P#=96_WV4OTF=?BZ;^4VXK$(III
M1L7?;]:'>$>'UE#5<@@](YI+.!6)2#)OMB//>84K!3,)[H($7J?=X"!D%.G[
MTON2JDYL/BHH=(_9>OXR_^U65RG"MNFT3QI^H'@QA^ PY#91#:OA4E)XHR-%
M!QM[ZY"DEQEZA4W5L.JX*U?3%#>"=!LJRP+N8S.?8!]15^?HFJ5ED53\:('Z
M_C-=/Y,DK4=G:DXUPQIL(L%K.ICW)K46B!:9/C9_Y6_UR/Y8K54R(T'O1GVP
MV9N^U$4U,K1[G:2D^9;OI;2%B.R$E9B<HAGCY?D]1MHI,0F7<75OO9++LJA4
MKH%$\%W![FWJF;UX;^U^F<2:'TFR_^Q=(RIVU)@#W.<)G=]7('5X&_RU(4RP
M%RF?&"1@^H]-#\Q%PWGJ!F/INE-8GJ"T&Z(T#E*?!/ZSG[Z?PEG-)5>@6J3&
M7[7/-G_U9H+#JV7)1C-57VEQI3$4[C07\O*WI$,WQ_2+4^?3;C(1\%P$90^[
MVJCD1P,J^6:]&K($JXW"L(+#GF,3T@(7R?P/F6))>DG<6YP[HMJ*R6R\PWBU
M)]5.#)?K%B<267RW^S<5]NWE'GU#%]E<C$<D:EME*0H,O3,8L]B?R83Y"D?$
M8OB_O%Y9+N,@@\I;D [94K#,C.M6F$_L(&KY-Y-+2_:])G6/+(5M#89F>/B+
MIT@UE2_6AVBA>A?6QZ.8\XFTUP65S@,?9'#Q7@G*H7QC0][C?$^L=/26SKS<
MM\/"FBP+]=8T*\QO>L]'J%@]L9MBQ=9=YZK+0=H:D-Y=MI[NVQ188M-*^6-9
MF5TV423.+B;$(2&&I:N24&CV]A99ZDIY!EI>79QQ2!_=MIR9L;X;-L%>J9B"
M]R.&Z$3*33:Z4^&IB%B)QT7%[RC"*9S[KINFZSQGY>OT9L!JX(NZ*AU?E@6/
MXHG)M'OGF1-YY>5*X5(6>NSF193LZ8CKU/3\]&JI!FT;\>Y4$DS+DBWUE^(-
M,Z:0XV>V^ *3[6=](2!;GX"^D<V*RTT@OJ9KI?_\^4.,CL.W2*> S@-*;8?H
M6DE:@3?;;)3?QI,%Z08WH6ER2A,DP:CMAFKV7,OKE2N30U-WSQ  7Q+8,9L%
MZ^&GDD,&7[%!(;?Y$(,'+Y\"T$RSVBB9DB2<85S!,YA)+I[4Y*JE%S,7##8
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MX#8@<. E[JPH8!9F@U]]SZ[5IA,T/[:[V?NBG0)-T9' .'$Y?.,VTX8J*J$
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MN+1FW%E/^15.(:>BW1W\J]4K6+Z$5PPX$*$'1S0:=*RKAMB+Z=P31KECR4=
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M.VK*JQ-^9_9CWG'_G9FQ;_YVE83<ABS'UE84)?!Z*5+8=:;V98<(_8_1A#G
M-8<EL@R[*<+<.7557$4H I85\ITKP>N#[>;#E<^-N$N0RS[@'R=<JNIZA^8B
M8UU40'75XD<PC,ZX0O@3YL%&K%[V@6*7BO#<O #+U( LQU'CM4B_<7]A]N"[
MI7)K=V"!)'*/?%V[S/J6+-LB>WY%3$21=XI?R8]W]CZ";?+S"%W^6K,9/FVE
MN*C<2V&YUB4%2>H7 D_?2,CT9,LM\]YM>H<^_/F'Z>JYP*G$+U7%12\CAHO)
MXS4I3'*?SD/.8H@4:,YAMG+$VLNM/S'THM:=-(1?U!Q93)\53L/P_D!.G(K[
MYY%^%N8;JQZ)D*+<4+*2>,_^0X)I>T@P;5]]>-)BBE[I7+CY"E.J3V0LC2[C
MY&0L99T.?1/#O&1QY1<ERHX41FU6S(=3)]@A=F/4Q'92@,4.IEY,3?%6UHQU
M\1VZLF:O<;\IS\:4/LF&%W'@YEV3)F&<8 '*&0999L<K*.>#WREWXLFTE[YP
M%BUP+,X:@XJ@Q'O.P;G&BFB6V:E,#Y7?9WOS"RY%&HD9Y\-C]0O%.,V,K0J1
M3MN%2&":&$F+=$1.1,8_F_C_]HY,=N$CY-%(E(&D#]N! \V@F)CF@NY%W4AS
M342D<*>!],B8@= ?/_L$72VP6W'#SWJ499*GR&$+.G)=&_2B\D>(:.#$-\>@
MPR"YO"JDLWWT0=-@9 @;E#/]&65'*6%A!KOQ??'@A:I\[Q+7],*^QQ:!E]Z.
M\[2?7W.V!)1^Y[@3D-'8!E3M=. U0H%WB"#B-<KTU<'WJ]=<J#<YT*'-4Q-/
M!JM*4=5.#6;:JBQ)DY\Q$#[RW"R\)PV_,3YJ]4_5<#24ELWFW!-&G9-8J9?H
M7NQ@KN?S>J>#QU[=._80-JAHQ/7V=O2QAQ\G;)&RG,Y%?=OJ^2.RY;S=.CF>
MZ,]TC<^^*A+;:Z-5W6QGF0;TP->"G*MU9D3&>(95"1]-UUHTN ^![VS"YAM$
M3H=S9][?7\PP/LL)>SFZY2D/R&R6]R=6!?MYE<YQQA?'Q83.N7N>W#QBV'>7
MVZV:0%WJTGVGTY0(>=^5EGVGY-Y[/_$&'@-Q@4.IGY#,'JZ0;\_(5N1+")9Y
MQDS8!ITM,7R9AK3[BVQRQ2<)OT=D-IO\D^K1T>*RWFFPFJ;Q:KF .S(Q:<54
M3 S&STG-C[)3VT8[*T_<]&<.O&%SL\4)$*C2CY"J:ZD,D^VJ<XR(-2Q)9-WH
M3Q4-58+V%[L6NE+3/)'XM^HN Q^&LXN5*36)T-;OU;@FUKLM*S$AG$Q^11*T
M>5"&FP3XM7,O9@ #KXE65J=^4=@&?<(Q69V/%J#I><3*B["TU]_Z:R2"57,M
M'&?UZ$L(_!9S(M D##EZ@GDW1(!5V4.+-*B&V:X@/QG'S'3 6;?FL$2A'T8%
M8_(865",[F15@9ML;8&M@8&*M8<[@O\=#CB@F3B]/Z,C/]&\B[X?>8UEF^&I
M NZ/,:C_O%N</2$<'7>D7[$J2-70E5>L[[9!U7*1#4.[\,_8W'BF'YR5J<8A
M@)45_PB=XB(K)TJ _D\MQ8B082W*$9>B$<;K?9%Q-Q_U5S?#5SS"<YUSHPF=
M+!N5=*\A?9IEO/J.XOFGT=T=@16/&&Z>MSB(.;H]<@?X;>N4T]217^ KP"H]
MD <S\ GEL3]S_:O7PPP^\;+;1K*;$6.\[_H=G6SULAW/@B^J?0ORH;ZBSA4@
MU/NS9E?::D_7MU]H_](1>4;LO1=Z3V@Q/I#$4[^)E3.4VV<9RA;K[J-TL*^6
MKT^I-%/<5PJI+U92% 599#0SD(G(##&^D%/B6/I<H;9/\/GJ,+6!.\8,\\I&
M)?DC^=HES@7)DQI8AB=Y5W-E]"AE2MG2OD,&Z\-*1BAA.^YJU4 5\GOI,9NR
M=%>=5"W/IQAR,+O%&WK[U)DW*?^W96/N"'^I243M*T'\73FJ:67^AF18/V>L
M4F183V?_$<-6+P>Y <<1<]*Z+M7W9H57&->LCZ0XV)$NN4@RS%!>7*F45XJ%
M?UORI71I_EHV-('^PU6;7I/,<D<44V,6:29H5/ZIOP84E<<WSY>.FYMOFI<&
M<-,7-.#'UZ%+#04H09=?^'A8M<-'7<WULO3^K#7WZ+,QHJU&]AI'7/:ML2-B
MH"5KQ9;\.Z0-W>"+- $7=;ZH,T9K K&)>)JO^L;T<R%BG/64XR<9)C!GJ1C-
M$NO%#=)47U2:ZZ!^+<X!UY4P.*IV7[0I(V2#$],=I:8N2[IC.L><W4Q9R3#B
M^6372VE\//1>>%MKR*S#0&K?(]:[;O/:)OCTX<^T877-)AE/:YJ1CH-HR:I!
MRD4.9:7X,\^7M?>JK2N7@V;ON1\QA!K_1@U.6(N$;L;\O!AB0] 5J_%A&4[4
MR2+/W_A7#"H-/ M\IFFOR^:MJNKZ?&+A,L_%K0G0>:+\_HK+Z:Y3V>],.8^B
M*E I(CW&EX!^JLL 3R$VWKY(,/K.HY]VA9JTLIO3GS=N XT&.&<.?ANE>N-6
MOYP%#+05W]#EG6ZMC:6_57K$0 DZVQOQW(J<>B8&=G>W-=]D33SX@A\QAAXB
M=ZC -ZV1*W0K?Q'\MYAKE23]Y^E;[PSD\ZHY\TYE2-][FU\*UG#\B?60Q-+E
M&1\%B&743<-MHVX8&V)D11M2V>-5MO*H,=T3.>+B,<B,ADHSH1*[W)+P/2H+
M6VI[31_^5I+^:J:LBY#F<X.RMV/N=XHW UH&UB>'@34$N&I'%$(Z=;L9CQAX
M+>JIV95D65JC?![%D^D:6FW>1CHV]X% 5.-NS9YP>"M@E/_>1:! [<?Y4(2D
M81OG;L2=E,=#TO5<0<Q'\9N_("'*+R3EN"B?Y(E04!].R4"FJ+61%?3GPNA4
M:D96N3_<,=(I;>T"=()EN:!WK7Y:83\19F1@L,=N>+FVIDM9]WTY.PF2(1WS
M[L-3@H;LHS.WPBW@KJN=0Z;HM82#+E538K5]!ILM!#5>&ZZ]8QRS:5]^5,0F
M5ZXJ]%5?2.O3NN((5*A;I;+?<Z*M0Y.?LQTT6O9E^OTTDWO ZH)PC(\<.MMC
M<J>"S8AG^XK)'K(]]'5*WQ24Z#YZS#,S,^6XUF0^CV_NNO*M4I^00L84EZS&
M*-:!X)EA1$Q0<(2E*DZ>O;02WQ?9GAK5.K'NP9DZ6O,>1U]L?6,LU!/*IJD=
MT?'Q0E\8 47#&@.;U=RJZ>MG!!5D+55_:O7]1%X7'T?I>& B,Q"Z2YVRXBX(
M]'23V\8/1?8R4[%(CJ#@+S57"CZ NI3.A-E09W&K4+:RC4N]6Y,$.A:.52_[
MDRJ2_:UFTK) *BI_P>X15\K3K!UD&^_=/\MX.%XX:O%YQZ]CW2CI</@L0\K%
MR@3BD^MT>:G"/YM$6OZNZ1U9XK P529G-I55F'PG$D&1VH;ZW(W3]@1O?FM;
M:IR@T"!_L6<)ZF%"66>.$]1_@ ,4Y2AR.MTZTI#JJ1,J+OT9<'97^"'!!@F-
MB?>*4"#B ]/ZY_7:="=>??81L)FC<,_44]DO63YA632LC%F V 8X-NR\X)&5
M>L>?KDLH)+P9?9(9J"?_ 8VH_SRMP\^]T";91:28H16N&P13VP/=.(A7O!][
M5Z.)D)+3M@-M6Y]%+ 0K4Q!*63H[<T?%,;Z,]-AA3##OYE)?>[__).C:K--1
MS#52X4O]3K^8/UH*.+MN5SE^=LB_L&.81:,)L3#]YKQ)Z6D!UTV_>3[HP^:)
M[Y=&=.!)V-:72$)SYM70-430CB:079,C8UX<<DNN.15,@!M:UL_[*VV11_]-
M/+.'[<,+<E"MW*3 G,9E8.E2V?+5PSN#3OET<SS20?'7QZ)9/KWIH2ED6O &
M&R!5$0MFTE)QSCZ_,'B.-+U*<P#L?"?6F,U:I.%ERT%QWI"B1$76?/:0])RH
M^NK3C5!=#8.);DEOZ/&KPO A&<]F>@70%_C&QPPB0^[O5I[MCES*R]?T?7A1
MU&+C)#N^V>Q58C0W3D/'."I8)5VZTMI$%%^R2]^1M1<(^N5Q\CI^\XF\0AJ$
M&FLXQ(F*=%DJ6/;%ZV"-JU V.*9]UI%Y"R#X[1B2.$XV'I,>J[\=+:AWXH&8
MJ'FI2-6"N%D-Z-BXR7=/=SXZ-FRJ[A_^LN&/DR/#%'.^EL+JX9$A15[W@<N*
M3PBK4SQ;9"&Y:.,@H?@ NUIT2AWLR<,VT*;'XC+R&8AL$#%8+:%[Y514[P-Q
M*]^.6LP+&LM)HX!5O%1?IM.(6L(15(AA=B+CI#D/@4ZK7%B6U78NNG?<.N[-
M\.*[W6H25+6$)EOACKEP0!M2A?O>:%IPW3=4QONN"XY[!GE>ABH"GKI())/5
M046S)*\'DG2UY'0&[,2RT$INVGXU- 4ENTO\ [$,( %VXJ:T$W2)F>B!O#22
MKF7IU22Q7 77NP_/Y(7+Q@.#[Z59W]C<-?_A0U<GL0+4$+/Z-_UU%39>'BZ
M%I9;JL*;=WL8HQUY&J ./L.5H(X\9>%/IF:-3XE_M;R-B<$GUACNU;S&L8GD
MZ2N*,#\X2W+250X&,;R9CBEZ"QX(4?L2OL%K/M:M\5RX4H-P89R0Z3:J";CF
MA,.?B"/:M< K.^:S\:/;._V>E;X$CXT^&SN]2LNF3E&T?*[X-:TDS/N5G!,U
M)<_;$&T&&N=O%\@J93L5F5VQZ!Q!!J=AD2('3<9M7\RBO?";RU369$9;N4$9
MGY,2-BRSB+/NB-1,4:9H:,'<K RVX^"W]H^LR]H$C1Z[??<L'24:^X$ZN@+/
M2\<R2KRWS/?Q5)J'IEAKA(67]-%LT;._Y\;LSE)K'R(BJV<21WW7Y1',\ F<
MUB>4MQU_R[8P]0".WC#E2+;?1C\'&UWQ1DWFR$5^(UN+;MSXY+E3^D9/ @)"
M_-I0^=ICLB+CDI[6('[)*7CO-=UT*D[,AA,#?QV>T$K#M5B=N1)YF5L&ILNI
M!)0]'9"/1Q8:BJ,3WM\J7_)C21SYI7"BZJ3T?I5E;4, 0VUM16D-=W!33JC!
M=3(E;K0?<(P:L6C?$V;B )_[U1XLE%&I., 1.;$N5<GEC;/?A2-N31D#,4KV
M+>W36G69)4/_B?N/A[;XW_N'JS)XO3Y5;_%EL30H/8-[9'A4X3@G%BC8W3<;
MQY^@O^<6_#G,32FPFZ/PFXV%5&HT+B0,4RQ?M5NJ8K_/[U6[S?"#-M]I9*A>
MK74":*8.P8N4.X(\(QM.B4?YD0DQB/[6G]WKZT2-O+CF=+\@IF24>4!QX>LC
M=$>^.E#RUR;0LA!+@=)?&K$[2T2GHV:J]X\Z_Y!DC73!)U[ RS'B(K40"Z,R
MZ1I&[BC\:GMI'^;$]]W</Q(QQ+S^Y3V.XX8VX&JO74REY72#JM\"7B.E1_A"
M#=4MBSEE8C[I\V=]?WFFP0KXO4+Q%V2*9;U%>&ZET0BE)FDFU(L=ZXZ\RKH*
ME>CB '>59I"_<_4]>/@$6MHCC08;Y!NP\948*#;RJ%/-6O>)1HGIN@Q4%'R@
M5^ZGC]M?X#,ORBVMJL[@IY/YH?9 >I"J90BE>"ZKZO2;PV ]D*6 3A!S\GN<
M/<0;P>_>)&MV;EF>"B  ]JN[>Y&4YAG5&IU;OCN-U85L2+^(^/U?,HK_/S8S
ML;Z"FIX/_.Y+R@[]'>0Q]=-Q*G:UB/W0,,W,"OV^X@CT_"^WC!Y%6?%/3/:9
M']SF*[U^*.6XL*;AQ!R43 H-J<4T3NJV-""[]:>(-#0=52/Y.KLJ-%44PE-3
M4Y/A"&L$:P%]!W1+,S-NKJX@>E.KBXA2M-*K09@YD-81,\J?1?YY!D*_N@ M
MO1;?X8."9X+:F9'";V/26;X6&:ZVB JT5MQ&GN)I>7:\!@YM:.KOS=H\^*9!
MA+2L2G>7FI6W4@= I(A:=D09IW,8[(8="MY>E#JZH:O\_QO4_R*[P5=33ZQT
M/BJ/+]NTM,@4B(D(C[!<E511^;3:Z3@4[(L97KRSUJ-4J/X7$G /NYJ]Z';-
M;(L<&$ B&"\N"F$'J6EI:96T=!\'A^7#%M)X+<!S(C1G'Y-'$_E+35VIZD)\
M/83Z!FP<.)F"*6[Y0!XS'7;W]PTNE9C3-K 6(,E[^ZT)S'V7UHN15^]$3YD&
M#]-)?,8.6@X\79#N;NLM+5'03?TZS\!S/]O6VRP/B829LFY39WVAS8.'@_T=
MW3]^1'\P,*2RC%J'Z 8X'YRIQXR >+E^^8\8ZY1&CQA.CQBP%@^NK%66DWMU
M<+/G ^=VZZ*[V8.YJ=AKT@? Y8.%$5KIA^O =,S_6-J/X(=HG9D)I=*:1CDF
M;I5I=S8&LIFWI;YP12V'N!%CIMRD86[HBN"H"W8^]!%C/TK8T:F,ZW+"%  ;
MF&6-R'$#\MJK9I(B4DO3<LJ0W.;7^GD 5(SR&6#WZX]!-8/7A]1.D5\*U4^&
M0$ZZ"[JZ/>'RR2Y"(N8\@")RP-^,L _1>[_;+3$ NQ)Q2B-OOR=U]_YV&.BY
M7_2 <T\,PL\\.&&'?'0#F7<UK/8-<:H@.&L"..\05DPA@C!*RAN?<\U5.36T
M/XX$K.SH:$X*7UZH:9M<&8DIJA++"I&>2OXGKF@C%^)NDMXM\!8:I?#E\M4:
MY=VO%B+'E [^)4_WS)S6=&Y-Y17T@UYO^#*(/"T0%M@'K5B)9/0O>!W5T*7A
M,/^((;[OV/V($4V?^QOY#][RSK@E$"KFLX(9-?NAJ,!Q@17B,:0GJ-Q?NM*^
MFQI.^X.%@%%X"$J8W^T*77M/3&MI'U7%:%]9T-KY>LI,4<KZ/KIMD6I?*#J[
MVJ/8K%%@<Y9/6)-A^V;*J-=XJ)2OU\[<[J?I_A3$SS. 8=<^:J-8WS?%7$=S
M:3D\_^Q@XU*"Q!!PJ+>GR'B(Y_F1E1G!CD#D'J"XA4W3K:YSYA@M:7LKEL^3
M*Y"1#1WSP!I4@B6OM&-7HY7@; X8^65I^[//09\+7$7[0^V00M>A?K\2EP%$
MR5VA!-&C:.A!"@I3;S15XE"[=;R0*$KZZN=/TVOF'["'[^IOX.D)D@$M@-H0
MM %H+1DMU013PV80D08^OTR\IA[5^]J1Y3V=<9_+5_VEJ5!@A6Z\9 ]EQ56%
M7)X]\7#5F@ T*0+&5.(A9?5BV!6:32>*\T$J47A846.]8=@U:DL"XHX>\D$V
MO4\'/&(D%S4!01K+X44_5=,9J;9^(CC+DY0WPG-H_2:5("7=6'&4.(UY8*_N
M&.UZYRJK,@DY=_[5RK!Y']W?"N^O+G$I*Y6>#P)&)L<BRP,LZ[ES%XHW*#SU
M:[@5+O401P8'!^=@U=NB6R1KE1A)O$6++FNDZ?RQ^69*$8BDL97T 420V$%M
M+Z)_I%WH2=(8LINZ .F)#B)EOZM $R/W2.4<WN^C+=@1-B838L.%%I7W"/F/
MPO&2"N]*B.CF^V:%OF0T]+2Y=^=-DB42"/FY$Q#.W=7TS)?RC0LWI:UYT*"]
M_(##K#&4$U=K'A\=5JAHIC$P)%6_X%:E2\"&"ZNT[#Q$)G]OOD@@ZL"Q*LA=
MU^EK*.A5+-=#0<CM>>PK4&7C)F]<1&02'E[/G"O*HLNEE3?V5!T.>MR=?6X)
M@!L;_&I%+!"[4M-A0ED?ZW'-S3I^X2V.>'$)READ^R@W 4&@<*Y<B!^U;H81
M'M,K#SP1D4AI%SV3NH2L20JG1H( !]&F&946#F3:8.0>9FTI^"0CW]\LH261
MF&0A3TWBGPC]B W>!J>EFT#_FIKNP@G7;_654)E[B@7"[@UB'<VKG*R-V#==
M:?G+YY94Q;)L&44<A, J$2O7<?#8@ZQP<)/O=IJL0QX= VEC3'RL5S@%GU_;
M+I;],02VF]17.C/@KBP5-]VGK&%%VF,IU\:"0-A&P"&LX;5,[1=]8:F5KL)B
M+@0Z3H;AE.I@,>G8-."_SLEF5U;[G;7F$0M:V=A8C0#USB-K&^3&<TJ3Y!R-
MV17XM6M(=.*L?G+EZ A(R"U7O!>_\/2]1R?*W"]AGM#]7?[,$1Q^'9# P5<K
M]YV4:D/;.ZN3+5B1V=\-8)[%EE>@^I!W9[@K"%\3H IKDO4N:3)[X2$ 38VW
M7K*TO:Y[20#(9>=BZ@<L=A(M$@*A YH3D?&LEOVLE[T(!3\F UM*D\(*7N>H
M'&^D59"^W(DVF:G;#LRE^V"]N0@GLJ%+K1T)158@J8$<]U1$,W^+>8I63 49
M'BR@H)RWZT=#X(;RG<C0N65$+-C^Q  *3:3;9#VNTN$QXK1-OV#O88O:"'PR
M.*RP/8CTU?HZ-RM:M^#GV-HY_I&L$#4J,>+-G= [ B2SA<[P:&1ZTOH(S;LO
MO@L?(/ 7SKT:#KN92-T&=3BD303"W2RO9^"]L\QDON:WPRZXM^Q2I.3B7:X6
MOBZ%D]!B9?J@G8&';J5QRKKKE]:PV&%[OV"@:K%GJZ[).?$O*!55OU.9XW51
MHYD+1(A?-2+=17HGW?"9MKYV1-<I> .6M@(2ISC>RI(J^'7W</'GQ><6!O&X
M]?7NBK@M)^H]<<$/U4/F^7/G7@(ZO/==A1_4^Z(%(K7ZMGBT[W6H@UCCJZ*$
MXLI@188W")YHAZS<2[RFA2!\LBQR[0?LB[+UM(>(+=<VH.MZ1.5Z+=S+P>['
MEC6:1.WA(G5@)?KJIBELXLK,I\Y,4S_5;6^=H>SWI.\[DX$8WIDMP[BHPEM6
MB]$,"13;1Z]L @O]&<YD-:\$XRM6+7Z>[R]=^ST33A<>,0ZF;!HSO'\4/&+@
M>U(?FDH@PAY:*<E;US<>H,U C>AET(R3U373P1637,K><0W>ZK-=N."$4H*:
MOO9:XC4Y$WGUPO@ B/'<2"E>(]"Q0&FU\6!U*/(I?*_>:VN8, Q!'Z\UD 0V
M.+$4H"=0P&.:;SD8+3PB*'8>)5P[M*XM<G'U]+X2?Y75;!@5?R\P@EO9K<)Z
MF=;X-TW6'S%8W1XQ7MYJ+6R;C(40P.K(\=-;9,O]^Q?62'&,%WBGVP'@_)X5
M3I7OXY_QE)9HG<$4C7WYX'^ZZ:&3FAJL[#/(-W2GAI>7,<W^L<OZ@]TE#6F1
M]6LJ:->5(I?YB>TTQ!)_T9'SS\;:LBN4U9'71T@+-:US3V'3MZ=/ Q@#AYZU
M/&*T1N/?.6OT-%QB/6*X_NV/:=X/7:KD):UMH+78$F()+,&KNJW0R\-?K9N4
MA6*AFZ%74=37*5D&N)FYMW69(H&1O@%,B]C3UVKM[\4V2FE(,J?OQ*#E1@M=
MW(ZY:<)BO+8QL5:UX10_9#G#FET'1@GVS!<.]MU$FPA(/W>Q-,D-W#O+EDZ.
M![5" -QJA',-1)TC3Y<HJU1C"CW<6ZB<RN\V2.UR.1,]KU3C7TK@8NF@#3K#
M=H8)3_HG?U*KS#F4EHKXV@^FJ;+O(?UN',B_[%Q:_6R[_Z18)6*=.%DI"R#M
MEB]</\2%>#)^G9OS/5_0EZU"\->6%(1&P#)QW&1]X%$H#5CA$'>FZ0!/5^+:
MN:%X9-C^Y;C%_%"%")/T%27&ART3]J-1#]:)05!(JT!7-91]GR)(P=K&:RJ<
MR,,%W\6>^&O?+8E\%A;0/,9M N"<L"74>]7LINVI.>I- '064%;6X19A9.*=
MH34UG1[ 0_#\^@\@[$N9?Z>@^+TC>CWN8_,@<2?X$*^[CN7T'U)5BH0 =HD1
MB][ ^<-8ZLX2OA>E =A90Q:M$M3W!?>47HBG2__]I31K\$!I*@IWQ>:=A;I&
M6)U6P7SCIX^5!0>X(GH(0H<?F_BOC+C:_U'IUSN_Z#"_$(%;BE2JL=+/('LO
M8[1YE)**$%+/:R9-*;7WW*^P)ED&?+?EA5)#DP<$:"K,JT6BC1<2(XF"B'I]
MSGT)$I7H4@#W3\4B)2@UKG!&E1K3I [^>O#-*+P,B$9?CN'YV@'_LA/9[>F3
MRZ%W)TQ&NS[\6:8+^632#K/0I*K"W7QQ@*G[GG7]9K_05[<X[L^?>"FN692@
MRV);':'PB\R8[9X.![W&<]CO\5N!LD.<30/W:GBM6*!OZ<TAV+>_"V=O-KI2
M@+8-?\_G#BDWY$_3&! W-*9$T)0>+"#I].T_Q3%D>S0R4W43$2U0Q#80W2!,
M5'SN[K&:L:F._.4@LEFHM[]';&5CU+4S= JRKUE?8]W\B@P!DFTDD'JTQC1H
MJV'"',EUN@YX=PXHK2D-NOVQM%6RX>=$%LV61?@_N39VN]H'6I,SH($K>39V
M_#G.>VDL<B$L*@>?Q@:LWO?=<I'N_\>>/3=RN<S%4Q[VWC^[E&.[JL.JJ0VG
M^T #=!ENG^?SEL,G^B&N@LM][-[245 59]R;P+K& D@(UB;E# ^ZLKF4LA6J
MZU!A_YH9L:?G+">]UTRB$N\3!9WP)\814"VNC(;<T-GH.?P<79A&CY6D!^1
MX(*.4T#./)8CHSC,P?\1RZG,S\YRL?I_)L9$.!-G^^D<=L-MO!2NL=WFKK>[
M[0:UJ4SNV.[$2P8DE7*J2+X<DG1\E820]@&#2(2[I92]*D8)\E5?ESF+2L5
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M_/1[CP#%=).L9(26"]0 &I#DY2<7)(+3U2UY2)F1FU8HZ42&!0R?7,69O?_
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MJ5VNDJH"GI.6)H!Z$B/9NL4R.KNM8]+>'S'C8G5XLSV;>>?DHKJ$;S>S@=>
M,,$H'B-%AU$>V<CEWC1!D2&!I!>= LCX]?OMQB]K#.\U>7]JRJ?<1#,2H2 U
MG\J5].GH7?FL1'&0F<'$31/4BQ]F+T8"[!<++&YN9VQ4U.%-CB(/J/7Z*S)0
MPM/17H5_&CU'"VL4V0FN=28NJA[.8;#Q43#=WQ0K^BTU/!WG%2H_45C]TYAQ
M+WXXMK&!! &1/(!>,T/T_;.V&$%,.+88$YU+E'1)&3 O>TL0=&["96.Y8OHG
MH8/%7WWUVBS,?Q1HK6HC.+E6,^F,$,H>11L,\O)"EUM0BB' XA<1!OF5OA,!
M9N1%]YXK_:?E62PZE(!D")_5@;"ZV(O#7/QXF1L=VA#3U-",;VK&%$4Z%+Y2
M4JA'GE5\CI@'#>YTYA(3QCSA4;W\PNY\?'Q!U17[.6L,_51SQPW5OV?/KDZ:
M2XY"3Q<,^_L0DX1.KM2-3$ZC3T^KM/[H\QXUG2\Q0-X_?PT$=7"'#=#W;&%Q
MN=<2\3]41?!Y,RV;%#8=,:BS<XQ=3!GEE=V,43"5BL$ZY3!(6<R"^DE@\?:<
M6ZYJP$K*?)EKV5IZ?A&V_$J<5O-C=XBWH\_:N2N'X1?EQQN,M(_?>5"7/RYS
MRLEZ7-$;*J%UWZ?4#.:T\<7?0MHO$214FOW]41YHV3$2!$@21Y ,.M34T]-[
M:!?1DG99/=?MOK$6)YX<EQ2YX]&%; ;=96;*90]97U*+U'3,&0NYCDL_]+[$
MI3:!)'OZLEA9"!+/OK?D&?6K+ W[]P]4MFV=,9CI"G(Y[M7[GF8BYH$M,F]G
MBL9@SH[I!>M:,2E1R+)F0X6@8K<W"67&>;GO$?&&">[?-C*>B[L_LUD6C$CE
MGMRJ;Q)56,@RO+T3-2WMX2(]9  %$=+2:GG[Z.@8"<:V6E=9CCEK!1+QG(;;
MI][KI;Y&:+XV8L![I\R9WG18X'7Z7F^[K(U\_)_<5^]2N6X#\5V:]3#).H=&
M9\[+H&49/Y]F='%-$%\TARK3VWJ"$:W4D*\_D('$ !JF TM#&4!@/7$ZVA1K
M:XDVL!=$Z3Z&JWBKJIQ5P7DW-]7]0Y7';LPAC@2&9M>Y>/J4^L5H!<S'TJR6
M+KJ:W78M-$J$%4<E/%*GDL2AZWP><P,WE P;-\M1^&;_?N< %](H%Q>?0RP#
MJD/'V0&/:2SHXV#K-PI$H1,:\_F'R=8#P.VKB>::Z9&OEH*2FYSLJ\8#,TXS
MA1UIKEKM6PWQQ#N/.G0N"2$+X_J2*AM,%8U[&&S[$2^Q='R;:T';3CI;,))_
M<86L<:1#U5OZP5V(JRN#I)W!5$J?M4BEE[:!A9XOXY#XX]%M<B; M'#>;?&*
M*.LBRK,%E1LD!!Z9I)@J8)?U:<U&>P4I@]V5/;2]3N46'SH>D:RSGW[_D,OG
M_FSE4\\9ZPJF:?T$1U,D6GA.YMMQ$_H5:S=YQ557C&0(NC\&69O94-YZ3!XY
M]D.<;B.YMWV?.:L4*TL<:[(7917:IHRE*)>9FD8D0V<+:H_PZ&Q$@=Q21FY]
MF3>;-,I[FZQR&Z)N'&_$*[ ;N])SBO./H8H%?I*F7/L.F]-#M1/MI2/RLZHN
M *).$;@S7$/TQ$F=DE#4B8\)AINH./>%F!8TY!O:MGT!B)A.6@9U1'.R[V&^
M3+E9A;\BCQ9];D#?^</(1.:^M5];7<'G)]GDYVY_E4WGV^%#J2]GAKU] MUF
M:;2+7%>;QI@SLY2E V?9#<&6Y'^E&;R[,YG+&A]%.:>%(VJ_K=*-M.L^KXRJ
MW:KSU6X(&BG[:F0X>KVI(#Q^H-*'>R*&;_=E!Z'QRSM9I]M,FM:IO .:T6SI
MLF\_![11=2KRG=LIPB+B=/:GDPT1.\ ]6/_1 I]2/R2\ 2L26="72'&^,KR0
M^ZC:+C"[SML#'^2X5A+=Y[<>F.FXNA%6CMLLN3WQ7+/ZM;VD2UF'AGPZDOWN
M1IO+\[Q4!1HHY'(/1$5[Y?']4SUG[=7VM7Y7.KI@^BU,)HZ"[\U/2XO 6D=B
MK+G@7%/"M=:R5HUNC[ (3%'ZEO;*I,]P]Z1HP^MI)I=+>(')A*^3EY>='4U1
MT+7F,@1H R0N9(R^C$YYY6B2ZF(3-<#V20__\<9V2X!:I6= @=']38AU1;+3
MNHS83=^21QGY.*R; W8G'8/ "N8+9N0[9B6;L?#SE!BI#5[AXRN:KDD5/%=I
M2/58;*Y*N>MW8YZZK_U&.<4>#JHO'^6:'HOWK)*53/;ID^H'AN[>[>E#79OO
MX);_*W,I??N617\<9_ L=6-^OW/V?7/GS,]M7Z,KHJN1V#1LGX\T6(HH!2(X
ME#FF3\/=7!?J\>FQ;-1 26F*D1,L%U\6;TK1_2HR);HOFWA26:SY*KX"W AF
MLQ&%^=URNLT C))@;<&_?:QV5[=ZC>TCP5.)H&K\$F5QOP1>T8*O;QO.P:Y%
M.FZ;*58UT*:@6=,CK2<Q7/=NVOTH)/$5&JBO"+27AJ\]]"9[J:.*,RX/C!I$
MS&P(CB@$MGEOS1#\Y[@$-1@@ <UO!^$:1=-G?521\[/YHE%9<5\ZNQK@,OT.
M)3^#OXO!>#X:W$&,-S#;F^F/OAH]JZ&$YGPPU'=UG:V,N,L4+DA:E(V!2MPV
M540T/*]"BXP^#,^W%[WU[-=273SKC@\&ZXP1RK=V2*OED^CH(*=ECZ<JSCAM
M:%<=HKX)P1Q/+N/M9C$[P890@<<2,@)UF@71=GWE3V*>M!55P)^AQ]PQUUY?
M/\A^EE0_H&'$6?)8H9S&4-)X#C9MY3@(10&ECDJS)Z;#^Q0C).D[:T!J/(Q]
M0[I8L$Y1S  DS(QVY.E&_X]H"D3J9G9),1U^$EKD=?IF8QX??=BB9A KB#GV
MOYG3'Z?7<)PZ;79ZW*Y7XFJ]P]?G%-4KL#P&E-*-%:QH9\Z,R.0JJEO%IS/?
M86F*]:&J/"E(N3,N#\LDB]V%X@AN][&V;-7>$Y[Q<*I9R3-:M0%SYE""1Y:-
M',<VV& ,9*36,22. -E%1!#%%2M$O1TKMJ,2DC;\+]5N3/O-2KM G)\VK957
M(?PR3J^6(V)*B73!!AZ7O!+_<39/>SK0J5_.YDTU$!H!AQ0DILIU;Z<J[.HO
MB*/6SE0D;_K&X7_Y=:.;ZUI3X2L9H[9??ET0(B]8RQTBOPX7RG?ZWM%!RI\N
M)13N.:ZA_?-M;,9\7E54&2LR5CZ_YZV>J%>M9+LO(4AR.&&H)5T-B-_6?X'Y
M\B+FQ9&H/S+ZI1^5GZSA^;B^K"NPQ-7W%*Z:(E26EC;HX@6!TBX7=\I%A>?<
M(C&>RYJ&F2]T\6Q,13Z+2RZEJX'+!CQ+=8&C;+240V0=GCW^<NO8MYZ[@KL;
M?FO8( S:E_!A0FH DG8D4)%U>OF@9:0^T.S^PBF#APX.RV5]X%SX"MI0DHE(
MSZ9%'+%50<5U;\/E%-"L)C6-JBC!;]5O:T6_+!BV.;YPO-W\6DN]BEM[//;]
MO*E$?]2J$!L?OMJT$.=B8YS4VRAY4-I,_T8%2D733'QWYQ173"ZI@,5=+Q&U
MIY5VMQ:,I"[\*YF'P?4Z8G#V/.YPEQXXFETN*F,E!*SGEDE1KS\TDK2KI[3G
MO-CYIO54+-94Y;R6/@S:2*<OW9VS[$F##IRN<9-')!FJE-^8[Y&< \OJWI,?
M%HB+MOTHXS$OW>6SSX3^@6E&1C:V;[6L0U6)T'1RQJ_!J21.EQ>Y^0C_:](.
M=5CBUU9Y;VY2H@D[#&,6J_$S$!10R*Y_VHA#:)7\"4UZ0C\S+FPZ^L4M[+6#
M_>U$[4[O2H%YR/?TP6#EH4641M!I0;G;:MM:/XI$YFNHS. 3Q&.+A\"R24.2
M\I)J.J"2H6"4KXR>@1GY9%(:5C8NRGA-,%GK!GS(J1I$,'*6SEBWF<!?COPB
MLW^MV^'1(X<.MNZ^_K[N!C#>L'18#WVSR&!8(!IAHS(4&(@,:RBG#2_+Q$<U
MPK%8K'6&(R:MU@D+[PX/CTA/S^22Z$N <XED]4^(=\0:C,G0/(-,^)!:*(JJ
M+]_U#J&6,_4L*77:?M=+O"D*I:.8]\Q]_96NE1J".-GGJ[P)K"W6A\B)1='3
M]B*W3ZD9;2NL;\K_1!YN"C3CL9$29G90B$$'.#T?/C']RZ=MWM*Q,<_4<;N6
MG#.=Y!DXAL_QR:$K&5^98#<?3[9R/Z\SHWU2<1M5N?,*4D.<8\:]3I07=%;'
MY%T MK1SIN]8U!\G3B/4^=SK_ @KV1'AM45ED9X_FLHB'7)Y3=@\PNO3OW?J
MN0VC)<09- T8]"X/ZS'$OU@5COP@X?0!"^^A!ZL-1K-%WCWZUSU_+ 2/B?A-
M6G$#,Q9K<XJ35]"/"BP:?4?V]B&9,:1JO*R.=PFR^-'3#^WH7"S#<'3#;Y/%
M?%P#*F*P,RC1,D$.3[0TSE^EX[T-I#W7[-DI7+D I 5+;)]4-?FX0&>F8?16
MK@N*0(-AE"\=%#HA!2*! UCRTVI]).G.#G2,HQ28L\ &%D F)*-ZP/#23C"#
M[\$% "!?^-[A&ZN8US;.F:)P"U)$EF#L0SGZI,'+[69Y.9E)&MJY5:(<3<;%
M&) -WP#R E!)0,:5.U$/T<YF"P67<>)U3$>-^?!'^3BX-==$+H^BU^P,209B
M #J:#%*.Z08  .LO5;,V8?_N3!$  %%=O+/<OZ?!X;,X'&;0@'Q8=9Q8;27,
M.+ED36%8#VW(,^:^KX_394T5X,E'$_NXF?%*:5VB!B6ET8GL'V7^[#OC4"JJ
M(CA3S;V:IW#)H=T+%H,YS=^^PW"3Y]FF0?W4S#K<K82>;@3AQ<&TOBM)/%[@
M7' <83O1Y1[Q=A2 ;#U:""8,ZMZ9WHQ7G1?]>&D(<%7Q A!:=;[$@>-LF)-O
M+0R*^/7E_Z;+L)\/J&]8#W'DOH7D7<W-0"O<I&-:GYW,)DWUW48TZV<S_N]P
M<_,?A&*U05YQ!Z<D"WTEF\H.+LJUO"FN'/'QOZN@IK1:).L&<T-#=5_C:\SA
M0'L^!L%OPX) C3IK7Q-@U.MD$Q:ZA\FI,N+1+)#,!RK_^G'\SA<A(9;++-RR
MLEQM'/?90WI,?'V-8A87N0JXIXHVSJ*C#IVXAJ*NB- JX(2+>S,T4_ED/*+M
M'\@?(*<6;JU=&AE.+O,+])(-K6DGS6KU&GDT%HL85TWB]:*?_I#);B%,%WZ*
M-OQG6#PV*/MZ20D!:D@&HG(J^W*-OJNJ7?W20XQ]5OETE3A;A(BHXN1/OUKT
M4'LBJ\AS],F!5L$'BUD9P[$1W6GE+_Z/&XMEC'_UX1>=O,?06QS>PUM]*/SW
MQ5$CT6QE(-LZVY=FS:@;^S;VZZX2IC//"D.?5[6-'$<!"R&]3^/Q?_7NR)_]
M?-'F\.$IWU+].DALN\@YU<^[:!0JDNZ'K)91MK$<QAV>)U%EN!@&/C>VCQ4L
M;L@"Y[]S/WRYD%0U( NCFDDY3%1RR'I(A9N_K+_UOZ37_WRND+"M$)S-QKC4
M>F]MK)*BS;<Y)NKT#@T<]BL),,B0J$!&3Q$+V!"JIG4RU3K,FO%L[,\T&LTN
M/]S-F0_Y6X4S-@F?^B&,]H C819O&%.Y:<;OK>T2)B+M=(!NI+XG$66R7SR5
MN:\S=\D@*S7Q7:?1-XL&)1OZTUN10-#L]10#_O\F^?W7G_MQ:]N?&GUV;F+&
MV+V(;H9FK@'$)2D121O>2FN71/ZBU1K7R9,8;FD3K5(OC%_CE+B0GPHW3+D_
MA(LL3J!W*.P9I]OZ Q#T4"4>C\/5L7J1RX=8S6 4_[*"J=YUL;\G5VHE"DP+
M/F"_H<+L4)(Z(;5]0/!3S*F@Y""6@]:ZI-)7@5DVX(O@--MB4^L].13!0MQ8
MM _A2Z3YL$\N3?DU31,3/G5#<(B',TJQ#LO0&?$0L.&$EO)E ST#9DR"O7BT
M>>;#FE\U$:P:B7LO]L"W=)0_ZES-(2OF_==]E9+@]TMBR3W6TYD;&50OZ+S_
M:W"-IO4"+_8;H2:SJ@(].%_!N-J&\Q'S5XR\_,'>GDOH+E+&[*\0A[3[>P;1
M2].X]B,7;FLNDY*?6D^^9:=39>#$AA$5?\EQ_94'#_K>YT*)5:0JD"?2<WT-
M7O.ATUD'/"X=BHL;<Q_M#KM=$^^4C(<ZSBR-9G[L&C6R5,^E*KEWT?8GB0?%
MYP>+.>C>O5&R]_''S6X. ,IPV5[1FY/;0;;9LM;8U>?DLG6&6:+_?@%K'+Q]
M;A19-SZH]O#27=,>:X^$!VTZ;F(?)#*C2Z:+EJ5?CWS^SY@"Y7-1;4MOXKA/
MXMT.3=Y!269@7<Z_]3-8@#IOO+Q+/:D<Q-"990-M <UU*%_.]]7O'^794I<&
M[?U5:WX:.SE)RR(?)TW8_>2+#6H8EJV@ [<(M5Q6T<AH&_K<$".9.A!Q:8_I
MY7]&L?\'T"6N0/YC5MY?V[4 APF:N>RDO\HZ0D=3O]E!X@LR&+]Z)?-U%.Q%
M95GU/G;L*Q2,E]RQFO;C^UGLKJS8.ID1XS_#YGK#>FK2%;ZS";* :=S.E'(O
M^:[[NMA];F@ !M792#G.UM"8#POYCSD#+A^ "CM;81LX'U^Z )#37IW&+8_]
M[":U'CN<+*\\_K6P$=CF-O;'I5T2SJ81HI6AXMB>1J;+W"!^Q%P [#7DV^0)
M=L4*:.OI[]HG#3HZPP-_RQ(4Q><(R+WT+Z<-7>\#AEJ;V@]O&L_"SE?Q^,(>
MV/X,0S#.X + 9,D@R<0 ^F5%-9B!E '#Y,_/2#,YW_O#WV;#3"KQCR+$ [+%
M1Y/BSB=X/6'[>E2Z1&/WW=#!7OUZ%?$+ "OW4NY#4=>U4=,N6G&V#5DF@XX?
MD5@L7*D*J.* <J=E)!E2=1>;/@+.I79TWN3>.L^ ^V-:L<L<CU9CQ-ZQZE>9
M_TV6CV*_M::2Z0'+D!./UN?SIZDXC?Y>+ZI(R53.;AA 'M]<@1%GQ@+AC5R]
MY8]3H=#YM'D]-[X,F^YMN1_A+1$QDS:4M+\YP8W50-8%><-D "+G1FY/BP\I
M3S>1#Y'#U5HN_Y#N/B)=V(K;MG^23OEC%UIU*R"$$KC;VM09D+DAV[KM]ECN
M?F$7E,QA/RQ*VB,:*]HK#>N.W;R&JEN#B@V[U&+3AD[FC 9VM /5!L<8QV4=
M;'H5L&O9\.,/D>(#9D#%M^DIX.4"*]$2?:&6#B2J>Q]29TQ>[^IN,3X4W&Q!
M6<Y0M"DG*-%[6"?RCTPN_%1W6NU$1'AE9GTD1F >Y&X]CGI<)QZ(,)+\'#-X
MZP+P]3#POD+\N$+>C\ NFA:':K7:*^7Q;PO7F8^NO8UYUO)-1ICMF]X='L$#
M%M:K;YH(0M^(=BQ9:X_-/Q(@#^E>=/./',=/]^4L.ILKD['-S>NI>R38-$EU
M$ V;T4, #3KEZPV(DH<%WG#/_HYI8*>>%&A"Q=]F]<;FMK_S;*,A"C.1I3G,
M<$.H]\K.<E#.5\\KX_&,)MKL1MKKX ++A#)XZD-:YS*>2=]FF9]AH1LG$B)9
M['\Q2B)MJC&GMYL^6_D?[WQ;;+H_L',@[F-^>?\,B01!H/LS)#VCVX(8G&,&
ME3R.<4RKM7E#M8 P'3DT8>'C&'N^3$9EBM&(I??>_/#]8.L?)[4E->!UFIR#
M9(DQIS8S>ZY,H Q62X>VPYJ!M9EE4H+%N_MM#PEF>Z:TPM[/^FG\:*Q/A;PV
M<$QAT[EC:F$Y,V,^#?0BD@P@DI(&D-0PH(==8@/MHM>G,:DYJ#BT5LU58/<%
M>92T<F@D>LMMILMRC(2+:!#KT#*T065!8^_7K&')6Z6"G5UYDRYH 5UC04>@
M$N3$/A3QLOD;4Y5R:[ZX\L1GM/8RM9JDT(A?VYJ)8H+5)8)(+D;29BD9CZ(D
M;'N6?:\W8BAWH/13]E>01RFWCK 7 *);]!Q^KW ;_9*3YYCF K B/G>L%;SY
M<.1SX$F3;OM6MWMMF,7745?$I% T;VUL>]U$44:O)S"=30P\A@+QW[1"F4&!
MMPTET#>?Y$H%-$"X?H:QJ3T/X*EZ+1"$1J<R!98648F=2)TK9&K&ID!$#VS9
MQ''>,5*@TC$*45N<*1)N[K).U$-Q>G.+Q6#Q]@L)TUM*$57J%/:K1?QR<Q;X
MYK!8K5[_?'_XC'YXHM[KJO#)_(V.PM$/)2)FRWU>-)=Y$CGIB]DU8/U%P8JX
MG\"UJ0TPD"S+%%YH/H9BT+WZBJAGT-G$<6NH'2N0E:BD $?4<DG*"WP>^OS3
M,8<]1[<PM3_A9]V9U8C2["K! C[T/4'7VIG="CKG1UX,)PNO2S8&$0CW.^V*
M)LWK%%8\[LVF/_Z ]_+$'CER]570T<>RV5EJ'5N52X=Y^R]OD?F*L]C/SXV8
MDLPDP;+5_<-@KP[JUF*(I*T9:+F/UO[*_<:R\@9LRSHQQQ*C$75D]O7)F*Y+
M_T2O@!QB,4V1]BK-&"CR?>.-50X5#%:(!W,KHU@PO1)"/SY $WU@Z]WB!QJ>
M/9,V(":KE^$K@S<J;L9> &(XR1< %H=6N: 'I8.=.7IF]7T=(L "9U/^:$;H
MWA<K!.GZ6X/<X#(&7L,>&N9O50ZEG1#'K7L5VEU &>M0AC::3PTCZR]*WQW$
M4LX*2(V'>C!*R]:".)1BCF([O)&Q>&R]>UR,A6.=,BA8/D&L4Z;(KTVW>V$*
MY3K0"XA.E(29!%P .A_/O'CQ85<UOW08V6\4;VTRJTSA,/KZU1/9Y O^5&I9
M/L=LE=A*4QR]*;VZ4G$#E]0SA]A'V*9M>MNL!!*RC+Q_VLTX335N9(BGUIL1
M&889H&I3+)[NQ9$%HC[19<V==<9EM^"U-EU[ RMW5>V4/O^9IW$W#[(*^XK1
M=NJ3U1>R*L:43+].>SC\=Y2]"S44P>)47[@QL\PEX\&LJ5"MV,;:(6_@@-%Z
MEEDA_//I)LUF5[#4XI]H<<,[U<-AT;_B6!D<?F!-E+& LE01$)MTOC]_Q: O
M/S,1.^K!"[_:^&U(HLY,]XY;I*& K"Y3X!I5';*U03!2B-UI@MYT**O$I0TP
M>>U1G05M5F.REJ5CW5+E!P+;5VH+,!F/%4[(:9'6T\K>ZF13:I4K,#6>C+3Y
MT0->\FF-#F8(4"C:#F\"KA0^W-M#*DD4,9)K5F"8'']BS]_C1;R>I5VU*EK/
MV))'>(GT&$]S^ZZ7P4?CZS)!^&EEW^T[J,=^A(8Z6N(N.G=7] *04'P!T!I@
MBBS:5D1+[Z;J66RD!S@G_V!!NBO.7P#^F59RCPKU#[3KA+/V?RM=B(\7Q&LX
M= '[)ER\KXR[_DB,K?FVVP!^BA<8:G_.,X6;0:1:J<HY^Y='MK@8X6J(4 *C
MQZZ'76UP8V-ZI"/&T]UZ1Z!6N,\%*7[V;9MT 6CIW'(^;1)2BF\],Z796D?=
M(3/QRS_$5W<]."C-=1]F78T0J6 0=^,V2I#6-@>>1!@)FR-P<)H1-R:KJ 9Y
MHZ^Q&#W04*>D5T\<:]V4BONA*KXQ#F*%2BFJQ[=;V],Q0<",'4:@F3%H%9W\
M:@:72.4<N4\^J[X/U_@HLB@\HI80>J8QC5L2O@ (EP4H52*8)RR47MCN>T]]
M&#(9P?9;/IVRD[;*L)NN*;[6;L:3)<W;8MFFMJGUM5N53^=5; (_?TU ^HA"
M/N4%[#"63,:B.M<MIL?,QPPZAIAJ)^BGOD3YT)O)F+G(\_6DY9BSS]"BF>(Y
M!V4Z!E/7357UG'54UJGOLK2<>^6,TYNYG\ZWTLM*3PBT"7Z ,,^(%>\?])NJ
M:TK=0&6UOW]KN_3.)9JYW";)?7Q9PIFMX<CU$X$2<*=?V<HP'XM%95,K.\V'
MO@Q*!OK[HFU]@C./[3V+(@N$%:2A,+G(AM96:9#OLCDU, !H(*KE(++1"=8@
MW%2V"*M86QO"F>G;.ZA_ 6M\J4VRK;PIAGW_HQ+$*I$8'=,.9;G7,P.^>D74
M,X"N774<7[B#9BE&U3)94FZA&!:H;ER-9?E4IXCTB+KS]3$Z!&C*33;%IAV!
M%OV$1)M;0*%5K"G!G!6/ ^_6SQ@N7 7!SQ)#Q\0VS5H]G7'>NY62Y9^4DB>7
M;]Z=]-8V6NL-PTUH]J0+*.S9 %DEGUPFF5KKF1\YL;:!6A6/<\LJV.<WF];,
MIGXTDM*<UT0%YL%)>I)?HOHF-]*BDT%3DN)V] 3C/M$6OH:F5O)&97BF[#(F
M0'Q->71RK)\82-<3RTHE-'E.XF^HY%J%J]X]L+O7BLFCTETC$*98+*?U^T3?
M\++;:PJ?^QX.OI"R=DZ'WE-%M5ETS>J0 ZK:#UU/=O6=A:4HF5'I9>D;:"@I
M4 I8I2O+,-%6UO.]DY:NK9*+7VIG=GK>M^$[E$TN1F;J J#["L=)[\:X*L5>
MD7<,U(FRH9'&&YL5*RI772F6TH'W_:W5=%#GBIHVVI_N+_EKIP16/)^X_P@S
M(1Z+S.0>#(@>JR^Q^).IJ$(:;&3LF(\O3J\+ 0<\PH8/T4+%#>Q^%A-M?%A[
ML!'YP86RJ:NKVKEJHK+0^E?#+*T\\S5]IZ.;TQEK,TWKT93U.[S>#4\[9+(3
M2">5>6L'^IYP+9UFYB'U_J]/4(9I248J]T.W$L4&6^PI)1H^_IL**0<GHC7P
M^R=1D3X0.WK0EO7. 1[.S0N1Z>\W 8JG2/251Y2YB1WC$?E\Q&/'W%M^<:C:
MFEU)2[4=F]#3BG*VVK*VN,)QZSL=RNEJY:M%_F_:Q"MJ"4:'])5]>=<U3+YI
MJUH$[H[0,&>0H6IQ,^ZI%8>)#;G"6^=3+4TC&7TT"N0%LC/&'T9"68)I$</$
M3F]W7*6/N)K:5DEX!%&IKD[.PM6'0>,V-[CV C#\W:FKD[6S$7P5X1"D!\D?
M;P>[CC*NZ0PBOF#!=.F57^^5*Y=.9:,9SM&20I>4<$Q./K;G6@*U()LL<O?N
M'+<T58CIG\XU83 $.GK?H6P-[O)]V/*&8+Z4&A0$90G&(HUGK^PXY3ODKA*7
M3_P,M1<_QID-^6EN(QTV,J9AV!B,#V]7X!0_BP +J]"\W/"D8&9%_K)U9N^[
MC7L5:IJ&WY#WZQSIGZPYLH4*5$0O+MXGK[!&'K^*^_Q="+O)$#%:'Y66EAZ=
M6K<_TP].]Y%D $%9*YP_FD/E(HL+>8A(#M^*:]F2/Q]PJ'NV9E=O_-GHX)?/
M:4@M'#7V"Q)P]U9/T;HU G;R;C=]XAA6:V)0 H*#:4-U^_%/,V\S@=O4$9%.
M7(7#IY2=1,@:Q]JLLXN)?["A*@T],4"A.,--(.-7_(L'N<,S73 ]1#JZMO0(
M[_*M5#0: J-3>K3WP::D2R7-BU T*E.62;H_:Y,4D.;^\7+S).DO.UJ=M\49
M?CU+;V.>&WT:3D'AXMQ*7T3#"ZJGWFU&8S$*+MT3EN!CMQF%T\WP<B.*,'!?
M(>HRV\H?&:UE!XAPS'B&XSR03AJ<<@$0B4^!VX31(&4/.B%*,XHY+!> O#,_
MUOTG4\H:J)^[-DU"2>/$B +^1W:F03&<O#=I[<H0F$->*\\=QJ?J+Z/)UCEZ
M.1ALS)B@$%>^:A'&,VMM+H.]ZS-:EN4M#CKF:WB' >P-,>^$@(T";C,DJP$K
MQ&&2C)T5,LO9/9'U&++-*Y=$MSPP1]ZT?]0_:\G=HDI.161Q8>&FV*?-6F\=
MYF[EY\VX:#*;//]A"*YL&'9F8N!&M-L^A]!*<*6[ZV/,7[X]?SA][N;K/VW.
M5]?53X(QBS(@Y<FB^=;P $GZ*15V,5XDK(Y^S#"Z!;CH^W=HQ^K;X9R;_Q,S
M[Q74UM*MB\H1&PS8QH Q:1DPF&R"R&'9)H/ ! $B").SB$)DEHW).2,D8)F,
M1,XBFIS!9!-$#D: R#D=_Z?NPZE=M^K>AUVU3S]TS?DR:\SN'N/[OM&CAK$[
M<:4)Y># M;GUJB^&!#2E:QS'TZ9BF7#J,3CE@=7*9E;6MX@)39KCJS\#Q>4Q
M ]OP)V?MX !^._'6TY5FH+GD4F0V96!ID)<Q>%X;0?5BP!EF@\&%Y@EVR"E
MGX"M3-9CZ!"M+<UII>LL0AN5O4=S]@A%*/28:V$27YKO'>;2;:N;A1K5Q8UZ
M=+6OI&>K?E2Q%$^UFUNO3&(E.+HF2!'?H\]-!)2%1WV2=YC.4IV3!9)OK-?Y
M$3XIF'=G?N9S5XZ=:ZOS>]SU#1V:?CH6:86-$=R8>C/VC"?#^!K;BM[A1A"^
M4X#::, 09H/RQ?R&$05UZI+V'VP:@TH-7M.7ZJUO/#MYP$Z'\7Q?[$]IOIUN
M[Z15,=@2O=BC,,G^AE&QLC5JOE^DEUZLVZ>2V7S"^_#9/&6B9Y&_H%61A=V
M,1ZN[HUI:&C,#A*OF'A&K1%L.1>^?O@8.#R_"&I6-762P5YU%1T=KQ2>&W5#
MQIT,VP5#;9H$3WI?:C]#9W2U%H_%51PZO+"T<%(3AE8(HR:?I+]&TFHZ:O6.
M#CDO,0\;MQ'7;@$^Q]W;U";SQG;-3Q86Y(4R_D.6D.%6,YX>\\YFA6&+G6!U
MH[&5LE,W/Q-1(0$%KX. T>BA4$8+T8U/O)W5[K)_$2[6Z/J:*Q U&-U!/S(A
MP][E+,=C@\3M^]L6WU8O.;RX(RJI(25A:04?V K!7.<"ZIEU5\/G;AB?7&S9
MQ92.GM_ O$GGA#L43&V9QE625I@:;B6HJ:,&*D_K%](0X2:7'WQF3"6^_;>>
ML4$.,UU]K;X'>WU@H/+ 5(6Z?#'@&A6T5;(;+L:*FW@#$?48:<]+QKX!*S^^
MFU/! ='K1ZBKH6J9(>>0 )^29A/-P"ZPSIB&9,B2//IMPR HP:*S:DSO(<K,
M(322.$]CU2@E=V;J&@TXI+)RQ>9=TZ9*4E"$D5=L'_/BI6XHD'2?H[.R#@VV
M'9&?OH+0%FL9G3(H:Y>JKGQ$8&^!):VF-KM%J-G33+3D-'Z XOMN[B[B'7Q^
MXFO6P7(J!I=G7W% )-07I]GFH<SL4;(IP.39#%_'';PH8@Q!L^?J[:!EDI;N
M?NXX-/A8LML15W*V:9RK;[6E/6P)[%2U[##0\M)-4C"3%BEUF/58>*[0+_[Q
M@2&)F1N=S-R+CN$QRC'CZ7-#_ UARP#>5=K<I1>6%5X8VEA"M*THJ' ,AQ6@
MW .$>O&F,")V:4S(*7APE8\R5_(O ("BZ][YT/'/_^G<'X!$ BK:PSEYNIQ?
MX918EIL0>?4FPV!,T].=M$K$QM<TOM-:0RS:6)XB)=M!_7W?\YEPTA,,E@-6
MOD35+JY%N36LAW%7/\N&6_/3F8_[(M9YBG3;?F%HWR@P5!NO;\Z7K88431%%
M69&O\CKM?$X# VF9N :<OQ\&,E=)<,:N?@K2%'JQB<X5I_CXN4.<//)E'F<$
M.K%3P&TV<F5U".#6^O_G7@FNGGW]7CA?K>3M_+E>H^N-PJNZRE=XOKA'6 L'
ME*2E/A4B+?=A([9Y<A#?>W$O1!W/D,_ZJ :&1P+?!6N_TR93)IJ$"Y6L>.&/
MN_ -ZHN9+]@LUEF! U^IG-PG2$W&1YT@3?:ZN*FW*.Y8P]=7]G57[^*0K8_O
M(-GTY)M?H:-1+,RLSH>TRY#?Y+;?MRGL%[@:\<OPKX-T>DGH6*2JA6;N:K)5
M17Y)]2P_IX[C1G$)<2E53%? *SE<KL$U;%P(\B2O D(VY%R;4H_(D#(?;RP:
M$<0J;0U6&ZJ;9G,^$57WQTJ,P+-Y=7RT=;$XV-"(6GFE&\-96 'F(:19Y[W\
M)PD5--? 2DGTSDJI"='593:9(2$Z<'/C7R#P8):D='ZKV&!DE:W)&F0O'<0P
MB7,,S.[>D827F(&V$SQ_=POQ74OW']2R6,G0)WXIFN0KR*0ZU2[D-"X?[0X]
MD/)8SB+J:NO^*JJ&2E95F-CU2A(K*EJ:7 _DJYF63R!O(I+(M$T)ZZFML2S$
MZ*\EXV3*>VZNK@@U]_;"W?GB9(4)Z-];40$U)XH<E@OR6[]UJ^VN99:\8@.[
M6([-1=P[F7*Q65GC$BZ_#$=7J66>#[E^IWH+;C>".VX=3I$Y./PBQD^ C-OG
MWVTAM:8R'?$Q5!IHC[#5R@3%BGKH;B(^,1"%CI3H]/?L\_M,-$6]1();!SR(
MM)3,@PF^GQE%JN#9?@:X\F)$279>-G(GQF)41YJJVA*^3>><1N&0\+,A(EP'
MB[3;;PH2FEA&23LR):MO#CW[HX;_\F.*,XHXRY#X/F77&#HE+>>YDB$](?I1
M0GWN6\L6DY0>S)\<L@;SW_AT#&0.F12W$G0;#ZNB_HQCK%9:\\UP7J-*4LNA
M#]S7/C;>6 #A0]J59&B=2LT%#*%(W%KICE_RIE_8UB8I>KW1VL1E9<</[NU"
M^YL\WYBVKF<GM#1B)H\R/N$-62H@9TKVAIVHZ""CJ[(GE.7Q)7(U># ,':"3
MC->P%S*D+MJ^HDH0J4)I:V69M+71I.MYIGQ;7Y#9] 2/M?7ES)*_FY?_W"XH
MXA1%C!U R:@PI;N%PRQ6V8!/W&DU;/.C( C7BJ@8>FTVQR&=W+UW<;&1*(];
M@+C)ID#&9F2LP52N^MP&Q=&2>LT,XT<XV$G%%=K.[^DD6V)_+ FD&Y=V;7!,
M*II8F+%+1L[2UT6\28H4L1@,)E8,6CG1<\7;+*GE_!WWF3KEK R7(-[IGZ3K
M3<YN.P#<2C&\2QO#B8OYU*L,G'K^]#!YIVP-Z)QER>/>":T.WQH:.A^("JS7
M\K#H8V?B7GJW^$8TLDD4Z_MOPA<;O[5!$E=1W"Q]7B\3E%93;R/7OKXF[M46
M6RNJM4<XTJ"OAFKHR5I'+VF-1G!Q7ZR!.X D]A<M 8;),A;QZ"CKUK%Y12S\
MW&A<K$6@>XG!JV-?$%W;Q5F^/\KZ9DG]O!,\WJMBCGB<,6 MG7KG_:6) 5/5
M->R<(^#G-2V7_,H"$["]:APU.\J#?5(L8^A>E:!$)C(W0^O9^SO=UQZSSU47
M6CSYTJKU*PONR?)[&F*BG#1X]HOL2V:J108BAE]Z65R6F]1L^@U0GL.U?Z?P
ME'SE47:*FN$G<=H\SO'I44Q@9T1J#X*LWL.B3.%W0;G!RFM^OWL2-]_'KR9+
MA%QUTY_EG[<6+N)5U3YVYA!HL+5;L10S[1".+?!F+:G:!#_02[X/,G,0XO(M
M038/*/LE!)3=!I7((OJE=*NG&XW-7\!Z5W>PA9X;5?QI%Q,$3S+*E!WXS-CT
M(R\3S1FS?.[XYN =ELP?WH/]EI*2%,B(V7]>8)>M.S(G%)/F+,?1PLN=]^>R
M",453I(?!WTR[*%;]7A%8]NS4Q<GC @:O&AJ8^#5V"!R$/VJ+@FI7/7$T(-\
M8$>4N)!8&-SVZP)Z!1TMTIGED\C0I,71 2V%,%AT1(-NIN5,-!IC4T783R.]
M]R$OW\LW-6SY[R*E%.=4F7<?8K\D>C/"U]?G6L0RW#,)(Z0HOZT0&BYC,@N0
MKJEM X6LS;C91"9?[?0.EY)@-H2U.(F=F_>!Z>=P+AE7E .=LI0*V\[3RE,=
MX^&*L\TQ;)K/ FA:*KT:SL]P$G1H8M"D<<?TX+JDP<#G-24W05)-9\U5[R<^
M1_N,$H)SR+<V'1/P<;[+<T-[XWW079!RQX.XM<XW>=)::7?5TF+WBYL_KKJF
MY>@5&WO*3YJ>'GYMNQDX>_/&2!&MK2)38J4\$_-H0XA.;UX<U:,-@OE$;8$L
MLS^+.M.>WJ>#>WU2NC,^UE_!J/7B$^V<_&N?QSB/<7)SBXK#IDQ#D(/-L.#[
M)C#E,W0#''G:L*/^-;5UCU;WSE-I;YQB4YWQJ$\2.F5%?F.Z9&>RN5TJ"7XP
M*+%",!$[4%7_R1,PMW;39%>H=-&5:^<_=CS[X(J9N5.UKISJTY<5&:9YHP-:
MM#&?^Q3+N6*97P%,U7C8M6-XSK=0*=?;UT_;!H(M([]J*MD"<V%-_@Z.D6>Z
MX-&6:!JZ0(H?F%N\CBCB,+H!N4]L^73O:'#6K$*<Z<@_%O'/]JNW$ZX-S5++
M1*N4'94,[R?*UZ@D-@\Z<F68F:<X3.=LB>",D4JP9972A2>L)%4R;REJ>5XL
M^&K7:$HX[O7-K\MW)7_H=A!I2:W5?<XZ653$C>>NWS#;1:G$Q':]@^B.["75
M1A2 LT=ZM?LZR)56NWZ>Y7B_2"YO.5U@R\*9=$?J(Z>*#@5I%*6^C:O(I$ >
ML-J?IM#6P^]Y_$Q (6(4+=_V"]AZ:[X;+[G48Z&XNW<-])I^3U!NN^;MK[_O
M@BW8]A3EA0GG9GC[I#WL+9)U,6G1IO:V>,5UG2,?]G7Z\_9O4:&S3D/)O82V
ML]<?6"Z6KSX>$5-JE)@$]R^A\J[<*+V7OWM9-%<GD;I1&/.BU%9.HE/D%JE(
MA4&QQW&2VGYUZ)0:M*AGS;TA+P<2!OTFU^80$)7M^Z-ZUGVF6$]URA)"8T=E
MH#(F)JJ(3+#)$O/XYET-FD]*L-!E*)W;<_ZVTE/+)IB.L4B]_O2=GY%;G'O_
MH:.QWR!A2E)L O/6QPUD6U'82><7^#'@0]3<7!#R2Z-5Y3.KS'_G]:8\_"#,
MDOHQ'8>I3Q3$[" 65[1T7$%[=Q.,#5]+] ()U9U*T1[;?HC7@SY<WA]&.D=_
MHL<8",6V=&8+R3V,&LST-*,5*OT*(RB#JGUKKV3;MSMCKFR(+4E^]SHRX*3[
M<%=\4'QS4V8RVL_+0,'UC2&9R$0S;5)[@?!"K52EQ9,8NIDB<(II$*E:G,Y@
MH#5C,)^_T</#*TW\A_,O8YEA#-[3<\#9^6XGV@P%FA!;U,'#TE_0*HPU9)Z'
M+OP8-I8+9:$+<%R:Y5VIA45DCE]F<#AW<08^@*NOWP)T>$$_0_*'->=Y#H!X
M;EO<J*]ZX^%#8U[QK.(H)P>O9[F_,3*_N#N,JBVSFC0,^-T&!.5%8B.7]=<D
M7P7U.BL,QK]5RY?W]Y A\(^Y13,D5/4+)\_L<L/@Q"-(I=CO=GI7>P1FHN0Y
MT<P4J=C6_FHW&+1M4VD1#C*H0LH+]R!5O_4]S[D;VZA+V!TW*0CID"RKPW53
M?.35V5S)\P NFRVI18S-J+AP1HEVGY171=R[6MA^5>)C(1PY[P-G+\S;F.))
M%S WXWOU=D(G[O7'-W -0L-PLYCO^ZM'BR>I"U#0,I& VW/EL+*GM*R'=J[K
M7[?W=!])1RX,U33!)<N6&CMUY(HE]P\&*<8J.^T3=7<^/9SV5>B%H^)'47Y,
MY,.;Z5ZM?3'/1,"7B:?6@B[E5U_*@%^#IT<-/6(,H7Z-,P(3:G9*-FL07M(9
M04=;6EA"1S#57L_?A3'O7Y%T/("MY*WZC/)[VNT8Y\["LH'3<;0%Z0]>L[ZN
MO(K0T1-4FYCU#C13BTNV"U?,Q3ML/FPZ&LPD:YD7_WJ,9RR\ML10-Q%#]'FQ
M[V<\]"H3W[@;]C%X(*.=GCU,(%/F=\Q1+0 VX^3!Z;)2D+"430D14J,S=G8I
M-8O7M5F4X'F_@\OBF$]\K*X<?CX?5R;C\EPK#/7M=_^L0NY:&+E]OS2HJ%!=
M:DIA"HQJG"JTI;$>:(A_KMZST;V?TE;R*"V'O.+LR\7ZC@PZV9B_O9G>OJXX
M83!#J5-A4(\F,\S+.N+?24>:J;2+^!S>-U]W=!NV5:_;!"[%K"*X?X-T3),8
M_MW&Y,PMO72XL+LRF:U@D;4QKD^VQXO:.%OF"V'FG5",?%#@:$&EAS[RD8R,
M#3U-NE$SRX._H\K?KJ59MZ4.J:2%2'RI9WR'O/I4[X-.6Y$[)%HE59]YO::#
M(9M@O6=X8W^;/BZ*YLT."T?VK6+J[]L*>H8/BK8AHNHS$SI*$WKJ2A.NW[^^
MY!W_;Y=X]^(6WF1(Q*W";@&QON5S37X-(MCNZ!=#@MDAZJ7:_740M9677>J8
M_-[*6T!US\U7@H%MMK;IVSR>O'=3FL\6PSE]'C"[2GUJ,^^M^F^W[?^2<>W
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M2C 9LCDUV9R=>Z<2+^8W;5:;*O3JS1F:R\OW3SW59(CH6X"ZZX5JNX>U+%_
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MUTWW/6U.RW=YS5XQ_;HOCRRVGM^0?Y!^W'I?#F^RZ!Y*NN'[W("EE+9CWN3
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MJ/86L&MR5'T](O$'C51Q[VC?$SK/B^J3_?]BZ+F);GCYP,G_L=,AV5K*BD?
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M20Z?KNYV(**O3Q)9S-%4*]'GPTZ);L+LI@Z[O9@ XO?.KZ[PY=0@H>2^/.3
M[[&@B+3SW]ASL^E!W,;/E*;>GF+EO2T7_H^;(H]@4#!H^[%AGLU>"EDCV.!9
ML%WO#V4'T;B*H%+]Z\P)#7$/J\JW5@.YLKK>Y0.U :28TJ%C6-XDLYA/:\0D
M7)W^#AP.8I HR+)#+NUE$=G%= Z3G&U2T]8QKG(6@\]:0=3F3NRXBM28',\K
M!]I.V;!XVKBYB#$#"K=@-QVV6J:.0GO]2P>:PX^?2Q\#W=--H:'^%U7-F3G>
M<MQZ%0\T"1W^8/J:U^-M=@B?[+ZM6T \HCY%VPQ>/5F1=^(\!9P'41NY^7+9
MY-FEAN/^T)TT,YX\,7'K-V43GIQ9825<-3VU(C'<RC><);*$/O;^%?:3@M:/
MNKN7\9)V4R*<9OI"T8,=,_O>#-_>5(!$;+]OD9&905.L]@]^:;;M[ T*,==_
M>2>-6E6O[5XN\]P!AV(P>ZFV]1CB-'+1#2V6QC(W/GR7G3,R3HJSD@?G#)P
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M57'SR<3C K]X_<<^'.H9[%JDNI(8#E4K0M[-S0V-5>AN]%#X:OG:7X#@I2M
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MCY)'2LV5KZ+'VH;^>7MC71)J(2RG656AH,C[4'<._"JQ@WR]5CX0R2.G*3@
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M^W4%>"*C/(6G?-9AC^(_MZ'].UC+J?OEVK6\;.)ZPR;C!4*$5ARZ_=$FIR2
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MB@.]+%8\Y'6Q?I6'TNDVIUE0LIP)E)'>YLNA[9PSM.Y@C3YM*8#";#W\6K_
MB"M@-,QI5FZP$XLYOP+H6]H1G(Z)HTK/*MD(N/DX=(-_+S]\B_FX!0Z4$;BH
M<? E95AF6EA+WU]MTK+QGH@';P&[+72F9X8++W!4=1<MS%0V2?'5RD'U]T0*
MEX(2[M13=GSB%XI*7,Y>YW\>%"9$M'G8.YNP;8XKP(I#[9U7I1YIORB$W/8<
M?[<(!+7[QB5\=Q/W.IBV5NG.#TZ*#Z8.5PA(X:JI[F@]?2/OR'<.3?>\V$>
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M>>-8?:_[-N$FY8Q\TR&05#BXICJ['E)8RY?KPC,D7XSYPX3[D=8,1[K )%%
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M'V>6(OGX@(_<&__^86I+%U*C4Z3IH&2W0_VY3X&M/]/^K+X\F$UOY:C8(\D
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ME1GR'I[I'\YE\6\?Z3MZ':OO9:IN7>Z/8?+YT5SH"A%;/A$>9--MUN4)2)+
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M/:NH]H_NL&V@M3%2;6;96:7,#Y8W/]1!'K)^"D[93ZT'!P@_C22WLWFW0/Q
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M$J3"AOOK(W>T!P=_K=GD/:CB[B.)>P^%SWM614M">[(&ERR7^(^PLW@%-K
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M4NDZ8K?PDC652D1F@N12/#Q&*,#JWK]=CNTDB;[(/-'1XK/=8I >*_6-PG%
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M$OW7(]73?C:%;/Q(V!FV=C>'+JF:P/0:&\7)FEM-^L7MKTG@Z ]4:_/*.L;
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M 24>2.@1T-;#W4L3G,AF2[JJMK?A\CQB3>UTCQ 3+)T@X7(",46,X>U_B(C
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M5//K8R=JUL6PY@CW7?;]6'923MN&W2UR?U;HLT0-E3>AGDEWB&HM!C(RV)_
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M,IHH9A)&-9"FF(+TK%+HA)+#P4<$UVH"Q6\?+X;S&NO^E$;O\%H"OH*89XU
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M;BE/;]7/MJW,L^M\HH8!RY;X:O01;EGT0NX)AU N=JHW!,Q";#O3-'GF.:-
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M,_C^SI8271G4ZZ0GJ(1DRR"DCOX^:U0,RT,V(Y29M0+G7I0MNJ*[3M#XVN8
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MM&,!>92\9YX$"E_5S=A6@8*\.$@;)N6T(GZXE]2)]\B9%I!#AGT WD0M8,2
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MAZ9\^H8\^W+<Z3_$/CEYCVOG:]1)M@>OOSPET70S-EU_@5S*1=-T9SA-G5K
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M:5@8[8_Y'7=5#@P,;N#9J^B*1;BIB0>Q(^><F3AD%F>20Y3H/J$38'9D>ZG
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MZO7L)D-3L63E-9$[=[Z1Z>N=H4,XSJ)?FV:H\(T-C41=)Z,C1E8A184:,?E
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M7J&?MZC]CE\3J;B,-\]"SG-#2H1ORP'O?S\1O\WY<Z-FNQ]1'')&I?N=]@5
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M[P+$R)FP!R8B2ZU!>+X!)ZG)DN2+1CK%SW KF=>,:JBGF A@/Y<SG6X2U^7
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M'4#9H/@4>>YQ@4"!@H@,)P],G5+75R1-I:IN!(R^-T1KV_;N_^IYXZ3+^DS
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M,2ZXZ?'[(IV]QZ$QJE7-^I=-;@4YF6>(>FKT/MY0*JS6*G&C9TA!0T%Q1&:
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M*7?O13>H'TS0@*?JG7O;SH#BVMO;'C(2U8NN'M'PTZW:*=V8V=R\Z<%"T-*
MN.XW08=D$O!>UQ=E$E3.H$F8@U!%']LXO>EH<U@I_[K-L05F=B3";M+(IHD2
ML/LM4X9T5?=<:GA"B+/V?7=GQ%(<4"WQ8H]%RNS'TI\LR1 Q3R\^C'-M-MT^
MM12U9VO9B+'1#FT.G'4'BO=VVDT'U=J;W![@TOPJ3\N0,8UQ) FD4N*6H"M$
MH/T$O5TR31_1]HI3S*8."0P8B&JY7<7S@)7 \TK]IP;')0LH3[V^5'LS\[0X
M&G&.#84A!JSKJ5EVB]A(#M(D?C6^4?N!NW(<O@+!>G4%A;FC2S6<LV2=1X(L
MD@L7V8WX(A=Z3(66[E_..ZW[=WO/H-/_E+?,&#Y6=#E^L:-&69,UH6["+A\9
MK[C1<3$CPBAJ%1<]TVJTCG^_^; +.(]9GISR0?02FKPV:0MX:FQJO8W(@,\/
MMD?;$DAPPGJ491-+8%R?^KBU[,RLL$:NKQHGJU^>9>6WU8)Z\'.)">928XW@
MR4>:-?'C,:DH/40\:BC1K&] R.DTMW&_-,$#,TL2=9'G_]N]P=%N#S,^'7,@
M1 JW4W09*%5D<MG6-]$];?-,5]^]7.\W[)/,!"7ESEE]J,7N4C>!6AW<'%Z.
M@:@[/$WBBYZ#T-TKH]C1GJQG[M+1&?2JQV8.E[F>>FW_Z/)4;QH#@R@IKV /
ME/[9YMD:5S;<\LVPBW(05\Q\Q))8! EA"7Y+_FI9D=NK0T*DJ;C)N?@#]^F(
M>_,KZR+VGRT,0H\9=COS!7.]"[&B%[.]R<L/)P<A@J>Q6=1(,6Y-7GXH"887
MEY!YHF9%#[N.!M\!>/*M%Q<N20=P5R'5#3NT=..$Q[2^%SV#3;$S*3LDK9)F
M9/8,4"8CWD_KUFEP2-*<PH44P?TW IM]_=W4H!*8U.Z*ZTO!1\X[\W4C77"K
M N=:AGB=UTDX;,5JT/>J"1 _WN%?"-67RWS$E,K,PR[+,@NPH#6AQ'6SG$+7
M<@DG__VIB8#[(N->JF76MD\^O(Q4+1U;551;$K;FPA$DN7Q$+147O%!S1@ 1
M(R!4UJ9(?7ZYQL,@4$%2>SH7#":WT#]UR9^NRJJK,W%R+%5P&M>RFJVV0.;I
MPI CZJKMAD((2PS#\O&F0P()D99.8AKNM[VEF)2O=5$!C<Z"/;%OG=,SV(CY
MCS,+1Y4G19/L(H;3JW\F=4%NF?)8*7F"JNBS1)'C2' U<'11+:>23_I%W$,Q
MQ,GN-E=>7<90;/I:SR:@*3K&56Y?X;<[5/S>:$O]$-^60XL:9T^9P_Y>!O@#
MB()2CU^*@,0 H;;P*/GE!^E0XYNN2^N+A>R+]*F/W*& !S!;PY#S^JO@X/W;
M-W> N/1*@EAS@&A?H(YT]AV@B'Z?L(<>6S+PEI;FA\RTSG[K#0Y6[Q17"%MK
M6*]P&1_I*$C_76#>R3GV:I!%]M&PY\B4C)D1;L&[2']YW&IY2# ,6M\TN(OY
M*WL./.4KN'&!J2?4)WW]L:S_LE07V@$DPI1.E_GY5K'2>;#KM+MK0IA)(\A4
M*=0P[T3# MPLS^A%V=S<Z@[PFI!]=-_3M3E"W%5M^YQ*'VS:?DOJ<L[JQI0D
M?QW)$$TH6F0?'Q!(0V 8H9YIT9%87_476L+XB::EQ>7?_=IS)(XF) 4OFCS6
MZX_+G:+,&O. .N;K.5X2DA;>N\L+*V.4.A':8D++;KGOV#&MT:6V[DE6";PO
MV*IEBIW,TYYNKMGVA*"C8B2 JZ-L+CH!#* [ -MI2U!.8>/!/=/RCB571P)2
M[TYE:@2?T+H]B4$Q=D.E'W$ZCYUK!G\.[;>1Y4KIO$^SG4W=3Y8UIV/IO?SX
MNFPL^B2";LAHIOEJV0[X"18?[I-N!677_0 K1+/H_.C9<(>F/#P4YU_Z873]
M9?YP951SX<U0P*&T?:]3J4R<;GBFG:Y)]]S6E.Y3$"VHHO92;DY]TC9!:1TD
M,%_P)4M0S"6]N 6D;;(,%65$FE+W</%[K+$R"='H(=#IMS5/A.9JAY0CR!)2
MDZ"V.$28UX,G3CV[B.C:X2CO&"I^A^6A% Y")JCHL/8:>V=CL$!6I@#F_$5S
MG!PXRO.-S6JG]@Q"\+FQWIK6[V%7U5"%;K?X^O+LD&:SG8O42?$ S/Z9)>WO
M6:FG@7IM0GX%M8Y4*JA1^T-;:S/FF>D2Q07WR0+!MMQNMD3-Z J!F4F.AT-*
M;'[D_7Q/;9QAJLR3@\HL:RAR!@!K2G(@?%R"<74*N4[/R$6 ;?;0K?P:X)SU
MX7UF[0!37?HHCC)"H;]3;W5M/5NZTGBWZG#K7+L+AWVK5$2+; UDU9V&.MI9
MR&]0['GRW3][6%O8/Q"T^H4#%Y\[.M&4:W_97<VZPILI8'-O&^6JE?CMDC(3
M6OV^;<C2 #]4<:V0[]*8[IX,!F9R47/E<327X&\<G;[Z5YPDNVRK%WQO,&&]
M/[LIWS=A6;0'4>I5%*_J"%T+@ECGRW"3]^EKP9]$D:2B5!*.CP"+J-),]XN,
M<:+N0D>3Q.G6;RT=BV\:1 ?3F\6*RIS*&&>ULO4-5%DMM*_KZW)':!J-AK\:
M?ZAV&00GJ%]"47B?'ZML0R?O -]NF01OJ>:0/N38#(59P5Y\6817&=#P&GC9
MBR/6YPQGY6'9)DHPBJY@\_IVDF3-3(7(H5OE>N%M-?GJ_D=)0K'SK:R'X*)B
M6];+..4EGZ8_SH8Y%?CCXVZZU-"9%K[IVS2_6K*N]DZ,49T QC<E'V+CO9@
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M75MT&T?4M:HG89>!NNSLV>0&/5VY_M,2FA0I*KBV!T.8.RE>Z/FL+"-LE>7
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ML_SINM81'4_3_):N,=BXG:RQ],9I+"=J> F:>4M(TR#5#RP[ZZ25Z7E[-)C
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MAH2B(&N*5,N#.@+X>1+68B$V+]"N1"U9J(-7&4\_> YM(:;F$XT)5[V/5LU
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M#1P IN@PC\12JP 8ZHE".X?D,'0@!$,43]>ORX\=T$[!5>,? =_(\^IR"1E
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M3Y)\+/F%[]#B.M+7X";@*#';;SS[\2AY/TGU15E68DD#5/.MLK;54:.X#-*
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M>CIB:<@?G+TFI;FC8^4@M,A&7J8D";&QE%V\=*/5)M#80="!IU80K420E<R
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MQE:K@:-[+IF^S&X@;_!M,WM\4LV)'G2I[J^->EGU4*/67L_5W]\5%#PZ>O]
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M!B!LKR]PJJ23#6NLG?7?CV*OJ;S_!0&>67X94/]A[\&@F@+4J<]F3SH5:!O
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MBGR!C:7_X]+D5@-#9RLJ-#BYVJ@0@SUH"X44!P 0LIW+0J$,#$)*F%*H+0'
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MELV$I'7;8_C.5GI4J(614@C8[5@XYVMG8RZF\W&#HU7C]_?C/"!")0\G=^J
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MCAO<MI*_Y/[N0SXD>U*6EL4B76U*5H4YXYFXP$]2'U^'+H+RL50 VEM#G5N
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M/B\BR9Q>V/=<IW*\GPHS.,F4^ "0T3??XE$P2O6XO';\SU!;V_ZD)DRUBKE
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M>1>+<:ITPCVIA5*5R,F)TQH!9KY)\42"ZPLH"CQXHU9:$KA5DKJTD2=*P'M
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MF<)^:B<4<T"+29_%I]YA-ES) ]"GM'4K0/:2&0J@&7PV0,RE@)<U0$W^B)5
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MV>-,(6B?RI%KK=WH-&DQ\.W($5-O(N4?RAYEFT5'W=,IER)C#]PF^"_<?:L
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M7]J;MTGGL9>AP&SF3/9"["IU3?2L?^'9"G_BO)2%02_)H&/+!E8R+$%DIF*
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M"?67L? RB0[[PQBI:2V;ZG^[KFBRNP?*4JJ[Q.''7S60#?I5]../):G'DIJ
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M0D_K+!=63M/L2E_#&*C<NBA\&4IR%J/4EEM$3;E^U]3,%$WO6+,,]"HT6QF
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M!<G?I(2T0@^/+'I1? O1?]F@Y4^ E8BDAW'0]6.WXMZS:6HOGY2V7??)K2=
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MS=S1T*-MPK2+5Q_0/KPKA>AO>65T\#$ L$UQ4A<0^)B?TR3'_:NHF.:WFRL
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M2INWN:F%&+ B108I$\Q*4TL1+U#_HT?0V-AB4/$;A$_L5Y@Y.2IMAZ5Q\_"
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MWY0A7\G/3GDH%4/)5H<U4BC?9$_\LGQOO((01:A"TMIC-]>$4I1<%SX<LP+
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M$,&]]#V7/MMJKJTN0:)(?1/\/NXFM6VT^C36IJ%HL4,I-I97F9U%T^(J4(=
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M@1*2-TU@WP^[;V3-DO5F4^9P%^S(MPEKDJ/MN)+<1 1Y!O/N,9D)/42D&-?
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M'Q[2BRDS$(@=A5T"#!8/$.#D1XZK/CNK(.KO$Y>0;%!>OB7 0\R(Y^*^UZ:
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M/FPW0_UU%3:K7\$1-_\A*U[=4<5!2^+>4N4,E_[\*(X=8HJCKH[F1Q,G'4_
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M"/O]ZE^=O7D&7#3>J'30=/!SFG-Y/SS6>N)=_;E27-B\5U/!?B\^W8*L^@R
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M#TV>0G(V'AZAD[I&=?($O6I>@]<4%;ACJ!'IP '?9L^0ZTR=X37I,P_SI(R
M)6SX+1XHJM0A[A*<DC"Y1*!]2!<4M<TE:+BR/-"(G$1-B0[MYC%;9J#;T=VC
M.38'OMG8%-RS=+R.S,@*VBDDY_+F_]J[9%SZ8)*S7$!QX7(+ZAG2RY5&J]*T
MY!YC\=Z!2+,SC(P1- U9<<OR#GHVCKUZV-O#/!:8GHSD?&K;*?QT8R@P=_O"
M46AM2[S9*+E*M[^K7_&S@X*^T4?PBPVHDXQ<04N"8[L41"LW(QG(PO%]":U0
M/F9AJ=_X<"$],EYO2'_?Y<X&_*N@39MO73RF5F/;D&#%JAHMV6HC,*YRXU2_
M2HM+E4\AACS,: ]_[!7>*:.XEMMXOZUI+O/]N)4C:+ B9\<XGR<(GNEKMJ1Q
M:6+CQ#$HI5-(366:/2 09<L@09<JB;)=1IBG:X[/PO;])$-SLW<Z2D-!18<Y
M(V^=.,QXH.S4:B51IF"[3E;S-^_I"^.DE#C+0N=#:?I0->OFM>:(8B(.LX5(
M97G<8NQB/*2^SQB0\,(.GG:,-IJ;,[)*7V.??7VKI&O(Y3,@I<T3'C[XU'C)
M4QLM\6@,R_+?\F"=NFG+_H21/")$N>8NS=5/;V7.#'S7N\VIL!VXY*)9A@-.
M@4H>2VDF.T1IS+8HTQ4W.BI,[$B3FJQPV6O0$T=A]ZF.@SU%:<_FQ;7<V?IM
MTW,9B,:M'$H&*XTV<W.N@^(R?;66U)",2^VGAP;4S"FVC0SZ6V-ML5T8"7C>
MF8R2,.CN\7([Q%RGB>K+'#"S%D'$$%V-MDUMAM!]PC-S:QMZ//9K>#JC3(G8
MW#8WSJ;65N'8#@N>I$-A7+Q]R3!=RSP#<3\P,MZ$:_R[EV3K28T$__0]:E*&
M_Z[7.73[<2#=,^X*%E[0:TO&1?*RLPWX+K2IZ3JPK*OX?0X\MNN&',>MWE[7
M9'%,]'%Z1;+U8$W_3#%^6J!VFV:BT&Z@N19B')$,=>XIB)H8FM<2XW0E+SY$
MWUT3_R5018\/T2=HX5Y4EF38 _)X @=X,#"/^6636VVV+WC^, B%+:&S3).8
M;U'CKK+AY38,U=.HP FE;,.ZI>L=G(X92Z1C06;VHV.JRM5:?;*K??9D>\*\
MT>Z[61&6A9?'S$#D[G>[#0.HL5?7A,S3V&UANT*X?.[^88[G'^+M,=!TTE1,
MN59R$\]$2T:)MYL&'3+>]($?W1D;G-O79C_HH&P4TUSY5'0<#MB659CH]AC4
M)93-%3/K1"^HN9N!4UK"&U56!S_*L'7)4N1@Z- X9@2QH'T_\9*9!.ESG"YK
M60S[G"]E)%9;[S=IPN0W6LP-%NL3'[6(B$?.5'!A@]($YF<8E.DRL6$TREU-
MC!+%> 1]J!'?V((Q_CBPN3)/:5KN5;M-2Z>TMAQG;3F7TU#6;#1-EK-AFCG8
M) HZJ,TWVWV')!I&]9<J>+9)ATJ$1Q%?D23EZ+4OYC%3TQ9P)!]H.2!9^\Z;
M.ZI4-)C%=AIYRTML2H%\?FPJJB#-9J)H'8=):\!<_)NZX]_OH=_97 7/[ CC
MLF1$-CN %U5W:&ZVH*1\QV'EVW6SG*LEVDTO!MQ0MFL%XMOX&],D1L0IC>:N
MJ(RB%K=XJ)S#0IK5"J06_NZ 7G5_O)=S6#;;'PKZX[U5M0U^8]%^VT9>H<&<
M2^(+S4-BSK-J'(*!)OSDTV,J'7&2L#[Y+BT.29EDX!A:A@E[4&G!@'6F<3G7
M45W?8!4U70)?(+?L-]VL,DJ[-BGUP].):!;N8F3&9ONG07/[GG$#IIP2$@W9
MC#ZVFHP]<NC#JS]1+S"-;2U[0;=VFXQC+]. %B&VO)+<(*?'S6AQ6[2/BP8;
MD),?'6]E!N-(F>+91.%UOH7VUOAMT8PYDB&R_OP=='8=YY65^B=H<@?R^XC/
MYD*)3=IT"J@Y78) S4/DN4UHBIJNW&<L+W9"I;I+3D87ZX?"@!K P9;%L:^-
M;M'N2[IM6^:T/YLL!^0-%"8<7%(.A0GHZF$A;23MZE7LR193HC8@0OF:\&QW
M/16YL!J.(+!C6F3<&+L^@N/[,P!XV^,YSGEA+"]<X6XY((2OR-7^13>ZH7$2
MG))_I,%V4C4]0JR:G!*0_MW-:F4JGKY\A[@BC@1DL4<])AOQFYO#]7!0KR7_
MZJK(;T$#39JGYM+[&: O:FOK2;%+\5B:#ZZ3MEKQZ<H=YG#N7='K2D)(Q2E'
M?=3"^>"QR)&PS69O@^R_"0JK/LV.6AJ6T+G.FMDNBS<0'^J7L4-;YGL:K:TX
M&%C8-8^+:5"0D1H6CG$G7E*+4&:/PAG4YI)J'/NL:_PB@M?]CP>XNTU$S$Y_
M. 2*!%VMQ.LHU.&TV4[CICSBH3(AY(<(&]3S&7D^2S$0*U.AI+N4#2U28#:[
M=;D=]7^CO(EV-QTG&#.E'U80$?PA"ZN%&!$#G< IPD2;-'$.Z.TN"1#.:;-
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MWXP5*#; 4I[O@V]8-QUF;E-G_(O<_QRYC+MO3[(DI1I.A N 7B_;0^/]8M,
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M%B($^&:Z8QX]HQW/9#"E+37>4\A@^6>-[<ZN7$$6,;5>' C[\CXC#_P9258
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M_#S4HC<V H*1$V&R:VL& Z5V)3;=DKXLKW-^%[K^(2(;)3_EO[*8%+K(QMC
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M)">-;-"4(8:T9%D13850$ZA)0P2$3N;T%*WRT'!"\ZY!3W9P;$GNO8MO<#=
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MYDH\O7?.1WRSX.J_/G\74I9#-!(,;.R'FB!F*B4._,2YS]MJSA8*,AJ<]+
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M_^]X>Y!U_W?-DXMXWZRT^\D*$"SD+XG(*R,S:],KI.-U#]%L'J+*@V$I:WL
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MQ.:O1I0XK@(V<%XCKQA"ESN=,[;)/_)3P"R@BU1SLS::SX04'G]2<,=-&K3
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M3?T;K0E1-JXQL[XX#*"!22]'D4P-$_;J9WX%_ JE_LP<EEJDL,DTX$+ZE&K
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MJ:_,49W1*61[.ZK[THME4CY6YQS(;.N ZT+4DMMFI56[PXGCY>PLK[*^]\9
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M:&JK;S1<][K?T5S\8XIK:].N6VQ:?4=D4MI[9D E]!S1-WL*(\38=$M1#(,
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ME^;#<NNB'#Y\3K 6\ BAQVSUZ1FJ>+;)\)P>__QR/F"$(ZPC:DXL#)K\<,"
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MN[7!( !<D#FF1=3W[H6I6SAJ#<X+U44,>T AK58U#B0M[QC8,FCMR.D6*M)
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M=$?K3$<)72[^?D5WMZ90YWT$R!'+ \B5I$*C1),DHN9/I!2PV\8P+++IL<F
M?1B9IITUPV-;NU*JI2AQ[KQ(VU:K7#5[HKBX2]XKYS([# R3W-!4TCI2\:P-
MB29M872\@ZT?ZK_\,H8_SM*0S5W@[>ID9"PW"'F+(L%H))9.T*#G6 )$9?M)
M%&J?&0)XZ @EWYOXSP@DE*#3@:S.L?(POW_EM<T6H?2N!E-._W!U#&^3.H]>
M1NCNC!JIF\EHI+3:P-)#4_.IW^0Q5%S[&YGL[=!_FSDAX$OK;:<)=6S!K#45
M,$^^8X[JVKLE]/XLL&,+GU%P\>[J$V2P:#K;:EX\QGE"K6IW7O#@@+HHNZ^!
M:CP$9WH 0:S$;YNQS?8JD5JD\.AF"V/TERE9VV8*48/'XU3GRD2R+QOP%WXO
M?84;N"<6*LUM+))#G<ZQC"/ERW!M\),?$#=R60VP2_6[@!0^::D_'G1R=0]>
M<8?T.U_WFXH9HX8)]ZS<+R*S:@TTQ^9:[(UB=6H+*U2Y"!PVFWO^A1Y3';DA
M,(;F<H.RGG8MCYZ:GAG+RC!H/7"0.Z6)O]'$T T=(-^O9H6$B\<(I@6K3EF,
MQ,=DS*M-)Y\)(,ER*$ZG7\J5V\F*L/[@,Y3=T(^E9]=:X]QY )NC-#WA@"H>
M^/@*'9N3YWJ[K\Y_EU4BK^5) OB(SG64 #32\!=,<D$)4)I$R->X+R%"G&&/
M%#P;1^^*_="\<VW:'YP]6#I7O.HU*#$NJ:(9%JGQ,?U& SV/"CM[7]+*NUFZ
MGV# 9,\,."_+\FXU_9 V-"9+QJ?:%46+!I:>=R3OWR6/O TJ8C6JSEE8YO8>
M==,3LMBO]W]G,98.D^C1:4G>?55$-6!'%-+'<]_\!_*'07K)PD6;Z)MD%RG(
MQC= '&0 F)+.![P((;2_$AM9_BEJ>M*8O>?^DN,J:'A/1&A"F%+^)\$=AT^G
M<C,E!,J@?I>3D;H3 _KA W]D7)3'QJ'QJ7)OOPV7M\!B3L0:,FVQF!SR8T\*
MLX#A[+P%D?YMUH^VWN_UK(&HU?%#\O>Q49HOWW1TD8_,]94?NCO4ZU%M;<G&
M)0J6[;*5 1#YX0<&S&ME(ME4@]/)!<1,J.&2I%.,N+'<_C[5?M^^ 3E*R;&,
M)7-/X"!;RLO1,2^9$[$OJLVC%MX-L'V*_GK??K_X[!A6]12+1;Y>=X(:<R5H
MG:];WCHE?E"C(\046TNVN22#!7&L[U14#.CXZ#?"+G]:MS >-9-E*C+CZ[N^
MIZ^QI-E8P)*\LXQJV75+K)3>$@SEL"JR+97]FJV4%E_K(B? '2&DA:[>2NSX
MR0"[>?20G= YR GEWW@S+FUCGU1@Y4'N5;3:*,V<0U5?K^2"539K S:35+>0
MTLQ+>U>G4DR?0/"C@4I^]CU>6^H#=G)]FJL4>,M:GX=VVI8HLL&E6UV;CQ4K
M)1FO#5K/<B,W[\-/HP<$C==9:JKM92391.YP*6&LO[T2,G,)<3'S*7A E!Y3
M7J1>8>O\*"13K%F1I^D@RYQW(\I0#Z(_/*N&6;2X@_Y"7E'S=5A"QS[_R]6X
M#KG^OKB?P2&JLL_IOE2_#G_GI<">]R:6(N66Q?O.^30SW=;/M:7DT=)AW[E"
M V;(!%R5K E9T6=QIVNDJT-=PA5/LG,E763;L_#>R#Q55*R,4.=ANA#=GBKN
MK8!LJ.ZH];2T'8(7_V5^Q4R)C=H"M*'T-QKUOBL+O*S6+7R^6G42;T&>=#0L
M.'SPD9'5;=!6S?-I:@-M?(-AA7R31I;XC#<3',&0DMX#UAF_SAE', ML2I(!
M@]\JY&ZVJBE>631>0K;6SC>B2"=\ KV4D@D:?J5@=#DK QN3_S@SEDXNY9T&
MKMO9!J&>3$%<E%Q(=?;*H.(::@Z$/KSMWQ(^I<]!(72YA]<MYG-QIZV])*?,
M=Z+$B[0U0T5XN?W4LK7@P2'Y)[G-'4=%Q?P"]7>UT[[4V]9-\EH.MH>-YM3K
MA=_K]LY/2N#Q7ZN^M,%/N@[5(BOHASQKL%)E>*4TXL.2!C69'W<^RK3LOOVF
MY.+:OCE8'(WKNF'LI*2G-^T6F=R9DK/L?D9E'T-NE@2KK^R792NQ!WEP/Y]>
M[&X&4;=Q]RAS8"4>Z:?>YOC>Q;9Q>L<[6;K;C7X:Q2X2$LL D_J7BPA"W[7M
MM9V"354:KQI@O)EMB0[3,)TU/:$15M,&'8-F:\%.,F3;7J'KZF-FVRS#D\&+
M/BZJ/H;6KTCQ,;[XJ[JYA!BE1L,AY[PODV)%;>T_.DO<N!O4OX?/1?76N PD
MX-Q.Y<-9<C=>I*!_TTLHMA2H]U#RI]J_T]O/SQC\MBNCN1E8T@]TF+>X]:D2
M>8\=)QT*ZO<L 697B4A$-'7B=Q/0.>VA,@';WS#8G6OESA"7*5D+,!;_+=IQ
MK":3Y1DAW5QQ#8JE,N_CFVEV53FE1[H[@HJ!Y3<VW,4XIGP^EO6*Y KM0R,0
M(6V4L,,(C^;*I9U@!_@W6HGHBH%@\U>[I26OF9%\MLKZS]2D+R7TH8^M%GH2
M(HH0I_473W MY#K,R4)$5#GS:)%'6:^8-#6*J8L5E;MK9P2-2LV?GN8!J?N>
M0D<5G^--ZTYK6XA^C5S4O>&F#=0S[0-5I;TNURY3KR#IGS.-.ZB57=BJT,7!
MRR2&O!DUPC5$+LSCYE.<SWGSV.Q%<52O<Z3392A]F[J B#:W2-:E+-0+S%E4
M3S?[Y@OOTD_&C6DXK(:QJU4$AE =F4 $!C2E@W]U[<;,4$I94Q Y/W+6]UPK
M]]PNHV(AZ]DV[T(Y*W^P?W&%++C5';5O)++VBV,P]E'HOK<>F>!>3 RR,"\>
MZ@AIK/"WLU&?CL)=^TJ,XF;G]<IN&W;;52)YIN.2P[-FIO;-Z5]%=PX3*;:]
MZ "(!,- GDL E*#FJX*C(Q"VQI'AUB.@+Y^!D5>2]R;[#]2[*8=AJU:'3-VN
M/0-']UEY_H2YHX8E'EY/K,IB #Z43LLKP#W"I(2!E/U8FD/^2W^OP4;^C.7G
MA\B%!$T0?U;NO*[:Y2"066IYQD/1W-&XE$E <=/B0C^^;(R?FR5QH&2];X@E
MTGAV3.BM"O_JV3Q!A;!K?S&E4DMK6DU.V4E#XBP4]:Q&W/RXR**L=!_YQ6)-
M+0UR@REYP0)D5Q\*;PR2;S>Y).H,ROG^GUB-PW:@)!3M:G8)*FW$O"0UB&=A
M](:B&[W_%C=!1IQG#QVRA^P0ZU@^(^RD*?PR7<87GP)+("6F[NVL3K DP@[5
MY5'X[KE;6.\>BHB%ELWOJJCLDIQDOIK#4^VV8BZ7UPZ1 Q[ARD33&N(T1N_[
M;O2X;$KB_]F/!&*6/B(Y,) 67VE.,$=AY6!$11C8-_/E&2SE$#)+L0;;K& >
M8!O@1=;(QZ%[6OSL>^>PI1#>RQQ\;;**+IS].<ADX;(-H97>^K!* >AG5*T.
MD)!'DF;L2',T"+35X59PI<I68[=HAK65C,^&Y_:*P9'0P8QL(@8P[6^T_[BD
MCX6V1E^WBS-C&JWKHV^-K3 .WD,E]/H)%0G E#)"- >BORTGI%OJJEDEIUWQ
M6JF!T^SSKJ];+;$GG($X.E$@B32 Y/!4=M,;[Z7-HZDSNU40P"-N2:PYS]YO
MI:88B])@LW[OA7U"3F4RTD1-YQ<$H\Z%-,$><6[7,OW%CY<5EE[ JI_6@-$<
M2OWB\?PO 1&[O4P-WM%#D NY0(AP^T:>#)U#?.P>:9?4_JT?IYO)^KFM]M-\
MR0RZ>%'[M-39M#I%P'.@TT2W"35D1<*&V&C]V:[,0GX >>D^7X8&5D<RZ:T\
MIFC:IVP ^3<U*MO]N>2)AOWC9\R0-($?Z-RC)+W]&3\8&&@[')3<]Y:*8BLM
MPB[]FOO=Y&>.];_NL$SMVOR0;8.2DWL6VY0T0;*F:]Z_5^!SN,:#7]>06EF+
M6.<GNG>N93 \>BU)$-/53MHPLI36#19_[*AC6-_QHF%C*F68GZ$(5MG9%N.H
MV[AC&Q6]QE59OENOS,/#"Y0[V]_LTHN!2!D^+PM[EG+$L=3H\<,F4WR >F[W
M%?D3 =2@O?H0MH#-LH;-52U'B?LT+&RNBCL>%2^RJ$_[V=U(AKLJ9[TTT:[-
MNDN^+DZ^!ZC7;%,BM-7I,X?Q;-(+%]&Q_FDSF\J:[,,F;<QS :[<#,F*=4"U
MB'5)6J;H&IM%^/0FC.JM,R%X08_G@_342H<K)17S4".9S-E03%[V\Z19>[N+
M+K%Q-L>P%RGD@I,K&?OH+ ()/V$[_LA)@=@TJBF7T:G@DX@!@Y(/U,/"+B6)
MKCL(A#S#X! (TV[U2;P@I_-%\0I94[6([([M0%%K\-+=E)V_<JQN+Z6WHQ8B
M;L0DSW;_-K?2,+35(-^N9D L =1S4B9HA^BVF%5\E-^ A[&\^]?F'MG0GHBN
MK*^+\=\7:FVME=PA$DX+XD[;UG:*W7T"GB5-:7XKIM/?2:5N?*0Z74NVN.7<
M*]V^\H0%RV'HP(LE,GA477D/67.B\85^T,#12UX"FU P /J+YDQ["FQ5&]+B
MJ5W#CMR]S&.YZ$8]+LG2>[-[@US5K;R[Q2?52VJD58NQ>+MIJN#P@E-M%3!<
M)H;>O K.7W>S32 0K='O7<9YLE@-EK>P)LO:%&:WQ>$G0K>=WBI4J[+K?UY"
M$!Q?GTP\Z.)+WM/U9- Y>C&50Q7^,O58_]>J,A',N-=B*W5>=XA)\>-HB9HL
M452U)FB4WTX\-U!"_EE-S*S;%37OOB('?DI@Q3.U8GVTA=N8@-(=/R_?>8\2
MWC5KDNDTJXY%"\V](Q.;NEG^:1;,]+9"=F$ #LXPL\/B!OGGNV(,=E\^WY#M
M4/6LPHR6+0 2.<Y@Z!P \FH?-ORN?)'\730LK/T0@GEJ8%ZIO7/(5U1)J>56
MV!2=IDI?$*,#4%:) OOBN]*6!"X:*%^%47[S?^02E%1!QBOGJ&7[W(WOQC+$
M]G/^.31'ZN>M#H%99BZ*X5EKQWC_FHLGBSN@*V3(XKYE^-&7W)X^=(;_%W=O
MV15G%VT+5H@0"!#<);@7+H4FN!/<(4#A+H5+7B1H<-<$AT(++P($ @6%IG H
MW)W@!.WW]J<^YY[1]X[SJ6^O'[#W6&,\>^TYUYI[/K^#TO;?UNOXTD,V:_Z:
MF<CF91HI:KON!FS+]W7]A#$=Z?)"PY9]TMISQ4&SND,@Z(;DU/F"C4S@[76(
M'>WWT+C.Q$>/Z&=OZ5YJ;L-6"A,?)Q\3?N@]<_M-^6PZ[MP(PG7_'I3\0./#
MB]T?1$"WG3M:AV#X>F]<\MRXR8ZO/7SRS;I-[EHKF[\=,G^T[^$D*'EF 4$5
MX&:6V^R81-RE5$GEM)'_!9OCP28GRD92L^NVMI >&*8VI8PQY*L>@>.=0(/Q
M7E]@O7J?+GAU5M,/VSQQ7GC)H/NO;.-ZQ06ZM@NF/'G2S$'REAN(ED+I-\I(
M6 OAG(!4:+'T%MCD!R,_+TVF2GYY1FVR[)9/K7+SL=BWYB23NEF:Q_=EJM()
M2+U'<C 8<>ZAO7^7Z*+=H%'TTP)<FP!L%I5PE$!8R=!WE%58WNW<Z%&SP996
MI_ (/75J,LU=I?>!S!Y1P29^T&*_CFK.IA"+<^/YT.8AEZ7S)ANBS!$G:G.&
M^(RA^F[]ZC C#^(A];IXG:JS@(]_?4EGZ=-\,7M3IX9E9DI:#? "ZE9:NM^M
M83MA0\KEYA==889,%&S+BMQ.5,;20<YA[3"03S)L=J927E#+DS4]GSZ<?._+
MV;W0@U?K"E"8]-?>[!36PEB[494UEZ?Q[1- \D6D_DZ@I4RZA 9B!BU%445P
MV-!TN?ZEMU)4/M=FDY&R8WC"9H/9M/,-^_EYSFU=>29A*QGW-6;\55W5P5[[
M5VB]WWS:TM4._V43,T<D )I2):.\X)R(;AU:)NP'HSDZ=+/EX>T_M:R_WFK6
MTO6A>#PV,_JV7X9'!M%PMX34*(:5@]H546;Y*4B1U#JG_ ^:,%2>*[&C Y<M
M3#A0=Y[?_SEP%)J:S>IBA#FS%:6P# O&%PJ:%?23GVJU<0OV+<TB7&FIJJ8P
MV4VDW_<XD10V'A J<C%X&(6V?'W5N5YQ9EI'RC^RX%=[]GNP!(Y\61= >6D1
MN3_[2U\\P)B2O[ +DK8&::5WX%U.C68QD#-D9"1RKTQ?CY/0R ^-T*TS+FJ8
MT@KO%;=.-[4LHP'B/Y_NK@3^7A/I2^Z3J_U1L933_07?V$U_H56X)GH^%XN&
MCY6*O^PX)C>[P5$TIE?7.<75,T[B>BK1##GCN-A_PA9K]L\ZE\C;&.DZG-2C
MI5_0L"4A43K!IG^:GL?13C780R4?JW+BF";61#RF2>(RSIN0XRPC49P97XVF
M"4]5\CPR>Z@E#458:E G=4M1X?@_[#LA(>G%A]=4X]YS+5T(69OCX 'IT"D=
M/5QVK++*=)=Q&TO]12$VX[XCS\-;Y11LA76U%KD4'P.L9KF8ERHA=,<87JGY
MUT!U.??<0JKG89X+RXW5X!:<3KSSULHWSGX'3#6C-2%BRBZJCM#V)(V6;9J)
M2I*]# 9_/^?RL,V!HS<[%Y%[X5.IX>*-MLYX]A#0_/W&-_2EY=ZT(^Z)S4EN
M,65D]V@SLN3HL-BG>6@<>W[9TIH&-G0TJ3SS>H?YQ$:@$/".SAZ2VO'G[;K@
M/B8]DE;1$Z.G+]@.6ELQ*3I7B^H8.[";7;&$ETTJ5?X6ROMQ>T'9F8-R_J!_
M9,&"?('F?@>'LLFEN;O3QLI^"#((-E=K9; 6N0/F!)BOYG@M^&K8^1\>BTK;
M*01\IS48VJJ-*5D4P:F.*]/X4W0"!'W:6E:Q+IEOE!5V_3BI46D/R=W]^:N,
M[)VPG?1?U>9R"V:VR202L+_)CV,QE:5V[\?#@CE\"/2%VL54D%!L=L.%?!@V
MQ;#!G_V ONF_0F8$:K56FV+<NTO]RIO"65-W.R;2@@7=BPO;V4WL;FGLK]<"
MIO_'2YVHBSXE"._\K3,X6O'UYCP_)W&?R"39.]Y"Z;]ZF+VTI)X6Z8U_G;V;
M"LH:%]8HQ)'NRX['Q<ZR3E43V:!)H 0J).UK B+0XV*L'@,:BC5ZG4W5:G[.
M6$$F_#<0F5]7^2T/"FT^U-A?#M38J[%<-# L;O(-?I2*LVD<G&:\[Z;>QHK#
MK"Z.UG>@5"[VPN_B?R^$G3P&A*T0G'!=*_Q8E:;?NGG3,\KR!/AQ;JE3:,AV
MA9C>:\>R3</4AP;SZ=]QC#>=?'UG*L[%Y%PMQ^6D2WJJ&9X4VX%S,$@795+C
M&C=MP/U/7U>[1-6R"0N09 I=H[MA>4:7F#);I\?0N/%^IJ;A1]I\ RS#+FLH
M(E%!BVTF#@12*2[; J6QR6/*!XM/2U<S+5]!66=-\JF=6^W)(/+<WG\?4,BC
M<-OD.C1)[J?X3<'0'\!NN>V(O-HV.Z9YFQ1Q>3VG9>%@1O)W:CL( _/4BHO?
MJZ/:KH./.P*&FQ#;3A[W]%_QR@N;:]XDCT(/*8IX*T,=O_[.NB3LN9%,IDO(
M>RWKJ5T5TC-T*&IY8KK>\U';:<:B$ST=:#\XT>8$B2_ES$P67\D/&Z)W+!S'
M0$YWW'$6-0(*66'9:9:!I=^9J<.)VCFM5:I'(;QNBD" 55W$;"7IS^U9K!;S
MW)5<F8,6T,O^SK0J_DR73)><'RLNM[FNG-R.W]7FN*^B8*3B1#>!<I $.@KW
MCOC&KY:T&<0<MLH,+Z&?O6YV[/A!B5,\ZVJSDI(WV4-CJGL:4OM.-;(:1_9=
MTL</V97T+(P01T(J\;29 RS(=&U;RI42HC0-*NQYJI97:Y53E B1K]?#L.EZ
ME] Y=-$85W(Z\!52898ZZM*)L1Q"4AH#1=YV%1=)IT">$SG5]_+Y+6O,>K4,
MU[LOOV+$)A&P@=4N@Y$D'09K^$W C"< R8H@U%E$^'3?RVD=G%XCH<$_O;WY
M:FY*^*9ID]^.K5RRMJU=,V;VDOAL"<%O>"XQC/@R$+8&A6"EI#&'%M<12KU;
M%O0<<FR?LL[DRUV)^KU0-%'B'":.0>;%X[W ,3)K-)4EV+BRUQQ\AQ'WNIU"
M^:69:*\+Z043FB/[K,A(29CL_R\$ [-M=##8:5A#VA%/96^/E3]G%O)QU6U:
MY&WN6DFN#Y$+-@Q%Q#54U&\MB7&'W1#R!:^,P&])^Q/B7WZ!%Y(G?##9YJ<S
MX@K#.JEI''0U,NR$+E[NO+[I\)I'LUHKJKG(M7-[E^M7&I]1NNH/?B7MIL+B
M_V?Y.QY*B.QK(J,^DFT#YS>O<WR=IEL<M  +OG+W//=0%'P6-%]0MRM:J^9B
M+L'^DA2N B7#F$E&&+L,X?YC(JC.](-*HK>17"QR).R+UQXFF^JLJ:H%AZC;
MGTM>LT+ZEDZG=./>_%^Q&HB5A0.'9:<.TH&&E,:#V.VYAI:Y/Q,HX2VM#HWM
M#_+G&R4&N'E; D18.[]^NM3]BFH1+CC='?CE4@J_,O^Y2"6,.L'=-HMKJM67
M_">P(2 U/7"H _< #8&IF/?P[,?>RRIP!]/W%B2,5BFEPG/ 0 S.1Z8NN'AW
M=&85F4;7,XY+*9.CZ/W-R)-//;(ML 7(IMF5(O[MN>F!$O,"DN' ^5"O<8.B
MMV9*&RCDDVV;D[!2MO;9_JK\1@>>=1+[0WAOZPF@_Y!<#<(5GFO!%$HC6)"(
MJ]=G O\>;F:L%K=53*(\8)_+J?(LN>:S5^9G:)/^O->#K9,G:%"U%0ZM4SU^
MY^J:*RDCK)V'7F<%<C1G+'INPAHSV \D,:T<'BIKA -5%DN[%F)JU8DX*3WE
M(48YYLK/1;2$UBQN7$J2>8TMUB3ND3_\'E"@M_<0T\^6;Z,[:GW&5SD[(;U
M?(5RJQW2)T!L?)+*SS&"FF79CS,U.H[3E?;Z;/O_5E-[-)K2'[XGR^<W/\1-
M51PY9;\!G%]]87/P!(CLK@KE@!*@Z_(E35J$VU92$=SE@Y&:UF="6\+R3P"G
MJ:*2$Q6W8(=G9IFQ('RE(^@HV"H;7$"EB%T4:R3J]#4T9\E8BN+1T3'XV?C7
M8=NMV5?"K5_VA6V-!ZSGOF;.JI6B9>9< LP'_!FN S1^3ANFRH^D\RD:Q?BD
MIJ6.B=/RI<F)X9D "5JXJ6RZ43NQM[2^NFJ+[%=^BBHEBLDP"*: WM_=S$H;
MYDG.+]"B-7@I4C,>7#9@^]Z+:4]^&ET]_HXMLR!WT11-9>#KN9/2(129T8CL
MDCNBTI^T2! S?Y7R4(""T%G/'?, ';GR0"ZT,,U[,BQ$WG"&9-'9&<Y8M*KZ
MW1K[_EOWZ. 6VX!1TY/%'*V4,SF5+?/%G6A?L'2IQ+"\2&[-GJ2O*]*!3"6D
ML]]PR+H?]$#7"@+*B-TDGN) !/;\6KG@P6<3V#M#7?*_S7],YSFI@H>'+&K2
M\A_3>QG*EO&&W8VN\WQ"OJ=]3C&WHL#A.+H;X#:$V3;:\K.X#S(U%_[Z/B-=
MX<UH-CF5"'49USX43P5S.>QQC 9,MZP*K=3$&^',Z$/UA<>^3GDKD_^B>VF6
M[E"\>S'+:DG-.;\.9CCPT(3XWICZ^Q:3P,]L-Y )+,ZEL?M2N%MPM%"E3[-8
MP1E!1F^1;510:@&B> $R9Z1@:W\E\?>88:\RQ6</H\,QRWOPV])!+G^<ZCSQ
MSE9:Q2%ENN>)?BK+FS"E66[WPYUO*YDO^8;#.N)#4K(.QSSFW/8W7])(T868
MGPU[7?[=-RF[?LL&(FB^Q,6+&LE,"]:#M9H/=3H%6,.[!;W[C6'[E0I-1C:<
M)+-""WW%%3.LMM-$@I^V]/? ,6R>8.[1*4D\6^Y?Z@<%A?SI-[46+= 6_S)=
M6-]4F77!B%!NG+$5>T?@>8OWE_,4O91.%:&^+KVO;N_ &EO,6CW(I,K.P+7?
M!V[#+]X$[D09=\;4',&"YP4K%HY]W5RC'2<C"7J4^NJKA>WH(*.6^\QZ,L"\
M-[XXL4&Y[%6U;U,!";5:0Y#O-Y:MV['PH7.9E9$NYB/E\@IFS*!Z,SO(TN"T
MLX+M2JUSD]/]Y?Q5;D=['=QUG\,80PWAGB/99M;K0LO_T]MZHL,<VN6]7+JL
MJY?FI;2X,!35O#=&BL!NC*WM@\J;' QSF 9E:1G&1*@Y6V\>#>)D_:];G_]E
M8!21=6#/H#L14UO.;1XV37.L,Q8@Y \]YJW\01J-2>(O8WAV-&U'["&:-WP/
M'V[)L+S(@[B7^OG 6K[J4O;1_FQQ#/1;F);O_U\W(4U9-_LG4(1*<*0X/1Z^
M52POQ]9P%R2/:W;JM+2%XTP\Q#Y/=C$P[JI96#;FA4871OJ&;0.%9EB.^17%
M!88>W=9/KY-MO#:<W_\Y_&^F^7]\B)9!OF\K@S:FAC.HHV)3!4L)5:W%ON]#
M8FN);8-UH)2MLU,.I%A)^TSS5!+J@40<25^0P4!E:Y\=EC%/LKC=A]FWWP>>
M!;AZR,9=:=C"PN9T\UTCCM&?QA-,&],O@KL;F#9]\(8_-1V:?PGJ#9W21PMD
M3=$4P8_&4"G,[_^ZRC5\+GX"&-?$]#V,3W6GWDU&FG!G3/U&SRQ/NBL:4FH+
MOWRFGPF=$L<*KJ-\? Z>JO2A[C2PJ>1X DQ@C[,!XS;/(_'*8^9H>$(HQVSI
MLO.9_:X906P.DC$#$>8>7E85'=7P -^%Y#2= ('K.&BABN>QA=:P05Z;F?GI
MC%_17^28,W@>>SK(0WK#KCSJV'>P\$^F]N?!PN=T#[N%^^K_WBB?R>Z?C>9N
MN+?*=&W;X>Z.YOD>DA0(&-80CO[QV>;T@Q:@\N/#I53D1S9C@=L)3X#6KNQ_
M06([?6+!XVNJ\#_"TR4+NF)I9GIJ<U_JC42+]3_5:KEKTVH4D@TZ.'@/K2(M
MB\J42[<R/&6HAUC#-UC9W;W//G5.EZ',2O2Y?%6#IB"NY1__R6PRYM+!2[4A
M>F[V.=&#6T2([=0YG309Y5%#8@;1S",13.5K//N$25;00#T;MF\]E>M_QJG]
MVT16EX?47NQ5Y=>P6N#$4CTG,>(K.W%'9*T0L0 S8SW/R%S1ZM%(=IZ@LO[I
MS5!!K$Z>9.&'1S>'Y<)@-4&#=ZV=+*_&:[P.EMPDG3.<UZ;*TA3!@AI-M;M5
MR=TQ#\T5 IZPMW%I!EK&=WO$22S4%6$1>"-:V@VI#<F3[BE<+/1EY +IT9FQ
M?LLR_/K\'^"N<TH#TO9%HW2\02@KCE@D-;(JN]YJ1W2,'Z/"=.FFT6^C%\_@
M!,AJ<I/? 6PQHX*89W([U2RRQ:_N4#/T1,18* JE#;FAB[S!;^*337WKG>VV
MQL0%DF;%QA'-_4[R*=U&=KU='T1\K?)BPAS71G=,;\7PF%=:$S_8W#.RU86E
MU/):7ZM8^WH4C-B] ]9C2,-+O (Z)UO#J*.VO'L6N$7>EX(L:^AI./Z1&&_E
MKBHWFG%G5K:"9N*2M"BWNC\!VG(&%+@[TN\%2!@_8;XS?W[J9'TIMO^F].9^
MW=C3'#D8_+-Z&=UI)Y4N0*,IOC.;/]U (ZH%'TT$]E:,:9U)@512LZE+$KSB
MH9]IFAUT%[K:RZ::CVA)TAW3Y:I_3CJ2#$[D)?\F"?BAHZ1RSXG!!B%F9*O(
M8/N6@6-M]T*3IGTLY"-UTR,3L(K4O"H/7>5^$'?VQK1MIZB% #)3:XT!!SO]
M^(LK=I%V@->KW#OV,3XIW/:AYQO',;&4R=H7LT&6!JUTD,Z;V0N[-1XJN+Y[
M3LQWABO7Z@RTCW;+7%YL5VN;[DASA^N80B-3!ZEF]'T55*-81"GI=\P.W+31
M*5.1WK3#TSJ*\AO-Q3?7)K3*<&NUB9.PT$*97C[]<TD28"-8PW6-Q$STVA4O
MUDX:&4Y%CO Z T3614N7^SSN0WX.=HEXM,]TV]7/GW3ZP_1-P'.;CI<KP.F#
MV38D Z$*_RO$Y@2+E[7;&O/N#?MP^ XKCR_YX,=6CR#F!["0O+[V-&ZU$-X^
MDRR/H5C=WE(/ ;VC$<S/T]<O+J)SP.FR;+E)ONOM;OQ(1ROH8X1SROX.^ZKT
M3NG;/LW!A'0B[HO\G:]PL:52"D.JGRXY2VZJVMYT] N<&+N_3_*EVU$'EW*U
M(CF]<D9"1.V*@UT^548?[$;QO-K8( J_[[I-/ U4]Q^> .4[DTU.N+^4ZIRQ
MY=8(!2"T[XVLDY)M#4;2'\R%]0I(A]Y2<H;5HA94&+ZK%-DBGG-]WJ&?).M!
M%Y*[ 8%>4BQT!S0[4V13RZE+/K7ZI1DGWREO5,E0?^:E@<J<:P_L9W*!A..!
MH*$LO*^KH%_N6^$:MD'6N<=K#<2"YY(ON_U%'QFDG%X99OOV#XT@8F>03<H6
M:KWRE6,R"D@84BT#N\2?>,!7NG)33.)S3"U\P:JU,T &\JK**)O?9QF*<$EM
M7]?U4]L<X<HA) A&600@K? /1 )C.-@)V>.6>@8K4Z6"F-_&1S#?DYJX!BQ-
M=H3N^_N^$4^<O"_)@.B+M0UX2F%:.]TZ3T;K#_3.'\E32:C%+6:R9S8H/[?K
M"EG>PZ"58I*4QARTB'D3L8 ]9DW8_./3#:C\D)5^6FDS?#XHJE5[*UY/:XQ4
MK=]2L,S=RNX5(L0TZ)N80J],G_Y:D5/S#0(_"9\@GMZ2OBBG",'/P,!=I69M
MS9C5PN R7_\)B<$4JYQ6HL[_J13!%_\)<_+9\Z#1F]0 M3]%*)&ZFMQM18CS
MT$("E>9'T7GCL:E _(>J;<=U6H5=!\K'<CN)Z0E'IG5)52SS1BU&DEYE.^:>
M,.#X:8$[<(6>T:C:?3(G,^-M;H<L03G4H9R?L(&#/JT@0Z&=KMF9;0T>76'%
M51B_QI4J^478H^ GP>0?L;R;A24YG9ZO$:-U?KM>1*_&W0>84UW3OO %!K;S
M87]OB'\"&) +AU[Y/^ON_E\).Y'F)TTN)AH-SI*9'M"#?1(9/G^HWLR!))E!
ME?XZY0:%!ZOXIUSO(0[V,,E#WW0S;2**,3XT.@]0DT@? G1-RI$)4&C7A)V8
MJTE]]=F7[,OX,OU50/_7=A;R;1I7;L!\I=$PPF:,7Z8SGO-JF(R6X9415]+.
M:_*#EZ?\I]:5=NH)\J=V!J<6J4*!-)?'A<:,ULMKD,DJ&J!"9@>D_^]Z(V'S
M0<3&;GFCT"UZ<+M,F2M?WH)$P(?E^QE&GP76Z9AK3!"$/=Z:1#)RT),UG K4
M@Y6/AN@PLP@4]&9R4",.!Y#HO)W;]F<FYN0RO-L\"*'!-Y$/A,--J+R$+2ZT
M O\R/7_C(]!@N\D69M3.6U*@*V3NV$' ,-D,?C-/F]U!A)"DHI]@>^G4Q76D
M]ZP^@----:)#/PZYVUDX<%2H9^:M5'185M:R9*?2H9=2IK;C"FON;'L0(&]G
M]6?,:A_[M]!'G?Q/HDM@6\1"*)6PDS &0_'K,5DZZU:.PXD@-?6]96(J5WT-
M77W0:_D4F-8"A5!#P3F$5T\U/BL+(5N"CQ=J03TI'.$[^?(O90OC-7=[P>CP
MQ+=DLS;[?G/V:F35L;LI%]3624E43(X/ICL"SP;RI>8V\3 CL"5]C3SJ$@/6
MO],NL$ _3%"6Y9K$VX>YY/*&5Z,^?2_*>1?&S*',$LX"!F*;^EC7OTJ[;'=>
MFE6J+=H3^T#&3A9C$HG4,6/@DFFST_<[S=EBB.1S;S2P)] =?P*0Q^*7 =V=
MK=_1*Z[6>JZ%I*-'F6>-P-GG.XXMMCE5^3)"KJY2IY"U)&?97.8/1.+>5>WT
M@6_2B?DZQ!%CG@0NIWU/@*\%!73M*PRAO68J&$^ W,!['9>WB\<'C[C*GW>>
M '\DG+ /NY;V2=K-6IT#];MG@_QG?KOBC0I1MX:C]24;;6#)'1MTV,WJOG!;
MGCZUTC'2XTS0F(3$IQX4/J;XRM>;-LL.,=]1/F3V\(;I25&&>N78TBD?F<OT
M\89G;EJ\GHX F::>%E>F*!*OS"O^ZG/WU?(3@!@M>RT.?P*$:W]B2_S#]P18
MCGDL6;EJ>Y8,/_'^L8^%."ZIEW2%V^C;7)DE%TW'V0Z7:!\\NL!10-VED(3&
M>E4[,Q$@N [>:.>D=,^?H\ &57[7F+GS,88)YJJ#F[[:C>#IXZXJ,>_<J:UM
M.WUN]PU<Q'+"2S!IPJG,+3:O TL6#%?:5G%Q"; Q7^U$:#"4_;:U(,(#QT5T
M[+QQWC?KK[Q>PG[CX,"=JH066Q^9J_T&O#T;)7"I5F%.21K@=(A6=*/8&@YY
MQ(:!A$G?/Y1\+!46B'^IW27D-FKS[0E ]V#T0..OB^$*9WFT7\Y;B65)?P(\
M+_YLC]D?]3?5_^U=D<?&S7[9YS,Z++S(,L>Q!'BKTX<!?HTE9$TN7%AH^U,%
MV8PF2;$+E6U2K5R[G]7-0$),U(RYN#>O<U%LW2)U6\^, <L;T<^H8Z=+QC4>
M3>Q<<3<>_^=J4W-9SATY_<H])<ZY#)LYV %BL;J09O7XI07_%$T<7?V ..IZ
M^^_#>YQ%YI.?.'_5AP@F9.NURV^PP56ST/2OQJ;D)G=1E^HJS^ZL-BY%DD4+
M%FEM=*L*GP#/-JV)TKJ!'N@S0'7Y1ZD2L96JMZ:NN:;)T\9>CKLWT>)D.)#4
M&_56@N=83O4:!NT63LV$FY-"2".?NC4S&3-RF//F@=^\H#]R/F)2$X17\QZT
M<H^WLF%7$7KL.^#V)],%L/OY>?YCW1,@A$7S6@Z]<H?+68%;=K-R-35"&[ZJ
MG^#X=Y\WD-/YN"8?V$]4H:]9L =/)VS$*UXDL4J6ITCU%1MBYK=[ B186S,C
M0[*X?2<550U$3R=7(N&.U=/%]D.*E(+G(HJVV3H*V@.LRM'Y;7,:VD4KKWSM
M6E6ZDDV7*?@A2]3S0(&"GU1=S_/P8+91V%("=S9OS4KBS30=W*B>BU-3JY@-
M[FC=UV\(<".9?J%@/C:N$YR6%E1*EH)WA!_TY7O!8F!V'%*)F_HG +\;_1/
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M//(F(]X6G"?YGBW*H5E*4*0YJWY 2,010&J+SQ>K2=74XS<\O9]=[9"1']/
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MT>$V<*9O&2+4.18?>H6]WF7@5!*Z+6'%W4RAC,PS*)GV2HHBW,8[]1O#D[Z
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MIXTS[0Y-[CJ"'+!_F.SS4'MWT(I_/$2-%<&68']\3)K,0G'RJ.=^?4E\753
M/F)%S95\:OD(7I9]W,WS>Q2K_,;/VKOQ-U94X+%1>O)MTGO6F_^<*0T^P"M\
M+_C=>$HWV1. V1<'-)GR9:;#+F]&M)(I2#?)Z]]:9G*S]1:X6 /SSG!A&AK[
M)W7H89$Z;G6[1_\X\QGJ?\>%&%-*.OXD=G8(>+!VHHWK/*.>:EOO<J$W-(\S
M;SYD=F>^8-/R)3L_:+.28YKL?,^P+-D5EE_(1:B\T[F0_=ZTL:Q._#)*ZYAJ
M;TS'R<BP/[--?V[@$ X54>*DK[G:%% 8]<'%=D@V,%KT1!'E7QIN(5[[HO H
M)34I/DPH\+I]QJ7=%QE3MYXLC\K-3#<1TV>'>1N/A+L$FZ18P#>L7;*5KBL/
M.B'X*%;<@D%)F":#FFCOJYX<A9*]]2\,N!FZ_ZB'AHO'S*+'5K<Q=;@+>N7!
M=HR%N_LO,]0K4Q1VO+N,-X1]3AH4?2?4A8@_:[_"+3,M7E8;4A67I>A)T6W#
M'?R/1N3N8J_<8G?HQ:3=.5#FR?87%^HO-7Y?D8Z.F(I&-YP^)'O?W>R1+O5-
M.Q[I7VR:I6("^1L-E&I-\X64O%YT5<.X47J_(G4^O" 2&ZYM&$IA*TKV_!\=
MW\T2=<%!TTW$F$>\-4W[L]$G0-%43M#%3?E?T$BL#+;Z ;>_[=;R2JWQ0I%U
M/VVRU(1U0D#S^GCQ8BFI$96DPGUX1#)?_DT?8W@JMA^+9U80;0?.JI_DJ:C'
M299X;-.0A8*+@SG[L7A*JCO;W,')KNX5_H\ -"XN!4-$M7=UC4]E[=@U5WT,
M,4^)D+1[F9%0 @TF0]M*/];<X%Z;^IN![&B'+SA;5LSKS:ZM2?'I\4FNN2V$
M?.,+'[A0YYBCI P5U<DC.96YKX!>\1OOI$/ALQ32F)($=RBG)\#"'YQ<S2*M
MRTWM)%UL%^VOKQNGP1E1Y;-%G'PJ@VW*+\A"2H(XA=7Q+L&4);+0%/ V@PW"
M:\[4![/,B-B4 >J+Q0)_4^9M\,&*1%=?7GLSEJG*KB>ZR!%_OB<NSXX"$<B/
MT=JI(T4)?.95%A4"=QBUTULOY_A*PBFD/2]6 *H1MUBHL1<P\DGN<#.19_@J
MK$(:?"5M,3S0:"V1,Q2@M03J(79>991>A6]_V4+?2J>9RL\336;<LE*8[4/-
M,U.SO)MBTX9F)B3_QC^VNIXBXZ'&:"Q'%6T"7+Y4@N<_0K1]"3G /QUJ_Z-0
MY4W1I:F\'0WW;6JK:TI<;?<S4&SL:P99#M@PYT!PK-R$,O^G 2UY/.=/I0B!
MO!W)K&<FTF%ZPU[NFAF'0W 6GRAN'<\.[2JU-OF.&O$Z;4=XQ:=E#OMVO9Q^
MM;\(;"^F(&L04GV.3/'9V#7TR&56H3MZ)S98J<I!O-:^0&N!P<V$SP=9FZ=
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M>6O1BB^(N:;YA_F.?FJ<7C&$WJNYXJP"YE>T_^W@33.]9[N^\O.([""7!<H
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M-1T=9#F0@RP/U KQ<%7.Z%9N&@431_W:FOHS&] :.&-V)KHEB$9-O!1Y":A
M_<]W-67(B%2K*<0:U4(L-0_I;&E&U#+4+YZUF9QH)CSB1#%_S\K.^SX\CFM1
MP"=B=+JA5X8](>/9_6;U3ME7Y-(<?VA??M&V6EU8 D9:3>0Y[)4$[S^M<F6W
MV1ZQ4H_4-9HG'-U-EVB&;BSQV,L2Y<1&_Y@A6O&(T&3(CI*B%E+7@DI/^K)D
MIPI&T[>PO+H&1)7%$/V"Z^Y5WKTRA*H^BP>6ED5*]OO+.%"&M<U]Y.$%TC1L
M)GK@.^ 4&A>I#X3BY-XA*#^=;T5C=YAH5\10J:0_2X4>ATKL&9A?T:#E4+(W
M_8/=+[K_/)2 '=;J%UF/!.D5Z_S>K9\;<0._MK_KR/2=AL.;YOUPJ[,VCWKD
M0K4U<*E)77.%;RCPC1NU>*& 6TP>_:^^:X /RV5\P,+ON]< @%O[ CVJN]=_
M.RWX&F!2H$@P ;C+W2:0?4*\ZK0&4ENUL_A20ZFP/&(QI78$6&E'>\!?LOK]
M#P")70.ZL:YS-#U[^AW^:4GL=3 6*5C\FHHX%!0]K<I3/Q6?;LRW9PEW'^C0
M"G/C)@#ZCX0S4<KZ\JKD16TZZ]C%=/C0<?PA^='*5J2S8V"^EE0ZHVQ7'C)!
MM2V2H-C8;.%[)[TIH7:?\B#3D.-$+5ZF3;1H+%E7F?+N00>1QF^VLJ,&Q\L$
M*Y+S\-XUY0]TIY[KZ9G(!(+'P$)]K7K'JK9Q>(ISFN,?K_.^6NJO?.KOBJU(
MR!TK237I(JI=*9BWTR_R?-S\WZ3I7#V.(GCS^9^\X\,^,JVOV@*']LRLQ(O%
M5=2K#V-U'CQI>D\L*H.HK^O+9KJT%S;LU8@9B(SXC,_,H!0>(%FZO :X>40*
MC>@\URO"X>DOK*[FAY3/:Z?PT4%+365!LNE5T2L'H_]3C^[I3:15ZK@[Z(&@
MX0KV<:ZZ#X>A,LW[896\ K1JBF^*W+N5)AA)-5G/H&]S+U3$K%I=UR0D]=8.
M3RUOG5 9)DVI'?>F%3'Q;&3@B:U<PG9_3_%SVG:$RS=PY#&.,VH_':&N-I^7
M6'X$_1 2"S5_AC+O/60(L^ 2=<O ?/8E;=EMK;2K=*BTM+12'O6,]J^.^2>3
M]_]Q(_@8'>;T%:<F$M6XVA:UHD:S=.#'63';[."0_GGT]\0+7/A2'H=,*5F*
M:9<#9X%\INMAIN;KE@OW<%D]FB0:9MF:7-N8G,H 8KBTA(4S8P(U*MY@9^*
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MCDTY1N+/B^=^S^E;)U&K&/7<4^!+T!!&>!:)#)/)#!4&1I0NO1P&B(W,FOK
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MC 3?;?*KK'2?TV,NGK.]+/2N?= <0O6\@O\!HZUV70++MP7%]^&MS8I2I@Y
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M0,'.D\M:9/*#HX3DPZ6Q^<>ZK5Z<.JZSQ@]^_^1.[O,7MSEDM3'T[*L@5(B
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MA7H<\;G4!(T06G<UH&92?QN,"I0+$[ ;/N.^S#RDD9_G;'P ^?QB8<GLU>+
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M%=@W2)<8EHZ6?*?XOC$FI07A1B--*DGY*-@V0-RWOHA^M=ARIU^^2:%Z5FN
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M2M@: OP1\A7[M0QCT:@AQW#:NZ=(9"!\95:N(?6!9;P9X7]"B5#X#6 #R,^
MO:J<3G@NIXB=V&U8+EBZ>-Q1, :YB*((R&O-1L B)B&I9G<"U@-T.V*Y9J=\
M_CL)IA#EHAMP8@S ?E-CTW4Y@_RD+C5VIAD-# 1V[7ED3'XWT,%[M9=11,5#
M[? N;7[QHU:7);Q8#EHEK66GR9"6<LY3M2=15!9NQUG&*M',[+0:H;DH;TJ6
M4MNXQ=!CFJU@9/8S\X68PY1+3HQA%+21!9-C9C#*)& N.ZV\HS#+08A929J/
M*F]H@.XCR7^DJ8[_0-CHE#3,$>=G:2W>C4Z F5T 4-ZVF2VX8BY(TD,\!20.
MB%][>WI'!2/VM9B!877G1W[CY%L]I,Y:#UDLTMU6\W3PRU/-!$F"1\  R@1V
M'5%^NN=22Z8GTS,AVRII &9I KW>2B<X#QT[V,UQ$TS17?42)'5PYY*:63<T
M"Q1/A *;#EX"<WB$6IE+L'E!.:0KD$:DJGD<D1[R#,><S9W\Q2KSWU#YCPN5
MV9>3!,KFLG@!T WP^.V_H=^Q!&%U0WK(:=K?E356)"E\B!8FX^Z6Y>_28KM&
M<63TIQ\C.  GJDG* %.K2&&_=(323/95WE<(18MZ6\E79=11KX_D>P/T&6]
M^"*S$DP^,5]EP,@EX^;==MW@YW#C8"1. ,A (T>&6[?J(37H<M(>;8[4)MN
M+0JT;A6R=4!5#^0;(<QG[5/-^@BI"<$@>>0\6?ZOQ)T2M?-+&<S2"& $(*C.
M5L/]L$V0MTNLE5QE2!;XO40+9;(\/:>>#) Y"J\AZOJ/*L=FMB\(^/QBM99-
M8:AT69X>@@,+.)YD!FB ]=5T/)B,@Z$GCK*XI$154H<@V[&1?4%1,XP5PS-P
M)&@#PEQ$#-NOG(0LMA H!9';-+^#]9M.=GD%;DYF+7],UT#:6<",'VD"D5 )
M=:TJHL8Y243)5MMG*)V3RB%"<*4+%T'[AI5$1;'X0:[8FN]2RS^@6-BOB7CL
M5-R/Y;'#I/ L!+1"BQUDQ_+5@9]G A^Q@>3RS95E-O>U7\(B?!1V8I=6YWK6
M4W4)UE;%:X%UHM:JF\IE^:Y:SW?BT<DGSI@%I!Y6^!"7"()BB;.G2X<>\A)V
M@KA1BDLKD5%7J0%-P!!EQU@9&]FDU C&0B#ECU>!)&E=OU*C),J5K]PL"_)Q
M CL"6">>KI=4TL-JU)ETA%TCPK:!XZ5T3!;$%TU- =>KMVA2;.)(E428');(
MZD.4J'>]EM,?LZPU<1)8*C[SW1CR)(YESM!#?IU2Q:$( L/^4.X#J0A1VA\A
MP'8 B:RGFJWR*(Z$5R X1+DP637$V:#V?(X\-$Z:428)#4>XVB.DVNY<VF?G
M]UHAR?^(Q(]IDZ^-4Z?67N%?D?/B**]TB?T@1(9#123;$KX:_6DAB#:/<,\(
MM*Z&! ,&(W\;2!!0*C>0&H")27=3#V& ;_P-41+&1H# F-Q?R:PLH(0 &P]H
MJ[4)^,@.S$/2HB]BRTY<KAY2C'XMRS^H9K2 H=ME^$8=!"H9!A%R?J;331#O
MPMI)J9WQ"4X5@)DXJ"1 0HU&+-8\DE HS?Q$$2Q'04#A0!!BKJE#D;$KA^B7
M.:=T88KQ78I*L1Y2BWZB#):[YW18QC@QU,(.USP2:@B R?-OB);J(2"O7B]9
MW$DOJ'LQ6M6'#,4L:]/>U1R04POSS[/SO*IUP7)715,-N6A,:]L +M%8&9'S
M*S3^'^.6'PSTT*V$I-/RM23Q@XH1VVYE+3]?L7#P;M@+H6"#+DO(W2>C[I5A
M6[7U0AS(#I\106XD1CJ:8,L5?J76]2LYRD/X">&[383:?XP)Y2T%_@!?M!IR
M%2M0=M)_(C4A^%K^I.JTLE-1-H ]SZYG^>1/%H_8-],[.!L(^;7LV&%H,Q.S
M?722]@OT8!T7Q,2X +_7T!=(O.#$D;!$X(=A,,FPGTF7X!Z3@OOI8DX&'M/(
MFE&NQNP=Q;%!4NVCA[0$M8$!>E#')\7K(1*EH1IYZ Z!S("CIJ10Q&]^%T[7
M@D&8#:)COC$*+TCI90)3%%YUWB^')W*,4;A3)K  HY#3K4:_L<+<-2#6+A4)
M\ ,YL5)8K2RQ>0FW(^Y4! \OO3Z "427Z5I4,2WD$S*,IRZ]1XTE]HV]66ND
M!5L+JYP!2DQF6Q?U%13]E19<I!S%VS=\!7FQ3 Q,7DEL*D-*3CEG;D*HF/'9
MI'?:&RII9\7B3ACX.NL)-[IY+9OSSZ/W203#='^K$CDRATEI94/3<#KTX,S*
M?YI6EN 5PA$[#TV="LJW_!C,O<BOT?J,#'? <Z*EK@]86&V11)#KA-HIH[:$
MK:M75H.5*%^05$7T$C2U(>D()IH4181(+9\ANDD>1Q1$(7(#N401/4P_2:A\
MHPWXK$8&]0,053 4A+A+,X58'*>J:230$006SR9-('=3Y?/)?A&LBW%?N[C.
MV?*ZNI<UB."HMLUV![EW4 ^TU*],4":@_^:L(?/"ZL26[;SGP7I('.N6.D;C
M.8 ZHHIO9)U6QT<.>@MBWD\9<B@!Z*/BB\HI"AO <7AO?@SB"X(RPFBQ\HF2
M4O.8A5J&C&NK]DP)I;B)O.N5C8KP6HHZCS@?I K(3NY+\&2C)>;%W#64:@,=
M BN8#*Y]/6W)%QB;4E:,$FC:Z$P@=RTZ"$RI8/X5',9'N5;QTZ7V"D&34_X@
M.ZF'!$_':3AN;68UXS&&:(>S1K3&:$<K5RAV?HWV J<:<0V/8HSV&G0D6,?!
M<'<'PF@+ON> %:CR*-[&)#E$*]X.<^V('XE!LGO4(>XJ-5*YM@^Y2\*([-6]
M!@@X/]T^LR2#3)/>A/Y, \AL196W8ACX?@#KJ9DI<^7[22SC.(>EP@P"\JD:
M-4P64E@2!:0VC&; 'T7:1I(1?U#.6O%8)OS1V3#9/X0RXH\*(!2&$H \^VV'
MV= 5H2$'H0![8P[B(0J)\*\YR+7.:J^<8\Q!XPC+1B28@AP%O\Z<\\; :WSM
M@>K5HTIQ0.?*S'9.&261F3)B5R/30VQ4\77(_##5 ,9;[7=3+6@@69;)NL=@
M^V,-6?7UI,:453%MV/A)4U8]+,71M#;&K,ISCC"P- 7!GJB'S#37? 33*K;+
M5>FG@(YV#T0*V9E%X%$ANDFHJ1[:9.(<,$7F\*QBA[G'">4B1UIDEQY2/D7^
MST.E7FJ0ZFKQ)AE\V1#JF$FI(V&/JG$WC2KX:"A+T$*R9!2*PD]%S=$(-66'
M05#%NJVI5S>V")$X#D:S5NZ:T!>6/(2QHUS2VE7K(D5LFT:U)Z7,((%S%AH(
M9(E$P^<:,5@L<!5U%FW"8(YFM>PN%LX$P8H'V?D&",975GT)]S**F\%^#TA\
M<&E1+TI@%ZV87]7--MUS"3;UJ_)@&\I&#D<I,T,H?6\<"@'-D/>FT1]&E</
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M/7#*&D :U6/7S%"!1B*+$C;BMH4ZKP;A_O[^3#:R3/ 2<_$!>L"J8K)NP"!
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M0F.S,_P)F2'+WVO8_.\,I. N+.=KVV$Q\ZW(V01?+*R@.65THYCYB0B6GZ6
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M?DB=Q$*Y1DR=SI@P:/(TAK4ZR-\U96/9/V81?]WB>UZ/S4(BV<_P-I4A%Y<
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ME6*1$BXWR36^:%[%D$]^M-G+^:,E'^^:6,T]T\ X[9C"ZW/S:_(:?Z#(*IY
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M'GP0WUV4&Z;+>.\R<\-< Z-KP79U\\U)]0V?EZ(W;+BA--:IEGO\W\+]"@]
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M;,_OSV?B_P@0\SQZ&J[A1Q=OO)JJ*P*D!P$J5):HJ4%LM@=&O#TK3WK\;^F
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MD>L33DB(9QE.X'_B=TV0%*C_B]:?,L/J[VH < D"3OEXF3<<QQ3*S_)BY3<
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M,S_Y/P'ZO;T?5.W05XX/GE!EON>(_.I_!GC1WH']EWZ_M;Q9Y?0=FO[9R#A
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M<&*>8S=DM.EW')HUW1*:!VZ\Q?B,J%YN?-!6XD/B%J[<K>P"8U,,ARX5!N7
MX(\.<)>QB%UH#Y^\J@4!\OFA0;!.SEQ7<VLS5DSR':EIGA(MI=J\#L1TOEBN
MO+I':^C#;[P,,+,?GS/V0K=F'7[#E]#!;Q02G9^_) ^-O_3(_[8>?^?[=1_!
MLR&[M-U?#+?NAKLAEPCD+*\,M=6(PSRY2I?(<5.]N8]4FQ6U>*Q(;&]D:53
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MM Y7,0T6./_9=NLJ9HSAM^XRGN,ZNV@P2A4-AN7$'O$@WC0'U*._L]IXG;V
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M;L#BL,5CSA>6Y3"(>-L9, M@B)[EV4B<%N2$3SU(;+Q-BM].H?VTDU"PY*O
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MRK*HH+7K3^>)] ;)ZKD6%HCTOJ>S(@FEL3VQ_-+V2.7[=W3)*CH-H]/[M:F
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MY,47112I+@6@_<F;M7F_L<:*;URUT_6YS)6]=.]1F>VB8(#++/>)V[/=2JZ
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M?RI"*@E8]CQ^KZ5S^EZO8:VXI,X;.D\?Q^7:_[*>#R<D\\J/?IJ%LQ,+R_0
M"XX9)0A;]2UK&E#X2@RAA=&"X2:](1I6F RE#,MIG<M*MJ,@R7P@0*B+F-\"
MRJ#G'^59E4D/20*FW@P.PS=$&A]E_+_/D_>>NWO:=?_7F@GHE..D7:(E'2[[
M8&VB68!4U3*H9!L;1Z>D?BAEDQ./*ASBIX7">\D2#!?SK\Q:1NL5Y9/0G=8>
MTZCIM1HU(3=1[9Q5G)@5GA)LYI+6'E.E3A,%G9B+?UMN:^Q[!TG]U]ZPQ2R*
MD?95+.^62D!W$-( XX.N^<^YA3E: 'D8WK",?+WKJ 1>."G18!A\X]F8V-H
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M984#<L8;95)KQY.*=LE?)1P1$.XF?,R,24?!/)_ MR_ .9+^ E< 6% :-"=
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M65'LXA-@]4G95CO912\BS2*6Z_D*'Z9KZJD,.Q49;ZRBIJ+%2+5!MZNYY&D
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MZO(ED.]Z'^(Q_$YI5<YX]!^V.I!"@QG9KYUEV$<U# #<ZD=NNBL?5O<PXR8
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M"(%/[M1.DV4>>UEQP/.:E":T$)[L@-;L1=-TG=4GX?HTE69_@3/?,4BL?IA
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M.Y14(#8_;S/><08-O=M4X<KDFAO>TD9N!8ZGWQ_IN>OOG)E:)B)8J8=&1<4
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MI'E3/MR<7%V??PO=2,B4#@QU/%LZ_A<GFBMU^R\7^DCD=S2T?_ZL,UUN=0/
M 1FKX6%_OCUYEVTOZ06A%'^S>P\SN\?L+'0("# >BV8O(+-65TCC_*A0F>O;
MQ"^7$#+Z_$]HYI-)B\ 9M')"IWFMOJF*C=3*3YWW0*?NF0@X=-8%"AQ#R604
MH5^[-,,>E0*<@.J\K,%5?C:;))4^_>#BCP>2E,7U+JU.(),Z+38<#>XHG0R(
MKH"8&I1&)3358TT!QIK81V.M$QW%?6]AR7C]MN]]?"_@[7!1-UXO$E,-;\$,
M;%[ 6+48G<H_YL#UQ5.H97\RLZCC^=7#%L6NS1.:;2>EK0@OQ5W-$]HL^^.0
M"2T#Y:_,F?Y3P;N1P'.NNU[?7E_B)[2MT?VXP<>!!T3@1?'\BO'9J]JC1Y5S
M);$GM&&OU6)@6IW@ZE\ZVPS\']<U+<*;C?W](E(W5H.&J^=2.<M9H(NQM/O\
M RTCK8H G;.W)<;^_KL41C[L!;<8['+'K4:_?;@*56/['WN2?SNSI$4QG^#6
M3"KI]4F(2XNDIB1Z!&*5^IG;61AV^&PJW$<T6$^_+W(-_*ZZ317+?C^Q<F68
MZ_^9SW+G2Y0OE^5&^95!2DV959<C#9P&WD+"EE%$-$96L QXR4.G@E,@$$F7
M'9D%RHCOF(*DZ(UBY^I7[PP:-)SKMY_O%W.84:W']'@Q2=5Q]GG_E+$'T>J%
MU=K=A"SGIM"\YSX<*JC56>B1&2**33ZBRE$P![D.\V[6C5[E.+(K=:T4+IG.
MN^"^BLM=/OAEO?S-\4USN#>A$]M"0>E7%+].NW)<R7Q&'Z@TU^I$+L/2-U^K
M@?&#E$<AB^!OS["ELG&DM[.VV:^VRSK"VW3QK1RX^"C6<7[$+>\HQK>>F6$B
MB X5W(Y1O6R74I)=E>.$M[R%^7HYD7DUA-C^;!Z%E9S3[?A(/ZF+,_,.1D66
MS2&ID/X 4C8URL$5B%" ]<F=M!:V@*E>].76Z+06O6ELU;G"7NTTT ^J?EJ0
M!ZVXBOE*3%VJ(9BY9,98<%P#F$)>PYLX^ :1"#5=N>((V6ML3O5B7:;B9WC+
MLL\4P'J<K.57(6LH73K$E9HC"\%,/!.-ZB8P.5BA.%54'C+X8\K2G"+\+'JT
MT2#7!W B!M6!"+A&D3)F)HU0STOS)LZG,--BN]K.17[E8@_*&O1U.IFOM)@=
M\U;89F)P)9>8'_T@O!'#_,+O+X9F&;G_UM#\_\M;_X^\924;$>$U="]9>CXY
M<Q+_(V$L?Q.>F=UM1T%,,J]5L=*D)DIEO\ CN4NV>HS7-%#:V'$F[[OL$W&!
MM@PK>,FZ/PI+;%GVT$769;]I38Q/3-RW;G;Y9B;D G/;()J"2DJE[3*D!S!Y
M\[K\>=:J*NHX<@M$N P7TGJLCKO<35;#>Z.C(OEP?A:33 T3;W^AK.-.=O@P
M7K%%Z!&I':\PV<*4/FYEAT/-8"J@U1H9PI' ,\:RF#++MQ+2VB:*X9/M'&4Q
M(/-!),JS(2?/XTLKW2[EAL'W%MOTZK?1:Y8WXB((2U=BWNJ([%XF9^AALN$2
MW)MX(:-R_SFFD&7?$QIAP]@1Y_@3&J<( 5=_M%,KL8M@"SI*8WC]L*.CX#P_
MJ+SV\S#?(EG%%-X;X*=FZS7$Z]W0J079<G/DZ& FWH3/=+4A,?;2W%"::$1B
M_"#3DJYK2?)QV5[ZPUGI2T1:YN=8C>GT/#>P[2U3_"[MUN]39Y*V3>$:$TKM
M@YD[73M$F^IP'2K2%YW'P-<QJ^\U+-W%7Z*1N0G,[15AZ4Q'9=4Q=;WA#A6E
M+"<XU^639EWD=J\Z'C,=JK5=[=4.Y[9CMC7@#E=(IJ+3-^&D4\#G+$$N6;I!
MKGT<D9=*4N48VEDT)<S2=HOYSX,U)#5X=6TS.ZOJ7%\XF9/6T^$:Q "XXIO8
M%,5)7P"0?D1;3?,9A_K"?ZFVR7\>?G7_'^IIJ>]FY?96I&W:8#F7K52:K*[U
MQ:Y3>L'BH9R6KEC&Q@C\:>N?T*[2#2BQ>/ETEW=7S!(<*)M!E(9\C2IKO3#Z
M* !R?U$Y@4%WVM+,#VVF*G63=\8UB+*C?@T@T&QS]728SSN\K4,\J'@HJ5OM
M$!]Q^>1IG'TU436U3#GKWG%&*;I@( J5YTC$J]GW21V3%B,-UVK*YX'#?>Y$
MQ-Y:O/X0'P]I^<9S@0.JAC"F6EL+WR8JK+F<A9QQA9%3RS"39=I"!C*?*9(Q
MX&XC6.L""8=K7CRP4?<,[=963*\O2O;?FM7@E8@D.$6!F78&3]8!3JXE?AO]
M2*!)DB0:V4 [>R"R4.5>^8+B.K"Q]S\T-FV)/^O W-WDR='\ZOA=]._B&IG@
M']+,8Y%1>EK6Y$:7\#;_:A#>0CI"81_V^VL:<Y4SW#HCZC8750L+W!.CNKQO
M:V;OBDV TX 1_2*S(K=#+UCTL,X]Y=6-?)R<'9;[#:9F>EZ*GL^7U^ *E(E,
M$XE#X8)<1L0UHP^C,T]U9FKW$>-BXL;#ON=="!=@JN??=6N5O^O62=GO J7)
MVSI%Y/97I)697'FSR(XPEGIW.[S"S$]E4W)KES<?+-A+ZTE^?731PE$<92G1
MF'50^BE;*<"PIM8FVV6AJ%\FN=#OSQ- =>CI=A16LMN@BB,$01D85..H"%C9
M-!O Z\3?=!1D,K19U.8M"%6KPVCR@@>B9)_3FQ+72;RN,PWE6NE:INF1_R:M
M4%[GQ[(;1[). 9JG98!UX9++MEA1\)J"<STPW?0\ 9:[/K5KD,)XPMTNYBO,
MO,9"9K9!OM<6=QYR;.G>[726+!8B?X$IW^+6&/^/ KDICY7Z+?VOFIU=4@,K
M?4.U^$>]3A-*L0TGV6/R:K3$OTK[!0$%K/3K=J"G<N4*1$WG4NC;#>1!?8E<
M35EN[]?7,ZIWJWH6! =J9"<O'E"+R.^\&E3V))IN"-<5[43))EX"I[Z /5(<
M;+=$QA&_0;.7A[3K#++$![:N;*0G0<XVPIF=(/FAURFL257.GHZ4^$(72C(@
M<_> $U"(JMD;Z.]%42$1U2:V(0I12?E4\N6F#!)6C.5+EAF_VJ_Y 3X^!6<;
M5F_ G*]H>!>*>%9T-ZN+^;K-*W3W#Y@;O,X)NWH\;#!HF2Q@K?1K12GORHL<
M3BUO"*0L$'+GK<6H.O:4):=E/^LY.V$;I>7TW>&*+9H\7R@DY&+OQ3L3DV@F
M:!>3[*S%IZ];FVIUU*5+C2*<"C#BRN&X63XOUB%DJE^\2/5293T)L*1.>$M8
MNF&W,#VJ=%5[%D[<%C*7GO7K"U&I.TH_LV3(Y(5:0HA_(OQG4;F^L3R+HT"G
MOU [ZZ&B#86:W:.7FO!.7;<C5D6=0*)3,OF?R&ND/2V00*S"7+-C_O&-R_)S
MB(OVJWE&Q1HHH=QV#;,;?#+'+Y;T+##:[V:*E<^1P,-/<2 _<V=M*UZ64(4W
MW2("+[PE?72ED"E*9ZAGG:%$0P:6) <KV*8.[=>ICF#Q&:H7)7:\"3Z).VF-
M>:3S^!ZHE&R#S'U">W;[Q46^X'&EZ@B;36EFK^7WZ;+-"X7N1: B$^I#F8#+
MF%+# (\4IW$DK]C:5M'X-M-F?[CJNXW^ =<WQ*354S7_IL/_^5;>-C.>UCB=
MN19HD7B+=EA0;M7/C%X.;@WROZ;C*4H5D=]X.3U;:1CQAD25T^+G3 EX4JTI
M;AJ?,FELDO3CR+:RVOK;7ZB&1OI! ]C [@M%R\GNS#7?M#:MHW?[6;*<4YJP
MUH[2_(N4;H/GV'+KC//YR7+-!X/W;WA? <F8/(OY%8J'DXM@VD<%%3T&R,/,
MXPL#S5UQ^D0_.T2].!.]P@&??&U*D1C?^60^86E]DJ]TBAS$/,D)BF/S,7A?
M@K?(A*!4N<]W3@^>%N'V>B=YIB(D4P6E+['30I/_WDM<HI@/C-H: 24I=L9&
M.6RS+"MI9G"ZG?[^H T,6$ORQ-NTF*=;P^QP& 1.*O'UC/1&N./\[[;%_I]W
M$0]1/Z'Q2 4>"Z<^GM%1.T//?_M,<LL<_>=/OXT]0Y&MJQ3[):#Z.?=.(A/?
M>_XPLF6^Z\&5QL*9$\AQ&= TZM B8KI)J!EG2;.-Y8(0,FB>S2_OWYIOV:;&
MKXVI[*!3=&V.E@EY"UF>E5]"RME5%NFY6SS#[=KU6L5[;M12^U0F _9>+;YB
M@"?(!&W:!#WXS;6$0'7MC^M/GB^E[(: YEV=YSW%UH&:1CX*)37F6L;K9]$I
MA26FBKE-@S!92AL8]YE:4L'8E4CAD/ZEN<Q$#71JB>A_:LSZ'WF ,G]*_V-2
MFE7S"6W-86)1%#Y3MGE$=/F6BL6O8XY,<D(HS@Q1Y@&R8"UEG?&-K2K>MT.V
MEW3W[J&7E;/V)*I6Z&FY['JOJ+EH[@@(7 -FNBA9AT+9_GB0_79K>Y;[P=>Z
M#T@JXU"PST.W"DN(,=O+!,]OE',\JS8S7^)2514N$U$9RFJTC8Q(F)(( W#@
M&1#,,=$[6[*ZYQ@_1",(5!,<=66E9+G!CP+ KTF&' &]ZS1.XWOT]L@\3Q Y
MGW()7:XE![:$\;_6<9EKD@T'_-=6I<M3"*0&90]$I\?D]QYHSUQ,/Q@087!&
M^"RMW^15,8VG' SFUGF,U?1K$EL?"LASEG_*;M$H_,_]A#Z;=#8EFCN-7LTA
M=-@E4&YZ 61@XF2!Z&,#WW/1:^7KA_NLK[S#QC>LI9!E/Y?56WO-\ ':^MJL
MZ1FY3\Y!FZ^*5QD@TVJU1B]5<#<):9,'L19<S)K!]XV/1579;"8]$U_M*VT.
M\N7:N(T1=HIE';.L97DTXQKIH_MX4>\!P=HR? ;LY"7%,GTF/#(NGH,95L3L
M#H+/HR%V"8N+:N!;A_WIVS.GO4&/FG-0CGR9D2T72P:?VX)XFUV8#1_>SZ@Z
M#<LM#F@KV]N@C.5)%.UC^0OGZM=?T[5ZSP;"R?.F!'5M!*9@;Z3N'7Z<</".
MU+@L#U7I$5K,T;)Q'L<>?TDZ)K"156RL5Q-QRE'<F!MTGH^&"I 4<IJT8V8J
MK#^+N&]==J!2MS3(;+<E>8@N&45&%%!?8+V;Y.]V5P3[Z+V^86W<X<P(.<1W
M95$\B59+2G7M4D=X]MCV+GGJ*CKS^43$Z\A+%?J)$_7P*DRHQ:4G@H*6X1Q5
MRRZ]"[9FY&V-G2U<T58-1)!,,\Z;)S1,\QZW;" V9;7Y1E13A>PITP<3JB>T
M/BNJ#OH&FEM0TA/:XNA[_FG')S0+_9<HKDR1C[$L_O);>2R9TCY_:.<8P!])
M F'ZB/0(OXA*<\,^N2,[U!;V!*^@DWE&G7X86^!:GV3&09^5MF%\J4&_6_7.
M^O(NG9@%OW-_0P]EM(3Y*"U/LLL__\&I*L $!L=;').H^*_9D3$9P2G6+6^T
MO4-9X>L;<TU*C  +R@\7M O"UFO4YH4@<:(P-E^NZ)\O=&[C_9B6N#<V_&$F
M3L=E_%]:9QW6]M"GT-$K^N7UR]$GWW"ES?Z"MY2Y)/ZJ&6)L+"5&$(3J[Q43
M'#^AR:?(:J<*#N@<7'4JJC+2&J6E3NM'KV^MP4)T-N3W32ZTS.SD64(<!K&;
M1]6';626!OJ:XP+F;E3@7VGQQ4R+@@HI"VP<A00E3V8=I$^?Q34S^_7@<*][
M6L)F!%TXN%6]EG&E]R,5: <3<,4_1W0 .>NA;.C (8VHN/CKSJH,C/41E*78
MB^<!/*(G(9.K=R,;@?=7!<",%8.M8@?IKH;"DM:07U6CPCB>ULL'TLZGJ?$^
M$SU?DQ2JO2*;3UQC>:X4T26GQ4P;+:4?.>E!DM.RJG@[&6&,H(@7.M.:.Z\:
M687YFT=L7B__L6/MJG%UD1IQUP1W\-T7)D#QT1>P /SW)%%D'[#+W S@G2/F
M$TZJO4G7\DR$G9Q<<S502//6X=XKE?;:.X*OI<N5F8ZOJAGTJ2<R5W5-8%#T
M7MB@RW,-OX\GGBSP!HLL=[=4RT5&AO$N2\FHRVL$/<N<E(Q>X3K-1!T;W[WH
M@#4ZJ2EWH4U8J]J,^]1@B.]0GQJ+^R^\#_R"(1E-.OMA.1;NTQI 30T+;'=L
MU[0^9 -][[U)&K+"L;/S!LE7N$Y9TP%_2_32Q':D=NPO]'%4$R/QE-"U#X]E
MU;*!<6-8Z15=4\Y!F:/%Y<.6L'\-$_[=)E7GK@/[8<MSZ?+=E+0;;6(C#24@
MC\]BOT/A'P?5\N^;<\UY.:>VW#;O4S(YGM NFAHIG]"ZPOJ/-LXU65.&=MI>
MY3;N: ?*HK92IIJ9H(Q"NY/T*I,^6]FES+B\GE4GSNQ@QY^,GWXX*VYG]HI5
M@Q&]N%PAI#5B7!0TLD)XG#_^B1ED7SP>?31W^ ^77,/JYY%MQ6/J?R:[19H=
MSI=WEKUWEK_#ZA:_"+$U+AT*L:TO%RP[U)XX2FN#+V'"8=(J%H7['H ;6^8F
MG<&=02W;)J^3H9)&ES6UHIP15RL %Q=O@_2IKEO_$]K,UL^P)S1T"HH.R ]Y
MB]Z?TM3U[6,SLH?MA/O"O A)<]Q%?>/Z/5HB_DZ7KU-'Z07B)1Y1/X>H]',W
MJILH6Q05/$'9J133I-EMJ3SE? 0^6/6=A?7)3.?C065E O5/:/KU]=$0H*8=
M7Z4JB\(6CLG'9;=6CY)\:N+@:<K!5;H_CY2VQGWB_Q=7W2:OZ"82/R!%EF]&
MQVI6_2/5A;5&9N/?=R[P^)+>&ZZ*M@Y+WP]<:X]]X/X7F\4V/;VX9C.I+[V6
MOYIX3]?APFZQZ+8 ;[1'9UNMW),79Z^]HRMW=:S6$((@+O+J$\_=[@'2Y@;2
MP;JT+:4%XJ703_E5:2G9]RP/BB5"GS?.9_$:<)CC;RM27-]536?&?(Q6=QWZ
ML &.0R XS@A>Z!5<R'GTT.%$"<CS#V%NR@R:XG,R'2C,_:C!A@9]V@*>^#ZZ
M"\2MAQ4]H74_]+$<>J47<AH^XBD2.9TE^ LV\"S&^RFC-"^:>L^D337R6!<A
M0-N#;*O84L[Q);<4"WT340^$HESM%QMF_HLAA4GULDFG$W=T!7(-3FM%]XPG
M--I"A< '!X?7@<<Y)W<WPB_M4Z[^R'W;FSUMU?'+_Q-W#(2?#LNPY73(ED0L
MO9@UB!SCQ2M9P2X;EK47.$X09IHFIUSZ/GF26!=3Z(1W3:(0JQIIR<-)7BX[
ME3?[Q!-:?*;4;G "",M(2,NG0J\AJB<X=F,6CVRD;C4E/.Z-N*#D>8.7_'23
M/ ;QZ8_$ R%,1,J0J:3Y<5D3V.HHC!I!V>SE4IF>:J\-B5L/I,M?0_AB3>6%
MG! B+G_S'9\JJXZS.5T0 ?!D)/)^+Y!3W6)4!2C/7_@ 7V=VF<ZJ4Z45,BI*
MX&T G$S3FCHC36'D^1R@V"7SICY?YXQGV#:!A**?,)J;CJ11Y"XF]+6'-'O!
MNHH\MFM#X1 G^U)I/=8Y(PJ97B!U,0N"M2K(1.);DW[\D&>U.40QM%BL$+TY
MP]6ST-4_>#5,+SDKJV]:M[[NH=-=*J5#1MM5F6:<V1K!6,LS/2/[E;^"0X2#
MM%;C.:8G/2#<S,,*!UR7Y&TQ$U:L!7!_7X8S%"#%L[!0MAR$.Y5OT9>(&I55
M+^69)E3]H)$<&5*\.Q.^#7+:43_[=:3*-%":*V>\D[$Q-#%@T1%VEFJ^UJ^!
MS;NXN6H1\MY^E+5?.+;04^0#LV^,QR<G)0/&=;CFR<5#XLI+C0EHY['F"-ZM
M_G9-=5^0J\#N5_0K/Y5L:%@BQ6HV16"<W.N6Q*I_%/BZOE'\!>%V3&[JNB*N
MCG.MA?$'VG,%TR$#PJS%GF6<["&+N)/$*DOI6]DU>S@S'GK]L0DLI>"/;#\F
M$T#TZ4!%83"D9X(Y>+'5@#/[N88"*:NBE9C2H,TDQ1.:'BR(XI[!+^!1"6@Z
M;Y]5,YW>+S=!R9,%F^46EB_;,ZP^W6J?<4=_P$XPNAAIN7O>4<R4;'U=1%2A
M.R;7[+/]W2$[]F (0=&:&\8KL8+VCV)V>&,-_&&S"= O O"&#1JN7K7G3 2X
M7/#]AZ!F/%N497EZ5?;M/P4UK1P?UW\):NSD'Z["]9L(O>!^^.D'P=#I>7*Q
MPY0!O_@TV1#JV$\^MPJ1QO-#!4*UEQOS9>J4@_-!J9A1B=N;2-"#F.GHC)<\
MKMOVK[I.1>@+0U]QY7QPBX<4H[9-YE$=7$>/-ZJHW_"#4:]$FQ4^AE%!=[L
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M[,.]HE[XV&MF[@L<ZR^;@>VK"UT94>.#L5<.+JK+?;;(^N_A7QPCU!+>"6#
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M'/K9J+[S8\G2]NJM3]<%WD_>2LBDG^S&,V%@>4'9J=:\%]VM7MP5(6?*CM>
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M)D9RU>529"X:3P,"/2-JHZ'/22"<NDBH-'M^W&6VK/C6X3R?E&'>5)E/_Z=
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M'#I;/B5Q2%*4=M-POZEYRWR<1:/G_$"!KL2'#7B;;=.8BNCE9,! SJ, B-_
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M3->XUUI8AYJM7\SZC_EC29"4Q'1BY91O6>5==:G_*3I)5BD/0S?"+G!]^#%
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MG;L2N/O1V:A00-^)>AT['ZR[JO2G@U,[[*B.-E7ZEW3?F.P(D4I95YY='P#
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ME("--+75*AI%MA&/;T[!<M*>'$N;2/NX6:2W)U6'B.ZPALO%V"7!0%U7%43
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M&;3&SNLF/_"V?[5!?,U'15/8:VM?YN"6>;ROWF;@_(?2?-_SH6__)6'GGGK
M.[6 %-@*Q7SSX)?<U>^V#&S4S\1MGX]HK,\@YC-5BXDR@[+QTZ3:8DY8+VV0
M3D-M?E:+KWOH#K6"<OP?#PGYSI[:\&UX#7:AUP3K!D2/)\P5FC"FTO4-4&[P
MN,F+K\GPJP?'\=I&AO8PW%+VF:JSO5<SYV,35ZY5=GY^DTM*-^G9?B:](SI8
MQ1KX:&=[L''D5FV%N:!?=.1F;J7!9W.^\E0ZZZMWOO3O0R&1H]3YRQ\R'_Z+
M>LEU$'L_R9CYH<2<X1^GGR\D+YA\>.)O;GS.TD^<EW+1O;_][0\X^^ZOYU Z
M%A?CU23UA:=XH,D>&/R^XW*4F;,X+M/XVCO*"KX'6%A?:+$/FDRR[G&6#;V-
M"HC]NA@S&W5]!DZ-%V6=4,_2XNLR:0RZ<5E-QQ. ')Y+'9OUK'5VO7)W]57.
M.ML,"Z/4+%8T!,>H]X"NNRGD@*7\!9H459!YF]56H!^C+E!#@@3N^+3@/W_H
MP#VT4TB^8QWT5NSBN^)8>V'S ><RNDS''V7C''-IB *[4;4Z2P=$02[B51Q_
MMGN_[-<?<OAFGXNC]_(CT)"UCS]_4'=O&#7.AV(&T6FEV *?)NN]=6;G9?*@
M1/I:,AWOJN^K,&J%#DN,A"A3&\E>X=\@0;461F(\=@&F.%_SVT9;OMN\_<]2
M\+Y?I/'8 IGJ=8L<>WU)82M%T36'0,F4M.5)]P2G'0&OY[<YY/*9B]:Q9S6!
MI559,_25V5$2^&Z!4?G18E6[F^2K)H15XH^HO?"O$CXX*_\IJEOAB X-1-DQ
M,Q;4H*N$=F-;&LSB?;U8-5N0Y.A-4"+2V"L=>6.V%/-IB^AY\<%4#T.^J<)C
M[=__UP7I)\SEE'M [?ZMB\].^!.!S7U?>E]!"I6MN4#Z'F_M]]&-ULF2 Q]#
MGFQA?C2[&M8)37$93L^R]D]QIW;%#)6X7N>X3NSTX!^T^2!!H&;PT[/NPBLN
MZ_3YGT'6HC-%1Q"R>6)'BV'BY?9N0@'-VCPWJW/8/)V @2:B_#2NP[2*2)"J
M?\3"=.(CK/HT&M3QR-,@//5#Q-A@SEKTJGH;,]/\[Q0(KQPJ$DLQA<<O8H:;
M4?(7*YMU-[_#I7I^%<NOT/*GH8LM8;I-BL_4.1&,D=C> ,#CA@6L8@URL9.L
M):G"&4_K8FL=ZSO4W-/Q5_+@*=E\4H@JK1Q9[5C%"@N-XH]:W]Y'9!]HDOG=
M8?$2C&%Q)/E'QH^8R43/&A8\[7C]4)UF/=3\9;R\6-5SE6>O1RTV+ER.SKV"
MX)OQUR:96%BL2>V2,$KA]XNJ0'"PXA#C@427*L&SWY;K&O/!LY^V+G%R/ZUP
MWTUFZE1 KU]NNGH)\VL%I''C=;L?[E8&9;&>HJ<(I9A\9U8<L_*1HMK1CVFC
M[$N:_&@7521BX679?DN9=W&80XE;M'7+*_-M\N1G(*:>K!#DF8$1E*ZGJ[N.
M8TZVIX'C=1V2:9V)SP$QQML#_M;WU]&GCD&L*Y +GNHOCV(('U&>KM41@&I+
MIDX\JBIC X.JQVSL(\LC7PA99=W@11-+49[H^_=@)E9;&%4K3'%@!&]FE7V)
MYR-I[B<9A84*W ."2=VMC3KJ?UW-[1?9J!:N[6FB:,,5V_K#IZUC32FP2->L
MC"2[0XTJS/JA3C+);X9D<;O$_+T%8*<YJ^M$5Q,'%/"J1-/\?'=KUUURPG6K
MV94\FP(HL-E@+B7PS,LIIUU&OK=0HTBL+J\SE91/BN8(P?2G)W,7!S=UJ.K3
M"\H5M-:&WP8RI[A%IS13<I"RW1?;DN275N,'9\G7POPEQ;H#(@TD,J4Z1K@(
MOJI,S:Z)9')9*&- /ZTF.%Z3[I6YWU><^G^XK@\"I=[6;-GI/]$X16%%'8\&
M>A>/-J@[E8K=M2(%N9QM%,<+LBOQAXM5OFA;+:O8D]&3<:C17 W2<H#SM/6N
MK)04HPE:5#A=1?/TUE<?L>DE7S!^L1X+K-K#<*0[@S1K*4_&)<>?^WZ'X)@E
MANVXM(>Z=$_^U#+\9.K%B)V4WTYE$LUT08<9BYY2E&@RZ']<0,# [K%@XI2Q
M7AB^8#M3.\*TF2H*F=KKI2VS/G;W5I'QRLC<+Q_0,+":I'XZ1X )TV_0&(7G
MMHN \WUA 999^-A;=<.@8#)#*N=7I 'I,R?RP!B?+\)L^SDY3 >C'3]JV V$
MJTJY_1LS' -C0B-I+6O#E#?:]$/*OOKQQPALL&'S=/9C%O(U9?$8DG.O4,7-
M&<(WWQ+?1;U=W ZB#_N5WZ=F,JU#Q&LFB.#7@E,FN*SJK4IC: @$7"I&$OW\
ME_CQS*.1VB!/R']3MBT,5'$Q:3!1-GF+K'V9AQL_71*CR3>3)1<KZ(RP[-*6
M@3YS1HM_+/!-EMOA5)KEIQH)$Z_62L=C30&?78_&BS^V+Y'A_;%2CB8V-M3V
M==8[1/#AX8/=U;UK',51UK-N"2HJ$%=PB)28^Y>6+/ T+O27VI^@R"PV]&^H
MR+_CR/^'0!%WO*82FB8K*V1-048^WKJ^O\ G"Z-C2:9QQ4@3<OJS^6LZWP2'
M8^S3&N,+L77^ 8[O>99YM9G!5&8U4"IJEKX!BY]S269YB,RDHIJ?F5332=U8
M6&EF3DRP,>:\TTY[N8$M<OY^V9'3)_082V8VAS8:7RQGGBE,?VP)(\M23YO8
MM.%4^T*#S:_?)"Y\3D=EE90ALCG'MO3EU'E.H%5/37&M)#$HF)Z5UX"O7\/=
MS$&-OZSSY:'(J>L"5@%S_J,\*VC]4X6V22*F^D,E=XMAK/C<P>BO'"_%-VU3
M_U]?N?])$,UD9IDS2>'5D"#X*,;R8R.EFR6XFP1-43V63LYI3&&U0PYL3M1A
MC_I.1V74W8M=RH4#-DG4ILZ1U@QYJM[O(>4 ;\N:<U!THMQ$A9MZYG,9>B]*
M0#LEP$3/'.=CO]EEU/DG@/@=NM8Z],FD+CG[&Y47,!;U#?0G"WGP2$FVC&;V
MC'E4ZGCM:[0NL:)]X-W=6F-U.0O0&7:&\=J]1KQ^-5."\K2DV>!UE_2C'!8?
MC=)XEM]JGZ>:0U((X1VOU0CX!KA"EY%_"3PR)_I]4;>#>?*_<O&>\8IPL9DG
MJ!SXJAPL(=E@UCXL0"F6!/PPL@)Q#Y(1N0[E1G,:7\\$&B4?L]Y)I4EFDA:]
M*+8>50H:CN@7Q!? KYEI2UL\I6[,/ 2;E0-4FTEH)?OA4[W4%)6N;BL6>"QD
MXMZ9P2';$UHX.:@9'RQ2PL0KO<2,M\(N7Y/VOHQ;)R8'B A+X4ZG)N[;6X=^
M]2:AH++I*#QS4@#+UN,*:6_%]#(GLIC7I<1I9[^,H:#M[B,3KGWNR%>_NJG3
MWI##R);5T9HYACU4Y]P*H[/$ [)!/Q8JCA4@HC74^ZD="C((/HO8S^X;:=?L
MT:-F&12^80#^"'J>I-Y,Z'/? ]YBD-P#I/4=GMB>5>5/UK7JSG/?32/$YD^+
MN@MZU?;&T=&YTUL')^$S##T??:NVEOFNG&+WZ3(\\C(1<IEFC#UJG_D\CUM#
M]_@@?7M*AY9:1:8D%OWCWI,'#ON<"@W0//%!05:@\QZV9*V$!Z^Z2DQEL!BN
MOXJQ,>%.!\!9\.(S/^OGE1QI$7X$),J>W7P8FU>)MTM60!"66\%6$D=9.<J9
M.NR=Q">L(?R,U/#U%OW4Z$JWXTS2DX$;F08:$F?VQ9CKHH("^'F"IXDIA_NH
M7">/E4YAF-;!^Z7+K%0!-<;4'A<SUI([W( !A]AK_,VWW52G:TJD4W]9![PI
M+Q;^FL)++I Y,ZMFF-U:6 -/G7'6>$?+&#Z:HFJ-1H]TCDTP/D-V$B7S6V>E
M**SD,,BR.>N-R0#A/2"Q/F7!2]UMTG/NV*ZL*JR\:S<)#S0Q,X'&9HH;&![I
MW@/+<Q:61 P8,Z1(&!!)9\\U.^S.JSOD6/7F.:+IW 7?<C(U,%<+?AA^*L4I
M[JC;LV#B(++6.3SG%F$ST,%)4R#DA" !ZN\*_!A_NIA18A298S.U=Y1$X+)<
MCSWQ5[9NUW2NJLN>8G?I\<).U:B $'5= WM+)ZT_#977/6_'>T:F%9):VRO-
M!;X;9B<#_;1J1F-7US=)0BIB0U]&9O_V$O2J*O^ F&%WU>G:Z@?&Z4.K4. 8
MC!<C= TZA1TU26DIL2XY6Q#C3*,DIMHMDA4J62C_W2\,@I3>V?=" 6MHS+RG
M.M\S\TDZHST&[2:I!L)!:4 T,_"UY CE=^A*=L]S<PI@LAN]F6 -N[EYUY.2
M<^D!;OG#\ZS]UU\W*]_5Q81^W<=*#51+I \UXQ24GT#6:4CI/X''"\E4[H5T
MULCS#;PR"54Z+ T_$\N>V/<5:S??$K6V1JM"E]S,?U<."6_IFE%)F3@T\AO+
M7S7E.]8)C>N+=V0WZ/5Y@PYNL:Y0HAW5Z N-_6&3_"UB,$0Y0E<Y\#KGVXW&
M<GAEX=8N1WYUSN>XPLD_44ZN1::%=0XC_@%&G>\O1W/.^+M-\V6J[6ZG8]T7
M6_*(-)1#(Q%^$3>O?<XS?1"\MT4 ;>B2051I^XG(>D@R,BR(Q^K*G7_R^_S^
MI8-QU(P+W?+\7JK0!7]NH]>29T,:A0?R>6=WY)K*,)8_E7)^NM*:!_KK,'VM
M.-W<#?IWRGAY9QW'7=63_>%IJMIY#&LWL4:6L>U[J^($S[OM42EH5D.D?HT,
M/?$-N:<EJ\D"ES)+1E[QT*HY&%5/%(D$F!D_&29:3H=0[72=X#+CY-SG2EGI
M<*7)")L"KQ.B!WB20=]";;,"NL;PE_$=F#4<?&RVX>.7I'PNK<1GMY*3H&>:
M_%1=6$F$\CK[^*\9IKG2A7=2Q?\T<GB(<;(N//</'ASSGIC !..'C&I^-$.1
M^4=5P/@+E]I?(K1Z>NS7RHF8DUC6#!KB[XCQI_TF+5+DX?E)1(Q/YW@>4:3C
MIY-7I&.>*S^ZR.\DLP:-SQAKV2LU,X.*FZDV]O5Z02ZKV>BOV\._'.<H[SA&
M]VI&V2U>ES.<MOJK<^:E$U&JO:2X^.N$[4O< U1MK_4 37\   Q;+R85M0**
MMN/&RPQ[17E-^'(EU&BOAR";2>MM8?Y5AQROO+TJ7^*A7N:\% \!UH13S]B*
MK Z?\ZS+"ESM%9K,!SRM38))BGB]RZW1?N_G>V0>G>[S&<M>:M$XL1[DE8B=
M7*\HIGWE(Y#N9FV/2XV'U$SU! 702[NZ5O^,J+64LWA49I,(-]@)@T3T\.VI
M_HJT+!N7Y9O^SE=F";4S0,U3MM+4+W76R!#2)S*OAUC/BN6#K"6F:F<D7_IH
M_Z92QC*7A_U)O#BHFV;LP0JLOZ.9-SRJG=1;3I=0HF#LWJV/+X*!D&;+"86*
MTY4#9:6S><-E97$].]9N6_WN/ *QJ';8&V'+)"D.-\V\RH_0EK=%>&]$9QL^
MWKT7P=2$\]X#:*M[BW=TW?,72E D],5.&,.(B>T"_2A+O)W I;-^#Y\B31!0
MJW;IXW);\'2I F*6H-K9#E]O(VX"I'L:,*39F^4E+*S8P+TS)NGHO,4Y8-0R
MPM7'DBJ(F-]2[02W+V])]H[;CMAHR<!W8S;6%6,/99(QYIXI>S.Q63O+3)V2
MP/UGZCG40F^%K3WS-*/$9XOGD@<_KWAEAJ1&[>RY@2@*"*6;U=F=DT?KQ%](
M4-IM%L/H-%9F%]DV6]_9,>>>MRT45NMWO,(DK-6WZ,_N3 Z(R_AMF1HF6 ",
M+>B?U._\6&FK7=K=U>Y0FT-\NI-E^2(OF)*PG8MP+EM2R(OM\6_2IBVOP3W2
M$\Z?ZW>H86);@^-HX5MR+B-+YFRQ>T 82-O'>MY\LL-V]>=N%2A32C6RSKS_
M&"JV>A)7 G<P*?>S(^ZO;J2OQ:00\+&#@:><_:2.U\\Y*AK<[P'/.LCXM@S(
M\Y]0LE(S:QF,BBRB0F[A=4H>-OX.,^3O<F)3XNU^A/W,>!6]KX))-G(/*'#5
M8P,YEBM:LNDX#9EVI+'M/@<]-U.&R!^ZQ@O,K;R6!.GJL#GO:^V0P=QYGCOW
M1S>3D1 J1 N+C'0MFHSRNCY]+YN@VYA?UP1G518K'Q+B0!XMF#DH35IEJJCX
M12=PD]E,@\)"DR&8U*HY6CL)J(K3> Y4G/$R;-1$0R7"*6,NAB&.]L?KZ+7B
M#JVRS/X*JU11[@;\3"=5[U3:.9#6V-K/2:*3%%YA')NC3ZC(@?&/JO!,?HDB
MCKD=QA?PUT\L!$0\906E8^K+1)7"83>>P<N!+&-1R8AQ\WR5^.#8UVO->:4N
M9R#0@G/[W,W8_\'<5T7%P6Q==D(( 0($=PCN[I[@UCAT\ 1W=P\2@DOC&MP=
M&H?@[M*X-=JX.\QWY^W^L\8>[JRIAWJK56M7G7.J]MFUZAR_W[T1Y##_F$E#
MO2L*'+!VXC,'0WH"QK(QQ;Z1^;C\ L,T#Z-;&J.(L27L3&P;=$VB-PJ/!48T
MK2TU5CA3Q%F0T[1@T,DQ2E:<10D&DK2X<2A5BON>JE[L8$% #3Y9HR]3_!(Y
M\ )?3_!JF/9XWB4S3U-E.+<L^$?E]?XCJC3&$P+![^%^S%= GK",2.C7:7E:
M'YQM7G9"_<<;#AL#N:$V2U)BDJF>>V2D$TRSOB \B\R>QAC2)D';I7JK52Y2
M*72CV&!611L8P?@7C:J\9 -1B^OO<&!'?;LSZ+P%(=#+-6FZE;NS?YHWW7:.
MYNNET34+*MY+%TNS_BSQRG&*UYJ2;%]98O.2=(<<M2Z]2<)G;R][/3_M;WY4
MYID49(=K0@7]D)O6%4+68RMO^O0!%B82B>K3712BX<HE@Y!D)CTC=1N(HW87
MD,"85BW.9[,?0>F%0?0?C_HYZU,$,ZO=#$\8SQK][JKX?GEW-J).FVP=QF9W
M'?PS!PY$I4#I,>A^E*ZG4XQC^L55N4X?7DJY&:=U4HCY8ZHS*_M34MB&4NW\
ML]B#J^6:A.,OVK$Z,G5(8J>!C?7'H]G1AALWZ:VAT0+W^+0M!I/-\A.2!MG\
ML"^]0.;O_1H+P[]0JZ_6MK-5?+NZHX*:6L(<EQ+[U^3G*HAYZ*,L0>5+UHE%
M+EY]XBA6>=^="8T6O2GUNPH*5D6E7+&2%4.I_ ZP97<X(C^ESR1O_3*O]O*Y
MR$Y;E:%T>>E,F":.;R[C*>R$92#6TCK;*RSOF]=!&1H>QGL7&Z$3ME6&DG+T
M93-BIGC3'+415<'#BYH?B8#98?:5:WMQ,8MZ!ON[YL+VV<EV\M?1_C'"K<NV
M)#V#'58)5M'NB8RZ^M9.!,?95%O"O=)$R8P;SVN[CI$A,\WZ(VA,7>."ZYX<
M0]YY\EF0>17;]6^FA-6:<L@'1584Y!C:1=#:\Y%F(9I*QVY;JI1-YY?2&A_-
M\#A<O9_R"TJMG9_(-76C5B=D_3"T#@0Y2VBW2#.G1S"!U:.F2X0CM8UU)Z2;
MUGG[@3HDO8FX$V](AD"J.\Z!J>X>@J@I[^Y"O%9<FI:NO/RU.[ D%>'605<$
M)9Y%T,,Y(:NAW'#)1,\OBT334%O8ZH4!:<VS0"_ZA[GA^R-EMF^T3L5?VMQ"
MUM+JP#K6.J?/-+8_/.>(K0IP7?*6J*I++65[%*BV,/F ))AT-6KGE2AYH".]
M0C $(U:S+GA&F^:#2B!ZG8BI0.C?L9T2C\P>].RD2JV3]M6*M2,=_0'Z%58>
M'/7(;'^=E"#[L@8;RU,\4$.1E-F)IFO!QA*GQ3/$(;>#8WR%\I=Q:C9A.C^=
MMZD2HF4](T-N>:$E^S50BD,P72.=G-9L1H]GVP5RZ@+Q$<ZH. NO0B]T4(.)
M%-"*RSW@^$C8"N:OLK89;HOFAD^2=$,G.=W\U>;Q,U@03+I V0WAC0^_B!;J
M6O6QUI7CO%(-OHIYTN:DW6;0[B\"N]&Z%5H6_2S6\L3":>&O (3\+^)L7>KW
MY8U[L%= _3\.7X7[1?<*@*AYT.YX;_KC+BK+)=B[RN,DF6AYZ=3!I/6? SW7
MGJ2^W!&]IS.%WIJQU=(+3Z_",0Q8N]AGCLC](S)57NHRE !9[-!U@J5]QK#H
MU]P.)++2VMM@($_G6H]$D74AM&Y\6H^[S88>):,VGJ/^,03+%<0"*] 0\BF@
M#I-M5@ GBL.H!T$'MWT2@V@'^4U5Q5[^CI1<B?IRMZ+%]HZKKO(A!O<L!?6V
M/\OS$ZAG\.8(RKC2,VH4]I&'&<UO:!UC,6/2"(\B$I5J&=ZC+9! [B9=YOQD
M7 WX.]42_O3U$SD^BU95W775D7)%B@MAH>.(X*L>I:,?#\59K>QILA7JTWPT
M(BC@11$/'G?!.7P%&,!WYY^+(!UM50<&.G"O9:;@58,*NL_PT+J2]['V2#S.
MT"/S#)%:*%"S6LQL7HWBL02A@3J"1\WK$(55.J?5UZYYI['%^NILJ0TRE3AF
M;[UP96U0%A06LOSIQG-)X5=R5,@;]20U:=YLAURETITVE])0^X3\. 9\!B>G
M8CV35 S-J>RT5N7B9& 6OS.^ZU_KAXZQ%;(%X1'$,J-RAP1IT8G;^:FYZK7<
M2(A.Y?S[-;!A?KTV-%]>\+1-51W<H]@KQSZ]UDCJSPV5DX6_E)>J3ZVO="^H
M?AC7Y+Y0.^P%66J&GN@-2*_Q!H^\C]E6L:2CG%.3ZJY5GL=:M"NR*H\]$6#_
M>B7&Z<=EVZYKWEE"\B5?_;KG;J<H];"O83ZH<*@I4KO#X(^X->D0)&9P AMM
M%7MJ<IS]V :,>%)L]_*1^'3J=$NMYJ(HGN#@%3!K+2/CJ)M2.MQ1IF&2(J-C
M.7M8L,M0D^1<7H'#=!A&S%NUB$$,$:SI,Y!:)FQ\?Z4A/S6TV.B%M_Q&PZZD
M$Z<P=;/P)'F+[1-W>0QWLP"2<"+O#-P2JOK0G^[%527E*&Y6848Y8K7X^)9E
M4P3S24.'>=+D7/&/^:[':@]WMY")U\N3?$*2R:(W:NZ(=)HO%^WY!;VC3*I*
MTK?]('PF0D_/6R$BCX8KAT"D?@.1JOQ5KDS1<V]%M6(LD.4A[MR(YQ4<!J*Y
M$YOV[0MU=6*T]NI>,#["MR1N-Y?KL3Q4)"4B6J525&/3T#;3.[:$8IN%FQU?
M4O9MM3E7A%&34CO@K.W+C8I6MEA;.\&?9]PC$NQ^'.E73L=P#/*XL<C/6 B_
MF:\UV/VSET8%7&[Q_JB_N$=+P]FAP=4[EJ 0B$DVNKWIK13;-G)H/42Z6,?H
MJ^S!4\[?4/KY^L>1X,.Z9*ZAU6FYT,>DI6W[I+7.^M/,VBZSU(I!$==@V:G2
M?D$"7KR3A%YV:QJ^2C'F<C',NO'8&-=3TFF8KK?^R<=DMP:1!" L*3&:8L']
M$A'-%&3+)CZ26,G! -'E+]\HC.0 ,\AV.,#>F+&T-_+T!\_=KDXU'D_AB!B7
M6UW<,O5UN [D]7\%Y1 5'U\VU$62FJ,2!)]-VH5I.!PXQ^'(NBJ)$] ?V]_%
M"=:XDJ^ZDZI/X0<C)D!=0A*85I.KK2Q63F*H5@6$9%$1*^6=)K2FB4P)U]'4
M(;_!KNS'/A3@N#U7GJG/GL"P.86MQH-.O'7'R[Q0#=O,/$JMD>7ZY/AKTV@B
M++1^-=M$6OLG^8ZQZOF^KV;]5^Z741HV4ADPE$((^D]VO/8#]3GKZ$P=_@?(
M_M0=N'0)CK$ =6=-J^>WV=HLM8U9;G+J*AN(G)%*_%5E9#?DNEE(',=MF!N>
MKTH[OMQJL2*<K5OI:7N2]BS,6\52;^JLNW0C0@0MW=CZX=8KDN46OUD ^_%%
M8R<A+JIHA1Y<VFQ/RIBSO,- +2\UK)=1BD](*]ZIW,%(]L4>2-/G*S'S&(:9
M40I7;KZ6\(X^+-5@O!VR9<FS03.ESJ%-@13W:6>L[(0;?E%251>KX8H,B/29
MG##1*W6-DV6W^[O3V!]46'8A5'K>]Y!0\)Z5?2;FX-K7OQ\MY2##"',AUB%G
MOR7&9,'=3C%":T^PQ)?S@-[X4Q]#M1H.K?.?(L.'6Q!OX[%(P_6.O_P%5'U^
M48\6?FTI@*0ADBG+'>0A4);5:2R\>9S48E7Q\Y&W-@YC59:TA%J[% S]INK$
M@XJZ7CP'S)%JL5;8YE(@)3?2*'>QSO2\5S3CFE.P$1I$Q>'J3NCC2).7E&4.
M3.EWS(A3?/HC<.##T8AJKNS70+)R8.D&]K(@[DY7 G\(#BS9M,R,ZT>EOEJE
MG9QC)GW?9&LY?5)N/\?EXI 7?#&YR(JM<""1._D_3S"BO'ERSK[5?P543CS'
M_37 CS#<'1H06Z%2]<>_WL"MO6NY;\YO8 ,2#Z"M+VWLN.\QEJ=EMOOK#PS7
M.EI6J+B.SY<<-V<F&X7*^;2&ES7'0C]TUVD[@6>R.GB)-]4:W$P0+#OPR3@-
M^,>F'F7S:BBS_VHW5D!N!^.A.Y_TR^Y:^KM<20G%M7O</^2Z*!CGS.718K'-
M^.50*N[Q\SJI!:M>8]W]O*\:-C 7.4B<S,V=7JW.+:)EY(N6I3,(J&MV%-'V
M:;-='>_0@LND3>>5,D08TXLV QL=P'ODS':J"E.D8A\QZSSZSG\[L@8646E?
MXE'%9DE_W]HQFZD72O2VT77$0%OCKD/R@C\7ECGPJ9,QE"2-H#P.$=* >1U&
MF[WC8]^=NR <>J/-+2OH;+B)^"$9.BU+\X;<U&E6TM?R"+7;68QP_UI*P,-"
M7Y.7D1**M7*+KQEF/N10KDTVVI.#^> PN$(?D*I&M0KS!.!UKN6+_/.=%#1#
M>=_$Z[=:T!=7@3I-)1_K@O:'$Q![A^*#0<'CU%#-1F_^TV2F6[2 ."4*#5&.
M4&'@UF,6AZT@B3_1BN.Z/-M (0;5@W?F,BE)94,%0TEJB\B,7D=3YH@59MZ@
MSPAK?9:BWH/J>*?/(K+;7<E#RJ5SX4G;9OX>:J-A3:I^E?/*.=^MP=@U;>_U
ME:\2AH%P5>,9;SO*U1K;),EX"Y]O'#&I(7Z-8C8B+0J>Z.;.!;3^+JZO(M,G
M\?H89NPX(;O.ZNP71$QXF*[?J3W/C,=@J-7#%?T[^CJR+7S$ XWXSR+9*\"1
M>E 1IPG=?P7S[H_@3Q ?B*DT([+I6W.Z2VQ([-P3!4S*6-'*JVXYE,K\9A3H
ME16<T)$^CZL+7CIB ?+!A>5 3)FG+E'37?I-4BX]'A!#+%%.EAJ=I/7#BT.0
M]3(SV)0&=E=7P0MDC3#]:>-FM\Y3)ED3,P>':Y+4GCN,ELKK9PFIVA0E8^">
MF#K]TK_S?'BZ<(X33JR]&H=K+;</R68+#!SJ1W& ?D/=W6_1O@7!CDC9&N"8
M-M^WZMQ#PX-]SO/Z1W7XQ<I(<Z_"*TV2!N7)>VO&7E2N7@$'<]CM=U%U[?''
M(+W(>1>>8P,%:/+XLUJ/SH(3UKE!WF*#4*9#1]()<LF3#U=/PA-K-[U:RAV[
M'SJK$VH)B..%[-EY$ VU)D6[)?[85IN*07ZAUK6"0?L'E5WX]L=ZA $[)O4Y
M/$$MX9)##QFT:JE<V95^5HS ![GJ0O&@MI-?AXH399W8,,\HFZKA:WYGDZUS
MC^7OWY>C+7ME)OA7HN-A0ZMY5=:J+7H[QO5GN>$/F^$')JE'_B'$;I\01UO,
M-5\8/4[L+&4R92$BG-XA@X^R-V/86 -!Q8-"YSPTURSN^W!+. EK/]O/AHEW
M)<]Z.Z+3V/R.:]:P3UV5/F/PY5ER]2<%+X6B8X18LC];+)TVYZQU1K,=PRX)
M5>44O+9JZ30>IGM#%;94=3I>QT=E07>_@=1U]M@US=,,"I&(/P7[7$4+KM(W
M"T+CG>?BUZO4DV17?Q2X+L74$8VOUC.K@M6F%K+\DM#/0^3;D0U]Z:A+J8=+
M*:%H8 X\I[@S7''8F.'6'#R]?/&2,F3DV;M?1+WV&X/I;,*0PD>EO,BZN0]'
M"U&.TL63/**CU13O[UT2>OB2]O:%8VT4F<U1>301-5%QKP1MYSD+D(=LE>=V
M5<=:!JK,&]Q<T'O/>!(B7;O3A7"=^\I'[06G.9DA<U2F%(L>?>G*V.47S3X^
M/WABCY&WW_PA_=;)DZPVT8N02CX%-0:4@[HP7RS;EIZ,Z-?[2K^P;CO'<1)*
M?52C%4_9$Q@+_(?&<QH3]/,ZJ"44#-@Y9X,)WHQQ%=@D^H.S\>T6UA[>_1ZS
M(GK9WY->\/WQ6]-<E?,J5=^VGH?3?7[D5@$LJ0]A[8GR6F?\WG0$5B9-X7,'
MT%5M%<&-Q\;36RY_@3-85_WZ3=W:)YQ[UU>]^6;3L:%3U_PB'A<=ZW^7KIAF
M/#J_. ONK]Y(VKCZ&/1Q^N"DT'^+B/0.F7T%(//?=MX".SB09O1 LX^A-NN%
M(V@ZOZ1FD_(#6M99+OJ^+S&VOR%(&Q'T@GW(74S7J+;;Q)9M8GT+U@57@D!^
M-1G5S>?F.6.J)^73+MFRHX6;!GAIPSM\FL#S;][2"\L8QO6)E99+HSV0(F$<
M27$Y[=5<38ZMEF\#)K.<&2]5=YV"[C(T0TB/>P:7TS$:WZ/ )A:_D5W<J2,>
M#MT9!1)#M0I$2J_=AMR>2_V5?*:H07'=VOU8G,5QDF<$Y@&O $Q[@>8#*/D7
M*YVL%7#!F;?'LIKBBGWRO [KU^L?>'K.\=6+<.VEWU8WK8+:^5K08(\Z2Q*%
MSZV07F4!2MELEG"\N4/]P>.Q7K]DX99M0[(3@XE&VJI"C9UB*#F;IJU?7BQX
M"4?G<(_,H+5KT:K63YA[),$[AJ")PD?IWC$HH9!>8Z\(JB]:E_$$$U;&]DA;
M8XK5ERIO1?BN<Y/-R$O;,I>@K]#7(?!GN@I?7'M6TR!1:^X"Y+G,Z51DXTE0
MHLF^D(5)(%=9P_Z7HX@KWX^9+)Y=]@+FX+1+%:NCD\GV(?/"*9%#9YFH]!,$
M-)9'!;O!:V^!']O;AE>-C"K$<\T[3A7GCVW]CN.KF%5-'<=",+K+;,SF;#KM
M$R&=OHTY/O%5$Y A%2/WS6V6*@C\V6\\8]@>6JN7X/C#GQ1PW9Y*OV.6@R&X
M'Q?KT-P3EE&101U4/7.BL5\5<1B:5MLWHHO/FV+W01!'O)7XQ\Q5>U:9:U+A
MUW[&NH,!IY;<L3S+:\*%\$?AS-$@"YP"7<J_O]2;$U1$U5$_^HCXFN2W-#DF
M[1[:2&@="O^!K6RC&3K*S,:IB=;9!C=PQ;N*+U:S5V8/"@6S)%1SLE 3;JK_
M"4YP&J;8Y'.(<)&8<QTY="U_^&)9>D_UW9@WFQ'R*"=A*2+W>7.)YR:N!A5B
MR5'KYES<MRPG/96STL+(DOZYE*W(<&,L+9-ZRNL\%E2F94D>B9W%/=^6I9QX
MG<4,/:UN@DQ>2W5[$2O(,NFYV3UA$[3;R\[B@ZY? 4K?;QDAE]:%TU:-BN%"
MNG3#M/S>:V]<E^$L77X>("]SU[$0*==*3M>E=CJ_06F-+6;<HF1"&ICK\[#!
MC+Q<"*JEI;?)+_8NN?IX>6F:;JO,"SCCU*&&N.4+3;3]16C1/Q,49Y[VVF8>
M)5NU;)O5Y51971BT=;C#DXCF>V*3PZ_)QDI6#D.N&AV RK#-+)*B33=,\82!
MKL!/'COS"N43ZB<\%F3,+LNVN#8[&>\;G<WWBH1OI+CT9XJ)QKV&7"#W1&$:
MD4HIZUH#"QE3RYPC!:F@_'56^T_EVIAFRMF?>.S3\##"U_-F2608W,E9OSFA
MROU5DI!9*4\DY!>9*OTSGZTE*LI)9Z;!E@;YZ1(0E!WO\&U:@<MH]1TUNB0X
MUFYG1H(?-<'%#VZH!*_K3@/1?=[043M%H]F^[H=#R]>WI"J8K.>6^EO2+?$V
MI7 \O%:>-'H(?U?)/3M(8R%3ET376A%33/1476$8IE0 I9WGS ZU:QTK_,05
MP-+5(99]+J1U+6D-CFJ$YDA3B?2H86":#U7(&7*5978WCNNLH!/B-Y09XL4^
MQN@>Z7VWPD9++OPO/$VPC@3#&$4RF:M;(8B@@+ZUCKHZEXMW8;.OHU#2+)5,
M['V2OJ5P2O-57J;??2W>*P ^,B<C[9(*(QX[;5BNL&_1SFXIL403^/1,_X@^
MVYDD KHS/ACX>II<,HD6#N("RW^N53T>3S,!ND=KUSOA<DRU*FS]/60AF8GS
MXK)2\9#K+U-H5.))#_T6/,N-;+&MUV)C/C>'++V<$=@FB4\:]C!U@/_;K=23
M2_@F43Q6&'*U/=''-7D^@K8Z;'TLD9JA)]]'B.F8Y68!K"EG=V<-(QI"UC5F
M3&I:URF1BR\+SMO6_S--JHTX17D@Z!@/X=>;*)11K6"8(PZ[6E.U#&1!.D2R
M@Z>SZ0P-0A)JX,!LE-7T"%PLUT.MH^DX1J")KFBTCP;QEC3-(4A "J'4[0!1
M3S#4M0$.'"/+U7I)6,6A,F8$+\UW.>3;C&WOM'.,1=NY&XA<F\VD1M48+ ^I
M7T/*_PQ3E[N98-GLVFEOF7(ARKNCZ923(][BOK#;T2\PIFN3&6K>J^I&@P.\
M??Y,VN&B95SB:FX;UYC%B& ['Y2^K<-8ZBLL1 O?U1NZN;WHW=58+40-<LZ.
MK7L";D)IFEDTB^L[%NO]TMN.PI]9+I/+%Y=HK3]5FE#](&F._CH::#$H)!N6
M_E=Q>(_PB&W&G/"-LF"[/0P#+MC/9P(V/?3+2MOJ64LKG2F7^W* SP+;UD[L
MT23[VSUY"Z*BFKER]Y"L8 ZGWJ11.TU]2TR@TE4"&B_,_@3ZBJX(7X@NT+KR
M-!U 2SEEQ1$\88(\],'?T_3@N9V:+(>@)(H?JRUJNK%B?XM3MRR<4I:5,_^(
M(^<D0._"-J?+F=GBZM:XXG6A4I> 5O>UZ&B8>PHU$,L@TZ=*1L>:,X3VHP].
M[:?:8J9(M[TZI)?*+]X;_Z%G()]HYB>2:G&L0MPCZCTU4\:./$:7>+TA\JET
M:/N(;IO!/,;]R@?A"BYU="C"M!\E'HBQ\GT(\<WZ_4HNH"JJX;V@*@[N95=G
MT/L3NL<D71[_'&P\#ZM&$;:4ISYHXF8E_6R357E;1U&()T<O9+#HF2&LL0O/
MK 1T?@/M#_@/0?H/-+SM_>,1]T>HO*SE8V^AX1&0)%+/&7]\_G1PH:%NNGBM
M_MHG8T$5-CQ\K$RPJ6@L$G4V.)PR7&Y,O"'&?HU(5*4M7=T]8X:!:S,J;65/
M=2H3R-@80D:&FTIQ:[!QN-205)GQGK;,T<.:DM9YSEW,S8<+F$%XYF [PA!&
M+NQ]]O\0*$*L?>_BZ(PS:IG6G2T2;SX$ N/[<_XK()6$W@VY>3ZB_>;/=2T_
M7RZA3*N?FBMGLS+A52$P;8^.0U9I_UO5IN,N5)$,<'5?4S)(9F)Q;#J(_L4N
MPO3B0*4.*&IN53;+R- (3;MIY%XEV)FD4/K&P+"[V!5ITUB-+S!QC:(2%1,A
MX^^ GRJ$'^Z3NGE+V\![W-DWR[*D8/]WRB39G7.X"H-9%U*=I1<N4S]<'AM?
MNTA4F3.6$3L,87!<S+AY/^"#\S3>I^SF9!^(YZD9AMUH=?X4,*>8K/(2$'*I
MO]EN:")=*UO(*V)OES<B+<Q1JX<_9578KQSDCN*P_Q<A@!]]783.GR<9*-:+
M\.L5, 75"U@_([%\H40N+CFI;WL%^**76G-+V$MTE[O4)BF$Z>Q"\D!%:A.!
MSN!><3N6+HSEK%> 3_.I\?OC_K<GKP#$9R]Y_ *R^7B?5-GYY7&1QA^_.'R4
MYHQU+;.$-'%5GJ\&#6YH#EDCKE(%O%%CDMO7&,2G6[,=#K-$K6S#6F^.<P53
MRQLTQ9W.W>KDF25UI+Z %DJ?X05=H^J"7LUJW<!TNC7]F41L*<I4J0]ZH9_(
M7)U0<H9/C)U \1IHEJ1%!^EUCOH0&F=]Z8T4&B_. ?;661'C#>96X86"QWM?
MIJ1F)N&A%D.6P30R(E.THWWDX0[^L^52&=);,0;&&FRBR>C= Z!=W3=MMQ9Q
MF*=Q^+.UB^E/X'Z5:@GK@21IIA,3?!<#&FNGV&:QS(\^(EL>$:SFL*H!_>HR
M6(N:ZU0:/EBJ1\JCII+*@0,4)R9DJ,F \4_8 <3%0*PMPK[[]R;3N)F+Q7RT
M$^[MGT^Q&VZ)JNLS&D/M)?UU8F*ES<<@X1<=7'TV0X3D@-+DEM3'159O(7&R
M3F#13_] >]:7/* _PW=F[.F(4M$\^/* =S;5U7C;PM)\E?PJ'@OU"ZJY45W8
MK?/UL&A+>TN2Y8[VT-VI!AMIK4YNMJ]1!>QSE26[P68DELG.B)LMU./<Y5^5
MF2OU!9U*_GME9LZRRA9X2@EE. ,^K<!8!DY!OW/&#6"WX)S)1\*VV61WY*\2
MQHI>>I1*?*F,?>:$H7?PLA.6&<T45[@(QQ9B]_!!"@/M@FK/%D.@#FFA7D%D
M7[X4M03)$Z?O!Q:?SF5N/V\GK_P3_#"B7Y/38Z5E;A\NDH5C%QL$U%@(@ZFR
ML?D]BP[4(ZO+RQJPA;23CVOPDO"4L;1M2$6_ )QE[Y;\)V;".L,IQ*+UDQ#L
M7MZ+/4Z)S::_0 &L(Z,=W%H"X#[6K^=&&_<6*:2GI:R"F]K]O>?Z6MOF6R04
M")86OQ3%!=Q!V3V6[^+%K.2+E]^)<DH0$Z+3M27!0%0>"$-"TK&K#67OBU8?
MO"87E\V!6EX3?5H<+V1S$-RW_?&V:&RZR5R2ZSTCW.,H)4)%K+(YBFKO[OGN
M.KTZ&V="Y@KB8$9)^1LSOY3]FF;B[?@(\8!IMAR"9B,&$X492L34YY&N5BB?
M3:,R=IAAU4T?J';)_FSO-G6HW;"Q3'Q7M[_HT<L9AEKKKP\*+7)^\N:]]_\=
M66OC5ALUZ8]ITEJA9.#:@F*RJT8$C(C<3C7L5A0D><*=;8QMY^;;&=LDR=5M
MY&8MEBHL4;MRY\"UY<M?Q).K&31FR":R?-P=Z#HSZ.$^[A?B6HYM4D&W)"=6
MOG]PY#N7I#L?J?UKN_YWX!7@1?< ]E_:0'S])PI:X_-"&!^"?NDU+P,-O)K'
M*V%X3PL5VT*'V).@?'B9?B)^YDVO9I<(H>PH>0-GRMW),RM7UBB@D._O>;D.
M7^'UAY5QHL*\>VO>@'D.C*B$VCK:Q/V*3*L:'@E$]7Y*)VOMK?%*)8.#VBG1
M76]Y'T!'-;K[*P#-_'%01$O,N</97^D9"\'_A3?[$G7+'N:FO&5M^J]BZZ&Z
M81ID#%>)6QR'N![%9<F?7375XW5%QU?K_:M8P>E)+$QSIK-'Z9P>5>J54W3&
M1@OY.75)43H)J?VXP\WLP-:;CZ8$;9%@LVEI7JF\7UB8I\NYYQ$W;)A"[C9K
MW Y2Q"T6!RV_*,,R"BD&;1(6QKDR 'O.9Y72/+.D+BWIY_!89:U#QO[2[7H3
M1;;?.X9O*K-WT4OS58>VRC?5F>##SSE;^CO"4EQ;;K<OZNZ!FJ(\]F.F?UX!
MY,_:SZ2>&F_M6FA?+-8RUL-I$U\!"'D!%DA]H?=@3XS'7$?8';PP8.HTF+AH
MK:;XK"%9I6S.,K''YY2)YR2]S&Y>LMWA%:"]?VQJ$@>5+I_"H$H6U5/K\JD<
M9Z!L%7MWHE,XU^&-+;N@PBJ-<"'BU!>AN6V2;#&68,74Z70/+VZTZFIUP15*
MCFC1ZY4KI><YW9'Z:)10<MOJ'.D6,)D9-.==R%N68(#R/(L1RG-P8S=K]-+1
M2.FJNW@W8 %KD#3]LW5T6F"D: CW:Y9B-EFGY5J^ .38?R,3=P3;/,FV"WD2
M=ON.5+J-H)*" ]5NGX-*;:KGB[ELAQMIS0_"I11D)=PGM8"0J@JM>(>YH42!
MA>(XY:6P047$\8?GLX2VLX,?0U&ZF)\R("/0Q!4G)$5P#U"F8.'!M>X0G7)+
MV#@_T*G12W6W3(Y4 B?X>E[1&)_@^*^4<M?4&+.]:!;4CN';3N3):8]MY&8"
ME3DK>FO>0<7PB=TQ$(3"%D-HU+>FLT2P$<(9;#&&9PEKDJ!5?/?S25YX6@RU
M!7CQ5OJMR10Q6^Q@/0RO0;5NI38>>#-O2;UVRT#60MLS7[EQS6WRF'2B>I*)
MU&>?0?*+ Q@PNQ[L''P/$U-,:)Q+^ES.R\=C5^F6EZ@E&S9$56)9&%MX<-=H
MQN@Q'$5:J)V.+7P[$2-=B__"4&NT0>$,>@5T8M,]YMJ>/O]*G$6,[: _'54=
MM[\V>TGQ\7T3_8(],9H^$+.*'?L*&- <?/<*L#T]!]:+.;=6W?'0(J32=0O,
M/.HX<R4O.]O96QT"PTJ;7'7S]:T?EOJS3 XXB6?,Y)6E#T>DPEN.AGO&\*H,
M<I2:OB)](&GVDR[=:T1[_(6>ET^!3:&N6$!IPB K_JF)X8,X#)%!7NU?G9Z;
M,<$]1P#)*^"%IU)&>Z>*A&3CB"4NGU1',R0F%I3DQ-E1%NPOP"%<6#HWHT6G
M8!*9TJ])/+!4!RL!XX3XE8P%;@J;4YC[43GCY_%];)HIN.LL]@J[N@S)L4PC
M81%EC[SW'7@?KCC8(#'-G'2@EE?C&,K+5)$XTNS)]_Y8*/E42V-Q*"8C8#JZ
M::7\0&X,/4FO9];B<N3G(\H]4@GSHSL0=/A4,CEO79;94VR495"".?OAM\+R
MP1Z4V#HEY#LQQ"AN99"&M4P89]O)B8![8J-RG9=X L&3.*>(>HQZ0-R)$+G4
M"Q77'^]]61,<6) 8:.?_AM<S<FP\CXLR5=Z5Y,=H1&3)JC+]=\0^\SWKN6]%
M$%W%418G=(J:I/AJY<&:T/ (B]S?L?#VQ#CM5EY@="5VOV)N""MP]9^85/W.
M;UGPKTM9OAP1V< LZ!=+_@SG4)-)3YP7Q---@4^]6[L^[#MSK4>46UK*T;#"
MG=4KH&?UZ(T,&D5=?<(KH%\3N;8II+H4OYVCP>UJ]!(5TI82F5VX0NU6]&%]
M^$23<+ W&3/>CW<B,Z,G\H;D0#;?F&#1(?GWVZ-GFTYN>]7L/FQ7_Y_3GRGP
M-TJ>YG4OSU\!2_Y3T/ _+ \ A,R7JE> 'ZWRK>3R^B,:4S'RRUWU*X#3GN(5
MX*(D[$^J,4F L/&RI8FDYM+U8_B=U;G![+UA+:]&1L&F]-3A-PVH3LLQ6RF3
M1B\U%JTA5^6 #@,7%EFX,WZOQQT\_3U;4'Q(]1?GO"U--_*O3Y;+&#J''VX2
MTVQAIDY [29IY,SWHJ2WH>XBC\*+Z2:)C&@Z##7Q5/E3##[O9/4PN0?5P.]0
MT7R^^:?R_6/Q+71D8M&E%A_#SII>C*(_O@+*)ZYZMC^AA%[]75O1WS7O51ZJ
M]+Y\]+.(<JZ\3DRWLEVE/(TCUHJJ*G72:NF;1])VA-2\W3,!?I51;)YK66YE
M(M-03EP6_6EQB RC&0K'/WTJUV?NO![A?_//\L<-&.X0('YX8096]7JS<309
MCQF@.)G'"*D[R,WM+=A$\!%#;B!+:@U"H>3'.'+/?!XM]RANO=.L?Z\+ALP<
MHTU00PQX*A*Q;J>- V-9CR=8790.LJ+2P5DNIMI2>MF.;]MKKV&]:O[[GQHK
MID 5?9,FZ8TN:6ITMJC6'9P.:0J;/&C!#IJ<2C/F;_3L@YB"<*3J=V_@?#5,
M%>7+\9L-YBY9)?7:6-SYB5J9.D&5"[RXN6T[>Q$;8S;$FF5SIX8WJ2>808+4
M*F&"+IK=EW\! NM/Z.LP\V+_$_<!^[-D6\!^P/^X\7AW4\U\YO/"^+!38B:U
MP@C+H><I)@9/(.(3'_:L/CXNQ@\>3Y/J&L5RH^1E7[^O>G=F75K1$H0<#G8]
MP1M7_)MC7,'M[/SIY66NNRKSK96E12?' Y_!XCD,QLN/3G48=I"V#">3..?/
MNVTR%7^T,XTV#J1Z>62J"Q00_\K7KU#S)!'I-!N'1697*?>+!6<&IG^?UR*R
M(M(L+3>E-,U=IVXEI!^B9<K$1YNGF-:F2@EE5<C80.*O3#[?/9 [5S^Q^Z1&
M*MMML=IIO]@25J'O;H6;+LASJ@>+)_&Q:>%$_5[KQ ,F(J,IFR&>UK"Y[@*/
M^WX^H,>3_O_+V-$C @0&G'EJ2<SN1ETTY^E:44:<[ T8!"2CYL]^N]X6%I5;
MH-*9Z6(NW?&$_SU_B,!4 _>I+IYGQ%%MW*%'?_Z?4U9ZI/-Q_U7WEU:Q&YDW
M/\4H0;TO!OS=-D#/N;?K-8R<::5O>S2GN95RA <C&^1F=N 5Y'WJE-_MYN2E
M&^QVZ/F0ZWL0S51,(V%=E+_HS)R(ILXVSID"2*9V7T:@F7);C5&WF3IP):<Q
MW5GOI5YSP1$3$2CK3'1+__KF;N[RD<!8444&>S^9EED^WO<M@;Q$O*].O/JM
M#IUB(-]CD3[69.&EE99[.(^W/G9T(W_+QS*)+;'AFPCC=Z[/X@94:%."%IU5
MBHO$_$;)SLBFW<BQJ\'CS@%[T+.CZ_R#]6ERK5.H</#,2FK;!;G+VA9F7R=P
MLH$EOA._$.[P$4.G?,OHMO5Z>T8;!)+3+K*?%!>;2I"-!";."0C]1HSI!.H6
M)*]A9+\"VLU)_9>*WZ$_B?I$_CDB#S.TM5'BZEFB3\-.+-A]5R]"N4B*:9@5
M"IUWZECCX FS8.S[-:'_W8))7S5,]6O=;=247#.[Q%/*$7+6/_QCE"VL,VI1
M+*PBZ>V@_G^ARZ5\ ]@O#"T>?OL98:^ ]PWTJ'Y73Z\ ]@[,%_H,FQ?:DN\"
M=SXT7E;@ZI9!IU#CI:TEA='],;'F"J)+]&5,>]45VU:O(@E'<XN2L8>(FX2A
M1;=W#WHW\8J[_0KQQO6"IH ]H0E!9^#7\UC'I"Z%*PO3FX[=+;1^2UHT+"!S
M:^/LCX;,SEXI/>9U5AO',^OR'8W!U,BZGI)70/10XB!0N?_K?=YW?^)VKA<D
MVS_$KX"SC1>3-827/?=.6)E90-F$[BO@MNI!YV4_D]N_8"4%_3= H-\5\Q].
M#X[J;.U$Z/QKZ_'67Y1)%&#GYW!U539Q?I'#5L-K3^BV#*SLZ*CD<F6P;+0N
MD>_=43I;*OHXNZAEUO6A/-*G*K<P+1IDU#5%G'"8RIWP ;H?<2[E*!TZX(O<
MU>$ML]!TZ -[QDK/84S/.(NAO19)JJC,2U-CL#VU-2(D6BP[=KB^FU<]G77J
MNU(KY=:^3!YM4VQ49-W\NH #+ -6V0"-74IMY!%;! 2\*I9BOH<W:!S%*1!L
M*TFC][P_OE(LHRI.C0CYI+%]BL]_?-SO@  -F$0O-TP;*3'?>C,:LW]8$^ L
MNQ\VAE[O\WUV&=(^?1NV=O;P,E'S>=?-9Z\Z?7SIXKJOPJ+<*+?=7*,>NM3[
M($GAT!A0@J/RW/Y$3' /4# 89>L[G9.'O *DEJ]M.O%<YG:"[D9N?)6!6ZN>
MSXZ/(3##OF7:W=V"V_),7SB_:EUQ2I5\;P2B\P&+'J\Z[: .:BZ;9!1PZE9E
M445I-'IY&[(F3?*8[&#$/*5J8HP!XP^'>L%9AN9]L:5#?(XU$[2=-X]&1C='
MXO,EE[C,/E&<][X"PNVRR%OH*/V[*N01W!Y&[06.:<Z:K/KG2BA[1TZRN!V<
MI4T/]'X@2?]L5FMX:ICF2>7*&J#-RINGSH,JUXF5KS+;N)DTC2,(/=%F&)=8
MK,41]5ASA'R??P4,EU7V+]T.U3^6#0W*0-GP@#^JMO1$3NF-^J4T2PK<5G.<
M@],%$ES\#K2T?5*81Q%2UVKF9FT%SM.+)*&?/I9>XSV5MFDO?NG/3[=8.& )
M[6?"ZZDM(AK#HET3%=#E*=CZS2N;+U4KPRB7D$_A&- $ZO7]AQ2=/V9.B457
MF+QE%45MUU0IOYI;)382Y8"PZ:HGS@]:*]X&B(NZZLXO/1I "D$)>IU*;2[8
MCXHSO>SV"1$*_$?WG&][,Q7@KH\#2I7NFK8<404;!4T_!Z>%C?8SMPB.74D;
M+NGDB%\$,8S7(7(]KF$9]$'!OW.X@O )_ZHK;_C,XA39WS]V&/1!W*LW="U6
M@7HIVBVTSH@J==D_="N." 2&G%HL%W<9JP><],P1)TKC7JJ>WO@/T>]B8TYL
MT6A#XB(23.""\B);DOIYNQBQJG7]=K'J[X%FX[JE1B2_^AV,TODG!A$RZ;KR
MC^8,<MJ_-&1PFHI71-'6U4^J@JSY96>!F[AO %FX0AF%-6K1]2T,XR4X(-J3
M[2)6SD)T(LW9@0P=N<;><_OUMKF?;<=DW&>/#B#Z*)[Q^M^5ND>$,9/UIB0:
M97$JC;KZ;]MN./8H<+3,+%N;J:<9R#HH4&"DO1JHG_W2&A78VLC%_J']XX*O
M@ 85E%X?:7V3.X6YA0RM.L=TD!.QX5$[ 63B-V3B)-RLM@S+*]FECU/\+2>K
MC.'Q<_S]Q=SB ZPA7FZ8!2R!Q43(M3U,THQ*\*3(E_J<?79T]@HP75HEO"[Z
ML>*AZUG;+C">LZ:\[$(Z[6<Z%9T3F3.Z)?U58H]V')BQMS-A@<QYIW<U1Z=^
MI;\U.Z?#DJ?]/'YJ99L9P0DV^GPR8!VWE(Q2AJ0\JDYO"D23+^GMH\E(KZ.O
M86@M&(H*P"J9Q=#Y>\**?$D'TM:I=T?S@KV_JA)@ZN7<P1L1G4\29P=3F@K*
MXZY(1F.Y_1QT8HS?C]WF4%)+?Z/J__/$3,Z7>/9M1UD>&1F7]?YBTL=:R6KI
M"_4&U$<&<REUY$WG5)C.(:5)(:^L'D5D,L%0%/B]R?_F",B/Z?T"TCNXB^#G
M^[NLD5I3^EW_W%U5H8]3WR6&#.IMXP9YKA-5K$B0UWV7B*(C@/4#ESUU)LK*
MX%QCZ!$AM\&O$U$](+AT;A/&U) V*FGKUVH8;+3$282"0AC/,?7IG*-\1BK?
MQ\3$VV32+E"2T9):/*&IRS$2<)Z>K#IY>Y*_Z"5A(9YG!-6UB[* NEM(#<=%
M4.@T]@@%)4M1,<=O?UTC;.>(U6T&4];(Y_BE-+WY:A]$N>@V]]0-9^A-Q3\%
M5<I,4U3$V^@5IKOHK-:?3/E6X/HE>$:?34V8$A@D4L7G=\C[<$N6FAHB4WWB
M'N_RVB;O$8"J^SG1?=]7P.N'F7^F:U3$];)-CL(DKN7&VU_X)&2;PW.\)9>?
MS\%K5YT=\%M)26#Q=UE('@F?P#+$)^()\:3%SS7^X'*V6^3]D^D:1X1-!KMP
M,.3WPN\BB=7JXD8K4#S2A2*X(<+R!];/F@,UW#UU#EGB;:[*]=AWT:N5&F/N
MJC7KO"Q9C7*Y,T9DBQ7)J,&]MGX5WP)#)*>QL.MFP.A$?;W24G]^:6D.PPO3
M:.B\:0?,+5!Z+O!A@ ..0O,":\'3-6PPF[$>_0@>FD2%T8_BB%:[QN!#Y 6W
MG4[=D3:3+%D?VH,$W?EQY\!4JDSL315<S\,!J&,HB)7..M-794-K<::>U+/]
M<)D7/Y[/6XX6!M5+$)J3VVT%!AO42R/FNL7PYMX-TYEQC'JXB.F61=[&HZY>
MD?F<2.1U*N.N,9O.*T<ES%,+5.N95%#A^!-UD;C+Z[GK<EBD>?Q#+_E9A9PS
M;K;?-03\AP2/7*B*?MJMC3-3K)NY=:;;5"N650Q:Y,TF]4;#UII<Q(A)*VJP
MFL<:ZK1S]"C!,*LQ,>DE,=75/W?J,XT-H=;@YD+FM$JCYE> X.7]WEAWW>#3
MXEJ&Z;>3,Z.JTHPX;VZ9\--[JHFNQN$9QR-EP_\0AO]$DQ.3LTT[U;T, O%2
M@7.P:XD6KLLOI$050FV+C$!QP5_N!J:S$1N[^[/KQ%Z0ABYB@*<G*!GF;O;P
M%,C%KF5;41?W&/@E?_;F!6;,V.T>O<M2&[%?>E*%@<(2<[V5.!6ZA[3_Y?\=
MFO=@5[*=<F7$)K9A=)!<DTG$F%A)N3/WS062C73\,J<V]:%@94=C0488J1#Z
M0'J$B1$,252^PSM?9368W?%S)0A"=K7DP"-_*:=[LK#B_9:U_7W/-):6TT'U
M#6[4AX7^K(1[%TPMK0&39 IAJ00*Q=K5(EZ.Y5ALWP=6$==7P)OL/:Z>B9O
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M8-^LQ"MMR(2SW$H_<C.MMN,,[F"67H*@CV\BU?BEK?*Q^)(Q_MC5D$WEB\K
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MHC7^L^'1V]8G+Q9) *HI]N:-;S0'>1]>&/]_\=$%!=&:RVT?-<4?+'#.3OC
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M^P*/ #.6E*/*F.01%8M";A77L*I3W)W&MA9]9S.UZ,PO]1!HS-'6V3P5D"U
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MWN71;069^[!X)M9[>5TI\\I-#QW1LG(WZBV^VLS@X<6RF$SW"<8A QDI6V-
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MU\MBY("= 91B*,6[@J*<H9Q=1'2G170[PUI/7G&88HA1BV6H?:_$B*JQD7P
M/_'!]MZ,:,4LDPU5,J33X8NS/8VWH:"@^ZG2-INJ=+K-CN[80HE9O(PY!9]
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MX??=.+'@<^O&:@[CYGJ]CP[S3S.;3C-NW U*LLSB$*' B+SD!L=9G3$76/>
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M >9]G^4!^S"Z;B<O)M=CL<1<\TKJQXW6WK75_DS+JBLFTF*[_GP^=[H!1.O
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M14CU8>:B%6>\M/!!W8<B^@55.14[,E#!\K:9O&+7H+!_U.]"_XSH%/K-,4W
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ML[V_>X4KD8*^SQ.U#^45C;)=^U'$#9ME\J]#M HW['V[0FZ@=0R/#%6KU3%
MLP1+T#K.F!^)&C->%P\?D6E4?%9V$BPD),)B2\G S!AC,U_2M&5+X>6T84&+
M@,JK9'R5H9'3 2I*FP,!+M%8,0!CB*C*P"K1[(AOZ!%HM,+6]5TCB*L9/!HP
MC8B*?P07;-E<87,<:MGN(M(!8C/FGJ#8:G/B<-!*KJG1<7#7LOZK;'F;B)@C
MOR@[,<5)5[B7Z;>E5%;A4<;5ZG0$QLN3N%*7O#CZHPEG8EATBIQL!J<KG$GQ
MBM7:^27VD4*@&<PMJ$SXM ?]"Y_VE\[$29$D?8NJ\Y3[(0&9K7%JO5,2-#JF
M^\0ZQ'_7\_L9;*ZS1]#M]1J044M#_DBCY+5)-[I:$!I[B65%"_%GON-JIGF?
M<_Y8+F-M=DVCM5BHK*&F&KRG;:Z<KH#[=1&%.' [X57%%.L@E=QS23Y[IBME
M$[FL%?_,%!1>V]G%'1X3.@EW=F?8%7:(;[8/^+@EV+3O63.?!=Z"5RA5"3=7
M5)ISO4(ME)DT-NTR\3F4L%X\\J,@_R_LO753'-S3]TF$D* )P=U=@EN !'<?
M7(+;X&XAP=T&9X#@,,"@@TMP!K=!9G )@4$"P0-DKWMKJ[9VZ]G:VMKGM_?^
M<7U>P-$^I_O;=>KTFD(4_6M DSZ]KQ@[VT^'_?/STQ5YN2%^'V9V=J:#%__K
M]Y+:\TNGZQW:+!,K L#4=   5X=%9O>_GJ[O/K>I7APH32/U<AX*C/&0RY11
MV2;:OVHWGOR41GXTK!2T8F:7H# H%53ND4,E0G^6EGTC+/"%T)&8DUR"G%KD
M%4._%85EN)AAK']%XBXCLS439?EQ1(+751S7[&^L21*&RIK4B=RJO!<\_]S"
M=$)>(/"OK4)<[4C=C/>Y\^+,DZGOVZ R1YP37$+%WR>J\R%S[P!<[?K3?$2(
ML0!U/Q<DV\JS*V+9++%A?EI4 GA_:TD@1UURNXZY>?U&R*&*W39^R2#;:)S:
ML3,:&V9W/@)0AW/5<S%1B6C5FDHXQ/$TROHK2-M]L*K5U#V(,7<YR=, \>*9
M7;XT;SFE_)E[V%>U>_N1W-#J"D8K>/UI\9O-ZA'V/.:NS99VNN]!B86JF?YS
MW^+H"U.,-<X??45.'0E[?S'LUPXIMJ,-;0(XF9&WME&5>LZS<'LR[?N]M/XK
M<0KFM( IB;$V(W[KUKU1O%>(;BMQDY/:2%*(3_1[483SLD"C6'3=8AXPVPX?
MZ+FB-UI":NK#4QKL$R:_778$#!?* BRYOF<H;*4N:DD)!N_8%GHNWQP8[[(D
MU9_C%_09F;C&AJ.(V%W&]1,^OJQ0'5V^#']U3>J@\+(EWZIHT7.(:2QO$ ]\
MQ5&@1GM=?RLP_" ?LM11#?3$47+&*VIE,I0]3'2KO^K&SPA9F9MKXN9,]0B\
M*K0I2*A?8[*IX9WYM/9R\01@='CP369/-[T=+W373?>D *S01FKNJ9C=\58'
M2*O@>C:$/?XY1@@I!AI4V8I?@8"-&]_^ I:^%@EIG*;\EI=VM<=(VR3YM2G0
MV?^@0%[+RK<\ MEQ[>4<,,"5#M@W,MF$(OQ<C:_?77ZU<YXN;%31$)/=$E'7
M\&QSJG,DIB=(R'IRTZI)=R%->:AB(8;5?FF74I8RQAJOL-R#N+RG."%D5\]T
M87+A3W4IZ!4);F/T5O-)YQO3R6(1YDM9X!9!_"XGH.-MR.W4\JI(O.:.%-VL
MJ;XD$GXOJ#:9^>$'7#>A1KB>_>T/(T!0.Q]%PW@T%KVG%8AYV/.9FY\%O3<I
MQ6'#-53^%$_ZFR/_X@N8:&<2>L6[VP"0!I-*RLBV-DZN7R__5DQC2"/W4<H;
MQ+0HD$$I8*8#8I*7)6+_.M-;S2QE73EMH*HH$AB'OKJ#FWT9[AY6UI [C\LW
M7XQWOE&'=ZH2#<C?_MBGU##NR# R'$IP>+K'/&.$N0"_UZG\!"MD@DJ*!! ,
M]HJ<%UJ?X=BYY]X]TBOD43H!)_7_)/N^BFK2,/S0]74E;9'I0!'L\BG9K%,1
MUT;E9U(:@&DR?'/O23.%N82FO!.WU7BR"PQE1JA"#0@1+R@>\EMQRD7L<HHT
MMP8>JR2I&WBIA5JXAYV-*V9/+#D4$2D-T]<#HY[M5FBMX_XZ^V/HJNDY(.<H
M07DU*FFMU75D?.2RMAL$VA*T0<Z]]>^&#6HG@ZUY8L:YQ_]BO/KU[+%M:8$S
M'#SH?\Z90 6=-6GY+$9,K:3WLY.PE]G;"L[(ICO:5<9VAF/M,+'WUL\T/\>D
M$'-*)7@'0]C\H=[!N#S/<KE3X51K$7E70E4ZU'CYN7% ]P 6DZXFP\UNV;1L
M/B(C,\+D@Q/.L^>=QJ.>8+/!@_%IG$#$WP4P<W9?4K!G0;U\UF$[L/A.8K4S
MV:)KH469[<#1$*M!* A-?BU4_7X^X(:UAA\>GL73>%L\^:M 7VGWNS^/D _'
M)BL?5YWC>YN]J;C5+/^K>"5>Q2H+!J).=C+$>XYSHT3)NQI@6BKN2ZL[V99)
M?> &"P^1F"?0FGX_\)L[K_DE\Y;"_G;W,8C ".E\4N$C7[2MP(^\]C8P[/&"
M\N)F*,M1,1FN9'13WSE6%I8/2OC/_/@%9D^(< L6>O^[Q_-/&('WU!\=M:[B
MS43$9SY7FPJ$N@D1V-:1%0\&2_(>,AL['+]+8Y]X'AZY('Y:5EU'334\]M".
M\^:_.Y/Q+_\1RKL.<LXM=E@BOC:1BQE.X;BO5=]-J,(RW(<2=A<A"C.( T.>
M->'25&=Z^'FWVN"9)\"$KC4VDI"=\-4>VO:V)##AD2VO^AX_]<DWVO_[9 _Q
M!'IEEM"MJD:C;M>-_.JIN%_^O:U##DRH;_ ?E>GS YLB0!6,QR^S0?#06;+"
MD86IGUZC7A3Y-CG%=TLH1D;\8MB2S)3[)BO@V2!U'EX_37<N_FF)< UK]3>D
MITNMZ 1*G6\\8T>[#8@,\1%Y1Z*"+D/E_8$6Y5RH3IUX*MT30=I'S3BR?"J.
M C-<'^IJ :A)BAT<6NLJ4R<!OD6.[MQ>KA615"_WMPWXU,.J0TK->A"&+4P]
M91W*%^Q-"5\NOF.P&9PUJHI^[;B(S[>G:!YO,U'DL<T=:.$;W38:]&XEH*&G
M^#KG>JS#=:OGGLJOER&,&^S[>N66GY+U3O?]Q5^,$[];OS\[KA97;Y]8:611
M[2!#/OK/_ YVQ6<XPB<VH3A"J;_,];*9,-SGTF!PGO6I>N''(-GL]*#('',
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M=$+5Q:URGZ7.ZZ*IG'],Z_PD" IIK_>_KF:[DXD-S"T4+IMY;[&8\?(AM/1
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M_N(?;_K'M&$V1QW85;34[X,HPPSM?Y6K[OU<ELL(2(]K__5A;;V94H.RQ&T
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M<\J/EOFBH8WN10O.!&0K8"<L*;TQ%5'Q^$JR)FBA9N+TPOX7X22.GR;"]55
M]NZ,6AYU%M\C!/1%-MA6V-:17(Y*:9[=[Z!?VHR8+VJ/RV.>KT<6G'W[P<W@
M97-9=6(P[S8K-:\.\:USR]>=%V%S6>0J>56D""-._6J$D#AWE$SSG14'MME>
MR&X7X1@_8)[$50]H1:[W1DHM1X8K\/1"-_GPH/*R.:EKF<_8*\,T.#4_?9X2
MVZ7K*T?3FRO305X1^>Y1 Z/.YJ$A3E8+FSMQ[5Q>L*R$LB[3+%#<M/TE<M'4
M[*8-ZB,*%7/1</+PTT(WMJBTVN[>&[\V<'F("_=Y!Q]#1,\@+T$'04&57;[T
M=$?UC14BAV-C=*=B)O3I=Z;WDB:ZY77Z9D7C*M"!11(>)I6?52$&'^/2NHYP
M:!GWN$ >QJG*Z()1:^::8K:R4,>V^1^E&]01Y_#RDHNX<$]6<.D7EU/3I*B,
MGFK8@Q\,9C>L*>.E*RL\8*;82D5A*7Z_BA-@"TQ@)[4'K-*,/T>2S#7L%E4P
MOG6_(D9%LW+:BUHPT2DF]>P4#IU9US;.D/9\.L,QU7./2R&\SQ_G6.MT839Q
MW:P%!#T[-#,%504QMDWLSU)+),9_+O<(ASXTU=S<O*R=Z2)=7)6_@=SP#5%+
MVC19;!RHR[,';?P)7.V$CT,G4%?43WJNN5&V0$PBL^!AE=6,#KG&#SF>:+P\
MKM$*L_[N'2IQ/HP$_"8J#F2(7 ?P7#K:6"?4 G'ENGDEO5>U5L9I'5',=Q7:
M _.=R[D\RM>H]JT7OLA]8$9RA]!P+X5LQ[Y^I+ 3KXJT]Z95Z(V+CD=&@8J\
M>74?*=#YBE!#R80RG1*NUH 7K[F8F'?M"T1<SX/"^1O1&0$!!CCVG*)ZR_SM
MPP)A.V3?[=CJHG3!X('FQ7WQODL;9'!$B0%U_6=U^LK=XRG(E+F 5B3_;-/2
M7#^ (U[,.O*UYT$&*S^/2FO07!J_/SQL>=5AAR1FZT=.Q=F?Q YD+P0F1%Z<
MN E!7&3"-?;@]X[L556*U>)9#48L9O:<4FF?.Z/K2(0U(.6C+S/1+K/X($14
M11UO<V)<RY<?/)$BL6777C9[Q$GZ;(VEA4,</](9R[W4=R@U*Z+/^"<(<LC(
MGU5VO(+*9[G6*Q!CJ=];!YXWCFBRCDJ],2<?N/H^?&KRNV.O8#)F02D7=Z]0
M10RAM@\T3T@S:_/A-@O@VF>!KUG:"H PP#SI]SP_>-^RH:)&IDZL)7^(,/KM
MK5.@G>M;K=G&0-#<#_TTA%*Q4&7&P])7>IH<'+^J^,.@?/)^6!Q G()S2 2I
M5EOUF?L9 Q-24]=S)/:^!)&QJQNSA"+U[++E\TVH$^$Q4231T3C^Q\C$01][
MW<=*V!EMU7N4(V:](?(C#F[1BE-Q$N&QP?%K(0KB8:<QYFH^6+NX7LLY\9C:
M6#9%SOYB\W*<EBXO#W:%/C7ISG%_8MQY+6'H'_-3U->\[E.2"<3+1JH5NT/A
M7#9)TJM];P%YYCM'V$&9;@RY5OBF!\E4W3EN)^!VZ/6XF^L;ZG]A8?)QWGHG
M-1G!SV1X5+%+S#$NW*<KIE$UBVNYZ/PMY'>.R6/D@L 7RO9HLL"OSM8&1.9#
M@H^>%$6-DRK >(K@^6IF3_Y JY* NGXZPUZE">]TX*#V&ZLSHC1-3C*A'P0Q
MH<2T7)P.'K\S36=V#,B]35<]B1]:6[QKN%U54T2,PW\<CA@R0$;*=8NMBRO*
MR*G6.3.3#X<T.7Q3=4$]JUNT^=BB*,A%X>#X]*3JB/_(&PK9N&"W7J>8,A*S
M %C^Q#P0#$3HFO?F\7.!?H<4;] *<-VOT[PL63#+X/?C"R=BM89$_^-1O**K
MDE6E[ Z#6E+JG!Y?'YO9!B!_2>##@V-[EAD<@QZ38;:4Z.6.]9:6I;)24X-J
MU>+5-)U4=NJ#>?H%!B/^(1PB#&CO;N)N] '!H_ZTA".!'ZVMN<*Y00YO 2K$
MY>3R*&_N??L1:K0 ^IOV<.TO!K]_3^3%(VW\70S>T[U0F9,R*NM#WN:[-&_
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M"8H->&>:QYY']A<CON#[G^_OA7X[.*L;D*6O3R][NWC@MH/?D ?MM3PM(FM
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M.!QJK)K"\@LLV7:'E/OMIEZF-H55FO[%T/IG;A,KXWZ),_Z3WF:"WG$:QAW
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M0Z4Y?/+U@?.FYQGKO<-I@?S%]YUFL%=&CI*B#_9"<G87L"C-?79'0_(\?\"
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M#H'IT@)^R(@Z.W\T\^A\A%APW["]]W7U$SRX+]NM=E\F^E +R+]MF+\C=,<
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M=Q%B2*9]8C#->)(:5&$">\Z!F%+[-Z&WRR"#\F SJWHAKL3GU2_FZC6%/93
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MUL=\]_Q:+)@&8*?RZA9%)YB^,BT;\C%**DJ^ZWCL6_&71#$@:[HD8>ZGNH^
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M !$              ( !     &%L9'@M,C R-# V,S N:'1M4$L! A0#%
M  @ ;H !68PD!)9Q^@  L@ / !$              ( !WJ\" &%L9'@M,C R
M-# V,S N>'-D4$L! A0#%     @ ;H !60O49FMV)   W+H!  \
M     ( !?JH# &%L9'@M97@Q,%\Q+FAT;5!+ 0(4 Q0    ( &Z  5G* X+?
M0PH  !)<   /              "  2'/ P!A;&1X+65X,3!?,BYH=&U02P$"
M% ,4    " !N@ %9;)_ O?((  "W/0  #P              @ &1V0, 86QD
M>"UE>#,Q7S$N:'1M4$L! A0#%     @ ;H !67GMBE,C"0  USX   \
M         ( !L.(# &%L9'@M97@S,5\R+FAT;5!+ 0(4 Q0    ( &Z  5DH
M6QFN0@8   PM   /              "  0#L P!A;&1X+65X,S)?,2YH=&U0
M2P$"% ,4    " !N@ %9]B&CM;[2"0!Y6PT $@              @ %O\@,
H:6UG,3,P.#@W-C8U7S N:G!G4$L%!@     (  @ [P$  %W%#0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>aldx-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aldx="http://www.aldeyra.com/20240630"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aldx-20240630.xsd" xlink:type="simple"/>
    <context id="C_808346d8-8add-488a-af8a-fcb254ad94f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_820ae58a-8aa6-4607-9edd-93c8f14eda0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aldx:JefferiesSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_841e49f2-f8fa-49e5-99ce-5c3d05827d57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_843cc0d2-4659-45e9-803e-1d495953e509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_847ea9b6-7712-40f6-975a-e4c8f6744f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-28</instant>
        </period>
    </context>
    <context id="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_872d021d-8d7a-415c-aeb0-071a12408727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_88eff217-da00-447c-80f0-c097fab822a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8a0ad11e-9a2d-4592-8375-3c6294aa068f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8ae5248f-56fc-4d37-937d-6f7c458af533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8b1c90f6-18eb-4001-b78a-e6751c433d4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8fc74b92-85f2-4f9d-916a-762e069ff326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_930eaf0d-182d-457d-8a25-2eb7dc5ce169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_960aacbe-fbab-4c63-a85d-c2285ac66c3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_96d3e115-830a-4157-ac6e-d8edcdd92568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_97b19cd6-75ad-4456-99d8-09b2da452e22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a212d05-0e21-49b7-9210-0c109f941d60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_a06e8e4e-16e8-4dde-9e9b-ffb7963feb18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a07ad80e-09c8-499d-9ae3-f20d8016d887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a0f7c50b-70af-4297-b9aa-41adb3adb312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a171b1df-4c92-4175-9e5f-fc3f4bc0789f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a65476d8-e4fe-4f45-94fc-12a4ca98f051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a8750d12-9271-493b-9774-aab5b1395f5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a9120b8c-dabf-419b-a873-3175c3e4920e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9ad5259-f5a0-4de2-8a29-68603609c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae29fbf4-5256-4883-8903-abc42ff33b2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">aldx:SecondAndThirdAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b3aea01f-e989-48fd-b9f6-75afb86f910e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_b5f0f1f6-82d5-4d52-a257-4f738b44ebd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_b7b49075-22e7-4aa3-8ae8-65ddb24b9fd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b945516c-a2fe-4ef4-b522-ac7685c78c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ba4aaa8b-9a25-4dae-b1bb-126e2ff2adc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ba8fec32-6fe2-4982-8ac2-8fed75b0a26a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_bb0d2bfe-e96f-4d70-8e2c-d454ec91262c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:CommonStockAfterFDAApprovalPriorToTenthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-28</instant>
        </period>
    </context>
    <context id="C_bb794176-2e9b-4405-a8ac-a7adab3cce8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_bc7df239-76b6-4890-8a10-e0ed9e21e2ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_c2017d1d-743c-43c9-91e8-cd1670c08fa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="C_c420c777-2dcb-48fa-9456-2026963c27cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c67b96d9-fd6c-4b3b-b38e-25799171694d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">aldx:SixthAndSubsequentAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c884d0fc-bcef-447d-a229-a6c5ade380f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cb6f8aff-b5a2-43c0-b4c7-168cf4972773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ce7c4b72-5b97-4a0e-8ea7-eeb870e832ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:CommonStockAfterFDAApprovalPriorToTwelfthAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="C_ce9c8181-658b-4601-b349-c64cda3f969b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aldx:JefferiesSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d16b308a-5d1b-46ab-9b7e-ef142ccd89bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="C_d2057004-303c-4ec3-b98a-2fce3b615d82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d3f16ce7-5180-4c42-a5f4-7353119a3125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d409ba4a-341b-44fb-b178-554996db8456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d45352fc-bf96-470b-b41f-a3eef457e016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="C_d46ad5a4-f2a8-4980-bd43-14f2b037e22b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d7a4bb9b-dbe9-47e8-b920-116470b0af89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d7bd3f39-df0b-41ee-912e-1db77d9d2cbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_d81bffd9-e22d-4296-b634-a77b7d9776fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_d9ab5c6a-9d40-4195-839e-643b592547c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc6e015f-4534-4370-bdb9-a7945e9ca45d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e0139f32-b214-4275-ae8a-16f436e3203c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_e0ad43ee-c467-4100-b399-f7960579d117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_e51b1aea-5294-4784-b720-49da7b57163b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5cc0746-8061-4e14-bb40-9336a2e95fc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aldx:FoundersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="C_e699a756-602d-48a6-8707-937ab2672bce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_eada7cb9-d8f4-4796-a84a-8755760815f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ebf661ea-8dd4-4850-bc1d-1fc69b508bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="C_ece659b6-3cda-4818-924c-f705aecc6e99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_eeb1ebd5-f0dc-4d5a-a53d-de4340ddcb8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_fa2877a2-040d-4ca1-96d6-0276098a9d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_faf7cb0d-6157-4f20-a7ac-312439f84084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_fb79a21e-fd07-4da1-8098-c1db3735b70c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_fd697598-618c-412c-a894-2682ae77ed63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ff12ec68-2fd5-4170-ba6e-4b15c2ff223c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0075fb28-2a17-4b2b-92f6-1abe0f5ca0ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_01391853-2657-4f02-b4dd-642d3c6e71c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_05cced33-c667-4b68-9ab8-068003720e62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_06ea7345-51c9-4c36-a9ba-2e750192f04f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="C_09af761f-3d1e-47a3-ba56-29b402f55cba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0c6b3071-64d9-4ac6-879c-7ab5b8feecfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0cb4447a-186f-4c30-9fe1-b6650981eee1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0d3c720f-35ff-43af-affa-e0f2ff358760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">aldx:HelioVisionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">aldx:TaxGrossUpPaymentChangeOfControlOrDivestureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-28</instant>
        </period>
    </context>
    <context id="C_0e649ed4-2953-4514-be22-df39d5e87435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0fa013e6-439f-4984-ad30-ef4b14ba2cf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_10f6bf02-b7a9-406c-8bc5-35aafa92828a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="C_1580d899-1ef3-48b3-8ee0-2947a0996507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_16a2a60d-0d62-4933-959e-b7fe028a37cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1992e0d5-9cc7-4f34-b9f5-65c44191df0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_1a45c428-5253-440c-8b4b-4acc1d500a7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_2083538c-d3e8-425e-af11-ff49a4b2d8a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_20b130d8-eac8-40f7-93bd-c629812ee1cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_215ae863-6dc1-4301-a3a7-f9b85b618132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_2168d68b-67be-44e7-815f-cebd869819ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2183c4fb-95a9-45e8-8593-0a184fe3bf8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_2377695c-39c4-4859-bd6c-1d4b3b5420f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_23d2488d-1f43-4650-839c-3f8956faa50b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_26f21088-fd82-4099-b10a-e221c702905e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_270782a4-00d0-4755-8b0e-33d563f70df1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2023-12-21</endDate>
        </period>
    </context>
    <context id="C_282ada39-a478-4e55-91a1-d5ab8c59d75f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="C_2869d481-18dc-4588-a73e-4a7189c37ae7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_296f06b9-5d06-47d8-9d77-8c2beb9797c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_2bff6b01-34c7-4499-90bb-790707bd6958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="C_36d41454-9864-4202-a51e-8d9e3f172bf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_3731cf74-643e-408a-91dd-f3a385d27749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_39c1e011-e9ae-4875-9500-c3cd89afff9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">aldx:StateAndFederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_40f99af9-00a1-419c-baf2-fe6d585df1ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-21</instant>
        </period>
    </context>
    <context id="C_42d94c98-9934-4c6a-b0fa-52973f777316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">aldx:CsbuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_44cef7b4-5749-4aaa-83b1-0dd0b0576672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_459e57d8-3560-4c3f-bc51-fdf45eed3a01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_481f3f0a-8710-4898-94d3-26fd583c6860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4a2131ac-d9f6-43b3-8527-47305ed8f104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4ac1801a-8726-4753-a2ce-890bbc37f3b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aldx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4db1176e-71d2-415e-8ae0-552b66496538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_4fd7b4a8-0fb4-40c1-9d8f-860b5e3f8919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_50415d91-456c-4345-a9e8-9a5bd2f7cfa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_51da8247-a19b-484d-a0e4-e21be178c20a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_5695a349-fc70-4db4-9dda-882a4f8e1db0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="C_5701f4e9-face-49d1-84bc-81d336191ded">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">aldx:ReverseRepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_5763b0ce-896c-424b-adb7-cf75ae931b87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_57c845a6-299a-49d1-989a-c6184ab8153e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_60a5b99d-584e-4c7b-9492-7224c914dd08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_61a04340-64f4-46ee-a35b-1ebbc1c4f8bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_621f912c-92a3-433e-800f-cd9932a4b216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6498b198-4aa0-4c05-874e-e075d11990e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_64ca8519-f2dc-42f4-84f7-7cd8b17311a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_659d8673-bb33-41b8-8d04-af77a63be73c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_6b7f665d-724a-4e0d-8cda-8a1d42dfea6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6dcdd5b4-ccce-449a-a571-48929e89299f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_733f6dcb-0419-40ba-b628-e28799994562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7357fd5b-2efe-455b-b17d-fa82ed547f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_76203581-137d-4ed8-9232-5c729556d7ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_7749ab03-e4ad-4f5d-a02f-52988e9238db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">aldx:FourthAndFifthAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:MEEIAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_783ee973-e8a0-419e-baed-08fbad7a4c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_788bedd8-2721-4594-a783-b6f8bc8b6ea1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7a559121-6521-4d20-bd8a-c5e91210cc67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">aldx:HerculesCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">aldx:TermLoanAdvanceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="C_7b436d9e-9e0b-472d-a52a-b050edddbb87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_7b9cc316-d571-44e9-92d7-4c988cd04578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_7e21e7ea-a69c-43f3-9f0d-2bd41f8e3aad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
        </entity>
        <period>
            <instant>2024-07-29</instant>
        </period>
    </context>
    <context id="C_7fa87fa1-8b12-44f5-9947-3868ccbde0f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001341235</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aldx:AbbvieOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>aldx:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_1db5701a-2432-477d-8543-8af568c033b3">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_36dee27a-22e8-4e58-b336-3f200b8ff37a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_3a4a7988-6450-466b-a1e8-15750269339c">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_dc2b3bf1-1b25-4bef-91fd-9e286e214934">0001341235</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      id="F_8287f335-848f-4569-a5bd-ca1496b4c0cc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      id="F_a72334fc-b806-4b63-90f8-3649fbd0921f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_cfa364d7-85e5-466e-bfca-390d21bf4e43">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_978e64ad-d237-4ff4-a157-f25a29d564e9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_13833983-6292-4cde-84ad-0ab01dab5492">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_c78eae54-681d-464b-98de-17b0152b2694">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_ed2f6cc6-b6f5-4ae3-8bb5-d52559c4a66d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_00b75560-0f08-4601-a317-2d8ea08119c5">001-36332</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_0794fec9-5834-4820-9394-3fb653c62ba1">ALDEYRA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_f07dbd2d-c2dc-423e-a48f-7a4bbb7dc530">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_93cac57c-f4fa-452a-b176-733064fa8e87">20-1968197</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_a495083c-c6eb-4502-b2ea-0f2a8ec3cfd1">131 Hartwell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_4a57d2c8-5f49-48e5-8b3e-3eaf9a3fbc09">Suite 320</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_50ec8c99-f345-4fd5-bf38-8a1f2dc6216c">Lexington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_0dbedaa3-0be0-4e59-8ca2-b0864c849e91">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_c7ef64fb-3b46-4729-aafe-ad3b9a3f5043">02421</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_10710ff9-b03e-4a8e-889c-7a1efca4eabc">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_9e0a0022-dc55-4e4f-a730-74078e4fb08f">761-4904</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_6fa2291c-8a88-4a76-9903-68801d4ed226">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_3d0e5827-063d-4865-9444-b0c76890ea02">ALDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_d63feb4c-c9e7-47b2-9bc5-f2fef72cd34c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_167cf4ae-55d7-4b28-8a7e-e85ccbf181aa">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_73c927e2-0126-4e00-a019-462423504769">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_4b35e902-b480-48ad-b95f-48fe9f2e35c6">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_d5047737-b1a6-4df1-87ed-84f96355f419">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_43d47a48-18c7-40f2-8bee-3db816656051">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_80f393ba-3153-483d-9300-f0989cdfd5da">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_7e21e7ea-a69c-43f3-9f0d-2bd41f8e3aad"
      decimals="INF"
      id="F_36f29a5b-fee7-4a9a-be9c-c1d3c8055d62"
      unitRef="U_shares">59421551</dei:EntityCommonStockSharesOutstanding>
    <aldx:CashAndMoneyMarketFunds
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_44c5bde9-1204-41e3-8c51-cf5df75a99c4"
      unitRef="U_USD">31029723</aldx:CashAndMoneyMarketFunds>
    <aldx:CashAndMoneyMarketFunds
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_ef7336c1-76b8-414b-ad04-b203579cb661"
      unitRef="U_USD">142823016</aldx:CashAndMoneyMarketFunds>
    <aldx:CashEquivalentReverseRepurchaseAgreements
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_2dd17309-44fd-45bb-94e8-803019eb5dd9"
      unitRef="U_USD">40000000</aldx:CashEquivalentReverseRepurchaseAgreements>
    <aldx:CashEquivalentReverseRepurchaseAgreements
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_e763a030-d946-4a4e-900f-ac23e98dc36f"
      unitRef="U_USD">0</aldx:CashEquivalentReverseRepurchaseAgreements>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_70afc0ab-b47d-4167-9222-883085ef2034"
      unitRef="U_USD">49301960</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_859f5ef2-595b-4aba-98e6-164188da1829"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_c82d8f7b-b71b-4973-9a19-4dff55a06d45"
      unitRef="U_USD">5317836</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_a1a0754a-6d11-4967-b795-604eda6a82d9"
      unitRef="U_USD">4987317</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_204f1711-adc5-4eee-8fa0-ae697aa77210"
      unitRef="U_USD">125649519</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_697115ba-7932-4dda-a534-a12b9c046e4d"
      unitRef="U_USD">147810333</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_7eec8b14-e851-4638-b874-612cc01eb13b"
      unitRef="U_USD">391595</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_8a167534-4dd3-4700-a7a5-216e245b0286"
      unitRef="U_USD">510814</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_ee1ba0ee-a15f-4665-bcec-bb58ae8a8752"
      unitRef="U_USD">2720</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_f0069c31-0fd5-4918-8536-618dd9023678"
      unitRef="U_USD">5764</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_fce968b4-cd40-4b7d-9413-3fe07052f6d1"
      unitRef="U_USD">126043834</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_94b88877-6dc6-4b46-9782-13420e251eb4"
      unitRef="U_USD">148326911</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_f79b7cf6-d698-4661-b104-e2c75c606ca2"
      unitRef="U_USD">254434</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_64f98db2-f5df-4e6d-9b66-5be27775a59a"
      unitRef="U_USD">1338057</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_3bfcd022-2aec-4e80-95c9-d3efd5ebe82c"
      unitRef="U_USD">5842802</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_4049e3e0-57c5-464c-98b6-e9a29021669d"
      unitRef="U_USD">5536464</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_05578a97-18ef-4b24-8f86-ec5766ac3cd3"
      unitRef="U_USD">15242327</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_b9723fcc-18b0-4700-b6cd-dbbe86bdd4af"
      unitRef="U_USD">15146546</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_e282e04e-aa9d-44cb-b6a4-6d0120e52dea"
      unitRef="U_USD">255039</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_ae89c379-626d-4e45-a441-b23ca3a01295"
      unitRef="U_USD">239183</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_83686550-f2b6-4400-ac2c-875f9df963fd"
      unitRef="U_USD">6000000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_34f1a0e5-9521-4dec-9073-80907e34aba3"
      unitRef="U_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_cd7457f8-4229-4db4-b9bf-ce0431a325a4"
      unitRef="U_USD">27594602</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_9030d672-f380-4dcf-9adc-5ce66cb1ccd7"
      unitRef="U_USD">22260250</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredLongTermLiabilityCharges
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_964b931c-91b6-457c-b023-d2e4c53b1b07"
      unitRef="U_USD">0</us-gaap:DeferredLongTermLiabilityCharges>
    <us-gaap:DeferredLongTermLiabilityCharges
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_cf8597f0-a347-4273-99f1-0be594b76c1f"
      unitRef="U_USD">6000000</us-gaap:DeferredLongTermLiabilityCharges>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_97460426-7761-44bc-832f-698e4dec4e43"
      unitRef="U_USD">138893</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_a97ce88b-911a-4707-97a2-436348e36c12"
      unitRef="U_USD">271631</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_b5e05d6c-5493-43a9-9be9-461b9c1f2c69"
      unitRef="U_USD">27733495</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_441ba01b-8765-4e2f-bc7b-dd654780b903"
      unitRef="U_USD">28531881</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_324cb96f-4703-450b-9035-c479926ab922"
      unitRef="U_USDollarShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_93914d99-0ccc-4e1c-a8f3-b8b5e6ca96ba"
      unitRef="U_USDollarShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_32316664-c5df-4bd3-a464-edc291c61d01"
      unitRef="U_shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_83738169-0799-4d35-a965-ae735532f4ef"
      unitRef="U_shares">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_029495e1-b352-4e2e-baea-03f7769acf10"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_66459643-5d55-42e6-9d15-0fde31977657"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_9fe53245-95f2-4e99-b396-4ad8f97ee520"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_0ff5a964-1f99-4a09-9cc5-dadb57c2c34b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_6d479d6e-9dbb-4b96-ba6d-629c6290af85"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_dfec83b8-0a2f-4536-a977-e0c07d69c3c5"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_85112325-b538-4881-b5da-722dbdd71d98"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_0fa47543-c507-452c-b51b-4496c86ef6f0"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_de42a599-2ad3-4691-9f1f-dad7c9b8b6b6"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_1184121a-cdab-4848-a16d-700195d6c3dc"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_932e6316-01f2-4330-a6ad-1aa5c84978a1"
      unitRef="U_shares">59414489</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_2c9cf937-a9bb-4304-b28f-529b3016450e"
      unitRef="U_shares">59414489</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_7f89a320-b389-40dc-827c-686e12ccb51d"
      unitRef="U_shares">59195951</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_d11e9536-2c89-4689-a40d-7a3f4c43cc4d"
      unitRef="U_shares">59195951</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_b7a6154e-fdd5-4c9e-b467-45a9977aa82b"
      unitRef="U_USD">59415</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_8ecfdf79-5ef7-4ab7-9de9-386fa3be8f48"
      unitRef="U_USD">59196</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_440b149a-5bc2-42ff-a513-1fa23b8dd6ee"
      unitRef="U_USD">517449424</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_482c6a35-bec2-4d72-9d9f-7a41bdf73f29"
      unitRef="U_USD">513994982</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_e3cec0ab-dcf6-4241-b45b-365fc0a618ea"
      unitRef="U_USD">-9658</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_8b673ba7-c002-4411-9e5e-a564f5cb7d60"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_e5702612-cb46-483f-8356-c8ab05d04e3f"
      unitRef="U_USD">-419188842</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_f599add6-be86-4006-91ff-68a7b3c15904"
      unitRef="U_USD">-394259148</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_4cb4cdc6-a888-4e13-8646-caac8668c667"
      unitRef="U_USD">98310339</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_9dbdbf64-02dc-4285-9e52-146d9ecd0442"
      unitRef="U_USD">119795030</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_5b20f2b4-53d4-4750-bd58-bb1350869b60"
      unitRef="U_USD">126043834</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_afec82f6-286f-4986-92f1-baba12e634b1"
      unitRef="U_USD">148326911</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_7f24ba6a-e856-4d7f-a98c-eec5571fd420"
      unitRef="U_USD">14969743</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_2c16d8d7-5ba0-4a09-94c3-5741af72ec78"
      unitRef="U_USD">6962907</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_074d7ced-0ef2-4de4-8b37-dc28650ea451"
      unitRef="U_USD">21153251</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_efa03baf-b74f-4cc4-b4d1-075bbcd9d745"
      unitRef="U_USD">18198767</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_19b677e6-70b8-4c0e-a029-fb4897d9f22f"
      unitRef="U_USD">3038064</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_71410d4c-9d1f-4728-8202-2332739d839a"
      unitRef="U_USD">3379750</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_40951b9b-5697-4b09-a7eb-2210bffa3e4c"
      unitRef="U_USD">6248420</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_f6d1e9f4-e742-436b-b67d-6df4d7845df6"
      unitRef="U_USD">8947167</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_eedae99b-6472-4e9c-bdb3-558fb373800e"
      unitRef="U_USD">-18007807</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_9d120443-456e-4947-a242-8f20064a2a71"
      unitRef="U_USD">-10342657</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_334293d5-1255-4ee4-9e1a-70af58f28495"
      unitRef="U_USD">-27401671</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_0fc3b847-6e42-4924-8df4-458023931ad2"
      unitRef="U_USD">-27145934</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_bc1faae8-cdbb-4275-91ce-eba49a1abbe4"
      unitRef="U_USD">1637836</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_74a7649e-da5a-4268-b970-6464250077df"
      unitRef="U_USD">1882800</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_c2483409-55d5-4684-ba1e-3d178e5a4806"
      unitRef="U_USD">3448105</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_c8f6e577-75ba-4399-a02b-e8d7bc2553f9"
      unitRef="U_USD">3561685</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_8487a070-8008-42f9-ae0e-22d18a62e74f"
      unitRef="U_USD">477601</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_2cabf363-7f1c-44bf-a0a6-de87bb5b47b3"
      unitRef="U_USD">527141</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_6723b2e2-9198-4644-b210-15ed52b592a8"
      unitRef="U_USD">976128</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_c7a27d7e-afd9-4f4c-99e3-c468c69bb747"
      unitRef="U_USD">1018428</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_633a300b-7ba9-4155-9e16-414939380e56"
      unitRef="U_USD">1160235</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_a6275db2-4c2e-450b-b89b-97eb3f98cd03"
      unitRef="U_USD">1355659</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_480503a0-7427-4989-8083-039d36429735"
      unitRef="U_USD">2471977</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_82f1a8de-0346-4c84-aa4c-cc6fcd8692e6"
      unitRef="U_USD">2543257</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_8de94615-6b8e-414c-a516-f23defa9f17f"
      unitRef="U_USD">-16847572</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_ab7d2e7e-bd81-4cf8-9360-b6ae7a4477d4"
      unitRef="U_USD">-8986998</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_4739dbda-43da-4fe9-abdf-f342a827ec53"
      unitRef="U_USD">-24929694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_c921fbea-8bad-4f99-8dee-98210657bc33"
      unitRef="U_USD">-24602677</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="2"
      id="F_d159496c-57a9-42da-bada-e69988f5e70a"
      unitRef="U_USDollarShare">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="2"
      id="F_bf2229c5-8e4e-49f7-84c7-427687df43cc"
      unitRef="U_USDollarShare">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="2"
      id="F_7c1c425a-4153-40c4-8d34-0a3e409aa57c"
      unitRef="U_USDollarShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="2"
      id="F_49bb99ab-217a-4739-ac5f-c9a32a11463d"
      unitRef="U_USDollarShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="2"
      id="F_fde7a6f2-0d99-4c24-a29a-b9416a6438e7"
      unitRef="U_USDollarShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="2"
      id="F_9e5f8502-c46b-493a-b59f-cf1d04ad944a"
      unitRef="U_USDollarShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="2"
      id="F_ace4f3c7-fe3f-4526-8948-5d4707fccbd1"
      unitRef="U_USDollarShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="2"
      id="F_19a811bb-f91d-412d-9eba-23e96de3fe95"
      unitRef="U_USDollarShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="INF"
      id="F_fbd960cf-b48f-4a06-8bb1-bbfab1c803e8"
      unitRef="U_shares">59414489</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="INF"
      id="F_a563cece-34a2-40a1-a825-684f57bb5023"
      unitRef="U_shares">59414489</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="INF"
      id="F_9d2e879a-d2ae-4de5-a6c7-741f00f97161"
      unitRef="U_shares">58791920</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="INF"
      id="F_0421445a-7342-4349-8e51-096db1016ab5"
      unitRef="U_shares">58791920</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_3456004b-50fe-4262-8e82-0b917cd2dbac"
      unitRef="U_shares">59414489</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_454d35db-9f88-4a91-8dc0-71f0558fc619"
      unitRef="U_shares">59414489</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="INF"
      id="F_bd63faa2-a304-41dd-a717-4bd4089f36fe"
      unitRef="U_shares">58791762</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="INF"
      id="F_4b7c07ef-9dfa-4bb7-aefc-d1679accdfcc"
      unitRef="U_shares">58791762</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_b348098b-1793-4fe4-bc88-ea3a4c74c935"
      unitRef="U_USD">-16847572</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_901a9346-182a-483f-ba0a-f06b55788b4a"
      unitRef="U_USD">-8986998</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_198c5297-12b0-480f-8296-566fae44d4ad"
      unitRef="U_USD">-24929694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_0ee6015c-09c3-4f91-9416-2ac553fe2f83"
      unitRef="U_USD">-24602677</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_607fe22e-d47c-4b40-b282-c013b730e07d"
      unitRef="U_USD">-6629</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_52e585e3-7b2b-4ba7-9862-6b2b7214e522"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_165d10cc-ec66-491b-8e44-5c569dfa48c9"
      unitRef="U_USD">-9658</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_f762e905-e77e-4e09-b653-750829b5861a"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_c466c693-8379-48da-a8b1-37e7d1054464"
      unitRef="U_USD">103938</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_730ea2ab-6b0b-4cf1-85ff-a8b8812f896c"
      unitRef="U_USD">-6629</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_92799375-8c7a-4240-b10e-c25cb84a0e91"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_0ffc1d08-7900-47c2-8de0-90e4a95d8164"
      unitRef="U_USD">-9658</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_fd4a1278-e8da-4ff0-be18-894f932601e2"
      unitRef="U_USD">103938</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_f792bfe1-e230-4eb8-9801-50b265c23155"
      unitRef="U_USD">-16854201</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_7188c171-01e8-4844-8283-2699e701cc2e"
      unitRef="U_USD">-8986998</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_51f4264b-6d94-4ea1-a8c1-5b436b876556"
      unitRef="U_USD">-24939352</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_65011c18-3c52-429b-896f-539a956055e8"
      unitRef="U_USD">-24498739</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_d7a4bb9b-dbe9-47e8-b920-116470b0af89"
      decimals="INF"
      id="F_ffe4ac15-9c5a-425c-acc4-29333f7ee0ce"
      unitRef="U_shares">59195951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d7a4bb9b-dbe9-47e8-b920-116470b0af89"
      decimals="0"
      id="F_e2ea0aaa-0e8f-4dae-a29e-611e1b65792e"
      unitRef="U_USD">59196</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a9ad5259-f5a0-4de2-8a29-68603609c343"
      decimals="0"
      id="F_8ca62164-5491-4a59-ac10-3b21fac9539f"
      unitRef="U_USD">513994982</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a212d05-0e21-49b7-9210-0c109f941d60"
      decimals="0"
      id="F_78088a47-dd9f-4a93-a464-af2db8518ebb"
      unitRef="U_USD">-394259148</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_42645eb6-efad-4b5f-ad71-f0581a44cbf8"
      unitRef="U_USD">119795030</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d"
      decimals="0"
      id="F_4b268d44-b9fe-42b7-b8bd-c484e15885e3"
      unitRef="U_USD">3436470</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_362d210f-85b6-4af7-ad8a-31fcb213e9ee"
      unitRef="U_USD">3436470</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e"
      decimals="INF"
      id="F_2f3f37d7-ce5c-414d-b592-49a313c8c8ee"
      unitRef="U_shares">6097</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e"
      decimals="0"
      id="F_99556b5c-068d-4e0a-a855-94945195158e"
      unitRef="U_USD">7</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d"
      decimals="0"
      id="F_c1480089-816a-40db-be7c-5b14b34dbd1a"
      unitRef="U_USD">18184</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_825bcab8-277d-428d-a704-3c24154fa7af"
      unitRef="U_USD">18191</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e"
      decimals="INF"
      id="F_51660a93-4e89-4f00-8b1d-78ca08ffdc5b"
      unitRef="U_shares">212441</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_57c845a6-299a-49d1-989a-c6184ab8153e"
      decimals="0"
      id="F_76670b6c-25ff-4c9a-8ad6-e74fc2c28351"
      unitRef="U_USD">212</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_b8243148-2bc9-4f4b-a81d-dafcee898a0d"
      decimals="0"
      id="F_c3705426-0257-41c0-b8aa-b2ee4ed8c16f"
      unitRef="U_USD">-212</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0fa013e6-439f-4984-ad30-ef4b14ba2cf3"
      decimals="0"
      id="F_25a75d04-2a91-4d2c-9da5-f40874ddaf52"
      unitRef="U_USD">-9658</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_80a923a0-1041-4b9b-af8a-c6bf824105e2"
      unitRef="U_USD">-9658</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <aldx:NetLoss
      contextRef="C_c884d0fc-bcef-447d-a229-a6c5ade380f5"
      decimals="0"
      id="F_dea655b8-fd2a-4f64-91d3-315e95d81516"
      unitRef="U_USD">-24929694</aldx:NetLoss>
    <aldx:NetLoss
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_9538e707-cdf8-49fb-a949-ac7e637a927b"
      unitRef="U_USD">-24929694</aldx:NetLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82"
      decimals="INF"
      id="F_075341fb-abe7-4cda-9ba1-410f301ee44c"
      unitRef="U_shares">59414489</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82"
      decimals="0"
      id="F_cd823c65-fb90-4aa3-89b0-bed0c4a9fb9c"
      unitRef="U_USD">59415</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a07ad80e-09c8-499d-9ae3-f20d8016d887"
      decimals="0"
      id="F_a3a506b2-9822-4f3f-a3d3-747766201586"
      unitRef="U_USD">517449424</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_872d021d-8d7a-415c-aeb0-071a12408727"
      decimals="0"
      id="F_d9506abe-0c3b-449c-9c61-a8e0932bcdda"
      unitRef="U_USD">-9658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8b1c90f6-18eb-4001-b78a-e6751c433d4d"
      decimals="0"
      id="F_99d04920-db2a-43fb-b9af-b74b23bc18ab"
      unitRef="U_USD">-419188842</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_c43cc4e6-047a-4a31-9ade-6d489a1db073"
      unitRef="U_USD">98310339</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_8a0ad11e-9a2d-4592-8375-3c6294aa068f"
      decimals="INF"
      id="F_9e70b38a-73a4-4fb5-8ec5-db62fad72e6b"
      unitRef="U_shares">58560078</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8a0ad11e-9a2d-4592-8375-3c6294aa068f"
      decimals="0"
      id="F_9ca3b9e5-2be4-4ddc-bf8e-bf9dc85d2e78"
      unitRef="U_USD">58560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_60a5b99d-584e-4c7b-9492-7224c914dd08"
      decimals="0"
      id="F_15af6f9c-1f78-433e-9710-4e4a180ee940"
      unitRef="U_USD">507770045</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_788bedd8-2721-4594-a783-b6f8bc8b6ea1"
      decimals="0"
      id="F_7c3ec55c-8c61-483b-b926-f81c59991398"
      unitRef="U_USD">-103938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_930eaf0d-182d-457d-8a25-2eb7dc5ce169"
      decimals="0"
      id="F_fb9eba5f-f78b-4b5c-98d5-2c95342c2ad7"
      unitRef="U_USD">-356716638</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_26f21088-fd82-4099-b10a-e221c702905e"
      decimals="0"
      id="F_70e85790-6484-4dd5-8144-94c056fccff8"
      unitRef="U_USD">151008029</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b"
      decimals="0"
      id="F_9cf4ab51-73e5-41e9-909c-0ede9ef37b1c"
      unitRef="U_USD">3316058</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_79615e9e-11dc-4da8-8f86-1022b2d222ef"
      unitRef="U_USD">3316058</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce"
      decimals="INF"
      id="F_daea1828-79bf-4560-abbc-545aa28ec959"
      unitRef="U_shares">9604</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce"
      decimals="0"
      id="F_a9d67b85-2060-40d5-a625-fbf41d8ec759"
      unitRef="U_USD">9</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b"
      decimals="0"
      id="F_3e62ee9a-6b66-47ab-9fd2-c583d0e69101"
      unitRef="U_USD">5283</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_5f124d11-cd45-4e15-b279-4d01742cec68"
      unitRef="U_USD">5292</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce"
      decimals="INF"
      id="F_2d786b59-d4b1-4562-9461-5055d8606b16"
      unitRef="U_shares">16272</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce"
      decimals="0"
      id="F_d7d020af-c83d-4e69-9ff0-15aee6bbc1a2"
      unitRef="U_USD">17</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b"
      decimals="0"
      id="F_54cddac3-4dbe-434c-9a1a-c8b0d5445f60"
      unitRef="U_USD">52542</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_b268ea39-1931-428b-891e-b268ca2af545"
      unitRef="U_USD">52559</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce"
      decimals="INF"
      id="F_90199538-5385-46ed-b518-5001b3b2265f"
      unitRef="U_shares">215253</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_76203581-137d-4ed8-9232-5c729556d7ce"
      decimals="0"
      id="F_23a4070e-321b-42e4-aea1-839625dcd85c"
      unitRef="U_USD">215</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_23d2488d-1f43-4650-839c-3f8956faa50b"
      decimals="0"
      id="F_a99649df-adf7-48cb-a52a-e0fe82f24218"
      unitRef="U_USD">-215</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ece659b6-3cda-4818-924c-f705aecc6e99"
      decimals="0"
      id="F_1c6a4ac5-5447-4895-842a-54644f8e6ef8"
      unitRef="U_USD">103938</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_b6d62279-b621-4bdf-82d8-d05b66c5eee7"
      unitRef="U_USD">103938</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <aldx:NetLoss
      contextRef="C_61a04340-64f4-46ee-a35b-1ebbc1c4f8bd"
      decimals="0"
      id="F_8f00f4ec-470d-4231-b6af-ca2ff47c1045"
      unitRef="U_USD">-24602677</aldx:NetLoss>
    <aldx:NetLoss
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_0cf54bdd-dde0-443b-b678-570d68e54939"
      unitRef="U_USD">-24602677</aldx:NetLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0"
      decimals="INF"
      id="F_8936b811-b903-47f9-b393-9795dca64120"
      unitRef="U_shares">58801207</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0"
      decimals="0"
      id="F_f8d5cb55-b242-421a-b0ca-e7a6740d9f71"
      unitRef="U_USD">58801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2183c4fb-95a9-45e8-8593-0a184fe3bf8a"
      decimals="0"
      id="F_4b32f7cc-2161-4ad3-a2d5-112ac6f4d1af"
      unitRef="U_USD">511143713</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_36d41454-9864-4202-a51e-8d9e3f172bf9"
      decimals="0"
      id="F_c9282d56-6d64-4578-9308-3a3d0bb0b658"
      unitRef="U_USD">-381319315</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694"
      decimals="0"
      id="F_a2e9c2a5-eb57-4808-80db-86476bc9db07"
      unitRef="U_USD">129883199</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_4db1176e-71d2-415e-8ae0-552b66496538"
      decimals="INF"
      id="F_a4fd502e-3b8a-4c59-926a-3ad4f6e4f98b"
      unitRef="U_shares">59414489</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4db1176e-71d2-415e-8ae0-552b66496538"
      decimals="0"
      id="F_5953f943-4415-4d4c-adab-a242de779d4d"
      unitRef="U_USD">59415</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6498b198-4aa0-4c05-874e-e075d11990e9"
      decimals="0"
      id="F_cf553e12-30fc-479e-a602-dec1662fa992"
      unitRef="U_USD">515704325</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fb79a21e-fd07-4da1-8098-c1db3735b70c"
      decimals="0"
      id="F_7a4d6b08-54db-411f-af36-ca164573393b"
      unitRef="U_USD">-3029</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_64ca8519-f2dc-42f4-84f7-7cd8b17311a4"
      decimals="0"
      id="F_6eb0bdd2-82eb-4d23-b2d4-070b2c88ffcc"
      unitRef="U_USD">-402341270</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a8750d12-9271-493b-9774-aab5b1395f5f"
      decimals="0"
      id="F_c389d26c-ea3b-42c0-ad4f-70a0713d5179"
      unitRef="U_USD">113419441</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cb6f8aff-b5a2-43c0-b4c7-168cf4972773"
      decimals="0"
      id="F_0a74dc15-fea4-410a-bb4d-b6e884c06832"
      unitRef="U_USD">1745099</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_43ca3c4f-e1d3-477d-b183-11b99ec9136c"
      unitRef="U_USD">1745099</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_960aacbe-fbab-4c63-a85d-c2285ac66c3e"
      decimals="0"
      id="F_710dd1ee-bead-4ed9-a202-b7a9d184bd4d"
      unitRef="U_USD">-6629</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_88706ea4-c654-4c35-8240-d4986bcea54e"
      unitRef="U_USD">-6629</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <aldx:NetLoss
      contextRef="C_d46ad5a4-f2a8-4980-bd43-14f2b037e22b"
      decimals="0"
      id="F_ce3c6e9c-f6c4-4745-9f94-d075a2c8c8b5"
      unitRef="U_USD">-16847572</aldx:NetLoss>
    <aldx:NetLoss
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_3d72210c-93c8-4c31-846e-1fa6236cdc94"
      unitRef="U_USD">-16847572</aldx:NetLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82"
      decimals="INF"
      id="F_ced665d6-9e28-4679-be56-3f0a5a341d86"
      unitRef="U_shares">59414489</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_d2057004-303c-4ec3-b98a-2fce3b615d82"
      decimals="0"
      id="F_e2371905-7686-41bb-b537-63ad4a457e47"
      unitRef="U_USD">59415</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a07ad80e-09c8-499d-9ae3-f20d8016d887"
      decimals="0"
      id="F_88ce522f-3453-403c-9de8-2440300a2dae"
      unitRef="U_USD">517449424</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_872d021d-8d7a-415c-aeb0-071a12408727"
      decimals="0"
      id="F_79685bb0-3e2b-4ef6-9d3a-f38d7d0092ca"
      unitRef="U_USD">-9658</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8b1c90f6-18eb-4001-b78a-e6751c433d4d"
      decimals="0"
      id="F_3d9490bd-eab2-4de9-b04a-955334202a45"
      unitRef="U_USD">-419188842</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_2561f52b-8781-49be-a1b7-05f274832fc6"
      unitRef="U_USD">98310339</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_2377695c-39c4-4859-bd6c-1d4b3b5420f4"
      decimals="INF"
      id="F_5d1fb261-6382-4046-ab8c-f50ae2c79e0e"
      unitRef="U_shares">58791603</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2377695c-39c4-4859-bd6c-1d4b3b5420f4"
      decimals="0"
      id="F_ce3e6f88-cab0-4a3e-8692-9f87158f870c"
      unitRef="U_USD">58792</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e0139f32-b214-4275-ae8a-16f436e3203c"
      decimals="0"
      id="F_0d14106f-1882-4d98-89a1-c2b1ba638fd6"
      unitRef="U_USD">509516738</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_51da8247-a19b-484d-a0e4-e21be178c20a"
      decimals="0"
      id="F_4927102f-89d3-4b41-956b-aab88ab78938"
      unitRef="U_USD">-372332317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eeb1ebd5-f0dc-4d5a-a53d-de4340ddcb8c"
      decimals="0"
      id="F_231fc2f7-312e-4e71-a891-6d05de6b1dd9"
      unitRef="U_USD">137243213</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7357fd5b-2efe-455b-b17d-fa82ed547f0b"
      decimals="0"
      id="F_92fc3ef9-be9f-4573-b504-1e64dcba31cd"
      unitRef="U_USD">1621692</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_37e25880-c3a1-4e6f-980d-3e8c11fffe76"
      unitRef="U_USD">1621692</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1992e0d5-9cc7-4f34-b9f5-65c44191df0e"
      decimals="INF"
      id="F_eea92bb9-8bb6-46dd-86c4-c10a6371c12d"
      unitRef="U_shares">9604</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1992e0d5-9cc7-4f34-b9f5-65c44191df0e"
      decimals="0"
      id="F_b32df5c0-d819-4cec-a593-d1ac815dd976"
      unitRef="U_USD">9</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7357fd5b-2efe-455b-b17d-fa82ed547f0b"
      decimals="0"
      id="F_29e18d14-ce80-4d92-8039-40b2ee87732e"
      unitRef="U_USD">5283</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_79f5ede1-63b8-4a76-ad71-2a26b3d2e6ae"
      unitRef="U_USD">5292</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <aldx:NetLoss
      contextRef="C_843cc0d2-4659-45e9-803e-1d495953e509"
      decimals="0"
      id="F_e2f3d35f-690a-428f-9122-e471175d7b83"
      unitRef="U_USD">-8986998</aldx:NetLoss>
    <aldx:NetLoss
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_616338de-2ad8-4da7-84d3-f6a981d796bf"
      unitRef="U_USD">-8986998</aldx:NetLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0"
      decimals="INF"
      id="F_7aace4f6-63ae-4fd8-a75b-b6bb7cd90998"
      unitRef="U_shares">58801207</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_58e2930c-f35e-496f-9a1f-b4b8704e9ab0"
      decimals="0"
      id="F_52428a29-8c9d-4d27-a9d1-7f678bc37dd3"
      unitRef="U_USD">58801</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2183c4fb-95a9-45e8-8593-0a184fe3bf8a"
      decimals="0"
      id="F_76bc4059-9e61-42d0-b56d-cdfbc1def660"
      unitRef="U_USD">511143713</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_36d41454-9864-4202-a51e-8d9e3f172bf9"
      decimals="0"
      id="F_5114c7d0-a6f9-47b9-9f3b-c5e4d769f9b5"
      unitRef="U_USD">-381319315</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694"
      decimals="0"
      id="F_9f6944c1-c429-48e9-a2c1-09909daced7e"
      unitRef="U_USD">129883199</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_80d96e08-0a6c-478c-bd8c-b5fd0bfc2f4f"
      unitRef="U_USD">-24929694</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_7b16304f-1a2c-4d91-8534-b2fd7a42f1eb"
      unitRef="U_USD">-24602677</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_0bfa6182-05b3-49de-8bb0-0fb522a5009d"
      unitRef="U_USD">3484366</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_c8828539-78bc-475e-9787-595af2602177"
      unitRef="U_USD">5763896</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_8a02b1d9-5145-491f-be26-7b07e73079e4"
      unitRef="U_USD">95781</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_9458cc82-ae60-4991-bda6-df533dc17bbc"
      unitRef="U_USD">187501</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_d1a16400-83a8-4c7b-994e-9778726211a0"
      unitRef="U_USD">697119</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_945333eb-0a56-4cd9-89e0-f3363e5547b7"
      unitRef="U_USD">14542</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:Depreciation
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_98375feb-dbc7-4c2a-93e5-c2baf774513b"
      unitRef="U_USD">122263</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_870bd640-fc5e-4c87-98dd-e02692a63142"
      unitRef="U_USD">131312</us-gaap:Depreciation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_cd82aeb3-bd4b-4664-9033-d4ba41ed3609"
      unitRef="U_USD">330519</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_d624454e-de50-4257-bbdf-49db16423355"
      unitRef="U_USD">-2918672</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_c6228272-6940-4b2b-be4f-52e946379ce7"
      unitRef="U_USD">-1083623</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_a6ed6c8d-c949-4170-989e-cd3a9d74245a"
      unitRef="U_USD">137191</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_61add888-5a93-4291-a6db-deda2b2a954f"
      unitRef="U_USD">141560</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_f28cdbcd-aa7f-42f3-965e-703a76f3e52d"
      unitRef="U_USD">-7323007</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_e1e8045a-d4f7-4a9d-bb30-128c6211a735"
      unitRef="U_USD">-23196985</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_51223eb9-0a3e-4451-8ab0-9289115dc29c"
      unitRef="U_USD">-22801654</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_6730f315-3fb6-4d39-a1a7-ec5c876b845c"
      unitRef="U_USD">60614499</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_d25f1b7e-41c1-4794-a823-a8f3c4baac8b"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_c6402bf6-502b-409c-b327-3e1be84be5b3"
      unitRef="U_USD">12000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_7597a7ff-656e-47fd-99fb-45a97d5f2645"
      unitRef="U_USD">30000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_cd017d97-efac-43ba-b2a7-3c07fc5ddc89"
      unitRef="U_USD">-48614499</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_e9859d13-b7ec-472c-9e0e-5c1534746a50"
      unitRef="U_USD">30000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_53033399-83b1-401b-b1d0-dc158da6e570"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_de8706af-0b83-45d9-9ef4-a950f7c63797"
      unitRef="U_USD">5292</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_b34208e8-ea18-442a-87f0-6757249c93f2"
      unitRef="U_USD">18191</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_99bedfa9-7dd2-4906-a371-e6cad6d0f2bb"
      unitRef="U_USD">52559</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_9432ba9d-cc41-4eee-a8f4-ff3b500fab98"
      unitRef="U_USD">18191</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_eb51f953-026b-4854-8747-6e53bdc3fb65"
      unitRef="U_USD">57851</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_ec6d2f4b-6e27-4129-8c0a-db3251f28928"
      unitRef="U_USD">-71793293</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_9c7e4773-c913-4d42-a09a-d862c9ccf928"
      unitRef="U_USD">7256197</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_377a201a-b41a-4cf3-818e-238b4d295d86"
      unitRef="U_USD">142823016</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_26f21088-fd82-4099-b10a-e221c702905e"
      decimals="0"
      id="F_e9373263-55df-4dbf-8876-cd174cf5ad7f"
      unitRef="U_USD">144419364</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_5ced7fc4-0806-4e9c-96bc-2bd4c811a5b0"
      unitRef="U_USD">71029723</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9b968c7d-c5ae-4ebd-a41b-9b49547f7694"
      decimals="0"
      id="F_b8ef33f4-e8d6-4ad4-8234-0046c7a4a22b"
      unitRef="U_USD">151675561</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_5ca5b831-a7b6-47c2-aaf4-4cda9672f3bf"
      unitRef="U_USD">884500</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_8cc8bb49-7db4-45c0-9413-d0390ae68ab5"
      unitRef="U_USD">823521</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_593aa239-2d4b-4b13-b709-eb4913cdd0fe">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;NATURE OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Aldeyra Therapeutics, Inc., together with its wholly-owned subsidiaries (the &#x201c;Company&#x201d; or &#x201c;Aldeyra&#x201d;), a Delaware corporation, is a clinical-stage biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s principal activities to date include research and development activities along with related general business planning, including raising capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_1ebd2804-b36b-4b3a-9db8-442ef2413c2f">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;BASIS OF PRESENTATION &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying interim condensed consolidated financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and related notes included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on March 7, 2024 (2023 Annual Report).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The financial information as of June 30, 2024, and the three and six months ended June 30, 2024 and 2023, respectively, is unaudited. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for the fair presentation of financial position, results of operations, and cash flows at the dates and for the periods presented, have been included. The balance sheet data as of December 31, 2023 was derived from audited consolidated financial statements. The results of the Company&#x2019;s operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on its current operating plan, and excluding any potential licensing and product revenue, the Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund the Company's currently projected operating expenses and debt obligations for at least the next 12 months from the date the financial statements are issued. The Company has based its projections of operating capital requirements on its current operating plan, which includes several assumptions that may prove to be incorrect, and the Company may use all of its available capital resources sooner than the Company expects. The Company will need to secure additional funding in the future, from one or more equity or debt financings, collaborations, or other sources, in order to carry out all of the Company&#x2019;s planned research and development activities and regulatory activities; commence or continue ongoing commercialization activities, including manufacturing, sales, marketing and distribution, for any of its product candidates for which the Company may receive marketing approval; or conduct any substantial, additional development requirements requested by the FDA. Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional funding, it could be forced to delay, reduce, or eliminate its research and development programs and its reproxalap commercialization efforts, whether alone or with others.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Curtailment of operations would cause significant delays in the Company&#x2019;s efforts to develop and introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company&#x2019;s management evaluates its estimates and assumptions on an ongoing basis. Management&#x2019;s most significant estimates in the Company&#x2019;s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were no changes to significant accounting policies during the six months ended June 30, 2024, as compared to those identified in the 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Annual Report.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to this new standard. However, given the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment, this policy is not expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to this new standard.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_f75027bd-91fd-4fc3-88c4-e209c3f653b3">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. The Company&#x2019;s management evaluates its estimates and assumptions on an ongoing basis. Management&#x2019;s most significant estimates in the Company&#x2019;s condensed consolidated financial statements include, but are not limited to, deferred and accrued research and development costs, stock-based compensation, and accounting for income taxes and related valuation allowance. Although these estimates and assumptions are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_f5041913-821c-417e-b48a-1a4f2cf9acc3">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were no changes to significant accounting policies during the six months ended June 30, 2024, as compared to those identified in the 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Annual Report.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_deb033ef-a16b-4f87-8f99-51946cd6cab1">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07). ASU 2023-07 is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to this new standard. However, given the Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment, this policy is not expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to this new standard.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_9a75437f-ce24-405e-83aa-1f2dd423500c"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_ae862508-82df-408a-aeef-fc6486d1953f">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Helio Vision Acquisition&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 28, 2019 (Closing Date), the Company acquired Helio Vision, Inc. (Helio) and thereby obtained rights to ADX-2191 pursuant to an Agreement and Plan of Merger dated as of January 24, 2019 (the Merger Agreement). As a result of the acquisition, the Company issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,407,006&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to the former securityholders and an advisor of Helio, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;246,562&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares issued in January 2021, pursuant to the terms of the acquisition agreement. In addition, the Company, subject to the conditions of the acquisition agreement, is contingently obligated to make additional payments to the former securityholders of Helio as follows: (a) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of common stock following approval by the FDA of a new drug application (NDA) for the prevention and/or treatment of proliferative vitreoretinopathy or a substantially similar label prior to the 10th anniversary of the Closing Date; and (b) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of common stock following FDA approval of an NDA for an indication (other than proliferative vitreoretinopathy or a substantially similar label) prior to the 12th anniversary of the Closing Date (the shares of common stock issuable pursuant to the preceding clauses (a) and (b) are referred to herein as the Milestone Shares), provided that in no event shall the Company be obligated to issue more than an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,248,885&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock in connection with the Helio acquisition. If the Company ceases to use commercially reasonably efforts to develop and obtain regulatory approval for ADX-2191, subject to the terms and conditions of the Merger Agreement, ADX-2191 and related intellectual property rights may revert back to an entity designated by the representative of the former Helio stockholders. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, in the event of certain change of control or divestitures by the Company, certain former convertible noteholders of Helio will be entitled to a tax gross-up payment in an amount not to exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that liability accounting is not required for the Milestone Shares under FASB ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (ASC 480). The Company also determined that the Milestone Shares meet the scope exception as a derivative under FASB ASC Topic 815, Derivatives and Hedging (ASC 815), from inception of the Milestone Shares through June 30, 2024. Accordingly, the Milestone Shares are evaluated under FASB ASC Topic 450, Contingencies (ASC 450) and the Company will record a liability related to the Milestone Shares if the milestones are achieved, and the obligation to issue the Milestone Shares becomes probable. At such time, the Company will record the cost of the Milestone Shares issued to the Helio founders as a compensation expense and to the other former securityholders of Helio as an in-process research and development expense if there is no alternative future use. No milestones related to the remaining Milestone Shares are considered probable of being achieved as of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_ebf661ea-8dd4-4850-bc1d-1fc69b508bcd"
      decimals="INF"
      id="F_c2b819b3-3702-4868-9522-6fba187d7a9d"
      unitRef="U_shares">1407006</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_e5cc0746-8061-4e14-bb40-9336a2e95fc4"
      decimals="0"
      id="F_2924875c-2607-4add-81f9-af2d21f86c63"
      unitRef="U_shares">246562</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_bb0d2bfe-e96f-4d70-8e2c-d454ec91262c"
      decimals="-5"
      id="F_282b0520-a62d-45c5-a420-28c34474422a"
      unitRef="U_USD">10000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_847ea9b6-7712-40f6-975a-e4c8f6744f6d"
      decimals="-5"
      id="F_4254215c-d353-4940-8cc4-8555ae759663"
      unitRef="U_USD">2500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <aldx:BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares
      contextRef="C_ce7c4b72-5b97-4a0e-8ea7-eeb870e832ed"
      decimals="INF"
      id="F_b5013f1a-fa13-4272-bd34-f44cf9a6c4ec"
      unitRef="U_shares">5248885</aldx:BusinessCombinationContingentConsiderationEquityInterestsIssuableNumberOfShares>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0d3c720f-35ff-43af-affa-e0f2ff358760"
      decimals="-5"
      id="F_dc003cda-7d47-46b0-9d7b-f1ddc9050035"
      unitRef="U_USD">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_d8b5385f-3e05-4970-a358-ff78da72d575">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;NET LOSS PER SHARE &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the three and six months ended June 30, 2024 and 2023, diluted weighted average common shares outstanding is equal to basic weighted average common shares due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;For the Three and Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,033,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,567,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,208,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total of common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,765,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,775,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_98dcf468-6fc6-4da6-a9d8-0de1891f3f39">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average shares outstanding, because such securities had an antidilutive impact:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:20.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;For the Three and Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,033,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,567,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,208,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total of common stock equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,765,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,775,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a65476d8-e4fe-4f45-94fc-12a4ca98f051"
      decimals="INF"
      id="F_bf7c1721-e5ac-49ee-857b-924ae6743b1c"
      unitRef="U_shares">8033741</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ba4aaa8b-9a25-4dae-b1bb-126e2ff2adc7"
      decimals="INF"
      id="F_232e6cdd-71ed-4c43-9572-b5c00cb942e8"
      unitRef="U_shares">8033741</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ba8fec32-6fe2-4982-8ac2-8fed75b0a26a"
      decimals="0"
      id="F_039b7e66-8758-4a81-88f8-2e21a6d2d291"
      unitRef="U_shares">6567153</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d81bffd9-e22d-4296-b634-a77b7d9776fb"
      decimals="0"
      id="F_89b1194a-7a6f-4a0c-9c77-7a8c8800166f"
      unitRef="U_shares">6567153</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b945516c-a2fe-4ef4-b522-ac7685c78c1a"
      decimals="INF"
      id="F_30ee5d6d-c372-4ee7-b157-277ca78177b4"
      unitRef="U_shares">732056</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c420c777-2dcb-48fa-9456-2026963c27cd"
      decimals="INF"
      id="F_117e09e3-425d-48f3-8b56-2139980a3f4a"
      unitRef="U_shares">732056</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b3aea01f-e989-48fd-b9f6-75afb86f910e"
      decimals="0"
      id="F_a42aa1aa-74c9-4430-afc0-fbbfa275a81e"
      unitRef="U_shares">1208100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20b130d8-eac8-40f7-93bd-c629812ee1cd"
      decimals="0"
      id="F_e2bf309b-9143-485d-8151-8032e5d38dce"
      unitRef="U_shares">1208100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="INF"
      id="F_1b4e9ccb-1928-448e-872e-b3ad36536a48"
      unitRef="U_shares">8765797</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_157a24a6-5a95-4344-8e6f-2af7b84f3a0d"
      unitRef="U_shares">8765797</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_6a0d1ca6-c281-4c52-8653-b23f47ede748"
      unitRef="U_shares">7775253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_bc65e839-08ef-469f-85e9-e084dce46397"
      unitRef="U_shares">7775253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_e5e7e38c-7d75-4c35-8583-ba9da2f2ab1e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024, cash, cash equivalents, and marketable securities were comprised of:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.4399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,434,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,434,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,434,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reverse repurchase agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,311,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Available for sale marketable securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,311,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash, cash equivalents, and current marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The contractual maturities of all available for sale securities were less than one year at June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, cash, and cash equivalents were comprised of:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.689%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,510,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,510,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,510,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,823,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,823,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,823,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; marketable securities held at December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_48751ec2-5a71-4294-86e4-6d88605f7fcc">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024, cash, cash equivalents, and marketable securities were comprised of:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:6.4399999999999995%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized&lt;br/&gt;Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Current&lt;br/&gt;Marketable&lt;br/&gt;Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,434,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,434,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,434,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reverse repurchase agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,311,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Available for sale marketable securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,311,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash, cash equivalents, and current marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,029,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, cash, and cash equivalents were comprised of:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.689%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.598%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,510,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,510,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;128,510,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,823,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,823,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,823,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:Cash
      contextRef="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43"
      decimals="0"
      id="F_49ce7676-35db-472d-a6d6-a334fb8ec953"
      unitRef="U_USD">3434204</us-gaap:Cash>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43"
      decimals="0"
      id="F_33d00b83-48d9-48a5-bd2b-592afa219c78"
      unitRef="U_USD">3434204</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_2bf5450b-1320-4ab2-92f1-b707f9f16e43"
      decimals="0"
      id="F_9cdbd174-d936-4562-9ed0-8443817362bc"
      unitRef="U_USD">3434204</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_8fc74b92-85f2-4f9d-916a-762e069ff326"
      decimals="0"
      id="F_bf6f354a-793f-4c75-8f65-c9ac33ed957f"
      unitRef="U_USD">27595519</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_8fc74b92-85f2-4f9d-916a-762e069ff326"
      decimals="0"
      id="F_39785e84-3da2-44b8-81c7-379458b3585f"
      unitRef="U_USD">27595519</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_8fc74b92-85f2-4f9d-916a-762e069ff326"
      decimals="0"
      id="F_9ca5e037-2bd1-466c-96e6-e14c696c8428"
      unitRef="U_USD">27595519</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <aldx:CashEquivalentReverseRepurchaseAgreement
      contextRef="C_01391853-2657-4f02-b4dd-642d3c6e71c3"
      decimals="0"
      id="F_240af1b3-2ae3-4c10-80c6-90dcb825c7c0"
      unitRef="U_USD">40000000</aldx:CashEquivalentReverseRepurchaseAgreement>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_01391853-2657-4f02-b4dd-642d3c6e71c3"
      decimals="0"
      id="F_72d4446a-952d-4ff4-9d28-d82ad0809656"
      unitRef="U_USD">40000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_01391853-2657-4f02-b4dd-642d3c6e71c3"
      decimals="0"
      id="F_652bbc33-4b92-42bc-a53c-f66945f0462c"
      unitRef="U_USD">40000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_621f912c-92a3-433e-800f-cd9932a4b216"
      decimals="0"
      id="F_02750459-1ba8-4fd1-8972-8843943f02cb"
      unitRef="U_USD">71029723</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_621f912c-92a3-433e-800f-cd9932a4b216"
      decimals="0"
      id="F_19db3acd-7a2d-4ded-902a-e7bf5a4a0832"
      unitRef="U_USD">71029723</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_621f912c-92a3-433e-800f-cd9932a4b216"
      decimals="0"
      id="F_cadb8cf4-a218-4389-ab5e-419c2a947040"
      unitRef="U_USD">71029723</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_659d8673-bb33-41b8-8d04-af77a63be73c"
      decimals="0"
      id="F_a4c8a285-03f7-4978-9e2e-b5cad2101f68"
      unitRef="U_USD">49311618</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_733f6dcb-0419-40ba-b628-e28799994562"
      decimals="0"
      id="F_98f340c4-cbcb-4dc4-b4c3-fa8a3e556e7e"
      unitRef="U_USD">486</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_733f6dcb-0419-40ba-b628-e28799994562"
      decimals="0"
      id="F_64806c9b-7a9d-45a8-b35d-32d4ac78b5c7"
      unitRef="U_USD">10144</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_659d8673-bb33-41b8-8d04-af77a63be73c"
      decimals="0"
      id="F_1e4becd1-40a1-49d3-843b-2db55a5daa97"
      unitRef="U_USD">49301960</us-gaap:DebtInstrumentFairValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_659d8673-bb33-41b8-8d04-af77a63be73c"
      decimals="0"
      id="F_2e5955e4-7748-4852-958c-f4c0103ba26c"
      unitRef="U_USD">49301960</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_09af761f-3d1e-47a3-ba56-29b402f55cba"
      decimals="0"
      id="F_1596e311-0cd3-4557-b4fd-9f9789a40315"
      unitRef="U_USD">49311618</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_50415d91-456c-4345-a9e8-9a5bd2f7cfa1"
      decimals="0"
      id="F_f7ced53b-382a-4a06-a70b-8fce9e588d56"
      unitRef="U_USD">486</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_50415d91-456c-4345-a9e8-9a5bd2f7cfa1"
      decimals="0"
      id="F_77f5a3ca-c112-4eff-8efd-da8e3b426a55"
      unitRef="U_USD">10144</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_09af761f-3d1e-47a3-ba56-29b402f55cba"
      decimals="0"
      id="F_0af89e23-8908-4fe4-9ba6-b0ecea824388"
      unitRef="U_USD">49301960</us-gaap:DebtInstrumentFairValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_09af761f-3d1e-47a3-ba56-29b402f55cba"
      decimals="0"
      id="F_8a18a13b-2e56-4f52-8d8e-86a080dff483"
      unitRef="U_USD">49301960</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_bae1f3f4-34e2-44f7-a7ea-d342370dc8ce"
      unitRef="U_USD">71029723</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_1a721f03-0e7f-4769-9c47-f90f8a64eb48"
      unitRef="U_USD">49301960</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:Cash
      contextRef="C_1580d899-1ef3-48b3-8ee0-2947a0996507"
      decimals="0"
      id="F_93b754b2-493a-4b27-b44c-0a15e414fd99"
      unitRef="U_USD">128510451</us-gaap:Cash>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_1580d899-1ef3-48b3-8ee0-2947a0996507"
      decimals="0"
      id="F_3cc68392-a1e3-4f44-bea7-8e52861760ce"
      unitRef="U_USD">128510451</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_1580d899-1ef3-48b3-8ee0-2947a0996507"
      decimals="0"
      id="F_6baacc8d-2dab-4568-8ce2-24b0c0e77370"
      unitRef="U_USD">128510451</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636"
      decimals="0"
      id="F_bee8a18d-e217-4956-b99e-6f6a1402ba8e"
      unitRef="U_USD">14312565</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636"
      decimals="0"
      id="F_209fc7ac-4111-442a-a393-9923107b3f49"
      unitRef="U_USD">14312565</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e54902c6-e1b2-4b91-8cf6-bc1485e75636"
      decimals="0"
      id="F_de7502a6-2aa8-4b76-a53f-92a00c1bef5c"
      unitRef="U_USD">14312565</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e"
      decimals="0"
      id="F_5c60b978-f3e3-4077-a2e2-10b85e7e9648"
      unitRef="U_USD">142823016</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e"
      decimals="0"
      id="F_a4973bf7-58dd-48c6-93ac-8a41cf491ebd"
      unitRef="U_USD">142823016</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a4245c98-6243-4b7a-be81-b8f8c9007b5e"
      decimals="0"
      id="F_9fd492d8-f194-4b81-b39a-229267a097df"
      unitRef="U_USD">142823016</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:MarketableSecurities
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_8e54d341-0cd9-4e3e-bd29-45d6e4a1c6b6"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_fd951b08-fb08-4469-94c7-2a355282663d">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;FAIR VALUE MEASUREMENTS &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value are performed in a manner to maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Quoted prices in active markets that are accessible at the market date for identical unrestricted assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s assets measured at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities (b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reverse repurchase agreements (c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,897,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,897,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. government agency securities are valued based on observable market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; liabilities measured at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 or December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments including clinical trial prepayments to contract research organizations and accounts payable are carried in the condensed consolidated financial statements at amounts that approximate their fair value based on the short maturities of those instruments. The carrying amount of the Company&#x2019;s term loan under the Hercules Credit Facility (as defined in Note 9) approximates market rates currently available to the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_0f722cbe-9a74-475c-8739-6c85591e6e64">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s assets measured at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,595,519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government agency securities (b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,301,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reverse repurchase agreements (c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,897,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,897,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.339%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.554%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total assets at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,312,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;U.S. government agency securities are valued based on observable market prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bb794176-2e9b-4405-a8ac-a7adab3cce8f"
      decimals="0"
      id="F_3453c0eb-9dcf-4d01-9356-9c5099a2c7c2"
      unitRef="U_USD">27595519</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4fd7b4a8-0fb4-40c1-9d8f-860b5e3f8919"
      decimals="0"
      id="F_ed4915a9-4dd2-4265-b77f-6e7637b60391"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ff12ec68-2fd5-4170-ba6e-4b15c2ff223c"
      decimals="0"
      id="F_af0160b3-c1dc-40ec-922e-82ab9dfbe5e5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b5f0f1f6-82d5-4d52-a257-4f738b44ebd5"
      decimals="0"
      id="F_6611f187-f013-435b-90d2-dfd90060d602"
      unitRef="U_USD">27595519</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_88eff217-da00-447c-80f0-c097fab822a1"
      decimals="0"
      id="F_b339e8f1-33fe-4895-bdab-41ed31907311"
      unitRef="U_USD">49301960</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_481f3f0a-8710-4898-94d3-26fd583c6860"
      decimals="0"
      id="F_fea16ee6-10de-47de-b9fd-0d0c2d08937b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d409ba4a-341b-44fb-b178-554996db8456"
      decimals="0"
      id="F_f5561c5f-8c9a-4cc7-a79b-057551894955"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_808346d8-8add-488a-af8a-fcb254ad94f8"
      decimals="0"
      id="F_0315416b-5579-44c4-842d-4b8c907151f8"
      unitRef="U_USD">49301960</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8ae5248f-56fc-4d37-937d-6f7c458af533"
      decimals="0"
      id="F_ff6ecb51-d83d-41b3-be2e-efc0e60d8dd4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5701f4e9-face-49d1-84bc-81d336191ded"
      decimals="0"
      id="F_4bc8c274-18f6-4bcf-8af9-2e9390ef3502"
      unitRef="U_USD">40000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a06e8e4e-16e8-4dde-9e9b-ffb7963feb18"
      decimals="0"
      id="F_879dbe73-3269-4a4c-8715-2f118e4c2e4c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_44cef7b4-5749-4aaa-83b1-0dd0b0576672"
      decimals="0"
      id="F_6f61ddbd-5136-4d1d-8f38-bf73865d4de4"
      unitRef="U_USD">40000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5763b0ce-896c-424b-adb7-cf75ae931b87"
      decimals="0"
      id="F_889dd24f-a8a7-4e02-bbb8-d88c02be6acd"
      unitRef="U_USD">76897479</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b9cc316-d571-44e9-92d7-4c988cd04578"
      decimals="0"
      id="F_582802f7-993c-4717-81e8-75babff112dc"
      unitRef="U_USD">40000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0c6b3071-64d9-4ac6-879c-7ab5b8feecfa"
      decimals="0"
      id="F_2cef5da1-9aad-49ae-aea9-c2a59496ec5b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_9ba98038-9c17-4380-a84f-75283ca325e3"
      unitRef="U_USD">116897479</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b7b49075-22e7-4aa3-8ae8-65ddb24b9fd6"
      decimals="0"
      id="F_575d2373-7b15-4e51-b573-da3f4a24b4d9"
      unitRef="U_USD">14312565</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d9ab5c6a-9d40-4195-839e-643b592547c8"
      decimals="0"
      id="F_92f32549-80f2-467c-8b2f-9bd83c82e5dd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fd697598-618c-412c-a894-2682ae77ed63"
      decimals="0"
      id="F_739cd3a2-b214-4a13-b917-4203bde874f2"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_97b19cd6-75ad-4456-99d8-09b2da452e22"
      decimals="0"
      id="F_e7700661-4e7e-4e18-abc2-e29bf3ec936e"
      unitRef="U_USD">14312565</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a9120b8c-dabf-419b-a873-3175c3e4920e"
      decimals="0"
      id="F_668e5531-0c4d-40de-8c7f-1c08d290a6c6"
      unitRef="U_USD">14312565</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_16a2a60d-0d62-4933-959e-b7fe028a37cb"
      decimals="0"
      id="F_e6b6f5e5-ea9b-437d-97eb-fefe3650290a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_eada7cb9-d8f4-4796-a84a-8755760815f4"
      decimals="0"
      id="F_c6ad3385-8325-4a0e-9ec6-ad68cc0a08bf"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_d35af3d6-4ed0-4dcb-846b-468382e9fe41"
      unitRef="U_USD">14312565</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_c2e0acac-7405-4b68-aacc-50dc71d9503b"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_98428a4e-e296-4181-809e-58396c720cdc"
      unitRef="U_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_d2ef8d34-a100-4f5f-9d60-a4183989da0e">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 were:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred research and development expenses, and deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,859,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,463,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,036,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;340,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Miscellaneous prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;421,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;183,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,317,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,987,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</aldx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_700185b0-db8d-48bb-ab19-dd9d36721ae9">&lt;p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 were:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.440000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred research and development expenses, and deposits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,859,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,463,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,036,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;340,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Miscellaneous prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;421,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;183,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,317,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,987,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</aldx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_d31dcd35-956f-48f1-b58a-930587900dfe"
      unitRef="U_USD">3859927</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_52520f6a-3dd5-46b2-b0d1-7565410cdf50"
      unitRef="U_USD">4463783</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:PrepaidInsurance
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_e1642bff-e51a-460f-bcc1-3abd590e8c41"
      unitRef="U_USD">1036223</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_96d9b357-5dbe-4b1d-b102-213869a5290f"
      unitRef="U_USD">340388</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_c220812b-c455-4ada-ad57-8eec1aec7d93"
      unitRef="U_USD">421686</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_78e0b7ea-3203-46a4-a75c-31940ea13d94"
      unitRef="U_USD">183146</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_74ea60db-3481-4f34-ab6d-2a63588ff974"
      unitRef="U_USD">5317836</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_63177ec8-a694-40c7-a20d-3a2db8f6d81b"
      unitRef="U_USD">4987317</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_4f5a498c-d0b6-4b27-8817-ae222934e56c">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ACCRUED EXPENSES &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 were:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.457%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,571,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,087,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,411,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,687,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;859,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;761,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,842,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,536,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_c32b5b7d-d366-4c52-846a-aa0b84a380b0">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023 were:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.457%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,571,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,087,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,411,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,687,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;859,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;761,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,842,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,536,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_f7b02a6f-3b49-441d-acb6-4d05540d954e"
      unitRef="U_USD">2571463</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_9ff542aa-0c7a-42a8-8a4a-612a7f34b6fb"
      unitRef="U_USD">3087937</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <aldx:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_52770bf3-6919-4ae3-a8b2-a975c0682ace"
      unitRef="U_USD">2411867</aldx:AccruedResearchAndDevelopmentExpenseCurrent>
    <aldx:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_3f4a1dd1-a69d-4fb8-9784-d52607d1ef5f"
      unitRef="U_USD">1687327</aldx:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_2fc53578-10b9-4fa0-b52c-ea14e14c7065"
      unitRef="U_USD">859472</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_1714bdac-eab0-4738-879c-2bbeee08e850"
      unitRef="U_USD">761200</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_b5896f1b-de79-4b6f-ba00-4d4fc415e55c"
      unitRef="U_USD">5842802</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_5fc5f1f9-9b61-46d3-8cbb-a6e2921943fa"
      unitRef="U_USD">5536464</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_484ec839-92d4-4570-ac05-c7eb2368b154">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;CREDIT FACILITY&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s current and long-term debt obligation consists of amounts the Company is obligated to repay under its credit facility with Hercules Capital, Inc. (Hercules). In March 2019, the Company entered into a Loan and Security Agreement (Loan and Security Agreement or Hercules Credit Facility) with Hercules and several banks and other financial institutions or entities, from time-to-time parties thereto (collectively, referred to herein as Lender), providing for a term loan of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, subject to the satisfaction of certain conditions contained therein, that is secured by a lien covering all of the Company&#x2019;s assets, other than the Company&#x2019;s intellectual property. The Loan and Security Agreement provided for (i) an initial term loan advance of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million at the Company&#x2019;s option, which expired unutilized on April 15, 2019; (ii) three additional term loan advances of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million each, at the Company&#x2019;s option, available to the Company upon the occurrence of certain pre-specified funding conditions prior to September 30, 2019 (2019 Tranche), March 31, 2020 (2020 Tranche), and March 31, 2021 (2021 Tranche); and (iii) a final additional term loan advance (Fourth Loan Tranche) of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million prior to December 31, 2021, at the Company&#x2019;s option, subject to approval by the Lender&#x2019;s investment committee. The 2019 Tranche was drawn down in full by the Company in September 2019 and the 2020 Tranche and 2021 Tranche expired unutilized prior to the Company satisfying the funding conditions for such tranche. On April 20, 2021, the Company entered into the First Amendment to the Loan and Security Agreement (First Amendment). The First Amendment, among other things, (i) increased the Fourth Loan Tranche from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and extended the deadline for drawing down the Fourth Loan Tranche to July 1, 2022; (ii) lowered the variable per annum rate of interest on borrowings under the Loan and Security Agreement from the greater of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and (b) the prime rate (as reported in the Wall Street Journal or any successor publication thereto) plus &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to the greater of (x) the Prime Rate (as defined therein) plus 3.10% or (y) 8.60%; (iii) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are required from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to July 1, 2022; and (iv) following the satisfaction of certain conditions, which conditions were satisfied in April 2021, further extended the expiration of the interest-only period and the deadline for drawing down the Fourth Loan Tranche to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Repayment of the aggregate outstanding principal balance of the term loan, in monthly installments, commences upon expiration of the interest-only period and continues through October 1, 2023 (Maturity Date). The First Amendment was determined to be a modification in accordance with FASB ASC Topic 470, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and did not result in extinguishment.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 22, 2022, the Company entered into the Second Amendment to the Loan and Security Agreement (Second Amendment), which became effective as of December 31, 2022 (Second Amendment Effective Date). The Second Amendment, among other things, (i) extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2023 to May 1, 2024; (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;extended the Maturity Date from October 1, 2023 to October 1, 2024; (iii) extended the availability of the Fourth Loan Tranche commitment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which remained conditioned on approval by the Lenders&#x2019; investment committee,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from May 1, 2023 to May 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;; and (iv) amended the Prepayment Charge (as defined therein) to equal &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the amount prepaid during the 12-month period following the Second Amendment Effective Date, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% thereafter. In addition, a supplemental end of term charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;292,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Supplemental End of Term Charge) shall be due on the earlier of (A) the Maturity Date, as amended, or (B) repayment of the aggregate amount of advances under the Loan and Security Agreement. The initial end of term charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,042,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (End &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of Term Charge) was paid&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2, 2023. The Second and Third Amendments were determined to be modifications in accordance with FASB ASC Topic 470, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and did not result in extinguishment.
&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 29, 2024, the Company entered into the Third Amendment to the Loan and Security Agreement (Third Amendment). The Third Amendment, among other things, extended the expiration of the period in which interest-only payments on borrowings under the Loan and Security Agreement are made from May 1, 2024 to October 1, 2024. On May 1, 2024, the Fourth Loan Tranche commitment expired unutilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Hercules Credit Facility, the Company incurred a commitment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, transaction costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;273,186&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, a fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon closing, the End of Term Charge, which was paid in October 2023, and the Company will be required to pay the Supplemental End of Term Charge. The fees and transaction costs are amortized to interest expense from 2019 through the Maturity Date using the effective interest method. The End of Term Charge was amortized to interest expense from 2019 through October 2023, and the Supplemental End of Term Charge is amortized to interest expense from December 2022 through the Maturity Date, both using the effective interest method. The effective interest rate was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024. At the Company&#x2019;s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus all fees and other amounts due under the Loan and Security Agreement as of the date of such prepayment.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million has been funded under the Loan and Security Agreement and no additional amounts were available to the Company for borrowing.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.05%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.333%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.809%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.613%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.196%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Term loan payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplemental end of term charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,242,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,146,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future principal payments, including the Supplemental End of Term Charge, are as follows for the years ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,292,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,292,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Loan and Security Agreement also contains certain events of default, representations, warranties and non-financial covenants of the Company. As of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company was in compliance with all covenants of the Hercules Credit Facility in all material respects. In addition, subject to the terms of the Loan and Security Agreement, the Company granted the Lender the right to purchase up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s equity securities, or instruments exercisable for or convertible into equity securities, sold to investors in financings upon the same terms and conditions afforded to such other investors.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_783ee973-e8a0-419e-baed-08fbad7a4c7b"
      decimals="-5"
      id="F_c4bf9e0a-c100-42d0-9f8f-75d73e1ecad1"
      unitRef="U_USD">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0075fb28-2a17-4b2b-92f6-1abe0f5ca0ed"
      decimals="-5"
      id="F_72c8550c-f4c9-4d0d-8e0f-fd9a4dc11ac1"
      unitRef="U_USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LongTermDebt
      contextRef="C_0e649ed4-2953-4514-be22-df39d5e87435"
      decimals="-5"
      id="F_197ad312-b6da-43a1-81d5-616c9ec17121"
      unitRef="U_USD">15000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_e0ad43ee-c467-4100-b399-f7960579d117"
      decimals="-5"
      id="F_4b21b552-50c6-454a-918e-ca2e9caaa074"
      unitRef="U_USD">10000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_06ea7345-51c9-4c36-a9ba-2e750192f04f"
      decimals="-5"
      id="F_e1f30db7-a9fc-4bc4-9935-ffcd63a59968"
      unitRef="U_USD">10000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="C_7a559121-6521-4d20-bd8a-c5e91210cc67"
      decimals="-5"
      id="F_1604da5e-e08e-4f2c-ba74-a1e366d734c5"
      unitRef="U_USD">20000000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      decimals="4"
      id="F_49635f68-16ad-4127-9a15-522e69718d32"
      unitRef="U_pure">0.091</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_0cb4447a-186f-4c30-9fe1-b6650981eee1"
      decimals="4"
      id="F_ef48ae65-b00a-466e-aeb2-cce6863ed51c"
      unitRef="U_pure">0.031</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <aldx:LineOfCreditFacilityInterestPaymentPeriod
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      id="F_7797f81e-bc45-49b9-bbac-3fa5d8161141">2021-05-01</aldx:LineOfCreditFacilityInterestPaymentPeriod>
    <aldx:LineOfCreditFacilityInterestPaymentExtensionPeriod
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      id="F_e86ccdf7-285b-460f-800a-c76ca16a624a">2023-05-01</aldx:LineOfCreditFacilityInterestPaymentExtensionPeriod>
    <us-gaap:LongTermDebtDescription
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      id="F_a0098b5d-00a8-4be2-a401-ba80ca9c8575">extended the Maturity Date from October 1, 2023 to October 1, 2024; (iii) extended the availability of the Fourth Loan Tranche commitment of $20 million, which remained conditioned on approval by the Lenders&#x2019; investment committee, from May 1, 2023 to May 1, 2024</us-gaap:LongTermDebtDescription>
    <us-gaap:LongTermDebt
      contextRef="C_c2017d1d-743c-43c9-91e8-cd1670c08fa8"
      decimals="-6"
      id="F_4dac0efd-cd85-40eb-a014-5030d0f9a4be"
      unitRef="U_USD">20000000</us-gaap:LongTermDebt>
    <aldx:LineOfCreditFacilityPrepaymentFeePercentage
      contextRef="C_2bff6b01-34c7-4499-90bb-790707bd6958"
      decimals="4"
      id="F_6f1503c4-3e12-4f05-8420-44c027430b77"
      unitRef="U_pure">0.0075</aldx:LineOfCreditFacilityPrepaymentFeePercentage>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="C_5695a349-fc70-4db4-9dda-882a4f8e1db0"
      decimals="2"
      id="F_ba1389ef-f96d-4826-8978-d130fa0aa646"
      unitRef="U_pure">0</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <aldx:SupplementalEndOfTermCharge
      contextRef="C_282ada39-a478-4e55-91a1-d5ab8c59d75f"
      decimals="0"
      id="F_8b537df2-55b8-4dfd-a5dc-e166d8bba5b6"
      unitRef="U_USD">292500</aldx:SupplementalEndOfTermCharge>
    <aldx:ExistingEndOfTermCharge
      contextRef="C_282ada39-a478-4e55-91a1-d5ab8c59d75f"
      decimals="0"
      id="F_4e5d14f9-d00d-44af-82ab-62ff8a7b3036"
      unitRef="U_USD">1042500</aldx:ExistingEndOfTermCharge>
    <aldx:LineOfCreditFacilityCommitmentCharge
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      decimals="0"
      id="F_6d5b5cce-87d2-4e6c-84fd-707386dec074"
      unitRef="U_USD">25000</aldx:LineOfCreditFacilityCommitmentCharge>
    <aldx:LineOfCreditFacilityTransactionCosts
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      decimals="0"
      id="F_36d9d07c-b8be-45e1-ba71-bc1ca2b97cf0"
      unitRef="U_USD">273186</aldx:LineOfCreditFacilityTransactionCosts>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="C_e699a756-602d-48a6-8707-937ab2672bce"
      decimals="0"
      id="F_b6b134e1-cecd-4b41-826f-eee771a0e2c2"
      unitRef="U_USD">375000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="C_96d3e115-830a-4157-ac6e-d8edcdd92568"
      decimals="3"
      id="F_6ecaf0dd-9b8e-4ec3-adb9-8bc2d7e60cf1"
      unitRef="U_pure">0.126</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_96d3e115-830a-4157-ac6e-d8edcdd92568"
      decimals="-6"
      id="F_b0d0bd48-5f10-49a5-b58b-c6aad7258473"
      unitRef="U_USD">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_ed17e823-1c1f-4813-bbb8-ea5b3e0ef797">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.05%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.333%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.809%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.613%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.196%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Term loan payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Supplemental end of term charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;173,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,242,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,146,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermLoansPayable
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_4940af1d-1701-44d6-94fb-761291f68adc"
      unitRef="U_USD">15000000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermLoansPayable
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_c9146644-cd7a-4dac-b5cb-35675d87ce3e"
      unitRef="U_USD">15000000</us-gaap:LongTermLoansPayable>
    <aldx:SupplementalEndOfTermCharges
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_d05e8099-3bc6-4a19-9772-0ecf10407e74"
      unitRef="U_USD">251643</aldx:SupplementalEndOfTermCharges>
    <aldx:SupplementalEndOfTermCharges
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_b6ce8772-0352-4f51-baee-d31a2f575413"
      unitRef="U_USD">173646</aldx:SupplementalEndOfTermCharges>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_8a44277c-921d-4a47-96e6-90673bdcd239"
      unitRef="U_USD">9316</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_1ff83abf-35ea-4aa0-abfe-a70992fd4df1"
      unitRef="U_USD">27100</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LinesOfCreditCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_0802ff9e-0a47-405c-aea3-99caceeb9489"
      unitRef="U_USD">15242327</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_b2f66d91-b10f-42e2-9979-558122fea7bb"
      unitRef="U_USD">15146546</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_11161256-911f-4c70-adfc-855af1ae59f4"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_76109eb2-0c00-41b5-8c03-58912c08621b"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_ac3d5515-46b0-46e1-b1ea-d5b3d1ee0b37">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future principal payments, including the Supplemental End of Term Charge, are as follows for the years ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,292,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,292,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_873277a6-aab2-4cd7-bccf-b64ba06e86b2"
      unitRef="U_USD">15292500</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_8d8667eb-22cc-4656-b700-f62a071f9276"
      unitRef="U_USD">15292500</us-gaap:LongTermDebt>
    <aldx:LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities
      contextRef="C_4a2131ac-d9f6-43b3-8527-47305ed8f104"
      decimals="-5"
      id="F_9cba11e1-123a-4c5c-a038-03f9b12608c5"
      unitRef="U_USD">2000000</aldx:LoanAgreementRightToPurchaseAggregateAmountOfEquitySecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_5852bb68-aaf3-4190-8fbd-89421505faca">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2021, the Company entered into an Open Market Sales Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt; SM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with Jefferies LLC (Jefferies), as sales agent (2021 Jefferies Sales Agreement), under which the Company had the ability to offer and sell, from time to time through Jefferies, shares of common stock providing for aggregate sales proceeds of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of June 30, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock may be sold under the 2021 Jefferies Sales Agreement, and no sales had previously been made pursuant to the 2021 Jefferies Sales Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_820ae58a-8aa6-4607-9edd-93c8f14eda0f"
      decimals="-5"
      id="F_965b2d39-c220-40b0-bc39-712b846cfab9"
      unitRef="U_USD">100000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ce9c8181-658b-4601-b349-c64cda3f969b"
      decimals="0"
      id="F_fd9c33d6-daee-4da8-8bb4-282f55c58b0c"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_88e5b16f-7190-4127-a922-d1c3627d5f0d">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;INCOME TAXES &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; current or deferred tax provision expenses for federal and state income taxes have been recorded as the Company has incurred losses since inception for tax purposes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In assessing the realizability of net deferred taxes in accordance with Accounting Standards Codification (ASC) 740, Income Taxes (ASC 740), the Company considers whether it is more likely than not that some portion or all the deferred tax assets will not be realized. Based on the weight of available evidence, primarily the incurrence of net losses since inception, anticipated net losses in the near future, reversals of existing temporary differences, and expiration of various federal and state attributes, the Company does not consider it more likely than not that some or all of the net deferred taxes will be realized. Accordingly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% valuation allowance has been applied against net deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended (Section 382 and 383), a corporation that undergoes an &#x201c;ownership change&#x201d; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; percentage points over such stockholders&#x2019; lowest percentage ownership during the testing period (generally three years). Transactions involving the Company&#x2019;s common stock, within the testing period, even those outside the Company&#x2019;s control, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on the Company&#x2019;s ability to utilize some or all its NOLs or credits could have a material adverse effect on the Company&#x2019;s results of operations and cash flows. Prior to December 31, 2021, the Company believes it underwent four ownership changes. However, management believes that its aggregate Section 382 and 383 limitation (including the additional limitation for recognized &#x201c;built-in-gains&#x201d;) is sufficient so that no current impairment of its pre-ownership change tax attributes is required. The Company does not believe an ownership change has occurred from December 31, 2021, through June 30, 2024, based on a review of its equity history during that period. Any future ownership changes, including those resulting from the Company&#x2019;s future financing activities, may cause its existing tax attributes to incur additional limitations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024, the Company is subject to tax in the U.S. (Federal and Massachusetts). The Company is open to examination for the tax years ended December 31, 2023, 2022, 2021, and 2020. In addition, any loss years remain open to the extent that losses are available for carryover to future years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740-10 which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. Accordingly, in the provision for income taxes, the Company recognizes interest accrued related to unrecognized tax benefits and penalties; however, management is currently unaware of any uncertain tax positions. As a result, the Company does not have any liabilities recorded including interest or penalties for uncertain tax positions.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Inflation Reduction Act (IRA) was enacted on August 16, 2022. Based on review of the IRA, the Company does not expect any impact to its tax provision. In particular, the Company does not expect to pay Corporate Alternative Minimum Tax (CAMT) in the next few years based on its projected losses. The IRA introduces a 15% CAMT for corporations whose average annual adjusted financial statement income for any consecutive three-tax-year period preceding the tax year exceeds $1 billion starting in 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_39c1e011-e9ae-4875-9500-c3cd89afff9e"
      decimals="0"
      id="F_e6e69f08-a9f4-4f04-a5e9-f819907109bd"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <aldx:DeferredTaxAssetsValuationAllowancePercentage
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="2"
      id="F_6b94da37-7730-4b25-ba1a-9bcc767962f5"
      unitRef="U_pure">1</aldx:DeferredTaxAssetsValuationAllowancePercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6dcdd5b4-ccce-449a-a571-48929e89299f"
      decimals="2"
      id="F_7efccabf-e043-47cc-9167-aea28a24ddb6"
      unitRef="U_pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_3eb90b74-3f1e-4f98-bc06-7ec4314d9bda">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company approved the 2013 Equity Incentive Plan in October 2013, which was amended in June 2016 and June 2018, (Amended 2013 Plan). The Amended 2013 Plan provided for the granting of stock options, restricted stock units (RSU), stock appreciation rights, and stock units to certain employees, members of the board of directors and consultants of the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company's Board of Directors approved the 2023 Equity Incentive Plan (2023 Equity Plan) to replace the Amended 2013 Plan. On June 30, 2023, the Company's stockholders approved the 2023 Equity Plan at the Company's 2023 annual meeting of stockholders. Pursuant to the 2023 Equity Plan, the Company will not make any further grants under the Amended 2013 Plan following June 30, 2023, though awards previously granted under the Amended 2013 Plan will remain outstanding. The 2023 Equity Plan is effective for a period of ten years after June 30, 2023, and a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,450,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, in addition to shares of the Company&#x2019;s common stock that are subject to awards granted under the Amended 2013 Plan that are outstanding as of such date and that are subsequently forfeited, cancelled, or expire before being exercised or settled in full, are authorized for issuance under the 2023 Equity Plan. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,542,805&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock available for grant under the 2023 Equity Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2022 the Company granted cash awards under its Management Cash Incentive Plan, as amended (the Management Cash Incentive Plan). The Management Cash Incentive Plan provides its participants with the opportunity to earn cash incentive awards for the achievement of goals relating to the performance of the Company and was adopted in 2016. The cash awards vest&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in four annual installments from the date of grant based on continued service and entitle the employees to receive a cash payment, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value to the amount by which the then value of the Company&#x2019;s common stock exceeds the base value. As of June 30, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was accrued as compensation expense for vested cash awards. There was no unrecognized expense as of June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2022, the Company granted performance cash settled bonus awards (CSBUs) under its Management Cash Incentive Plan. As the performance criteria had been met, the awards will vest in four annual installments from the date of grant based on continued service, and entitle the employees to receive a cash payment for each vested CSBU, on the earlier of (i) four years from the date of grant or (ii) a change of control, equal in value of the closing price per share of the Company's common stock on the Nasdaq Capital Market (Nasdaq) on the payment date. As of June 30, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was accrued as compensation expense for CSBUs as the Performance Criteria was met in February 2023. There was no unrecognized expense as of June 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes stock-based compensation expense over the requisite service period. The Company's share-based awards are accounted for as equity instruments, except for cash awards and CSBUs, which are accounted for as liabilities. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The amounts included in the consolidated statements of operations relating to stock-based compensation associated with the two equity incentive plans, cash awards, and CSBUs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; are as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;862,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,898,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,053,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;901,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,586,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,710,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,935,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,573,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,484,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,763,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes activity relating to stock options under the incentive plans for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,868,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,376,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;179,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,033,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,829,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#x2019;s common stock on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the per share exercise price of the underlying options.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024, unamortized stock-based compensation for stock options outstanding was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.66&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. Total unrecognized compensation cost will be adjusted for future forfeitures, if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes activity relating to restricted stock units (RSUs) for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.746%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.658%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.277000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;944,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Settled in common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; RSUs granted during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The total grant date fair value of RSUs vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024. As of June 30, 2024, the outstanding RSUs had unamortized stock-based compensation of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with a weighted-average remaining recognition period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.07&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and an aggregate intrinsic value of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,928,226&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for issuance under the 2016 Employee Stock Purchase Plan (2016 ESPP). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the weighted-average grant-date fair value, and total stock-based compensation expense recognized related to the 2016 ESPP are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.389%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average grant-date fair value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_d7bd3f39-df0b-41ee-912e-1db77d9d2cbe"
      decimals="INF"
      id="F_eb638100-ab18-4d53-aeee-3f39575bbcf3"
      unitRef="U_shares">5450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_fa2877a2-040d-4ca1-96d6-0276098a9d96"
      decimals="INF"
      id="F_51ed82d5-cf1f-4275-a8e5-a8180eaaaa08"
      unitRef="U_shares">3542805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="-5"
      id="F_f49b9376-8c8f-4429-a816-615217e79e08"
      unitRef="U_USD">200000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_42d94c98-9934-4c6a-b0fa-52973f777316"
      decimals="-5"
      id="F_2b40ad5f-f243-4c53-a81a-de7413edb14e"
      unitRef="U_USD">1700000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_a425bff8-af48-42fe-bd55-945c9dc16b9a">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The amounts included in the consolidated statements of operations relating to stock-based compensation associated with the two equity incentive plans, cash awards, and CSBUs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; are as follows: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.53%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.222000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,034,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;862,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,898,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,053,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;901,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;711,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,586,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,710,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,935,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,573,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,484,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,763,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6b7f665d-724a-4e0d-8cda-8a1d42dfea6c"
      decimals="0"
      id="F_3f24e8b8-2692-4758-939b-8d437e451042"
      unitRef="U_USD">1034174</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a171b1df-4c92-4175-9e5f-fc3f4bc0789f"
      decimals="0"
      id="F_84d5e98c-e77a-4e2a-95b3-174e56f4d9df"
      unitRef="U_USD">862370</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_296f06b9-5d06-47d8-9d77-8c2beb9797c4"
      decimals="0"
      id="F_799edaa2-4934-442b-8a73-bb925d198d42"
      unitRef="U_USD">1898358</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7b436d9e-9e0b-472d-a52a-b050edddbb87"
      decimals="0"
      id="F_a234032f-28ae-4657-b795-1d6a7daaf9a8"
      unitRef="U_USD">3053738</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2083538c-d3e8-425e-af11-ff49a4b2d8a7"
      decimals="0"
      id="F_12637a31-23b7-4e3d-9719-db3814bdebae"
      unitRef="U_USD">901355</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_05cced33-c667-4b68-9ab8-068003720e62"
      decimals="0"
      id="F_099e3531-3d16-42f9-95f7-93645e6a0434"
      unitRef="U_USD">711170</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2869d481-18dc-4588-a73e-4a7189c37ae7"
      decimals="0"
      id="F_23cbfc1c-6f08-4035-9f05-b9b10b4f9159"
      unitRef="U_USD">1586008</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bc7df239-76b6-4890-8a10-e0ed9e21e2ff"
      decimals="0"
      id="F_374ecc00-977d-4b16-8fe9-c9f7da23b1cd"
      unitRef="U_USD">2710157</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_47d772f7-3980-4c2d-8a3a-9bcca9f13ac5"
      decimals="0"
      id="F_a89dba84-c8b5-4a67-95a6-af078709d442"
      unitRef="U_USD">1935529</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a45c428-5253-440c-8b4b-4acc1d500a7d"
      decimals="0"
      id="F_2fa21d2c-46e5-4e14-a076-0780b1832c33"
      unitRef="U_USD">1573540</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="0"
      id="F_6fff1029-7e10-45a3-b72e-61f3957b9efe"
      unitRef="U_USD">3484366</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6b13adea-7a49-45fe-8ba6-161e7f4fc7bb"
      decimals="0"
      id="F_84e019a5-52f8-46f1-ae87-946a816ca99e"
      unitRef="U_USD">5763895</us-gaap:AllocatedShareBasedCompensationExpense>
    <aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_0fa16303-c789-47b5-882a-7104cfa0c862">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes activity relating to stock options under the incentive plans for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,868,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,376,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;179,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,033,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,829,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.86&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#x2019;s common stock on &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the per share exercise price of the underlying options.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</aldx:ScheduleOfStockOptionExerciseActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="INF"
      id="F_f25a7d6f-d8d6-4ddb-8cb3-f20a823bb12a"
      unitRef="U_shares">5868816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="2"
      id="F_906502d5-da95-4876-83ea-310d734711b2"
      unitRef="U_USDollarShare">6.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_dc6e015f-4534-4370-bdb9-a7945e9ca45d"
      id="F_37d69f58-e7fa-4844-b039-26c82db2b7ca">P6Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_2168d68b-67be-44e7-815f-cebd869819ec"
      decimals="0"
      id="F_8895e7b1-3343-430f-859a-51f2f0401b45"
      unitRef="U_USD">3996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_0c602021-f3a4-4f0c-b1e8-92e056cac67c"
      unitRef="U_shares">2376328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="2"
      id="F_33b9c0aa-4320-4fbc-b98e-0925815ad2b7"
      unitRef="U_USDollarShare">3.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_79531353-d9fa-4aa4-a0af-962a337f01a6"
      unitRef="U_shares">179897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="2"
      id="F_58bbf816-243b-4d8d-aadb-adce7267a04f"
      unitRef="U_USDollarShare">7.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="INF"
      id="F_2b4089f1-c1a7-4ee1-ab4a-52b123634fdf"
      unitRef="U_shares">31506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="2"
      id="F_9211eecf-93ba-4598-8739-071c7022845e"
      unitRef="U_USDollarShare">4.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_faa65864-c002-4ee8-9d30-d29e56fc3fd9"
      unitRef="U_shares">8033741</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="2"
      id="F_ea4c26b8-a96b-45e0-93f3-e5b2463283e3"
      unitRef="U_USDollarShare">5.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_79749130-9217-47d0-b861-4e4685e93a00">P7Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="INF"
      id="F_b75f7c6e-5d56-445c-9288-be277e5962dd"
      unitRef="U_shares">4829541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="2"
      id="F_cfc8c25e-0289-494b-814f-5539709aac1f"
      unitRef="U_USDollarShare">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_4cb487c4-2c67-4ebe-a34b-b3aae9ee234e">P5Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharePrice
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="2"
      id="F_5323937a-25b3-46db-8cb3-c3402b409934"
      unitRef="U_USDollarShare">3.31</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_215ae863-6dc1-4301-a3a7-f9b85b618132"
      decimals="-5"
      id="F_c5500879-5c11-426c-94f5-42a78220bf37"
      unitRef="U_USD">10200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3731cf74-643e-408a-91dd-f3a385d27749"
      id="F_59256f85-8495-45d4-b6bf-cf90db83a4b8">P2Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_dd973f3a-ec71-416c-8f6b-5414b97edac0">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes activity relating to restricted stock units (RSUs) for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.746%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.658%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.277000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;944,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Settled in common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;732,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_d3f16ce7-5180-4c42-a5f4-7353119a3125"
      decimals="0"
      id="F_22e300e6-7f9d-4440-b6b4-652972f12a89"
      unitRef="U_shares">944497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_d3f16ce7-5180-4c42-a5f4-7353119a3125"
      decimals="2"
      id="F_c8056629-75a5-43f6-9d0b-a08f6afab5e4"
      unitRef="U_USDollarShare">5.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <aldx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod
      contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187"
      decimals="0"
      id="F_e2055e61-cc7a-4f16-9dba-2d9d8aaa1806"
      unitRef="U_shares">-212441</aldx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockInPeriod>
    <aldx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue
      contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187"
      decimals="2"
      id="F_4f14a042-435f-4eb9-a28c-f93e46fc6c66"
      unitRef="U_USDollarShare">5.33</aldx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSettledInCommonStockWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af"
      decimals="0"
      id="F_de5d5895-16f6-4167-bbe6-e1f53c0222d1"
      unitRef="U_shares">732056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af"
      decimals="2"
      id="F_7c8d903b-19ce-424b-b57a-38f64edeefe9"
      unitRef="U_USDollarShare">5.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187"
      decimals="0"
      id="F_77f14ba0-9656-4b66-a287-95b1ae68e448"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187"
      decimals="-5"
      id="F_fee1ed23-1799-4714-a1c0-ca833ce36781"
      unitRef="U_USD">1100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af"
      decimals="-5"
      id="F_a15981ae-3d77-44ab-b90a-1ba532104fa2"
      unitRef="U_USD">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_dfb0a79f-dbad-4277-b7e6-6f017cee3187"
      id="F_e123be98-bd02-4e3d-966a-ae4656d516bd">P2Y25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_86cb1dc8-274c-4f99-8f45-a901dcd6d6af"
      decimals="-5"
      id="F_5e0f4743-ead4-4a7a-8922-67169123f89e"
      unitRef="U_USD">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4ac1801a-8726-4753-a2ce-890bbc37f3b6"
      decimals="INF"
      id="F_8944c9a0-f59f-4406-9f3b-f72d56ebd5c9"
      unitRef="U_shares">2928226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_40691c4a-6a10-4003-a95d-31d21fe5ffed">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the weighted-average grant-date fair value, and total stock-based compensation expense recognized related to the 2016 ESPP are as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.389%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average grant-date fair value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_faf7cb0d-6157-4f20-a7ac-312439f84084"
      decimals="2"
      id="F_236b345b-919d-460f-a565-c63e06bc5587"
      unitRef="U_USDollarShare">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_841e49f2-f8fa-49e5-99ce-5c3d05827d57"
      decimals="2"
      id="F_eaa80e8d-f566-4ffe-9d27-76b64c66de74"
      unitRef="U_USDollarShare">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_faf7cb0d-6157-4f20-a7ac-312439f84084"
      decimals="0"
      id="F_242b91e9-b1de-4515-afec-835e7eb3d386"
      unitRef="U_USD">9505</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_841e49f2-f8fa-49e5-99ce-5c3d05827d57"
      decimals="0"
      id="F_d5b08a28-2fe9-4d68-a2a9-8d687ecdf1d2"
      unitRef="U_USD">26734</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_55922230-581a-41af-8d3e-70c478c7b405">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;LEASES&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company currently leases an office used to conduct business. The Company regularly evaluates the renewal options and when they are reasonably certain of exercise, the Company includes the renewal period in its lease term. As the Company&#x2019;s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. In November 2023, the Company entered into a lease amendment that extended the lease by 12 months through December 31, 2024 and contained two options to extend the term of the lease for an additional 12 months each. Each option shall be exercisable, if at all, by giving a nine month written notice to the landlord. In April 2024, the Company extended the option to extend the term of the lease for an additional 12 months into December 2025, which will have no impact on the balance sheet as the option to extend the term of the lease for an additional 12 months was accounted for as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024, the Company maintained an unamortized Right-Of-Use asset with a corresponding operating lease liability of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; based on the present value of the minimum rental payments in accordance with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The weighted average discount rate used for leases as of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. The weighted average remaining lease term as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.50&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. The operating lease expense for the six months ended June 30, 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Maturities and balance sheet presentation of the Company&#x2019;s lease liabilities for all operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024 remaining total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: effect of discounting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s gross future minimum payments under all non-cancelable operating leases as of June 30, 2024, are:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.829%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:23.05pt;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="margin-left:23.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="-5"
      id="F_116ae19f-5ca2-4814-96ff-9e74ede143d2"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="3"
      id="F_6ae17582-053f-43fa-b72e-747a99f840ab"
      unitRef="U_pure">0.091</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      id="F_78c3e64d-b42e-4403-a7a7-46774d0da402">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      decimals="-2"
      id="F_081bc664-a00e-488f-ae4e-2b9dc96e0dde"
      unitRef="U_USD">140300</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_7e2c2e3f-3dda-4a6f-9035-140478762874">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Maturities and balance sheet presentation of the Company&#x2019;s lease liabilities for all operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 is as follows:&lt;/span&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024 remaining total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: effect of discounting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;255,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s gross future minimum payments under all non-cancelable operating leases as of June 30, 2024, are:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.829%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.902%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:23.05pt;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="margin-left:23.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;423,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;285,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.75pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_83749ca6-b9fa-46cf-80b9-05bd85d85c77"
      unitRef="U_USD">423132</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_38b45052-ff82-4846-a9dc-90188c5cabea"
      unitRef="U_USD">29200</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_a444cfc6-cc0f-4d8e-bf44-eac4495a4e3b"
      unitRef="U_USD">393932</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_5467b1e8-93e9-412a-9edb-284ce2bfc7d6"
      unitRef="U_USD">255039</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_3ae893d5-e157-4c24-8b01-09ad4a2d315f"
      unitRef="U_USD">138893</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_3d4d08fc-5eb9-4054-9202-a09208f3b0e5"
      unitRef="U_USD">393932</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_1681ee0a-7ae5-43d6-9e59-9f869016c95e"
      unitRef="U_USD">423132</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_8d8537ae-d0aa-4fed-accc-8658bd84140a"
      unitRef="U_USD">137928</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_ce8d4c02-fc10-404b-9d4f-b00e50057205"
      unitRef="U_USD">285204</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_918737af-3c79-444a-b95f-a56895918021"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_301946c8-c057-410e-81cf-87592afb5a49"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_25ef7d49-428c-4d2d-a0b6-9bdfa69476cd">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;COMMITMENTS AND CONTINGENCIES &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company&#x2019;s request in such capacity. The term of the indemnification is for the officer&#x2019;s or director&#x2019;s lifetime. Through June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company had not experienced any losses related to these&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;indemnification &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;obligations and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related reserves were established.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;In-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;MEEI Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is developing ADX-2191 pursuant to an Exclusive License Agreement with Massachusetts Eye and Ear Infirmary (MEEI) originally entered into in July 2016 between MEEI and Helio Vision, Inc., as amended, (MEEI Agreement). The Company assumed the MEEI Agreement in connection with its 2019 acquisition of Helio Vision.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant and subject to the MEEI Agreement, the Company obtained an exclusive, worldwide license from MEEI to develop and commercialize ADX-2191 under certain patents and patent applications, and other licenses to intellectual property (MEEI Patent Rights). The Company has agreed to use commercially reasonable efforts, to develop ADX-2191, and to meet certain specified effort and achievement benchmarks by certain dates.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In consideration for the rights licensed under the MEEI Agreement, Helio Vision issued MEEI a number of shares of its preferred stock and Helio Vision agreed to pay non-creditable non-refundable license maintenance fees to MEEI of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on each of the second and third anniversary of the MEEI Agreement, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on each of the fourth and fifth anniversary of the MEEI Agreement and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the sixth and each subsequent anniversary of the MEEI Agreement during the term of such agreement. In addition, Helio Vision was obligated to make future sales-dependent milestone payments to MEEI of up to the low seven figures in the aggregate, as well as royalty payments to MEEI at a rate which, as a percentage of net sales, is in the low single digits for products that incorporate or use the MEEI Patent Rights in the United States and as a percentage in the low single digits for products that incorporate or use the MEEI Patent Rights outside the United States. The Company is also obligated under the MEEI Agreement to pay MEEI a percentage of certain sublicense revenue that it receives in connection with entering into any sublicensing arrangements with any third parties, at a percentage rate which tiers downward from low-double digits to mid-single digits based on the date of the sublicense. Following the Company&#x2019;s acquisition of Helio Vision, the Company became obligated to make any future payments owed under the MEEI Agreement. There is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional equity consideration issuable under the MEEI Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The MEEI Agreement will remain in effect until the expiration date of the last to expire patent licensed under the MEEI Agreement. The Company may terminate the MEEI Agreement with timely written notice to MEEI. MEEI has the right to terminate the MEEI Agreement if it, subject to certain specified cure periods, ceases all business operations with respect to licensed products, fails to pay amounts due under the MEEI Agreement, fail to comply with certain due diligence obligations, defaults in the Company's obligation to maintain insurance, one of the Company's officers is convicted of a felony relating to the manufacture, use, sale or importation of licensed products, the Company materially breaches any provisions of the MEEI Agreement or in the event of its insolvency or bankruptcy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the event of an early termination of the MEEI Agreement, all rights licensed and developed by the Company under the MEEI Agreement may revert back to MEEI. The Company has agreed to indemnify MEEI for certain claims that may arise under the MEEI Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 31, 2023, a purported stockholder filed a putative class action lawsuit (the Securities Class Action) in the U.S. District Court for the District of Massachusetts, against the Company and certain current and former officers, captioned Juliana Paice v. Aldeyra Therapeutics, Inc., et al. (No. 23-cv-11737). On January 2, 2024, the lead plaintiff filed an amended complaint. The lawsuit alleges violations by the defendants of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The plaintiff alleges that the defendants made false or misleading statements or failed to disclose certain information concerning (i) the New Drug Application (NDA) for and the prospects of ADX-2191 for the treatment of primary vitreoretinal lymphoma and (ii) the NDA for and the prospects of reproxalap for the treatment of dry eye disease. The lawsuit seeks, among other things, compensatory damages on behalf of herself and all persons and entities that purchased or otherwise acquired the Company's securities between January 7, 2021, and October 16, 2023, as well as attorneys&#x2019; fees and costs. On March 4, 2024, defendants filed a motion to dismiss the amended complaint, the plaintiff filed its opposition to the motion on April 18, 2024, and defendants filed a reply to plaintiff's opposition on May 20, 2024. Oral argument on the motion to dismiss was heard on July 24, 2024. The Company disputes the plaintiff's claims and intends to vigorously defend the suit. At this time, the Company cannot reasonably predict the outcome or estimate potential losses, if any, that could result from this matter.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 7, 2024, a purported stockholder of the Company filed a derivative complaint in the U.S. District Court for the District of Massachusetts, captioned Fawaz Al-Jaljouli v. Todd C. Brady, et al. (No. 24-cv-10585), against certain of the Company&#x2019;s executive officers and directors, and naming the Company as a nominal defendant. The derivative complaint alleges, purportedly on behalf of the Company, breach of fiduciary duty and violations of Section 14(a) of the Securities Exchange Act of 1934. The claims are based on substantially identical allegations as the complaint in the Securities Class Action. The lawsuit seeks, among other things, an award of damages, certain changes to the Company&#x2019;s corporate governance, and attorneys&#x2019; fees and costs. On June 24, 2024, the plaintiff voluntarily dismissed all claims without prejudice.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, from time to time, the Company is subject to litigation and claims arising in the ordinary course of business but, except as stated above, the Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceedings against them that the Company believes could have a material adverse effect on the Company's business, operating results, cash flows, or financial condition.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <aldx:IndemnificationObligationsClaimsOutstanding
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_4af45cee-3cef-45fd-b350-d2a36271bc84"
      unitRef="U_USD">0</aldx:IndemnificationObligationsClaimsOutstanding>
    <aldx:CashReserveForIndemnitiesAndGuarantees
      contextRef="C_7d86d2a2-dd3c-423b-b09f-28e40e7ac6d6"
      decimals="0"
      id="F_2f64432d-0e26-4bef-9e6c-6ae1779ad4e0"
      unitRef="U_USD">0</aldx:CashReserveForIndemnitiesAndGuarantees>
    <aldx:NonCreditableNonRefundableLicenseMaintenanceFees
      contextRef="C_ae29fbf4-5256-4883-8903-abc42ff33b2e"
      decimals="0"
      id="F_788931a1-d0b9-4a39-a50a-7a3d1b97f6da"
      unitRef="U_USD">15000</aldx:NonCreditableNonRefundableLicenseMaintenanceFees>
    <aldx:NonCreditableNonRefundableLicenseMaintenanceFees
      contextRef="C_7749ab03-e4ad-4f5d-a02f-52988e9238db"
      decimals="0"
      id="F_ded39bb5-0f37-4f45-83ee-196ffaa4450a"
      unitRef="U_USD">25000</aldx:NonCreditableNonRefundableLicenseMaintenanceFees>
    <aldx:NonCreditableNonRefundableLicenseMaintenanceFees
      contextRef="C_c67b96d9-fd6c-4b3b-b38e-25799171694d"
      decimals="0"
      id="F_66f8fc5e-48c0-4aeb-aa66-1f282c0a5317"
      unitRef="U_USD">35000</aldx:NonCreditableNonRefundableLicenseMaintenanceFees>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_e51b1aea-5294-4784-b720-49da7b57163b"
      decimals="0"
      id="F_7202da4c-a1ff-475f-8e45-b1dbaeb1a0e3"
      unitRef="U_USD">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_a0f7c50b-70af-4297-b9aa-41adb3adb312"
      id="F_47cfd135-9d10-417c-8cfb-923ad1676470">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;SIGNIFICANT AGREEMENTS&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;AbbVie Option Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 31, 2023 (the Option Agreement Effective Date), the Company entered into an exclusive option agreement (the Option Agreement) with AbbVie Inc. (AbbVie), pursuant to which the Company granted AbbVie an exclusive option (the Option) to obtain (a) a co-exclusive license in the United States to facilitate a collaboration with the Company to develop, manufacture and commercialize reproxalap in the United States, (b) an exclusive license to develop, manufacture and commercialize reproxalap outside the United States, (c) a right of first negotiation for compounds that are owned or otherwise controlled by the Company in the field of ophthalmology relating to treating conditions of the ocular surface, and (d) a right to review data for any other compounds that are owned or otherwise controlled by the Company in the fields of ophthalmology and immunology before such data is shared with any other third party (the Collaboration Agreement). AbbVie has paid the Company a non-refundable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in consideration of the Option (the Option Payment).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 21, 2023, pursuant to the Option Agreement, AbbVie extended the period during which it may exercise the Option (the Exercise Period Extension) by paying the Company a non-refundable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the Option Extension Fee). As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to the Company at any time during the period following the Option Agreement Effective Date until the earlier of (a) the tenth (10th) business day after the date, if any, that the Company receives approval from the U.S. Food and Drug Administration of the NDA for reproxalap in dry eye disease (the FDA Decision) and (b) the date that is eighteen (18) months after the Option Agreement Effective Date. If the Collaboration Agreement is entered into, the Option Payment and the Option Extension Fee will be credited against the upfront cash payment payable by AbbVie.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon AbbVie&#x2019;s delivery of the agreement execution notice and the parties entering into the Collaboration Agreement, AbbVie would pay the Company a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront cash payment, less the Option Payment and the Option Extension Fee. In addition, the Company would be eligible to receive up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in regulatory and commercial milestone payments, inclusive of a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone payment payable if the FDA Decision is received prior to or after the execution of the Collaboration Agreement. In the United States, the Company would share profits and losses with AbbVie from the commercialization of reproxalap according to a split of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for AbbVie and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for the Company. Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap. As of August 1, 2024, AbbVie has not exercised the Option.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had recognized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; collaboration revenue and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of deferred collaboration revenue, long-term, related to the Option Agreement and Exercise Period Extension. During th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;e three months ended  June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the deferred collaboration revenue was moved from a long-term liability to a current liability on the Company&#x2019;s balance sheet as a result of the Option expiring pursuant to the terms of the Option Agreement in less than one year if not exercised. The Company concluded, using ASC 606 by analogy for recognition considerations as the Option Agreement was not considered to be a vendor-customer relationship, that the transaction price is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the Transaction Price), and all other amounts are excluded from the Transaction Price as they relate to fees that can only be achieved subsequent to the exercise of the Option. The Transaction Price was allocated to the single unit of account, the Option to enter into a future Collaboration Agreement which is a material right, as the Option Extension Fee and the Option Payment are creditable against the upfront payments payable by AbbVie if the Collaboration Agreement is entered into. The Company concluded that all other performance obligations were immaterial promises in the context of the Option Agreement and did not represent additional units of account. The Company will begin to recognize revenue, if and, when the Option is exercised or when the Option expires.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <aldx:NonRefundablePayment
      contextRef="C_d45352fc-bf96-470b-b41f-a3eef457e016"
      decimals="-6"
      id="F_f6ca0e37-f3a1-4d14-b73f-57e60f4fbf27"
      unitRef="U_USD">1000000</aldx:NonRefundablePayment>
    <aldx:NonRefundablePayment
      contextRef="C_40f99af9-00a1-419c-baf2-fe6d585df1ee"
      decimals="-6"
      id="F_eac7d1ce-be6f-40f3-be53-e78e9688a772"
      unitRef="U_USD">5000000</aldx:NonRefundablePayment>
    <aldx:UpfrontCashPayment
      contextRef="C_40f99af9-00a1-419c-baf2-fe6d585df1ee"
      decimals="-6"
      id="F_0845df52-0992-4fd7-bbba-afaebd38d002"
      unitRef="U_USD">100000000</aldx:UpfrontCashPayment>
    <aldx:MilestonePayments
      contextRef="C_270782a4-00d0-4755-8b0e-33d563f70df1"
      decimals="-6"
      id="F_96d9c2cc-b387-4b59-b799-737fcc1b6e94"
      unitRef="U_USD">300000000</aldx:MilestonePayments>
    <aldx:MilestonePayments
      contextRef="C_10f6bf02-b7a9-406c-8bc5-35aafa92828a"
      decimals="-6"
      id="F_dd26199b-20c0-4d81-81f3-1f4e69544aba"
      unitRef="U_USD">100000000</aldx:MilestonePayments>
    <aldx:SplitProfitsAndLossesPercentage
      contextRef="C_40f99af9-00a1-419c-baf2-fe6d585df1ee"
      decimals="2"
      id="F_0614faf3-ff0e-4e9d-90c1-6621abd7fad4"
      unitRef="U_pure">0.60</aldx:SplitProfitsAndLossesPercentage>
    <aldx:SplitProfitsAndLossesPercentage
      contextRef="C_d16b308a-5d1b-46ab-9b7e-ef142ccd89bb"
      decimals="2"
      id="F_64941569-90f2-4c60-ae9c-c4025151819d"
      unitRef="U_pure">0.40</aldx:SplitProfitsAndLossesPercentage>
    <us-gaap:Revenues
      contextRef="C_459e57d8-3560-4c3f-bc51-fdf45eed3a01"
      decimals="-6"
      id="F_577899ef-60a0-4743-895d-d557379d70e8"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:DeferredRevenue
      contextRef="C_7fa87fa1-8b12-44f5-9947-3868ccbde0f8"
      decimals="-5"
      id="F_32dfcc79-35da-4443-8b0a-5df01e826e3e"
      unitRef="U_USD">6000000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_7fa87fa1-8b12-44f5-9947-3868ccbde0f8"
      decimals="-5"
      id="F_94fa04a4-9e92-4903-be12-3e29f0cd14f3"
      unitRef="U_USD">6000000</us-gaap:RevenueRemainingPerformanceObligation>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_f7ced53b-382a-4a06-a70b-8fce9e588d56"
          xlink:label="F_f7ced53b-382a-4a06-a70b-8fce9e588d56"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1596e311-0cd3-4557-b4fd-9f9789a40315"
          xlink:label="F_1596e311-0cd3-4557-b4fd-9f9789a40315"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_77f5a3ca-c112-4eff-8efd-da8e3b426a55"
          xlink:label="F_77f5a3ca-c112-4eff-8efd-da8e3b426a55"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8a18a13b-2e56-4f52-8d8e-86a080dff483"
          xlink:label="F_8a18a13b-2e56-4f52-8d8e-86a080dff483"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0af89e23-8908-4fe4-9ba6-b0ecea824388"
          xlink:label="F_0af89e23-8908-4fe4-9ba6-b0ecea824388"
          xlink:type="locator"/>
        <link:footnote id="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc" xlink:label="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes, if material, in other comprehensive income.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f7ced53b-382a-4a06-a70b-8fce9e588d56"
          xlink:to="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1596e311-0cd3-4557-b4fd-9f9789a40315"
          xlink:to="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_77f5a3ca-c112-4eff-8efd-da8e3b426a55"
          xlink:to="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8a18a13b-2e56-4f52-8d8e-86a080dff483"
          xlink:to="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0af89e23-8908-4fe4-9ba6-b0ecea824388"
          xlink:to="FNT_b0a40b95-f404-40e8-910d-e65110ad67dc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_af0160b3-c1dc-40ec-922e-82ab9dfbe5e5"
          xlink:label="F_af0160b3-c1dc-40ec-922e-82ab9dfbe5e5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3453c0eb-9dcf-4d01-9356-9c5099a2c7c2"
          xlink:label="F_3453c0eb-9dcf-4d01-9356-9c5099a2c7c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6611f187-f013-435b-90d2-dfd90060d602"
          xlink:label="F_6611f187-f013-435b-90d2-dfd90060d602"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7700661-4e7e-4e18-abc2-e29bf3ec936e"
          xlink:label="F_e7700661-4e7e-4e18-abc2-e29bf3ec936e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_92f32549-80f2-467c-8b2f-9bd83c82e5dd"
          xlink:label="F_92f32549-80f2-467c-8b2f-9bd83c82e5dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_575d2373-7b15-4e51-b573-da3f4a24b4d9"
          xlink:label="F_575d2373-7b15-4e51-b573-da3f4a24b4d9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_739cd3a2-b214-4a13-b917-4203bde874f2"
          xlink:label="F_739cd3a2-b214-4a13-b917-4203bde874f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ed4915a9-4dd2-4265-b77f-6e7637b60391"
          xlink:label="F_ed4915a9-4dd2-4265-b77f-6e7637b60391"
          xlink:type="locator"/>
        <link:footnote id="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106" xlink:label="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds included in cash and cash equivalents in the consolidated balance sheets, are valued at quoted market prices in active markets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_af0160b3-c1dc-40ec-922e-82ab9dfbe5e5"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3453c0eb-9dcf-4d01-9356-9c5099a2c7c2"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6611f187-f013-435b-90d2-dfd90060d602"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7700661-4e7e-4e18-abc2-e29bf3ec936e"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_92f32549-80f2-467c-8b2f-9bd83c82e5dd"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_575d2373-7b15-4e51-b573-da3f4a24b4d9"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_739cd3a2-b214-4a13-b917-4203bde874f2"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ed4915a9-4dd2-4265-b77f-6e7637b60391"
          xlink:to="FNT_7b6d55f9-7531-46e6-82b4-c7cb680d0106"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_fea16ee6-10de-47de-b9fd-0d0c2d08937b"
          xlink:label="F_fea16ee6-10de-47de-b9fd-0d0c2d08937b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0315416b-5579-44c4-842d-4b8c907151f8"
          xlink:label="F_0315416b-5579-44c4-842d-4b8c907151f8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b339e8f1-33fe-4895-bdab-41ed31907311"
          xlink:label="F_b339e8f1-33fe-4895-bdab-41ed31907311"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f5561c5f-8c9a-4cc7-a79b-057551894955"
          xlink:label="F_f5561c5f-8c9a-4cc7-a79b-057551894955"
          xlink:type="locator"/>
        <link:footnote id="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6" xlink:label="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">U.S. government agency securities are valued based on observable market prices in active markets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fea16ee6-10de-47de-b9fd-0d0c2d08937b"
          xlink:to="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0315416b-5579-44c4-842d-4b8c907151f8"
          xlink:to="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b339e8f1-33fe-4895-bdab-41ed31907311"
          xlink:to="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f5561c5f-8c9a-4cc7-a79b-057551894955"
          xlink:to="FNT_372efea2-4133-4e26-bd8e-6161de9bb4f6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_ff6ecb51-d83d-41b3-be2e-efc0e60d8dd4"
          xlink:label="F_ff6ecb51-d83d-41b3-be2e-efc0e60d8dd4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4bc8c274-18f6-4bcf-8af9-2e9390ef3502"
          xlink:label="F_4bc8c274-18f6-4bcf-8af9-2e9390ef3502"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6f61ddbd-5136-4d1d-8f38-bf73865d4de4"
          xlink:label="F_6f61ddbd-5136-4d1d-8f38-bf73865d4de4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_879dbe73-3269-4a4c-8715-2f118e4c2e4c"
          xlink:label="F_879dbe73-3269-4a4c-8715-2f118e4c2e4c"
          xlink:type="locator"/>
        <link:footnote id="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627" xlink:label="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reverse repurchase agreements are recorded at fair market value, which is determined based on the most recent observable inputs for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ff6ecb51-d83d-41b3-be2e-efc0e60d8dd4"
          xlink:to="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4bc8c274-18f6-4bcf-8af9-2e9390ef3502"
          xlink:to="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6f61ddbd-5136-4d1d-8f38-bf73865d4de4"
          xlink:to="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_879dbe73-3269-4a4c-8715-2f118e4c2e4c"
          xlink:to="FNT_c1545a9d-fa0a-4ca6-bef3-1743b2546627"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_8895e7b1-3343-430f-859a-51f2f0401b45"
          xlink:label="F_8895e7b1-3343-430f-859a-51f2f0401b45"
          xlink:type="locator"/>
        <link:footnote id="FNT_30fce50e-09e3-4718-8fe5-35e6214b0ffd" xlink:label="FNT_30fce50e-09e3-4718-8fe5-35e6214b0ffd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in this table was calculated on the positive difference, if any, between the closing price per share of the Company&#x2019;s common stock on </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 of </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.31</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the per share exercise price of the underlying options.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8895e7b1-3343-430f-859a-51f2f0401b45"
          xlink:to="FNT_30fce50e-09e3-4718-8fe5-35e6214b0ffd"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
